0000885725-23-000008.txt : 20230223 0000885725-23-000008.hdr.sgml : 20230223 20230223162014 ACCESSION NUMBER: 0000885725-23-000008 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 128 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 23659932 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-K 1 bsx-20221231.htm 10-K bsx-20221231
000088572512/312022FYfalsehttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent00008857252022-01-012022-12-310000885725us-gaap:CommonStockMember2022-01-012022-12-310000885725bsx:SeniorNotedue2027Member2022-01-012022-12-310000885725bsx:A550MCPSSeriesAMember2022-01-012022-12-3100008857252021-06-30iso4217:USDiso4217:USDxbrli:shares00008857252023-01-31xbrli:shares00008857252021-01-012021-12-3100008857252020-01-012020-12-3100008857252022-12-3100008857252021-12-310000885725us-gaap:PreferredStockMember2021-12-310000885725us-gaap:PreferredStockMember2020-12-310000885725us-gaap:PreferredStockMember2019-12-310000885725us-gaap:PreferredStockMember2022-01-012022-12-310000885725us-gaap:PreferredStockMember2021-01-012021-12-310000885725us-gaap:PreferredStockMember2020-01-012020-12-310000885725us-gaap:PreferredStockMember2022-12-310000885725us-gaap:CommonStockMember2021-12-310000885725us-gaap:CommonStockMember2020-12-310000885725us-gaap:CommonStockMember2019-12-310000885725us-gaap:CommonStockMember2022-01-012022-12-310000885725us-gaap:CommonStockMember2021-01-012021-12-310000885725us-gaap:CommonStockMember2020-01-012020-12-3100008857252020-12-310000885725us-gaap:CommonStockMember2022-12-310000885725us-gaap:TreasuryStockMember2021-12-310000885725us-gaap:TreasuryStockMember2020-12-310000885725us-gaap:TreasuryStockMember2019-12-310000885725us-gaap:TreasuryStockMember2022-01-012022-12-310000885725us-gaap:TreasuryStockMember2021-01-012021-12-310000885725us-gaap:TreasuryStockMember2020-01-012020-12-310000885725us-gaap:TreasuryStockMember2022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2021-12-310000885725us-gaap:AdditionalPaidInCapitalMember2020-12-310000885725us-gaap:AdditionalPaidInCapitalMember2019-12-310000885725us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000885725us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000885725us-gaap:AdditionalPaidInCapitalMember2022-12-310000885725us-gaap:RetainedEarningsMember2021-12-310000885725us-gaap:RetainedEarningsMember2020-12-310000885725us-gaap:RetainedEarningsMember2019-12-310000885725us-gaap:RetainedEarningsMember2022-01-012022-12-310000885725us-gaap:RetainedEarningsMember2021-01-012021-12-310000885725us-gaap:RetainedEarningsMember2020-01-012020-12-310000885725us-gaap:RetainedEarningsMember2022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100008857252019-12-3100008857252021-08-062021-08-060000885725bsx:MITechCoLtdMember2022-06-15xbrli:pure0000885725bsx:MITechCoLtdMember2022-06-152022-06-15iso4217:KRW0000885725bsx:ApolloEndosurgeryIncMember2022-11-290000885725bsx:ApolloEndosurgeryIncMember2022-11-292022-11-290000885725bsx:MITechCoLtdMember2022-11-292022-11-290000885725bsx:AcotecScientificHoldingsLimitedMemberus-gaap:SubsequentEventMember2023-02-200000885725bsx:MITechCoLtdMemberus-gaap:SubsequentEventMember2023-01-012023-02-230000885725bsx:AcotecScientificHoldingsLimitedMemberus-gaap:SubsequentEventMember2023-01-012023-02-230000885725bsx:BaylisMedicalMember2022-01-012022-12-310000885725bsx:BaylisMedicalMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMember2022-01-012022-12-310000885725srt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMember2022-01-012022-12-310000885725us-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMember2022-12-310000885725us-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMember2022-01-012022-12-310000885725us-gaap:OtherIntangibleAssetsMembersrt:WeightedAverageMemberbsx:BaylisMedicalMember2022-01-012022-12-310000885725bsx:PreventiceSolutionsIncMember2021-03-012021-03-010000885725bsx:PreventiceSolutionsIncMember2021-03-010000885725bsx:FarapulseIncMember2021-08-062021-08-060000885725bsx:FarapulseIncMember2021-08-060000885725bsx:FarapulseMember2022-01-012022-12-310000885725bsx:LumenisLTDMember2021-09-012021-09-010000885725bsx:DevoroMedicalIncMember2021-11-082021-11-080000885725bsx:DevoroMedicalIncMember2021-11-080000885725bsx:A2021AcquisitionsMember2022-01-012022-12-310000885725bsx:PreventiceSolutionsIncMember2022-01-012022-12-310000885725bsx:LumenisLTDMember2022-01-012022-12-310000885725bsx:AllOther2021AcquisitionsMember2022-01-012022-12-310000885725bsx:PreventiceSolutionsIncMember2022-12-310000885725bsx:LumenisLTDMember2022-12-310000885725bsx:AllOther2021AcquisitionsMember2022-12-310000885725bsx:A2021AcquisitionsMember2022-12-310000885725bsx:PreventiceSolutionsIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725bsx:PreventiceSolutionsIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000885725bsx:PreventiceSolutionsIncMembersrt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000885725bsx:PreventiceSolutionsIncMemberus-gaap:OtherIntangibleAssetsMember2022-12-310000885725bsx:PreventiceSolutionsIncMemberus-gaap:OtherIntangibleAssetsMember2022-01-012022-12-310000885725bsx:PreventiceSolutionsIncMemberus-gaap:OtherIntangibleAssetsMembersrt:WeightedAverageMember2022-01-012022-12-310000885725bsx:LumenisLTDMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725bsx:LumenisLTDMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000885725bsx:LumenisLTDMembersrt:WeightedAverageMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000885725bsx:LumenisLTDMemberus-gaap:OtherIntangibleAssetsMember2022-12-310000885725bsx:LumenisLTDMemberus-gaap:OtherIntangibleAssetsMember2022-01-012022-12-310000885725bsx:LumenisLTDMemberus-gaap:OtherIntangibleAssetsMembersrt:WeightedAverageMember2022-01-012022-12-310000885725us-gaap:InProcessResearchAndDevelopmentMemberbsx:LumenisLTDMember2022-12-310000885725bsx:LumenisLTDMemberus-gaap:InProcessResearchAndDevelopmentMembersrt:WeightedAverageMember2022-01-012022-12-310000885725bsx:AllOther2021AcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725bsx:AllOther2021AcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000885725srt:MinimumMemberbsx:AllOther2021AcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000885725srt:MaximumMemberbsx:AllOther2021AcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-12-310000885725us-gaap:InProcessResearchAndDevelopmentMemberbsx:AllOther2021AcquisitionsMember2022-12-310000885725us-gaap:InProcessResearchAndDevelopmentMembersrt:WeightedAverageMemberbsx:AllOther2021AcquisitionsMember2022-01-012022-12-310000885725us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberbsx:SpecialtyPharmaceuticalsMember2021-03-010000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2022-01-012022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2022-01-012022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:WeightedAverageMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2022-01-012022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:WeightedAverageMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RevenueBasedPaymentsMember2022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberbsx:RevenueBasedPaymentsMember2022-01-012022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMemberbsx:RevenueBasedPaymentsMember2022-01-012022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RevenueBasedPaymentsMembersrt:WeightedAverageMember2022-01-012022-12-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RevenueBasedPaymentsMembersrt:WeightedAverageMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310000885725us-gaap:PatentsMember2022-12-310000885725us-gaap:PatentsMember2021-12-310000885725us-gaap:OtherIntangibleAssetsMember2022-12-310000885725us-gaap:OtherIntangibleAssetsMember2021-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2021-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310000885725bsx:MedsurgMember2020-12-310000885725bsx:CardiovascularMember2020-12-310000885725bsx:MedsurgMember2021-01-012021-12-310000885725bsx:CardiovascularMember2021-01-012021-12-310000885725bsx:MedsurgMember2021-12-310000885725bsx:CardiovascularMember2021-12-310000885725bsx:MedsurgMember2022-01-012022-12-310000885725bsx:CardiovascularMember2022-01-012022-12-310000885725bsx:MedsurgMember2022-12-310000885725bsx:CardiovascularMember2022-12-310000885725bsx:November2019AggregateOfferingMember2020-12-31iso4217:EUR0000885725bsx:December2027NotesMember2022-12-310000885725bsx:MITechCoLtdMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:NetInvestmentHedgingMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:NetInvestmentHedgingMember2021-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-31bsx:units0000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2022-01-012022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2022-01-012022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2021-01-012021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2021-01-012021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2020-01-012020-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2020-01-012020-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeignCurrencyDenominatedInDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2020-01-012020-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2020-01-012020-12-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2022-12-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2022-12-310000885725us-gaap:InterestRateContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2022-12-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2022-01-012022-12-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2021-01-012021-12-310000885725us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2020-01-012020-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-12-310000885725us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000885725us-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2021-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2021-12-310000885725us-gaap:FairValueInputsLevel3Member2022-12-310000885725bsx:LicensingArrangementAssetsMember2022-01-012022-12-310000885725bsx:LicensingArrangementAssetsMembersrt:WeightedAverageMember2022-01-012022-12-310000885725srt:MinimumMemberbsx:LicensingArrangementLiabilitiesMember2022-01-012022-12-310000885725srt:MaximumMemberbsx:LicensingArrangementLiabilitiesMember2022-01-012022-12-310000885725srt:WeightedAverageMemberbsx:LicensingArrangementLiabilitiesMember2022-01-012022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementAssetsMember2020-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementAssetsMember2021-01-012021-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementAssetsMember2021-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementAssetsMember2022-01-012022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementAssetsMember2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementLiabilitiesMember2020-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementLiabilitiesMember2021-01-012021-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementLiabilitiesMember2021-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementLiabilitiesMember2022-01-012022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbsx:LicensingArrangementLiabilitiesMember2022-12-310000885725bsx:May2022NotesMember2022-12-310000885725bsx:May2022NotesMember2021-12-310000885725bsx:October2023NotesMember2022-12-310000885725bsx:October2023NotesMember2021-12-310000885725bsx:March2024NotesMember2022-12-310000885725bsx:March2024NotesMember2021-12-310000885725bsx:May2025NotesMember2022-12-310000885725bsx:May2025NotesMember2021-12-310000885725bsx:June2025NotesMember2022-12-310000885725bsx:June2025NotesMember2021-12-310000885725bsx:March2026NotesMember2022-12-310000885725bsx:March2026NotesMember2021-12-310000885725bsx:December2027NotesMember2021-12-310000885725bsx:March2028SeniorNotesMember2022-12-310000885725bsx:March2028SeniorNotesMember2021-12-310000885725bsx:March2028NotesMember2022-12-310000885725bsx:March2028NotesMember2021-12-310000885725bsx:March2029NotesMember2022-12-310000885725bsx:March2029NotesMember2021-12-310000885725bsx:June2030NotesMember2022-12-310000885725bsx:June2030NotesMember2021-12-310000885725bsx:March2031NotesMember2022-12-310000885725bsx:March2031NotesMember2021-12-310000885725bsx:March2034NotesMember2022-12-310000885725bsx:March2034NotesMember2021-12-310000885725bsx:November2035NotesMember2022-12-310000885725bsx:November2035NotesMember2021-12-310000885725bsx:March2039NotesMember2022-12-310000885725bsx:March2039NotesMember2021-12-310000885725bsx:January2040NotesMember2022-12-310000885725bsx:January2040NotesMember2021-12-310000885725bsx:March2049NotesMember2022-12-310000885725bsx:March2049NotesMember2021-12-310000885725us-gaap:SeniorNotesMember2022-12-310000885725us-gaap:SeniorNotesMember2021-12-310000885725us-gaap:InterestRateSwapMember2022-12-310000885725us-gaap:InterestRateSwapMember2021-12-310000885725us-gaap:CapitalLeaseObligationsMember2022-12-310000885725us-gaap:CapitalLeaseObligationsMember2021-12-310000885725bsx:May2022NotesMember2022-03-310000885725bsx:The2018FacilityDomainus-gaap:RevolvingCreditFacilityMember2021-05-100000885725bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember2022-12-310000885725bsx:ActualCovenantMember2022-12-310000885725bsx:RequirementAsOfMarch312021Member2022-12-310000885725bsx:RequirementFourQuartersFollowingMaterialAcquisitionMember2022-12-310000885725bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember2022-12-310000885725bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember2022-12-310000885725bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember2022-12-310000885725bsx:RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember2022-12-310000885725us-gaap:CommercialPaperMember2022-01-012022-12-310000885725bsx:TheOfferingAggregatePrincipalAmountMember2022-12-310000885725bsx:March2025NotesMember2022-12-31utr:Rate0000885725bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember2022-12-3100008857252022-10-012022-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2022-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2021-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2021-01-012021-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2021-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2021-01-012021-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2021-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2021-01-012021-12-310000885725srt:MinimumMember2022-12-310000885725srt:MaximumMember2022-12-310000885725srt:MaximumMember2022-01-012022-12-310000885725us-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:OtherNoncurrentLiabilitiesMember2021-12-310000885725us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310000885725us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310000885725bsx:DeferredTaxAssetsDomain2022-12-310000885725bsx:DeferredTaxAssetsDomain2021-12-310000885725bsx:DeferredTaxLiabilitiesDomain2022-12-310000885725bsx:DeferredTaxLiabilitiesDomain2021-12-3100008857252021-07-012021-09-300000885725us-gaap:SubsequentEventMember2023-01-312023-01-31bsx:Unit00008857252022-08-052022-08-050000885725bsx:A550MCPSSeriesAMember2020-05-270000885725bsx:A550MCPSSeriesAMember2020-05-272020-05-270000885725bsx:A550MCPSSeriesAMember2022-12-310000885725bsx:A550MCPSSeriesAMembersrt:MinimumMember2022-01-012022-12-310000885725bsx:A550MCPSSeriesAMembersrt:MaximumMember2022-01-012022-12-310000885725bsx:A550MCPSSeriesAMemberus-gaap:SubsequentEventMember2023-01-302023-01-300000885725us-gaap:CommonStockMember2020-05-272020-05-270000885725us-gaap:CommonStockMember2020-05-2700008857252020-12-140000885725bsx:A2011LtipPlanMember2020-10-010000885725us-gaap:CostOfSalesMember2022-01-012022-12-310000885725us-gaap:CostOfSalesMember2021-01-012021-12-310000885725us-gaap:CostOfSalesMember2020-01-012020-12-310000885725us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000885725us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000885725us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310000885725us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000885725us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000885725us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000885725srt:MinimumMember2022-01-012022-12-310000885725srt:MinimumMember2021-01-012021-12-310000885725srt:MaximumMember2021-01-012021-12-310000885725srt:MinimumMember2020-01-012020-12-310000885725srt:MaximumMember2020-01-012020-12-3100008857252021-02-1700008857252020-02-1800008857252019-02-210000885725us-gaap:StockCompensationPlanMember2020-01-012020-12-310000885725us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000885725us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000885725us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000885725bsx:A550MCPSSeriesAMember2022-01-012022-12-310000885725bsx:A550MCPSSeriesAMember2021-01-012021-12-310000885725bsx:A550MCPSSeriesAMember2020-01-012020-12-31bsx:reportablesegments0000885725bsx:MedsurgMember2020-01-012020-12-310000885725bsx:CardiovascularMember2020-01-012020-12-310000885725bsx:BSXReportableSegmentsMember2022-01-012022-12-310000885725bsx:BSXReportableSegmentsMember2021-01-012021-12-310000885725bsx:BSXReportableSegmentsMember2020-01-012020-12-310000885725bsx:OtherMember2022-01-012022-12-310000885725bsx:OtherMember2021-01-012021-12-310000885725bsx:OtherMember2020-01-012020-12-310000885725bsx:TotalAllocatedToReportableSegmentsMember2022-01-012022-12-310000885725bsx:TotalAllocatedToReportableSegmentsMember2021-01-012021-12-310000885725bsx:TotalAllocatedToReportableSegmentsMember2020-01-012020-12-310000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2022-01-012022-12-310000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2021-01-012021-12-310000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2020-01-012020-12-310000885725bsx:SpecialChargesMember2022-01-012022-12-310000885725bsx:SpecialChargesMember2021-01-012021-12-310000885725bsx:SpecialChargesMember2020-01-012020-12-310000885725bsx:OtherMember2022-01-012022-12-310000885725bsx:OtherMember2021-01-012021-12-310000885725bsx:OtherMember2020-01-012020-12-310000885725bsx:TotalAllocatedToReportableSegmentsMember2022-12-310000885725bsx:TotalAllocatedToReportableSegmentsMember2021-12-310000885725us-gaap:CorporateMember2022-12-310000885725us-gaap:CorporateMember2021-12-310000885725bsx:ConsolidatedBSXDomain2022-12-310000885725bsx:ConsolidatedBSXDomain2021-12-310000885725country:US2022-12-310000885725country:US2021-12-310000885725country:IE2022-12-310000885725country:IE2021-12-310000885725country:CR2022-12-310000885725country:CR2021-12-310000885725bsx:OtherCountriesMember2022-12-310000885725bsx:OtherCountriesMember2021-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2022-01-012022-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMember2022-01-012022-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2021-01-012021-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMember2021-01-012021-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2020-01-012020-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:GlobalEndoscopyEndoReportingUnitMember2020-01-012020-12-310000885725country:USbsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-01-012022-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-01-012022-12-310000885725country:USbsx:GlobalUrologyandPelvicHealthReportingUnitMember2021-01-012021-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2021-01-012021-12-310000885725country:USbsx:GlobalUrologyandPelvicHealthReportingUnitMember2020-01-012020-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2020-01-012020-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2022-01-012022-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2021-01-012021-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMember2021-01-012021-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2020-01-012020-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:GlobalNeuromodulationNmReportingUnitMember2020-01-012020-12-310000885725country:USbsx:MedsurgMember2022-01-012022-12-310000885725us-gaap:NonUsMemberbsx:MedsurgMember2022-01-012022-12-310000885725country:USbsx:MedsurgMember2021-01-012021-12-310000885725us-gaap:NonUsMemberbsx:MedsurgMember2021-01-012021-12-310000885725country:USbsx:MedsurgMember2020-01-012020-12-310000885725us-gaap:NonUsMemberbsx:MedsurgMember2020-01-012020-12-310000885725country:USbsx:InterventionalCardiologyTherapiesMember2022-01-012022-12-310000885725bsx:InterventionalCardiologyTherapiesMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:InterventionalCardiologyTherapiesMember2022-01-012022-12-310000885725country:USbsx:InterventionalCardiologyTherapiesMember2021-01-012021-12-310000885725bsx:InterventionalCardiologyTherapiesMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:InterventionalCardiologyTherapiesMember2021-01-012021-12-310000885725country:USbsx:InterventionalCardiologyTherapiesMember2020-01-012020-12-310000885725bsx:InterventionalCardiologyTherapiesMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:InterventionalCardiologyTherapiesMember2020-01-012020-12-310000885725bsx:WatchmanMembercountry:US2022-01-012022-12-310000885725bsx:WatchmanMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:WatchmanMember2022-01-012022-12-310000885725bsx:WatchmanMembercountry:US2021-01-012021-12-310000885725bsx:WatchmanMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:WatchmanMember2021-01-012021-12-310000885725bsx:WatchmanMembercountry:US2020-01-012020-12-310000885725bsx:WatchmanMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:WatchmanMember2020-01-012020-12-310000885725country:USbsx:CardiacRhythmManagementMember2022-01-012022-12-310000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:CardiacRhythmManagementMember2022-01-012022-12-310000885725country:USbsx:CardiacRhythmManagementMember2021-01-012021-12-310000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:CardiacRhythmManagementMember2021-01-012021-12-310000885725country:USbsx:CardiacRhythmManagementMember2020-01-012020-12-310000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:CardiacRhythmManagementMember2020-01-012020-12-310000885725country:USbsx:ElectrophysiologyEPMember2022-01-012022-12-310000885725bsx:ElectrophysiologyEPMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:ElectrophysiologyEPMember2022-01-012022-12-310000885725country:USbsx:ElectrophysiologyEPMember2021-01-012021-12-310000885725bsx:ElectrophysiologyEPMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:ElectrophysiologyEPMember2021-01-012021-12-310000885725country:USbsx:ElectrophysiologyEPMember2020-01-012020-12-310000885725bsx:ElectrophysiologyEPMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:ElectrophysiologyEPMember2020-01-012020-12-310000885725country:USbsx:GlobalCardiologyReportingUnitMember2022-01-012022-12-310000885725bsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:GlobalCardiologyReportingUnitMember2022-01-012022-12-310000885725country:USbsx:GlobalCardiologyReportingUnitMember2021-01-012021-12-310000885725bsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:GlobalCardiologyReportingUnitMember2021-01-012021-12-310000885725country:USbsx:GlobalCardiologyReportingUnitMember2020-01-012020-12-310000885725bsx:GlobalCardiologyReportingUnitMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:GlobalCardiologyReportingUnitMember2020-01-012020-12-310000885725country:USbsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-01-012022-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:NonUsMember2022-01-012022-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-01-012022-12-310000885725country:USbsx:GlobalPeripheralInterventionsPiReportingUnitMember2021-01-012021-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:NonUsMember2021-01-012021-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2021-01-012021-12-310000885725country:USbsx:GlobalPeripheralInterventionsPiReportingUnitMember2020-01-012020-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMemberus-gaap:NonUsMember2020-01-012020-12-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2020-01-012020-12-310000885725country:USbsx:CardiovascularMember2022-01-012022-12-310000885725bsx:CardiovascularMemberus-gaap:NonUsMember2022-01-012022-12-310000885725country:USbsx:CardiovascularMember2021-01-012021-12-310000885725bsx:CardiovascularMemberus-gaap:NonUsMember2021-01-012021-12-310000885725country:USbsx:CardiovascularMember2020-01-012020-12-310000885725bsx:CardiovascularMemberus-gaap:NonUsMember2020-01-012020-12-310000885725country:USbsx:OtherMember2022-01-012022-12-310000885725bsx:OtherMemberus-gaap:NonUsMember2022-01-012022-12-310000885725country:USbsx:OtherMember2021-01-012021-12-310000885725bsx:OtherMemberus-gaap:NonUsMember2021-01-012021-12-310000885725country:USbsx:OtherMember2020-01-012020-12-310000885725bsx:OtherMemberus-gaap:NonUsMember2020-01-012020-12-310000885725country:US2022-01-012022-12-310000885725us-gaap:NonUsMember2022-01-012022-12-310000885725country:US2021-01-012021-12-310000885725us-gaap:NonUsMember2021-01-012021-12-310000885725country:US2020-01-012020-12-310000885725us-gaap:NonUsMember2020-01-012020-12-310000885725bsx:USExcludingOtherNetSalesMember2022-01-012022-12-310000885725bsx:USExcludingOtherNetSalesMember2021-01-012021-12-310000885725bsx:USExcludingOtherNetSalesMember2020-01-012020-12-310000885725us-gaap:EMEAMember2022-01-012022-12-310000885725us-gaap:EMEAMember2021-01-012021-12-310000885725us-gaap:EMEAMember2020-01-012020-12-310000885725srt:AsiaPacificMember2022-01-012022-12-310000885725srt:AsiaPacificMember2021-01-012021-12-310000885725srt:AsiaPacificMember2020-01-012020-12-310000885725bsx:LatinAmericaandCanadaMember2022-01-012022-12-310000885725bsx:LatinAmericaandCanadaMember2021-01-012021-12-310000885725bsx:LatinAmericaandCanadaMember2020-01-012020-12-310000885725bsx:EmergingMarketsMember2022-01-012022-12-310000885725bsx:EmergingMarketsMember2021-01-012021-12-310000885725bsx:EmergingMarketsMember2020-01-012020-12-31bsx:countries0000885725bsx:ExecutiveRetirementPlanMember2022-12-310000885725bsx:InternationalRetirementPlansMember2022-12-310000885725bsx:ExecutiveRetirementPlanMember2021-12-310000885725bsx:UKPlanMember2021-12-310000885725bsx:InternationalRetirementPlansMember2021-12-310000885725us-gaap:DomesticPlanMember2022-12-310000885725bsx:OtherInternationalPlansMember2022-12-310000885725us-gaap:DomesticPlanMember2021-12-310000885725bsx:UKPlanMember2021-12-310000885725bsx:OtherInternationalPlansMember2021-12-310000885725us-gaap:OtherContractMemberus-gaap:FairValueInputsLevel1Member2021-12-310000885725us-gaap:OtherContractMemberus-gaap:FairValueInputsLevel2Member2021-12-310000885725us-gaap:OtherContractMemberus-gaap:FairValueInputsLevel3Member2021-12-310000885725us-gaap:OtherContractMember2021-12-310000885725us-gaap:FairValueInputsLevel1Memberbsx:UKPlanMember2021-12-310000885725bsx:UKPlanMemberus-gaap:FairValueInputsLevel2Member2021-12-310000885725us-gaap:FairValueInputsLevel3Memberbsx:UKPlanMember2021-12-310000885725us-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000885725bsx:UKPlanMember2022-12-3100008857252018-01-012018-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or
For the fiscal year ended December 31, 2022
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware04-2695240
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                         (Zip Code)

508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per shareBSX PR ANew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes: ☑ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes: ☐ No ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes: ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorted period that the registrant was required to submit such files). Yes: ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes: ☐ No ☑
The aggregate market value of the registrant’s common stock held by non-affiliates was approximately $53.2 billion based on the last reported sale price of $37.27 of the registrant’s common stock on the New York Stock Exchange on June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter. (For this computation, the registrant has excluded the market value of all shares of common stock of the registrant reported as beneficially owned by executive officers, and directors of the registrant; such exclusion shall not be deemed to constitute an admission that any such person is an affiliate of the registrant.)


The number of shares outstanding of Common Stock, $0.01 par value per share, as of January 31, 2023 was 1,434,780,104.
Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement to be filed within 120 days of December 31, 2022 with the Securities and Exchange Commission in connection with its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.



TABLE OF CONTENTS
   
 
  
 
  
 
  
 


2

PART I

ITEM 1. BUSINESS

Our Company

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 40 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of healthcare. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Business Strategy

We operate pursuant to five strategic imperatives. We aim to: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities. We believe that our execution of these strategic imperatives will help us deliver on our mission, drive innovation and increase value for our customers and employees, while strengthening our leadership position in the medical device industry and delivering profitable revenue growth.

We expect to continue to invest in our core franchises and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share, leverage our relationships with leading physicians and their clinical research programs, accelerate the time to bring new products to market and gain access to worldwide technological developments that we can implement across our product lines. Our research and development efforts are focused largely on the development of next-generation and novel technology offerings across multiple programs and all divisions. In the past several years, we have completed numerous acquisitions in support of our growth strategy, both strengthening our core franchises and expanding into high growth adjacent markets. We continue to develop digital tools and technologies that enable us to compete more effectively and deliver first class remote physician education, drive deeper patient engagement and increase digitally-enabled sales force productivity.

We have a firm commitment to corporate social responsibility and living our values as a global business and global corporate citizen. This includes taking actions to combat discrimination and advancing equality and diversity, including through financial support of racial equity initiatives in the communities where we live and work, protecting the environment, investing in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly. Refer to discussion of Community Outreach below and Corporate Sustainability included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for additional information regarding measures we are undertaking.

Product Offerings

Our core businesses are organized into two reportable segments: MedSurg and Cardiovascular. The following describes our key product offerings and new product innovations by reportable segment.

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative, less invasive technologies. Our product offerings include the following:

•Resolution 360™ Clips and Resolution 360™ ULTRA Clips, hemostatic clipping technology designed to stop and help prevent bleeding during endoscopic procedures,
•WallFlex™ Biliary Stent Systems, used for relieving biliary obstructions by providing bile drainage in both malignant and benign strictures,
3

•AXIOS™ Stents and Electrocautery Enhanced Delivery Systems, the first, and currently only stents systems in the U.S. indicated for endoscopic drainage of pancreatic pseudocysts,
•SpyGlass™ DS II Direct Visualization Systems and SpyGlass™ Discover Digital Catheters, the first single-use scopes to enable physicians to take a single-stage approach to diagnostic and therapeutic procedures in the pancreaticobiliary system, including treating patients with bile duct stones,
•EXALT™ Model D Single-Use Duodenoscopes for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures, the first U.S. Food and Drug Administration (FDA)-cleared single-use (disposable) duodenoscopes on the market,
•Acquire™ Endoscopic Ultrasound Fine Needle Biopsy Devices, which are designed to obtain larger tissue specimens for histological assessment and diagnosis of diseases such as pancreatic cancer, liver cancer and stomach lesions and
•our infection prevention portfolio, designed to minimize the risk of infection transmission and improve operational efficiencies by streamlining manual cleaning or eliminating the need for cleaning and tracking.

Urology

Our Urology business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Our product offerings include the following:

•a comprehensive line of stone management products, including ureteral stents, catheters, baskets, guidewires, sheaths and balloons,
•LithoVue™ Single-Use Digital Flexible Ureteroscopes, which deliver detailed high-resolution digital images for high-quality visualization and seamless navigation,
•Lumenis Pulse™ Holmium Laser Systems with MOSES™ Technology, complemented by a full line of laser fibers and accessories used in urology and otolaryngology procedures,
•our Prosthetic Urology portfolio, which includes AMS 700™, our penile implants to treat erectile dysfunction and AMS 800™, our urinary control systems to treat male urinary incontinence,
•GreenLight XPS™ Laser System, MoXy™ Fiber, and Rezūm™ Systems for treatment of BPH and
•SpaceOAR™ Hydrogel Systems which help reduce side effects that men may experience after receiving radiotherapy to treat prostate cancer, together with our SpaceOAR VUE™ Hydrogel, providing clinicians with enhanced product visualization.

In the third quarter of 2022, we launched the Rezūm™ Water Vapor Therapy System in Japan following regulatory approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) and received approval of a new reimbursement category from Japan’s Central Social Insurance Medical Counsel (Chuikyo) for both the device and procedure.

In the first quarter of 2023, we received FDA clearance for and will begin a limited market release of our LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System, the first ureteroscope system with the ability to monitor intrarenal pressure in real-time during ureteroscopy procedures.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Our product offerings include the following:

•Precision Montage™ and WaveWriter Alpha™ Spinal Cord Stimulator (SCS) Systems, designed to provide improved pain relief to a wide range of patients who suffer from chronic pain, with proprietary features such as Multiple Independent Current Control, our Illumina 3D™ Proprietary Programming Software and FAST™ Therapy for profound parathesia-free pain relief in minutes, used by physicians to target specific areas of pain and customize stimulation of nerve fibers more precisely,
•our G4™ Generator and consumable portfolio in Radiofrequency Ablation (RFA) for pain management used by physicians to treat patients with chronic pain,
•Our Cognita™ Practice Optimization suite of tools designed to increase awareness, streamline patient management, and sustain long-term outcomes for patients,
•Vercise Gevia™ and Vercise Genus™ Deep Brain Stimulation (DBS) Systems for the treatment of Parkinson's disease, tremor, and intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions and
4

•Superion™ Indirect Decompression Systems, minimally-invasive devices used to improve physical function and reduce pain in patients with moderate lumbar spinal stenosis (LSS).

Our Vercise™ DBS Systems are approved in the U.S. as an adjunctive therapy that aids in reducing some of the symptoms of moderate to advanced Parkinson’s disease as well as for patients diagnosed with essential tremor. The Vercise Genus™ DBS platform features a full portfolio of primary cell and rechargeable MRI conditional systems with Bluetooth connectivity and the Cartesia™ Directional Lead, providing multi-directional stimulation designed for greater precision, intended to minimize side effects for patients. In 2022, we further expanded our portfolio with Image Guided Programming with the US release of Stimview™ XT, a proprietary DBS visualization software developed in collaboration with Brainlab AG, providing clinicians with real-time, 3D visualization and stimulation of brain anatomy.

Cardiovascular

Cardiology

Interventional Cardiology Therapies (ICTx)

Our Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. Our product offerings include the following:

•OptiCross™ IVUS Imaging Catheters,
•iLab™ Ultrasound Imaging Systems with Polaris Software, designed to enhance the diagnosis and treatment of blocked vessels and other heart disorders, compatible with our full line of imaging catheters,
•AVVIGO™ Guidance Systems and AVVIGO™ Guidance System II, incorporating high-definition IVUS all in a mobile or integrated platform,
•ROTAPRO™ Rotational Atherectomy Systems, which regulate the flow of air to the advancer, controlling burr rotation speed, and also monitor and display burr rotation speed and rotational atherectomy procedural time,
•SYNERGY™, SYNERGY MEGATRON™ and SYNERGY™ XD Everolimus-Eluting Platinum Chromium Coronary Stent Systems, featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating,
•Safari2™ Pre-Shaped Guidewires, intended to facilitate the introduction and placement of interventional devices within the heart,
•ACURATE neo2™ Aortic Valve Systems for use in transcatheter aortic valve replacement (TAVR) procedures and
•SENTINEL™ Cerebral Embolic Protection Systems, used to reduce the risk of stroke in TAVR procedures and is clinically proven to decrease cerebral embolization and its associated neurological effects.

Watchman

Our WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Devices are designed to close the left atrial appendage in patients with non-valvular atrial fibrillation who are at risk for ischemic stroke. WATCHMAN™ is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally.

Cardiac Rhythm Management

Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Our product offerings include the following:

•the RESONATE™ family of implantable cardioverter defibrillators (ICD) and implantable cardiac resynchronization therapy defibrillators (CRT-D), including our proprietary HeartLogic™ Heart Failure (HF) Diagnostic and SmartCRT™ Technology with Multisite pacing in CRT-D,
•EMBLEM™ MRI S-ICD System, the world's first, and currently only, commercially available subcutaneous implantable cardiac defibrillators (S-ICD), which provides physicians the ability to treat patients who are at risk for sudden cardiac arrest without touching the heart,
•ACCOLADE™ family of pacemakers and implantable cardiac resynchronization therapy pacemakers (CRT-P),
•ACUITY™ X4 Quadripolar LV Leads, RELIANCE™ family of ICD Leads and our INGEVITY™ Pacing Leads,
•LATITUDE™ Remote Patient Management Systems, which allow for more frequent monitoring and better guided treatment decisions by enabling physicians to monitor implantable system performance remotely,
5

•LUX-Dx™ Insertable Cardiac Monitor (ICM) systems, long-term diagnostic devices implanted in patients to detect arrhythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke and syncope and
•BodyGuardian™ remote cardiac monitoring systems provide a full range of mobile health solutions and remote monitoring services, ranging from ambulatory cardiac monitors – including short and long-term holter monitors – to cardiac event monitors and mobile cardiac telemetry.

Our entire transvenous defibrillator portfolio leverages our EnduraLife™ Battery Technology and has magnetic resonance imaging (MRI) conditional labeling when used with our current generation of leads.

Electrophysiology

Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, including a broad portfolio of therapeutic and diagnostic catheters and a variety of equipment used in the Electrophysiology lab. Our product offerings include the following:

•Rhythmia™ Mapping Systems, catheter-based, 3-D cardiac mapping and navigation solutions designed to help diagnose and guide treatment of a variety of arrhythmias,
•cardiac ablation catheters including the Blazer™, IntellaNav™, IntellaNav Stablepoint™ and IntellaTip MiFi Open-Irrigated Ablation Catheter families, featuring a unique Total Tip Cooling™ Design and DIRECTSENSE™ Software for monitoring radiofrequency (RF) energy delivery during procedures,
•IntellaMap Orion™ Mapping Catheters, for use with our Rhythmia Mapping System to provide high-density, high-resolution maps of the heart,
•Farapulse™ Pulsed Field Ablation (PFA) Systems for the treatment of atrial fibrillation (AF),
•POLARx™ Cryoablation Systems for the treatment of AF and
•intracardiac ultrasound catheters, delivery sheaths and other accessories

On February 14, 2022, we completed our acquisition of Baylis Medical Company, Inc (Baylis Medical), which has developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. In the second quarter of 2022, we received FDA 510(k) clearance for and launched the VersaCross Connect™ LAAC Access Solution developed by Baylis Medical, providing safe and efficient access to the left side of the heart.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Our broad peripheral portfolio includes stent systems, balloon catheters, guidewires, atherectomy and thrombectomy systems, embolization devices, radioactive microspheres, radiofrequency and cryotherapy ablation systems, microcatheters and drainage catheters.

Our peripheral arterial product offerings include:

•EPIC™ and Innova™ Self-Expanding Stent Systems,
•Eluvia™ Drug Eluting Vascular Stent Systems, innovative stents built on the Innova stent platform, designed to deliver a sustained dosage of paclitaxel during the time when restenosis is most likely to occur,
•Mustang™, Coyote™ and Sterling™ PTA Balloon Catheters designed for a wide variety of peripheral angioplasty procedures and
•Ranger™ Drug-Coated Balloons, innovative balloons built on the Sterling balloon platform, featuring a low-dose of paclitaxel.

In the third quarter of 2022, we launched an ELUVIA™ line extension, introducing the longest-length available for treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery. We are also the first company to provide physicians with both a drug-eluting stent and drug-coated balloon option for the treatment of patients with PAD.

6

Our venous disease product offerings include the following:

•AngioJet™ Thrombectomy Systems, used in endovascular procedures to remove blood clots from blocked arteries and veins and our AngioJet Zelante DVT™ Thrombectomy Catheters to treat deep vein thrombosis,
•WOLF Thrombectomy™ Platform, which is designed to mechanically remove the clots without damaging blood vessels, while also minimizing blood loss,
•EKOS™ Ultrasound Assisted Thrombolysis systems used to treat pulmonary embolisms and
•Varithena™ Polidocanol Injectable Foam used to improve the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Our interventional oncology product offerings include the following:

•TheraSphere™ Y-90 radioactive glass microspheres used in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer,
•Renegade™ HI-FLO™ Fathom™ Microcatheter and Guidewire System and Interlock™ - 35 Fibered IDC™ and 18 Fibered IDC™ Occlusion System for peripheral embolization,
•EMBOLD™ Detachable Coil System, used for arterial and venous embolizations in the peripheral vasculature, and
•ICEFX™ and Visual ICE™ Cryoablation Systems for destruction of tissue, using image-guided needles to enable cryoablation visualization for optimal tumor coverage.

Markets

Competition

We encounter significant competition across our product lines and in each market in which we sell our products and solutions, some from companies that may have greater financial, sales and marketing resources than we do. Our primary competitors include Abbott Laboratories and Medtronic plc, as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. In certain countries, and particularly in China, we also face competition from domestic medical device companies that may benefit from their status as local suppliers. We also face competition from non-medical device companies, which may offer alternative therapies for disease states that could also be treated using our products, or from companies offering technologies that could augment or replace procedures using our products.

We believe that our products and solutions compete primarily on their ability to deliver both differentiated clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive and cost effective manner. We also compete on ease of use, comparative effectiveness, reliability and physician familiarity. In the current environment of managed care, with economically motivated buyers, consolidation among healthcare providers, increasing prevalence and importance of regional and national tenders, increased competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price, value, reliability and efficiency. We believe the current global economic conditions and healthcare reform measures could continue to put additional competitive pressure on us, including on our average selling prices, overall procedure rates and addressable market sizes. We recognize that our continued competitive success will depend upon our ability to:

•offer products and solutions that provide differentiated clinical and economic outcomes,
•create or acquire innovative, scientifically advanced technologies,
•apply our technology and solutions cost-effectively and with superior quality across product lines and markets,
•develop or acquire proprietary products and solutions,
•attract and retain qualified personnel,
•obtain patent or other protection for our products,
•obtain required regulatory and reimbursement approvals,
•continually provide quality products and enhance our quality systems,
•supply sufficient inventory at competitive prices to meet customer demand.

7

Research and Development

Our investment in research and development is critical to driving our future growth. Our investment in research and development supports the following:

•internal research and development programs, regulatory design and clinical science, as well as other programs obtained through our strategic acquisitions and alliances, and
•engineering efforts that incorporate customer feedback into continuous improvement efforts for currently marketed and next-generation products.

We have directed our development efforts toward innovative technologies designed to expand current markets or enter adjacent markets. We continue to transform how we conduct research and development by identifying best practices, driving efficiencies and optimizing our cost structure, which we believe will enable increased development activity and faster concept-to-market timelines. Focused, cross-functional teams take a formal approach to new product design and development, helping us to manufacture and offer innovative products consistently and efficiently. Involving cross-functional teams early in the process is the cornerstone of our product development cycle. We believe this collaboration allows our teams to concentrate resources on the most viable and clinically relevant new products and technologies and to maximize cost and time savings as we bring them to market.

In addition to internal development, we work with hundreds of leading research institutions, universities and clinicians around the world to develop, evaluate and clinically test our products. We continue to expand our collaborations to include research and development teams in our emerging market countries; these teams will focus on both global and local market requirements at a lower cost of development. We believe that these efforts will play a significant role in our future success.

Marketing and Sales

In 2022, we marketed our products and solutions to approximately 36,000 hospitals, clinics, outpatient facilities and medical offices in 130 countries worldwide. Large group purchasing organizations, hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. Each of our businesses maintains dedicated sales forces and marketing teams focused on physicians who specialize in the diagnosis and treatment of different medical conditions, as well as on key hospital service line administrators.

The majority of our net sales are derived from countries in which we have direct sales organizations. We also have a network of distributors and dealers who offer our products in certain countries and markets. We expect to continue to leverage our infrastructure in markets where commercially appropriate and use third party distributors in those markets where it is not economical or strategic to establish or maintain a direct presence.

Resources

Manufacturing and Raw Materials

We are focused on continuously improving our supply chain effectiveness, strengthening our manufacturing processes and increasing operational efficiencies within our organization worldwide. In doing so, we seek to focus our internal resources on the development and commercial launch of new products and the enhancement of existing products. We also drive continuous improvement in product quality through process controls and validations, supplier and distribution controls and training and tools for our operations team. In addition, we remain focused on examining our operations and general business activities to enhance our operational effectiveness by identifying cost-improvement opportunities.

We remain committed to maintaining appropriate investments to ensure supply chain stability. We have an ongoing supplier resiliency program which identifies and mitigates risk and have taken measures to mitigate the impact of challenges within the global supply chain, including those caused in part by the COVID-19 pandemic. We consistently monitor our inventory levels, manufacturing, sterilization and distribution capabilities and partnerships and maintain recovery plans to address potential disruptions. Many components used in the manufacturing of our products are readily fabricated from commonly available raw materials or off-the-shelf items available from multiple supply sources; however, certain items are custom made to meet our specifications.

On an on-going basis, we track supplier status and inventory in risk areas and take action to prevent shortages, monitoring safety stock levels and building up product supplies as warranted, and mitigating risk of technology and material shortages by identifying new vendors.
8


We have experienced increased levels of unpredictability in the supply of certain raw materials and components used in the manufacturing of our products. While we continue to believe we will have access to the raw materials and components that we need, these supply chain dynamics could result in increased costs to us or an inability to fully meet customer demand for certain of our products.

Proprietary Rights and Patent Litigation

We rely on a combination of patents, trademarks, trade secrets and other forms of intellectual property to protect our proprietary rights. We generally file patent applications in the U.S. and other countries where patent protection for our technology is appropriate and available. We hold patents worldwide that cover various aspects of our technology. In addition, we hold exclusive and non-exclusive licenses to a variety of third-party technologies covered by patents and patent applications. In the aggregate, these intellectual property assets and licenses are of material importance to our business; however, we believe that no single patent, technology, trademark, intellectual property asset or license is material in relation to our business as a whole.

We rely on non-disclosure and non-competition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary technology. There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry, particularly in the areas in which we compete. We continue to defend ourselves against claims and legal actions alleging infringement of the patent rights of others. Additionally, we may find it necessary to initiate litigation to enforce our patent rights, to protect our trade secrets or know-how and to determine the scope and validity of the proprietary rights of others. Accordingly, we may seek to settle some or all of our pending litigation, particularly to manage risk over time. Settlement may include cross licensing of the patents that are the subject of the litigation as well as our other intellectual property and may involve monetary payments to or from third parties.

We maintain insurance policies providing limited coverage against securities claims. We are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. See Note I – Commitments and Contingencies to our 2022 consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for a discussion of intellectual property, product liability and other litigation and proceedings in which we are involved.

Regulatory Environment

Medical Device Regulatory Approvals

The medical devices that we manufacture, market and commercialize are subject to regulation by numerous worldwide regulatory bodies, including the U.S. FDA and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing development, testing, manufacturing, labeling, marketing and distribution. Medical devices are also generally subject to varying levels of regulatory control based on risk level of the device.

In the U.S., authorization to distribute a new device can generally be met in one of two ways. The first process requires that a premarket notification (510(k)) be made to the FDA to demonstrate that the device is as safe and effective as, or substantially equivalent to, a legally marketed device (the “predicate” device). Applicants must submit performance data to establish substantial equivalence. In some instances, data from human clinical trials must also be submitted in support of a 510(k) premarket notification. If so, these data must be collected in a manner that conforms to the applicable Investigational Device Exemption (IDE) regulations. The FDA must issue a decision finding substantial equivalence before commercial distribution can occur. Changes to cleared devices that could not significantly affect the safety or effectiveness of the device can generally be made without additional 510(k) premarket notifications; otherwise, a new 510(k) is required.

The second process requires the submission of a premarket approval (PMA) application to the FDA to demonstrate that the device is safe and effective for its intended use. This approval process applies to most Class III devices and generally requires clinical data to support the safety and effectiveness of the device, obtained in adherence with IDE requirements. The FDA will approve the PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose and that the proposed manufacturing is in compliance with the Quality System Regulation (QSR). For novel technologies, the FDA may seek input from an advisory panel of medical experts and seek their views on the safety, effectiveness and benefit-risk of the device. The PMA process is generally more detailed, lengthier and more expensive than the 510(k) process.

9

In the European Union (EU), we are required to comply with the Medical Device Regulation (MDR or EU MDR) which became effective May 2021, superseding the existing Medical Device and Active Implantable Medical Device Directives. Medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021) can continue to be sold during the applicable transition period or until the CE Certificate expires, whichever comes first, providing there are no significant changes to the design or intended use. The CE Mark, which is required to sell medical devices in the EU is affixed following a Conformity Assessment and either approval from the appointed independent Notified Body or through self-certification by the manufacturer. The selected pathway to CE marking is based on device risk classification. CE marking indicates conformity to the applicable General Safety and Performance Requirements (GSPRs) for the MDR. The MDR changes multiple aspects of the regulatory framework for CE marking, such as increased clinical evidence requirements, changes to labelling, and new requirements, including Unique Device Identification (UDI), and many new post-market reporting obligations. MDR also modifies and increases the compliance requirements for the medical device industry and will continue to require significant investment over the next few years to transition all products. The CE mark continues to be a prerequisite for successful registration in many other global geographies. In addition, other EU countries continue to impose significant local registration requirements despite the implementation of MDR, and the United Kingdom has introduced new requirements following its exit from the EU.

We are also required to comply with the regulations of every other country where we commercialize products before we can launch or maintain new products on the market, including regulations that have been introduced in many countries in the Middle East and Southeast Asia that previously did not have medical device regulations, or had minimal regulations. In Japan we are required to comply with Japan’s Ministry of Health, Labor and Welfare (MHLW) regulations. In conjunction with the MHLW, the Pharmaceutical and Medical Device Agency is an independent agency that is responsible for reviewing drug and medical device applications and works with the MHLW to assess new product safety, develop comprehensive regulations, and monitor post-market safety.

The FDA and other worldwide regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order recall or market withdrawal of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the Food, Drug and Cosmetic Act and the Safe Medical Devices Act, pertaining to medical devices, or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities in the countries where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with local laws and regulations.

International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of each country to which the device is exported.

Our quality system is designed to enable us to satisfy various international quality system regulations, including those of the U.S. FDA with respect to products sold in the U.S. All of our medical device manufacturing facilities and distribution centers are certified under the ISO 13485 quality system standard, established by the International Standards Organization (ISO) for medical devices, which includes requirements for an implemented quality system that applies to component quality, supplier control, product design and manufacturing operations.

Healthcare Policies and Reimbursement

Political, economic and regulatory influences around the world continue to subject the healthcare industry to potential fundamental changes that could substantially affect our results of operations. We maintain a global Government Affairs presence, headquartered in Washington, D.C., to actively monitor and advocate on myriad legislation and policies that may potentially impact us, both on a domestic and an international front. The Government Affairs office works closely with members of Congress and committee staff, the White House and administration offices, state governors, legislatures and regulatory agencies, embassies and global governments on issues affecting our business. The Government Affairs office also advocates for public policy that benefits our employees and the patients we serve, and supports the communities in which we live.

Our products are purchased principally by hospitals, physicians and other healthcare providers around the world that typically bill various third-party payers, including government programs (e.g., Medicare and Medicaid in the U.S.) and private insurance payers, for the items and services provided to their patients. Government and private sector initiatives related to limiting the
10

growth of healthcare costs (including price regulation), coverage and payment policies, comparative effectiveness reviews of therapies, technology assessments, price transparency and healthcare delivery and payment structure reforms, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to place increased emphasis on the delivery of treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our products and technologies generate favorable clinical outcomes, value and cost efficiency, while also being less invasive than alternatives, the resources necessary to demonstrate value to our customers, patients, payers and other stakeholders are significant and new therapies may take significantly longer periods of time to gain widespread adoption.

Implementation of cost containment initiatives and healthcare reforms in significant markets such as the U.S., China, Australia, and other markets may limit the price of, or the level at which reimbursement is provided for, our products or procedures using our products, which in turn may make it less likely that a hospital or physician will select our products to treat patients.

Environmental Regulation and Management

We are subject to various environmental laws, directives and regulations both in the U.S. and abroad. Our operations involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. We are focused on continuous improvement in environmental metrics with a goal of reducing pollution, minimizing depletion of natural resources and reducing our overall environmental footprint. Specifically, we are working to optimize energy and resource usage, ultimately reducing greenhouse gas emissions and waste. Refer to Corporate Sustainability included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.

Human Capital

At Boston Scientific, our work is guided by core values that define our culture and empower our employees, including Caring, Diversity, Global Collaboration, High Performance, Meaningful Innovation and Winning Spirit. As of December 31, 2022, we had approximately 45,000 employees, of which approximately 56 percent were outside the U.S. We believe the collective talent of our employees and our shared corporate culture and values give us a competitive advantage.
Hiring, developing and retaining talented employees are key parts of our strategy and are critical to our success, particularly in the current environment of labor shortages and unprecedented job market conditions. We strive to do this by fostering a diverse, equitable and inclusive workplace, providing competitive pay and benefits and flexible work conditions, offering ongoing employee growth and development opportunities and cultivating a culture that prioritizes employee health, safety and well-being.

Diversity, Equity and Inclusion

We do our best work to advance health care when we have a diverse range of perspectives and experience on our team. Innovation thrives in a culture of engagement, inclusion and equity. The society in which we live and the customers and patients we serve are diverse and our employees at all levels of the organization must reflect this. In recent years, we have made steady progress to increase the overall representation of employees who identify as women and as African American/Black, Asian, Hispanic/Latinx, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races (together, multicultural talent). As of December 31, 2022, women represented 30 percent of our Board of Directors, and 49 percent of our employees. In addition, 36 percent of employees in the U.S. and Puerto Rico identified as multicultural.

We are committed to our goal of making further progress toward expanding our workforce diversity. In 2020, we set measurable Diversity, Equity & Inclusion (DE&I) goals with our “3UP by 2023” initiative, which included aspirations of a three percentage point increase in representation of both women and multicultural talent at the supervisor and manager level to 43 percent and 23 percent, respectively, by December 31, 2022. As of December 31, 2022, 42.6 percent of management roles were held by women and, within the U.S and Puerto Rico, 22.6 percent were held by multicultural employees. While we are making progress, our work is far from over. We are committed to intentional action to drive meaningful change. We listen to our employees and use that feedback to complement and expand our existing DE&I programs to emphasize initiatives aimed at developing our pipeline of talent and fostering a psychologically safe and inclusive workplace for all. Additionally, our Executive Committee and our Board of Directors have oversight of employee diversity metrics and hiring trends. As evidence of our commitment to expand DE&I, in 2021, we introduced an ESG scorecard, including DE&I metrics, to our Annual Bonus Plan.

In addition, our ten Employee Resource Groups (ERGs) are at the heart of our DE&I strategy. ERGs are voluntary, company-sponsored employee groups that foster and celebrate our diverse work environment. They provide forums for us to learn from
11

one another, celebrate our uniqueness and develop inclusive leadership skills. We support each ERG by designating global and local executive sponsors and providing financial resources. Our ERG chapters around the world collaborate across the business at all levels and are powerful voices for change in the company.

Additionally, our approach to supplier selection involves building DE&I throughout the Boston Scientific supplier network. We are committed to the increased and sustained support of diverse businesses that share our dedication to improving the quality of patient care. As part of our strategy to combat racism, we have taken steps to further expand the number of Black-owned enterprises that provide supply chain services for our business in the U.S., and are also supporting small and diverse vendors by shortening our standard payment terms.

Compensation and Benefits

We offer competitive, performance-based compensation programs, recognizing that employee well-being, safety, culture, engagement and recognition are all critical to a healthy work environment and productive workforce. We offer programs that acknowledge, respect and support an individual’s life and work choices. Our holistic programs are guided by overall workforce health, focusing on physical, financial and emotional well-being as well as a healthy work environment. We believe that investing in employee well-being leads to improved performance for the individual and the organization.

As part of our broader rewards portfolio, we offer competitive pay and benefits that are flexible and affordable to meet the individual needs of our employees. In addition to cash-based salaries, our rewards portfolio includes cash bonus programs, sales incentives, stock awards, recognition awards, health insurance, paid time off and family leave, retirement savings plans, childcare and Employee Assistance Programs that encourage overall well-being, including help with finances, inclusive family planning and support, elder/child care, legal support and mental health resources.

Equal pay for equal work is rooted in our values and foundational to fostering an inclusive environment. Pay equity is an important part of our long-standing global compensation planning practices. Sustaining pay equity requires constant measurement and attention, so we regularly conduct comprehensive audits, internal and external analyses and company-wide benchmarking of salaries to identify and eliminate disparities. In addition, we periodically contract with an independent, third party to assess pay equity across all positions. Our most recent pay equity study, completed in 2021, reported no statistically significant pay disparity for approximately 99 percent of our employees across gender globally and for multicultural talent in the U.S. and Puerto Rico. We continue to educate and train our people, update policies and expand benefits to decrease bias, increase gender and racial representation within our organization, and foster a culture where all employees feel valued and included.

Employee Health and Safety

We take a global approach to prioritizing and monitoring employee health and safety and we strive to foster a safety-oriented culture in all of our offices and facilities. We set health and safety goals which measure the number of injuries per 100 employees for the global organization. Our Employee Health & Safety Global and Regional Councils review performance monthly to discuss trends and risks, as well as opportunities for improvement. We have obtained ISO 45001:2018 Occupational Health and Safety Management System at eight of our key global locations. This is a globally recognized standard for employee Occupational Health and Safety, established by the International Standards Organization, which provides a voluntary framework to identify key occupational health and safety aspects associated with our business helping to deliver continuous improvement. We have established a company-wide safety goal of 0.25 or fewer injuries per 100 employees by 2030, cutting our year-over-year incident rate by approximately 50 percent from a base year of 2019. As of December 31, 2022, we have achieved a safety level of 0.28 per 100 employees.

Employee Growth and Development

Developing our people professionally is one of the most important things we do. We have robust succession planning to ensure our future leaders are ready to assume roles as they become available. At every level of the company, employees have access to training and tools they can use to advance their skills and expertise and create greater possibilities for their careers. We offer professional and technical courses, including on-the-job training, skills-based learning, mentoring opportunities and leadership development programs for high-potential employees.

Employee Engagement

We seek ongoing feedback from our employees to better understand what we are doing well and, conversely, how we can improve their experience. In addition to encouraging ongoing communication and feedback between employees and their
12

managers, we conduct periodic employee engagement surveys to ensure all employees have an opportunity to share their insights and we take appropriate action in response. As evidence of our commitment to foster employee engagement, we include these metrics within the ESG scorecard that forms part of our Annual Bonus Plan.

Community Outreach

We are united by a goal to make a difference in the lives of the over 33 million patients we serve annually. The Boston Scientific Caring value guides us in the work we do each day including how we invest in the well-being of communities. We work to advance possibilities in our three focus areas of health, STEM education and community. Our efforts evolve frequently as do the pressing needs of our communities. In 2022, we focused on supporting Ukrainian refugees, providing aid to those impacted by natural disasters and addressing the basic needs of underserved populations in communities where we live and work. In February 2023, we provided donations to charitable organizations providing earthquake relief efforts in Türkiye and Syria, including overnight stays, meals, hygiene items and critical emergency supplies.

Our global community programs empowered employees to participate in and influence the way we care for local communities through volunteerism and personal donations. Many employees chose to support their communities through use of the Employee Matching Gifts program, which was doubled in 2022 on Giving Tuesday, the global day of giving that highlights the importance of supporting local communities around the world during the holiday season. Through employee contributions and the Boston Scientific match, a total of nearly $2 million was donated in 2022. In February 2023, we launched an additional match campaign through our Employee Matching Gifts Program for aid to Türkiye and Syria and are also providing volunteer opportunities for our employees based in Türkiye to give back to their local communities.

We have also collaborated with non-profit community organizations to decrease health disparities and reduce the risk for chronic disease for the underserved by increasing access to healthcare and screenings. Within many of the communities in which we operate, we have launched and funded a multi-year program to combat racism, inequity and injustice focused on five pillars: community, economic empowerment, education, healthcare disparities and government policies. We also continue our long-term Close the Gap initiative, which focuses on raising awareness and empowering healthcare providers to reach more patients of color, fight longstanding inequities, and address barriers to care. Through Close the Gap, hospitals and health systems are provided with zip code level data that highlight the disease prevalence and disparities occurring in their communities. The information, along with our health equity resources, allows health care administrators and providers to focus on improving care to underserved populations within their communities.

We are also passionate about inspiring young learners to see themselves in a Science, Technology, Engineering and Math (STEM) roles in the future. Employees on our global STEM teams worldwide work with underrepresented K-12 students to share their passion for STEM by providing interactive product demos, development programs, and hands-on activities for young learners in their communities.

Seasonality

Our net sales are influenced by many factors, including product launches, acquisitions, regulatory and reimbursement approvals, patient, physician and employee holiday schedules and other macro-economic conditions. While our consolidated net sales do not reflect any significant degree of seasonality, customer purchases of our medical devices have historically been lower in the first and third quarters of the year.

Available Information

Copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), are available free of charge on our website (www.bostonscientific.com) as soon as reasonably practicable after we electronically file the material with or furnish it to the U.S. Securities and Exchange Commission (SEC). Additionally, the SEC maintains an internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Printed copies of these posted materials are also available free of charge to stockholders who request them in writing from Investor Relations, 300 Boston Scientific Way, Marlborough, MA 01752-1234. Information on our website or linked to our website is not incorporated by reference into this Annual Report on Form 10-K.

Safe Harbor for Forward-Looking Statements

13

Certain statements that we may make from time to time, including statements contained in this Annual Report on Form 10-K and information incorporated by reference into this Annual Report on Form 10-K, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Annual Report on Form 10-K are based on certain risks and uncertainties, including the risk factors described in Item 1A under the heading “Risk Factors” and the specific risk factors discussed below and in connection with forward-looking statements throughout this Annual Report on Form 10-K, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Annual Report on Form 10-K. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; the impact of the COVID-19 pandemic on our operations and financial results; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict, including those that have emerged or may increase in significance or likelihood as a result of the COVID-19 pandemic. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A. Risk Factors contained within this Annual Report on Form 10-K filed with the SEC, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this Annual Report on Form 10-K.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, see Item 1A. Risk Factors.

Our Businesses
•The impact of the COVID-19 pandemic and economic conditions created in part by the pandemic on worldwide economies, financial markets, manufacturing and distribution systems, including disruption in the manufacture or supply of certain components, materials or products, and business operations,

•Labor shortages and the impact of inflation on the cost of raw materials and direct labor,

•Risks associated with challenging or uncertain domestic and international economic conditions, including those related to rising interest rates, inflation, currency devaluations or economies entering into periods of recession,

•The impact of natural disasters, climate change, additional future public health crises and other catastrophic events on our ability to manufacture, distribute and sell our products,

•The impact of competitive offerings, value-based procurement practices, government-imposed payback provisions and changes in reimbursement practices and policies on average selling prices for our products,

14

•The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

•The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

•The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,
 
•Variations in clinical results, reliability or product performance of our and our competitors' products,

•Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

•The effect of consolidation and competition in the markets in which we do business or plan to do business,

•Our ability to achieve our projected level or mix of product sales, as some of our products are more profitable than others,

•Our ability to attract and retain talent, including key personnel associated with recent acquisitions, and to maintain our robust corporate culture,

•The impact of enhanced requirements to obtain and maintain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval,
 
•The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies,

•The issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission, and

•The impact of potential goodwill and intangible asset impairment charges on our results of operations.

Regulatory Compliance, Litigation and Data Protection

•The impact of healthcare policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other healthcare reform legislation,

•Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

•The effect of global legal, regulatory or market responses to climate change, including increased compliance burdens and costs to meet regulatory obligations,

•Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,

•The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

•Costs and risks associated with current and future asserted litigation,

•The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provisions and cash flows,
15

 
•The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

•The possibility of failure to protect our intellectual property rights and the outcome of patent litigation,

•Our ability to operate properly our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/ Ukraine war, and

•The potential impact to internal control over financial reporting relating to potential restrictions to access to consigned inventory at customer locations for our inventory count procedures.

Innovation and Certain Growth Initiatives

•The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

•Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

•Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable net sales growth opportunities as well as to maintain the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

•Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

•Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,

•Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

•The potential failure to successfully integrate and realize the expected benefits, including cost synergies, from the strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

•Our dependency on international net sales to achieve growth, and our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in Emerging Markets such as Brazil, India and China,

•The timing and collectability of customer payments, as well as our ability to continue factoring customer receivables where we have factoring arrangements, or to enter new factoring arrangements with favorable terms,

•The impact on pricing due to national and regional tenders, including value-based procurement practices and government-imposed payback provisions,

•Geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures,

16

•The impact of the Russia/Ukraine war and tension between China/Taiwan, and related, downstream effects thereof, including the impact of sanctions on U.S. manufacturers doing business in these regions,

•Protection of our intellectual property,

•Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA, EU MDR and similar laws in other jurisdictions,

•Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,

•The impact of significant developments or uncertainties stemming from changes in the U.S. government following congressional elections, including changes in U.S. trade policies, tariffs and the reaction of other countries thereto, particularly China, and

•The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, operating expenses and resulting profit margins.

Liquidity

•Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and financial covenant compliance,

•Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

•The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

•The unfavorable resolution of open litigation matters, exposure to additional loss contingencies and legal provisions,

•The impact of examinations and assessments by domestic and international taxing authorities on our tax provisions, financial condition or results of operations,

•The possibility of counterparty default on our derivative financial instruments, and

•Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

•Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs and

•Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.
17

ITEM 1A. RISK FACTORS
In addition to the other information contained in this Annual Report on Form 10-K and the exhibits hereto, the following risk factors should be considered carefully in evaluating our business. Our business, financial condition, cash flows or results of operations could be materially adversely affected by any of these risks. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements set forth at the end of Item 1. Business of this Annual Report on Form 10-K. The considerations and risks that follow are organized within relevant headings but may be relevant to other headings as well. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business, financial condition, cash flows or results of operations.
General Risks

Challenging domestic and international economic conditions could adversely affect our business, financial condition, cash flows and results of operations.

Uncertainty around inflationary pressures, rising interest rates and monetary policy could potentially cause new, or exacerbate existing, economic challenges that we may face. These conditions could worsen, or others could arise, if the U.S. and global economies were to enter recessionary periods, triggered or exacerbated by monetary policy designed to curb inflation. If there were a general economic downturn, we may experience decreased customer spending or demand for our products and services, and our customers’ ability to pay for our products on a timely basis, or at all, may be impacted. The same economic conditions could also adversely affect our third-party vendors, including those that we utilize in our supply-chain and manufacturing operations, which may lead to a reduction or interruption in the supply of materials and components used in manufacturing our products or increase the price of such materials or components, as well as the distributors and dealers who offer our products in certain countries and markets. Inflationary pressure may also increase certain operational costs, including due to wage increases, or increases in the cost of materials or components. These adverse economic conditions or events could adversely affect our business, results of operations or financial condition.

Further, uncertainty about global economic conditions, including those resulting from credit and sovereign debt issues, has caused and may continue to cause disruption in the financial markets, including diminished liquidity and credit availability. These conditions may adversely affect our suppliers, leading them to experience financial difficulties or be unable to borrow money to fund their operations, which could cause disruptions in our ability to produce our products. Our customers may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability or decision to purchase our products, particularly capital equipment, or to pay for our products that they purchase on a timely basis, if at all. In addition, we have accounts receivable factoring programs in certain European and Asian countries. Deterioration of the global economy or increase in sovereign debt issues may impact our ability to transfer receivables to third parties in certain of those countries. Third parties, such as banks, offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt. This could result in terminations of, or changes to the costs or credit limits of our existing factoring programs. Such terminations or changes could have a negative impact on our cash flow and days sales outstanding. Uncertain or challenging economic conditions could also lead to greater fluctuations in foreign currency exchange rates, which could adversely impact our results of operations and financial performance.

There can be no assurance that there will not be further deterioration in the global economy. Accordingly, we cannot predict to what extent global economic conditions, including negative or uncertain economic conditions, sovereign debt issues and increased focus on healthcare systems and costs in the U.S. and abroad, may impact negatively our average selling prices, net sales and profit margins, operations, procedural volumes and reimbursement rates from third party payers. In addition, economic and financial market conditions, including rising interest rates, and other factors beyond our control may adversely affect our ability to borrow money in the credit markets, access the capital markets and obtain financing for mergers and acquisitions (M&A) or other general purposes.
Market Risks
We face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry, which could have an adverse effect on our business, financial condition or results of operations.
The medical device markets in which we participate are highly competitive. We encounter significant competition across our product lines and in each market in which our products are sold from various medical device companies. Some of our competitors may have greater financial and marketing resources than we do, including as a result of consolidation among companies in our industry. Our primary competitors include Abbott Laboratories and Medtronic plc, as well as a wide range of medical device companies that sell a single or limited number of competitive products or which participate in only a specific
18

market segment or segments. We also face competition from non-medical device companies, including pharmaceutical companies and providers of various diagnostic tests, which may offer alternative therapies or diagnostics for disease states also amenable to treatment or diagnosis using our products. New competitors may emerge in the future, potentially including companies introducing new sales or distribution models to our industry or leveraging genomic robotic, navigation, and/or other automation technologies. Digital technologies have and may continue to increase in their applicability and importance to various aspects of our business, operating and competitive environments, R&D pipeline and product portfolio. We believe we will need to develop new and enhanced digital capabilities and competences in order to remain competitive.
In addition, the medical device markets in which we participate are characterized by extensive research and development and rapid technological change. Developments by other companies of products and/or services, processes or technologies may make our products or proposed products obsolete or less competitive and may negatively impact our net sales. It is necessary for us to devote continued efforts and financial resources to the development or acquisition of scientifically advanced technologies and products. In addition, we will need to apply our technologies cost-effectively across product lines and markets, obtain patent and other protection for our technologies and products, obtain required regulatory and reimbursement approvals and successfully manufacture and market our products consistent with our quality standards. If we fail to develop or acquire new products or enhance existing products, such failure could have a material adverse effect on our business, financial condition or results of operations. In addition, a delay in the timing of the launch of next-generation products and the overall performance of, and continued physician confidence in, those products may result in declines in our market share and have an adverse impact on our business, financial condition or results of operations.
We may experience declines in market size, average selling prices for our products, medical procedure volumes and our share of the markets in which we compete, which may materially adversely affect our results of operations and financial condition.
We continue to experience pressures across many of our businesses due to competitive activity, increased market power of our customers as the healthcare industry consolidates, national and regional government tenders, economic pressures experienced by our customers, staffing shortages within healthcare facilities that have and may continue to negatively impact demand for our products, public perception of our products, and the impact of managed care organizations and other third-party payers. These and other factors may adversely impact market sizes, as well as our share of the markets in which we compete, the average selling prices for our products or medical procedure volumes. There can be no assurance that the size of the markets in which we compete will increase, that we will be able to hold or gain market share or compete effectively on the basis of price or that the number of procedures in which our products are used will increase. Decreases in market sizes or our market share and declines in average selling prices or procedural volumes could materially adversely affect our results of operations or financial condition.

Continued consolidation in the healthcare industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit or eliminate our ability to sell to certain of our significant market segments, which could have an adverse effect on our business, financial condition or results of operations.
Numerous initiatives and reforms by legislators, regulators and third-party payers to curb the rising cost of healthcare, and to increase access to care, have catalyzed a consolidation of aggregate purchasing power within the markets in which we sell our products. Additionally, a growing number of countries have instituted or are contemplating introducing regional or national tender processes driven primarily by price. In some cases, such processes may favor local companies to multinational companies like Boston Scientific. In other instances, multinationals may be subject to a separate tender bidding process in which they compete only with each other and not with domestic companies. Further, in certain markets, the regulatory process through which new medical devices are approved may be faster and/or less burdensome for domestic companies compared to multinationals. As the healthcare industry consolidates, competition to provide products and services is expected to continue to intensify, resulting in pricing pressures, decreased average selling prices and the exclusion of certain suppliers from important market segments. We expect that market demand, government regulation, third-party coverage and reimbursement policies, government contracting requirements and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers, which may increase competition, exert further downward pressure on the prices of our products and services and may adversely impact our business, financial condition or results of operations.

19

Healthcare cost containment pressures, government payment and delivery system reforms, changes in private payer policies, and marketplace consolidations could decrease the demand for our products, the prices which customers are willing to pay for those products and/or the number of procedures performed using our devices, which could have an adverse effect on our business, financial condition or results of operations.

Our products are purchased principally by hospitals, physicians and other healthcare providers around the world that typically bill various third-party payers, including government programs, authorities or agencies (e.g., Medicare and Medicaid in the U.S.) and private health plans, for the healthcare supplies and services provided to their patients. Governments and payers may institute changes in healthcare delivery or payment systems that may reduce funding for services or encourage greater scrutiny of healthcare costs. The ability of customers to obtain appropriate reimbursement for their products and services is critical to the success of medical technology companies because it affects which products customers purchase and the prices they are willing to pay. Reimbursement and funding vary by country and can significantly impact the acceptance of new products and technologies and the use of established products and technologies. We may find limited demand for otherwise promising new products unless reimbursement approval is obtained from private and governmental third-party payers. Further legislative or administrative reforms to the reimbursement systems in the U.S., Japan, China, or other countries in a manner that significantly reduce or eliminate reimbursement for procedures using our medical devices, including price regulation, site of service requirements, competitive bidding and tendering, coverage and payment policies, comparative effectiveness of therapies, heightened clinical data requirements, technology assessments and managed-care arrangements, could have a material adverse effect on our business, financial condition or results of operations
Geopolitical Risks
We are subject to a number of market, business, financial, legal and regulatory risks and uncertainties with respect to our international operations that could have a material impact on our business, financial condition or results of operations.
International net sales accounted for 40 percent of our global net sales in 2022. An important part of our strategy is to continue pursuing growth opportunities in net sales and market share outside of the U.S. by expanding global presence, including in Emerging Markets. Our international operations are subject to a number of market, business and financial risks and uncertainties, including those related to our use of channel partners, go-to-market strategies, geopolitical and economic instability, foreign currency exchange and interest rate fluctuations, competitive product offerings, local changes in healthcare financing and payment systems and healthcare delivery systems, local product preferences and requirements, including preferences for local manufacturers, workforce instability, weaker intellectual property protection in certain countries than exists in the U.S. and longer accounts receivable cycles. Such risks and uncertainties may adversely impact our ability to implement our growth strategy in these markets and, as a result, our sales growth, market share and operating profits from our international operations may be adversely affected.
Our international operations are subject to established and developing legal and regulatory requirements for medical devices in each country in which our products are marketed and sold. Most foreign countries have medical device regulations. Further, most countries outside of the U.S. require product approvals be renewed or re-certified on a regular basis in order to continue to be marketed and sold there. In addition, several countries that previously did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded, or plan to expand, existing regulations, including requiring local clinical data in addition to global clinical data. These factors have caused or may cause us to experience more uncertainty, risk, expense and delay in obtaining approvals and commercializing products in certain jurisdictions, which could adversely impact our net sales, market share and operating profits from our international operations.
Further, international markets are affected by economic pressure to contain healthcare costs, which can lead to more rigorous evidence requirements and lower reimbursement rates for either our products directly or procedures in which our products are used. Governments and payers may also institute changes in healthcare delivery systems that may reduce funding for services, seek payback from market participants, or encourage greater scrutiny of healthcare costs. In addition, certain international markets may also be affected by foreign government efforts to reference reimbursement rates in other countries. All of these types of changes may ultimately reduce selling prices of our products and/or reduce the number of procedures in which our products are used, which may adversely impact our net sales, market share and operating profits from our international operations.
In addition, our international operations are subject to other established and developing U.S. and foreign legal and regulatory requirements, including FCPA and/or similar laws in other countries and U.S. and foreign import and export controls and licensing requirements, trade protection and embargo measures and customs laws. Global businesses, including those in the medical device industry, are facing increasing scrutiny of, and heightened enforcement efforts with respect to, their international operations. Any alleged or actual failure to comply with legal and regulatory requirements may subject us to
20

government scrutiny, civil and/or criminal proceedings, sanctions and other liabilities, which may have a material adverse effect on our international operations, financial condition, results of operations and/or liquidity.

The US-China relationship will continue to shape the geopolitical stage. Legislation aimed at boosting competitiveness of U.S. businesses may have unintended effects on our business. We may also face greater competition in China, among other countries, from domestic medical device companies that may benefit from their status as local manufacturers and suppliers. Ultimately, tariffs and other protectionist measures, as well as prolonged uncertainty, may have adverse effects on our ability to source and manufacture products in a timely and cost effective manner, thereby adversely affecting our business.

Lastly, sanctions and export restrictions are expected to continue to proliferate, leading to greater uncertainty in emerging and growth markets. Notably the Russia/Ukraine war has created barriers to doing business in Russia, and the tension between China/Taiwan has created geopolitical shifts in Asia. Any significant changes in the political, economic, financial, competitive, legal and regulatory or reimbursement conditions where we conduct, or plan to expand, our international operations may have a material impact on our business, financial condition or results of operations.
Credit and Financial Risks
If we are unable to manage our debt levels, maintain investment grade credit ratings at the three ratings agencies, or if we experience a disruption in our cash flows, it could have an adverse effect on our cost of borrowing, financial condition or results of operations.
As part of our strategy to maximize stockholder value, we use financial leverage to manage our cost of capital. Our outstanding debt balance was $8.935 billion as of December 31, 2022. Although we currently have investment grade ratings at Moody's Investor Service, Standard & Poor's Rating Service and Fitch Ratings, our inability to maintain investment grade credit ratings could increase our cost of borrowing funds in the future and reduce our access to liquidity. Uncertain or negative economic conditions, as well as rising interest rates, could also increase our cost of borrowing in the future or reduce our access to liquidity. Delays in our product development and new product launches could result in disruption in our cash flow or our ability to continue to effectively manage our debt levels, which could have an adverse effect on our cost of borrowing, financial condition or results of operations. In addition, our credit agreements contain a financial covenant that require us to maintain a minimum specified leverage ratio and place other limits on our business. If we are unable to satisfy this covenant, we may be required to obtain waivers from our lenders and no assurance can be made that our lenders would grant such waivers on favorable terms or at all and we could be required to repay any borrowings on demand.
We may record future intangible asset impairment charges related to one or more of our global reporting units, which could materially adversely impact our results of operations.

We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. We assess goodwill for impairment at the reporting unit level. We also test our indefinite-lived intangible assets at least annually, or more frequently if impairment indicators are present, and we review intangible assets subject to amortization quarterly for impairment. In evaluating the potential for impairment, we make assumptions regarding estimated revenue projections, growth rates, cash flows and discount rates.
On a quarterly basis, we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill and other intangible assets. Relatively small declines in the future performance and cash flows of a reporting unit or asset group, changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses, or small changes in other key assumptions, may result in the recognition of significant asset impairment charges, which could have a material adverse impact on our results of operations.
Business and Operational Risks
Failure to integrate acquired businesses into our operations successfully could adversely affect our business, financial condition and operating results.
As part of our strategy to realign our business portfolio, we have completed multiple acquisitions in recent years and may pursue additional acquisitions in the future. Our integration of acquired businesses requires significant efforts, including corporate restructuring and the coordination of information technologies, research and development, sales and marketing, operations, regulatory, supply chain, manufacturing, quality systems and finance. These efforts result in additional expenses and involve significant management time. Some of the factors that could affect the success of our acquisitions include, among others, the effectiveness of our due diligence process, our ability to execute our business plan for the acquired companies, the
21

strength of the acquired technology, results of clinical trials, regulatory approvals and reimbursement levels of the acquired products and related procedures, the continued performance of critical transition services, our ability to adequately fund acquired in-process research and development projects and retain key employees and our ability to achieve synergies with our acquired companies, such as increasing sales of our products, achieving cost savings and effectively combining technologies to develop new products. In addition, foreign acquisitions involve unique risks, including those related to integration of operations across different geographies, cultures and languages, currency risks and risks associated with the economic, political, legal and regulatory environment in specific countries. Our failure to manage successfully and coordinate the growth of the acquired companies could have an adverse impact on our business and our future growth. In addition, we cannot be certain that the businesses we acquire will become profitable or remain so, and if our acquisitions are not successful, we may record related asset impairment charges in the future or experience other negative consequences on our operating results.
We may not be successful in our strategy relating to future strategic acquisitions of, investments in, or alliances with, other companies and businesses.

Our strategic acquisitions, investments and alliances are intended to further expand our ability to offer customers effective, high quality medical devices. We face competition for acquisitions from other healthcare and non-healthcare acquirers, financial sponsors, and from the market for Initial Public Offerings (IPOs). Some of our competitors in the medical device sector may have access to substantially greater amounts of cash than we do that could be deployed into M&A or strategic investments if they so choose. The market for IPOs may also reduce the opportunities available to us for M&A and/or cause us to need to pay higher prices. If we are unsuccessful in our acquisitions, investments and alliances, it may adversely impact our ability to grow our business. Any potential future acquisitions we consummate may be dilutive to our earnings and may require additional debt or equity financing, depending on their size or nature. The success of our strategy relating to future acquisitions, investments or alliances will depend on a number of factors, including our ability to:

•identify suitable opportunities for acquisition, investment or alliance, if at all,
•manage acquisition, investment or alliance opportunities within our capital capacity and prioritize those investments to execute on our strategy,
•manage our due diligence process to uncover potential issues with targets,
•finance any future acquisition, investment or alliance on terms acceptable to us, if at all,
•complete acquisitions, investments or alliances in a timely manner on terms that are satisfactory to us, if at all,
•successfully integrate and operate acquired businesses,
•successfully identify and retain key target employees,
•comply with applicable laws and regulations, including foreign laws and regulations, and
•protect intellectual property and prevail in litigation related to newly acquired technologies. 

We may not realize the expected benefits from our restructuring and optimization initiatives, our long-term cost savings programs may result in an increase in short-term expenses and our efforts may lead to unintended consequences.

We monitor the dynamics of the economy, the healthcare industry and the markets in which we compete, and assess opportunities for improved operational effectiveness and efficiency and to better align expenses with revenues, while preserving our ability to make investments in research and development projects, capital and our people, which we believe is important to our long-term success. As a result of these assessments, we have undertaken prior restructuring and optimization initiatives to enhance our growth potential and position us for long-term success. On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan) intended to support our efforts to expand operating performance and meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value. The 2023 Restructuring Plan will further build on our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and expanding operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include optimizing certain functional capabilities to better support business growth and achieve cost synergies. These activities are expected to be initiated in the first quarter of 2023, and substantially completed by the end of 2025. The 2023 Restructuring Plan is expected to result in total pre-tax charges of approximately $450 million to $550 million and reduce gross annual pre-tax expenses by approximately $225 million to $275 million by the end of 2025 as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs. These measures could yield unintended consequences, such as distraction of our management and employees, reduced employee productivity, business disruption, and inability to attract or retain key personnel, which could negatively affect our business, sales, financial condition and results of operations. Moreover, our restructuring and optimization initiatives result in charges and expenses which impact
22

our operating results. We cannot guarantee that the activities under our restructuring plans or other optimization initiatives will result in the desired efficiencies and estimated cost savings.
Our future growth is dependent upon the development of new products and enhancement of existing products, which requires significant research and development, clinical trials and regulatory approvals, all of which may be very expensive and time-consuming and may not result in commercially viable products.
In order to develop new products and enhance existing products, we focus our research and development programs largely on the development of next-generation and novel technology offerings across multiple programs and businesses. The development of new products and enhancement of existing products requires significant investment in research and development, clinical trials and regulatory approvals. The results of our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, innovate and develop new products, complete clinical trials, obtain regulatory approvals and reimbursement in the U.S. and abroad, manufacture products in a cost-effective manner, obtain appropriate intellectual property protection for our products and gain and maintain market approval of our products. There can be no assurance that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance. If we are unable to develop and launch new products and enhanced products, our ability to maintain or expand our market position in the markets in which we participate may be materially adversely impacted. Further, we are continuing to investigate and have completed several acquisitions that involve opportunities to further expand our presence in and diversify into, priority growth areas by accessing new products and technologies. There can be no assurance that our investments will be successful or that we will be able to access new products and technologies on terms favorable to us, or that these products and technologies will achieve commercial feasibility, obtain regulatory approval or gain market acceptance. A delay in the development or approval of new products and technologies or our decision to reduce or terminate our investments may adversely impact the contribution of these technologies to our future growth.
Additionally, certain products or groups of products, in particular new products or enhancements of existing products, may have a disproportionate impact on our business, financial condition and results of operations. Failure to meet growth projections, poor clinical outcomes, increasing regulatory requirements, launch delays and inability to effectively scale manufacturing and achieve targeted margins with respect to any of these products or groups of products in particular may materially adversely impact on our business, financial condition and results of operations.
The global COVID-19 pandemic and related impacts have had, and could in the future have, an adverse effect on our operations, financial performance and cash flows. We are unable to predict the extent to which the pandemic or a similar health crisis and related impacts may adversely impact our business operations, financial performance, results of operations, financial position and the achievement of our strategic objectives.

Our operations, financial performance and cash flows have been, and could in the future continue to be, negatively impacted by the COVID-19 pandemic and the risks and challenging macroeconomic conditions caused by the pandemic, including, but not limited to, disruptions in economic activity, global supply chains and labor markets, operational challenges such as site shutdowns, workplace disruptions or limited provider capacity to perform procedures using our products that were deferred as a result of the pandemic, volatile financial market dynamics and significant volatility in price and availability of goods and services. These and other risks and uncertainties related to the COVID-19 pandemic and its related impacts could adversely affect our business operations, financial position, results of operations and the achievement of strategic objectives. Because the severity, magnitude, and ultimate duration of the COVID-19 pandemic, or similar health crisis, and its economic consequences are uncertain, subject to rapid change, and difficult to predict, the pandemic’s future potential impact on our business, results of operations and financial performance remains uncertain and difficult to predict. Further, the ultimate impact of the COVID-19 pandemic or similar health crisis on our results of operations and financial performance depends on many factors that are not within our control, including, but not limited, to: governmental, business and individuals’ actions that have been and in the future may be taken in response to the pandemic or similar public health crises, the impact of the pandemic and actions taken in response on global and regional economies, general economic uncertainty in key global markets and financial market volatility, global economic conditions and levels of economic growth; and any continuing economic effects of the COVID-19 pandemic even after it has subsided. The COVID-19 pandemic and related impacts may also have the effect of heightening many of the other risks described in the risk factors in this Annual Report on Form 10-K.
Interruption of our supply chain or manufacturing operations, including resulting from natural disasters, further public health crises and other catastrophic events or other events outside of our control, could adversely affect our results of operations and financial condition.
Our products are designed and manufactured in technology centers around the world, either by us or third parties. In most cases, the manufacturing of any specific product is concentrated in one or a few locations. Factors such as a failure to follow specific
23

internal protocols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. In the event of an interruption in manufacturing, we may be unable to quickly move to alternate means of producing affected products or to meet customer demand. In the event of a significant interruption, for example, as a result of a failure to follow regulatory protocols and procedures, we may experience lengthy delays in resuming production of affected products due primarily to needs for regulatory approvals. As a result, we may experience loss of market share, which we may be unable to recapture and harm to our reputation, which could adversely affect our results of operations and financial condition.
Disruptions in the supply of the materials and components used in manufacturing our products by third-party vendors or the sterilization of our products could adversely affect our results of operations and financial condition.
We purchase the majority of the materials and components used in manufacturing our products from third-party vendors. Certain of these materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements. In certain cases, we may not be able to establish additional or replacement vendors for such materials or components in a timely or cost effective manner, largely as a result of FDA regulations that require validation of materials and components prior to their use in our products and the complex nature of our and many of our vendors' manufacturing processes. Further, uncertain or negative economic conditions, including as a result of inflationary pressures, rising interest rates or impacts from the COVID-19 pandemic, could negatively affect our third-party vendors, which could lead to a reduction or interruption in the supply of materials and components used in manufacturing our products or increase the price of such materials or components. A reduction or interruption in the supply of materials and components used in manufacturing our products, an inability to timely develop and validate alternative sources if required or a significant increase in the price of such materials or components could adversely affect our results of operations and financial condition.

In addition, many of our products require sterilization prior to sale and we utilize a mix of internal resources and contract sterilizers to perform this service. To the extent we or our contract sterilizers are unable to sterilize our products, whether due to capacity, availability of materials for sterilization, regulatory or other constraints, including federal and state regulations on the use of ethylene oxide, we may be unable to transition to alternative internal or external resources or methods in a timely or cost effective manner or at all, which could have a material impact on our results of operations and financial condition.

If we are unable to attract or retain key talent, it could have an adverse effect on our business, financial condition and results of operations.

In our industry, there is substantial competition for key personnel in the regions in which we operate and we may face increased competition for such employees. Our business depends to a significant extent on the continued service of senior management and other key personnel, the development of additional management personnel and the hiring of new qualified employees. There can be no assurance that we will be successful in retaining and developing existing personnel or recruiting new personnel. The loss of one or more key employees, our ability to attract or develop additional qualified employees or any delay in hiring key personnel could have material adverse effects on our business, financial condition or results of operations. Additionally, the COVID-19 pandemic has given rise to conditions that have created a highly competitive environment for talent. A shortage of skilled labor could also require higher wages that would increase labor costs. Our ability to attract and retain key talent at all levels of our organization has been and could continue to be challenged by these conditions, and inability to attract and retain talent could result in material adverse impacts to our business and results of operations.

Legal and Regulatory Risk Factors

Healthcare policy changes may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Political, economic and policy influences are leading the healthcare industry to make substantial structural and financial changes that will continue affecting our results of operations. Government and private sector initiatives aimed at limiting the growth of healthcare costs (including price regulation), coverage and payment policies, comparative effectiveness of therapies, technology assessments, increasing price transparency and reforming healthcare delivery and payment structures, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to put increased emphasis on the delivery of treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our products and technologies generate favorable clinical outcomes, value and cost efficiency, while also being less invasive than alternatives, the resources and evidence necessary to demonstrate value to our customers, patients, payers and other stakeholders may be significant, and it may take a significant period of time to gain widespread adoption. Moreover, there can be no assurance that our strategies will succeed for every product.

24

We cannot predict the specific healthcare programs and regulations that will be ultimately implemented by various regional and national governments. However, any changes that lower reimbursements for either our products and/or procedures using our products reduce medical procedure volumes and/or increase cost containment pressures on us or others in the healthcare sector could adversely affect our business and results of operations.

We are subject to extensive and dynamic medical device regulation, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products.
Our products, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug and Cosmetic Act (FDC Act), by comparable agencies in foreign countries and by other regulatory agencies and governing bodies. Under the FDC Act, medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S. In the EU, we are required to comply with the new Medical Device Regulation (MDR or EU MDR) effective May 2021 which supersedes the Medical Device Directives. Medical devices which have a valid CE Certificate to the current Directives (issued before May 2021) can continue to be sold until the earlier of May 2024 or when the CE Certificate expires, providing there are no significant changes to the design or intended use. Updates to the legislative text of the EU MDR were adopted by the European Parliament and are currently being reviewed for adoption by the Council of the European Union, including an extension of the transitional period to 2027 for class IIb and III and 2028 for class I and IIa medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). The CE Mark is applied following approval from an independent notified body or declaration of conformity. The process of obtaining marketing approval or clearance from the FDA or by comparable agencies in foreign countries for new products, or with respect to enhancements or modifications to existing products, could:

•take a significant period of time,
•require the expenditure of substantial resources,
•involve rigorous pre-clinical and clinical testing, as well as increased post-market surveillance,
•require changes to products and
•result in limitations on the indicated uses of products.
 
In addition, exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country of origin or legal manufacturer first. Most countries outside of the U.S. require that product approvals be renewed or recertified on a regular basis, generally every four to five years. The renewal or recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance. Where renewal or recertification applications are required, they may need to be renewed and/or approved in order to continue selling our products in those countries. There can be no assurance that we will receive the required approvals for new products or modifications to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive post-market study requirements.

Our global regulatory environment is becoming increasingly stringent and unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals, as well as the clinical and regulatory costs of supporting those approvals. Several countries that did not previously have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded on existing regulations. Certain regulators are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data. While harmonization of global regulations has been pursued, requirements continue to differ significantly among countries. We expect this global regulatory environment will continue to evolve, which could impact our ability, or increase the time and cost, to obtain future approvals for our products.
The FDA and other worldwide regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing practices, recordkeeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA can take action against a company that promotes "off-label" uses. The FDA may also enjoin and restrain a company for certain violations of the FDC Act and other amending laws pertaining to medical devices, or initiate action for criminal prosecution of such violations. Any adverse regulatory action, depending on its magnitude, may restrict a company from effectively marketing and selling its products, may limit a company's ability to obtain future premarket clearances or approvals and could result in a substantial modification to our
25

business practices and operations. International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements.
Regulations regarding the development, manufacture and sale of medical devices are evolving and subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition and results of operations. Later discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances or approvals, seizures or recalls of products, physician advisories or other field actions, operating restrictions and/or criminal prosecution. We may also initiate field actions as a result of a failure to strictly comply with our internal quality policies. The failure to receive product approval clearance on a timely basis, suspensions of regulatory clearances, seizures or recalls of products, physician advisories or other field actions, or the withdrawal of product approval by the FDA or by comparable agencies in foreign countries could have a material adverse effect on our business, financial condition or results of operations.
Our products are continually subject to clinical trials and other analyses conducted by us, our competitors or other third parties, the results of which may be unexpected, or perceived as unfavorable by the market, and could have a material adverse effect on our business, financial condition or results of operations.
As a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations and trial endpoints. Unexpected or inconsistent clinical data from existing or future clinical trials or other analyses conducted by us, by our competitors or by third parties, including acquired businesses prior to acquisition by us, or the FDA's or the market's perception of this clinical data, may adversely impact our ability to obtain product approvals, our position in, and share of, the markets in which we participate and our business, financial condition, results of operations or future prospects.
The medical device industry and its customers continue to face scrutiny and regulation by governmental authorities and are often the subject of numerous investigations, often involving marketing and other business practices or product quality issues including device recalls or advisories. These investigations could result in the commencement of civil and criminal proceedings; imposition of substantial fines, penalties and administrative remedies, including corporate integrity agreements, stipulated judgments or exclusion; diversion of our employees' and management's attention; imposition of administrative costs and have an adverse effect on our financial condition, results of operations and liquidity; and may lead to greater governmental regulation in the future.
The medical devices we design, develop, manufacture and market are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. These authorities continue to closely scrutinize our industry. We have received and in the future may receive, subpoenas and other requests for information from Congress and state and federal governmental agencies, including, among others, the U.S. Department of Justice (DOJ), the Office of Inspector General of the Department of Health and Human Services (HHS) and the Department of Defense, as well as from foreign governments and agencies. The requests and/or subpoenas we have received relate primarily to financial arrangements with healthcare providers, regulatory compliance and sale and/or product promotional practices. We have cooperated with these subpoenas and other requests for information and expect to continue to do so in the future. We cannot predict when a matter will be resolved, the outcome of the matter or its impact on us and cooperation may involve significant costs, including document production costs. An adverse outcome in any matter could include the commencement of an investigation, civil and criminal proceedings, substantial fines, penalties and administrative remedies, including exclusion from government reimbursement programs, entry into Corporate Integrity Agreements (CIAs) with governmental agencies and amendments to any existing CIAs. In addition, resolution of any matter could involve the imposition of additional and costly compliance obligations. Cooperation with requests and investigations from external agencies result in employee resource costs and diversion of employee focus. If any requests or investigations continue over a long period of time, they could divert the attention of management from the day-to-day operations of our business and impose significant additional administrative burdens on us. These potential consequences, as well as any adverse outcome from these requests or investigations, could have a material adverse effect on our financial condition, results of operations and liquidity.
In addition, certain foreign governments, state governments (including that of Massachusetts, where we are headquartered) and the U.S. federal government have enacted legislation aimed at increasing transparency of our interactions with healthcare providers. As an example, compliance with the U.S. Physician Payment Sunshine Act requires us by law to disclose payments and other transfers of value to all U.S. physicians and U.S. teaching hospitals at the U.S. federal level made after August 1, 2013. Any failure to comply with these legal and regulatory requirements could impact our business. In addition, we have and may continue to devote substantial additional time and financial resources to further develop and implement enhanced structure, policies, systems and processes to comply with enhanced legal and regulatory requirements, which may also impact our business.
26

We anticipate that governmental authorities will continue to scrutinize our industry closely and that additional regulation may increase compliance and legal cost and exposure to litigation and have additional adverse effects on our operations.
Changes in tax laws, unfavorable resolution of tax contingencies, or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.
We are subject to income taxes as well as non-income based taxes and tariffs, in the U.S. and numerous foreign jurisdictions. We are subject to ongoing tax audits in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits to determine the appropriateness of our tax provision, and we have established contingency reserves for material, known tax exposures. However, the calculation of such tax exposures involves the application of complex tax laws and regulations in many jurisdictions, as well as interpretations as to the legality under European Union state aid rules of tax advantages granted in certain jurisdictions. Therefore, there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial condition.

Changes in tax laws and regulations, or their interpretation and application, in the jurisdictions where we are subject to tax could materially impact our effective tax rate. The U.S. enacted the Tax Cuts and Jobs Act (TCJA) on December 22, 2017 and the Inflation Reduction Act on August 16, 2022. We expect the U.S. Treasury to issue future notices and regulations regarding the application and interpretation of these laws which could have a significant impact on our future results of operations as could interpretations made by the Company in the absence of regulatory guidance and judicial interpretations.

The Group of Twenty (G20), the Organization for Economic Co-operation and Development (OECD), the European Commission (EC) and individual taxing jurisdictions where we and our affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD/G20 Inclusive Framework (IF) on base erosion and profit shifting (BEPS) includes actions intended to equip governments with domestic and international rules and instruments to address tax avoidance, ensuring that profits are taxed where economic activities generating the profits are performed and where value is created. The actions include a two-pillar solution to address the tax challenges of the digitalized economy. Pillar One focuses on how profits are allocated between taxing jurisdictions and Pillar Two creates a 15% global minimum tax. On December 31, 2022 South Korea became the first country to enact Pillar Two into national law. On December 15, 2022, the Council of the (EU) European Union unanimously adopted a directive intended to provide EU member states a framework to implement the Pillar Two global minimum tax into their national laws by 2024. Additional countries including the United Kingdom and Japan are taking steps to implement Pillar Two into their national law. Currently, significant uncertainty exists regarding the detailed Pillar Two rules, whether such rules will be implemented consistently across taxing jurisdictions, how such rules interact with existing national tax laws and whether such rules are consistent with existing tax treaty obligations. Accordingly, the final adoption, implementation, and interpretation of Pillar Two across all jurisdictions where we do business could have a material adverse impact on our financial position, results of operations, and cash flows.

The tax laws in the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could have a material adverse effect on our business. Furthermore, changes in customs laws and regulations in the U.S. and various foreign jurisdictions could have a material impact on our results of operations or financial condition.

Our operations in Puerto Rico, Costa Rica and Malaysia presently benefit from various tax incentives and grants. Unless these incentives and grants are extended, they will expire between 2027 and 2034. If we are unable to renew, extend, or obtain new incentive and grants, the expiration of the existing incentives and grants could have a material impact on our financial results in future periods.

We may not effectively be able to protect our intellectual property or other sensitive data, which could have a material adverse effect on our business, financial condition or results of operations.

The medical device market in which we participate is largely technology driven. Physician customers have historically moved quickly to new products and new technologies. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. However, intellectual property litigation is inherently complex and unpredictable and appellate courts can overturn lower court decisions. Furthermore, as our business increasingly relies on technology systems and infrastructure, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation. Finally, our ability to protect novel business models is uncertain.

27

Competing parties in our industry frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These forces frequently drive settlement not only of individual cases, but also of a series of pending and potentially related and unrelated cases. In addition, although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

A number of third parties have asserted that our current and former product offerings infringe patents owned or licensed by them. We have similarly asserted that products sold by our competitors infringe patents owned or licensed by us. Adverse outcomes in one or more of the proceedings against us could limit our ability to sell certain products in certain jurisdictions, or reduce our operating margin on the sale of these products and could have a material adverse effect on our financial condition, results of operations or liquidity.

Patents and other proprietary rights are and will continue to be essential to our business, and our ability to compete effectively with other companies will be dependent upon the proprietary nature of our technologies. We rely upon trade secrets, know-how, continuing technological innovations, strategic alliances, and licensing opportunities to develop, maintain and strengthen our competitive position. We pursue a policy of generally obtaining patent protection in both the U.S. and abroad for patentable subject matter in our proprietary devices and attempt to review third-party patents and patent applications to the extent publicly available in order to develop an effective patent strategy, avoid infringement of third-party patents, identify licensing opportunities and monitor the patent claims of others. We own numerous U.S. and foreign patents and have numerous patent applications pending. We also are party to license agreements pursuant to which patent rights have been obtained or granted in consideration for cash, cross-licensing rights or royalty payments. No assurance can be made that any pending or future patent applications will result in the issuance of patents, that any current or future patents issued to, or licensed by, us will not be challenged or circumvented by our competitors, or that our patents will not be found invalid. In addition, we may have to take legal action in the future to protect our patents, trade secrets or know-how or to assert them against claimed infringement by others. Any legal action of that type could be costly and time consuming and no assurances can be made that any lawsuit will be successful. We are generally involved as both a plaintiff and a defendant in a number of patent infringement and other intellectual property-related actions. The invalidation of key patents or proprietary rights that we own, or an unsuccessful outcome in lawsuits to protect our intellectual property, could have a material adverse effect on our business, financial condition or results of operations.

In addition, the laws of certain countries in which we market and plan on manufacturing some of our products in the near future, do not protect our intellectual property rights to the same extent as the laws of the U.S. If we are unable to protect our intellectual property in these countries, it could have a material adverse effect on our business, financial condition or results of operations.

Furthermore, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses and unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. While we have invested to protect our intellectual property, products and other data and continue to work diligently in this area, there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber-attacks or other events. Such events could have a material adverse effect on our reputation, business, financial condition or results of operations.
Pending and future intellectual property litigation could be costly and disruptive to us.
We operate in an industry that is susceptible to significant intellectual property litigation and, in recent years, it has been common for companies in the medical device field to aggressively challenge the patent rights of other companies. We are currently the subject of various patent litigation proceedings and other proceedings described in more detail under Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. Intellectual property litigation is expensive, complex and lengthy and its outcome is difficult to predict. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial condition, results of operation or liquidity. Pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel. In the event that our right to market any of our products is successfully challenged, we may be required to obtain a license on terms which may not be favorable to us, if at all. If we fail to obtain a required license or are unable to design around a patent, our business, financial condition or results of operations could be materially adversely affected.
28


Pending and future product liability claims and other litigation, including private securities litigation, stockholder derivative suits and contract litigation, may adversely affect our financial condition and results of operations or liquidity.

The design, manufacturing and marketing of medical devices of the types that we produce entail an inherent risk of product liability claims. Many of the medical devices that we manufacture and market are designed to be implanted in the human body for long periods of time or indefinitely. A number of factors could result in an unsafe condition or injury to, or death of, a patient with respect to these or other products that we manufacture or sell, including physician technique and experience in performing the surgical procedure, component failures, manufacturing flaws, design defects, off-label use or inadequate disclosure of product-related risks or product-related information. These factors could result in product liability claims, a recall of one or more of our products or a safety alert relating to one or more of our products. Product liability claims may be brought by individuals or by groups seeking to represent a class.

We are currently the subject of product liability litigation proceedings and other proceedings described in more detail under Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. The outcome of litigation, particularly class action lawsuits, is difficult to assess or quantify. Plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts, including not only actual damages, but also punitive damages. The magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time. In addition, the cost to defend against any future litigation may be significant. Product liability claims, securities and commercial litigation and other litigation in the future, regardless of the outcome, could have a material adverse effect on our financial condition, results of operations or liquidity. Additionally, we maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The fact that we do not maintain third-party insurance coverage for all categories of losses increases our exposure to unanticipated claims and adverse decisions and these losses could have a material adverse effect on our financial condition, results of operations or liquidity.
Any failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business, financial condition and results of operations.

As a medical device manufacturer, we are required to register our establishments and list our devices with the FDA and are subject to periodic inspection by the FDA for compliance with its Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the Federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA which may result in observations on Form 483 and in some cases warning letters that require corrective action. In the European Community, we are required to maintain certain International Standards Organization (ISO) certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Many other countries in which we do business have similar requirements and other foreign governments or agencies may subject us to periodic inspections. If we, or our manufacturers, fail to adhere to quality system regulations or ISO requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations.

We rely on the proper function, availability and security of information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations.

We rely on information technology (IT) and operational technology (OT) systems, including technology from third party vendors, manufacture and ship our products, as well as to process, transmit and store electronic information in our day-to-day operations. Similar to other large multi-national companies, the size and complexity of our IT systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. Various other factors may also cause system failures or security breaches, including power outages, natural disasters, inadequate or ineffective backups, issues with upgrading or creating new systems or platforms, vulnerabilities in third-party software or services, errors by our staff or third-party service providers, or breaches in the security of these technologies. Malicious actors may attempt to trick staff to disclose information to gain access to our systems and/or data. If our incident response, disaster
29

recovery, and business continuity plans fail, they could result in adverse impacts to our business operations and our financial results.

Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information and changing customer patterns. In addition, third parties have and may continue to attempt to hack into our products to obtain data relating to patients, or alter the intended functionality of our medical devices, or disrupt performance of our products, or access our proprietary information and the technology from third party vendors that we rely upon may have defects or vulnerabilities which, in turn, create vulnerabilities or disruptions in our system. Cyber-attacks continue to evolve in complexity and scope, and inherently may be difficult to detect. We have seen, and could continue to see, software and supply-chain vulnerabilities and malware, which could affect our systems and the systems of our third-party vendors and business partners. Any failure by us to maintain or protect our IT or OT systems, products and data integrity, including from cyber-attacks, intrusions or other breaches, could result in outages or unauthorized access to patient data and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations, or, in the worst case, could result in harm to patients. In addition, such attackers may make demands for ransom, which could result in financial loss, or, if we determine not to pay such ransom, other harm, loss, or misappropriation of our data and assets. Such failure, or demonstration of vulnerability to such failure, may also result in additional regulatory scrutiny. We also grow our company through acquisitions and may face risks associated with defects and vulnerabilities in their systems as we work to integrate the acquisitions into our IT system.

In the U.S., federal and state privacy and security laws require certain parts of our operations to protect the confidentiality of personal information including patient medical records and other health information, and to comply with other requirements with respect to personal data. In Europe, the Data Protection Directive requires us to manage individually identifiable information in the EU and, the General Data Protection Regulation (GDPR) may impose fines of up to four percent of our global revenue. Internationally, some countries have also passed laws that require individually identifiable data on their citizens to be maintained on local servers and that may restrict transfer or processing of that data. We strive to meet the expectations of applicable regulations, however, there is no guarantee that we will avoid enforcement actions by governmental bodies or civil actions based on this growing body of regulations. Enforcement actions could be costly and interrupt regular operations of our business. Any of these events, in turn, may cause us to lose existing customers, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other healthcare professionals, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition or results of operations.

Our business and operations are subject to risks related to climate change.
The effects of global climate change present risks to our business. Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, including manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business. Climate change and natural disasters could also result in physical damage to our facilities as well as those of our suppliers, customers, and other business partners, which could cause disruption in our business and operations or increase costs to operate our business. Additionally, increased environmental regulation, including to address climate change, may result in increases in our costs to operate our business or restrict certain aspects of our activities. The extent and severity of climate change impacts are unknown, and therefore, the scope of potential impact on our business may be difficult to predict and it may be difficult to adequately prepare.

Our business could be negatively impacted by corporate social responsibility and sustainability matters.
In recent years, there has been an increased focus from certain investors, customers, employees, and other stakeholders concerning corporate social responsibility and sustainability matters. From time to time, we announce certain initiatives, including goals, regarding our focus areas, which include environmental matters, including carbon emissions and renewable energy goals, responsible sourcing, social investments and diversity, equity and inclusion. We may fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could fail in accurately reporting our progress on such initiatives and goals. Such failures could be due to changes in our business. Moreover, the standards by which corporate social responsibility and sustainability efforts and related matters are measured are developing and evolving, and certain areas are subject to assumptions that could change over time. In addition, we could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. Any such matters, or related corporate social responsibility
30

and sustainability matters, could have a material adverse impact on our future results of operations, financial position and cash flows.
31

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES
Our world headquarters is located in the U.S, in Marlborough, Massachusetts, with principal regional headquarters located in Singapore and Voisins-le-Bretonneux, France. As of December 31, 2022, we maintained 15 principal manufacturing facilities, including eight in the U.S. and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia, and one in Brazil, as well as various distribution and technology centers around the world. Many of these facilities produce and manufacture products for more than one of our divisions, and also perform research activities. Our products are distributed worldwide from primary customer fulfillment centers in Massachusetts, the Netherlands, Malaysia and Japan. The following is a summary of our facilities as of December 31, 2022 (in approximate square feet):
Owned(1)
Leased(2)
Total
U.S.4,043,041 1,038,419 5,081,460 
International2,424,123 2,026,634 4,450,757 
 6,467,164 3,065,053 9,532,217 
(1)    Includes our principal manufacturing facilities in Minnesota, Ireland, Puerto Rico and Coyol, Costa Rica, our manufacturing facility in Malaysia, our primary customer fulfillment centers in Massachusetts, the Netherlands, Malaysia and Japan, as well as our global headquarters located in Marlborough, Massachusetts.
(2)    Includes our principal manufacturing facilities in California, Indiana, Brazil and Heredia, Costa Rica, as well as our regional headquarters located in Singapore and Voisins-le-Bretonneux, France.

ITEM 3. LEGAL PROCEEDINGS
See Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-Kand incorporated herein by reference.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

32

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

The principal market on which our common stock is traded is the New York Stock Exchange (NYSE) under the symbol “BSX.”
Holders of Record
As of January 31, 2023, there were 5,752 holders of record of our common stock.
Dividends
We did not pay a cash dividend in 2022, 2021 or 2020 on our common stock and currently we do not intend to pay cash dividends on our common stock. We may consider declaring and paying a cash dividend in the future; however, there can be no assurance that we will do so.
Securities Authorized for Issuance under Equity Compensation Plans
Please see Item 12. "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" under Part III of this Annual Report on Form 10-K for information on where to find information required by Item 201(d) of Regulation S-K.
Purchases of Equity Securities by the Issuer and Affiliated Purchases
On December 14, 2020, our Board of Directors approved, and we announced, a new stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock (2020 Share Repurchase Program). We made no share repurchases in 2022 or 2021 and, as of December 31, 2022, had the full $1.000 billion remaining available under the 2020 Share Repurchase Program. Refer to Note J – Stockholders' Equity to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information.
There were no purchases of equity securities by the issuer or affiliated purchases in the fourth quarter of 2022, required to be reported here.

33

Stock Performance Graph
The graph below compares the five-year total return to stockholders on our common stock with the return of the Standard & Poor’s (S&P) 500 Stock Index and the S&P Healthcare Equipment Index. The graph assumes $100 was invested in our common stock and in each of the named indices on December 31, 2017 and that any dividends were reinvested.
bsx-20221231_g1.jpg

Note: The stock price performance shown on the graph above is not indicative of future price performance. This graph shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
34

ITEM 6. RESERVED
Not applicable.
35

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Boston Scientific Corporation and its subsidiaries for the years ended December 31, 2022 and 2021. For a full understanding of our financial condition and results of operations, this discussion should be read in conjunction with our consolidated financial statements and accompanying notes included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.
For additional information on our financial condition and results of operations for the year ended December 31, 2020, refer to our previously filed Annual Report on Form 10-K.
Economic Trends
Uncertainty around inflationary pressures, rising interest rates, monetary policy and changes in tax laws could potentially cause new, or exacerbate existing, economic challenges that we may face, including the impact of foreign currency fluctuations on our results of operations. These conditions could worsen, or others could arise, if the U.S. and global economies were to enter recessionary periods, triggered or exacerbated by monetary policy designed to curb inflation. Existing and future potential geopolitical dynamics, including matters related to the Russia/Ukraine war, as well as the tension between China/Taiwan, may create economic, supply chain, energy, and other challenges, which impact, and may in the future negatively impact our business. In particular, international conflicts may result in sanctions, tariffs, and other measures that restrict international trade and negatively affect our business operations and results. In 2022, we experienced increases in cost and limited availability of raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain, as well as increases in wage costs and the cost and time to distribute our products. In 2023, we expect the impact of macroeconomic and supply chain conditions on our business to be similar to 2022.

COVID-19 Pandemic

In March 2020, the World Health Organization declared COVID-19, including all additional variations and strains thereof, a global pandemic (COVID-19 pandemic). Economic conditions created in part by the COVID-19 pandemic, have had, and may in the future have, a negative impact on our profitability. Further, the resurgence of COVID-19 infections and the emergence of new, more contagious variant strains of COVID-19, as well as staffing shortages within healthcare facilities, may negatively impact demand for our products, net sales, gross profit margin and operating expenses as a percentage of net sales. While the COVID-19 pandemic and related impacts may continue to negatively impact our performance to an extent, we continue to believe our long-term fundamentals remain strong and we intend to manage through these challenges with strategic focus and the winning spirit of our global team.


36

Executive Summary
Financial Highlights and Trends

In 2022, we generated net sales of $12.682 billion, compared to $11.888 billion in 2021. This increase of $794 million, or 6.7 percent, included operational1 growth of 11.1 percent and the negative impact of 440 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 8.7 percent in 2022 and the positive impact of 240 basis points from our acquisitions of Preventice Solutions, Inc. (Preventice), Farapulse, Inc. (Farapulse), the global surgical business of Lumenis, LTD (Lumenis) and Baylis Medical Company Inc. (Baylis Medical) for which there is less than a full period of comparable net sales. The increase in our net sales was primarily driven by recent acquisitions as well as the strength and diversity of our product portfolio coupled with growth in the underlying markets in which we compete and strong commercial execution. Refer to the Business and Market Overview section for further discussion of our net sales by global business.

Our reported net income available to common stockholders in 2022 was $642 million, or $0.45 per diluted share. Our reported results for 2022 included certain charges and/or credits which are excluded by management for purposes of assessing operating performance, totaling $1.816 billion (after-tax), or $1.26 per diluted share. Excluding these items, adjusted net income available to common stockholders1 for 2022 was $2.459 billion, or $1.71 per diluted share.

Our reported net income available to common stockholders in 2021 was $985 million, or $0.69 per diluted share. Our reported results for 2021 included certain charges and/or credits which are excluded by management for purposes of assessing operating performance, totaling $1.351 billion (after-tax), or $0.94 per diluted share. Excluding these items, adjusted net income available to common stockholders1 for 2021 was $2.336 billion, or $1.63 per diluted share.

















1 Operational net sales growth rates, which exclude the impact of foreign currency fluctuations, and other adjusted measures, including organic net sales, which exclude certain items required by generally accepted accounting principles in the United States (U.S. GAAP), are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.
2 Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
37

The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Results of Operations for a discussion of each reconciling item:
Year Ended December 31, 2022
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Available to Common Stockholders
Impact per Share(3)
Reported$1,141 $443 $698 $(55)$642 $0.45 
Non-GAAP adjustments:
Amortization expense803 (109)694 — 694 0.48 
Intangible asset impairment charges132 (29)102 — 102 0.07 
Acquisition/divestiture-related net charges (credits)285 53 338 — 338 0.24 
Restructuring and restructuring-related net charges (credits)110 (14)96 — 96 0.07 
Litigation-related net charges (credits)173 (40)133 — 133 0.09 
Investment portfolio net losses (gains)(30)2 (28)— (28)(0.02)
European Union (EU) Medical device regulation (MDR) implementation costs71 (10)62 — 62 0.04 
Debt extinguishment charges194 (45)149 — 149 0.10 
Deferred tax expenses (benefits)— 140 140 — 140 0.10 
Discrete tax items— 129 129 — 129 0.09 
Adjusted$2,880 $366 $2,514 $(55)$2,459 $1.71 
 Year Ended December 31, 2021
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Available to Common Stockholders
Impact per Share(3)
Reported$1,076 $36 $1,041 $(55)$985 $0.69 
Non-GAAP adjustments:
Amortization expense741 (65)676 — 676 0.47 
Intangible asset impairment charges370 (51)318 — 318 0.22 
Acquisition/divestiture-related net charges (credits)(450)(2)(453)— (453)(0.32)
Restructuring and restructuring-related net charges (credits)191 (22)169 — 169 0.12 
Litigation-related net charges (credits)430 (98)331 — 331 0.23 
Investment portfolio net losses (gains)181 (43)137 — 137 0.10 
European Union (EU) Medical device regulation (MDR) implementation costs49 (4)45 — 45 0.03 
Deferred tax expenses (benefits)— 132 132 — 132 0.09 
Discrete tax items— (5)(5)— (5)(0.00)
Adjusted$2,587 $196 $2,391 $(55)$2,336 $1.63 

(3) For 2022 and 2021, the effect of assuming the conversion of our Series A 5.5% Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP Net income (loss) and Adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our consolidated statements of operations, for purposes of calculating GAAP Net income (loss) available to common stockholders.
38

Business and Market Overview

In the first quarter of 2022, we reorganized our operational structure and have aggregated our core businesses, each of which generate revenues from the sale of medical devices into two reportable segments: MedSurg and Cardiovascular. Within the Cardiovascular segment, the newly formed Cardiology division represents the combined former Rhythm Management and Interventional Cardiology divisions. We have revised prior periods to conform to the current year presentation. The following section describes our results of operations by reportable segment and business unit. For additional information on our businesses and their product offerings, see Item 1. Business of this Annual Report on Form 10-K.

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative, less invasive technologies. Net sales of Endoscopy products of $2.221 billion represented 18 percent of our consolidated net sales in 2022. Endoscopy net sales increased $80 million, or 3.7 percent, in 2022 compared to 2021. This increase included operational net sales growth of 8.1 percent and the negative impact of 440 basis points from foreign currency fluctuations. These year-over-year changes were primarily driven by our biliary franchise led by our AXIOS™ Stent and Delivery System and our single-use imaging franchise, including our EXALT™ D Single-use Duodenoscope, as well as our infection prevention and hemostasis franchises.

Urology

Our Urology business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Net sales of Urology products of $1.773 billion represented 14 percent of our consolidated net sales in 2022. Urology net sales increased $190 million, or 12.0 percent, in 2022 compared to 2021. This increase included operational net sales growth of 14.9 percent and the negative impact of 290 basis points from foreign currency fluctuations.

Operational net sales growth included organic net sales growth of 9.7 percent in 2022 and the positive impact of 530 basis points from our acquisition of Lumenis in the third quarter of 2021. Organic net sales growth was driven by our stone management franchise led by our LithoVue™ System, our prosthetic urology franchise and our prostate health franchise led by our Rezum™ System and SpaceOAR™ Hydrogel.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Net sales of Neuromodulation products of $917 million represented seven percent of our consolidated net sales in 2022. Neuromodulation net sales increased $8 million, or less than one percent, in 2022 compared to 2021. This increase included operational net sales growth of 3.5 percent and the negative impact of 260 basis points from foreign currency fluctuations. Operational net sales performance reflects growth within our spinal cord stimulation (SCS) franchise driven by our WaveWriter Alpha™ SCS System, strong procedural volumes of our Vercise Genus™ DBS systems as well as the recent launch of the Vercise™ 2-in-1 lead extension, largely offset by the impact of reimbursement challenges in the U.S. related to our Vertiflex Superion™ Indirect Decompression System.

Cardiovascular

Cardiology

Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart. Net sales of Cardiology products of $5.932 billion represented 47 percent of our consolidated net sales in 2022. Cardiology net sales increased $510 million, or 9.4 percent, in 2022 compared to 2021. This increase included operational net sales growth of 14.5 percent and the negative impact of 510 basis points from foreign currency fluctuations. Operational net sales growth included organic net sales growth of 10.4 percent in 2022 and the positive impact of 400 basis points from our acquisitions of Preventice, Farapulse and Baylis Medical in the first and third quarter of 2021 and the first quarter of 2022, respectively.

39

Organic sales growth was primarily driven by continued market expansion of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN™ FLX LAAC Device, as well as performance of our cardiac diagnostics franchise, POLARx™ and Farapulse™ ablation systems and percutaneous coronary intervention guidance franchises.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $1.899 billion represented 15 percent of our consolidated net sales in 2022. Peripheral Interventions net sales increased $79 million, or 4.4 percent, in 2022 compared to 2021. This increase included operational net sales growth of 9.1 percent and the negative impact of 480 basis points from foreign currency fluctuations.

Operational net sales growth was primarily driven by our Ranger™ Drug-Coated Balloon and Eluvia™ Drug-Eluting Stent System, as well as our interventional oncology franchise led by our Therasphere™ Y-90 Radioactive Glass Microspheres.

Emerging Markets

As part of our strategic imperative to drive global expansion, we seek to grow net sales and market share by expanding our global presence, including in Emerging Markets. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. Our Emerging Markets net sales represented 14 percent of our consolidated net sales in 2022 and 12 percent in 2021. In 2022, our Emerging Markets net sales grew 20.0 percent on a reported basis including operational net sales growth of 29.3 percent and the negative impact of 930 basis points from foreign currency fluctuations, compared to 2021. Operational net sales growth was driven primarily by growth in China and India as we continued to focus on globalization and execute new product launches.
40

Results of Operations
Net Sales
The following table provides our net sales by reportable segment and business unit, and the relative change in growth on a reported basis:
Year Ended December 31,2022 versus 20212021 versus 2020
(in millions)202220212020
Endoscopy$2,221 $2,141 $1,780 3.7%20.3%
Urology1,773 1,583 1,286 12.0%23.1%
Neuromodulation917 909 761 0.9%19.5%
MedSurg4,911 4,633 3,827 6.0%21.0%
Cardiology5,932 5,422 4,290 9.4%26.4%
Peripheral Interventions1,899 1,820 1,577 4.4%15.4%
Cardiovascular7,831 7,242 5,866 8.1%23.4%
12,742 11,875 9,694 7.3%22.5%
Other(4)
(60)13 219 (+100.0)%(93.9)%
Net Sales$12,682 $11,888 $9,913 6.7%19.9%
(4) In 2022, amounts reflect sales reserves established for Italian government payback provisions, not allocated to reportable segments, which are being disputed in the Italian court system. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

Refer to Executive Summary for further discussion of our net sales and a comparison of our 2022 and 2021 net sales.

In 2021, we generated net sales of $11.888 billion compared to $9.913 billion in 2020. This increase of $1.975 billion, or 19.9 percent, included operational growth of 18.7 percent and the positive impact of 130 basis points from foreign currency fluctuations. Operational net sales included $212 million in 2021 associated with our acquisitions of Preventice, Farapulse and Lumenis, for which there was less than a full prior period of comparable net sales. Operational net sales also included $202 million in 2020 associated with our intrauterine health franchise and the Specialty Pharmaceuticals business, divested in the second quarter of 2020 and first quarter of 2021, respectively. The increase in our 2021 net sales was primarily driven by the recovery of elective and semi-emergent procedure volumes compared to 2020 when the COVID-19 pandemic had a more significant impact on our net sales.






41

Gross Profit
Our gross profit was $8.727 billion in 2022 and $8.177 billion in 2021. As a percentage of net sales, our gross profit remained flat at 68.8 percent in 2022 compared to 2021. The following is a reconciliation of our gross profit margins and a description of the drivers of the change from period to period:
Gross Profit Margin
Year Ended December 31, 202065.0%
Sales pricing, volume and mix1.2%
Abnormal production variances1.3%
LOTUS Edge™ discontinuation0.9%
Net impact of foreign currency fluctuations(0.3)%
All other, including other period expense0.7%
Year Ended December 31, 202168.8%
Manufacturing and supply costs(0.6)%
Net impact of foreign currency fluctuations1.3%
Sales pricing, volume and mix(0.2)%
All other, including other period expense(0.5)%
Year Ended December 31, 202268.8%

Our gross profit margin for 2022 was flat compared to 2021. Global supply chain disruption drove increased manufacturing and supply costs, including inflation on costs of certain raw materials and components, direct labor and freight, as well as inefficiencies in our manufacturing plants due to constraints in material availability. The negative impact on our gross profit margin due to global supply chain disruption was offset by foreign currency fluctuations that drove gains on our foreign currency hedging contracts.

The primary factors contributing to the increase in our gross profit margin for 2021 compared to 2020 were higher sales volumes and favorable product mix associated with the resumption of the procedures using higher-margin products following reduced elective procedure volumes due to the COVID-19 pandemic. In addition, our gross profit margin in 2020 was negatively impacted by abnormal production variances attributable to manufacturing plant shut-downs, inventory charges related to the discontinuation of our LOTUS platform and sales return reserves due to our WATCHMAN FLX™ consignment conversion. These improvements were partially offset by price declines related primarily to sales of our coronary drug-eluting stent systems and foreign currency fluctuations. In addition, macro-environment factors negatively impacted our gross profit margin, including the cost of operating manufacturing plants with COVID-19 specific health and safety measures and increases in costs of certain raw materials, direct labor and freight.

EU MDR Implementation Costs

The European Union Medical Device Regulation (EU MDR) replaced the existing European Medical Devices Directive (MDD) and Active Implantable Medical Device Directive (AIMDD) regulatory frameworks, and manufacturers of medical devices were required to comply with EU MDR beginning in May 2021 for new product registrations and by May 2024 for medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). Updates to the legislative text of the EU MDR were adopted by the European Parliament and are currently being reviewed for adoption by the Council of the European Union, including an extension of the transitional period to 2027 for class IIb and III and 2028 for class I and IIa medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021).

We began our implementation efforts in late 2019 and have incurred cumulative expenses of $245 million through December 31, 2022, which are primarily being recorded within Cost of product sold. We expect to incur total expenses of approximately $400 million to $450 million over the transition period.

42

Operating Expenses
The following table provides a summary of our key operating expenses:
Year Ended December 31,
 202220212020
(in millions)$% of Net Sales$% of Net Sales$% of Net Sales
Selling, general and administrative expenses$4,520 35.6 %$4,359 36.7 %$3,787 38.2 %
Research and development expenses1,323 10.4 %1,204 10.1 %1,143 11.5 %

Selling, General and Administrative (SG&A) Expenses

In 2022, our SG&A expenses increased $161 million, or 4 percent compared to 2021 and were 100 basis points lower as a percentage of net sales. The increase in SG&A expenses was due primarily to higher selling costs driven by higher global net sales.

In 2021, our SG&A expenses increased $572 million, or 15 percent compared to 2020 and were 150 basis points lower as a percentage of net sales. The increase in SG&A expenses was primarily due to higher selling costs driven by higher global net sales and the targeted lifting of spending controls implemented in 2020 in response to the then escalating COVID-19 pandemic. In addition, SG&A expenses in 2021 were further impacted by higher restructuring-related spend and acquisition-related costs.

Research and Development (R&D) Expenses

We remain committed to advancing medical technologies and investing in meaningful research and development projects across our businesses. In 2022, our R&D expenses increased $119 million, or 10 percent compared to 2021, and were 30 basis points higher as a percentage of net sales as a result of targeted investments across our businesses. We expect to continue to make investments in clinical trials and innovative technologies to maintain a pipeline of new products that we believe will address unmet clinical needs and contribute to profitable sales growth.

In 2021, our R&D expenses increased $61 million, or 5 percent compared to 2020, and were 140 basis points lower as a percentage of sales, as a result of investments across our business.

Other Operating Expenses
The following provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance; refer to Additional Information for a further description.

Amortization Expense

Our amortization expense relates to intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents. In 2022, Amortization expense increased $62 million, or 8 percent, as compared to 2021. The increase was driven by the addition of amortizable intangible assets associated with recent acquisitions. In 2021, Amortization expense decreased $48 million, or 6 percent, as compared to 2020. The decrease was driven by the divestiture of the Specialty Pharmaceuticals business, partially offset by the addition of amortizable intangible assets associated with recent acquisitions.

Intangible Asset Impairment Charges

We recorded Intangible asset impairment charges of $132 million in 2022 and $370 million in 2021. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management’s decision to discontinue commercialization of the VICI VENOUS STENT™ System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&D program due to the incremental time and cost required to complete the program and bring the technology to market.
43

Refer to Critical Accounting Estimates for a discussion of key assumptions used in our intangible asset impairment testing and future events that could have a negative impact on the recoverability of our intangible assets.

Contingent Consideration Net Expense (Benefit)

To recognize changes in the fair value of our contingent consideration liability, we recorded net charges of $35 million in 2022 and net benefits of $136 million in 2021. In 2022, the net charges related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to our 2021 acquisition of Farapulse. This increase was partially offset by a reduction in the contingent consideration liability for certain acquisitions for which we reduced the probability of achievement of associated regulatory and commercialization-based milestones upon which payment is conditioned. In 2021, the net benefits related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&D program. Refer to Note B – Acquisitions and Strategic Investments to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional details related to our contingent consideration arrangements.

Restructuring and Restructuring-related Net Charges

On November 15, 2018, our Board of Directors approved, and we committed to, a global restructuring program (the 2019 Restructuring Plan). The 2019 Restructuring Plan was intended to support our effort to improve operating performance and meet anticipated market demands by ensuring that we were appropriately structured and resourced to deliver sustainable value to patients and customers. Key activities under the 2019 Restructuring Plan included supply chain network optimization intended to maximize our global manufacturing and distribution network capacity and building functional capabilities to support business growth. These activities were initiated in 2019 and substantially completed in 2022, following a one-year extension and expansion approved by our Board of Directors on February 22, 2021.

The following table provides a summary of cumulative pre-tax charges associated with the 2019 Restructuring Plan, by major type of cost, of which approximately $404 million resulted in cash outlays:
Type of Cost (in millions)
Total Amount Incurred
Restructuring charges:
Termination benefits$73
Other(1)
54
Restructuring-related expenses:
Transfer costs232
Other(2)
102
 $461
(1)    Consists primarily of consulting fees and costs associated with contractual cancellations.
(2)    Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.



We recorded restructuring charges pursuant to FASB ASC Topic 420, Exit or Disposal Cost Obligations related to the 2019 Restructuring Plan of $24 million in 2022, $38 million in 2021, and $32 million in 2020. In addition, we recorded restructuring-related charges within Cost of products sold, Selling, general and administrative expenses, and Research and development expenses of $86 million in 2022, $134 million in 2021, and $84 million in 2020 associated with activities under the 2019 Restructuring Plan.

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program. For additional information, refer to “2023 Restructuring Plan” under the heading Liquidity and Capital Resources below.





44

LOTUS Discontinuation

On November 17, 2020, we announced a global, voluntary recall of all unused inventory of our LOTUS Edge™ Aortic Valve System, and our decision to retire the entire LOTUS™ Valve platform. We recorded restructuring and restructuring-related net charges associated with the product discontinuation of $20 million in 2021 and $55 million in 2020. The restructuring activities were completed in 2021 and resulted in total pre-tax restructuring and restructuring-related net charges of approximately $75 million.

In addition, during 2020 we recorded $119 million of inventory charges within Cost of products sold and $8 million of Intangible asset impairment charges associated with the product discontinuation.

Litigation-related Net Charges (Credits)

We recorded litigation-related net charges of $173 million in 2022 and $430 million in 2021, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with the financial covenant required by our credit agreements. Refer to Note I – Commitments and Contingencies to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional discussion of our material legal proceedings

Interest Expense
The following table provides a summary of our Interest expense and average borrowing rate:
(in millions)Year Ended December 31,
202220212020
Interest expense$(470)$(341)$(361)
Weighted average borrowing rate5.0 %3.6 %3.6 %
Interest expense and our average borrowing rate increased in 2022, compared to the prior year, primarily due to $194 million of charges associated with the early extinguishment of $3.275 billion of certain of our senior notes, including payment of tender premiums and the acceleration of unamortized debt issuance costs. As of December 31, 2022, the weighted average borrowing rate associated with our outstanding senior notes was 2.6 percent. Refer to Liquidity and Capital Resources, as well as Note D – Hedging Activities and Fair Value Measurements and Note E – Contractual Obligations and Commitments to our consolidated financial statements contained in Item 8. of this Annual Report on Form 10-K for information regarding our debt obligations.
Other, net
The following are the components of Other, net:
 Year Ended December 31,
(in millions)202220212020
Interest income$10 $4 $3 
Net foreign currency gain (loss)(31)(27)(32)
Net gains (losses) on investments(1)250 383 
Other income (expense), net(16)(9)7 
 $(38)$218 $362 

In 2021, in connection with our acquisitions of Farapulse, Preventice and Devoro Medical, Inc. we remeasured the fair value of our previously-held interests in the acquired companies, which resulted in $475 million of gains recognized in Other, net. In addition, we recorded a loss of $178 million in 2021 and a gain of $363 million in 2020 on our investment in Pulmonx
45

Corporation (Pulmonx) presented in Other, net associated with the remeasurement of our investment to fair value based on observable market prices, as well as the disposition of our remaining ownership.

The gains on previously held interests are included within Acquisition/divestiture-related net charges (credits) and the Pulmonx net gain (loss) is included in Investment portfolio net losses (gains) presented in the reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Financial Summary for the reconciliation and Additional Information for a discussion of management's use of non-GAAP financial measures.

Tax Rate
The following table provides a summary of our reported tax rate:
Year Ended December 31,
 202220212020
Reported tax rate38.9 %3.3 %2.9 %
Impact of certain receipts/charges(1)
(19.1)%13.0 %8.3 %
19.8 %16.3 %11.2 %
(1)    These receipts/charges are taxed at different rates than our effective tax rate.

The change in our reported tax rate for 2022 compared to 2021, relates primarily to the jurisdictional mix of earnings and the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These receipts and charges include intangible asset impairment charges, acquisition/divestiture-related net charges, restructuring and restructuring-related net charges, litigation-related net charges, debt extinguishment net charges, as well as certain discrete tax items primarily related to restructuring activities, and tax windfall benefits associated with share-based payments.

In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91 million to release the reserves related to these years. We received a refund of $62 million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years.

On August 16, 2022, the Inflation Reduction Act of 2022 (Inflation Reduction Act) was enacted into law by the U.S. government and includes a new corporate alternative minimum tax of 15 percent on the adjusted financial statement income (AFSI) of corporations with average AFSI exceeding $1.0 billion over a three-year period. Additionally, the Inflation Reduction Act imposes a 1 percent excise tax on the fair market value of net corporate stock repurchases. These provisions are effective beginning in 2023.

See Note H – Income Taxes to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional details on our tax rate.
46


Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future. Please refer to Contractual Obligations and Commitments below for additional details on our future payment obligations and commitments.

As of December 31, 2022, we had $928 million of unrestricted Cash and cash equivalents on hand, comprised of $673 million invested in money market funds and time deposits and $256 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer.

In 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility or our commercial paper program as of December 31, 2022, resulting in an additional $2.220 billion of available liquidity. In anticipation of our purchase of a majority stake in Acotec Scientific Holdings Limited (Acotec), a Chinese medical technology company, which closed on February 20, 2023, we reserved approximately $530 million of our borrowing capacity under the 2021 Revolving Credit Facility in the fourth quarter of 2022 as proof of funds, as required by Hong Kong guidelines. We funded the acquisition using cash on hand and, as a result, have full borrowing capacity under the 2021 Revolving Credit Facility as of the date of filing of this Annual Report on Form 10-K.

For additional details related to our debt obligations, including our financial covenant requirement, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K, which is incorporated herein by reference.
The following provides a summary and description of our net cash inflows (outflows):
Year Ended December 31,
(in millions)202220212020
Cash provided by (used for) operating activities$1,526 $1,870 $1,508 
Cash provided by (used for) investing activities(2,011)(1,597)(411)
Cash provided by (used for) financing activities(548)(95)293 
Operating Activities
In 2022, cash provided by (used for) operating activities decreased $344 million compared to 2021. This decrease was primarily due to changes in working capital, including higher levels of inventory and accounts receivable. In 2021, cash provided by operating activities increased $362 million compared to 2020. This increase was primarily due to comparatively higher net sales and operating income compared to the prior year.

Cash provided by (used for) operating activities included litigation-related payments of $282 million in 2022, $441 million in 2021 and $420 million in 2020, related primarily to transvaginal mesh litigation.
Investing Activities
In 2022, cash provided by (used for) investing activities primarily included net cash payments of $1.542 billion for the acquisitions of Baylis Medical and Obsidio, Inc, as well as Purchases of property, plant and equipment and internal use software of $588 million partially offset by Proceeds from settlements of hedge contracts of $56 million and Proceeds from royalty rights of $70 million.
47

In 2021, cash provided by (used for) investing activities primarily included payments of $2.258 billion for the acquisitions of Preventice, Lumenis, Farapulse and Devoro and Purchases of property, plant and equipment and internal use software of $554 million, partially offset by proceeds of $826 million from the divestiture of the Specialty Pharmaceuticals business and net Proceeds from investments and acquisitions of certain technologies of $279 million primarily from the disposition of our shares in Pulmonx.
Financing Activities
During the second quarter of 2022, we completed a public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. For more information, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. Cash provided by (used for) financing activities in 2022 also included Payments of contingent consideration previously established in purchase accounting of $335 million as well as Payments on short-term borrowings of $250 million.
In 2021, cash provided by (used for) financing activities primarily included Payments for royalty rights of $85 million and Cash dividends paid on preferred stock of $55 million, partially offset by Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans of $110 million.
Our liquidity plans are subject to a number of risks and uncertainties, including those described in Item 1A. Risk Factors of this Annual Report on Form 10-K, some of which are outside our control. Macroeconomic conditions, adverse tax and litigation matter outcomes and other risks and uncertainties could limit our ability to successfully execute our business plans and adversely affect our liquidity plans.

Debt

The following table presents the current and long-term portions of our total debt:
 As of
(in millions)December 31, 2022December 31, 2021
Current debt obligations$20 $261 
Long-term debt8,915 $8,804 
Total debt$8,935 $9,065 

The following table presents the portions of our total debt that are comprised of fixed and variable rate debt instruments, which are presented on an amortized cost basis:
 As of
(in millions)December 31, 2022December 31, 2021
Fixed-rate debt instruments$8,910 $9,048 
Variable rate debt instruments25 17 
Total debt$8,935 $9,065 

As of December 31, 2022, we were in compliance with the financial covenant required by the credit facilities described above. For additional details related to our debt obligations, including our financial covenant requirements, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

48

Equity

During 2022 we received $136 million in proceeds from stock issuances related to our stock option and employee stock purchase plans, compared to $110 million in 2021. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of employees. Stock-based compensation expense related to our stock ownership plans was $220 million in 2022 and $194 million in 2021. Stock-based compensation expense varies from period to period based upon, among other factors, the timing, number and fair value of awards granted during the period, forfeiture levels related to unvested awards and employee contributions to our employee stock purchase plan, as well as the retirement eligibility of stock award recipients.

On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 or 2021, and had the full amount available under the authorization as of December 31, 2022. There were approximately 263 million shares in treasury as of December 31, 2022 and 2021.

Contractual Obligations and Commitments
(in millions)20232024202520262027ThereafterTotal
Debt obligations(1)
$— $504 $1,567 $255 $960 $5,700 $8,986 
Interest payments(2)
240 231 217 198 192 1,587 2,664 
Lease obligations80 66 55 43 34 214 492 
Purchase obligations(2)
755 119 71 35 19 21 1,021 
Legal reserves(3)
231 — — — — — 231 
One-time transition tax122 117 146 — — — 386 
$1,428 $1,037 $2,056 $531 $1,205 $7,522 $13,780 
(1) Debt obligations are comprised of our senior notes outstanding as of December 31, 2022. This does not include unamortized debt issuance discounts, deferred financing costs and gain on fair value hedges or finance lease obligations. Refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information.
(2) In accordance with U.S. GAAP, these obligations relate primarily to expenses associated with future periods and, with the exception of accrued interest, are not reflected in our consolidated balance sheet as of December 31, 2022. Interest payments included above are calculated based on rates and required fees applicable to our outstanding debt obligations as of December 31, 2022 described in Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K. Interest payments above do not include interest on variable rate debt instruments.
(3)    Timing of payment for our long-term liability for legal matters that are probable and estimable as of December 31, 2022 is uncertain and as such it is excluded from the table above. Refer to Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information.

The amounts in the table above with respect to purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business. The table above does not include:

•Any future obligations to make payments of contingent consideration pursuant to certain of our acquisition agreements, due to the exact amount and timing of payments being uncertain. Refer to Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,

•Unrecognized tax benefits, accrued interest and penalties and other related items because the timing of their future cash settlement is uncertain. Refer to Note H – Income Taxes to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,

•Acquired IPR&D projects that require future funding to complete. We estimate that the total remaining cost to complete acquired IPR&D projects is between $55 million and $65 million. Net cash inflows from the projects currently in development are expected to continue through 2039, following the respective launches of these technologies in the U.S. and Europe. Certain of our acquisitions also involve the potential payment of contingent
49

consideration, but the timing and amounts are uncertain. See Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information,

•Holders of our MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations,

•The definitive agreement, entered into on June 15, 2022, with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech) for approximately $230 million, which we are working towards closing during the second quarter of 2023, and the definitive agreement, entered into on November 29, 2022, to acquire 100 percent of the fully diluted equity of Apollo Endosurgery, Inc. for approximately $615 million, which is expected to close during the first half of 2023, subject to customary closing conditions. Additionally, on February 20, 2023, we completed the acquisition of a majority stake in Acotec for approximately $520 million using cash on hand. See Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for more information.

2023 Restructuring Plan

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). The 2023 Restructuring Plan is intended to meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value.

The 2023 Restructuring Plan will further build on our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and expand operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include optimizing certain functional capabilities to better support business growth and achieve cost synergies. These activities are expected to be initiated in the first quarter of 2023, and substantially completed by the end of 2025.

While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs.

The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in future cash outlays, and reduce gross annual pre-tax expenses by approximately $225 million to $275 million by the end of 2025 as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. The following table provides a summary of our estimates of total pre-tax charges associated with the 2023 Restructuring Plan by major type of cost:

Type of Cost (in millions)
Total Estimated Amount Expected to be Incurred
Restructuring charges:
Termination benefits(1)
$60-$80
Other(2)
40-60
Restructuring-related expenses:
Transfer costs250-280
Other(3)
100-130
 $450-$550
(1)    Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.
(2)    Consists primarily of consulting fees and costs associated with contractual cancellations.
(3)    Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.
50

Legal Matters

For a discussion of our material legal proceedings see Note I – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.

Critical Accounting Policies and Estimates
Our financial results are affected by the selection and application of accounting policies and methods. We have adopted accounting policies to prepare our consolidated financial statements in conformity with U.S. GAAP.
To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, including our contingent liabilities, as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting periods. Our actual results may differ from these estimates. We consider estimates to be critical (i) if we are required to make assumptions about material matters that are uncertain at the time of estimation or (ii) if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: Revenue Recognition, Inventory Provisions, Valuation of Intangible Assets and Contingent Consideration Liability, Goodwill Valuation, Legal and Product Liability Accruals and Income Taxes.
See Note A – Significant Accounting Policies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information related to our accounting policies and our consideration of these critical accounting areas.
Revenue Recognition

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. The use of alternative assumptions could impact the period over which revenue is recognized.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers and record these as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered.

51

Post-Implant Services

We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. We forward accrue the costs to provide these services at the time the devices are sold by estimating the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.
Inventory Provisions
We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.
Valuation of Intangible Assets and Contingent Consideration Liability
We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. Further, for those arrangements that involve potential future contingent consideration, we record on the date of acquisition a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. We re-measure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, useful life or probability of achieving clinical, regulatory or revenue-based milestones could result in different purchase price allocations and recognized amortization expense and contingent consideration expense or benefit in current and future periods.
We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or adjustment to the remaining useful life. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset is determined not recoverable, we will write the carrying value down to fair value in the period the impairment is identified. We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. The use of alternative assumptions, including estimated cash flows, discount rates and alternative estimated remaining useful lives could result in different calculations of impairment.
In addition, we test our indefinite-lived intangible assets at least annually for impairment and reassess their classification as indefinite-lived assets, or more frequently if indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350). If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to fair value. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates.
Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and
52

Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

In performing annual impairment assessments, when a quantitative test is performed, we typically use only the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We historically selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures the fair value of our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach.

In applying the income approach, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows.

Although we use consistent methodologies in developing the assumptions and estimates underlying the fair value calculations used in our impairment tests, these estimates are uncertain by nature and can vary from actual results. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates.

Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to, the following:

•decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, inclusive of those resulting from macroeconomic conditions, including inflationary pricing pressures and reductions in reimbursement levels,

•declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies and market and/or regulatory conditions that may cause significant launch delays or product actions,

•decreases in our forecasted profitability due to an inability to implement successfully and achieve timely and sustainable cost improvement measures consistent with our expectations,

•negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products,

•the level of success of ongoing and future research and development efforts, including those related to acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new products,

•the level of success in managing the growth of acquired companies, achieving sustained profitability consistent with our expectations, establishing government and third-party payer reimbursement, supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfully,

•changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses and

•increases in our market-participant risk-adjusted weighted average cost of capital and increases in our market-participant tax rate and/or changes in tax laws or macroeconomic conditions.

Negative changes in one or more of these factors, among others, could result in future impairment charges.

53

Legal and Product Liability Accruals

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. Litigation and product liability matters are inherently uncertain, and the outcomes of individual matters are difficult to predict and quantify. As such, significant judgment is required in determining our legal and product liability accruals. Our estimates related to our legal and product liability accruals may change as additional information becomes available to us, including information related to the nature or existence of claims against us, trial court or appellate proceedings, and mediation, arbitration or settlement proceedings.

Income Taxes

We establish reserves when we believe that certain positions are likely to be challenged despite our belief that our tax return positions are fully supportable. The calculation of our tax liabilities involves significant judgment based on individual facts, circumstances and information available in addition to applying complex tax regulations in various jurisdictions across our global operations. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must determine it is more likely than not the position will be sustained, and the measurement of the benefit is calculated as the largest amount that is more than 50 percent likely to be realized upon resolution of the benefit. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, results of operations, financial position and/or cash flows.

As part of the Tax Cut and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as a part of continuing operations.

New Accounting Pronouncements
Refer to Note P – New Accounting Pronouncements to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for additional information on standards implemented during 2022 and standards to be implemented in future periods.
Additional Information

Corporate Sustainability

Our sustainable environmental, social and governance practices underpin all aspects of our global business. Our approach is aligned with the United Nations Sustainable Development Goals and our material topics and practices are informed by a broad range of internal and external stakeholders – locally, nationally and globally. Our employees around the world work with suppliers and other organizations that share our commitment to these practices that help address issues related to health inequity, economic disparity, climate change and environmental protection. These efforts are supported by our cross-functional Corporate Social Responsibility Steering Committee, our Corporate Social Responsibility Council, our Environmental Health and Safety teams and policies, our Global Council for Inclusion, as well as our local, regional and national employee and community engagement programs. In addition, our Executive Committee performance is measured, among other things, against global gender and U.S. (inclusive of Puerto Rico) multicultural goals and performance against annual renewable electricity and carbon emissions goals.

We are also making measurable progress toward shaping a better future for our planet by proactively addressing energy consumption, carbon emissions and waste management. We have committed to a goal of carbon neutrality for Scope 1 and Scope 2 carbon emissions in our manufacturing and key distribution sites by 2030. Our Global Real Estate, Facilities, Environment, Health & Safety function is responsible for rigorously measuring, assessing and reporting progress toward these goals globally. We are focused on a “C3” strategy: Cutting energy use, Converting to renewable energy sources and Compensating with carbon offset projects where needed. Our Global Headquarters and U.S. distribution center in Massachusetts, and our manufacturing plants in Dorado, Puerto Rico and Coyol, Costa Rica all utilize solar energy from on-site installations. Our goal is to fully source or generate electricity from renewable sources by 2024, and by 2027, our goal is that 90
54

percent of all energy used across our manufacturing and key distribution sites, will be from renewable sources, representing an important milestone toward our 2030 carbon neutrality commitment.

In 2022, we obtained additional ISO 50001:2018 - Energy Management Systems certification for our manufacturing plants in Maple Grove and Arden Hills, Minnesota and in Dorado, Puerto Rico. This brings the total number of ISO 50001:2018 certified sites in our global network to twelve. We have also obtained ISO 14001:2015 - Environment Management Systems certification at our major manufacturing plants and Tier 1 distribution centers around the world, as well as our Global Headquarters. These are globally recognized standards for employee Energy and Environmental Management Systems, established by the International Standards Organization, which provides a voluntary framework to identify key energy and environmental aspects associated with our business. Using these management systems and the specific attributes of our certified locations, we continue to improve our energy and environmental performance. We also have 12 Leadership in Energy and Environmental Design (LEED) certified buildings on campuses in the U.S., Latin America, Europe and Asia. LEED is an internationally recognized certification program that seeks to ensure the mindful development, construction and maintenance of buildings in a way that benefits occupants and the environment by reducing waste and conserving resources.

Cybersecurity

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues, including those involving vulnerabilities introduced by our use of third-party software, are analyzed by subject matter experts and a crisis committee for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to our financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our escalation framework. In addition, we have established procedures to ensure that members of management responsible for overseeing the effectiveness of disclosure controls are informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made, as appropriate. 

International conflicts, including, but not limited to the Russia/Ukraine war and tension between China/Taiwan, have heightened cybersecurity risks on a global basis. While there is significant uncertainty around implications of cybersecurity attacks resulting from such conflicts, we have taken steps to better understand our readiness, including the resilience of our critical business functions, with the goal of reducing the impact if such an event were to occur.
Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share we exclude certain charges (credits) from GAAP net income and GAAP net income available to common stockholders, which include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."

The GAAP financial measure most directly comparable to adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) available to common stockholders and GAAP net income (loss) per common share - assuming dilution, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods.
55

To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Annual Report on Form 10-K.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) available to common stockholders adjusted net income (loss) per share, operational and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures as well as reasons for excluding each of these individual items. In each case, management has excluded the item for purposes of calculating the relevant non-GAAP financial measure to facilitate an evaluation of our current operating performance and a comparison to our past operating performance:

Adjusted Net Income (loss), Adjusted Net Income (loss) Available to Common Stockholders and Adjusted Net Income (loss) per Share

•Amortization expense - We record intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents at historical cost and amortize them over their estimated useful lives. Amortization expense is excluded from management's assessment of operating performance due to its non-cash nature and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•Goodwill and other intangible asset impairment charges - These amounts represent write-downs of certain goodwill and/or other intangible asset balances. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment and test our goodwill and other indefinite-lived intangible assets at least annually for impairment. If we determine the carrying value of the amortizable intangible asset is not recoverable, goodwill of a reporting unit is impaired or it is more likely than not that the indefinite-lived asset is impaired, we will write the carrying value down to fair value in the period identified. Impairment charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•Acquisition/divestiture-related net charges (credits) - These adjustments may consist of (a) contingent consideration fair value adjustments; (b) gains on previously held investments; (c) due diligence, deal fees and other fees and costs related to our acquisition and divestiture transactions; (d) inventory step-up amortization and accelerated compensation expense; (e) integration and exit costs; and (f) separation costs and gains or losses primarily associated with the sale of a business or portion of a business. The contingent consideration fair value adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration. Gains on previously held investments, due diligence, deal fees and other fees and costs, inventory step-up amortization, accelerated compensation expense, and other expenses and gains or losses associated with divestitures or acquisitions can be highly variable and not representative of ongoing operations. Integration, separation and exit costs, include contract cancellations, severance and other compensation-related charges and costs, project management fees and costs, and other direct costs associated with the integration of our acquisitions or separation of our divested businesses. These integration, separation and exit activities take place over a defined timeframe and have distinct project timelines, are incremental to activities and costs that arise in the ordinary course
56

of our business and are not considered part of our core, ongoing operations. These acquisition/divestiture-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring initiatives take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring initiatives typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, during the fourth quarter of 2020 and first half of 2021, we incurred restructuring and restructuring-related net charges associated with management’s decision to retire the LOTUS platform. These restructuring plans are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•Litigation-related net charges (credits) - These adjustments include certain significant product liability and other litigation-related charges and credits. We record these charges and credits, which we consider to be unusual or infrequent and significant, within the litigation-related charges line in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within selling general and administrative expenses. Certain litigation-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•EU MDR implementation costs - These adjustments represent certain incremental costs specific to complying with new regulatory requirements in the EU. EU MDR replaced the existing European Medical Devices Directive (MDD) regulatory framework, and manufacturers of medical devices were required to comply with EU MDR beginning in May 2021 for new product registrations and by May 2024 for medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). Updates to the legislative text of the EU MDR were adopted by the European Parliament and are currently being reviewed for adoption by the Council of the European Union, including an extension of the transitional period to 2027 for class IIb and III and 2028 for class I and IIa medical devices which have a valid CE Certificate to the prior Directives (issued before May 2021). We expect to incur significant expenditures in connection with the adoption of the EU MDR requirements and we consider the adoption of EU MDR to be a significant change to a regulatory framework, and therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters. As such, certain of these costs are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•Debt extinguishment net charges (credits) - These amounts relate to the early extinguishment of certain outstanding principal amounts of our senior notes. Certain debt extinguishment net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•Investment portfolio net losses (gains) - These amounts represent write-downs or fair value remeasurement gains and losses related to our investment portfolio. Each reporting period, we evaluate our investments without a readily determinable fair value to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value and determine if the impairment is other-than-temporary, and recognize an impairment loss. In addition, for those investments accounted for under the measurement alternative method of accounting, we record gains and losses to remeasure the carrying value of the investments to their fair values based on observable market prices or implied market values. Investment impairment charges and fair value remeasurements can be highly variable dependent on external market factors and conditions
57

relative to the underlying investee, which are generally outside of the control of management, as such these amounts are excluded from management's assessment of performance.

•Deferred tax expenses (benefits) - This adjustment relates to a significant non-cash tax benefit arising from an intra-entity asset transfer of intellectual property completed in the fourth quarter of 2019 which resulted in our recording a $4.102 billion net deferred tax asset. The deferred tax benefit associated with the establishment of the net deferred tax asset as well as any deferred tax expense resulting from the reversal of the deferred tax asset are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•Discrete tax items - These items represent adjustments of certain tax positions including those which a) are related to the finalization of the enactment date impact of the TCJA, or b) are related to the tax consequences of a non-GAAP adjustment item booked in a prior period. These discrete tax items are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

Operational Net Sales

•The impact of foreign currency fluctuations is highly variable and difficult to predict. Accordingly, management excludes the impact of foreign currency fluctuations for purposes of reviewing net sales and growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Organic Net Sales

•Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.

Rule 10b5-1 Trading Plans by Executive Officers

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units. These plans are entered into at a time when the person is not in possession of material non-public information about our company. We disclose details regarding individual Rule 10b5-1 Trading Plans on the Investor Relations section of our website.

58

Management’s Annual Report on Internal Control over Financial Reporting
As the management of Boston Scientific Corporation, we are responsible for establishing and maintaining adequate internal control over financial reporting. We designed our internal control process to provide reasonable assurance to management and the Board of Directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
We assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control–Integrated Framework (2013 framework). Based on our assessment, we believe that, as of December 31, 2022, our internal control over financial reporting is effective at a reasonable assurance level based on these criteria.

In accordance with the SEC Staff 's interpretive guidance for newly acquired businesses, we are permitted to omit an assessment of an acquired business's internal control over financial reporting from our assessment of internal control for up to one year from the acquisition date. As such, we have excluded Baylis Medical Company Inc., acquired on February 14, 2022, from our annual assessment of internal controls over financial reporting as of December 31, 2022. This business represented less than one percent of total assets as of December 31, 2022 and approximately one percent of net sales for the year then ended.

Ernst & Young LLP, an independent registered public accounting firm, has issued an audit report on the effectiveness of our internal control over financial reporting. This report, in which they expressed an unqualified opinion, is included below.
 /s/ Michael F. Mahoney /s/ Daniel J. Brennan 
    
 Michael F. Mahoney  Daniel J. Brennan 
 Chief Executive Officer  Executive Vice President and Chief
Financial Officer		 

59


Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Boston Scientific Corporation

Opinion on Internal Control Over Financial Reporting

We have audited Boston Scientific Corporation’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Boston Scientific Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.

As indicated in the accompanying Management’s Annual Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Baylis Medical Company Inc., which is included in the 2022 consolidated financial statements of the Company and constituted less than 1% of total assets as of December 31, 2022 and approximately 1% of revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Baylis Medical Company Inc.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2022 consolidated financial statements of the Company and our report dated February 23, 2023 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
60

/s/ Ernst & Young LLP
Boston, Massachusetts
February 23, 2023
61


ITEM 7A.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.

Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily manufacturing operations outside the U.S.) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $7.324 billion as of December 31, 2022 and $8.381 billion as of December 31, 2021. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $208 million as of December 31, 2022 compared to $298 million as of December 31, 2021. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $254 million as of December 31, 2022 compared to $364 million as of December 31, 2021. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impact on our earnings.

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of December 31, 2022 and December 31, 2021. As of December 31, 2022, $8.986 billion in aggregate principal amount of our outstanding debt obligations were at fixed interest rates, representing approximately 100 percent of our total debt, on an amortized cost basis. As of December 31, 2022, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

See Note D – Hedging Activities and Fair Value Measurements to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K for further information regarding our derivative financial instruments.
62


Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of
Boston Scientific Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Boston Scientific Corporation (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 23, 2023 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
63


Description of the Matter
Business Combinations
As disclosed in Note B to the consolidated financial statements, during 2022, the Company completed the acquisition of Baylis Medical Company Inc. for a purchase price of $1.46 billion, net of cash acquired. The transaction was accounted for as a business combination.

Auditing the Company’s accounting for the acquisition was complex due to the significant estimation required by management to determine the fair value of identified intangible assets, which totaled $657 million and principally consisted of developed technology. A significant emphasis is placed on the appropriateness of the estimates used by management to determine the fair value of acquired intangible assets due to the sensitivity of the respective fair values to the underlying assumptions. The Company used an income approach to measure the technology-related intangible assets. The significant assumptions used to estimate the value of the intangible assets included discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates, estimates of technological obsolescence, operating profit margin and market participant synergies. These significant assumptions are forward looking and could be affected by future economic and market conditions.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the Company’s accounting for acquisitions. For example, we tested controls over the identification and valuation of intangible assets, including the valuation models and underlying assumptions used to develop such estimates. We read the purchase agreement, evaluated the significant assumptions and methods used in developing the fair value estimates, and tested the recognition of (1) the tangible assets acquired and liabilities assumed at fair value; (2) the identifiable intangible assets acquired at fair value; and (3) goodwill measured as a residual.

To test the estimated fair value of the intangible assets, we performed audit procedures that included, among others, evaluating the Company's use of the income approach and testing the significant assumptions used in the model, as described above. We evaluated the completeness and accuracy of the underlying data used in the analyses. For example, we compared the significant assumptions to current industry, market and economic trends, to the assumptions used to value similar assets in other acquisitions, to the historical results of the acquired business and to other guideline companies within the same industry. We involved our valuation professionals to assist with our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates.




/s/ Ernst & Young LLP
We have served as the Company’s auditor since 1992.

Boston, Massachusetts
February 23, 2023

64

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended December 31,
(in millions, except per share data)202220212020
Net sales$12,682 $11,888 $9,913 
Cost of products sold3,956 3,711 3,465 
Gross profit8,727 8,177 6,448 
Operating expenses:
Selling, general and administrative expenses4,520 4,359 3,787 
Research and development expenses1,323 1,204 1,143 
Royalty expense47 49 45 
Amortization expense803 741 789 
Goodwill impairment charges— — 73 
Intangible asset impairment charges132 370 460 
Contingent consideration net expense (benefit)35 (136)(100)
Restructuring net charges (credits)24 40 52 
Litigation-related net charges (credits)173 430 278 
Loss (gain) on disposal of businesses and assets22 (78)— 
 7,078 6,978 6,528 
Operating income (loss) 1,649 1,199 (80)
Other income (expense):
Interest expense(470)(341)(361)
Other, net(38)218 362 
Income (loss) before income taxes1,141 1,076 (79)
Income tax expense (benefit)443 36 2 
Net income (loss)698 1,041 (82)
Preferred stock dividends(55)(55)(33)
Net income (loss) available to common stockholders$642 $985 $(115)
Net income (loss) per common share — basic$0.45 $0.69 $(0.08)
Net income (loss) per common share — assuming dilution$0.45 $0.69 $(0.08)
Weighted-average shares outstanding
Basic1,430.5 1,422.3 1,416.7 
Assuming dilution1,439.7 1,433.8 1,416.7 










See notes to the consolidated financial statements.
65

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Year Ended December 31,
(in millions)202220212020
Net income (loss)$698 $1,041 $(82)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment(94)(125)76 
Net change in derivative financial instruments63 170 (137)
Net change in defined benefit pensions and other items37 11 (1)
Total other comprehensive income (loss)6 56 (63)
Total comprehensive income (loss)$704 $1,096 $(145)






















































See notes to the consolidated financial statements.
66

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
 As of December 31,
(in millions, except share and per share data)20222021
ASSETS  
Current assets:  
Cash and cash equivalents$928 $1,925 
Trade accounts receivable, net1,970 1,778 
Inventories1,867 1,610 
Prepaid income taxes264 205 
Other current assets731 799 
Total current assets5,760 6,317 
Property, plant and equipment, net2,446 2,252 
Goodwill12,920 11,988 
Other intangible assets, net5,902 6,121 
Deferred tax assets3,942 4,142 
Other long-term assets1,500 1,410 
TOTAL ASSETS$32,469 $32,229 
LIABILITIES AND STOCKHOLDERS’ EQUITY 
Current liabilities: 
Current debt obligations$20 $261 
Accounts payable862 794 
Accrued expenses2,160 2,436 
Other current liabilities761 783 
Total current liabilities3,803 4,274 
Long-term debt8,915 8,804 
Deferred tax liabilities144 310 
Other long-term liabilities2,035 2,220 
Commitments and contingencies
Stockholders’ equity: 
Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021
— — 
Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021
17 17 
Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021
(2,251)(2,251)
Additional paid-in capital20,289 19,986 
Accumulated deficit(750)(1,392)
Accumulated other comprehensive income (loss), net of tax:269 263 
Total stockholders’ equity17,573 16,622 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$32,469 $32,229 

See notes to the consolidated financial statements.
67

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY


Year Ended December 31,
(in millions, except share data)202220212020
Preferred stock shares outstanding
   Beginning10,062,500 10,062,500 — 
Preferred stock issuance— — 10,062,500 
   Ending10,062,500 10,062,500 10,062,500 
Common stock shares outstanding
   Beginning1,688,810,052 1,679,911,918 1,642,488,911 
Common stock issuance— — 29,382,500 
Stock-based compensation7,823,941 8,898,134 8,040,507 
   Ending1,696,633,993 1,688,810,052 1,679,911,918 
Preferred stock
   Beginning$— $— $— 
Preferred stock issuance— — — 
   Ending— $— — 
Common stock
   Beginning$17 $17 $16 
Common stock issuance— — — 
Stock-based compensation— — — 
   Ending$17 $17 $17 
Treasury Stock
Beginning$(2,251)$(2,251)$(1,717)
Repurchase of common stock— — (535)
Ending$(2,251)$(2,251)$(2,251)
Additional Paid-In Capital
Beginning$19,986 $19,732 $17,561 
Preferred stock issuance— — 975 
Common stock issuance— — 975 
Stock-based compensation303 254 221 
Ending$20,289 $19,986 $19,732 
Accumulated Deficit
Beginning$(1,392)$(2,378)$(2,253)
Net income (loss)698 1,041 (82)
Cumulative effect adjustment for adoption of ASU 2016-13— — (10)
Preferred stock dividends(55)(55)(33)
Ending$(750)$(1,392)$(2,378)
Accumulated Other Comprehensive Income (Loss), Net of Tax
Beginning$263 $207 $270 
Changes in other comprehensive income (loss), net of tax:
Foreign currency translation adjustment(94)(125)76 
Derivative financial instruments63 170 (137)
Defined benefit pensions and other items37 11 (1)
Ending$269 $263 $207 
Total stockholders' equity$17,573 $16,622 $15,326 

See notes to the consolidated financial statements.
68

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(in millions)202220212020
Net income (loss) $698 $1,041 $(82)
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Loss (gain) on disposal of businesses and assets22 (78)— 
Depreciation and amortization1,136 1,093 1,123 
Deferred and prepaid income taxes(63)(124)(82)
Stock-based compensation expense220 194 170 
Goodwill and other intangible asset impairment charges132 370 533 
Net loss (gain) on investments and notes receivable1 (250)(333)
Contingent consideration net expense (benefit)35 (136)(100)
Inventory step-up amortization32 34 58 
Debt extinguishment costs194 — — 
Other, net125 78 244 
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable(220)(279)335 
Inventories(321)(346)(65)
Other assets(209)(134)(265)
Accounts payable, accrued expenses and other liabilities(255)408 (28)
Cash provided by (used for) operating activities1,526 1,870 1,508 
Purchases of property, plant and equipment and internal use software(588)(554)(376)
Proceeds from sale of property, plant and equipment12 14 12 
Payments for acquisitions of businesses, net of cash acquired(1,542)(2,258)(3)
Proceeds from (payments for) investments and acquisitions of certain technologies(24)279 (146)
Proceeds from disposal of certain businesses and assets5 826 15 
Proceeds from royalty rights70 82 87 
Proceeds from (payments for) settlements of hedge contracts56 15 — 
Cash provided by (used for) investing activities(2,011)(1,597)(411)
Payment of contingent consideration previously established in purchase accounting(335)(15)(49)
Payments for royalty rights(75)(85)(97)
Payments on short-term borrowings(250)— (2,950)
Proceeds from short-term borrowings, net of debt issuance costs— — 2,245 
Net increase (decrease) in commercial paper(1)— (714)
Payments on borrowings from credit facilities— — (1,919)
Proceeds from borrowings on credit facilities— — 1,916 
Payments on long-term borrowings and debt extinguishment costs(3,184)— (1,260)
Proceeds from long-term borrowings, net of debt issuance costs3,270 — 1,683 
Cash dividends paid on preferred stock(55)(55)(28)
Net proceeds from issuance of preferred stock in connection with public offering— — 975 
Net proceeds from issuance of common stock in connection with public offering— — 975 
Payments for repurchase of common stock— — (535)
Cash used to net share settle employee equity awards(53)(50)(59)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans136 110 111 
Cash provided by (used for) financing activities(548)(95)293 
Effect of foreign exchange rates on cash(9)(6)(2)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents(1,042)173 1,388 
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period2,168 1,995 607 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,126 $2,168 $1,995 

See notes to the consolidated financial statements.
69

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (SUPPLEMENTAL INFORMATION)
Year Ended December 31,
(in millions)202220212020
Supplemental Information
Cash (received) paid for income taxes, net$662 $302 $207 
Cash paid for interest450 338 359 
Fair value of contingent consideration recorded in purchase accounting— 440 — 
Non-cash impact of transferred royalty rights(70)(82)(87)
(in millions)As of December 31,
Reconciliation to amounts within the consolidated balance sheets:202220212020
Cash and cash equivalents$928 $1,925 $1,734 
Restricted cash and restricted cash equivalents included in Other current assets
149 188 208 
Restricted cash equivalents included in Other long-term assets
48 55 52 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,126 $2,168 $1,995 









































See notes to the consolidated financial statements.
70

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE A – SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments, Note I – Commitments and Contingencies and Note J – Stockholders' Equity.

Accounting Estimates

To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.

Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the
71

customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents

Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in Other long-term assets within our consolidated balance sheets are related to deferred compensation plans.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.

We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses is adequate as of December 31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.
 
Revenue Recognition

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers:

•We have a contract with a customer that creates enforceable rights and obligations,
•Promised products or services are identified,
•The transaction price, or the amount we expect to receive, is determinable and
•We have transferred control of the promised items to the customer.

72

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Post-Implant Services

We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.

Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a
73

liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.

Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.

We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.

Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.

Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.

Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.

Indefinite-lived Intangibles and IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological
74

feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.

For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.

Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.

For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.
75

Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and Other, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

Investments in Publicly Traded and Privately-Held Entities

For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value.

Net gains and losses and impairments associated with our investment portfolio are included within Other, net in our consolidated statements of operations.

Income Taxes

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We
76

recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.

Legal and Product Liability Costs

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.

Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations. We record such costs into expense over the employee’s future service period, if any.

Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within Restructuring net charges (credits) in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within Costs of products sold, Selling, general and administrative expenses and Research and development expenses within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within Costs of products sold or Selling, general and administrative expenses in our consolidated statements of operations.

Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar.

Foreign currency transaction gains and losses are included within Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.

77

Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.

Research and Development

We expense research and development (R&D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles and IPR&D above for our policy regarding R&D projects acquired in connection with our business combinations and asset purchases.


NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.

On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urological procedures. The agreement, whereby we will purchase approximately 64 percent of the outstanding shares of M.I. Tech, consists of an upfront purchase price of KRW 291.2 billion or approximately $230 million at foreign currency exchange rates locked into at the time of the agreement via forward currency contracts. We are working towards closing the acquisition during the second quarter of 2023, subject to customary regulatory approvals. The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will provide physicians with more treatment options to meet specific patient needs.

On November 29, 2022, we announced our entry into a definitive agreement to acquire 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement provides for an upfront cash payment of $10.00 per share, approximately $615 million, and is expected to close during the first half of 2023, subject to customary closing conditions. The Apollo business will be integrated into our Endoscopy division.

On February 20, 2023, we completed the acquisition of a majority stake in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or approximately $520 million at foreign currency exchange rates as of closing using cash on hand. The Acotec portfolio complements our existing Peripheral Interventions portfolio and will strengthen our presence in China.

2022 Acquisition

On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.
78


Purchase Price Allocation

The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 

The final purchase price allocation was comprised of the following components:
(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:
Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

2021 Acquisitions

On March 1, 2021, we completed our acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company with a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and an additional revenue-based milestone payment of $216 million made during the second quarter of 2022. The Preventice business is being managed by our Cardiology division.

79

On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, up to $92 million in additional clinical and regulatory milestone payments, as well as future revenue-based payments. We have made combined milestone and revenue based payments of $114 million to date. The Farapulse business is being integrated into our Cardiology division.

On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that has developed and commercialized energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired. The Lumenis business is being integrated into our Urology division.

On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately-held company which has developed the WOLF Thrombectomy® Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division.

Purchase Price Allocation

The final purchase price for the acquisitions completed during 2021 were comprised of the components presented below, which represents the determination of the fair value of identifiable assets acquired and liabilities assumed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations.

(in millions)PreventiceLumenisAll OtherTotal
Payment for acquisition, net of cash acquired$706 $1,032 $519 $2,258 
Fair value of contingent consideration221 — 218 440 
Fair value of prior interest269 — 287 556 
$1,197 $1,032 $1,025 $3,254 

The final purchase price allocation for these acquisitions was comprised of the following components:
(in millions)PreventiceLumenisAll OtherTotal
Goodwill$926 $534 $594 $2,053 
Amortizable intangible assets237 423 465 1,125 
Indefinite-lived intangible assets— 69 43 112 
Other assets acquired65 297 9 372 
Liabilities assumed(32)(282)(11)(325)
Net deferred tax liabilities— (9)(75)(84)
$1,197 $1,032 $1,025 $3,254 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.

80

In 2022, we recorded certain measurement period adjustments primarily related to our prior year acquisition of the surgical business of Lumenis. We recorded an accrued income tax liability within Other non-current liabilities within our consolidated balance sheet of $183 million related to uncertain tax positions assumed in connection with the acquisition. We expect to be indemnified for the majority of such tax obligations and we recognized a corresponding indemnification asset of $177 million within Other non-current assets within our consolidated balance sheets. Interest and penalties accrued on the tax liability are being recorded within Income tax expense (benefit) and corresponding adjustments to the indemnification asset are being recorded in Other, net within our accompanying consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note Note G – Supplemental Balance Sheet Information for further details regarding our indemnification asset.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:
Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Preventice:
Amortizable intangible assets:
Technology-related$215 910%
Other intangible assets22 810%
$237 
Lumenis:
Amortizable intangible assets:
Technology-related$388 1211%
Other intangible assets35 1111%
Indefinite-lived intangible assets:
IPR&D69 N/A12%
$492 
All Other:
Amortizable intangible assets:
Technology-related$465 1216%-17%
Indefinite-lived intangible assets:
IPR&D43 N/A17%
$508 

2021 Divestiture

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of five facilities and approximately 280 employees globally.

In 2020, we recorded Goodwill impairment charges of $73 million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020.



81

Contingent Consideration

Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
Balance as of December 31, 2020$196 
Amount recorded related to current year acquisitions440 
Contingent consideration net expense (benefit)(136)
Contingent consideration payments(15)
Balance as of December 31, 2021$486 
Contingent consideration net expense (benefit)35 
Contingent consideration payments(371)
Balance as of December 31, 2022$149 

The payments made during 2022 were primarily related to our 2021 acquisitions of Farapulse and Preventice. As of December 31, 2022, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $417 million. The net expense of $35 million recorded in 2022 related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to Farapulse. The net benefit of $136 million recorded in 2021 related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&D program. Refer to Note C – Goodwill and Other Intangible Assets for further details.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of December 31, 2022Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$13 millionDiscounted Cash FlowDiscount Rate1%-2%2%
Probability of Payment10%-25%22%
Projected Year of Payment2023-20252024
Revenue-based Payments$136 millionDiscounted Cash FlowDiscount Rate6 %-14%7%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to our R&D, regulatory and commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2022.

82

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:
As of December 31,
(in millions)20222021
Equity method investments$188 $259 
Measurement alternative investments(1)
216 142 
Publicly-held securities(2)
2 10 
Notes receivable1 — 
$407 $412 
(1)    Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations.
(2)    Publicly-held equity securities are measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations.

These investments are classified as Other long-term assets within our consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

In 2021, we recorded a $178 million loss on our investment in Pulmonx Corporation presented in Other, net associated with the remeasurement of our investment during the period to fair value based on observable market prices, as well as the disposition of our remaining ownership. As of December 31, 2022, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $232 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
 As of December 31, 2022As of December 31, 2021
(in millions)Gross Carrying AmountAccumulated
Amortization/
Write-offs		Gross Carrying AmountAccumulated
Amortization/
Write-offs
Technology-related$12,397 $(7,378)$11,957 $(6,754)
Patents486 (394)494 (398)
Other intangible assets1,960 (1,400)1,900 (1,325)
Amortizable intangible assets$14,843 $(9,173)$14,351 $(8,476)
Goodwill$22,820 $(9,900)$21,888 $(9,900)
IPR&D112 126 
Technology-related120 120 
Indefinite-lived intangible assets$232 $246 

The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of Baylis Medical completed in the first quarter of 2022.

Intangible asset impairment charges were $132 million in 2022, $370 million in 2021 and $460 million in 2020. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management’s decision
83

to discontinue commercialization of the VICI VENOUS STENT™ System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&D program due to the incremental time and cost required to complete the program and bring the technology to market. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management’s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.

The following represents our goodwill balance by reportable segment.
(in millions)MedSurgCardiovascularTotal
Balance as of December 31, 2020$3,707 $6,243 $9,951 
Goodwill acquired544 1,520 2,064 
Foreign currency fluctuations and other changes(5)(21)(27)
Balance as of December 31, 2021$4,246 $7,741 $11,988 
Goodwill acquired— 1,030 1,030 
Foreign currency fluctuations and other changes(10)(88)(98)
Balance as of December 31, 2022$4,237 $8,684 $12,920 

In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing.

In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.

Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing.

Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2022 is as follows (in millions):
Fiscal Year
2023$781 
2024741 
2025683 
2026665 
2027625 

These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December 31, 2022.
84


NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; net investments in certain subsidiaries; and, during 2022 prior to our acquisition of M.I. Tech, the purchase price of M.I. Tech, which was denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within AOCI to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense in our consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December 31, 2022 and 2021, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in
85

2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net in our consolidated statements of operations.

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the KRW denominated purchase price of M.I. Tech. As of December 31, 2022, we had entered into $228 million in aggregate notional amount of these contracts.

Interest Rate Hedging Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2022 and December 31, 2021.

In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within AOCI was a $8 million loss as of December 31, 2022 and a $24 million loss as of December 31, 2021.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2022 and December 31, 2021. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of December 31,
20222021
Forward currency contractsCash flow hedge$2,725 $3,996 
Forward currency contractsNet investment hedge365 493 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated4,235 3,892 
Total Notional Outstanding$8,321 $9,378 
(1)    Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.

The remaining time to maturity as of December 31, 2022 is within 48 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature within the next year. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

86

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Year Ended December 31, 2022
Forward currency contracts
Cash flow hedges$276 $(62)$214 Cost of products sold$3,956 $(209)$47 $(162)
Net investment hedges(2)
41 (10)32 Interest expense470 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
61 (14)47 Other, net38 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense470 16 (4)13 
Year Ended December 31, 2021
Forward currency contracts
Cash flow hedges$268 $(60)$208 Cost of products sold$3,711 $(54)$12 $(42)
Net investment hedges(2)
56 (13)43 Interest expense341 (13)3 (10)
Foreign currency-denominated debt
Net investment hedges(3)
82 (19)64 Other, net(218)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense341 5 (1)4 
Year Ended December 31, 2020
Forward currency contracts
Cash flow hedges$(99)$22 $(77)Cost of products sold$3,465 $(83)$19 $(64)
Net investment hedges(2)
(37)8 (29)Interest expense361 (24)5 (19)
Foreign currency-denominated debt
Net investment hedges(3)
(89)21 (68)Other, net(362)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense361 5 (1)4 
(1)    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2)    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3)    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.

87

As of December 31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging InstrumentFASB ASC Topic 815 DesignationLocation on Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contractsCash flow hedgeCost of products sold$223 
Forward currency contractsNet investment hedgeInterest expense10 
Interest rate derivative contractsCash flow hedgeInterest expense(3)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)Location on Consolidated Statements of OperationsYear Ended December 31,
202220212020
Net gain (loss) on currency hedge contractsOther, net$(53)$(16)$73 
Net gain (loss) on currency transaction exposuresOther, net21 (12)(105)
Net currency exchange gain (loss)$(31)$(27)$(32)


88

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
Location on Consolidated Balance Sheets(1)
As of December 31,
20222021
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$196 $183 
Forward currency contractsOther long-term assets149 169 
  345 352 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets36 42 
Total Derivative and Nonderivative Assets $381 $394 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$— $32 
Forward currency contractsOther long-term liabilities1 6 
Foreign currency-denominated debt(2)
Other long-term liabilities952 1,011 
  953 1,049 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities52 22 
Total Derivative and Nonderivative Liabilities$1,005 $1,071 
(1)We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2)Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
89

Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 December 31, 2022December 31, 2021
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$673 $— $— $673 $1,632 $— $— $1,632 
Publicly-held securities2 — — 2 10 — — 10 
Hedging instruments— 381 — 381 — 394 — 394 
Licensing arrangements— — 127 127 — — 246 246 
 $674 $381 $127 $1,182 $1,642 $394 $246 $2,282 
Liabilities        
Hedging instruments$— $1,005 $— $1,005 $— $1,071 $— $1,071 
Contingent consideration liability— — 149 149 — — 486 486 
Licensing arrangements— — 159 159 — — 281 281 
 $— $1,005 $308 $1,313 $— $1,071 $767 $1,838 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $673 million invested in money market funds and time deposits as of December 31, 2022 and $1.632 billion as of December 31, 2021, we held $256 million in interest-bearing and non-interest-bearing bank accounts as of December 31, 2022 and $293 million as of December 31, 2021.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We own the contractual right to receive 50 percent of the future Zytiga™ Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these instruments. Royalty payments we receive reduce the fair value of the financial asset and are presented within Proceeds from royalty rights, and payments we remit to inventors reduce the fair value of the financial liability and are presented within Payments for royalty rights within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, Transfers and Servicing. Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as Non-cash impact of transferred royalty rights in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.

We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2022. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement.

90

The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2022 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of December 31, 2022Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Financial Asset$127 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2023-20252024
Financial Liability$159 millionDiscounted Cash FlowDiscount Rate12%-15%13%
Projected Year of Payment2023-20262024
(1)    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2020$365 
Proceeds from royalty rights(163)
Fair value adjustment (expense) benefit44 
Balance as of December 31, 2021$246 
Proceeds from royalty rights(141)
Fair value adjustment (expense) benefit22 
Balance as of December 31, 2022$127 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2020$407 
Payments for royalty rights(166)
Fair value adjustment expense (benefit)41 
Balance as of December 31, 2021$281 
Payments for royalty rights(145)
Fair value adjustment expense (benefit)23 
Balance as of December 31, 2022$159 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations was $8.203 billion as of December 31, 2022 and $10.196 billion as of December 31, 2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
91


NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $8.935 billion as of December 31, 2022 and $9.065 billion as of December 31, 2021, with current maturities of $20 million as of December 31, 2022 and $261 million as of December 31, 2021. The debt maturity schedule for our long-term debt obligations is presented below:
Issuance DateMaturity DateAs of December 31,
Coupon Rate(1)
(in millions, except interest rates)20222021
October 2023 Senior Notes(4)
August 2013October 2023$— $244 4.125%
March 2024 Notes(4)
February 2019March 2024504 850 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,067 — 0.750%
May 2025 Senior Notes(4)
May 2015May 2025— 523 3.850%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior Notes(4)
February 2019March 2026255 850 3.750%
December 2027 Senior Notes(3)
November 2019December 2027960 1,021 0.625%
March 2028 Senior Notes(3)
March 2022March 2028800 — 1.375%
March 2028 Senior Notes(4)
February 2018March 2028344 434 4.000%
March 2029 Senior Notes(4)
February 2019March 2029272 850 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031800 — 1.625%
March 2034 Senior Notes(3)
March 2022March 2034534 — 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.750%
March 2039 Senior Notes(4)
February 2019March 2039450 750 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior Notes(4)
February 2019March 2049650 1,000 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2023 - 2049(76)(76)
Unamortized Gain on Fair Value Hedges2022— 3 
Finance Lease ObligationVarious5 6 
Long-term debt $8,915 $8,804 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)    Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2)    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2022 and 2021, respectively.
(4)    Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within Current Debt Obligations within our consolidated balance sheets as of December 31, 2021.
92


Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:

Fiscal Year
2023$— 
2024504 
20251,567 
2026255 
2027960 
Thereafter5,700 

Revolving Credit Facility

On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility as of December 31, 2022 or December 31, 2021.

Financial Covenant

As of December 31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
 Covenant Requirement
as of December 31, 2022		 Actual
as of December 31, 2022
Maximum permitted leverage ratio(1)
3.75 times 2.57 times
(1) Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions due to our funding of these acquisitions using cash on hand.

The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2022, we had $265 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $1.455 billion in the aggregate. As of December 31, 2022, we had $866 million of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

93

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2022 and 2021.

Senior Notes

We had senior notes outstanding of $8.986 billion as of December 31, 2022 and $9.121 billion as of December 31, 2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in Interest expense within our consolidated statements of operations.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):

As of December 31, 2022As of December 31, 2021
Factoring ArrangementsAmount
De-recognized		Weighted Average Interest RateAmount
De-recognized		Weighted Average Interest Rate
Euro denominated$161 2.4 %$141 2.1 %
Yen denominated194 0.6 %223 0.6 %
Renminbi denominated13 3.1 %11 3.2 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $135 million as of December 31, 2022 and $134 million as of December 31, 2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2022 and December 31, 2021, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.

94

Future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were as of December 31, 2022 (in millions):
Fiscal YearUnrecorded Purchase Obligations
2023$755 
2024119 
202571 
202635 
202719 
Thereafter21 
 $1,021 


NOTE F – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, Leases, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 54 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

Our operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Refer to Note E – Contractual Obligations and Commitments for information regarding our finance leases. The following table presents supplemental balance sheet information related to our operating leases:
As of December 31,
(in millions)20222021
Assets
Operating lease right-of-use assets in Other long-term assets
$386 $435 
Liabilities
Operating lease liabilities in Other current liabilities
61 71 
Operating lease liabilities in Other long-term liabilities
347 389 

95

The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
As of December 31,
20222021
Weighted average remaining lease term10 years10 years
Weighted average discount rate3.3%2.6%

Our operating lease cost under FASB ASC Topic 842 was $91 million in 2022, $90 million in 2021 and $92 million in 2020.

The following table presents supplemental cash flow information related to our operating leases:
Year Ended December 31,
(in millions)20222021
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows from operating leases$91 $87 

Right-of-use assets obtained in exchange for operating lease obligations were $43 million and $68 million for the years ended December 31, 2022 and 2021.

The following table presents the maturities of our operating lease liabilities as of December 31, 2022 (in millions):
Fiscal yearOperating Leases
2023$80 
202466 
202555 
202643 
202734 
Thereafter214 
Total future minimum operating lease payments492 
Less: imputed interest(84)
Present value of operating lease liabilities$408 
96


NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying consolidated balance sheets are as follows:
Trade accounts receivable, net
 As of December 31,
(in millions)20222021
Trade accounts receivable$2,079 $1,886 
Allowance for credit losses(109)(108)
 $1,970 $1,778 

The following is a rollforward of our Allowance for credit losses:
Year Ended December 31,
(in millions)202220212020
Beginning balance$108 $105 $74 
Cumulative effect adjustment for adoption of ASU 2016-13n/an/a10 
Credit loss expense35 28 49 
Write-offs(35)(25)(27)
Ending balance$109 $108 $105 
Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset’s contractual life.

Inventories
 As of December 31,
(in millions)20222021
Finished goods$1,171 $1,029 
Work-in-process147 128 
Raw materials548 452 
 $1,867 $1,610 

Approximately 27 percent of our finished goods inventory as of December 31, 2022 and approximately 30 percent as of December 31, 2021 was at customer locations pursuant to consignment arrangements or held by sales representatives.

Other current assets
 As of December 31,
(in millions)20222021
Restricted cash and restricted cash equivalents$149 $188 
Derivative assets232 226 
Licensing arrangements60 132 
Other290 254 
 $731 $799 

97

Property, plant and equipment, net
 As of December 31,
(in millions)20222021
Land$137 $109 
Buildings and improvements1,695 1,523 
Equipment, furniture and fixtures3,297 3,287 
Capital in progress598 605 
 5,728 5,525 
Less: accumulated depreciation3,282 3,273 
 $2,446 $2,252 

Depreciation expense was $333 million in 2022, $352 million in 2021 and $333 million in 2020.

Other long-term assets
 As of December 31,
(in millions)20222021
Restricted cash equivalents$48 $55 
Operating lease right-of-use assets386 435 
Derivative assets149 169 
Investments407 412 
Licensing arrangements67 114 
Indemnification asset172 — 
Other271 225 
 $1,500 $1,410 

Accrued expenses
 As of December 31,
(in millions)20222021
Legal reserves$231 $264 
Payroll and related liabilities830 848 
Rebates352 350 
Contingent consideration74 289 
Other674 686 
 $2,160 $2,436 

98

Other current liabilities
 As of December 31,
(in millions)20222021
Deferred revenue$220 $208 
Licensing arrangements79 138 
Taxes payable232 209 
Other230 228 
 $761 $783 

Other long-term liabilities
 As of December 31,
(in millions)20222021
Accrued income taxes$597 $442 
Legal reserves212 284 
Contingent consideration75 197 
Licensing arrangements80 143 
Operating lease liabilities347 389 
Deferred revenue289 276 
Other434 489 
 $2,035 $2,220 

NOTE H – INCOME TAXES

Our Income (loss) before income taxes consisted of the following:
Year Ended December 31,
(in millions)202220212020
Domestic$(1,119)$(648)$(660)
Foreign2,260 1,724 581 
$1,141 $1,076 $(79)

99

The related expense (benefit) for income taxes consisted of the following:
Year Ended December 31,
(in millions)202220212020
Current
  Federal$51 $18 $(29)
  State19 33 (35)
  Foreign381 127 151 
451 178 87 
Deferred
  Federal(92)(256)(26)
  State(32)(3)(6)
  Foreign117 117 (53)
(7)(142)(85)
$443 $36 $2 

The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:
Year Ended December 31,
202220212020
U.S. federal statutory income tax rate21.0 %21.0 %(21.0)%
State income taxes, net of federal benefit0.7 %2.5 %16.6 %
Domestic taxes on foreign earnings15.3 %6.8 %155.4 %
Effect of foreign taxes(3.8)%(14.3)%(40.7)%
Acquisition-related4.4 %(8.1)%(16.7)%
Research credit(4.5)%(3.0)%(43.0)%
Valuation allowance(1.3)%0.8 %(42.0)%
Goodwill impairment charges— %— %3.7 %
Compensation-related0.6 %(0.6)%(7.7)%
Non-deductible expenses0.4 %0.4 %64.4 %
Uncertain tax positions7.7 %1.2 %(96.8)%
Intra-entity asset transfers— %— %10.2 %
Return to provision(2.1)%(5.7)%(37.3)%
Change in tax rates(0.2)%1.9 %51.8 %
Other, net0.7 %0.4 %6.0 %
38.9 %3.3 %2.9 %

100

Significant components of our deferred tax assets and liabilities are as follows:
 As of December 31,
 (in millions)
20222021
 Deferred Tax Assets:
 
Inventory costs and related reserves$19 $10 
Tax benefit of net operating losses and credits511 620 
Reserves and accruals304 324 
Restructuring-related charges6 14 
Litigation and product liability reserves103 127 
Investment write-down38 31 
Compensation related136 130 
Federal benefit of uncertain tax positions9 8 
Intangible assets3,668 3,546 
Capitalized R&D160 67 
Property, plant and equipment2 14 
Other— 35 
 4,954 4,926 
Less: valuation allowance(1,004)(1,014)
 3,950 3,912 
 Deferred Tax Liabilities:
  
Unrealized gains and losses on derivative financial instruments117 79 
Other34 — 
151 79 
 Net Deferred Tax Assets
3,799 3,833 
Prepaid on intercompany profit264 205 
 Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,062 $4,038 

Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):
Location on Consolidated Balance SheetsAs of December 31,
Component20222021
Prepaid on intercompany profitPrepaid income taxes$264 $205 
Non-current deferred tax assetDeferred tax assets3,942 4,142 
Deferred Tax Assets and Prepaid on Intercompany Profit 4,206 4,348 
Non-current deferred tax liabilityDeferred tax liabilities144 310 
Deferred Tax Liabilities 144 310 
Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,062 $4,038 

As of December 31, 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $464 million. As of December 31, 2021, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $560 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $47 million as of December 31, 2022, and $60 million as of December 31, 2021. These tax attributes expire periodically beginning in 2023.

After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.004 billion as of December 31, 2022, and $1.014 billion as of December 31, 2021. The decrease in the valuation allowance as of December 31, 2022, compared to December 31, 2021, is primarily due to the release of valuation allowances on certain U.S. state net operating losses and tax credit carryforwards due to the repatriation of foreign earnings, offset by the concurrent build of the valuation allowance on
101

other state attributes. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $56 million in 2022, a charge of $81 million in 2021 and a benefit of $78 million in 2020.

We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $162 million in 2022, $149 million in 2021 and $64 million in 2020. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on Net income (loss) per common share - assuming dilution was $0.11 for 2022, $0.10 for 2021 and $0.04 for 2020. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $21 million in 2022, $27 million in 2021 and $30 million in 2020. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on Net income (loss) per common share - assuming dilution was $0.02 in each of the years 2022, 2021 and 2020. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $17 million in 2022 and $0 in 2021 and 2020. The impact on Net income (loss) per common share - assuming dilution was $0.01 in 2022 and de minimis in 2021 and 2020.

As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December 31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. As of December 31, 2020, we had $261 million of gross unrecognized tax benefits, of which a net $183 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 Year Ended December 31,
(in millions)202220212020
Beginning Balance$255 $261 $455 
Additions based on positions related to the current year88 8 28 
Additions based on positions related to prior years177 41 6 
Reductions for tax positions of prior years(20)(36)(186)
Settlements with taxing authorities(1)(2)(27)
Statute of limitation expirations(8)(17)(15)
Ending Balance$492 $255 $261 
We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2016 and substantially all material state and local income tax matters through 2014. We have concluded substantially all foreign income tax matters through 2015.

In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91 million to release the reserves related to these years. We received a refund of $62 million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $77 million accrued for gross interest and penalties as of December 31, 2022, $43 million as of December 31, 2021, and $41 million as of December 31, 2020. Net tax expense related to interest and penalties was immaterial in 2022, 2021 and 2020. The increase in our net tax expense related to interest and penalties as of December 31, 2022, compared to December 31, 2021, is related to reaching settlements with taxing authorities.

It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $75 million.

For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&P) that we previously deferred from U.S. income taxes. As a result of various audit activities, the revised amount of transition tax was approximately $937 million as of December 31, 2022, as compared to $938 million as of December 31, 2021. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun
102

remitting the required installment payments, with a balance remaining of $386 million as of December 31, 2022. In addition, we have provided for U.S. state income taxes of $14 million on all U.S. dollar-denominated E&P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.

We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.


NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $443 million as of December 31, 2022, and $548 million as of December 31, 2021, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of our legal accrual for transvaginal surgical mesh product claims is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in Other current assets of $149 million as of December 31, 2022, and $188 million as of December 31, 2021. Refer to Note A – Significant Accounting Policies for additional information.

103

We recorded litigation-related net charges of $173 million in 2022, $430 million in 2021 and $278 million in 2020, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity. The charges recorded in 2020 were also inclusive of a reserve related to claims made by a coalition of state attorneys general, which has since been settled.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. The Company has also asserted patents against Cook in Germany and the United Kingdom. Trials are scheduled in the United Kingdom in February 2023 and in Germany in April 2023.

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. The Company intends to appeal the jury's verdict.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. While our U.S. case count has remained materially the same over the past three years, we have increased our reserve to account for changes in our estimates regarding settlement and litigation activity. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims and expect that more cases will go to trial in the coming years than have gone to trial in the past several years. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh
104

products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. Under the terms of the Court-approved Scheduling Order, Counsel for Mr. Errichiello was required to file an Amended Complaint on or before June 4, 2021, which they did. The Amended Complaint seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. In response, the Company brought a Motion to Dismiss the Amended Complaint which it filed on July 19, 2021. On December 20, 2022, the Court granted in part and denied in part the Company’s motion to dismiss. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund and Diane Nachbaur, two stockholders of the Company, on July 26, 2021, and July 29, 2021, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items.

105

Matters Concluded Since December 31, 2021

On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen and BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021 and alleged that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen’s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On December 17, 2021, the court granted BTG’s motion to dismiss the qui tam action. On January 10, 2022, the court granted the parties’ stipulation of dismissal with prejudice as to the claims of the direct purchaser plaintiff, whose claims had been stayed in the October 12, 2021, order compelling arbitration.

On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolved the dispute. The settlement did not have a material impact on our financial position or results of operations.

On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro Corp. (Nevro) in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro's Senza™ Spinal Cord Stimulation (SCS) System. The Company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On July 29, 2022, the parties reached a confidential settlement agreement, pursuant to which the Company agreed to make a payment to Nevro of $85 million to resolve all pending litigation between the parties, including this matter and the 18-cv-664 and 21-cv-258 matters described below.

On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro’s Senza™ I and Senza™ II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringed five Nevro patents. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.

On February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of Delaware (21-cv-258). The complaint alleged infringement of five Nevro patents by certain of the Company’s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.

The Company was previously named a defendant in multiple filed product liability cases involving our Greenfield Vena Cava Filter, which we discontinued marketing and actively selling in the fourth quarter of 2018. Most of the filed cases were part of a consolidated matter in Middlesex County, Massachusetts. We had also received notice of multiple additional unfiled claims. As of December 31, 2022, we have entered into master settlement agreements, the last of which was finalized on January 12, 2023, to resolve all but a small handful of these cases and claims.

106


NOTE J – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2022, our MCPS had an aggregate liquidation preference of $1.006 billion.

Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations.

Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $100 per share plus accumulated and unpaid dividends.

Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between 2.3834 and 2.9197 shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023.

The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions.

During 2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared and we paid quarterly cash dividends of $14 million, or $1.3750 per MCPS share to holders, representing dividend periods through November 2022. On January 30, 2023, the Committee declared a cash dividend of $1.3750 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. We have presented cumulative, unpaid dividends within Accrued expenses within our consolidated balance sheets as of December 31, 2022.

Common Stock

We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Holders of common stock are junior to holders of MCPS in terms of liquidation preference.

On May 27, 2020, we completed an offering of 29,382,500 shares of common stock at a public offering price of $34.25 per share. The net proceeds from the common stock offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. We used a portion of the net proceeds from the May 27, 2020 MCPS and
107

common stock offerings to repay remaining amounts outstanding under our previous term loan credit agreement that matured on April 20, 2021 and to pay related fees, expenses and premiums. The remaining proceeds were used for general corporate purposes.

In 2020, we repurchased approximately 15.7 million shares of our common stock pursuant to our 2013 share repurchase program for a total of approximately $535 million in cash, which represented the full amount remaining under the existing authorization.

On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 and had the full amount available under the authorization as of December 31, 2022.

There were approximately 263 million shares in treasury as of December 31, 2022 and 2021.

NOTE K – STOCK INCENTIVE AND PURCHASE PLANS

Employee and Director Stock Incentive Plans

In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 175 million as of December 31, 2022. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee.

Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs), RSUs and deferred stock units (DSUs) issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.

The following presents the impact of stock-based compensation on our consolidated statements of operations:
 Year Ended December 31,
(in millions, except per share data)202220212020
Cost of products sold$12 $11 $9 
Selling, general and administrative expenses167 147 130 
Research and development expenses41 36 30 
 220 194 170 
Income tax (benefit) expense(32)(29)(28)
 $188 $165 $142 
Net impact per common share - basic$0.13 $0.12 $0.10 
Net impact per common share - assuming dilution$0.13 $0.12 $0.10 








108

Stock Options

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 Year Ended December 31,
 202220212020
Options granted (in thousands)
3,287 3,822 3,819 
Weighted-average exercise price$44.02 $37.69 $41.79 
Weighted-average grant-date fair value$13.64 $10.77 $10.44 
Black-Scholes Assumptions   
Expected volatility28 %29 %23 %
Expected term (in years, weighted)
6.15.95.8
Risk-free interest rate1.42%-3.87%0.66%-1.20%0.27%-1.72%

Expected Volatility

We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.

Expected Term

We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.

Risk-Free Interest Rate

We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.

Expected Dividend Yield

We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.

109

Information related to stock options under stock incentive plans are as follows:
Stock Options
(in thousands)
Weighted
Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 201923,065 $19 
Granted3,819 42 
Exercised(3,096)13 
Cancelled/forfeited(666)27 
Outstanding as of December 31, 202023,122 $24 
Granted3,822 38 
Exercised(4,796)13 
Cancelled/forfeited(699)26 
Outstanding as of December 31, 202121,448 $29 
Granted3,287 44 
Exercised(2,745)17 
Cancelled/forfeited(502)34 
Outstanding as of December 31, 202221,489 $32 5.9297 
Exercisable as of December 31, 202213,674 27 4.6258 
Expected to vest as of December 31, 20227,535 41 8.238 
Total vested and expected to vest as of December 31, 202221,209 $32 5.9$296 
The total intrinsic value of stock options exercised was $72 million in 2022, $137 million in 2021 and $84 million in 2020.

Non-Vested Stock

We value RSAs, RSUs and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:
Non-Vested
Stock Award Units
(in thousands)
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 201911,079 $29 
Granted3,609 41 
Vested(1)
(4,147)25 
Forfeited(554)34 
Balance as of December 31, 20209,987 $34 
Granted4,240 $39 
Vested(1)
(3,823)$31 
Forfeited(658)36 
Balance as of December 31, 20219,745 $37 
Granted3,854 $45 
Vested(1)
(3,482)$36 
Forfeited(680)44 
Balance as of December 31, 20229,438 $41 
(1)The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.

The total vesting date fair value of shares that vested was approximately $150 million in 2022, $148 million in 2021 and $172 million in 2020.

110

Market-based RSU and DSU Awards

During 2022 and 2021, we granted market-based RSU awards, and in 2020, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Healthcare Index over a three-year performance period. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based RSU's and DSUs that satisfied the market performance criteria.

We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 202220212020
AwardsAwardsAwards
Stock price on date of grant$44.19 $37.50 $42.16 
Measurement period (in years)
2.92.92.9
Risk-free rate1.71 %0.20 %1.37 %
We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.

Free Cash Flow Performance-based RSU and DSU Awards

During 2022 and 2021, we granted free-cash flow performance-based RSU awards, and in 2020, we granted free-cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based RSUs and DSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Executive Compensation and Human Resources Committees of our Board of Directors, based on our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st of each year and ending December 31st. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs and DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs and DSUs that satisfied the performance criteria.

The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2022:
2022 AFCF2021 AFCF2020 AFCF
Fair value, net of forfeitures to date (in millions)
$7 $12 $6 
Achievement of target payout88 %131 %89 %
Year-end stock price used in determining fair value$46.27 $42.48 $35.95 

We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.

Expense Attribution

We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.
111


We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, Compensation – Stock Compensation allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December 31, 2022, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Unrecognized Compensation Cost

We expect to recognize the following future expense for awards outstanding as of December 31, 2022:
 Unrecognized
 Compensation Cost
(in millions) (1)
Weighted Average Remaining
Vesting Period
(in years)
Stock options$38  
Non-vested stock awards181  
 $219 1.7
(1)Amounts presented represent compensation cost, net of estimated forfeitures.

Employee Stock Purchase Plan

In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan now provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2022, there were approximately 11 million shares available for future issuance under the employee stock purchase plan. We temporarily suspended our global employee stock purchase plan for the offering period for the second half of 2020 due to cost-savings initiatives in response to the COVID-19 pandemic and resumed the plan beginning with the offering period for the first half of 2021.

Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
Year Ended December 31,
202220212020
Shares issued or to be issued (in thousands)
2,850 2,578 1,387 
Range of purchase prices$31.68 -$32.31 $29.98 -$36.11 $29.84 
Expense recognized (in millions)
$28 $24 $10 

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.







112

NOTE L – WEIGHTED AVERAGE SHARES OUTSTANDING

Year Ended December 31,
(in millions)202220212020
Weighted average shares outstanding - basic1,430.5 1,422.3 1,416.7 
Net effect of common stock equivalents9.2 11.5 — 
Weighted average shares outstanding - assuming dilution1,439.7 1,433.8 1,416.7 

The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:
Year Ended December 31,
(in millions)202220212020
Common stock equivalents(1)
n/an/a14
Stock options outstanding(2)
636
MCPS(3)
242414
(1)    Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our Net loss position in this period.
(2)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(3)    Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information.

We base Net income (loss) per common share - assuming dilution upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

In 2022, 2021 and 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented in our consolidated statements of operations, for purposes of calculating Net income (loss) available to common stockholders.

NOTE M – SEGMENT REPORTING

In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our consolidated statements of operations and are included in the reconciliation below. Refer to Note N – Revenue for net sales by reportable segment presented in accordance with U.S. GAAP.

113

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.
 Year Ended December 31,
Net sales202220212020
MedSurg$5,057 $4,616 $3,844 
Cardiovascular8,161 7,212 5,913 
Total net sales of reportable segments 13,218 11,828 9,756 
Other(1)
(60)13 219 
Impact of foreign currency fluctuations(476)47 (65)
$12,682 $11,888 $9,913 

Year Ended December 31,
Income (loss) before income taxes202220212020
MedSurg$1,625 $1,524 $1,156 
Cardiovascular2,113 1,888 1,043 
Total operating income of reportable segments 3,737 3,412 2,198 
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(436)(406)(424)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs
(789)(1,070)(1,208)
Amortization expense(803)(741)(789)
Other(1)
(60)4 143 
Operating income (loss) 1,649 1,199 (80)
Other income (expense), net(508)(123)1 
Income (loss) before income taxes$1,141 $1,076 $(79)
(1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

Operating income of reportable segments as a percentage of net sales of reportable segmentsYear Ended December 31,
202220212020
MedSurg32.1 %33.0 %30.1 %
Cardiovascular25.9 %26.2 %17.6 %

Year Ended December 31,
Depreciation expense202220212020
MedSurg$88 $91 $90 
Cardiovascular245 261 240 
Total depreciation expense of reportable segments333 352 330 
Other(1)
— — 3 
Consolidated depreciation expense$333 $352 $333 

114

As of December 31,
Total assets20222021
MedSurg$2,501 $2,178 
Cardiovascular5,205 4,417 
Total assets of reportable segments7,706 6,595 
Goodwill12,920 11,988 
Other intangible assets, net5,902 6,121 
All other corporate assets5,941 7,525 
 $32,469 $32,229 

As of December 31,
Long-lived assets20222021
U.S.$1,241 $1,190 
Ireland478 436 
Costa Rica246 185 
Other countries481 440 
Property, plant and equipment, net2,446 2,252 
Goodwill12,920 11,988 
Other intangible assets, net5,902 6,121 
Operating lease right-of-use assets in Other long-term assets
386 435 
 $21,653 $20,795 
115


NOTE N – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:
Year Ended December 31,
202220212020
BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$1,341 $880 $2,221 $1,222 $919 $2,141 1,000 $780 $1,780 
Urology1,257 516 1,773 1,120 463 1,583 918 368 1,286 
Neuromodulation715 202 917 713 196 909 610 151 761 
MedSurg3,312 1,599 4,911 3,055 1,578 4,633 2,528 1,299 3,827 
Interventional Cardiology Therapies744 1,485 2,228 778 1,431 2,209 728 1,247 1,975 
Watchman915 103 1,019 729 100 829 253 71 324 
Cardiac Rhythm Management1,337 763 2,100 1,214 805 2,019 992 712 1,704 
Electrophysiology275 310 585 128 237 365 118 169 287 
Cardiology3,271 2,662 5,932 2,850 2,572 5,422 2,091 2,199 4,290 
Peripheral Interventions1,048 850 1,899 996 824 1,820 888 689 1,577 
Cardiovascular4,319 3,512 7,831 3,846 3,396 7,242 2,979 2,888 5,866 
Other1
— — (60)10 4 13 193 27 219 
Total Net Sales$7,632 $5,111 $12,682 $6,911 $4,978 $11,888 $5,701 $4,212 $9,913 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

Year Ended December 31,
Geographic Regions202220212020
U.S.$7,632 $6,901 $5,508 
Europe, Middle East and Africa2,526 2,518 2,097 
Asia-Pacific2,116 2,070 1,781 
Latin America and Canada469 386 307 
Other1
(60)13 219 
Total Net Sales$12,682 $11,888 $9,913 
Emerging Markets(2)
$1,715 $1,429 $1,138 
(2)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying consolidated balance sheets. Our deferred revenue balance was $509 million as of December 31, 2022 and $484 million as of December 31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the
116

average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $156 million in 2022 that was included in the above contract liability balance as of December 31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period.

In 2020, we recorded $179 million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX™ Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed.

Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.

NOTE O – CHANGES IN OTHER COMPREHENSIVE INCOME

The following table provides the reclassifications out of Other comprehensive income, net of tax:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(86)214 36 163 
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(150)1 (157)
Total other comprehensive income (loss)(94)63 37 6 
Balance as of December 31, 2022$(1)$269 $1 $269 
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2020$218 $36 $(47)$207 
Other comprehensive income (loss) before reclassifications12 208 8 228 
(Income) loss amounts reclassified from accumulated other comprehensive income(137)(38)3 (173)
Total other comprehensive income (loss)(125)170 11 56 
Balance as of December 31, 2021$93 $206 $(36)$263 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.

The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by immaterial income tax impacts in 2022 and in 2021.
117


NOTE P – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2022, we implemented the following standards, which did not have a material impact on our financial position or results of operations.

ASC Update No. 2021-05

In July 2021, the FASB issued ASC Update No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis.

ASC Update No. 2022-06

In December 2022, the FASB issued ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.

Standards to be Implemented

In March 2022, the FASB issued ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.

In March 2022, the FASB issued ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.

In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.

In September 2022, the FASB issued ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50). Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No.
118

2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.

No other new accounting pronouncements, issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.

NOTE Q – EMPLOYEE RETIREMENT PLANS

Defined Benefit Pension Plans

Domestic Retirement Plans

Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan.

We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied.

U.K. Plan

As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.

Other International Retirement Plans

In addition, we maintain retirement plans covering certain international employees.

119

We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2022 and 2021, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:
 As of December 31, 2022
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded
PBO Recognized
Domestic Retirement Plans$50 $55 $— $55 
Other International Retirement Plans140 152 101 51 
 $190 $207 $101 $105 

 As of December 31, 2021
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded PBO Recognized
Domestic Retirement Plans$56 $59 $— $59 
U.K. Plan209 209 205 3 
Other International Retirement Plans214 234 130 103 
 $478 $502 $336 $166 

A rollforward of the changes in the PBO for our retirement plans is as follows:
 Year Ended December 31,
(in millions)20222021
Beginning obligations$502 $532 
Acquired plans— 4 
Service costs13 17 
Interest costs3 3 
Actuarial (gain) loss(54)(7)
Plan curtailments/settlements(191)— 
Plan amendments and assumption changes(25)(6)
Benefits paid(6)(22)
Impact of foreign currency fluctuations(37)(20)
Ending obligation$207 $502 

The critical assumptions associated with our employee retirement plans for 2022 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans5.32%n/a2.00%
Other International Retirement Plans2.62%2.27%3.00%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

120

The critical assumptions associated with our employee retirement plans for 2021 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans2.40%n/a1.50%
U.K. Plan0.70%0.70%n/a
Other International Retirement Plans0.82%2.16%2.60%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 Year Ended December 31,
(in millions)20222021
Beginning fair value$336 $355 
Acquired plans— 1 
Actual return on plan assets(2)5 
Employer contributions16 12 
Participant contributions1 2 
Plan curtailments/settlements(185)— 
Actuarial gain (loss)(25)(4)
Benefits paid(9)(22)
Impact of foreign currency fluctuations(32)(13)
Ending fair value$101 $336 

For our defined benefit plans, excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.

Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.

The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:
As of
December 31, 2021
(in millions)Level 1Level 2Level 3Total
Buy-in contracts$— $— $205 $205 
Total assets$— $— $205 $205 

121

Changes in the fair value of the U.K. Plan Level 3 assets were as follows:
(in millions)Buy-in Contracts
Balance as of December 31, 2021$205 
Actual return on plan assets0 
Employer contributions1 
Plan curtailments/settlements(160)
Actuarial gain (loss)(24)
Benefits paid(2)
Impact of foreign currency fluctuations(22)
Balance as of December 31, 2022$— 

Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December 31, 2022. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:
(in millions)Post Retirement Benefits
2023$15 
20248 
202513 
202614 
202714 
2028 - 203270 

Defined Contribution Plan

We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.
122

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (CEO) and Executive Vice President and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that as of December 31, 2022, our disclosure controls and procedures were effective.
Management’s Annual Report on Internal Control over Financial Reporting
Management’s annual report on our internal control over financial reporting is contained in Item 7 of this Annual Report on Form 10-K.
Report of Independent Registered Public Accounting Firm on Internal Control over Financial Reporting
The report of Ernst & Young LLP on our internal control over financial reporting is contained in Item 7 of this Annual Report on Form 10-K.
Changes in Internal Control over Financial Reporting
During the quarter ended December 31, 2022, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
During 2022, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation is expected to occur in phases over the next several years. As the phased implementation occurs, it may result in changes to our processes and procedures which may result in changes to our internal controls over financial reporting. As such changes occur, we will evaluate quarterly whether they materially affect our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

2023 Restructuring Plan

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). The 2023 Restructuring Plan is intended to meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value.

The 2023 Restructuring Plan will further build on our Global Supply Chain Optimization strategy, which is intended to simplify our manufacturing and distribution network by transferring certain production lines among facilities and expand operational efficiencies and resiliency. Key activities under the 2023 Restructuring Plan will also include optimizing certain functional capabilities to better support business growth and achieve cost synergies. These activities are expected to be initiated in the first quarter of 2023, and substantially completed by the end of 2025.

While we expect limited role reductions as a result of these restructuring activities, we anticipate that our overall employee base will remain relatively unchanged upon completion of the 2023 Restructuring Plan as new jobs are created in areas of growth and resources are deployed to support an expanding portfolio and growing global market needs.

123

The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in future cash outlays. The following table provides a summary of our estimates of total pre-tax charges associated with the 2023 Restructuring Plan by major type of cost:

Type of Cost (in millions)
Total Estimated Amount Expected to be Incurred
Restructuring charges:
Termination benefits(1)
$60-$80
Other(2)
40-60
Restructuring-related expenses:
Transfer costs250280
Other(3)
100-130
 $450-$550
(1)    Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.
(2)    Consists primarily of consulting fees and costs associated with contractual cancellations.
(3)    Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.
124

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Our independent registered public accounting firm is Ernst & Young LLP, New York, NY, (PCAOB ID 42).
The information required by this Item is set forth in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2022 and is incorporated into this Annual Report on Form 10-K by reference.

125

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)(1) Financial Statements.
The response to this portion of Item 15 is set forth under Item 8.
(a)(2) Financial Statement Schedules.
The response to this portion of Item 15 (Schedule II) follows the signature page to this report. All other financial statement schedules are not required under the related instructions or are inapplicable and therefore have been omitted.
(a)(3) Exhibits (* documents filed or furnished with this report, # compensatory plans or arrangements)
  
EXHIBIT
NO.
 TITLE
 
   
3.1 
3.2
 
3.3
4.1 Specimen Certificate for shares of the Company's Common Stock (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1. File No. 33-46980).
 
4.2 
 
4.3 
 
4.4 
 
4.5 
 
4.6 
 
126

4.7 
 
4.8 
 
4.9 
 
4.10
4.11
4.12
4.13
4.14
4.15
4.16
4.17
4.18
4.19
4.20
127

4.21
4.22
4.23
4.24
10.1 
10.2
 
10.3 
 
10.4
10.5 
Transaction Agreement, dated as of January 8, 2006, as amended, between the Company and Abbott Laboratories (incorporated herein by reference to Exhibit 10.47, Exhibit 10.48, Exhibit 10.49 and Exhibit 10.50 to the Company's Annual Report on Form 10-K for year ended December 31, 2005, filed on March 1, 2006, and Exhibit 10.1 to the Company's Current Report on Form 8-K filed on April 7, 2006, File No. 1-11083).
 
10.6
 
10.7 
 
10.8 
 
10.9 
Form of Boston Scientific Corporation Excess Benefit Plan, as amended (incorporated herein by reference to Exhibits 10.1 and 10.4 to the Company's Current Reports on Form 8-K filed on July 5, 2005 and December 22, 2008, respectively, File No. 1-11083).#
128

 
10.10
10.11 
 
10.12
10.13 
 
10.14 
10.15 
 
10.16 
 
10.17 
 
10.18 
10.19 
10.20
10.21 
 
10.22 
 
10.23 
 
129

10.24 
 
10.25 
 
10.26 
 
10.27 
 
10.28
10.29
10.30
10.31
10.32
10.33
10.34
10.35
10.36
130

10.37
10.38
10.39
10.40
10.41
10.42
10.43
10.44
10.45
10.46
10.47
10.48
10.49
131

10.50
10.51
10.52
10.53
10.54
10.55*
10.56*
10.57*
10.58*
10.59
10.60
10.61
10.62
10.63
132

10.64
10.65*
10.66*
10.67*
10.68*
10.69*
10.70*
10.71
10.72*
10.73
10.74
10.75
10.76*
10.77*
10.78*
133

10.79*
10.80*
10.81*
10.82
10.83*
10.84*
10.85*
10.86
10.87
10.88
10.89
21*
23*
31.1*
31.2*
32.1*
32.2*
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
134

101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)

ITEM 16. FORM 10-K SUMMARY
None.
135

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
Dated: February 23, 2023Boston Scientific Corporation
 By: /s/ Daniel J. Brennan
     
    Daniel J. Brennan
    Executive Vice President and Chief Financial Officer
    (duly authorized officer and principal financial officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
     
Dated: February 23, 2023 By: /s/ Daniel J. Brennan
    Daniel J. Brennan
    Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)
     
Dated: February 23, 2023 By: /s/ Michael F. Mahoney
     
    Michael F. Mahoney
    Director, Chairman of the Board,
President and Chief Executive Officer
    (Principal Executive Officer)
     
Dated: February 23, 2023 By:  /s/ Jonathan R. Monson
    Jonathan R. Monson
    Senior Vice President, Global Controller and Chief Accounting Officer
    (Principal Accounting Officer)
     
Dated: February 23, 2023 By: /s/ Nelda J. Connors
     
    Nelda J. Connors
    Director
     
136

     
Dated: February 23, 2023 By: /s/ Charles J. Dockendorff
     
    Charles J. Dockendorff
    Director
     
     
Dated: February 23, 2023 By: /s/ Yoshiaki Fujimori
     
    Yoshiaki Fujimori
    Director
     
     
Dated: February 23, 2023 By: /s/ Donna A. James
     
    Donna A. James
    Director
     

     
Dated: February 23, 2023 By:  /s/ Edward J. Ludwig
     
    Edward J. Ludwig
    Director
     

     
Dated: February 23, 2023 By: /s/ David J. Roux
    David J. Roux
    Director
     
137

     
Dated: February 23, 2023 By: /s/ John E. Sununu
     
    John E. Sununu
    Director
     
     
Dated: February 23, 2023 By: /s/ David S. Wichmann
     
    David S. Wichmann
    Director
     

     
Dated: February 23, 2023 By: /s/ Ellen M. Zane
     
    Ellen M. Zane
    Director
     
138


Schedule II
VALUATION AND QUALIFYING ACCOUNTS
Description (in millions)
Balance at
 Beginning of Year
Cumulative effect adjustment for adoption of ASU 2016-13(1)
Credit loss exposure(1)
Write-offs(2)
Balance at
End of Year
Year Ended December 31, 2022:
Allowances for credit losses$108 n/a35 (35)$109 
Year Ended December 31, 2021:
Allowances for credit losses$105 n/a28 (25)$108 
Year Ended December 31, 2020:
Allowances for uncollectible accounts$74 10 49 (27)$105 
(1) Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.
(2) Represents actual write-offs of uncollectible accounts.


139
 EX-10.55 2 ex1055-2020grantxnqagreeme.htm EX-10.55 Document
Exhibit 10.55
Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

%%OPTION_DATE,’Month DD, YYYY’%-%




%%FIRST_NAME%-% %%LAST_NAME%-%
(“Optionee”)























EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS



    Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

This Global Non-Qualified Stock Option Agreement (the “Agreement”), dated %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Company. This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

    1.    Grant of Stock Option. The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth on herein (the “Option Shares”) at the price set forth herein (the “Grant Price”). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date.

    2.    Term and Vesting of Stock Option. Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from %%OPTION_DATE,’Month DD, YYYY’%-% until %%EXPIRE_DATE_PERIOD1,’Month DD, YYYY’%-% (the “Expiration Date”) and shall vest in accordance with the vesting schedule. If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

    3.    Exercise of Stock Option. While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares. Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following: (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if you reside in a country where the local laws and/or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and/or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.

    The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised. The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.

–Rev 1.2020
1


    Upon the Company’s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares. However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

    4.    Termination of Employment.

        a.    In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.

        b.    Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option. 

        c.    In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.

        d.    Upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares. Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited; provided, however, that the Committee, in its sole discretion, may extend the exercise period and/or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option). Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).

        e.    Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited.

        f.    The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

        g.    Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.

–Rev 1. 2020
2


        h.    Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

        i.    If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

        j.    If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    5.    Change in Control. To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence. If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines. If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control. If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.

    6.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 6, shall have the meaning set forth below:

–Rev 1. 2020
3


            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    7.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    8.    Transferability. Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members. During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.

    9.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.

    Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of

–Rev 1. 2020
4

Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.

    All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility. In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Stock Option is intended to be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    10.    Repatriation and Legal/Tax Compliance Requirements. If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).

11.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the

–Rev 1. 2020
5

Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    12.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;


–Rev 1. 2020
6

(b)the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;

(c)all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Stock Option is not intended to replace any pension rights or compensation;

(g)the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;
(k)for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the

–Rev 1. 2020
7

income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.

    13.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

    14.    Not a Public Offering. Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law.

    15.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    16.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.

    17.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

    18.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given

–Rev 1. 2020
8

or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    19.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    20.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    21.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    22.    Choice of Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and/or to be performed.

    23.    Award Subject to Plan; Conflicts.    The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement

–Rev 1. 2020
9

by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

    24.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    25.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable

26.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    27.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.


–Rev 1. 2020
10

SIGNATURE PAGE
    
    IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.

Option Shares of Stock: %%TOTAL_SHARES_GRANTED%-%

Grant Price: %%OPTION_PRICE,’$999,999,999.99’%-%

Vesting Schedule:

Percent of
Stock Option		Date Vested
25%%%VEST_DATE_PERIOD1%-%
25%%%VEST_DATE_PERIOD2%-%
25%%%VEST_DATE_PERIOD3%-%
25%%%VEST_DATE_PERIOD4%-%



                    BOSTON SCIENTIFIC CORPORATION        
image_0.jpg                image_1.jpg
                    Michael F. Mahoney
President and Chief Executive Officer


OPTIONEE



By: SIGNED BY ELECTRONIC SIGNATURE


BY ELECTRONICALLY ACCEPTING THE AWARD, YOU AGREE THAT (i) SUCH ACCEPTANCE CONSTITUTES YOUR ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) YOU AGREE TO BE BOUND BY THE PROVISIONS OF

–Rev 1. 2020
11

THE PLAN, THE AGREEMENT AND THE ADDENDUM; (iii) YOU HAVE REVIEWED THE PLAN, THE AGREEMENT AND THE ADDENDUM IN THEIR ENTIRETY, HAVE HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTAND ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND THE ADDENDUM; (iv) YOU HAVE BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN AND THE TAX SUPPLEMENT TO THE U.S. PROSPECTUS FOR YOUR COUNTRY, IF APPLICABLE; AND (v) YOU HEREBY AGREE TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND THE ADDENDUM.

–Rev 1. 2020
12

BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED
PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 19 of the Agreement, if you transfer your residence and/or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”) COUNTRIES1 AND SWITZERLAND

1.    Personal Data. This provision replaces Section 11 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and
1 For the avoidance of doubt, references to the EU / EEA in this Addendum include the United Kingdom.

–Rev 1. 2020
13

operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.


–Rev 1. 2020
14

AUSTRALIA

1.    Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your vested Stock Option will no longer be exercisable after the earlier of: (i) thirty (30) days from the date of termination of employment; and (ii) the Expiration Date specified in Section 2 of the Agreement.

2.    Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

AUSTRIA

No country-specific provisions.

BELGIUM

1.    Acceptance of Stock Option. In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to:
Boston Scientific
Green Square
Lambroekstraat 5D
1831 Diegem
Belgium
Attn.: Nathalie Derue

I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date.

The undersigned acknowledges that he/she has been encouraged to discuss this matter with a financial and/or tax advisor and that this decision is made in full knowledge.

Employee Signature:        _______________________________

Employee Printed Name:    _______________________________

Date of Acceptance:        _______________________________

If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

2.    Undertaking for Qualifying Option. If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for Belgium tax purposes pursuant to the article 43, §6 of the Belgian law of 26 March 1999, you

–Rev 1. 2020
15

may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death). If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above.
Employee Signature:        _______________________________

Employee Printed Name:    _______________________________
    
BRAZIL

1.    Compliance with Law. By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

2.    Labor Law Policy and Acknowledgement. This provision supplements Section 12 of the Agreement:

By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.

CANADA

1.    Use of Previously Owned Shares. Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.

2.    Personal Data. This provision supplements Section 11 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

3.    Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (i.e., the New York Stock Exchange).

4.    Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

–Rev 1. 2020
16


Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.     Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of: (i) the period set forth in Section 4 of the Agreement; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (“SAFE”)); and (iii) the Expiration Date specified in Section 2 of the Agreement.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.


–Rev 1. 2020
17

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 12 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Stock Option Upon Termination of Employment. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is being provided to comply with the Stock Option Act.

FINLAND

No country-specific provisions.

FRANCE

1.    Nature of the Award. The Stock Option is not granted under the French specific regime provided by Articles L225-177-1 and seq. of the French commercial code.

2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté

–Rev 1. 2020
18

conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

1.    Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

2.    IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

3.    Wages. The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

4.    Nature of Scheme. You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”).

INDIA

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.


–Rev 1. 2020
19

ITALY

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.    Plan. This provision supplements Section 12 of the Agreement: You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

1.    Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

2.    Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 11 of the Agreement in its entirety:


–Rev 1. 2020
20

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.

You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.

MEXICO

1.    Acknowledgement of the Agreement. By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;

–Rev 1. 2020
21

(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option.
Reconocimiento del Contrato. Al aceptar la Opción, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Apéndice, mismos que ha revisado. Usted reconoce, además, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Apéndice. También reconoce que ha leído y aprueba de forma expresa los términos y condiciones establecidos en la sección doce 12 del contrato que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan su participación en el mismo son ofrecidos por la Compañía de forma totalmente discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    La Compañía y sus afiliados no son responsables por cualquier disminución en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opción.
2.    Labor Law Acknowledgement and Policy Statement. By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.

–Rev 1. 2020
22

Reconocimiento de Ley Laboral y Declaración de la Política. Al aceptar el Otorgamiento de la Opción, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es únicamente responsable de la administración del Plan. Usted además reconoce que su participación en el Plan, la concesión de Opción y cualquier adquisición de acciones de conformidad con el Plan no constituyen una relación de trabajo entre Usted y Boston Scientific Corporation, ya que Usted está participando en el Plan sobre una base totalmente comercial y su único patrón es una sociedad mercantil Mexicana (“Boston Scientific-México”). Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participación en el Plan no establecen ningún derecho entre Usted y su Patrón, Boston Scientific-México, y no forman parte de las condiciones de trabajo y/o prestaciones otorgadas por Boston Scientific-México, y cualquier modificación al Plan o su terminación no constituirá un cambio o perjuicio de los términos y condiciones de su trabajo.
Usted además entiende que su participación en el Plan es resultado de una decisión unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y/o discontinuar su participación en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.
Finalmente, Usted declara que no se reserva acción o derecho alguno para presentar una reclamación o demanda en contra de Boston Scientific Corporation por cualquier compensación o daño o perjuicio en relación con cualquier disposición del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representación, accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamación o demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information. 

Warning

This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.


–Rev 1. 2020
23

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

–Rev 1. 2020
24


PHILIPPINES

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

RUSSIA

1.    U.S. Transaction. You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
2.    Cashless Exercise Provision. Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.

3.    Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.


–Rev 1. 2020
25

SINGAPORE

Private Placement. The grant of the Stock Option under the Plan is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
a.    Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.
b.    The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
c.    Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 11 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.

–Rev 1. 2020
26


SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.

You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment. In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

No country-specific provisions.


–Rev 1. 2020
27

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Stock Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

1.     Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 9 of the Agreement:
Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or

–Rev 1. 2020
28

withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 9 of the Agreement.

2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

6721321-v7\GESDMS

–Rev 1. 2020
29
 EX-10.56 3 ex1056-2020grantxrsuagreem.htm EX-10.56 Document

Exhibit 10.56


Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Deferred Stock Unit Award Agreement

%%OPTION_DATE,’Month DD, YYYY’%-%




%%FIRST_NAME%-% %%LAST_NAME%-%
(“Participant”)






















EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS



Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Deferred Stock Unit Award Agreement

This Global Deferred Stock Unit Award Agreement (the “Agreement”), dated %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Award of Deferred Stock Units by the Committee under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Units. The Committee hereby grants you that number of Deferred Stock Units as set forth in this Agreement (the “Units”). Each Unit represents the Company’s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement. This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.

    2.    Vesting. The Units shall vest and shares of Stock will be issued to you according to the vesting schedule set forth in this Agreement. Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below, in approximately equal annual installments on each of the four (4) consecutive anniversaries of the Grant Date, beginning on the first anniversary of the Grant Date. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date. No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest. Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and/or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in your country of residence (or country of employment, if different). Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    3.    Participant’s Rights in Stock. The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.

    4.    Death. In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution. Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.
–Rev 1.2020
1




    5.    Retirement. If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date. In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety. Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.

    In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

    6.     Disability. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you. Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.

    7.    Other Termination of Employment; Certain Vesting Conditions. If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause. Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above. For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

    8.    Change in Control of the Company. In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement. In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in
–Rev 1.2020
2



Control. Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or
–Rev 1.2020
3



authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

    12.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    13.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your
–Rev 1.2020
4



salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    14.    Repatriation and Legal/Tax Compliance Requirements. If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).
    
–Rev 1.2020
5



15.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    16.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:

–Rev 1.2020
6



(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services
–Rev 1.2020
7



for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    17.    Not a Public Offering. The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    20.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.

    21.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic
–Rev 1.2020
8



system established and maintained by the Company or a third party-designated by the Company.
    
22.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    23.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    24.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    25.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    26.    Award Subject to the Plan; Conflicts. The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the
–Rev 1.2020
9



Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

    27.    Governing Law and Venue The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and/or to be performed.

    28.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    29.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

30.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    31.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.
–Rev 1.2020
10



SIGNATURE PAGE

     IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.


Number of Deferred Stock Units: %%TOTAL_SHARES_GRANTED%-%

Vesting Schedule

25%

%%VEST_DATE_PERIOD1%-%
25%%%VEST_DATE_PERIOD2%-%
25%%%VEST_DATE_PERIOD3%-%
25%%%VEST_DATE_PERIOD4%-%



                    image_02b.jpgBOSTON SCIENTIFIC CORPORATION        
                image_1b.jpg
                    Michael F. Mahoney
President and Chief Executive Officer


PARTICIPANT



By: SIGNED BY ELECTRONIC SIGNATURE


BY ELECTRONICALLY ACCEPTING THE AWARD, YOU AGREE THAT (i) SUCH ACCEPTANCE CONSTITUTES YOUR ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) YOU AGREE TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND THE ADDENDUM; (iii) YOU HAVE REVIEWED THE PLAN, THE AGREEMENT AND THE ADDENDUM IN THEIR ENTIRETY, HAVE HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTAND ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND THE ADDENDUM; (iv) YOU HAVE BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS
–Rev 1.2020
11



TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN AND THE TAX SUPPLEMENT TO THE U.S. PROSPECTUS FOR YOUR COUNTRY, IF APPLICABLE; AND (v) YOU HEREBY AGREE TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND THE ADDENDUM.

–Rev 1.2020
12



BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO DEFERRED STOCK UNITS GRANTED
PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”) COUNTRIES1 AND SWITZERLAND    

1.    Personal Data. This provision replaces Section 15 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation,
1 For the avoidance of doubt, references to the EU / EEA in this Addendum include the United Kingdom.
–Rev 1.2020
13



administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

–Rev 1.2020
14



AUSTRALIA

1.    Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

2.    Tax Information. The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

AUSTRIA

No country-specific provisions.

BELGIUM

No country-specific provisions.

BRAZIL

1.    Compliance with Law. By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

2.    Labor Law Policy and Acknowledgement. This provision supplements Section 16 of the Agreement:

By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Units, if any, is not part of your remuneration from employment.

CANADA

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

2.    Personal Data. This provision supplements Section 15 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

–Rev 1.2020
15



3.    Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

4.    Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account.

2.    Mandatory Sale of Shares Following Termination of Employment. You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

–Rev 1.2020
16



3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 16 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

–Rev 1.2020
17



COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Units upon Termination of Service. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is provided to comply with the Stock Option Act.

FINLAND

No country-specific provisions.

FRANCE

1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. of the French commercial code.

2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).

–Rev 1.2020
18



2.    Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

3.    IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

4.    Wages. The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

5.    Nature of the Program. The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court, tribunal or legal/regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.

INDIA

No country-specific provisions.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ISRAEL

1.    Immediate Sale Restriction. Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold. You acknowledge and agree that the Company is authorized to issue sales instructions to the Company’s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale. You also agree to sign any agreements, forms and/or consents that may be reasonably requested by the Company or the Company’s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company’s designated broker with respect to such matters. When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale. The remaining proceeds will be paid to you as soon as practicable.
–Rev 1.2020
19




You acknowledge that neither the Company nor the Company’s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale. Due to fluctuations in the Stock price and/or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest. You understand and agree that the Company assumes no liability for any fluctuations in the Stock price and/or any applicable exchange rate.

2.    Securities Law Information.  The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.

ITALY

Plan. This provision supplements Section 16 of the Agreement:
You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

1.    Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

2.    Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 15 of the Agreement in its entirety:

–Rev 1.2020
20



You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan. You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.
–Rev 1.2020
21




MEXICO

1.    Acknowledgement of the Agreement. By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the “Nature of Grant” section of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units.
Reconocimiento del Contrato. Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusión de este Apéndice, que le ha examinado. Usted reconoce, además, que usted acepta todas las disposiciones del Plan y del Contrato. Usted también reconoce que ha leído y, concretamente, y aprobar de forma expresa los términos y condiciones establecidos en la “Naturaleza del Otorgamiento” que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan y su participación en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminución en el valor de las acciones adquiridas en la adquisición de los Unidades.
2.    Labor Law Acknowledgement and Policy Statement. By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
–Rev 1.2020
22



You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ausencia de Relación Laboral y Declaración de la Política. Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es el único responsable de la administración del Plan. Además, usted acepta que su participación en el Plan, la concesión de los Unidades y cualquier adquisición de acciones en el marco del Plan no constituyen una relación laboral entre usted y Boston Scientific Corporation porque usted está participando en el Plan en su totalidad sobre una base comercial y su único empleador es una sociedad mercantil Mexicana (“Boston Scientific-Mexico”). Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participación en el Plan no establece ningún derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y / o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificación del Plan o la terminación de su contrato no constituirá un cambio o deterioro de los términos y condiciones de su empleo.
Además, usted entiende que su participación en el Plan es causada por una decisión discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y/o suspender su participación en el Plan en cualquier momento, sin responsabilidad alguna para con usted.
Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

–Rev 1.2020
23



NEW ZEALAND

Securities Law Information.

Warning

This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

–Rev 1.2020
24



4.Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PHILIPPINES

Settlement in Cash. Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and/or filing with the Philippines Securities and Exchange Commission.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

RUSSIA
1.    U.S. Transaction. You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
2.    Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the
–Rev 1.2020
25



Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.
Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and/or to pay any proceeds related to the Units to you through local payroll.
SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
a.    Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.
b.    The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
c.    Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

–Rev 1.2020
26



SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.

You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment. In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.

–Rev 1.2020
27



BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

No country-specific provisions.

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

–Rev 1.2020
28



UNITED KINGDOM

1.     Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.

2.     Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

6721372-v6\GESDMS
–Rev 1.2020
29
 EX-10.57 4 ex1057-2020grantxrsabodawa.htm EX-10.57 Document
Exhibit 10.57

BOSTON SCIENTIFIC CORPORATION

RESTRICTED STOCK AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s 2011 Long Term Incentive Plan, as amended from time to time (the “Plan”).

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of shares set forth on the Signature Page of this Agreement (the “Restricted Stock”) of the Company’s Stock, subject to the restrictions set forth below. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Restricted Stock.

2.    Restrictions on Shares of Stock. Shares of Restricted Stock awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 12 below.

3.    Lapse of Restrictions. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control of the Company), shares of Restricted Stock awarded hereunder shall become free of the forfeiture restrictions described in Section 5 hereof on the last day of the Participant’s current term as a non-employee director of the Company.

4.    Participant’s Rights in Restricted Stock. The shares of Restricted Stock awarded hereunder shall be evidenced in the manner as the Company may determine. Any shares of Stock issued shall be registered in the name of the Participant and any certificates representing those shares of Stock may be held by the Company and not be delivered to the Participant until the lapse of all forfeiture restrictions with respect to the shares of Restricted Stock. The Participant agrees to deliver a stock power, endorsed in blank, relating to the shares of Restricted Stock awarded hereunder, if so requested by the Company. During the period that shares of Restricted Stock are subject to forfeiture (subject, however, to Section 12 of this Agreement relating to
-Rev. 12.2019

limits on transferability), the Participant will have all the rights of a stockholder of the Company with respect to the shares of Restricted Stock, including the right to receive dividends and the right to vote the shares of Restricted Stock.

5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause (as defined in Section 4.a(4)(C) of the Plan) prior to the end of the Participant’s current term as a non-employee director of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall be free of restrictions pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such shares of Restricted Stock shall be immediately and automatically forfeited to the Company. If the Participant experiences a Separation From Service from the Company for cause (as defined in Section 4.a(4)(C) of the Plan), any shares of Restricted Stock awarded hereunder that have not been delivered to the Participant shall be immediately and automatically forfeited to the Company.

6.    Change in Control of the Company. In the event of a Change in Control of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall immediately be free of restrictions.

7.    Consideration for Restricted Stock. The shares of Restricted Stock are being issued for no cash consideration.

8.    Legend on Certificate. The certificates representing the shares of Restricted Stock awarded hereunder, if delivered to the Participant prior to the lapse of the forfeiture restrictions, shall bear a legend substantially in the following form:

The transferability of this certificate and the shares of common stock represented hereby are subject to the terms and conditions (including forfeiture) of a Boston Scientific Corporation Long-Term Incentive Plan and a Restricted Stock Award Agreement entered into between the registered owner and Boston Scientific Corporation. Copies of the Plan and Agreement are on file in the offices of Boston Scientific Corporation at 300 Boston Scientific Way, Marlborough, MA 01752, USA.

In addition, certificates representing shares of Restricted Stock shall also bear an Affiliate Legend.

2
-Rev. 12.2019

9.    Delivery of Stock. The Company shall not be obligated to deliver any shares of Restricted Stock awarded hereunder until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with, and (ii) all other legal matters in connection with the issuance and delivery of such shares of Restricted Stock have been approved by the Company’s legal department.

10.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the shares of Restricted Stock awarded hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. If the Participant elects pursuant to Code Section 83(b) to recognize taxable income in connection with the award of Restricted Stock pursuant to this Agreement, the Participant must notify the U.S. Internal Revenue Service (with a copy to the Company) of such election in writing within thirty (30) days of the Grant Date and must pay in cash to the Company the amount of withholding and other tax obligations associated with the election or make other arrangements satisfactory to the Company for the payment thereof. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock award, and (b) does not commit to structure the terms of the award to reduce or eliminate the Participant’s liability for Tax-Related Items.

The Company shall have the right and is hereby authorized to withhold Tax-Related Items required by law to be withheld with respect to the shares of Restricted Stock awarded hereunder from any compensation or other amount owing to the Participant, as may be necessary in the opinion of the Company to satisfy all such Tax-Related Items, requirements and withholding obligations. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

11.    Investment Intent. The Participant acknowledges that the acquisition of the Restricted Stock is for investment purposes without a view to distribution thereof.

12.    Limits on Transferability. Until the restrictions imposed upon the Restricted Stock by this Agreement lapse in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the shares of Restricted Stock awarded and accepted hereby are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by the Participant. Transfers of shares of
3
-Rev. 12.2019

Stock by the Participant are subject to the Company’s Stock Trading Policy and any applicable laws, rules and regulations.

    13.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Restricted Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.

    14.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

    The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all shares of Restricted Stock awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list
4
-Rev. 12.2019

with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired under the Plan. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant shares of Restricted Stock or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

15.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of shares of Restricted Stock is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of shares of Restricted Stock, even if shares of Restricted Stock have been granted in the past;

(c)    all decisions with respect to future grants of shares of Restricted Stock, if any, will be at the sole discretion of the Administrator;
5
-Rev. 12.2019


(d)    the grant of the shares of Restricted Stock and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of shares of Restricted Stock hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the shares of Restricted Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the shares of Restricted Stock resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the shares of Restricted Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the shares of Restricted Stock or of any amount due to the Participant upon lapse of restrictions on the Restricted Stock or the subsequent sale of any shares of Stock acquired.

    16.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Restricted Stock under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Restricted Stock is not subject to the supervision of securities authorities outside the United States.

    17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or
6
-Rev. 12.2019

amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Restricted Stock and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Restricted Stock and participation in the Plan or future grants of Restricted Stock that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
20.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Restricted Stock, be drawn up in English. The Participant acknowledges that he/she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Restricted Stock translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

21.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”).
7
-Rev. 12.2019

Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

    22.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Restricted Stock, any shares of Stock acquired pursuant to the Restricted Stock and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

23.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    24.    Award Subject to the Plan; Conflicts. The award of Restricted Stock granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Restricted Stock granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the award of Restricted Stock subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

8
-Rev. 12.2019

25.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

26.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

27.    Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

28.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

29.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

9
-Rev. 12.2019

IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: 2011 LONG TERM INCENTIVE PLAN
Number of Shares: %%TOTAL_SHARES_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION
    
                image_02.jpgimage_12.jpg
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i) SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT’S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iv) THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.

6721493-v3\GESDMS
10
-Rev. 12.2019
 EX-10.58 5 ex1058-2020grantxdsubodawa.htm EX-10.58 Document
Exhibit 10.58

BOSTON SCIENTIFIC CORPORATION

DEFERRED STOCK UNIT AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s 2011 Long Term Incentive Plan, as amended from time to time (the “Plan”).

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of Deferred Stock Units set forth on the Signature Page of this Agreement (the “Units”). Each Unit represents the Company’s commitment to issue to the Participant one share of Stock, subject to the conditions set forth in this Agreement. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of Units.

2.    Restrictions on Units. Units awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 11 below.

3.    Vesting. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control Event (as defined in the Director Deferred Compensation Plan)), the Units awarded hereunder shall vest in full on the last day of the Participant’s current term as a non-employee director of the Company.

4.    Participant’s Rights in Stock. The shares of Stock, if and when issued to the Participant pursuant to this Agreement, shall be registered in the Participant’s name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will the Participant be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested and the underlying shares of Stock have been issued to the Participant.
-Rev. 12.2019


5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause (as defined in Section 4.a(4)(C) of the Plan) prior to the end of the Participant’s current term as a non-employee director of the Company, any Units awarded hereunder that remain unvested shall vest pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such Units shall be immediately and automatically forfeited. If the Participant experiences a Separation From Service from the Company for cause (as defined in Section 4.a(4)(C) of the Plan), any Units awarded hereunder that have not been settled shall be immediately and automatically forfeited.

6.    Change in Control Event. In the event of a Change in Control Event (as defined in the Director Deferred Compensation Plan), any unvested Units shall immediately vest in full.

7.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

8.    Issuance of Stock. Shares of Stock will be issued in settlement of vested Units within sixty (60) days after the earlier of (i) a Change in Control Event or (ii) the Participant’s Separation From Service (as defined in the Director Deferred Compensation Plan). Notwithstanding the foregoing, in the event that a Participant is a Specified Employee (as defined in the Director Deferred Compensation Plan) at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant’s Separation From Service is by reason of the Participant’s death, then any Units that becomes payable under the Plan due to the Participant’s Separation From Service will be paid six (6) months and one (1) day after the date on which the Participant’s Separation From Service occurs.

The Company shall not be obligated to issue any shares of Stock until (a) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

Further, notwithstanding anything in the Agreement to the contrary, if the Participant resides outside the United States, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company to obtain the approval of or complete any legal or regulatory
2
-Rev. 12.2019

filing with any governmental and/or regulatory body in the Participant’s country of residence. Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require the Participant to sell such shares of Stock immediately or within a specified time following the Participant’s Separation From Service (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant’s behalf).

9.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the grant, vesting and settlement of Units hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) does not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate the Participant’s liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if the withholding of Tax-Related Items is required, the Company may hold back from the total number of shares of Stock to be delivered to the Participant, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of Units, the Participant expressly consents to the withholding of shares of Stock and/or cash as provided for hereunder.

Alternatively, the Participant hereby authorizes the Company (on the Participant’s behalf and at the Participant’s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from the Participant’s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares
3
-Rev. 12.2019

of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.

All other Tax-Related Items related to the grant or vesting of Units and any shares of Stock delivered in settlement thereof are the Participant’s sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant’s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A. Notwithstanding any action or inaction by the Administrator, the Participant is exclusively responsible for any tax consequences under Code Section 409A resulting from the award of Units.

10.    Investment Intent. The Participant acknowledges that the acquisition of the Units and underlying shares of Stock is for investment purposes without a view to distribution thereof.

11.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the Units awarded under this Agreement are not transferable and the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and applicable laws, rules and regulations. Shares of Stock issued to the Participant in certificate form or to the Participant’s book entry account upon settlement of the Units may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant’s book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    12.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the Units and/or cash acquired under the Plan (including, but not limited to, dividends and any
4
-Rev. 12.2019

proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.

13.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

    The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s
5
-Rev. 12.2019

participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon settlement of the Units. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant Units or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

14.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)    all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)    the grant of the Units and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of Units hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;
6
-Rev. 12.2019


(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the Units or of any amount due to the Participant pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    15.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Units under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Units is not subject to the supervision of securities authorities outside the United States.

    16.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Units and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

    17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is
7
-Rev. 12.2019

considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

    18.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
19.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. The Participant acknowledges that he/she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    20.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”). Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the
8
-Rev. 12.2019

Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

    21.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

22.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    23.    Award Subject to the Plan; Conflicts. The award of Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Units granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Units subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

24.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

9
-Rev. 12.2019

25.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

26.     Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

27.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

28.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

10
-Rev. 12.2019

IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: 2011 LONG TERM INCENTIVE PLAN
Number of Units: %%TOTAL_UNITS_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION
    
                image_03.jpgimage_13.jpg
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i) SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT’S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iv) THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.

6721483-v3\GESDMS
11
-Rev. 12.2019
 EX-10.65 6 ex1065-2021grantxnqagreeme.htm EX-10.65 Document
Exhibit 10.65


    Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Plan. Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

    1.    Grant of Stock Option. The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth in your Equity Award and Acceptance Summary (the “Option Shares”) at the price set forth herein (the “Grant Price”). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date.

    2.    Term and Vesting of Stock Option. Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from date of grant until the “Expiration Date” and shall vest in accordance with the vesting schedule. If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

    3.    Exercise of Stock Option. While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares. Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following: (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if you reside in a country where the local laws and/or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and/or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.

    The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised. The notice and payment in full of the Option Shares being exercised,

–Rev 1.2021
1

must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.

    Upon the Company’s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares. However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

    4.    Termination of Employment.

        a.    In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.

        b.    Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option. 

        c.    In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.

        d.    Upon termination of your employment for reasons other than for Cause (as defined in Section 4.e. below), death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares. Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited; provided, however, that the Committee, in its sole discretion, may extend the exercise period and/or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option). Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).

        e.    Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited. For purposes of this Agreement, “Cause” means a felony conviction or your failure to contest prosecution for a felony, or your misconduct or dishonesty that is harmful to the business or reputation of the Company.


–Rev 1. 2021
2

        f.    The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

        g.    Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.

        h.    Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

        i.    If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

        j.    If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    5.    Change in Control. To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence. If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines. If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control. If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.

    6.    Recoupment Policy.


–Rev 1. 2021
3

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 6, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    7.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    8.    Transferability. Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members. During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.

–Rev 1. 2021
4


    9.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.

    Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.

    All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility. In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Stock Option is intended to be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply

–Rev 1. 2021
5

with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    10.    Repatriation and Legal/Tax Compliance Requirements. If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).

11.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. You understand that you may, at

–Rev 1. 2021
6

any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    12.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;

(c)all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Stock Option is not intended to replace any pension rights or compensation;

(g)the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);


–Rev 1. 2021
7

(j)unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;
(k)for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.

    13.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

    14.    Not a Public Offering. Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law.

    15.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    16.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom

–Rev 1. 2021
8

awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.

    17.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

    18.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    19.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    20.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    21.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or

–Rev 1. 2021
9

to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    22.    Choice of Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and/or to be performed.

    23.    Award Subject to Plan; Conflicts.    The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

    24.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    25.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable

26.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    27.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.


–Rev 1. 2021
10

    
    IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.



                    BOSTON SCIENTIFIC CORPORATION        
image_0d.jpg                image_1d.jpg
                    Michael F. Mahoney
President and Chief Executive Officer































–Rev 1. 2021
11


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 19 of the Agreement, if you transfer your residence and/or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

1.    Personal Data. This provision replaces Section 11 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and

–Rev 1. 2021
12

operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.


–Rev 1. 2021
13

AUSTRALIA

1.    Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your vested Stock Option will no longer be exercisable after the earlier of: (i) thirty (30) days from the date of termination of employment; and (ii) the Expiration Date specified in Section 2 of the Agreement.

2.    Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

AUSTRIA

No country-specific provisions.

BELGIUM

1.    Acceptance of Stock Option. In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to:
Boston Scientific
Green Square
Lambroekstraat 5D
1831 Diegem
Belgium
Attn.: Nathalie Derue

I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date.

The undersigned acknowledges that he/she has been encouraged to discuss this matter with a financial and/or tax advisor and that this decision is made in full knowledge.

Employee Signature:        _______________________________

Employee Printed Name:    _______________________________

Date of Acceptance:        _______________________________

If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

2.    Undertaking for Qualifying Option. If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation

–Rev 1. 2021
14

for Belgium tax purposes pursuant to the article 43, §6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death). If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above.
Employee Signature:        _______________________________

Employee Printed Name:    _______________________________
    
BRAZIL

1.    Compliance with Law. By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

2.    Labor Law Policy and Acknowledgement. This provision supplements Section 12 of the Agreement:

By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.

CANADA

1.    Use of Previously Owned Shares. Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.

2.    Personal Data. This provision supplements Section 11 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

3.    Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (i.e., the New York Stock Exchange).

4.    Nature of Grant. The following provision supplements Section 12(k) of the Agreement:


–Rev 1. 2021
15

For purposes of the Stock Options, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation
explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Stock Options, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

5.    Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.

CHILE

Securities Law Information. The offer of the Stock Option constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of the Stock Option is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Stock Option is not registered in Chile, the Company is not required to provide public information about the Stock Option or the shares of Stock in Chile. Unless the Stock Option and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.

–Rev 1. 2021
16

Esta oferta de opción sobre acciones (“Opción”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Opción se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Opciónes de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública respecto de los Opciónes or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.     Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of: (i) the period set forth in Section 4 of the Agreement; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (“SAFE”)); and (iii) the Expiration Date specified in Section 2 of the Agreement.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the

–Rev 1. 2021
17

Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 12 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Stock Option Upon Termination of Employment. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is being provided to comply with the Stock Option Act.

FINLAND

No country-specific provisions.


–Rev 1. 2021
18

FRANCE

1.    Nature of the Award. The Stock Option is not granted under the French specific regime provided by Articles L225-177 and seq. of the French commercial code.

2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

1.    Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

2.    IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

3.    Wages. The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

4.    Nature of Scheme. You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”).


–Rev 1. 2021
19

INDIA

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ISRAEL

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Securities Law Information.  The grant of Stock Options under the Plan does not constitute a public offering under the Securities Law, 1968.

ITALY

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.    Plan. This provision supplements Section 12 of the Agreement: You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

1.    Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any

–Rev 1. 2021
20

income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

2.    Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 11 of the Agreement in its entirety:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.

You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.

MEXICO

1.    Acknowledgement of the Agreement. By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option.
Reconocimiento del Contrato. Al aceptar la Opción, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Apéndice, mismos que ha revisado. Usted reconoce, además, que acepta todas las disposiciones del Plan, y del contrato, incluyendo

–Rev 1. 2021
21

este Apéndice. También reconoce que ha leído y aprueba de forma expresa los términos y condiciones establecidos en la sección doce 12 del contrato que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan su participación en el mismo son ofrecidos por la Compañía de forma totalmente discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    La Compañía y sus afiliados no son responsables por cualquier disminución en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opción.
2.    Labor Law Acknowledgement and Policy Statement. By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ley Laboral y Declaración de la Política. Al aceptar el Otorgamiento de la Opción, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es únicamente responsable de la administración del Plan. Usted además reconoce que su participación en el Plan, la concesión de Opción y cualquier adquisición de acciones de conformidad con el Plan no constituyen una relación de trabajo entre Usted y Boston Scientific Corporation, ya que Usted está participando en el Plan sobre una base totalmente comercial y su único patrón es una sociedad mercantil Mexicana (“Boston Scientific-México”). Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participación en el Plan no establecen ningún derecho

–Rev 1. 2021
22

entre Usted y su Patrón, Boston Scientific-México, y no forman parte de las condiciones de trabajo y/o prestaciones otorgadas por Boston Scientific-México, y cualquier modificación al Plan o su terminación no constituirá un cambio o perjuicio de los términos y condiciones de su trabajo.
Usted además entiende que su participación en el Plan es resultado de una decisión unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y/o discontinuar su participación en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.
Finalmente, Usted declara que no se reserva acción o derecho alguno para presentar una reclamación o demanda en contra de Boston Scientific Corporation por cualquier compensación o daño o perjuicio en relación con cualquier disposición del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representación, accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamación o demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information. 

Warning

This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.


–Rev 1. 2021
23

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

5. Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PERU

Securities Law Information. The grant of the Stock Option is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you

–Rev 1. 2021
24

acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

Additional Acknowledgement of Nature of Plan and the Stock Option. By accepting the Stock Option, you understand, acknowledge and agree that the Stock Option is being granted ex gratia by the Company.
PHILIPPINES

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of the Stock Option, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea opțiune de stoc, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA

1.    U.S. Transaction. You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States.

–Rev 1. 2021
25

In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
2.    Cashless Exercise Provision. Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.

3.    Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.

4.    Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
5.    Labor Law Information. If you continue to hold shares of Stock acquired upon exercise of the Stock Option after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of the Stock Option to a cashless sell-all exercise and/or to pay any proceeds related to the Stock Option to you through local payroll.
SAUDI ARABIA

Securities Law Information. The grant of the Stock Option is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Stock Option under the Plan is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i)

–Rev 1. 2021
26

after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
1.    Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.
2.    The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
3.    Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
4.    Boston Scientific Corporation Equity Award and Acceptance Summary: This
document can be accessed at https://us.etrade.com/home -> My Stock Plan ->
Holdings -> click on a grant date and select “View Grant Documents”.

You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 11 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.


–Rev 1. 2021
27

In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.

You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment. In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 9 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 9 of the Agreement, in accepting the grant of the Stock Option, you authorize the Company to sell shares of Stock otherwise deliverable to you upon exercise of the Stock Option to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.


–Rev 1. 2021
28

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Stock Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

1.     Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 9 of the Agreement:
Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or

–Rev 1. 2021
29

withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 9 of the Agreement.

2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

170801730-v7\NA_DMS

–Rev 1. 2021
30
 EX-10.66 7 ex1066-2021grantxrsuagreem.htm EX-10.66 Document
Exhibit 10.66

EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS

Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Restricted Stock Unit Award Agreement

This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (the “Award”) by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Units. The Committee hereby grants you that number of Restricted Stock Units as set forth in your Equity Award and Acceptance Summary (the “Units”). Each Unit represents the Company’s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement. This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.

    2.    Vesting. The Units shall vest and shares of Stock will be issued to you in accordance with the schedule provided in your Equity Award and Acceptance Summary. Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date. No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest. Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and/or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in your country of residence (or country of employment, if different). Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    3.    Participant’s Rights in Stock. The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.

    4.    Death. In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution. Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.
–Rev 1.2021
1


    5.    Retirement. If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date. In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety. Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.

    In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

    6.     Disability. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you. Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.

    7.    Other Termination of Employment; Certain Vesting Conditions. If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause. For purposes of this Agreement, “Cause” means a felony conviction or your failure to contest prosecution for a felony, or your misconduct or dishonesty that is harmful to the business or reputation of the Company. Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above. For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

    8.    Change in Control of the Company. In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement. In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but
–Rev 1.2021
2

which have not yet been issued will be issued immediately prior to the Change in Control. Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or
–Rev 1.2021
3

authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

    12.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    13.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or
–Rev 1.2021
4

sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    14.    Repatriation and Legal/Tax Compliance Requirements. If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).
    
15.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as
–Rev 1.2021
5

described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    16.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

–Rev 1.2021
6

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and
–Rev 1.2021
7

value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    17.    Not a Public Offering. The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    20.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.

    21.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
22.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings
–Rev 1.2021
8

entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    23.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    24.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    25.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    26.    Award Subject to the Plan; Conflicts. The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

–Rev 1.2021
9

    27.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and/or to be performed.

    28.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    29.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

30.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    31.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.

IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.

BOSTON SCIENTIFIC CORPORATION
image_01a.jpg




Michael F. Mahoney
President and Chief Executive Officer

–Rev 1.2021
10

BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO RESTRICTED STOCK UNITS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND    

1.    Personal Data. This provision replaces Section 15 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.
–Rev 1.2021
11


The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

AUSTRALIA

Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a
–Rev 1.2021
12

legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

Tax Information. The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

AUSTRIA

No country-specific provisions.

BELGIUM

No country-specific provisions.

BRAZIL

Compliance with Law. By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

Labor Law Policy and Acknowledgement. This provision supplements Section 16 of the Agreement:

By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Units, if any, is not part of your remuneration from employment.

CANADA

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

Personal Data. This provision supplements Section 15 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

Nature of Grant. The following provision supplements Section 16(k) of the Agreement:

–Rev 1.2021
13

For purposes of the Units, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.

CHILE

Securities Law Information. The offer of the Units constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of Units is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Units are not registered in Chile, the Company is not required to provide public information about the Units or the shares of Stock in Chile. Unless the Units and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.
–Rev 1.2021
14

Esta oferta de Unidades de Acciones Restringidas (“Units”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Units se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Units de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública respecto de los Units or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account. If the Company changes its designated broker, you acknowledge and agree that the Company may transfer any shares of Stock issued under the Plan to the new designated broker, if necessary for legal or administrative reasons. You agree to sign any documentation necessary to facilitate the transfer of shares of Stock.

Mandatory Sale of Shares Following Termination of Employment. You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred
–Rev 1.2021
15

to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 16 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

–Rev 1.2021
16

DENMARK

Treatment of Units upon Termination of Service. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is provided to comply with the Stock Option Act.

FINLAND

No country-specific provisions.

FRANCE

Nature of the Award. The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).

Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong
–Rev 1.2021
17

law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

Wages. The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

Nature of the Program. The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court, tribunal or legal/regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.

INDIA

No country-specific provisions.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ISRAEL

Immediate Sale Restriction. Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold. You acknowledge and agree that the Company is authorized to issue sales instructions to the Company’s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale. You also agree to sign any agreements, forms and/or consents that may be reasonably requested by the Company or the Company’s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company’s designated broker with respect to such matters. When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale. The remaining proceeds will be paid to you as soon as practicable.

You acknowledge that neither the Company nor the Company’s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale. Due to fluctuations in the Stock price and/or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest. You understand and agree that the Company assumes no liability for any fluctuations in the Stock price and/or any applicable exchange rate.

–Rev 1.2021
18

Securities Law Information.  The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.

ITALY

Plan. This provision supplements Section 16 of the Agreement:
You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 15 of the Agreement in its entirety:

–Rev 1.2021
19

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan. You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896;. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896;
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.

MEXICO

Acknowledgement of the Agreement. By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the “Nature of Grant” section of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units.
–Rev 1.2021
20

Reconocimiento del Contrato. Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusión de este Apéndice, que le ha examinado. Usted reconoce, además, que usted acepta todas las disposiciones del Plan y del Contrato. Usted también reconoce que ha leído y, concretamente, y aprobar de forma expresa los términos y condiciones establecidos en la “Naturaleza del Otorgamiento” que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan y su participación en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminución en el valor de las acciones adquiridas en la adquisición de los Unidades.
Labor Law Acknowledgement and Policy Statement. By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ausencia de Relación Laboral y Declaración de la Política. Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es el único responsable de la administración del Plan. Además, usted acepta que su participación en el Plan, la concesión de los Unidades y cualquier adquisición de acciones en el marco del Plan no constituyen una relación laboral entre usted y Boston Scientific Corporation porque usted está participando en el Plan en su totalidad sobre una base comercial y su único empleador es una sociedad mercantil Mexicana (“Boston Scientific-Mexico”). Derivado de lo anterior,
–Rev 1.2021
21

usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participación en el Plan no establece ningún derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y / o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificación del Plan o la terminación de su contrato no constituirá un cambio o deterioro de los términos y condiciones de su empleo.
Además, usted entiende que su participación en el Plan es causada por una decisión discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y/o suspender su participación en el Plan en cualquier momento, sin responsabilidad alguna para con usted.
Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information.

Warning

This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
–Rev 1.2021
22

Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

5.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PERU

Securities Law Information. The grant of Units is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

–Rev 1.2021
23

Additional Acknowledgement of Nature of Plan and the Units. By accepting the Units, you understand, acknowledge and agree that the Units are being granted ex gratia by the Company.

PHILIPPINES

Settlement in Cash. Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and/or filing with the Philippines Securities and Exchange Commission.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of Units, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea unităților de Unit-uri, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA
U.S. Transaction. You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an
–Rev 1.2021
24

authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.
Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
Labor Law Information. If you continue to hold shares of Stock acquired upon settlement of the Units after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and/or to pay any proceeds related to the Units to you through local payroll.
SAUDI ARABIA

Securities Law Information. The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

–Rev 1.2021
25

3.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.

You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically
–Rev 1.2021
26

result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment. In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 13 of the Agreement, in accepting the grant of the Units, you authorize the Company to withhold shares of Stock or to sell shares of Stock otherwise deliverable to you upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

–Rev 1.2021
27

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.

2.     Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the
–Rev 1.2021
28

grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

170801729-v7\NA_DMS
–Rev 1.2021
29
 EX-10.67 8 ex1067-2021grantxtsragreem.htm EX-10.67 Document
Exhibit 10.67



Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: TSR PERFORMANCE SHARE PROGRAM -
Award Date: %%OPTION_DATE,'Month DD, YYYY'%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%


BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Total Shareholder Return Performance Share Program (the “Program”) for the period beginning January 1, 2021 and ending on December 31, 2023 (the “Performance Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions. Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Section 8 of this Agreement and Appendix B, and the satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the
-Rev. 1.2021        TSR Program

Company intends to award shares of Stock hereunder to you at the end of the Performance Period. Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period. Except as set forth in Section 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2022, the Award shall be forfeited in its entirety.

    7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2023, as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units
-Rev. 1.2021    2    TSR Program

set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount as calculated in accordance with the terms of the Program. In the event that a Change in Control occurs prior to January 1, 2022, the Award shall be forfeited in its entirety.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2023, as determined by the Committee immediately prior to the consummation of the Change in Control.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December 31, 2021 and a Change in Control occurs after December 31, 2021, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2023, as determined by the Committee immediately prior to the consummation of the Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and if, in the judgment of the Board, you commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

-Rev. 1.2021    3    TSR Program

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or
-Rev. 1.2021    4    TSR Program

sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted
-Rev. 1.2021    5    TSR Program

legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise
-Rev. 1.2021    6    TSR Program

unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.    

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 1.2021    7    TSR Program

APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN


The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows:

TSR Performance
Percentile Rank
Performance Share Units
as a Percent of Target
80th Percentile or above200%
50th Percentile100%
30th Percentile40%
Below 30th Percentile
0%
-Rev. 1.2021        TSR Program

APPENDIX B

This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.

Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.

This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of January 2021. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.

In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).

Section I.     All Countries Outside the United States

Nature of Grant. In accepting the grant, you acknowledge that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with
-Rev. 1.2021        TSR Program

the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your
-Rev. 1.2021        TSR Program

consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
 
Section II.     Country-Specific Terms and Conditions

COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

1.    Data Privacy: If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.
-Rev. 1.2021        TSR Program


You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

1.    Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee
-Rev. 1.2021        TSR Program

identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide
-Rev. 1.2021        TSR Program

Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE

1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.


*    *    *    *    *
170801727-v4\NA_DMS
-Rev. 1.2021        TSR Program
 EX-10.68 9 ex1068-2021grantxfcfagreem.htm EX-10.68 Document
Exhibit 10.68

Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: FCF PERFORMANCE SHARE PROGRAM
Award Date: %%OPTION_DATE,'Month DD, YYYY'%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%



BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Free Cash Flow Performance Share Program (the “Program”) for the performance period beginning January 1, 2021 and ending on December 31, 2021 (the “Performance Period”) and the three-year service period beginning on January 1, 2021 and ending on December 31, 2023 (the “Service Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions and Service Period. Subject to the eligibility conditions described in Section 7 of this Agreement, except as
-Rev. 1.2021        FCF Program

otherwise provided in Sections 5, 6 and 8 of this Agreement and Appendix B, and the satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Service Period (December 31, 2023). Shares of Stock shall be issued within thirty (30) days following the end of the Service Period based on actual performance during the Performance Period as determined at the first Committee meeting following the end of the Performance Period. Except as set forth in Sections 5, 6 and 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Service Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law) on or before the end of the Performance Period, shares of Stock shall be issued during the period January 1, 2022 to March 15, 2022, based on actual performance as determined at the first Committee meeting following the Performance Period. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability after the end of the Performance Period, shares of Stock shall be issued within seventy (70) days following your termination of employment based on actual performance during the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2021, but prior to the end of the Service Period, shares of Stock shall be issued to you within seventy (70) days following your Retirement on a prorated basis based on actual performance. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of the Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Service Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2022, the Award shall be forfeited in its entirety.

    7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Service Period as set forth in Section 3 above.

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2021, but prior to the end of the Service Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual
-Rev. 1.2021    2    FCF Program

performance as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Service Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with terms of the Program. In the event that a Change in Control occurs prior to January 1, 2022, the Award shall be forfeited in its entirety. In the event that your employment with the Company or an Affiliate terminates prior to a Change in Control as a result of death, Disability, or Retirement occurring after December 31, 2021, and a Change in Control occurs after December 31, 2021, then shares of Stock for any Units that have vested under Section 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control.

    Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change of Control on outstanding Awards which is in effect as of the Change of Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.
-Rev. 1.2021    3    FCF Program


    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or
-Rev. 1.2021    4    FCF Program

sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted
-Rev. 1.2021    5    FCF Program

legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise
-Rev. 1.2021    6    FCF Program

unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 1.2021    7    FCF Program

APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN



The Performance Share Units will pay out in shares of Stock in a range of 0% to 150% of the number of Performance Share Units as follows:

Performance
Percent to Plan
Units Vesting
125% or above150%
110%120%
100%100%
90%80%
50%25%
Less than 50%0%



-Rev. 1.2021        FCF Program

APPENDIX B
This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.
Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.
This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of January 2021. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.
In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.
Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).
Section I.     All Countries Outside the United States
Nature of Grant. In accepting the grant, you acknowledge that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with
-Rev. 1.2021        FCF Program


the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and
(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.
Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your
-Rev. 1.2021        FCF Program


consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.
Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) ”tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
Section II.     Country-Specific Terms and Conditions
COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND
1.    Data Privacy. If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:
You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.
-Rev. 1.2021        FCF Program


You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

1.    Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships
-Rev. 1.2021        FCF Program


held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.
-Rev. 1.2021        FCF Program



When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE
1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.
2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

*    *    *    *    *
170801718-v4\NA_DMS
-Rev. 1.2021        FCF Program

 EX-10.69 10 ex1069-2021grantxrsabodawa.htm EX-10.69 Document
Exhibit 10.69

BOSTON SCIENTIFIC CORPORATION

RESTRICTED STOCK AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the “Plan”).

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of shares set forth on the Signature Page of this Agreement (the “Restricted Stock”) of the Company’s Stock, subject to the restrictions set forth below. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Restricted Stock.

2.    Restrictions on Shares of Stock. Shares of Restricted Stock awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 12 below.

3.    Lapse of Restrictions. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control of the Company), shares of Restricted Stock awarded hereunder shall become free of the forfeiture restrictions described in Section 5 hereof on the last day of the Participant’s current term as a non-employee director of the Company.

4.    Participant’s Rights in Restricted Stock. The shares of Restricted Stock awarded hereunder shall be evidenced in the manner as the Company may determine. Any shares of Stock issued shall be registered in the name of the Participant and any certificates representing those shares of Stock may be held by the Company and not be delivered to the Participant until the lapse of all forfeiture restrictions with respect to the shares of Restricted Stock. The Participant agrees to deliver a stock power, endorsed in blank, relating to the shares of Restricted Stock awarded hereunder, if so requested by the Company. During the period that shares of Restricted Stock are subject to forfeiture (subject, however, to Section 12 of this Agreement relating to
-Rev. 01.2021

limits on transferability), the Participant will have all the rights of a stockholder of the Company with respect to the shares of Restricted Stock, including the right to receive dividends and the right to vote the shares of Restricted Stock.

5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant’s current term as a non-employee director of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall be free of restrictions pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such shares of Restricted Stock shall be immediately and automatically forfeited to the Company. If the Participant experiences a Separation From Service from the Company for cause, any shares of Restricted Stock awarded hereunder that have not been delivered to the Participant shall be immediately and automatically forfeited to the Company. For purposes of this Agreement, “cause” means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant’s misconduct or dishonesty that is harmful to the business or reputation of the Company.

6.    Change in Control of the Company. In the event of a Change in Control of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall immediately be free of restrictions.

7.    Consideration for Restricted Stock. The shares of Restricted Stock are being issued for no cash consideration.

8.    Legend on Certificate. The certificates representing the shares of Restricted Stock awarded hereunder, if delivered to the Participant prior to the lapse of the forfeiture restrictions, shall bear a legend substantially in the following form:

The transferability of this certificate and the shares of common stock represented hereby are subject to the terms and conditions (including forfeiture) of a Boston Scientific Corporation Long-Term Incentive Plan and a Restricted Stock Award Agreement entered into between the registered owner and Boston Scientific Corporation. Copies of the Plan and Agreement are on file in the offices of Boston Scientific Corporation at 300 Boston Scientific Way, Marlborough, MA 01752, USA.

In addition, certificates representing shares of Restricted Stock shall also bear an Affiliate Legend.
2
-Rev. 01.2021


9.    Delivery of Stock. The Company shall not be obligated to deliver any shares of Restricted Stock awarded hereunder until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with, and (ii) all other legal matters in connection with the issuance and delivery of such shares of Restricted Stock have been approved by the Company’s legal department.

10.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the shares of Restricted Stock awarded hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. If the Participant elects pursuant to Code Section 83(b) to recognize taxable income in connection with the award of Restricted Stock pursuant to this Agreement, the Participant must notify the U.S. Internal Revenue Service (with a copy to the Company) of such election in writing within thirty (30) days of the Grant Date and must pay in cash to the Company the amount of withholding and other tax obligations associated with the election or make other arrangements satisfactory to the Company for the payment thereof. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock award, and (b) does not commit to structure the terms of the award to reduce or eliminate the Participant’s liability for Tax-Related Items.

The Company shall have the right and is hereby authorized to withhold Tax-Related Items required by law to be withheld with respect to the shares of Restricted Stock awarded hereunder from any compensation or other amount owing to the Participant, as may be necessary in the opinion of the Company to satisfy all such Tax-Related Items, requirements and withholding obligations. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

11.    Investment Intent. The Participant acknowledges that the acquisition of the Restricted Stock is for investment purposes without a view to distribution thereof.

12.    Limits on Transferability. Until the restrictions imposed upon the Restricted Stock by this Agreement lapse in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the shares of Restricted Stock awarded and accepted hereby are not transferable and shall not be sold, transferred, assigned, pledged, gifted,
3
-Rev. 01.2021

hypothecated or otherwise disposed of or encumbered by the Participant. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and any applicable laws, rules and regulations.

    13.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Restricted Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.

    14.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

    The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all shares of Restricted Stock awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list
4
-Rev. 01.2021

with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired under the Plan. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant shares of Restricted Stock or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

15.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of shares of Restricted Stock is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of shares of Restricted Stock, even if shares of Restricted Stock have been granted in the past;

(c)    all decisions with respect to future grants of shares of Restricted Stock, if any, will be at the sole discretion of the Administrator;
5
-Rev. 01.2021


(d)    the grant of the shares of Restricted Stock and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of shares of Restricted Stock hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the shares of Restricted Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the shares of Restricted Stock resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the shares of Restricted Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the shares of Restricted Stock or of any amount due to the Participant upon lapse of restrictions on the Restricted Stock or the subsequent sale of any shares of Stock acquired.

    16.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Restricted Stock under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Restricted Stock is not subject to the supervision of securities authorities outside the United States.

    17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or
6
-Rev. 01.2021

amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Restricted Stock and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Restricted Stock and participation in the Plan or future grants of Restricted Stock that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
20.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Restricted Stock, be drawn up in English. The Participant acknowledges that he/she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Restricted Stock translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

21.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”).
7
-Rev. 01.2021

Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

    22.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Restricted Stock, any shares of Stock acquired pursuant to the Restricted Stock and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

23.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    24.    Award Subject to the Plan; Conflicts. The award of Restricted Stock granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Restricted Stock granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the award of Restricted Stock subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

8
-Rev. 01.2021

25.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

26.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

27.    Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

28.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

29.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

9
-Rev. 01.2021

IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN
Number of Shares: %%TOTAL_SHARES_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION
image_01.jpg    
                image_11.jpg
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i) SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT’S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iv) THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.

170801724-v4\NA_DMS
10
-Rev. 01.2021
 EX-10.70 11 ex1070-2021grantxrsubodawa.htm EX-10.70 Document
Exhibit 10.70

BOSTON SCIENTIFIC CORPORATION

RESTRICTED STOCK UNIT AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the “Plan”).

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of Restricted Stock Units set forth on the Signature Page of this Agreement (the “Units”). Each Unit represents the Company’s commitment to issue to the Participant one share of Stock, subject to the conditions set forth in this Agreement. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of Units.

2.    Restrictions on Units. Units awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 11 below.

3.    Vesting. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control Event (as defined in the Director Deferred Compensation Plan)), the Units awarded hereunder shall vest in full on the last day of the Participant’s current term as a non-employee director of the Company.

4.    Participant’s Rights in Stock. The shares of Stock, if and when issued to the Participant pursuant to this Agreement, shall be registered in the Participant’s name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will the Participant be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested and the underlying shares of Stock have been issued to the Participant.
-Rev. 1.2021


5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant’s current term as a non-employee director of the Company, any Units awarded hereunder that remain unvested shall vest pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such Units shall be immediately and automatically forfeited. If the Participant experiences a Separation From Service from the Company for cause, any Units awarded hereunder that have not been settled shall be immediately and automatically forfeited. For purposes of this Agreement, “cause” means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant’s misconduct or dishonesty that is harmful to the business or reputation of the Company.

6.    Change in Control Event. In the event of a Change in Control Event (as defined in the Director Deferred Compensation Plan), any unvested Units shall immediately vest in full.

7.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

8.    Issuance of Stock. Shares of Stock will be issued in settlement of vested Units within sixty (60) days after the earlier of (i) a Change in Control Event or (ii) the Participant’s Separation From Service (as defined in the Director Deferred Compensation Plan). Notwithstanding the foregoing, in the event that a Participant is a Specified Employee (as defined in the Director Deferred Compensation Plan) at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant’s Separation From Service is by reason of the Participant’s death, then any Units that becomes payable under the Plan due to the Participant’s Separation From Service will be paid six (6) months and one (1) day after the date on which the Participant’s Separation From Service occurs.

The Company shall not be obligated to issue any shares of Stock until (a) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

Further, notwithstanding anything in the Agreement to the contrary, if the Participant resides outside the United States, the Company may, in its sole discretion, settle the Units in the
2
-Rev. 01.2021

form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in the Participant’s country of residence. Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require the Participant to sell such shares of Stock immediately or within a specified time following the Participant’s Separation From Service (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant’s behalf).

9.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the grant, vesting and settlement of Units hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) does not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate the Participant’s liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if the withholding of Tax-Related Items is required, the Company may hold back from the total number of shares of Stock to be delivered to the Participant, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of Units, the Participant expressly consents to the withholding of shares of Stock and/or cash as provided for hereunder.

Alternatively, the Participant hereby authorizes the Company (on the Participant’s behalf and at the Participant’s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold
3
-Rev. 01.2021

any amount necessary to pay the Tax-Related Items from the Participant’s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.

All other Tax-Related Items related to the grant or vesting of Units and any shares of Stock delivered in settlement thereof are the Participant’s sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant’s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A. Notwithstanding any action or inaction by the Administrator, the Participant is exclusively responsible for any tax consequences under Code Section 409A resulting from the award of Units.

10.    Investment Intent. The Participant acknowledges that the acquisition of the Units and underlying shares of Stock is for investment purposes without a view to distribution thereof.

11.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the Units awarded under this Agreement are not transferable and the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and applicable laws, rules and regulations. Shares of Stock issued to the Participant in certificate form or to the Participant’s book entry account upon settlement of the Units may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant’s book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

4
-Rev. 01.2021

    12.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the Units and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.

13.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

    The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

5
-Rev. 01.2021

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon settlement of the Units. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant Units or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

14.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)    all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)    the grant of the Units and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further,
6
-Rev. 01.2021

the award of Units hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the Units or of any amount due to the Participant pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    15.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Units under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Units is not subject to the supervision of securities authorities outside the United States.

    16.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Units and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

    17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the
7
-Rev. 01.2021

shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

    18.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
19.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. The Participant acknowledges that he/she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    20.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”). Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and
8
-Rev. 01.2021

conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

    21.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

22.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    23.    Award Subject to the Plan; Conflicts. The award of Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Units granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Units subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

24.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be
9
-Rev. 01.2021

conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

25.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

26.     Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

27.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

28.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

10
-Rev. 01.2021

IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN
Number of Units: %%TOTAL_UNITS_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION
image_010.jpg    
                image_18.jpg
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i) SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT’S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iv) THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.

170801717-v5\NA_DMS
11
-Rev. 01.2021
 EX-10.72 12 ex1072-amendmentto2021revo.htm EX-10.72 Document
        Exhibit 10.72


Execution Version

AMENDMENT
AMENDMENT, dated as of December 21, 2022 (this “Amendment”), to the Credit Agreement, dated as of May 10, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among (i) BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Borrower”), (ii) the several banks and other financial institutions from time to time parties thereto (the “Lenders”) and (iii) WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent for the Lenders thereunder (in such capacity, the “Administrative Agent”).
W I T N E S S E T H:
WHEREAS, the Borrower, the Lenders and the Administrative Agent are parties to the Credit Agreement;
WHEREAS, the Borrower intends to consummate the Target Acquisition (as defined below) pursuant to the terms and conditions set forth in the Takeover Offer Document (as defined below);
WHEREAS, in connection with the Target Acquisition, the Borrower has requested that the Lenders consent to the amendments to the Credit Agreement and the other agreements as set forth herein to, among others, modify the conditions to the agreement of the Lenders to make Loans requested by the Borrower set forth in Section 7.2 of the Credit Agreement during the Certain Funds Period (as defined below); and
WHEREAS, the Lenders and the Administrative Agent are willing to agree to such amendments to the Credit Agreement and such other agreements, subject to the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the Borrower, the Lenders and the Administrative Agent hereby agree as follows:
SECTION 1.Defined Terms. Terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. As used in this Amendment, the following terms shall have the following meanings:
“Acquisition Co”: Boston Scientific Group plc, a public limited company incorporated under the laws of the Republic of Ireland, which is wholly-owned by the Borrower.
“Bridge Credit Agreement”: that certain credit agreement, dated as of December 9, 2022, among (i) the Borrower, (ii) the several banks and other financial institutions or entities from time to time parties thereto as lenders, and (iii) Citibank, N.A., as administrative agent.
“Business Day”: any day on which The Stock Exchange of Hong Kong Limited is open for the transaction of business that is not a Saturday, Sunday or other day that is a legal holiday under the laws of the State of New York or is a day on which banking institutions in such state are authorized or required by law to close.
“Certain Funds Commitment Period”: the period from and including the Amendment Effective Date and ending on the occurrence of any Mandatory Cancellation Event.
“Certain Funds Commitments”: During the Certain Funds Period, Revolving Credit Commitments under the Credit Agreement in an amount of $530,000,000 which are subject only to the satisfaction of the Certain Funds Conditions during the Certain Funds Period. Each Revolving Lender shall be deemed to have a Certain Funds Commitment during the Certain Funds Period in an amount equal to its Revolving Credit Commitment Percentage of the aggregate Certain Funds Commitments.

        2




“Certain Funds Conditions”: (a) the Borrowing Date will be a date within the Certain Funds Commitment Period, (b) the Administrative Agent shall have received the notice of Borrowing in accordance with subsection 2.2 of the Credit Agreement, (c) on the date of the notice of Borrowing delivered pursuant to subsection 2.2 of the Credit Agreement and on the proposed Borrowing Date, (i) no Certain Funds Default shall be continuing or would result from the proposed Borrowing and (ii) all Certain Funds Representations shall be true or, if a Certain Funds Representation does not already include a materiality concept, true in all material respects, (d) the Administrative Agent shall have received a certificate, dated the Borrowing Date and signed by the President, a Vice President or a Financial Officer of the Borrower, confirming the applicable requirements of clause (c) of this definition have been satisfied, (e) the Administrative Agent shall have received all fees due and payable on or prior to the Borrowing Date under the Loan Documents on or prior to the Borrowing Date, (f) it not being illegal for any Lender to lend and there being no injunction or restraining order prohibiting any Lender from lending its portion of the Loans or restricting the application of the proceeds thereof; provided, that such Lender has used commercially reasonable efforts to make the Loans through an Affiliate of such Lender not subject to such legal restriction; provided further, that the occurrence of such event in relation to one Lender shall not relieve any other Lender of its obligation to make Loans hereunder and (g) the Takeover Offer shall have become wholly unconditional in accordance with the terms of the Takeover Offer Document, in each case, without giving effect to (and there shall not have been) any modifications, amendments, consents, requests or waivers by the Borrower or the Acquisition Co except to the extent permitted pursuant to Section 6(b) of this Amendment.

“Certain Funds Default”: means an Event of Default arising from any of the following, with respect to the Borrower or the Acquisition Co only, other than to the extent that such Event of Default relates to circumstances affecting any member of the Target Group:
(a)    subsection 10(a) of the Credit Agreement as it relates to the payment of principal, interest or other fees under this Agreement in respect of the Certain Funds Commitments;
(b)    subsection 10(b) of the Credit Agreement as it relates to a Certain Funds Representation;
(c)    subsection 10(c) of the Credit Agreement as it relates to a failure to perform the covenants set forth in subsection 8.4(b), subsection 9.2 or subsection 9.4 of the Credit Agreement and Section 6(b) of this Amendment (other than paragraphs (vii), (viii) and (x) thereof), in each case only insofar as such covenants apply to the Borrower or the Acquisition Co and (in respect of any procurement obligation) each of the Borrower and the Acquisition Co shall use its best efforts in complying with its procurement obligations but any failure to perform the covenants by any other person that is not the Borrower or the Acquisition Co shall not constitute a breach of its obligations or a Certain Funds Default; or
(d)    subsection 10(g) of the Credit Agreement in respect of the Borrower or the Acquisition Co, but excluding, in relation to involuntary proceedings, any Event of Default caused by a frivolous or vexatious action, proceeding or petition in respect of which no order or decree in respect of such involuntary proceeding shall have been entered.
“Certain Funds Draw”: a Borrowing of Revolving Credit Loans in Dollars by the Borrower under the Certain Funds Commitments under the Credit Agreement to finance those purposes set out in the definition of Certain Funds Purposes.
“Certain Funds Period”: the period commencing on the later of (i) the Amendment Effective Date and (ii) date of the Rule 3.5 Announcement, and ending at the Certain Funds Termination Time.
“Certain Funds Purposes”:

        3




(i)    payment (directly or indirectly) of all or part of the cash price payable by the Acquisition Co to the holders of the Target Shares subject to the Takeover Offer in consideration of the acquisition of such Target Shares pursuant to the Takeover Offer; and
(ii)    financing (directly or indirectly) the fees, costs and expenses in respect of the Transactions and any stamp duty and any other taxes payable in connection with the Target Acquisition.
“Certain Funds Representations”: each of the representations set out in subsections 6.2, 6.3, 6.4, 6.7, 6.9, 6.10, 6.15 of the Credit Agreement and Section 4(b) of this Amendment, other than to the extent that such representations relates to facts and circumstances affecting any member of the Target Group and in each case only insofar as such representations apply to the Borrower or the Acquisition Co.
“Certain Funds Termination Time”: 11:59 p.m. (Hong Kong Time) on the first date on which a Mandatory Cancellation Event occurs or exists.
“Executive” means the Executive Director of the Corporate Finance Division of the Securities and Futures Commission of Hong Kong or any delegate of the Executive Director.
“Mandatory Cancellation Event”:
the occurrence of any of the following conditions or events:
(a)the Takeover Offer lapses, terminates or is withdrawn with the consent of the Executive (or all consideration payable by the Acquisition Co to the holders of the Target Shares for acceptances validly tendered under the Takeover Offer prior to such lapse, withdrawal or termination (and all fees, costs and expenses (including stamp duty) which are necessary to complete the purchase by Acquisition Co of such Target Shares from such holders) have been paid) or
(b)it becomes illegal for all the Lenders to lend or there is any injunction or restraining order prohibiting all the Lenders from lending the Loans or restricting the application of proceeds thereof, and the Lenders were unable to make the Loans through their respective Affiliates which are not subject to such legal restriction; or
(c)the date falling one hundred twenty (120) days after the date on which the Takeover Offer Document is issued (or such other date as the Lenders may agree in writing with the Borrower).
“Materially Adverse Amendment”: a modification, amendment or waiver to or of the terms or conditions of the Takeover Offer compared to the terms and conditions that are included in the draft of the Rule 3.5 Announcement delivered pursuant to Section 3(c) of this Amendment that is, in the opinion of the Lenders (acting reasonably having consulted in good faith with the Borrower), materially adverse to the interests of the Lenders (taken as a whole), it being acknowledged (i) a waiver of a pre-condition which then becomes a condition to be satisfied in connection with the Target Acquisition; and (ii) such modification, amendment or waiver as required by the Takeovers Code or the Executive, would not be materially adverse to the interests of the Lenders.

        4




“Minimum Acceptance Condition”: valid acceptances of the Takeover Offer being received in respect of a minimum of 156,725,925 Shares (representing approximately 50.01% of the Company’s issued share capital as at the date of the Rule 3.5 Announcement).
“Offer Documents”: the Takeover Offer Document and the Rule 3.5 Announcement.
“Original Rule 3.5 Announcement”: as defined in Section 6(b)(i) of this Amendment.
“Rule 3.5 Announcement” means an announcement pursuant to Rule 3.5 of the Takeovers Code.
“Takeover Offer”: means any voluntary conditional partial cash offer by or on behalf of the Acquisition Co to acquire a maximum of 203,702,962 shares in the Target in the issued share capital of the Target (representing 65% of the issued Target Shares), substantially on the terms and the conditions set out in the Rule 3.5 Announcement.
“Takeover Offer Document”: means the composite offer and response document to be jointly issued by or on behalf of the Acquisition Co and the Target to shareholders of the Target (other than the Acquisition Co and parties acting in concert with it) in accordance with the Takeovers Code containing, among other things, details of the Takeover Offer, as maybe be revised or supplemented as appropriate.
“Takeovers Code” means the Code on Takeovers and Mergers published by the Securities and Futures Commission of Hong Kong, as amended from time to time.
“Target”: Acotec Scientific Holdings Limited, a company incorporated in the Cayman Islands with limited liability, whose shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 6669).
“Target Acquisition”: the acquisition by the Acquisition Co of the Target Shares which are subject to the Takeover Offer pursuant to the Takeover Offer Document.
“Target Group”: the Target and its subsidiaries.
“Target Shares”: up to 65 % of the issued and to be issued ordinary share capital of the Target at the date of the Takeover Offer.
“Transaction Costs”: all fees, costs and expenses incurred or payable by the Borrower or any of its Subsidiaries in connection with the Transactions.
“Transactions”: the (i) execution and delivery of this Amendment and the Bridge Credit Agreement, (ii) the borrowing of Loans pursuant to the Certain Funds Draw and the use of the proceeds thereof, (iii) the consummation of the Target Acquisition and (iv) the payment of Transaction Costs.
SECTION 2.Certain Funds Conditionality. Notwithstanding the conditions to each Loan set forth in Section 7.2 of the Credit Agreement, the only conditions to the Certain Funds Draw with respect to the Certain Funds Commitments during the Certain Funds Period shall be the satisfaction of the Certain Funds Conditions.
SECTION 3.Conditions to Effectiveness. This Amendment shall become effective on the date (the “Amendment Effective Date”) on which (a) the Borrower, the Administrative Agent and the Majority Lenders shall have executed and delivered to the Administrative Agent this Amendment, (b) all fees and expenses payable to the Administrative Agent, the other Agents and any Lender on or prior to the Amendment Effective Date shall have been paid, (c) the Administrative Agent shall have received a copy, certified by the Borrower, of the issued Rule 3.5 Announcement in form and substance reasonably satisfactory to the Administrative Agent; it being acknowledged that the draft provided to the

        5




Administrative Agent as of December 12, 2022 is satisfactory to the Administrative Agent and (d) the Borrower shall have delivered a notice of termination of all outstanding commitments under the Bridge Credit Agreement to the Administrative Agent and Citibank, N.A. The Administrative Agent shall promptly notify the Borrower and the Lenders upon satisfaction of the conditions set out in paragraph (a), (b) and (c) and such notice shall also confirm the status to (i) the conditions remaining for the occurrence of the Amendment Effective Date and (ii) the Certain Funds Conditions, and such notice shall be conclusive and binding.
SECTION 4.Representation and Warranties. To induce the Administrative Agent to enter into this Amendment, the Borrower hereby represents and warrants to the Administrative Agent and all of the Lenders as of the Amendment Effective Date that:
(a)Corporate Power; Authorization; Enforceable Obligations.
(i)The Borrower has the corporate power and authority, and the legal right, to make and deliver this Amendment and to perform the Loan Documents, as amended by this Amendment, to which it is a party and has taken all necessary corporate action to authorize the execution, delivery and performance of this Amendment and the performance of the Loan Documents, as so amended, to which it is a party.
(ii)No consent or authorization of, filing with (other than the Borrower’s public filing of the Amendment on Form 8-K, if applicable), or notice to or other act by or in respect of, any Governmental Authority or any other Person is required with respect to the Borrower or any of its Subsidiaries in connection with the execution and delivery of this Amendment or with the performance, validity or enforceability of the Loan Documents, as amended by this Amendment, to which the Borrower is party.
(iii)This Amendment has been duly executed and delivered on behalf of the Borrower.
(iv)This Amendment and each Loan Document, as amended by this Amendment, to which the Borrower is a party constitutes a legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms, subject to the effects of bankruptcy, examination, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.
(b)Offer Documents and Related Documents. On the first Borrowing Date in respect of a Certain Funds Draw, the Borrower has delivered to the Administrative Agent complete and correct copies of the Offer Documents when issued, including all schedules and exhibits thereto. The release of the Rule 3.5 Announcement and the posting of the Offer Documents have been or will be, prior to their release or posting (as the case may be), duly authorized by the Acquisition Co and to the best knowledge of the Borrower, the Target. Each of the material obligations of the Acquisition Co under the Offer Documents is or will be, when entered into and delivered, the legal, valid and binding obligation of the Acquisition Co, enforceable against such Persons in accordance with its terms in each case, except as may be limited by (i) bankruptcy, insolvency, examination or other similar laws affecting the rights and remedies of creditors generally and (ii) general principles of equity.
(c)Representations and Warranties. The representations and warranties (except for those made in subsections 6.13 and 6.14 of the Credit Agreement) made by the Borrower in or pursuant to the Loan Documents are true and correct in all material respects on and as of the Amendment Effective Date, after giving effect to the effectiveness of this Amendment, as if made on and as of the Amendment Effective Date (it being understood that the only conditions to the making of the Certain Funds Draw under the Certain Funds Commitments are the Certain Funds Conditions).

        6




SECTION 5.Actions by Lenders During Certain Funds Period.
(a)During the Certain Funds Period and notwithstanding any provision to the contrary in the Loan Documents, none of the Lenders nor the Administrative Agent shall, unless (x) a Certain Funds Default has occurred and is continuing or would result from a proposed Borrowing, (y) a Certain Funds Representation remains untrue or, if a Certain Funds Representation does not already include a materiality concept, untrue in any material respect or (z) it is illegal for such Lender to lend and/or there is an injunction or restraining order prohibiting such Lender from lending its portion of the Loans or restricting the application of the proceeds thereof (provided, that such Lender used commercially reasonable efforts to make its portion of the Loans through an Affiliate of such Lender not subject to such legal restriction; and provided further, that the occurrence of an illegality event in relation to one Lender shall not relieve any other Lender of its obligations to make Loans hereunder), be entitled to:
(i)cancel any of its Certain Funds Commitments;
(ii)rescind, terminate or cancel the Loan Documents or the Certain Funds Commitments or exercise any right or remedy or make or enforce any claim under the Loan Documents it may have to the extent to do so would prevent or limit the making of a Loan for Certain Funds Purposes;
(iii)refuse to participate in the making of the Certain Funds Draw for Certain Funds Purposes unless the Certain Funds Conditions, as applicable, have not been satisfied;
(iv)exercise any right of set-off or counterclaim in respect of a Loan for Certain Funds Purposes to the extent to do so would prevent or limit the making of the Certain Funds Draw for Certain Funds Purposes; or
(v)cancel, accelerate or cause repayment or prepayment of any amounts owing under any Loan Document to the extent to do so would prevent or limit the making of the Certain Funds Draw for Certain Funds Purposes;
provided that, immediately upon the expiry of the Certain Funds Period all such rights, remedies and entitlements shall be available to the Lenders and the Administrative Agent notwithstanding that they may not have been used or been available for use during the Certain Funds Period.
(b)During the Certain Funds Period, the Revolving Lenders shall not make any Revolving Credit Loans to the Borrower to the extent that, after giving effect thereto, the aggregate Available Revolving Credit Commitments of the Revolving Lenders would be less than the Certain Funds Commitments, other than the Certain Funds Draw (it being understood that a Revolving Lender shall not be deemed to be a Defaulting Lender solely as a result of complying with the provisions of this clause (b)).
(c)Notwithstanding anything to the contrary in subsection 13.6 of the Credit Agreement, during the Certain Funds Period no Lender shall assign any Commitment or Loan or any other interest of such Lender hereunder or under the other Loan Documents without the prior written consent of the Administrative Agent and (in respect of its Certain Fund Commitment) unless a Certain Funds Default has occurred and is continuing, the Borrower, and if such Lender assigns, transfers, participates or sub-participates prior to the expiry of the Certain Funds Period (in accordance with this subsection 13.6) in respect of any of its Certain Funds Commitment without the consent of the Borrower, such Lender shall:
(i)remain liable to fund the amount of such Certain Funds Commitment during the Certain Funds Period notwithstanding such assignment, transfer, participation or sub-participation of such Certain Funds Commitment and provided further that if the assignee, transferee, participant, sub-participant defaults on its obligation to provide

        7




its pro rata share of a Loan to be made during the Certain Funds Period (a “Non-Funding Transferee”) then the Lender which has made the assignment, transfer, participation or sub-participation agrees to provide the amount that the Non-Funding Transferee was obliged to provide up to the amount that such Lender had assigned to such Non-Funding Transferee; and
(ii)unless the Borrower provides its written consent, retain the unrestricted right to exercise all voting and similar rights in respect of its Certain Funds Commitments including for the avoidance of doubt any rights to approve any amendment or waiver until the expiry of the Certain Funds Period, free of any obligation to act on the instructions of any other person.
SECTION 6.Actions by the Borrower During Certain Funds Period.

(a)During the Certain Funds Commitment Period and notwithstanding any provision to the contrary in the Loan Documents, the Borrower shall not rescind, terminate or cancel the Loan Documents or the Commitments (or request any Revolving Credit Loans to the extent that, after giving effect thereto, the aggregate Available Revolving Credit Commitments of the Revolving Lenders would be less than the Certain Funds Commitments, other than the Certain Funds Draw), and shall ensure that at least $530,000,000 of Revolving Credit Commitments remains available under the Credit Agreement for the Certain Funds Purposes.
(b)The Borrower will, or cause the Acquisition Co to:
(i)[reserved].
(ii)Comply in all material respects with the Takeover Code (subject to any waivers or dispensations granted by the Executive) in relation to any Takeover Offer.
(iii)Except as consented to by the Administrative Agent in writing (such consent not to be unreasonably withheld, delayed or conditioned), ensure that the Takeover Offer Document corresponds in all material respects to the terms and conditions of the Takeover Offer as contained in the Rule 3.5 Announcement, subject to any variations which are not Materially Adverse Amendments and changes as required pursuant to the Takeovers Code or required by the Executive.
(iv)Ensure that the Takeover Offer Document contains all the material terms and conditions of the Takeover Offer and ensure that the conditions to the Takeover Offer include an Acceptance Condition set at a level at not less than the Minimum Acceptance Condition.
(v)Except as consented to by the Administrative Agent in writing (such consent not to be unreasonably withheld, delayed or conditioned), not amend, treat as satisfied or waive (i) any term or condition of the Takeover Offer Document (other than the Acceptance Condition), as applicable, other than any such amendment, treatment or waiver which is not a Materially Adverse Amendment, or (ii) the Acceptance Condition if the effect of such amendment, treatment or waiver would be that the Acceptance Condition would be capable of being satisfied at a level less than the Minimum Acceptance Condition.
(vi)Not take any action, and procure that no Person acting in concert with it takes any action, which would require the Borrower or the Acquisition Co (as the case may be) to make a mandatory offer for the Target Shares in accordance with Rule 26 of the Takeovers Code or which would require a change to be made to the terms of the Takeover Offer pursuant to the Takeovers Code which change, if made voluntarily, would be a Materially Adverse Amendment.

        8




(vii)Provide the Administrative Agent with copies of the Takeover Offer Document and such information as it may reasonably request regarding the current level of acceptances subject to any confidentiality, legal, regulatory or other restrictions relating to the supply of such information.
(viii)Promptly deliver to the Administrative Agent or the receiving agent any written agreement between the Borrower or the Acquisition Co (as the case may be) and the Target to the extent material to the interests of the Lenders in relation to the consummation of the Target Acquisition (in each case, upon such documents or agreements being entered into by the Borrower or the Acquisition Co (as the case may be), and all other material announcements and documents published by the Borrower or the Acquisition Co (as the case may be) or delivered by the Borrower or the Acquisition Co (as the case may be) to the Executive pursuant to the Takeover Offer (other than the cash confirmation) and all legally binding agreements entered into by the Borrower or the Acquisition Co (as the case may be) in connection with a Takeover Offer, in each case to the extent the Borrower, acting reasonably, anticipates they will be material to the interests of the Lenders in connection with the Transactions, except to the extent it is prohibited by legal (including contractual) or regulatory obligations or restrictions from doing so.
(ix)Not declare the Takeover Offer unconditional as to acceptances until the Minimum Acceptance Condition has been satisfied.
(x)Not make any public announcement or public statement (other than in the relevant Offer Documents or the Borrower’s public filing of the Amendment on Form 8-K, if applicable) concerning the Credit Agreement or the Lenders in connection with the financing of the Target Acquisition without the prior consent of the Administrative Agent (such consent not to be unreasonably withheld, delayed or conditioned) unless required to do so by the Takeovers Code, the Executive, other competent regulatory body, stock exchange, or by a court of competent jurisdiction.
SECTION 7.Other Certain Funds Matters.
(a)Notwithstanding anything in the Credit Agreement to the contrary, for a period commencing on the Amendment Effective Date and ending on the date falling 120 days after the date on which the Target Acquisition is consummated (the “Clean-Up Date”), notwithstanding any other provision of any Loan Document, any breach of covenants, misrepresentations or other default which arises with respect to the Target Group will not be deemed a breach of a covenant, misrepresentation or a default or an Event of Default, as the case may be, if:
(A)it is capable or remedy and reasonable steps are being taken to remedy it;
(B)the circumstances giving rise to it have not knowingly been procured by or approved by the Borrower; and
(C)it is not reasonably likely to have a Material Adverse Effect.
If the relevant circumstances are continuing on or after the Clean-Up Date, there shall be a breach of covenant, misrepresentation or default or Event of Default, as the case may be, notwithstanding the above.
SECTION 8.Payment of Expenses. The Borrower agrees to pay or reimburse the Administrative Agent for all of its reasonable and documented out-of-pocket costs and expenses incurred in connection with this Amendment, any other documents prepared in connection herewith and the transactions contemplated hereby, including, without limitation, the reasonable and documented fees and disbursements of counsel to the Administrative Agent.

        9




SECTION 9.No Other Amendments; Confirmation. Except as expressly amended, modified and supplemented hereby, the provisions of the Credit Agreement and the other Loan Documents are and shall remain in full force and effect.
SECTION 10.Governing Law; Counterparts.
(a)This Amendment and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York. The provisions of subsections 13.12 and 13.17 of the Credit Agreement are incorporated herein, mutatis mutandis.
(b)This Amendment may be executed by one or more of the parties to this Amendment on any number of separate counterparts (including by facsimile transmission or in electronic (i.e., “pdf” or “tif”) format), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Amendment shall be deemed to include Electronic Signatures (as defined below), deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be. “Electronic Signatures” means any electronic symbol or process attached to, or associated with, any contract or other record and adopted by a person with the intent to sign, authenticate or accept such contract or record.
SECTION 11.Miscellaneous.
(a)Upon and after the Amendment Effective Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to “the Credit Agreement”, “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as modified hereby.  This Amendment shall constitute a Loan Document.
(b)The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under any of the Loan Documents, nor, except as expressly provided herein, constitute a waiver or amendment of any provision of any of the Loan Documents. It is the intent of the parties hereto, and the parties hereto agree, that this Amendment shall not constitute a novation of the Credit Agreement, any other Loan Document or any of the rights, obligations or liabilities thereunder.


IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective proper and duly authorized officers as of the day and year first above written.
BOSTON SCIENTIFIC CORPORATION


By: /s/ Robert J. Castagna______________
Name: Robert J. Castagna    
Title: Vice President and Treasurer    


Signature Page to Amendment to Credit Agreement

WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent and as a Lender


By: /s/ Darin Mullis_________________________
Name: Darin Mullis
Title: Managing Director



BANK OF AMERICA, N.A., as a Lender


By: /s/ Darren Merten____________________
Name: Darren Merten
Title: Director



BARCLAYS BANK PLC
as a Lender


By: /s/ Warren Veech III____________________
Name: Warren Veech III
Title: Vice President



CITIBANK, N.A.,
as a Lender


By: /s/ Richard Rivera__________________
Name: Richard Rivera
Title: Vice President



JPMORGAN CHASE BANK, N.A., as a Lender and as an Issuing Lender


By: /s/ James Kyle O’Donnell____________________
Name: James Kyle O’Donnell
Title: Vice President





SOCIETE GENERALE,
as a Lender


By: /s/ Richard Bernal____________________
Name: Richard Bernal
Title: Managing Director

Signature Page to Amendment to Credit Agreement




BNP PARIBAS,
as a Lender


By: /s/ Andy Strait____________________
Name: Andy Strait
Title: Managing Director


By: /s/ John Bosco____________________
Name: John Bosco
Title: Managing Director



DNB Capital LLC.,
as a Lender


By: /s/ Devan Patel____________________
Name: Devan Patel
Title: Senior Vice President

By: /s/ Bret Douglas____________________
Name: Bret Douglas
Title: Senior Vice President



Goldman Sachs Bank USA,
as a Lender


By: /s/ Dan Martis____________________
Name: Dan Martis
Title: Authroized Signatory





MUFG BANK, LTD.,
as a Lender


By: /s/ Jack Lonker____________________
Name: Jack Lonker
Title: Authorized Signatory



ROYAL BANK OF CANADA,
as a Lender


Error! No property name supplied.        12/8/2018
Signature Page to Amendment to Credit Agreement


By: /s/ Scott MacVicar____________________
Name: Scott MacVicar
Title: Authorized Signatory



THE BANK OF NOVA SCOTIA,
as a Lender


By: /s/ Arjun Talwalkar____________________
Name: Arjun Talwalkar
Title: Director



The Toronto-Dominion Bank, New York Branch,
as a Lender


By: /s/ Mike Tkach____________________
Name: Mike Tkach
Title: Authorized Signatory



U.S. BANK NATIONAL ASSOCIATION,
as a Lender


By: /s/ Maria Massimino____________________
Name: Maria Massimino
Title: Senior Vice President





Allied Irish Bank Plc,
as a Lender


By: /s/ Susan O’Herlihy____________________
Name: Susan O’Herlihy pp to Mick Murray
Title: Business Unit Head



DEUTSCHE BANK AG NEW YORK BRANCH,
as a Lender


By: /s/ Ming K. Chu____________________
Name: Ming K. Chu
Title: Director

By: /s/ Annie Chung____________________
Name: Annie Chung
Title: Director
Error! No property name supplied.        12/8/2018
Signature Page to Amendment to Credit Agreement





INTESA SANPAOLO S.p.A., New York Branch,
as a Lender


By: /s/ Jordan Schweon____________________
Name: Jordan Schweon
Title: Managing Director


By: /s/ Jennifer Feldman Facciola____________
Name: Jennifer Feldman Facciola
Title: Business Director



STANDARD CHARTERED BANK,
as a Lender


By: /s/ Kristopher Tracy____________________
Name: Kristopher Tracy
Title: Director, Financing Solutions




Error! No property name supplied.        12/8/2018
Signature Page to Amendment to Credit Agreement
 EX-10.76 13 ex1076-2022grantxnqagreeme.htm EX-10.76 Document
Exhibit 10.76

    Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Plan. Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

    1.    Grant of Stock Option. The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth in your Equity Award and Acceptance Summary (the “Option Shares”) at the price set forth herein (the “Grant Price”). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date.

    2.    Term and Vesting of Stock Option. Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from date of grant until the “Expiration Date” and shall vest in accordance with the vesting schedule. If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

    3.    Exercise of Stock Option. While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares. Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following: (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if you reside in a country where the local laws and/or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and/or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.

    The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised. The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.

–Rev 12.2021
1


    Upon the Company’s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares. However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

    4.    Termination of Employment.

        a.    In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.

        b.    Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option. 

        c.    In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.

        d.    Upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares. Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited; provided, however, that the Committee, in its sole discretion, may extend the exercise period and/or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option). Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).

        e.    Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited.

        f.    The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

        g.    Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.

–Rev 12. 2021
2


        h.    Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

        i.    If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

        j.    If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    5.    Change in Control. To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence. If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines. If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control. If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.

    6.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 6, shall have the meaning set forth below:

–Rev 12. 2021
3


            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    7.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    8.    Transferability. Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members. During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.

    9.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.

    Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of

–Rev 12. 2021
4

Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by withholding shares of Stock to be issued upon exercise of the Stock Option, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Stock Option, notwithstanding that a number of shares of Stock are withheld solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.

    All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility. In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Stock Option is intended to be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    10.    Repatriation and Legal/Tax Compliance Requirements. If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).

–Rev 12. 2021
5


11.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.


–Rev 12. 2021
6

    12.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;

(c)all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Stock Option is not intended to replace any pension rights or compensation;

(g)the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;
(k)for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms

–Rev 12. 2021
7

of your employment agreement, if any; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.

    13.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

    14.    Not a Public Offering. Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law.

    15.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    16.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.

    17.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise

–Rev 12. 2021
8

prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

    18.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    19.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    20.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    21.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    22.    Choice of Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and/or to be performed.

    23.    Award Subject to Plan; Conflicts.    The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This

–Rev 12. 2021
9

Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

    24.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    25.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable

26.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    27.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.


–Rev 12. 2021
10

    
    IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.



                    BOSTON SCIENTIFIC CORPORATION        
image_0b.jpg                image_1c.jpg
                    Michael F. Mahoney
President and Chief Executive Officer
































–Rev 12. 2021
11

BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 19 of the Agreement, if you transfer your residence and/or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Personal Data. This provision replaces Section 11 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

–Rev 12. 2021
12


The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

AUSTRALIA

Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates

–Rev 12. 2021
13

for any reason, your vested Stock Option will no longer be exercisable after the earlier of: (i) thirty (30) days from the date of termination of employment; and (ii) the Expiration Date specified in Section 2 of the Agreement.

Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

AUSTRIA

No country-specific provisions.

BELGIUM

Acceptance of Stock Option. In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to:
Boston Scientific
Green Square
Lambroekstraat 5D
1831 Diegem
Belgium
Attn.: Nathalie Derue

I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date.

The undersigned acknowledges that he/she has been encouraged to discuss this matter with a financial and/or tax advisor and that this decision is made in full knowledge.

Employee Signature:        _______________________________

Employee Printed Name:    _______________________________

Date of Acceptance:        _______________________________

If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

Undertaking for Qualifying Option. If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for Belgium tax purposes pursuant to the article 43, §6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option

–Rev 12. 2021
14

upon your death). If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above.
Employee Signature:        _______________________________

Employee Printed Name:    _______________________________
    
BRAZIL

Compliance with Law. By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

Labor Law Policy and Acknowledgement. This provision supplements Section 12 of the Agreement:

By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.

CANADA

Use of Previously Owned Shares. Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.

Personal Data. This provision supplements Section 11 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (i.e., the New York Stock Exchange).

Tax Information. All or a portion of the shares of Stock subject to the Stock Option may be “non-qualified securities” within the meaning of the Income Tax Act (Canada).

Nature of Grant. The following provision supplements Section 12(k) of the Agreement:

For purposes of the Stock Options, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of

–Rev 12. 2021
15

termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation
explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Stock Options, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.

CHILE

Securities Law Information. The offer of the Stock Option constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of the Stock Option is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Stock Option is not registered in Chile, the Company is not required to provide public information about the Stock Option or the shares of Stock in Chile. Unless the Stock Option and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.

–Rev 12. 2021
16

Esta oferta de opción sobre acciones (“Opción”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Opción se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Opciónes de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública respecto de los Opciónes or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of: (i) the period set forth in Section 4 of the Agreement; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (“SAFE”)); and (iii) the Expiration Date specified in Section 2 of the Agreement.

Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.

Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

–Rev 12. 2021
17


The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 12 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Stock Option Upon Termination of Employment. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is being provided to comply with the Stock Option Act.

FINLAND

No country-specific provisions.

FRANCE

Nature of the Award. The Stock Option is not granted under the French specific regime provided by Articles L225-177 and seq. of the French commercial code.


–Rev 12. 2021
18

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

Wages. The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

Nature of Scheme. You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”).

INDIA

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

INDONESIA

No country-specific provisions.

–Rev 12. 2021
19


IRELAND

No country-specific provisions.

ISRAEL

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Securities Law Information.  The grant of Stock Options under the Plan does not constitute a public offering under the Securities Law, 1968.

ITALY

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Plan. This provision supplements Section 12 of the Agreement: You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

KAZAKHSTAN

Securities Law Information. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of Shares to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for

–Rev 12. 2021
20

this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 11 of the Agreement in its entirety:


–Rev 12. 2021
21

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.

You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.

–Rev 12. 2021
22


MEXICO

Securities Law Information. You expressly recognize and acknowledge that the Company’s grant of the Stock Option and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Stock Option may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Acknowledgement of the Agreement. By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option.
Reconocimiento del Contrato. Al aceptar la Opción, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Apéndice, mismos que ha revisado. Usted reconoce, además, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Apéndice. También reconoce que ha leído y aprueba de forma expresa los términos y condiciones establecidos en la sección doce 12 del contrato que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan su participación en el mismo son ofrecidos por la Compañía de forma totalmente discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    La Compañía y sus afiliados no son responsables por cualquier disminución en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opción.

–Rev 12. 2021
23

Labor Law Acknowledgement and Policy Statement. By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ley Laboral y Declaración de la Política. Al aceptar el Otorgamiento de la Opción, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es únicamente responsable de la administración del Plan. Usted además reconoce que su participación en el Plan, la concesión de Opción y cualquier adquisición de acciones de conformidad con el Plan no constituyen una relación de trabajo entre Usted y Boston Scientific Corporation, ya que Usted está participando en el Plan sobre una base totalmente comercial y su único patrón es una sociedad mercantil Mexicana (“Boston Scientific-México”). Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participación en el Plan no establecen ningún derecho entre Usted y su Patrón, Boston Scientific-México, y no forman parte de las condiciones de trabajo y/o prestaciones otorgadas por Boston Scientific-México, y cualquier modificación al Plan o su terminación no constituirá un cambio o perjuicio de los términos y condiciones de su trabajo.
Usted además entiende que su participación en el Plan es resultado de una decisión unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y/o discontinuar su participación en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.
Finalmente, Usted declara que no se reserva acción o derecho alguno para presentar una reclamación o demanda en contra de Boston Scientific Corporation por cualquier compensación o daño o perjuicio en relación con cualquier disposición del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representación,

–Rev 12. 2021
24

accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamación o demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information. 

Warning

This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:

–Rev 12. 2021
25

1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

5. Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PERU

Securities Law Information. The grant of the Stock Option is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

Additional Acknowledgement of Nature of Plan and the Stock Option. By accepting the Stock Option, you understand, acknowledge and agree that the Stock Option is being granted ex gratia by the Company.

PHILIPPINES

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

POLAND

No country-specific provisions.

–Rev 12. 2021
26


PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of the Stock Option, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea opțiune de stoc, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA

U.S. Transaction. You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
Securities Law Information. You acknowledge that the Stock Option, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. The shares of Stock acquired pursuant to the Plan have not and will not be registered in Russia and, therefore, neither the Stock Option nor the shares of Stock may be used for offering or public circulation in Russia.
Cashless Exercise Provision. Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.

–Rev 12. 2021
27


Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.

The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.

Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
Labor Law Information. If you continue to hold shares of Stock acquired upon exercise of the Stock Option after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of the Stock Option to a cashless sell-all exercise and/or to pay any proceeds related to the Stock Option to you through local payroll.
SAUDI ARABIA

Securities Law Information. The grant of the Stock Option is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Stock Option under the Plan is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.


–Rev 12. 2021
28

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
1.    Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.
2.    The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
3.    Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
4.    Boston Scientific Corporation Equity Award and Acceptance Summary: This
document can be accessed at https://us.etrade.com/home -> My Stock Plan ->
Holdings -> click on a grant date and select “View Grant Documents”.

You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 11 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.


–Rev 12. 2021
29

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.

You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment. In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 9 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 9 of the Agreement, in accepting the grant of the Stock Option, you authorize the Company to sell shares of Stock otherwise deliverable to you upon exercise of the Stock Option to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Stock Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly

–Rev 12. 2021
30

available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 9 of the Agreement:
Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

–Rev 12. 2021
31


Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 9 of the Agreement.

Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

405238364-v3\NA_DMS

–Rev 12. 2021
32
 EX-10.77 14 ex1077-2022grantxrsuagreem.htm EX-10.77 Document
Exhibit 10.77


Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Restricted Stock Unit Award Agreement

This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (the “Award”) by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Units. The Committee hereby grants you that number of Restricted Stock Units as set forth in your Equity Award and Acceptance Summary (the “Units”). Each Unit represents the Company’s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement. This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.

    2.    Vesting. The Units shall vest and shares of Stock will be issued to you in accordance with the schedule provided in your Equity Award and Acceptance Summary. Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date. No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest. Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and/or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in your country of residence (or country of employment, if different). Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    3.    Participant’s Rights in Stock. The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.

    4.    Death. In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution. Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.

–Rev 12.2021
1

    5.    Retirement. If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date. In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety. Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.

    In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

    6.     Disability. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you. Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.

    7.    Other Termination of Employment; Certain Vesting Conditions. If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause. Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above. For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

    8.    Change in Control of the Company. In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement. In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control. Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of
–Rev 12.2021
2

a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection
–Rev 12.2021
3

with the issuance and delivery of the shares have been approved by the Company’s legal department.

    12.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    13.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the
–Rev 12.2021
4

Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    14.    Repatriation and Legal/Tax Compliance Requirements. If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).
–Rev 12.2021
5

    
15.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    16.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:

–Rev 12.2021
6

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Administrator shall have the exclusive discretion to determine when you are no longer actively providing
–Rev 12.2021
7

services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    17.    Not a Public Offering. The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    20.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.

    21.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic
–Rev 12.2021
8

system established and maintained by the Company or a third party-designated by the Company.
    
22.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    23.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    24.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    25.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    26.    Award Subject to the Plan; Conflicts. The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.
–Rev 12.2021
9


    27.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and/or to be performed.

    28.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    29.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

30.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    31.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.

IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.

BOSTON SCIENTIFIC CORPORATION
image_0c.jpg




Michael F. Mahoney
President and Chief Executive Officer

–Rev 12.2021
10

BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO RESTRICTED STOCK UNITS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND    

Personal Data. This provision replaces Section 15 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.
–Rev 12.2021
11


The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

AUSTRALIA

Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a
–Rev 12.2021
12

legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

Tax Information. The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

AUSTRIA

No country-specific provisions.

BELGIUM

No country-specific provisions.

BRAZIL

Compliance with Law. By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

Labor Law Policy and Acknowledgement. This provision supplements Section 16 of the Agreement:

By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Units, if any, is not part of your remuneration from employment.

CANADA

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

Personal Data. This provision supplements Section 15 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

Nature of Grant. The following provision supplements Section 16(k) of the Agreement:

–Rev 12.2021
13

For purposes of the Units, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.

CHILE

Securities Law Information. The offer of the Units constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of Units is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Units are not registered in Chile, the Company is not required to provide public information about the Units or the shares of Stock in Chile. Unless the Units and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.
–Rev 12.2021
14

Esta oferta de Unidades de Acciones Restringidas (“Units”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Units se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Units de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública respecto de los Units or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account. If the Company changes its designated broker, you acknowledge and agree that the Company may transfer any shares of Stock issued under the Plan to the new designated broker, if necessary for legal or administrative reasons. You agree to sign any documentation necessary to facilitate the transfer of shares of Stock.

Mandatory Sale of Shares Following Termination of Employment. You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred
–Rev 12.2021
15

to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 16 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

–Rev 12.2021
16

DENMARK

Treatment of Units upon Termination of Service. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is provided to comply with the Stock Option Act.

FINLAND

No country-specific provisions.

FRANCE

Nature of the Award. The Units are not granted under the French specific regime provided by Articles L. 225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).

Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong
–Rev 12.2021
17

law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

Wages. The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

Nature of the Program. The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court, tribunal or legal/regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.

INDIA

No country-specific provisions.

INDONESIA

No country-specific provisions.

IRELAND

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

ISRAEL

Immediate Sale Restriction. Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold. You acknowledge and agree that the Company is authorized to issue sales instructions to the Company’s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale. You also agree to sign any agreements, forms and/or consents that may be reasonably requested by the Company or the Company’s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company’s designated broker with respect to such matters. When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale. The remaining proceeds will be paid to you as soon as practicable.

You acknowledge that neither the Company nor the Company’s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale. Due to fluctuations in the Stock price and/or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest. You understand and agree that the Company assumes no liability for any fluctuations in the Stock price and/or any applicable exchange rate.
–Rev 12.2021
18


Securities Law Information.  The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.

ITALY

Plan. This provision supplements Section 16 of the Agreement:
You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPANHyperlink 'https://urldefense.proofpoint.com/v2/url?u=https-3A__us.etrade.com_home&d=DQMGaQ&c=ptMoEJ5oTofwe4L9tBtGCQ&r=dqXjWr1ZkgMeQUKG5xPbfMpFSFecYMcz6uxhhZHJRU6iuwzyUxW2uCfy7XvygFjB&m=iuAM0nNqCfilUazM_Aa47l6Xaj7hBqlwmt7IsxS7MCI&s=2E9ozXpVgHY9i5FUdeuo9WU0u0w8YIJ3qQW4Eo_Oh6k&e=' in document 'ex1056-2020grantxrsuagreem.htm' is not allowed. Return to your document and replace with a document hyperlink or URL beginning with https://www.sec.gov/Archives/edgar/data/ or https://www.sec.gov/ix?doc.

No country-specific provisions.

KAZAKHSTAN

Securities Law Information. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of shares of Stock to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 15 of the Agreement in its entirety:

–Rev 12.2021
19

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan. You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896.

MEXICO

Securities Law Information. You expressly recognize and acknowledge that the Company’s grant of the Units and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Acknowledgement of the Agreement. By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the “Nature of Grant” section of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units.
Reconocimiento del Contrato. Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusión de este Apéndice, que le ha examinado. Usted reconoce, además, que usted acepta todas las disposiciones del Plan y del Contrato. Usted también reconoce que ha leído y, concretamente, y
–Rev 12.2021
20

aprobar de forma expresa los términos y condiciones establecidos en la “Naturaleza del Otorgamiento” que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan y su participación en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminución en el valor de las acciones adquiridas en la adquisición de los Unidades.
Labor Law Acknowledgement and Policy Statement. By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ausencia de Relación Laboral y Declaración de la Política. Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es el único responsable de la administración del Plan. Además, usted acepta que su participación en el Plan, la concesión de los Unidades y cualquier adquisición de acciones en el marco del Plan no constituyen una relación laboral entre usted y Boston Scientific Corporation porque usted está participando en el Plan en su totalidad sobre una base comercial y su único empleador es una sociedad mercantil Mexicana (“Boston Scientific-Mexico”). Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participación en el Plan no establece ningún derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y / o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificación del
–Rev 12.2021
21

Plan o la terminación de su contrato no constituirá un cambio o deterioro de los términos y condiciones de su empleo.
Además, usted entiende que su participación en el Plan es causada por una decisión discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y/o suspender su participación en el Plan en cualquier momento, sin responsabilidad alguna para con usted.
Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information.

Warning

This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
–Rev 12.2021
22

No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

5.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PERU

Securities Law Information. The grant of Units is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

Additional Acknowledgement of Nature of Plan and the Units. By accepting the Units, you understand, acknowledge and agree that the Units are being granted ex gratia by the Company.
–Rev 12.2021
23


PHILIPPINES

Settlement in Cash. Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and/or filing with the Philippines Securities and Exchange Commission.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of Units, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea unităților de Unit-uri, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA
U.S. Transaction. You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
Securities Law Information. You acknowledge that the Units, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. The shares of Stock acquired pursuant to the Plan have not and will
–Rev 12.2021
24

not be registered in Russia and, therefore, neither the Units nor the shares of Stock may be used for offering or public circulation in Russia.
Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.
The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.
Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
Labor Law Information. If you continue to hold shares of Stock acquired upon settlement of the Units after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and/or to pay any proceeds related to the Units to you through local payroll.
SAUDI ARABIA

Securities Law Information. The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
–Rev 12.2021
25

1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

3.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be
–Rev 12.2021
26

considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.

You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment. In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 13 of the Agreement, in accepting the grant of the Units, you authorize the Company to withhold shares of Stock or to sell shares of Stock otherwise deliverable to you upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority, FINMA.

–Rev 12.2021
27

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).
–Rev 12.2021
28


Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.

Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

405238353-v3\NA_DMS
–Rev 12.2021
29
 EX-10.78 15 ex1078-2022grantxtsragreem.htm EX-10.78 Document
Exhibit 10.78



Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: TSR PERFORMANCE SHARE PROGRAM -
Award Date: %%OPTION_DATE,’Month DD, YYYY’%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%


BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Total Shareholder Return Performance Share Program (the “Program”) for the period beginning January 1, 2022 and ending on December 31, 2024 (the “Performance Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions. Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Section 8 of this Agreement and Appendix B, and the satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the
-Rev. 12.2021        TSR Program

Company intends to award shares of Stock hereunder to you at the end of the Performance Period. Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period. Except as set forth in Section 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2023, the Award shall be forfeited in its entirety.

    7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2024, as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units
-Rev. 12.2021    2    TSR Program

set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount as calculated in accordance with the terms of the Program. In the event that a Change in Control occurs prior to January 1, 2023, the Award shall be forfeited in its entirety.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2024, as determined by the Committee immediately prior to the consummation of the Change in Control.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December 31, 2022 and a Change in Control occurs after December 31, 2022, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2024, as determined by the Committee immediately prior to the consummation of the Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and if, in the judgment of the Board, you commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

-Rev. 12.2021    3    TSR Program

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including,
-Rev. 12.2021    4    TSR Program

without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in
-Rev. 12.2021    5    TSR Program

certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

-Rev. 12.2021    6    TSR Program

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.    

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 12.2021    7    TSR Program

APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN


The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows:

TSR Performance
Percentile Rank
Performance Share Units
as a Percent of Target
80th Percentile or above200%
50th Percentile100%
30th Percentile40%
Below 30th Percentile
0%
-Rev. 1.2021        TSR Program

APPENDIX B

This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.

Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.

This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2021. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.

In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).

Section I.     All Countries Outside the United States

Nature of Grant. In accepting the grant, you acknowledge that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with
-Rev. 12.2021        TSR Program

the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your
-Rev. 12.2021        TSR Program

consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
 
Section II.     Country-Specific Terms and Conditions

COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.
-Rev. 12.2021        TSR Program


You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee
-Rev. 12.2021        TSR Program

identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide
-Rev. 12.2021        TSR Program

Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE

Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.


*    *    *    *    *
405238355-v3\NA_DMS
-Rev. 12.2021        TSR Program
 EX-10.79 16 ex1079-2022grantxfcfagreem.htm EX-10.79 Document
Exhibit 10.79


Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: FCF PERFORMANCE SHARE PROGRAM
Award Date: %%OPTION_DATE,’Month DD, YYYY’%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%



BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Free Cash Flow Performance Share Program (the “Program”) for the performance period beginning January 1, 2022 and ending on December 31, 2022 (the “Performance Period”) and the three-year service period beginning on January 1, 2022 and ending on December 31, 2024 (the “Service Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions and Service Period. Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Sections 5, 6 and 8 of this Agreement and Appendix B, and the
-Rev. 12.2021        FCF Program

satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Service Period (December 31, 2024). Shares of Stock shall be issued within thirty (30) days following the end of the Service Period based on actual performance during the Performance Period as determined at the first Committee meeting following the end of the Performance Period. Except as set forth in Sections 5, 6 and 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Service Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law) on or before the end of the Performance Period, shares of Stock shall be issued during the period January 1, 2023 to March 15, 2023, based on actual performance as determined at the first Committee meeting following the Performance Period. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability after the end of the Performance Period, shares of Stock shall be issued within seventy (70) days following your termination of employment based on actual performance during the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2022, but prior to the end of the Service Period, shares of Stock shall be issued to you within seventy (70) days following your Retirement on a prorated basis based on actual performance. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of the Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Service Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2023, the Award shall be forfeited in its entirety.

    7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Service Period as set forth in Section 3 above.

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2022, but prior to the end of the Service Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance as determined by the Committee immediately prior to the consummation of
-Rev. 12.2021    2    FCF Program

the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Service Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with terms of the Program. In the event that a Change in Control occurs prior to January 1, 2023, the Award shall be forfeited in its entirety. In the event that your employment with the Company or an Affiliate terminates prior to a Change in Control as a result of death, Disability, or Retirement occurring after December 31, 2022, and a Change in Control occurs after December 31, 2022, then shares of Stock for any Units that have vested under Section 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control.

    Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change of Control on outstanding Awards which is in effect as of the Change of Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

-Rev. 12.2021    3    FCF Program

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including,
-Rev. 12.2021    4    FCF Program

without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in
-Rev. 12.2021    5    FCF Program

certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

-Rev. 12.2021    6    FCF Program

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 12.2021    7    FCF Program

APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN



The Performance Share Units will pay out in shares of Stock in a range of 0% to 150% of the number of Performance Share Units as follows:

Performance
Percent to Plan
Units Vesting
125% or above150%
110%120%
100%100%
90%80%
50%25%
Less than 50%0%



-Rev. 1.2021        FCF Program

APPENDIX B
This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.
Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.
This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2021. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.
In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.
Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).
Section I.     All Countries Outside the United States
Nature of Grant. In accepting the grant, you acknowledge that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with
-Rev. 12.2021        FCF Program


the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and
(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.
Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your
-Rev. 12.2021        FCF Program


consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.
Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) ”tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
Section II.     Country-Specific Terms and Conditions
COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND
Data Privacy. If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:
You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.
-Rev. 12.2021        FCF Program


You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships
-Rev. 12.2021        FCF Program


held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.
-Rev. 12.2021        FCF Program



When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE
Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.
Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

*    *    *    *    *
405238356-v3\NA_DMS
-Rev. 12.2021        FCF Program

 EX-10.80 17 ex1080-2022grantxrsabodawa.htm EX-10.80 Document
Exhibit 10.80

BOSTON SCIENTIFIC CORPORATION

RESTRICTED STOCK AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the “Plan”).

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of shares set forth on the Signature Page of this Agreement (the “Restricted Stock”) of the Company’s Stock, subject to the restrictions set forth below. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Restricted Stock.

2.    Restrictions on Shares of Stock. Shares of Restricted Stock awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 12 below.

3.    Lapse of Restrictions. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control of the Company), shares of Restricted Stock awarded hereunder shall become free of the forfeiture restrictions described in Section 5 hereof on the last day of the Participant’s current term as a non-employee director of the Company.

4.    Participant’s Rights in Restricted Stock. The shares of Restricted Stock awarded hereunder shall be evidenced in the manner as the Company may determine. Any shares of Stock issued shall be registered in the name of the Participant and any certificates representing those shares of Stock may be held by the Company and not be delivered to the Participant until the lapse of all forfeiture restrictions with respect to the shares of Restricted Stock. The Participant agrees to deliver a stock power, endorsed in blank, relating to the shares of Restricted Stock awarded hereunder, if so requested by the Company. During the period that shares of Restricted Stock are subject to forfeiture (subject, however, to Section 12 of this Agreement relating to
-Rev. 12.2021

limits on transferability), the Participant will have all the rights of a stockholder of the Company with respect to the shares of Restricted Stock, including the right to receive dividends and the right to vote the shares of Restricted Stock.

5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant’s current term as a non-employee director of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall be free of restrictions pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such shares of Restricted Stock shall be immediately and automatically forfeited to the Company. If the Participant experiences a Separation From Service from the Company for cause, any shares of Restricted Stock awarded hereunder that have not been delivered to the Participant shall be immediately and automatically forfeited to the Company. For purposes of this Agreement, “cause” means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant’s misconduct or dishonesty that is harmful to the business or reputation of the Company.

6.    Change in Control of the Company. In the event of a Change in Control of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall immediately be free of restrictions.

7.    Consideration for Restricted Stock. The shares of Restricted Stock are being issued for no cash consideration.

8.    Legend on Certificate. The certificates representing the shares of Restricted Stock awarded hereunder, if delivered to the Participant prior to the lapse of the forfeiture restrictions, shall bear a legend substantially in the following form:

The transferability of this certificate and the shares of common stock represented hereby are subject to the terms and conditions (including forfeiture) of a Boston Scientific Corporation Long-Term Incentive Plan and a Restricted Stock Award Agreement entered into between the registered owner and Boston Scientific Corporation. Copies of the Plan and Agreement are on file in the offices of Boston Scientific Corporation at 300 Boston Scientific Way, Marlborough, MA 01752, USA.

In addition, certificates representing shares of Restricted Stock shall also bear an Affiliate Legend.
2
-Rev. 12.2021


9.    Delivery of Stock. The Company shall not be obligated to deliver any shares of Restricted Stock awarded hereunder until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with, and (ii) all other legal matters in connection with the issuance and delivery of such shares of Restricted Stock have been approved by the Company’s legal department.

10.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the shares of Restricted Stock awarded hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. If the Participant elects pursuant to Code Section 83(b) to recognize taxable income in connection with the award of Restricted Stock pursuant to this Agreement, the Participant must notify the U.S. Internal Revenue Service (with a copy to the Company) of such election in writing within thirty (30) days of the Grant Date and must pay in cash to the Company the amount of withholding and other tax obligations associated with the election or make other arrangements satisfactory to the Company for the payment thereof. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock award, and (b) does not commit to structure the terms of the award to reduce or eliminate the Participant’s liability for Tax-Related Items.

The Company shall have the right and is hereby authorized to withhold Tax-Related Items required by law to be withheld with respect to the shares of Restricted Stock awarded hereunder from any compensation or other amount owing to the Participant, as may be necessary in the opinion of the Company to satisfy all such Tax-Related Items, requirements and withholding obligations. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

11.    Investment Intent. The Participant acknowledges that the acquisition of the Restricted Stock is for investment purposes without a view to distribution thereof.

12.    Limits on Transferability. Until the restrictions imposed upon the Restricted Stock by this Agreement lapse in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the shares of Restricted Stock awarded and accepted hereby are not transferable and shall not be sold, transferred, assigned, pledged, gifted,
3
-Rev. 12.2021

hypothecated or otherwise disposed of or encumbered by the Participant. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and any applicable laws, rules and regulations.

    13.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Restricted Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.

    14.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

    The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all shares of Restricted Stock awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list
4
-Rev. 12.2021

with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired under the Plan. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant shares of Restricted Stock or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

15.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of shares of Restricted Stock is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of shares of Restricted Stock, even if shares of Restricted Stock have been granted in the past;

(c)    all decisions with respect to future grants of shares of Restricted Stock, if any, will be at the sole discretion of the Administrator;
5
-Rev. 12.2021


(d)    the grant of the shares of Restricted Stock and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of shares of Restricted Stock hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the shares of Restricted Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the shares of Restricted Stock resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the shares of Restricted Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the shares of Restricted Stock or of any amount due to the Participant upon lapse of restrictions on the Restricted Stock or the subsequent sale of any shares of Stock acquired.

    16.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Restricted Stock under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Restricted Stock is not subject to the supervision of securities authorities outside the United States.

    17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or
6
-Rev. 12.2021

amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Restricted Stock and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Restricted Stock and participation in the Plan or future grants of Restricted Stock that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
20.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Restricted Stock, be drawn up in English. The Participant acknowledges that he/she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Restricted Stock translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

21.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”).
7
-Rev. 12.2021

Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

    22.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Restricted Stock, any shares of Stock acquired pursuant to the Restricted Stock and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

23.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    24.    Award Subject to the Plan; Conflicts. The award of Restricted Stock granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Restricted Stock granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the award of Restricted Stock subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

8
-Rev. 12.2021

25.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

26.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

27.    Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

28.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

29.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

9
-Rev. 12.2021

IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN
Number of Shares: %%TOTAL_SHARES_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION
image_011.jpg    
                image_19.jpg
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i) SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT’S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iv) THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.

405238369-v3\NA_DMS
10
-Rev. 12.2021
 EX-10.81 18 ex1081-2022grantxrsubodawa.htm EX-10.81 Document
Exhibit 10.81

BOSTON SCIENTIFIC CORPORATION

RESTRICTED STOCK UNIT AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time (the “Plan”).

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of Restricted Stock Units set forth on the Signature Page of this Agreement (the “Units”). Each Unit represents the Company’s commitment to issue to the Participant one share of Stock, subject to the conditions set forth in this Agreement. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of Units.

2.    Restrictions on Units. Units awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 11 below.

3.    Vesting. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control Event (as defined in the Director Deferred Compensation Plan)), the Units awarded hereunder shall vest in full on the last day of the Participant’s current term as a non-employee director of the Company.

4.    Participant’s Rights in Stock. The shares of Stock, if and when issued to the Participant pursuant to this Agreement, shall be registered in the Participant’s name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will the Participant be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested and the underlying shares of Stock have been issued to the Participant.
-Rev. 12.2021


5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause prior to the end of the Participant’s current term as a non-employee director of the Company, any Units awarded hereunder that remain unvested shall vest pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such Units shall be immediately and automatically forfeited. If the Participant experiences a Separation From Service from the Company for cause, any Units awarded hereunder that have not been settled shall be immediately and automatically forfeited. For purposes of this Agreement, “cause” means a felony conviction of the Participant or the failure of the Participant to contest prosecution for a felony, or the Participant’s misconduct or dishonesty that is harmful to the business or reputation of the Company.

6.    Change in Control Event. In the event of a Change in Control Event (as defined in the Director Deferred Compensation Plan), any unvested Units shall immediately vest in full.

7.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

8.    Issuance of Stock. Shares of Stock will be issued in settlement of vested Units within sixty (60) days after the earlier of (i) a Change in Control Event or (ii) the Participant’s Separation From Service (as defined in the Director Deferred Compensation Plan). Notwithstanding the foregoing, in the event that a Participant is a Specified Employee (as defined in the Director Deferred Compensation Plan) at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant’s Separation From Service is by reason of the Participant’s death, then any Units that becomes payable under the Plan due to the Participant’s Separation From Service will be paid six (6) months and one (1) day after the date on which the Participant’s Separation From Service occurs.

The Company shall not be obligated to issue any shares of Stock until (a) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

Further, notwithstanding anything in the Agreement to the contrary, if the Participant resides outside the United States, the Company may, in its sole discretion, settle the Units in the
2
-Rev. 12.2021

form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in the Participant’s country of residence. Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require the Participant to sell such shares of Stock immediately or within a specified time following the Participant’s Separation From Service (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant’s behalf).

9.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the grant, vesting and settlement of Units hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) does not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate the Participant’s liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if the withholding of Tax-Related Items is required, the Company may hold back from the total number of shares of Stock to be delivered to the Participant, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, the Participant is deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. The Participant will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of Units, the Participant expressly consents to the withholding of shares of Stock and/or cash as provided for hereunder.

Alternatively, the Participant hereby authorizes the Company (on the Participant’s behalf and at the Participant’s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any
3
-Rev. 12.2021

agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from the Participant’s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.

All other Tax-Related Items related to the grant or vesting of Units and any shares of Stock delivered in settlement thereof are the Participant’s sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant’s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A. Notwithstanding any action or inaction by the Administrator, the Participant is exclusively responsible for any tax consequences under Code Section 409A resulting from the award of Units.

10.    Investment Intent. The Participant acknowledges that the acquisition of the Units and underlying shares of Stock is for investment purposes without a view to distribution thereof.

11.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the Units awarded under this Agreement are not transferable and the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and applicable laws, rules and regulations. Shares of Stock issued to the Participant in certificate form or to the Participant’s book entry account upon settlement of the Units may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant’s book entry account or restricted legend(s) affixed
4
-Rev. 12.2021

to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    12.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the Units and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.

13.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

    The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list with
5
-Rev. 12.2021

the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon settlement of the Units. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant Units or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

14.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)    all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;
6
-Rev. 12.2021


(d)    the grant of the Units and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of Units hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the Units or of any amount due to the Participant pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    15.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Units under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Units is not subject to the supervision of securities authorities outside the United States.

    16.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Units and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.
7
-Rev. 12.2021


    17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

    18.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
19.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. The Participant acknowledges that he/she is proficient in the English language and understands the terms of this Agreement or has had the ability to consult with an advisor who is proficient in the English language. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    20.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”).
8
-Rev. 12.2021

Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

    21.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

22.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    23.    Award Subject to the Plan; Conflicts. The award of Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Units granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Units subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

24.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of
9
-Rev. 12.2021

litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

25.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

26.     Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

27.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

28.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

10
-Rev. 12.2021

IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN
Number of Units: %%TOTAL_UNITS_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION
image_08.jpg    
                image_16.jpg
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

BY ELECTRONICALLY ACCEPTING THE AWARD, THE PARTICIPANT AGREES THAT (i) SUCH ACCEPTANCE CONSTITUTES THE PARTICIPANT’S ELECTRONIC SIGNATURE IN EXECUTION OF THIS AGREEMENT; (ii) THE PARTICIPANT AGREES TO BE BOUND BY THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iii) THE PARTICIPANT HAS REVIEWED THE PLAN, THE AGREEMENT AND ANY ADDENDUM IN THEIR ENTIRETY, HAS HAD AN OPPORTUNITY TO OBTAIN THE ADVICE OF COUNSEL PRIOR TO ACCEPTING THE AWARD AND FULLY UNDERSTANDS ALL OF THE PROVISIONS OF THE PLAN, THE AGREEMENT AND ANY ADDENDUM; (iv) THE PARTICIPANT HAS BEEN PROVIDED WITH A COPY OR ELECTRONIC ACCESS TO A COPY OF THE U.S. PROSPECTUS FOR THE PLAN; AND (v) THE PARTICIPANT HEREBY AGREES TO ACCEPT AS BINDING, CONCLUSIVE AND FINAL ALL DECISIONS OR INTERPRETATIONS OF THE ADMINISTRATOR OR ITS DULY AUTHORIZED DELEGATE UPON ANY QUESTIONS ARISING UNDER THE PLAN, THE AGREEMENT AND ANY ADDENDUM.

405238328-v3\NA_DMS
11
-Rev. 12.2021
 EX-10.83 19 ex1083-offerletterartbutch.htm EX-10.83 Document




Exhibit 10.83



April 1, 2022

Arthur Butcher
ADDRESS LINE
ADDRESS LINE

Dear Art:
Congratulations on your promotion to Executive Vice President and Group President, Medsurg and APAC effective May 2, 2022. You will continue to be a member of Boston Scientific’s Executive Committee, an “executive officer” under the U.S. federal securities laws and an “officer” for purposes of Section 16 of the Exchange Act. You will continue to report to Michael Mahoney, Chairman, President and CEO. This letter and the Agreement Concerning Employment summarize our understanding of the terms of your employment.  We look forward to you formally accepting this offer.
COMPENSATION
Boston Scientific’s compensation programs provide our employees with significant compensation opportunities on a pay for performance basis.  The objective of these programs is to recognize and reward both individual and company performance during the performance year (defined as January 1st through December 31st of each year).
Base Salary:  Your base salary for this position will be $25,000.00 currently payable bi-weekly, equivalent to $650,000 on an annualized basis. Your performance and base salary will generally be reviewed on an annual basis during the normal executive review process and approved by the Executive Compensation and Human Resources Committee.  Your next performance and base salary review will be conducted during the normal executive review process, expected to commence in the first quarter of 2023.

Annual Bonus Plan:  You will continue to be eligible to participate in the Boston Scientific Corporation Annual Bonus Plan, subject to its terms. The Annual Bonus Plan provides employees with the opportunity for a variable financial incentive in recognition of performance each year.  Your 2022 annual target incentive will be increased from 70% to 75% of your base salary.  Your actual award will be based on your achievement of individual goals and the company's achievement of corporate performance goals.  Under the plan, generally you must be an employee on the date of payment to be eligible to earn and receive any bonus payment.
Deferred Bonus Plan: You will continue to be eligible to participate in the Boston Scientific Corporation Deferred Bonus Plan starting in 2022, subject to its terms. This plan allows you to save additional tax-deferred money for your future by deferring a portion of your annual bonus awarded under the Annual Bonus Plan. Specifically, under the plan, on an annual basis, you can elect to defer up to 75% of the Annual Bonus Plan bonus awarded to you subject to the provisions of the Plan. The open enrollment will be in June 2022 for the 2022 plan year (paid in Q1 2023) and every subsequent year following for which you are eligible

Promotional Equity Grant: As part of this offer, we are offering you an equity incentive award having a total value of $700,000 on the date of grant, which we expect to be May 2, 2022, subject to the approval of the Executive Compensation and Human Resources Committee.  Your award will be made pursuant to the Amended and Restated 2011 Boston Scientific Long-Term Incentive Plan (2011 LTIP) and the relevant award agreement. The equity incentive award could be in the form of Restricted Stock Units (RSUs) or non-qualified stock options or a mix of both RSUs and non-qualified stock options, depending on your preference. Both RSUs and non-qualified options will vest 25% per year, beginning on first anniversary of date of grant, and options expire on the 10th anniversary of the grant date. The election form will be sent under separate cover shortly after you have formally accepted this offer.

Thereafter, your performance and entitlement to long term incentive compensation grants will be reviewed in the normal course, on an annual basis. The mix of stock vehicles and target value for your level will be evaluated annually by the Executive Compensation and Human Resources Committee of the Boston Scientific Board of Directors. The current program provides for an equal mix of Total Shareholder Return Performance Shares (TSR PSP), Free Cash Flow Performance Shares (FCF PSP), Restricted Stock Units (RSU’s) and Non-Qualified Stock Options.



BENEFITS
You will remain eligible to continue participation in all benefit programs for which you were previously eligible and enrolled. Boston Scientific reserves the right to change and/or terminate any aspect of our benefit offerings, including employer contributions toward benefits.
EMPLOYMENT AT WILL
You will remain an “at will” employee of Boston Scientific.  This means that you remain free to resign at any time.  Likewise, Boston Scientific will continue to have the right to terminate your employment at any time, with or without reason or notice.  Acceptance of this transfer acknowledges your continued understanding and acceptance of the “at will” nature of your employment.


ACCEPTANCE
This offer is contingent upon the following:
• An acceptance no later than April 4, 2022;

• A signed Agreement Concerning Employment
Please indicate your acceptance by acknowledging below.
Art, we would like to congratulate you on this well-deserved promotion and wish you continued success. We look forward to your acceptance of this offer. 
Sincerely,
/s/ Michael F. Mahoney
Michael F. Mahoney              Chairman, President and Chief Executive Officer




Agreed to and Accepted by: /s/ Arthur Butcher                 Date: 4/2/2022 Arthur Butcher

Enclosures:
Agreement Concerning Employment


























 EX-10.84 20 ex1084-offerletterjeffmirv.htm EX-10.84 Document
Exhibit 10.84


    One Boston Scientific Place
    Natick, MA 01760-1537
    508.650.8000


December 11, 2012

Mr. Jeffrey Mirviss
ADDRESS LINE
ADDRESS LINE

Dear Jeff:

Based on your role within Boston Scientific, we are very pleased to offer you the position of Senior Vice President and President, Peripheral Interventions reporting to Michael Mahoney, President and Chief Executive Officer, effective January 1, 2013. As part of this offer, you will become a member of Boston Scientific's Executive Committee. Upon acceptance of this offer, you will be provided the following relative to compensation and benefits:

BASE SALARY
Your base salary will be $13,076.93 currently payable bi-weekly, equivalent to $340,000 on an annualized basis. This base pay increase is inclusive of any 2013 CMS merit award. Your performance and compensation will continue to be reviewed on an annual basis starting with the 2014 CMS cycle.

ANNUAL BONUS PLAN
The Boston Scientific performance year currently runs from January 1st through December 31st of each year. The Boston Scientific Corporation Annual Bonus Plan provides employees with the opportunity for a variable financial incentive in recognition of performance in a given year. Per the current plan, your 2013 annual target incentive will be increased from 45% to 50% of base salary. Your actual award will be based on your achievement of individual goals and the company's achievement of corporate performance goals. Under the current plan, you must be an active employee on the date of payment to receive any award pay-out under the plan.

ANNUAL EQUITY PROGRAM
You will continue to be eligible for consideration for an annual equity incentive as per Boston Scientific's Long Term Incentive Program during the normal executive review process. An award will depend on both company and individual performance. The current program provides for a mix of performance shares, options, and deferred stock units.    ·

CHANGE IN CONTROL AGREEMENT
Boston Scientific also provides Change in Control agreements to its key executives. In general, the Change in Control agreement entitles you as a member of our Executive Committee to a lump sum payment of three times your base salary and assumed on-plan incentive bonus if either your employment is terminated (other than for cause) or if your duties are diminished following a change in control of Boston Scientific. A copy of the Executive Committee level agreement will be distributed to you in the coming weeks.

EXECUTIVE RETIREMENT PLAN
As an Executive Committee Member, if you "Retire" from Boston Scientific (as that term is defined in our Executive Retirement Plan), you may be eligible to receive certain Executive Committee level benefits provided under that plan. A copy of Boston Scientific's Executive Retirement Plan is attached for your information.

DEFERRED BONUS PROGRAM:
You will continue to be eligible to participate in the Boston Scientific Corporation Deferred Bonus Plan. This plan allows you to save additional tax-deferred money for your future by deferring a portion of your annual bonus awarded under the Annual Bonus Plan. Specifically, under the plan, on an annual basis, you can elect to defer up to 75% of the Annual Bonus Plan bonus awarded to you starting with 2013 or any subsequent year.


BENEFITS
You will continue to be eligible for Boston Scientific's current U.S. benefit programs. Please understand that the company reserves the right to unilaterally amend or terminate any of these programs, or to require or change employee premium contributions toward benefits.

EMPLOYMENT AT WILL
Upon acceptance of this offer you will remain an "at will" employee of Boston Scientific. This means that you will be free to resign at any time. Likewise, Boston Scientific will have the right to terminate your employment at any time

Exhibit 10.84

with or without reason or notice. Acceptance of this offer acknowledges your understanding and acceptance of the "at will" nature of your employment.

ACCEPTANCE
This offer letter is contingent upon the following:
An acceptance date of no later than December 14, 2012;
Your immediate signing of the 2012 Agreement Concerning Employment.

Jeff, we believe this opportunity to be a mutually-rewarding one and look forward to your contributions and success with Boston Scientific.

Sincerely,

/s/ Michael Mahoney

Michael Mahoney
President and Chief Executive

Agreed to and Accepted by: /s/ Jeffrey B. Mirviss______________________________ Date: 14 Dec 2022
Jeffrey B. Mirviss

Enclosures
Agreement Concerning Employment
The Boston Scientific Corporation Executive Retirement Plan


 EX-10.85 21 ex1085-arnonxemployeedirec.htm EX-10.85 Document
EXHIBIT 10.85













BOSTON SCIENTIFIC CORPORATION
NON-EMPLOYEE DIRECTOR
DEFERRED COMPENSATION PLAN

As Amended and Restated Effective January 1, 2023























BOSTON SCIENTIFIC CORPORATION
NON-EMPLOYEE DIRECTOR
DEFERRED COMPENSATION PLAN

As Amended and Restated Effective January 1, 2023

Table of Contents
Page



Article 1 Nature and Purpose of Plan
1.1    Nature
1.2    Purpose
Article 2 Participation
2.1    Commencement of Participation
2.2    Duration of Participation
Article 3 Elections and Account
3.1    Deferral Election
3.2    Deemed Elections
3.3    Deferred Account
3.4    Account Records
Article 4 Payment of Deferred Amounts
4.1    Payment of Deferred DSU Accounts
4.2    Designation of Beneficiary
4.3    Delay For Specified Employees
4.4    Change in Control Event
Article 5 Nature of Claims for Benefit Payments
5.1    Obligation of the Company
5.2    Participants’ Rights Unsecured
Article 6 Administration
6.1    Plan Administrator
6.2    Powers of the Committee as Administrator
6.3    Finality of Committee Determinations
6.4    Claims Procedures
6.5    Indemnification
6.6    Right to Suspend Benefits and Correct Errors
6.7    Incapacity
6.8    Legal Holidays
Article 7 Amendment or Termination of the Plan
Article 8 Miscellaneous
8.1    No Assignment or Alienation
8.2    Limitation of Rights
8.3    Receipt and Release
8.4    No Effect on Future Service as a Director
8.5    Severability
8.6    Successor Company
8.7    Headings and Subheadings
8.8    Governing Law
Article 9 Definitions and Rules of Construction
9.1    Definitions
9.2    Rules of Construction

    ii








    iii

Article 1

Nature and Purpose of Plan
1.1Nature. This document is an amendment and complete restatement, effective January 1, 2023, of the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan. Amounts deferred under the Plan prior to January 1, 2023 will be governed by the terms of the Plan as in effect immediately prior to the effective date of this restatement. The Plan is intended to be a nonqualified deferred compensation plan within the meaning of Code section 409A, to be construed and administered in accordance with the Section 409A Standards.
1.2Purpose. The purpose of the Plan is to provide deferred compensation for the Company’s non-employee directors by providing Eligible Directors with an opportunity to defer a portion of their Compensation.
Article 2

Participation
1.1Commencement of Participation. An Eligible Director will become a Participant by filing an election form in accordance with the provisions of Section 3.1.
1.2Duration of Participation. A Participant will remain a Participant until he or she has received all payments to which he or she is entitled under the terms of the Plan.
Article 3

Elections and Account
1.1Deferral Election.
(a)    Prior to the beginning of each Plan Year, each Eligible Director may elect in writing, in the manner and on the form prescribed by the Committee, to defer payment of all or a portion of the Eligible Director’s Compensation by making one or both of the following elections:
    (i)    An election to defer payment of all or a portion, in increments of 25%, of the Director’s Cash Compensation and have that deferred amount converted to RSUs and credited to a Deferred Account pursuant to Section 3.4.
    (ii)    An election to defer payment of all or a portion, in increments of 25%, of the Director’s Equity Compensation and have that portion credited, as RSUs, to a Deferred Account pursuant to Section 3.3.
A Participant’s deferral election for a Plan Year will become irrevocable on the day preceding the first day of the Plan Year.

    (b)    If an individual becomes an Eligible Director after the beginning of a Plan Year and has not been eligible to participate in this Plan (or any other plan required to be aggregated with this Plan under the Section 409A Standards) at any time during the 24-month period ending on the date he or she becomes an Eligible Director, then, within thirty (30) days after the date the individual becomes an Eligible Director, he or she may make one or both of the elections described in Section 3.1(a) above with respect to Compensation for the Plan Year for services
    1

performed after the date the election is made, subject to any prorating that may be required under the Section 409A Standards. A deferral election made under this paragraph (b) will become irrevocable on the date the election is made.

3.2 Deemed Elections. If a Participant fails to make a timely deferral election in accordance with Section 3.1 for a Plan Year, the Participant will be deemed to have made the following elections:
(a)The Participant will be deemed to have elected not to defer any portion of his Cash Compensation for the Plan Year.
(b)The Participant will be deemed to have elected not to defer any portion of his Equity Compensation for the Plan Year.
3.3 Deferred Account. A Deferred Account will be established for any Participant who makes an election described in Section 3.1(a)(i) or (a)(ii) for any Plan Year. For each Plan Year for which a Participant makes an election described in Section 3.1(a)(i), the Participant’s Deferred Account will be credited with RSUs equal to the quotient (rounded down to the next whole number) of (A) divided by (B), where (A) is the dollar value of the Cash Compensation that the Participant elected to defer, and (B) is the closing price per share of Company Stock on the date the Cash Compensation would have been paid to the Participant in the absence of the Participant making an election described in Section. 3.1(a)(i). For each Plan Year for which a Participant makes an election described in Section 3.1(a)(i) with respect to a portion of his or her Equity Compensation (the “Deferred Portion”), the Participant’s Deferred Account will be credited with a number of RSUs equal to the number of Restricted Stock Units that would have been granted to the Participant under the LTIP if the Participant had elected to receive the Deferred Portion in the form of Restricted Stock Awards rather than as RSUs deferred under the Plan.
3.4 Account Records. Participants will be able to access records of their Deferred Account balances online or telephonically through the appropriate record keeper.
Article 4

Payment of Deferred Amounts
1.1Payment of Deferred Accounts. Upon the Participant’s Separation From Service for any reason, the total number of vested RSUs credited to the Participant’s Deferred Account will be settled in shares of Company Stock (with one share of Company Stock payable for each whole RSU) and distributed to the Participant within 60 days after the Participant’s Separation From Service. Any RSUs that are not vested as of the date of the Participant’s Separation From Service will be forfeited. The extent to which RSUs are vested will be determined by the terms of the LTIP and any applicable award agreement.
1.2Designation of Beneficiary. A Participant may designate a Beneficiary or Beneficiaries under the Plan to receive payment of the Participant’s Deferred Account upon the Participant’s death by submitting a completed Beneficiary designation to the Committee’s designated record keeper, in the form and manner prescribed by the Committee or its designee, before the Participant’s death. If the Participant fails to designate a Beneficiary, or if no designated Beneficiary survives the Participant, the Participant’s Beneficiary will be the Participant’s estate.
1.3Delay For Specified Employees. Because the Plan is only for Eligible Directors (those who are not employees of the Company), it is not expected that any Participants will be
    2

Specified Employees. However, in the event that a Participant is a Specified Employee at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant’s Separation From Service is by reason of the Participant’s death, then any amount that becomes payable under the Plan due to the Participant’s Separation From Service will be paid on the first day that is six months after the date on which the Participant’s Separation From Service occurs.
1.4Change in Control Event. Notwithstanding any other Plan provision, if a Change in Control Event occurs, then any unvested RSUs credited to the Participant’s Deferred Account will become vested, and all RSUs credited to the Participant’s Deferred Account will be settled in shares of Company Stock (with one share of Company Stock payable for each whole RSU) and distributed to the Participant following the date on which the Change in Control Event occurs.
Article 5

Nature of Claims for Benefit Payments
1.1Obligation of the Company. The Company will establish on its books a liability with respect to its obligations for benefits payable under the Plan to Participants and their Beneficiaries.
1.2Participants’ Rights Unsecured. The Plan is unfunded. The right of any Participant to receive payment of deferred amounts under the provisions of the Plan will be an unsecured claim against the general assets of the Company. The maintenance of individual Participant Accounts is for bookkeeping purposes only. The Company is not obligated to acquire, segregate, or set aside, in trust or otherwise, any assets of any kind for the discharge of its obligations under the Plan, nor will any Participant have any property rights in any particular assets held by the Company, whether or not held for the purpose of funding the Company’s obligations under the Plan.

Article 6

Administration
1.1Plan Administrator. The Committee will be the administrator of the Plan and will have full discretionary power and authority to administer the Plan in all of its details.
1.2Powers of the Committee as Administrator. The Committee’s powers as administrator of the Plan will include, but will not be limited to, the following discretionary authority, in addition to all powers and authority provided elsewhere in the Plan:
(a)to make and enforce such rules, regulations, and procedures, consistent with the terms of the Plan, as the Committee deems necessary or proper for the efficient administration of the Plan;
(b)to interpret the terms and provisions of the Plan and to decide any and all questions arising under the Plan, including, without limitation, the right to remedy possible ambiguities, inconsistencies, or omissions by a general rule or particular decision;
(c)to determine the amounts to be distributed to any Participant or Beneficiary in accordance with the terms of the Plan and determine the person or persons to whom such amounts will be distributed;
    3

(d)to allocate or delegate its powers to other persons; and
(e)to appoint persons to carry out administrative and recordkeeping functions with respect to the Plan.
1.3Finality of Committee Determinations. Determinations by the Committee and any interpretation, rule, or decision adopted by the Committee under the Plan, or in carrying out or administering the Plan, will be final and binding for all purposes and upon all interested persons in the absence of clear and convincing evidence that the determination or interpretation was made arbitrarily or capriciously.
1.4Claims Procedures. Any person making a claim for benefits under the Plan must submit the claim in writing to the Committee or its designee. If the Committee or its designee denies the claim in whole or in part, it will issue to the claimant a written notice explaining the reasons for the denial (with specific reference to the Plan provisions on which the denial is based) and identifying any additional information or documentation that might enable the claimant to perfect the claim. The claimant may, within 60 days of receiving a written notice of denial, submit a written request for reconsideration to the Committee or its designee, together with a written explanation of the basis for the request. The Committee or its designee will consider any such request and will provide the claimant with a written decision, which will include a written explanation of the reasons for the decision (with reference to the specific Plan provisions on which the decision is based). All interpretations, determinations, and decisions of the Committee with respect to any claim will be final and conclusive in the absence of clear and convincing evidence that the interpretation, determination, or decision was made arbitrarily or capriciously.
1.5Indemnification. The Company agrees to indemnify and hold harmless any member of the Committee, any employee or former employee to whom the Committee delegates or allocates any of the Committee’s responsibilities under the Plan, and any employee or former employee who has been asked to assist the Committee in any way (together, the “indemnified persons”) against any liability (including, without limitation, payment of attorney’s fees) that the indemnified person may incur as a result of the discharge of his or her duties and responsibilities in good faith under the Plan.
1.6Right to Suspend Benefits and Correct Errors. To the extent consistent with the Section 409A Standards, the Committee or its designee may delay any payment until satisfied as to the correctness of the payment or the person to receive the payment or to allow filing in any court of competent jurisdiction for a legal determination of the benefits to be paid and the person to receive them. The Committee specifically reserves the right to correct errors of every sort, and each Participant hereby agrees, on his own behalf and on behalf of any Beneficiary, to any method of error correction specified by the Committee or its designee. The Committee is authorized to recover any payment made in error.
1.7Incapacity. If the Committee or its designee determines that any person entitled to benefits under the Plan is a minor, an incompetent person, or other person incapable of providing a valid receipt, then any payment due to that person may be paid for the benefit of that person to the person’s spouse, parent, or other party providing or reasonably appearing to provide for the care of that person, unless a duly qualified guardian or other legal representative has been appointed, in which case payment will be made to that guardian or legal representative.
1.8Legal Holidays. If any day on (or on or before) which action under the Plan must be taken falls on a Saturday, Sunday, or legal holiday, that action may be taken on (or on or before) the next succeeding day that is not a Saturday, Sunday, or legal holiday; provided that
    4

this Section 6.8 does not permit any action that must be taken in one calendar year to be taken in any subsequent calendar year.
Article 7

Amendment or Termination of the Plan
The Company hopes and expects to continue the Plan in effect, but it reserves the right to amend the Plan, by action of the Board of Directors or its designee, in any respect at any time (retroactively if the Company so provides) and to terminate the Plan. Any amendment or termination will be set forth in a written instrument and signed by a duly authorized representative of the Company. In the event of an amendment or termination of the Plan, a Participant’s benefits will not be less than the amount credited to the Participant’s Deferred Account immediately prior to the amendment or termination.
Article 8

Miscellaneous
1.1No Assignment or Alienation. No payee may assign any payment due him under the Plan. No benefits at any time payable under the Plan will be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, attachment, garnishment, levy, execution, or other legal or equitable process or encumbrance of any kind. Any attempt to alienate, sell, transfer, assign, or otherwise encumber any Plan benefit, whether payable presently or in the future, will be void.
1.2Limitation of Rights. Neither the establishment nor amendment of the Plan, nor the payment of any benefits, will be construed as giving any individual any legal or equitable right against the Company or the Committee. In no event will the Plan be deemed to constitute a contract between any individual and the Company or the Committee.
1.3Receipt and Release. Any payment of a benefit under the Plan to any Participant or Beneficiary will be in full satisfaction of all claims with respect to the benefit under the Plan against the Company and the Committee.
1.4No Effect on Future Service as a Director. Nothing in the Plan, nor any action taken under the Plan, shall be construed as giving any Participant a right to continue as a Director or require the nomination of a Participant for a future term as a Director.
1.5Severability.     If any provision of the Plan is held by a court of competent jurisdiction to be invalid or unenforceable, the remaining provisions will remain fully enforceable.
1.6Successor Company. In the event of the dissolution, sale, merger, consolidation, or reorganization of the Company, provision may be made by which a successor to all or a major portion of the Company will have all of the powers, duties, and responsibilities of the Company under the Plan.
1.7Headings and Subheadings. Headings and subheadings are inserted for convenience only and are not to be considered in the construction of the provisions of the Plan.
1.8Governing Law. To the extent not preempted by federal law, the Plan will be governed by, and construed and administered in accordance with, the laws of the Commonwealth of Massachusetts.
    5

Article 9

Definitions and Rules of Construction
1.1Definitions. As used in the Plan, the following words and phrases, when capitalized, have the following meanings:
(a)“Account” means, with respect to a Participant, a bookkeeping account established for the Participant pursuant to Article 3 as a Deferred Account.
(b)“Affiliate” means (1) any corporation that is a member of a controlled group of corporations (as defined in Code section 414(b)) of which the Company is also a member, (2) any trade or business, whether or not incorporated, that is under common control (as defined in Code section 414(c)) with the Company, (3) any trade or business that is a member of an affiliated service group (as defined in Code section 414(m)) of which the Company is also a member, or (4) to the extent required by regulations issued under Code section 414(o), any other organization. The term “Affiliate,” however, does not include any corporation or unincorporated trade or business prior to the date on which that corporation, trade, or business satisfies the affiliation or control tests of (1), (2), (3), or (4) above.
(c)“Beneficiary” means the person or persons designated pursuant to Section 4.5 to receive benefits under the Plan in the event of a Participant’s death.
(d)“Board of Directors” means the Board of Directors of the Company.
(e) “Cash Compensation” means, with respect to an Eligible Director for a Plan Year, the Compensation payable to the Eligible Director for the Plan Year in the form of cash as an annual retainer or committee chair fees.
(f)“Change in Control Event” means a change in the ownership or effective control of the Company or a change in the ownership of a substantial portion of the assets of the Company, as determined in accordance with the Section 409A Standards, including §1.409A-3(i)(5).
(g)“Code” means the Internal Revenue Code of 1986, as amended from time to time. Reference to a particular section of the Code includes reference to any regulations issued by the Department of Treasury under that section and any notices and other releases issued by the Internal Revenue Service interpreting or implementing that section.
(h)“Committee” means the Executive Human Resources and Compensation Committee of the Board of Directors.
(i)“Company” means Boston Scientific Corporation.
(j)“Company Stock” means common stock of the Company.
(k)“Compensation” means, with respect to an Eligible Director for a Plan Year, the annual fees payable by the Company to the Eligible Director for the Plan Year, including retainer fees and committee chair fees and equity-based awards to be granted under the LTIP, for serving as a member of the Board of Directors.
(l)“Deferred Account” means, with respect to a Participant, the Account established for the Participant pursuant to Section 3.3.
    6

(m)“Director” means a member of the Board of Directors.
(n)“Eligible Director” means a Director who is not an employee of the Company or any of its Affiliates.
(o)“Equity Compensation” means, with respect to an Eligible Director for a Plan Year, Compensation for the Plan Year that is payable to the Eligible Director in the form of equity-based awards under the LTIP.
(p)“LTIP” means the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan, as amended from time to time, and any successor to that plan.
(q)“Participant” means an Eligible Director who becomes a participant in the Plan pursuant to Section 2.1 and has not ceased to be a Participant pursuant to Section 2.2.
(r)“Plan” means the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as set forth in this document, as amended from time to time.
(s)“Plan Year” means a calendar year beginning on or after January 1, 2023.
(t)“Restricted Stock Units or RSUs” means equity compensation awarded to a grantee in the form of notional units of Company Stock, in accordance with section 13 (Defined Terms) of the LTIP, and that are settled and paid to the grantee in the form of shares of Company Stock at the rate of one share of Company Stock for each RSU. Note that when the RSUs are deferred, they vest according to the RSU agreement applicable to the award and are settled and distributed to a Participant in shares of Company Stock in accordance with Section 4.1 following the Participant’s Separation From Service.
(u)“Restricted Stock Award” means an Award of Stock subject to forfeiture to the Company if specified conditions are not satisfied.
(v)“Section 409A Standards” means the applicable requirements and standards for nonqualified deferred compensation plans established by Code section 409A.
(w)“Separation From Service” means, with respect to a Participant, the expiration of the contract under which services are performed by the Participant for the Company and its Affiliates if the expiration constitutes a good-faith and complete termination of the Participant’s contractual relationship with the Company and all of its Affiliates within the meaning of the Section 409A Standards, including §1.409A-1(h).Whether a Separation From Service has occurred will be determined in accordance with the Section 409A Standards, including §1.409A-1(h). The Committee may, but need not, elect in writing, subject to the applicable limitations under the Section 409A Standards, any of the special elective rules prescribed in §1.409A-1(h) for purposes of determining whether a Separation From Service has occurred. Any such written election will be deemed to be part of the Plan.
(x)“Specified Employee” has the meaning given in Code section 409A(a)(2)(B)(i).
    7

1.2Rules of Construction. The following rules of construction will govern in interpreting the Plan:
(a)Words used in the masculine gender will be construed to include the feminine gender, where appropriate, and vice versa.
(b)Words used in the singular will be construed to include the plural, where appropriate, and vice versa.
(c)If any provision of the Plan is held to be illegal or invalid for any reason, that provision will be deemed to be null and void, but the invalidation of that provision will not otherwise impair or affect the Plan.    
        (d)    The Plan is intended to comply with Code section 409A, and it will be construed and administered accordingly. The provisions of the Plan and all deferral elections under Plan will be effected, construed, interpreted, and applied in a manner consistent with Section 409A Standards. To the extent that any terms of the Plan or a deferral election would subject any Participant to gross income inclusion, interest, or additional tax pursuant to Code section 409A, those terms are to that extent superseded by the applicable Section.image_06.jpg
























    
    8
 EX-21 22 exhibit21-listofsubsidiari.htm EX-21 Document

EXHIBIT 21
List of worldwide subsidiaries of Boston Scientific Corporation as of January 31, 2023

Structure of ownership and control:

Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities.
Acurate Industria e Comercio Ltda. (Brazil)
American Medical Systems Europe B.V. (The Netherlands)
Baylis Medical UK Limited (England)
BAYLIS Medical (Deutschland) GmbH (Germany)
Baylis Medical Company Inc. (Canada)
Baylis Medical France S.A.R.L. (France)
Baylis Medical USA Inc. (Delaware)
Biocompatibles UK Limited (England)
Biocompatibles, Inc. (Delaware)
Boston Scientific (Malaysia) Sdn. Bhd. (Malaysia)
Boston Scientific (South Africa) Proprietary Limited (South Africa)
Boston Scientific (Thailand) Ltd. (Thailand)
Boston Scientific (UK) Limited (England)
Boston Scientific AG (Switzerland)
Boston Scientific Argentina S.A. (Argentina)
Boston Scientific Asia Pacific Pte. Ltd. (Singapore)
Boston Scientific Benelux NV (Belgium)
Boston Scientific Ceska republika s.r.o. (Czech Republic)
Boston Scientific Chile SpA (Chile)
Boston Scientific Clonmel Limited, in liquidation (Ireland)
Boston Scientific Colombia Limitada (Colombia)
Boston Scientific Comercial de Costa Rica BSCR, S.R.L. (Costa Rica)
Boston Scientific Cork Limited, in liquidation (Ireland)
Boston Scientific de Costa Rica S.R.L. (Costa Rica)
Boston Scientific de Mexico, S.A. de C.V. (Mexico)
Boston Scientific del Caribe, Inc. (Puerto Rico)
Boston Scientific do Brasil Ltda. (Brazil)
Boston Scientific Far East B.V. (The Netherlands)
Boston Scientific Gesellschaft m.b.H. (Austria)
Boston Scientific Group plc (Ireland)
Boston Scientific Gulf for Trading (Saudi Arabia)
Boston Scientific Hellas S.A. (Greece)
Boston Scientific Hong Kong Limited (Hong Kong)
Boston Scientific Iberica, S.A. (Spain)
Boston Scientific India Private Limited (India)
Boston Scientific International B.V. (The Netherlands)
Boston Scientific International Finance Limited (Ireland)
Boston Scientific International S.A. (France)
Boston Scientific International Sdn. Bhd. (Malaysia)
Boston Scientific Ireland Limited, in liquidation (Ireland)
Boston Scientific Israel Ltd. (Israel)
Boston Scientific Japan K.K. (Japan)
Boston Scientific Korea Co., Ltd. (Korea)
Boston Scientific Korea Holding Co., Ltd. (Korea)
Boston Scientific Limited (England)
Boston Scientific Limited (Ireland)


Boston Scientific LLC (Russian Federation)
Boston Scientific Ltd./Boston Scientifique Ltee. (Canada)
Boston Scientific Medical Device (Malaysia) Sdn. Bhd. (Malaysia)
Boston Scientific Medical Device Limited (Ireland)
Boston Scientific Medical Technology (Shanghai) Co., Ltd. (China)
Boston Scientific Medizintechnik GmbH (Germany)
Boston Scientific Middle East FZ-LLC (UAE)
Boston Scientific Middle East SAL (Offshore) (Lebanon)
Boston Scientific Nederland B.V. (The Netherlands)
Boston Scientific Neuromodulation Corporation (Delaware)
Boston Scientific New Zealand Limited (New Zealand)
Boston Scientific Nordic AB (Sweden)
Boston Scientific Peru S.A.C. (Peru)
Boston Scientific Philippines, Inc. (Philippines)
Boston Scientific Polska Sp. z o.o. (Poland)
Boston Scientific Portugal - Dispositivos Medicos, Lda (Portugal)
Boston Scientific Pty Ltd (Australia)
Boston Scientific Romania S.R.L. (Romania)
Boston Scientific S.A.S. (France)
Boston Scientific S.p.A. (Italy)
Boston Scientific Scimed, Inc. (Minnesota)
Boston Scientific Technology & Engineering Services Private Limited (India)
Boston Scientific TIP Gerecleri Limited Sirketi (Turkey)
Boston Scientific Vietnam Company Limited (Vietnam)
Bravo Bidco Limited (England)
BSC International Medical Trading (Shanghai) Co., Ltd. (China)
BSC Medical Device Technology (Shanghai) Co., Ltd. (China)
BTG IM Holdings Ltd. (Israel)
BTG International (Holdings) Limited (England)
BTG International Canada Inc. (Canada)
BTG International Limited (England)
BTG Limited (England)
BTG Management Services Limited (England)
Cardiac Pacemakers, Inc. (Minnesota)
CeloNova BioSciences Germany GmbH, in liquidation (Germany)
DeVoro Medical Inc. (Delaware)
eCardio Sequoia Blocker Corp. (Delaware)
Electron Acquisition Corporation (Delaware)
EndoChoice Holdings, Inc. (Delaware)
EndoChoice, Inc. (Delaware)
EndoChoice Israel Ltd., in liquidation (Israel)
EP Technologies, Inc. (Delaware)
Farapulse, Inc. (Delaware)
Galil Medical Inc. (Delaware)
Galil Medical Ltd. (Israel)
Golden Woods Services, LLC (Texas)
Guidant Delaware Holding Corporation (Delaware)
Guidant Europe NV (Belgium)
Guidant Puerto Rico B.V. (The Netherlands)
Hong Kong Medtech Trading Limited, in liquidation (Hong Kong)
Laguna Holdco Ltd. (Israel)
Lumenis (Australia) Pty. Ltd. (Australia)
Lumenis (HK) Limited (Hong Kong)
Lumenis (Italy) S.r.l. (Italy)


Lumenis (Singapore) Pte. Ltd. (Singapore)
Lumenis (UK) Limited (England)
Lumenis Holdings Inc. (Delaware)
Lumenis Inc. (Massachusetts)
Lumenis India Private Limited (India)
Lumenis Ltd. (Israel)
Lumenis Medical Laser Equipment Trading (Beijing) Co., Ltd. (China)
Notebook Merger Sub, Ltd. (Delaware)
NXT Merger Corp. (Delaware)
Obsidio, Inc. (Delaware)
Preventice Services, LLC (Delaware)
Preventice Solutions, Inc. (Delaware)
Preventice Technologies, Inc. (Delaware)
Provensis Limited (England)
PT Boston Scientific Indonesia (Indonesia)
RMI Acquisition Corp. (California)
Robert S. Smith, M.D., Inc. (Georgia)
SNS Merger Corp. (Delaware)
Special K Merger Corp. (Delaware)
Stream Enterprises LLC (Delaware)
Symetis SA (Switzerland)
Target Therapeutics, Inc. (Delaware)
Textile Merger Sub, Inc. (Delaware)
Zuma Investment Pty Ltd (Australia)
34 Biomedical Merger Corp. (Delaware)
9357-1867 Quebec Inc. (Canada)

 EX-23 23 exhibit23-2022eyconsent.htm EX-23 Document

EXHIBIT 23

Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the following Registration Statements:
 
(1)    Registration Statement (Form S-3 Nos. 333-262937, 333-238526, 333-76346, 333-61994, and 333-64991) of Boston Scientific Corporation,

(2)    Registration Statement (Form S-4 Nos. 333-131608 and 333-22581) of Boston Scientific Corporation,

(3)    Registration Statement (Form S-8 Nos. 333-25033, 333-25037, 333-36636, 333-61056, 333-61060, 333-76380, 333-98755, 333-111047, 333-131608, 333-133569, 333-134932, 333-151280, 333-174620, 333-174622, 333-188905, 333-196672, 333-241022, and 333-264754) of Boston Scientific Corporation;
 
of our reports dated February 23, 2023, with respect to the consolidated financial statements and schedule of Boston Scientific Corporation and the effectiveness of internal control over financial reporting of Boston Scientific Corporation included in this Annual Report (Form 10-K) of Boston Scientific Corporation for the year ended December 31, 2022.


/s/ Ernst & Young LLP
Boston, Massachusetts 
February 23, 2023



 EX-31.1 24 exhibit311-ceo302202210xk.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:

1 I have reviewed this Annual Report on Form 10-K of Boston Scientific Corporation;
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4 The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5 The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 23, 2023 /s/ Michael F. Mahoney 
  Michael F. Mahoney 
  Chief Executive Officer 


 EX-31.2 25 exhibit312-cfo302202210xk.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:

1 I have reviewed this Annual Report on Form 10-K of Boston Scientific Corporation;
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4 The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5 The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 23, 2023 /s/ Daniel J. Brennan 
  Daniel J. Brennan 
  Executive Vice President and Chief Financial Officer 


 EX-32.1 26 exhibit321-ceo906202210xk.htm EX-32.1 Document

EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:
 (1)   the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

   
By:/s/ Michael F. Mahoney
 Michael F. Mahoney 
 Chief Executive Officer 
   
 February 23, 2023 
 


 EX-32.2 27 exhibit322-cfo906202210xk.htm EX-32.2 Document

EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:
 (1)   the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

   
By:/s/ Daniel J. Brennan
 Daniel J. Brennan 
 Executive Vice President and Chief Financial Officer 
   
 February 23, 2023 


 GRAPHIC 28 image_01.jpg begin 644 image_01.jpg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�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image_010.jpg begin 644 image_010.jpg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�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image_011.jpg begin 644 image_011.jpg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�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image_02.jpg begin 644 image_02.jpg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�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image_03.jpg begin 644 image_03.jpg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�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image_06.jpg begin 644 image_06.jpg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end GRAPHIC 34 image_08.jpg begin 644 image_08.jpg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�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image_11.jpg begin 644 image_11.jpg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end GRAPHIC 36 image_12.jpg begin 644 image_12.jpg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end GRAPHIC 37 image_13.jpg begin 644 image_13.jpg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end GRAPHIC 38 image_16.jpg begin 644 image_16.jpg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end GRAPHIC 39 image_18.jpg begin 644 image_18.jpg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end GRAPHIC 40 image_19.jpg begin 644 image_19.jpg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end EX-101.SCH 41 bsx-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Balance Sheet Paranthetical link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquisitions and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Hedging Activities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Contractual Obligations and Commitments link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Stock Inventive and Purchase Plans link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Employee Retirement Plans (Notes) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Schedule II link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Fair Value Measures and Disclosures (Policies) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Commitment and Contingencies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Acquisitions and Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Contractual Obligations and Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Stock Incentive and Purchase Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Employee Retirement Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Acquisitions and Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Contractual Obligations and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Income Taxes (Details - Rate Table) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Income Taxes Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Stock Incentive and Purchase Plans (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Changes in Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Employee Retirement Plans (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Schedule II (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 42 bsx-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 43 bsx-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 44 bsx-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental Information Supplemental Cash Flow Information [Abstract] Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Current State and Local Tax Expense (Benefit) Current State and Local Tax Expense (Benefit) ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) [Policy Text Block] ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Other Intangible Assets [Member] Other Intangible Assets [Member] Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five Foreign Currency Contracts, Liability, Fair Value Disclosure Derivative Liability Devoro Medical, Inc. Devoro Medical, Inc. [Member] Devoro Medical, Inc. Watchman Watchman [Member] Watchman Security Exchange Name Security Exchange Name Equity Securities, FV-NI Equity Securities, FV-NI, Current EMEA [Member] EMEA [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Payment of contingent consideration previously established in purchase accounting Payment for Contingent Consideration Liability, Financing Activities Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Derivatives, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Other Current Assets [Abstract] Other Current Assets [Abstract] Other Current Assets Subsequent Event Type [Domain] Subsequent Event Type [Domain] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Requirement, four quarters following material acquisition Requirement, four quarters following material acquisition [Member] Requirement, four quarters following qualified acquisition Amortization expense Amortization expense Amortization of Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Acquired Finite-lived Intangible Asset, Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Payment of contingent consideration Payment of contingent consideration Payment of contingent consideration Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Issuance of Senior Long-term Debt Deferred Tax Assets Deferred Tax Assets, Net Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Actual, Covenant [Member] Actual, Covenant [Member] Actual Covenant. Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Research and Development Expense [Member] Research and Development Expense [Member] Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition [Axis] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Requirement, as of March 31, 2021 Requirement, as of March 31, 2021 [Member] Requirement, as of March 31, 2021 Local Phone Number Local Phone Number Tax Rate [Axis] Tax Rate [Axis] Tax Rate [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Decrease in Unrecognized Tax Benefits is Reasonably Possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021 Preferred Stock, Value, Issued Dividends, Cash Dividends, Cash Shares Issued, Price Per Share Shares Issued, Price Per Share Retained Earnings [Member] Retained Earnings [Member] Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO COSTA RICA COSTA RICA Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] ASC Update No. 2020-10 Codification Improvements ASC Update No. 2020-10 Codification Improvements [Policy Text Block] ASC Update No. 2020-10 Codification Improvements Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Trade accounts receivable Increase (Decrease) in Accounts Receivable transition tax payment remaining Transition Tax Payment Remaining Transition Tax Payment Remaining Other Intangible Assets (Textuals) [Abstract] Other Intangible Assets (Textuals) [Abstract] Other Intangible Assets (Textuals) [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Derivative Instruments and Hedging Activities Disclosure [Abstract] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Estimated Litigation Liability, Noncurrent Estimated Litigation Liability, Noncurrent Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items] [Line Items] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Payments on short-term borrowings Repayments of Short-term Debt Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Net income (loss) per common share — basic Earnings Per Share, Basic Covenant [Axis] Covenant [Axis] Covenant. Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] Net proceeds from issuance of preferred stock in connection with public offering Proceeds from Issuance of Convertible Preferred Stock Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number March 2028 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Schedule of Investments [Table] Schedule of Investments [Table] Commercial Paper [Member] Commercial Paper [Member] Deferred Tax Liabilities, Net Deferred Tax Liabilities, Net Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Derivative Asset, Fair Value, Gross Asset Derivative Asset, Fair Value, Gross Asset Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Entity Voluntary Filers Entity Voluntary Filers Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Plan Name [Axis] Plan Name [Axis] Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Long-term Debt Long-term Debt Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill impairment charges Goodwill, Impairment Loss Goodwill, Impairment Loss contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Restricted cash equivalents included in Other long-term assets Restricted Cash Equivalents included in Other long-term assets Restricted Cash Equivalents, Noncurrent Acotec Scientific Holdings Limited Acotec Scientific Holdings Limited [Member] Acotec Scientific Holdings Limited Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Stock Issuance (Par value) Stockholders' Equity, Period Increase (Decrease) Indemnification asset Indemnification asset Indemnification asset Statement, Scenario [Axis] Scenario [Axis] Scenario [Axis] Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Covenant [Domain] Covenant [Domain] Covenant. Payments for Royalties Payments for Royalties Schedule of Defined Benefit Plans Disclosures [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table Text Block] Goodwill and other intangible asset impairment charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High, Including Prior Interest Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Unamortized Gain on Fair Value Hedges Interest Rate Swap [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases annualweightedaverageforfeiturerate annualweightedaverageforfeiturerate Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends Entity Interactive Data Current Entity Interactive Data Current Future Amortization Expense, Year Four Finite-Lived Intangible Asset, Expected Amortization, Year Four Effective Income Tax Rate Reconciliation, Tax Credits, Research Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Class of Stock Disclosures [Abstract] Class of Stock Disclosures [Abstract] Reconciliation of Assets from Segment to Consolidated [Table Text Block] Reconciliation of Assets from Segment to Consolidated [Table Text Block] Retirement Plan Name [Axis] Retirement Plan Name [Axis] Contingent consideration net expense (benefit) Contingent consideration net expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Measurement period - market based awards Measurement period - market based award Measurement period - market based awards Balance Sheet Location [Domain] Balance Sheet Location [Domain] Emerging Markets total number of countries Emerging Markets total number of countries Emerging Markets total number of countries Subsequent Events, Policy [Policy Text Block] Subsequent Events, Policy [Policy Text Block] Unrecognized Tax Benefits Unrecognized Tax Benefits Deferred Tax Assets, Gross Deferred Tax Assets, Gross Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding pension benefit obligation, benefits paid pension benefit obligation, benefits paid pension benefit obligation, benefits paid Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Derivative Asset, Current Derivative Asset, Current Entity Address, State or Province Entity Address, State or Province Options expected to vest, weighted average exercise price Options expected to vest, weighted average exercise price Options expected to vest, weighted average exercise price Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Deferred tax assets Deferred Income Tax Assets, Net Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Current liabilities: Liabilities, Current [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accounting Policies [Abstract] Accounting Policies [Abstract] Consolidated Balance Sheet (Parenthetical) [Abstract] Consolidated Balance Sheet (Parenthetical) Defined Benefit Plan, Expected Future Benefit Payment, Year Four Defined Benefit Plan, Expected Future Benefit Payment, Year Four Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Derivative Instrument [Axis] Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. Tax Adjustments, Settlements, and Unusual Provisions Tax Adjustments, Settlements, and Unusual Provisions Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Current Federal Tax Expense (Benefit) Current Federal Tax Expense (Benefit) Operating Lease, Liability Operating Lease, Liability Document Transition Report Document Transition Report Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021 Common Stock, Value, Issued Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Lessee, Operating Leases Lessee, Operating Leases [Text Block] ACQUISITIONS AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] 2021 Acquisitions 2021 Acquisitions [Member] 2021 Acquisitions Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Ownership [Axis] Ownership [Axis] Deferred Foreign Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Goodwill and Other Intangible Assets Goodwill [Line Items] Class of Stock [Axis] Class of Stock [Axis] Summary of Income Tax Contingencies [Table Text Block] Summary of Income Tax Contingencies [Table Text Block] Inventory, Work in Process, Net of Reserves Inventory, Work in Process, Net of Reserves Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Other current assets Prepaid Expense and Other Assets, Current Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Accrued expenses Accrued liabilities, current Accrued Liabilities, Current Net sales Revenue from Contract with Customer, Excluding Assessed Tax Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Income Tax Examination, Penalties and Interest Accrued Income Tax Examination, Penalties and Interest Accrued Expense related to matching contributions Expense related to matching contributions Expense related to matching contributions Inventory, Finished Goods, Net of Reserves Inventory, Finished Goods, Net of Reserves Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segment operating income as percentage of net sales Share-based Payment Arrangement, Option [Member] Share-based Payment Arrangement, Option [Member] Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Deferred Tax Assets, Property, Plant and Equipment Deferred Tax Assets, Property, Plant and Equipment Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Standard Product Warranty, Policy Standard Product Warranty, Policy [Policy Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other income (expense): Other Nonoperating Income (Expense) [Abstract] SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] the Offering - early redemption of combined aggregate principal SN the Offering - early redemption of combined aggregate principal SN [Member] the Offering - early redemption of combined aggregate principal SN Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months Requirement, eighth quarter and thereafter following qualified acquisition Requirement, eighth quarter and thereafter following qualified acquisition [Member] Requirement, eighth quarter and thereafter following qualified acquisition Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Business Combination, Contingent Consideration Arrangements [Abstract] Business Combination, Contingent Consideration Arrangements [Abstract] Entity Information [Line Items] Entity Information [Line Items] ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method [Policy Text Block] ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method Other, net Other Nonoperating Income (Expense) Deferred tax assets [Domain] Deferred tax assets [Domain] Deferred tax assets Proceeds from royalty rights Payments for (Proceeds from) Other Investing Activities In Process Research and Development, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Business Combinations [Abstract] Business Combinations [Abstract] Maximum [Member] High end of range [Member] Maximum [Member] Inventory, Raw Materials, Net of Reserves Inventory, Raw Materials, Net of Reserves Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Impact of foreign currency fluctuations on net sales Impact of foreign currency fluctuations on net sales Impact of foreign currency fluctuations on net sales Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) City Area Code City Area Code Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Amount of employees total compensation eligible for GESOP purchase Amount of employees total compensation eligible for GESOP purchase Amount of employees total compensation eligible for GESOP purchase Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net Restricted cash and restricted cash equivalents included in Other current assets Restricted Cash and Cash Equivalents, Current Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] IRELAND IRELAND Payments on long-term borrowings and debt extinguishment costs Repayments of Senior Debt Deferred tax liabilities [Domain] Deferred tax liabilities [Domain] Deferred tax liabilities Payments for repurchase of common stock Payments for repurchase of common stock Payments for Repurchase of Common Stock Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Loss (gain) on disposal of businesses and assets Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Land Land Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Percent of finished goods at consignment Percent of finished goods at consignment Percent of finished goods at consignment Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Proceeds from short-term borrowings, net of debt issuance costs Proceeds from Short-term Debt Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Share-based Payment Arrangement, Expense, Tax Benefit Share Price Share Price Share-based Payment Arrangement [Member] Share-based Payment Arrangement [Member] Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Supplemental Balance Sheet Information Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Licensing arrangements Licensing arrangements Licensing arrangements Requirement, seventh quarter following qualified acquisition Requirement, seventh quarter following qualified acquisition [Member] Requirement, seventh quarter following qualified acquisition Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Deferred Tax Liabilities, Gross Deferred Tax Liabilities, Gross Business Acquisition [Line Items] Business Acquisition [Line Items] Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) Equity Method Investments Equity Method Investments Valuation Technique, Discounted Cash Flow [Member] Valuation Technique, Discounted Cash Flow [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Apollo Endosurgery, Inc. Apollo Endosurgery, Inc. [Member] Apollo Endosurgery, Inc. Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination statement [Axis] statement [Axis] statement [Axis] Business Combination, Indemnification Assets, Amount as of Acquisition Date Business Combination, Indemnification Assets, Amount as of Acquisition Date Preferred Stock, Dividends, Per Share, Cash Paid Preferred Stock, Dividends, Per Share, Cash Paid Income tax expense (benefit) Income Tax Expense (Benefit) Income Tax Expense (Benefit) Defined Benefit Plan, Expected Future Benefit Payment, Year Three Defined Benefit Plan, Expected Future Benefit Payment, Year Three APAC [Member] Asia Pacific [Member] Deferred Tax Assets, Inventory Deferred Tax Assets, Inventory Unrecognized Compensation Cost - Non-vested stock awards Unrecognized Compensation Cost - Non-vested stock awards Unrecognized Compensation Cost - Non-vested stock awards Entity Tax Identification Number Entity Tax Identification Number Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, to be Paid Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] weighted average remaining vesting period weighted average remaining vesting period weighted average remaining vesting period Purchase Obligations, Future Minimum Payments, Due in Four Years Purchase Obligation, to be Paid, Year Four Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Employee Stock Ownership Plan (ESOP), Compensation Expense Employee Stock Ownership Plan (ESOP), Compensation Expense Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Stock-based compensation Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Weighted Average Number of Shares [Table Text Block] Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity in Months country_US excluding Other Net Sales US excluding Other Net Sales [Member] US excluding Other Net Sales March 2049 Notes [Member] March 2049 Notes [Member] March 2049 Notes March 2039 Notes [Member] March 2039 Notes [Member] March 2039 Notes Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Disposal Group Name [Domain] Disposal Group Name [Domain] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Operating Income Unallocated to Segment Operating Income Unallocated to Segment Operating Income Unallocated to Segment Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Litigation Case [Axis] Litigation Case [Axis] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Domestic Plan Domestic Plan [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Schedule of Changes in Projected Benefit Obligations [Table Text Block] Schedule of Changes in Projected Benefit Obligations [Table Text Block] Long-term Purchase Commitment Long-term Purchase Commitment [Table Text Block] Weighted Average (Member) Weighted Average [Member] Range of the target number of performance-based DSUs awarded Range of the target number of performance-based DSUs awarded Range of the target number of performance-based DSUs awarded Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Type of Adoption [Domain] Accounting Standards Update [Domain] Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Auditor Location Auditor Location Requirement, sixth quarter and thereafter following qualified acquisition [Member] Requirement, sixth quarter following qualified acquisition [Member] Requirement, sixth quarter following qualified acquisition [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Cumulative effect adjustment for adoption of ASC 2016-13 Accounts Receivable, Change in Method, Credit Loss Expense (Reversal) Trade accounts receivable, net Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current Other countries [Member] Other countries [Member] Other countries [Member] Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement Use of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] compensation expense, per share - diluted compensation expense, per share - diluted compensation expense, per share - diluted Goodwill, Translation and Purchase Accounting Adjustments Goodwill, Translation and Purchase Accounting Adjustments Title of 12(b) Security Title of 12(b) Security Common Stock, Shares Authorized Common Stock, Shares Authorized Common Stock, Shares Authorized Net income (loss) available to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Document Type Document Type compensation expense, per share - basic compensation expense, per share - basic compensation expense, per share - basic Audit Information [Abstract] Audit Information Product and Service [Domain] Product and Service [Domain] SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Business Combination, Contingent Consideration, Liability Fair value of contingent consideration Business Combination, Contingent Consideration, Liability Unrecognized Compensation Cost - Stock Options Unrecognized Compensation Cost - Stock Options Unrecognized Compensation Cost - Stock Options Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility [Member] Revolving Credit Facility [Member] December 2027 Notes [Member] December 2027 Notes [Member] December 2027 Notes Divestiture, agreement, transfer of facilities Divestiture, agreement, transfer of facilities Divestiture, agreement, transfer of facilities Measurement Frequency [Axis] Measurement Frequency [Axis] Federal benefit of uncertain tax positions Federal benefit of uncertain tax positions Federal benefit of uncertain tax positions Lease, Cost Lease, Cost [Table Text Block] Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis] Geographical [Axis] Geographical [Axis] Net Investment Hedging [Member] Net Investment Hedging [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Interest Expense [Member] Interest Expense [Member] Yen Denominated Factoring Arrangements [Member] Yen Denominated Factoring Arrangements [Member] Yen denominated factoring arrangements. Investment, Policy Investment, Policy [Policy Text Block] Corporate Segment Corporate Segment [Member] Unrealized Gain (Loss) on Investments Unrealized Gain (Loss) on Investments Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021 Treasury Stock, Value Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] New Accounting Pronouncements, Policy New Accounting Pronouncements, Policy [Text Block] New Accounting Pronouncements, Policy June 2025 Notes [Member] June 2025 Notes [Member] June 2025 Notes HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Restructuring net charges (credits) Restructuring Charges Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items] Business Combination, Consideration Transferred, Additional Revenue Payment, period Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items] Future Amortization Expense, Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Three Proceeds from borrowings on credit facilities Proceeds from Long-term Lines of Credit Legal reserves Estimated Litigation Liability, Current Business Combinations Policy [Policy Text Block] Business Combinations Policy [Policy Text Block] Accrued Royalties, Current Accrued Royalties, Current Derivative [Table] Derivative [Table] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Document Period End Date Document Period End Date March 2031 Notes March 2031 Notes [Member] March 2031 Notes Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three Stock Repurchase Program, Number of Shares Authorized to be Repurchased Stock Repurchase Program, Number of Shares Authorized to be Repurchased Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution International retirement plans [Member] International retirement plans [Member] International retirement plans [Member] Deferred State and Local Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Property, plant and equipment, net [Table Text Block] Property, Plant and Equipment [Table Text Block] Licensing arrangements, liability Licensing arrangements, liability Licensing arrangements, liability Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Income Statement Location [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net Electrophysiology (EP) Electrophysiology (EP) [Member] Electrophysiology (EP) Operating expenses Operating Expenses Preferred stock dividends Dividends, Preferred Stock, Cash Schedule of Expected Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution Property, plant and equipment Property, Plant and Equipment, Gross Accounts Receivable, Allowance for Credit Loss (beginning balance) Accounts Receivable, Allowance for Credit Loss (ending balance) Accounts Receivable, Allowance for Credit Loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Foreign Exchange Contract (Member) Foreign Exchange Contract [Member] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Accrual for legal matters that are probable and estimable Loss Contingency Accrual Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Farapulse, Inc. Farapulse, Inc. [Member] Farapulse, Inc. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. [Policy Text Block] ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Patents [Member] Patents [Member] Entity Current Reporting Status Entity Current Reporting Status Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Amount Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Legal Costs, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] Reported tax rate Effective Income Tax Rate Reconciliation, Percent Trade accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Deemed Consolidated EBITDA [Member] Deemed Consolidated EBITDA Deemed Consolidated EBITDA Current debt obligations Debt, Current Debt, Current Production Related Impairments or Charges Production Related Impairments or Charges Shares, Issued Ending Balance (Shares Issued) Shares, Issued United States [Member] UNITED STATES UNITED STATES Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Taxes Payable, Current Taxes Payable, Current Voting power of all classes of stock Voting power of all classes of stock Voting power of all classes of stock Common Stock, Capital Shares Reserved for Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Purchase Obligations, Future Minimum Payments Due, Current Purchase Obligation, to be Paid, Year One Assuming dilution Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Income (Loss) from Continuing Operations before Income Taxes, Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic INCOME TAXES Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution Share-based Compensation, Stock Options, Activity [Table Text Block] Share-based Payment Arrangement, Option, Activity [Table Text Block] Significant Accounting Policies Significant Accounting Policies [Table] Significant Accounting Policies [Table] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Purchase Obligations, Future Minimum Payments Due Purchase Obligation Credit Facility [Axis] Credit Facility [Axis] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Tax Incentives in Puerto Rico Tax Incentives in Puerto Rico Tax Incentives in Puerto Rico Range of the target number of market-based DSUs awarded Range of the target number of market-based DSUs awarded Range of the target number of market-based DSUs awarded Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Deferred Tax Assets, in Process Research and Development Deferred Tax Assets, in Process Research and Development Entity Shell Company Entity Shell Company Schedule of Short-term Debt [Table Text Block] Schedule of Short-term Debt [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain] [Domain] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Maturities of Lease Liabilities Maturities of Lease Liabilities [Table Text Block] Maturities of Lease Liabilities Litigation Status [Domain] Litigation Status [Domain] Loss Contingencies [Table] Loss Contingencies [Table] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Stock Incentive and Ownership Plans [Abstract] Stock Incentive and Purchase Plans [Abstract] Stock Incentive and Purchase Plans [Abstract] Statement [Table] Statement [Table] Foreign currency denominated in debt [Member] Foreign currency denominated in debt [Member] Foreign currency denominated in debt Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Deferred Tax Assets, Other Deferred Tax Assets, Other Defined Benefit Plan, Expected Future Benefit Payment, Year Five Defined Benefit Plan, Expected Future Benefit Payment, Year Five Tax incentives in Malaysia Tax incentives in Malaysia Tax incentives in Malaysia Derivatives Not Designated as Hedging Instruments (Table Text Block) Derivatives Not Designated as Hedging Instruments [Table Text Block] Contract with Customer, Liability [Abstract] Contract with Customer, Liability [Abstract] Range [Axis] Statistical Measurement [Axis] Preventice Solutions, Inc. [Member] Preventice Solutions, Inc. [Member] Preventice Solutions, Inc. Subsequent Event [Member] Subsequent Event [Member] Deferred Tax Assets, Operating Loss Carryforwards, Foreign Deferred Tax Assets, Operating Loss Carryforwards, Foreign Schedule of Other Assets [Table Text Block] Schedule of Other Assets [Table Text Block] Goodwill Goodwill Goodwill Deferred Revenue Deferred Revenue November 2019 Aggregate Offering [Member] November 2019 Aggregate Offering [Member] November 2019 Aggregate Offering Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] March 2025 Notes March 2025 Notes [Member] March 2025 Notes Schedule of Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Table Text Block) Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Operating Lease, Cost Operating Lease, Cost March 2034 Notes March 2034 Notes [Member] March 2034 Notes Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Hedging Designation [Domain] Hedging Designation [Domain] Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Pension and Other Postretirement Plans, Policy [Policy Text Block] Pension and Other Postretirement Plans, Policy [Policy Text Block] Schedule of Notional Amounts of Outstanding Derivative Positions (Table Text Block) Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Operating Loss Carryforwards Defined Benefit Plan, Interest Cost Defined Benefit Plan, Interest Cost Payroll and related liabilities Employee-related Liabilities, Current Interest Rate Contract [Member] Interest Rate Contract [Member] Income Statement Location [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Range [Domain] Statistical Measurement [Domain] the Offering - aggregate principal amount the Offering - aggregate principal amount [Member] the Offering - aggregate principal amount Operating Income (Loss) Allocated to Reportable Segments Operating Income (Loss) Allocated to Reportable Segments Operating Income (Loss) Allocated to Reportable Segments Disposal Group, Including Discontinued Operation, Consideration Disposal Group, Including Discontinued Operation, Consideration Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Other long-term assets Other long-term assets (total) Other Assets, Noncurrent Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Segments [Axis] Segments [Axis] Segments [Axis] Licensing arrangement liabilities (Member) Licensing arrangement liabilities [Member] Licensing arrangement liabilities Proceeds from (payments for) settlements of hedge contracts Payments for (Proceeds from) Hedge, Investing Activities In Process Research and Development [Member] In Process Research and Development [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] the 2018 Facility [Domain] the 2018 Facility [Domain] the 2018 Facility Entity File Number Entity File Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Divestiture, agreement, transfer of global employees Divestiture, agreement, transfer of global employees Divestiture, agreement, transfer of global employees Retirement Plan Name [Domain] Retirement Plan Name [Domain] Litigation-related net charges (credits) Litigation Settlement, Expense Litigation Settlement, Expense Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Long-term debt Long-term Debt and Capital Lease Obligations Long-term Debt and Lease Obligation MedSurg [Member] MedSurg [Member] MedSurg [Member] Prepaid income taxes Prepaid Taxes Senior Note due 2027 [Member] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Unrecognized Compensation Cost Unrecognized Compensation Cost Unrecognized Compensation Cost Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Deferred Tax Assets, Operating Loss Carryforwards, Domestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Cardiovascular [Member] Cardiovascular [Member] Cardiovascular [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Executive Retirement Plan Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Farapulse Farapulse [Member] Farapulse Debt Instrument [Axis] Debt Instrument [Axis] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Other Sundry Liabilities, Current Other Sundry Liabilities, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Segment operating income as percentage of net sales [Table Text Block] Segment operating income as percentage of net sales [Table Text Block] Segment operating income as percentage of net sales Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule Of Segment Reporting Information By Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other long-term liabilities [Table Text Block] Other Noncurrent Liabilities [Table Text Block] Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Contingent consideration Business Combination, Contingent Consideration, Liability, Current Gain (Loss) on Disposition of Assets Gain (Loss) on Disposition of Business Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite Lived Intangible Assets Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Net change in defined benefit pensions and other items Net change in defined benefit pensions and other items Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Goodwill (Roll Forward) Goodwill (Textuals) [Abstract] Goodwill (Textuals) [Abstract] Interventional Cardiology Therapies Interventional Cardiology Therapies [Member] Interventional Cardiology Therapies Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Common stock issuance (Value in excess of par) Stock Issued During Period, Value, New Issues (Common stock) Stock Issued During Period, Value, New Issues (Common stock) Purchase Obligations, Future Minimum Payments, Due in Three Years Purchase Obligation, to be Paid, Year Three Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Operating Lease, Payments Operating Lease, Payments Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table] Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table] Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Share-based compensation, net of tax benefit Share-based compensation, net of tax benefit Share-based compensation, net of tax benefit effective income tax reconciliation, compensation-related Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent Preferred Stock, Dividend Rate, Percentage Preferred Stock, Dividend Rate, Percentage Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Net (credits) charges to expenses Accounts Receivable, Credit Loss Expense (Reversal) Inventory step-up amortization InventoryStepUpAmortization Inventory Step Up Amortization Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased Transfer of Financial Assets Accounted for as Sales [Table Text Block] Transfer of Financial Assets Accounted for as Sales [Table Text Block] Convertible Preferred Stock, Terms of Conversion Preferred Stock, Convertible, Terms Assets, Fair Value Disclosure Assets, Fair Value Disclosure TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Effective Income Tax Rate Reconciliation, Other Adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other Other Accrued Liabilities, Current Net change in derivative financial instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Benefits Paid Global Cardiology Reporting Unit Global Cardiology Reporting Unit [Member] Global Cardiology Reporting Unit [Member] Property, plant and equipment, net Property, Plant and Equipment, Net [Abstract] Derivative [Line Items] Derivative [Line Items] Schedule of Other Current Assets [Table Text Block] Schedule of Other Current Assets [Table Text Block] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] EARNINGS PER SHARE Earnings Per Share [Text Block] Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Operating expenses: Operating Expenses [Abstract] Defined Benefit Plan, Expected Future Benefit Payment, Year Two Defined Benefit Plan, Expected Future Benefit Payment, Year Two Net Deferred Tax Liabilities and Prepaid on Intercompany Profit Net Deferred Tax Assets and Prepaid on Intercompany Profit Net Deferred Tax Assets and Prepaid on Intercompany Profit Minimum [Member] Minimum [Member] Minimum [Member] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block] [Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Specialty Pharmaceuticals [Member] Specialty Pharmaceuticals [Member] Specialty Pharmaceuticals Gross profit Gross Profit Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Purchase Obligations, Future Minimum Payments, Due in Five Years Purchase Obligation, to be Paid, Year Five Financial and Nonfinancial Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Selling, general and administrative expenses Selling, General and Administrative Expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Consolidated BSX [Domain] Consolidated BSX [Domain] Consolidated BSX Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Business Acquisition, Percentage of Voting Interests Acquired Business Acquisition, Percentage of Voting Interests Acquired Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] June 2030 Notes [Member] June 2030 Notes [Member] June 2030 Notes Revenue Recognition, Policy [Policy Text Block] Revenue [Policy Text Block] Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five Payments for acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired CONTRACTUAL OBLIGATIONS AND COMMITMENTS Debt Disclosure [Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Deferred Tax Assets, Goodwill and Intangible Assets Deferred Tax Assets, Goodwill and Intangible Assets Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-based Payment Arrangement [Text Block] Options expected to vest, weighted average remaining contractual life Options expected to vest, weighted average remaining contractual life Options expected to vest, weighted average remaining contractual life Senior Notes [Member] Senior Notes [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Investment [Table Text Block] Investment Holdings, Schedule of Investments [Table Text Block] Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Stock issuance (Shares) Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Number of reportable segments Number of Reportable Segments Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Foreign Currency Transaction Gain (Loss), before Tax Net gain (loss) from foreign currency transaction exposures Foreign Currency Transaction Gain (Loss), before Tax Other International Plans Other International Plans [Member] Other International Plans Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Other expense, net Nonoperating Income (Expense) Inventory, Net [Abstract] Inventory, Net [Abstract] Goodwill, Acquired During Period Goodwill, Acquired During Period Commitments and contingencies Commitments and Contingencies Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current October 2023 Notes [Member] October 2023 Notes [Member] October 2023 Notes [Member] Payments for royalty rights Payments for royalty rights Payments for royalty rights Accrued Income Taxes, Noncurrent Accrued Income Taxes, Noncurrent Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Compensation and Employee Benefit Plans [Text Block] Compensation and Employee Benefit Plans [Text Block] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Disposal Group Classification [Axis] Disposal Group Classification [Axis] Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Free Trade Zone Regime Tax Incentive Free Trade Zone Regime Tax Incentive Free Trade Zone Regime Tax Incentive Auditor Name Auditor Name Cover [Abstract] Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Effective Income Tax Rate Reconciliation, Return to provision Effective Income Tax Rate Reconciliation, Return to provision Effective Income Tax Rate Reconciliation, Return to provision Royalty expense Royalty Expense Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Treasury Stock, Shares Treasury Stock, Shares Other Current Liabilities [Table Text Block] Other Current Liabilities [Table Text Block] All Other 2021 Acquisitions All Other 2021 Acquisitions [Member] All Other 2021 Acquisitions Significant Accounting Policies [Abstract] Significant Accounting Policies [Abstract] Significant Accounting Policies [Abstract] Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Defined Benefit Plan, Acquired and Established Plan Changes, PBO Defined Benefit Plan, Acquired and Established Plan Changes, PBO Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Executive Retirement Plan Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Cash Cash Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements Financial Instrument [Axis] Financial Instrument [Axis] Short-term Debt [Line Items] Short-term Debt [Line Items] Finance Lease Obligation Capital Lease Obligations [Member] Purchase Obligations, Future Minimum Payments, Due in Two Years Purchase Obligation, to be Paid, Year Two Cash dividends paid on preferred stock Payments of Dividends Payments of Dividends Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Common Stock [Member] Common Stock [Member] Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Operating income (loss) Operating income allocated to reportable segments Operating Income (Loss) Operating Lease, Liability, Current Operating Lease, Liability, Current Future Amortization Expense, Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Two Hedging Designation [Axis] Hedging Designation [Axis] Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Technology-Based Intangible Assets [Member] Technology-Based Intangible Assets [Member] ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 [Policy Text Block] ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 Qualified options exercise price Non-vested stock awards exercise price Non-vested stock awards exercise price Treasury Stock [Member] Treasury Stock [Member] Preferred Stock, Liquidation Preference Per Share Preferred Stock, Liquidation Preference Per Share Fair value of market based awards Fair value of market based awards Fair value of market based awards Baylis Medical Baylis Medical [Member] Baylis Medical Purchase Obligations, Future Minimum Payments, Due Thereafter Purchase Obligation, to be Paid, after Year Five Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Income Taxes Paid Income Taxes Paid Operating Lease, Liability, Current Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Derivative, Notional Amount Derivative, Notional Amount Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Benefits Paid 2011 LTIP Plan [Member] 2011 LTIP Plan [Member] 2011 LTIP Plan [Member] Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Purchases of property, plant and equipment and internal use software Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Accumulated Benefit Obligation Defined Benefit Plan, Accumulated Benefit Obligation Executive retirement plan [Member] Executive retirement plan [Member] Executive retirement plan [Member] Exercise price of the fair market value of our common stock on the date of grant Exercise price of the fair market value of our common stock on the date of grant Exercise price of the fair market value of our common stock on the date of grant Future Amortization Expense, Year One Finite-Lived Intangible Asset, Expected Amortization, Year One Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Deferred and prepaid income taxes Cash flow impact of deferred income tax expense (benefit) Cash flow impact of deferred income tax expense (benefit) Market-based awards, valuation assumptions [Table Text Block] Market-based awards, valuation assumptions [Table Text Block] Market-based awards, valuation assumptions [Table Text Block] Common Stock, Shares, Issued Common Stock, Shares, Issued Common Stock, Shares, Issued Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets BSX Reportable Segments BSX Reportable Segments [Member] BSX Reportable Segments Entity Address, City or Town Entity Address, City or Town Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt November 2035 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) [Policy Text Block] ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) Retirement Plan Type [Axis] Retirement Plan Type [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Interest expense Interest Expense Interest Expense U.K. Plan U.K. Plan [Member] U.K. Plan Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Defined Benefit Plan, Expected Future Benefit Payment, Year One Defined Benefit Plan, Expected Future Benefit Payment, Year One Debt extinguishment costs Net currency exchange gain (loss) Net currency exchange gain (loss) Net currency exchange gain (loss) Accumulated deficit Retained Earnings (Accumulated Deficit) Litigation Case [Domain] Litigation Case [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans Other, Other Long-term Assets Other, Other Long-term Assets Other, Other Long-term Assets Entity Filer Category Entity Filer Category Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Net loss (gain) on investments and notes receivable Gain (Loss) on Investments Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Derivative Instruments, Gain (Loss) [Table Text Block] Derivative Instruments, Gain (Loss) [Table Text Block] Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Supplemental Balance Sheet Information (Textuals) Supplemental Balance Sheet Information (Textuals) [Abstract] Supplemental Balance Sheet Information (Textuals) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total stockholders’ equity Total Stockholders' Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Amendment Flag Amendment Flag Statement, Equity Components [Axis] Equity Components [Axis] Allowance for doubtful accounts SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Cardiac Rhythm Management Cardiac Rhythm Management [Member] Cardiac Rhythm Management Antidilutive Securities [Axis] Antidilutive Securities [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Fair value of the Free Cash Flow (FCF) performance awards Fair value of the Free Cash Flow (FCF) performance awards Fair value of the Free Cash Flow (FCF) performance awards Inventories Inventories Inventory, Net Consolidated Cash Flow Supplemental Disclosure [Abstract] Consolidated Cash Flow Supplemental Disclosure [Abstract] Consolidated Cash Flow Supplemental Disclosure [Abstract] Deferred Federal Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Lumenis LTD Lumenis LTD [Member] Lumenis LTD Schedule of Income Tax Rate Reconciliation [Line Items] Schedule of Income Tax Rate Reconciliation [Line Items] [Line Items] for Schedule of Income Tax Rate Reconciliation [Table] Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Product and Service [Axis] Product and Service [Axis] Measurement alternative investments (1) Equity Securities without Readily Determinable Fair Value, Amount Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return March 2028 Senior Notes March 2028 Senior Notes [Member] March 2028 Senior Notes Preferred stock dividends Dividends, Preferred Stock, Stock Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Investments [Abstract] Statement [Line Items] Statement [Line Items] Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months Stock-based compensation (Shares) Stock Issued During Period, Shares, Period Increase (Decrease) Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Requirement, as of December 31, 2021 and through remaining term of facility Requirement, as of December 31, 2021 and through remaining term of facility [Member] Requirement, as of December 31, 2021 and through remaining term of facility Investments Investments Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Retirement Plan Type [Domain] Retirement Plan Type [Domain] Notes receivable Debt Securities, Available-for-sale Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Accrued expenses Accrued Liabilities, Current [Abstract] Property, Plant and Equipment by Type [Axis] Long-Lived Tangible Asset [Axis] Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Valuation Allowance Income Taxes [Abstract] Income Taxes [Abstract] Income Taxes [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Target payout of Free Cash Flows (FCF) performance awards Target payout of Free Cash Flows (FCF) performance awards Target payout of Free Cash Flows (FCF) performance awards Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Document Annual Report Document Annual Report Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Preferred stock issuance (Value in excess of par) Stock Issued During Period, Value, New Issues (Preferred stock) Stock Issued During Period, Value, New Issues (Preferred stock) Proceeds from Royalties Received Proceeds from Royalties Received Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax May 2022 Notes [Member] May 2022 Notes [Member] May 2022 Notes [Member] May 2022 Notes [Member] Net proceeds from issuance of common stock in connection with public offering Proceeds from Issuance of Common Stock TOTAL ASSETS Assets Other Accrued Liabilities, Noncurrent Other Accrued Liabilities, Noncurrent Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Plan Name [Domain] Plan Name [Domain] Interest Paid, Excluding Capitalized Interest, Operating Activities Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment Trade accounts receivable, net [Table Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Derivative, Name [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Significant Accounting Policies [Text Block] Significant Accounting Policies [Text Block] Short-term Debt Short-term Debt Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Litigation Status [Axis] Litigation Status [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Other Assets, Miscellaneous, Current Other Assets, Miscellaneous, Current Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three Effective Income Tax Rate Reconciliation, Nondeductible Expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic Net income (loss) per common share — assuming dilution Earnings Per Share, Diluted Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Segment [Domain] Segments [Domain] Payments on borrowings from credit facilities Repayments of Long-term Lines of Credit Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number Diluted Shares Outstanding Adjustment Defined Benefit Plan, Service Cost Defined Benefit Plan, Service Cost Contractual Obligation, Fiscal Year Maturity Contractual Obligation, Fiscal Year Maturity [Table Text Block] Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions Tax Rate [Domain] Tax Rate [Domain] Tax Rate [Domain] March 2026 Notes [Member] March 2026 Notes [Member] March 2026 Notes Non-US [Member] Non-US [Member] Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs Special Charges [Member] Special Charges [Member] Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Contract with Customer, Liability Contract with Customer, Liability Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Deferred tax liabilities Deferred Income Tax Liabilities, Net Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization March 2024 Notes [Member] March 2024 Notes [Member] March 2024 Notes Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Deferred Tax Liabilities, Derivatives Deferred Tax Liabilities, Derivatives Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Assets (segment reporting) Other Assets Other Operating Income (Expense), Net Other Operating Income (Expense), Net Financial Instruments [Domain] Financial Instruments [Domain] Cost of products sold Cost of Goods and Services Sold Cost of Goods and Services Sold Litigation and Debt Exclusion from EBITDA Litigation and Debt Exclusion from EBITDA Exclusion of litigation payments and any debt Issued to fund tax deficiency payments Proceeds from disposal of certain businesses and assets Proceeds from Divestiture of Businesses Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] M.I. Tech Co., Ltd M.I. Tech Co., Ltd [Member] M.I. Tech Co., Ltd Change in Contract with Customer, Liability [Abstract] Change in Contract with Customer, Liability [Abstract] Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Loss Contingencies [Line Items] Loss Contingencies [Line Items] Deferred Tax Assets, Tax Deferred Expense Deferred Tax Assets, Tax Deferred Expense Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Net increase (decrease) in commercial paper Proceeds from (Repayments of) Commercial Paper Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Benefit Obligation statement [Domain] statement [Domain] [Domain] for statement [Axis] Lender Name [Axis] Lender Name [Axis] Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Derivative Asset Derivative Asset Deferred Tax Liabilities, Other Deferred Tax Liabilities, Other AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Other assets Increase (Decrease) in Other Operating Assets Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Other Current Liabilities [Member] Other Current Liabilities [Member] Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Licensing arrangement assets (Member) Licensing arrangement assets [Member] Licensing arrangement assets Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Goodwill, Gross Goodwill, Gross Total debt Debt and Lease Obligation Schedule of Goodwill [Table] Schedule of Goodwill [Table] Maximum Leverage Ratio Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Payment for Settlement Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] revenue-based payments [Member] revenue-based payments [Member] revenue-based payments [Member] Entities [Table] Entities [Table] Net income (loss) Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract] Supplemental Balance Sheet Information Related to Leases Supplemental Balance Sheet Information Related to Leases [Table Text Block] Supplemental Balance Sheet Information Related to Leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two Current assets: Assets, Current [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Deferred Revenue, Current Deferred Revenue, Current Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Fair Value, Measurements, Recurring [Member] Fair Value, Recurring [Member] Utilization of allowances Utilization of allowances Accounts Receivable, Allowance for Credit Loss, Writeoff STOCKHOLDER'S EQUITY Stockholders' Equity Note Disclosure [Text Block] Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Supplemental Cash Flow Information Related to Leases Supplemental Cash Flow Information Related to Leases [Table Text Block] Supplemental Cash Flow Information Related to Leases Future Amortization Expense, Year Five Finite-Lived Intangible Asset, Expected Amortization, Year Five Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Auditor Firm ID Auditor Firm ID Accrued Rebates, Current Accrued Rebates, Current Accrued Rebates, Current Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Increase (decrease) in operating assets and liabilities, excluding purchase accounting: Increase (Decrease) in Operating Capital [Abstract] Other, net Other, net Other, net March 2029 Notes [Member] March 2029 Notes [Member] March 2029 Notes Entity Listing, Par Value Per Share Entity Listing, Par Value Per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Other Contract Other Contract [Member] Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined benefit plan, plan assets, actuarial gain loss Defined benefit plan, plan assets, actuarial gain loss Class of Stock [Domain] Class of Stock [Domain] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Ownership [Domain] Ownership [Domain] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A Buildings and improvements Buildings and Improvements, Gross Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Long-Lived Assets Long-Lived Assets Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Other Assets, Current Other Assets, Current Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans Proceeds from Stock Plans Options expected to vest Options expected to vest Options expected to vest Other Other [Member] Other Deferred Tax Assets, Prepaid on Intercompany Profit Deferred Tax Assets, Prepaid on Intercompany Profit Deferred Tax Assets, Prepaid on Intercompany Profit Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract] Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Derivative Liability, Fair Value, Gross Liability Derivative Liability, Fair Value, Gross Liability January 2040 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] Stockholders' Equity Note [Abstract] Preferred Stock [Member] Preferred Stock [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Capital in progress Construction in Progress, Gross Cost of Sales [Member] Cost of Sales [Member] Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Current Foreign Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) May 2025 Notes [Member] May 2025 Notes [Member] May 2025 Notes [Member] Preferred Stock, Liquidation Preference, Value Preferred Stock, Liquidation Preference, Value Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset EX-101.PRE 45 bsx-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 46 image_0.jpg begin 644 image_0.jpg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�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image_01a.jpg begin 644 image_01a.jpg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�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image_02b.jpg begin 644 image_02b.jpg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�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image_0b.jpg begin 644 image_0b.jpg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�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image_0c.jpg begin 644 image_0c.jpg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�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image_1.jpg begin 644 image_1.jpg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end GRAPHIC 52 image_1b.jpg begin 644 image_1b.jpg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end GRAPHIC 53 image_1c.jpg begin 644 image_1c.jpg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end GRAPHIC 54 image_0d.jpg begin 644 image_0d.jpg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�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image_1d.jpg begin 644 image_1d.jpg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end GRAPHIC 56 bsx-20221231_g1.jpg begin 644 bsx-20221231_g1.jpg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
XML 58 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
 12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Firm ID 42
Auditor Location Boston, Massachusetts
XML 59 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Net sales $ 12,682 $ 11,888 $ 9,913
Cost of products sold 3,956 3,711 3,465
Gross profit 8,727 8,177 6,448
Operating expenses:      
Selling, general and administrative expenses 4,520 4,359 3,787
Research and development expenses 1,323 1,204 1,143
Royalty expense 47 49 45
Amortization expense 803 741 789
Goodwill impairment charges 0 0 73
Intangible asset impairment charges 132 370 460
Contingent consideration net expense (benefit) 35 (136) (100)
Restructuring net charges (credits) 24 40 52
Litigation-related net charges (credits) 173 430 278
Gain (Loss) on Disposition of Assets 22 (78) 0
Operating expenses 7,078 6,978 6,528
Operating income (loss) 1,649 1,199 (80)
Other income (expense):      
Interest expense (470) (341) (361)
Other, net (38) 218 362
Income (loss) before income taxes 1,141 1,076 (79)
Income tax expense (benefit) 443 36 2
Net income (loss) 698 1,041 (82)
Preferred stock dividends 55 55 33
Net income (loss) available to common stockholders $ 642 $ 985 $ (115)
Net income (loss) per common share — basic $ 0.45 $ 0.69 $ (0.08)
Net income (loss) per common share — assuming dilution $ 0.45 $ 0.69 $ (0.08)
Weighted-average shares outstanding      
Basic 1,430,500 1,422,300 1,416,700
Assuming dilution 1,439,700 1,433,800 1,416,700
XML 60 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Net income (loss) $ 698 $ 1,041 $ (82)
Other comprehensive income (loss), net of tax:      
Foreign currency translation adjustment (94) (125) 76
Net change in derivative financial instruments 63 170 (137)
Net change in defined benefit pensions and other items 37 11 (1)
Total other comprehensive income (loss) 6 56 (63)
Total comprehensive income (loss) $ 704 $ 1,096 $ (145)
XML 61 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 928 $ 1,925
Trade accounts receivable, net 1,970 1,778
Inventories 1,867 1,610
Prepaid income taxes 264 205
Other current assets 731 799
Total current assets 5,760 6,317
Property, plant and equipment, net 2,446 2,252
Goodwill 12,920 11,988
Other intangible assets, net 5,902 6,121
Deferred tax assets 3,942 4,142
Other long-term assets 1,500 1,410
TOTAL ASSETS 32,469 32,229
Current liabilities:    
Current debt obligations 20 261
Accounts payable 862 794
Accrued expenses 2,160 2,436
Other current liabilities 761 783
Total current liabilities 3,803 4,274
Long-term debt 8,915 8,804
Deferred tax liabilities 144 310
Other long-term liabilities 2,035 2,220
Commitments and contingencies
Preferred Stock, Shares Issued 10,062,500 10,062,500
Stockholders’ equity:    
Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021 $ 0 $ 0
Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021 $ 17 $ 17
Treasury Stock, Shares 263,289,848 263,289,848
Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021 $ (2,251) $ (2,251)
Additional paid-in capital 20,289 19,986
Accumulated deficit (750) (1,392)
Accumulated Other Comprehensive Income (Loss), Net of Tax 269 263
Total stockholders’ equity 17,573 16,622
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 32,469 $ 32,229
XML 62 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheet Paranthetical - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Consolidated Balance Sheet (Parenthetical) [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 50,000,000 50,000,000
Preferred Stock, Shares Issued 10,062,500 10,062,500
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued 1,696,633,993 1,688,810,052
Treasury Stock, Shares 263,289,848 263,289,848
XML 63 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Preferred Stock [Member]
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Shares, Issued at Dec. 31, 2019   0 1,642,488,911        
Total Stockholders' Equity at Dec. 31, 2019   $ 0 $ 16 $ (1,717) $ 17,561 $ (2,253) $ 270
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock issuance (Shares)   10,062,500 29,382,500        
Stock-based compensation (Shares)     8,040,507        
Stock Issuance (Par value)   $ 0 $ 0        
Treasury Stock, Value, Acquired, Cost Method       (535)      
Preferred stock issuance (Value in excess of par)         975    
Common stock issuance (Value in excess of par)         975    
Stock-based compensation     $ 0   221    
Net income (loss) $ (82)         (82)  
Cumulative effect adjustment for adoption of ASC 2016-13 10         (10)  
Preferred stock dividends           (33)  
Ending Balance (Shares Issued) at Dec. 31, 2020   10,062,500 1,679,911,918        
Other comprehensive income (loss), net of tax:              
Foreign currency translation adjustment 76           76
Net change in derivative financial instruments (137)           (137)
Net change in defined benefit pensions and other items 1           (1)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2020 $ 15,326 $ 0 $ 17 (2,251) 19,732 (2,378) 207
Other comprehensive income (loss), net of tax:              
Common Stock, Shares, Issued 1,679,911,918            
Stock issuance (Shares)   0 0        
Stock-based compensation (Shares)     8,898,134        
Stock Issuance (Par value)   $ 0 $ 0        
Treasury Stock, Value, Acquired, Cost Method       0      
Preferred stock issuance (Value in excess of par)         0    
Common stock issuance (Value in excess of par)         0    
Stock-based compensation     $ 0   254    
Net income (loss) $ 1,041         1,041  
Cumulative effect adjustment for adoption of ASC 2016-13           0  
Preferred stock dividends           (55)  
Ending Balance (Shares Issued) at Dec. 31, 2021   10,062,500 1,688,810,052        
Other comprehensive income (loss), net of tax:              
Foreign currency translation adjustment (125)           (125)
Net change in derivative financial instruments 170           170
Net change in defined benefit pensions and other items (11)           11
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2021 $ 16,622 $ 0 $ 17 (2,251) 19,986 (1,392) 263
Other comprehensive income (loss), net of tax:              
Common Stock, Shares, Issued 1,688,810,052            
Stock issuance (Shares)   0 0        
Stock-based compensation (Shares)     7,823,941        
Stock Issuance (Par value)   $ 0 $ 0        
Treasury Stock, Value, Acquired, Cost Method       0      
Preferred stock issuance (Value in excess of par)         0    
Common stock issuance (Value in excess of par)         0    
Stock-based compensation     0   303    
Net income (loss) $ 698         698  
Cumulative effect adjustment for adoption of ASC 2016-13           0  
Preferred stock dividends           (55)  
Ending Balance (Shares Issued) at Dec. 31, 2022   10,062,500          
Other comprehensive income (loss), net of tax:              
Foreign currency translation adjustment (94)           (94)
Net change in derivative financial instruments 63           63
Net change in defined benefit pensions and other items (37)           37
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2022 $ 17,573 $ 0 $ 17 $ (2,251) $ 20,289 $ (750) $ 269
Other comprehensive income (loss), net of tax:              
Common Stock, Shares, Issued 1,696,633,993            
XML 64 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Net income (loss) $ 698,000,000 $ 1,041,000,000 $ (82,000,000)
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities      
Loss (gain) on disposal of businesses and assets 22,000,000 (78,000,000) 0
Depreciation and amortization 1,136,000,000 1,093,000,000 1,123,000,000
Deferred and prepaid income taxes (63,000,000) (124,000,000) (82,000,000)
Stock-based compensation expense 220,000,000 194,000,000 170,000,000
Goodwill and other intangible asset impairment charges 132,000,000 370,000,000 533,000,000
Net loss (gain) on investments and notes receivable 1,000,000 (250,000,000) (333,000,000)
Contingent consideration net expense (benefit) 35,000,000 (136,000,000) (100,000,000)
Inventory step-up amortization 32,000,000 34,000,000 58,000,000
Debt extinguishment costs 194,000,000 0 0
Other, net 125,000,000 78,000,000 244,000,000
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:      
Trade accounts receivable (220,000,000) (279,000,000) 335,000,000
Inventories (321,000,000) (346,000,000) (65,000,000)
Other assets (209,000,000) (134,000,000) (265,000,000)
Accounts payable, accrued expenses and other liabilities (255,000,000) 408,000,000 (28,000,000)
Cash provided by (used for) operating activities 1,526,000,000 1,870,000,000 1,508,000,000
Investing Activities      
Purchases of property, plant and equipment and internal use software (588,000,000) (554,000,000) (376,000,000)
Proceeds from sale of property, plant and equipment 12,000,000 14,000,000 12,000,000
Payments for acquisitions of businesses, net of cash acquired (1,542,000,000) (2,258,000,000) (3,000,000)
Proceeds from disposal of certain businesses and assets 5,000,000 826,000,000 15,000,000
Proceeds from royalty rights 70,000,000 82,000,000 87,000,000
Proceeds from (payments for) settlements of hedge contracts 56,000,000 15,000,000 0
Proceeds from (payments for) investments and acquisitions of certain technologies (24,000,000) 279,000,000 (146,000,000)
Cash provided by (used for) investing activities (2,011,000,000) (1,597,000,000) (411,000,000)
Financing Activities      
Payment of contingent consideration previously established in purchase accounting (335,000,000) (15,000,000) (49,000,000)
Payments for royalty rights (75,000,000) (85,000,000) (97,000,000)
Payments on short-term borrowings (250,000,000) 0 (2,950,000,000)
Proceeds from short-term borrowings, net of debt issuance costs 0 0 2,245,000,000
Net increase (decrease) in commercial paper (1,000,000) 0 (714,000,000)
Payments on borrowings from credit facilities 0 0 (1,919,000,000)
Proceeds from borrowings on credit facilities 0 0 1,916,000,000
Payments on long-term borrowings and debt extinguishment costs (3,184,000,000) 0 (1,260,000,000)
Proceeds from long-term borrowings, net of debt issuance costs 3,270,000,000 0 1,683,000,000
Cash dividends paid on preferred stock (55,000,000) (55,000,000) (28,000,000)
Net proceeds from issuance of preferred stock in connection with public offering 0 0 975,000,000
Net proceeds from issuance of common stock in connection with public offering 0 0 975,000,000
Payments for repurchase of common stock 0 0 (535,000,000)
Cash used to net share settle employee equity awards (53,000,000) (50,000,000) (59,000,000)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans 136,000,000 110,000,000 111,000,000
Cash provided by (used for) financing activities (548,000,000) (95,000,000) 293,000,000
Effect of foreign exchange rates on cash (9,000,000) (6,000,000) (2,000,000)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (1,042,000,000) 173,000,000 1,388,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 2,168,000,000 1,995,000,000 607,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 1,126,000,000 2,168,000,000 1,995,000,000
Supplemental Information      
Income Taxes Paid 662,000,000 302,000,000 207,000,000
Interest Paid, Excluding Capitalized Interest, Operating Activities 450,000,000 338,000,000 359,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 0 440,000,000 0
Non-cash impact of transferred royalty rights $ (70,000,000) $ (82,000,000) $ (87,000,000)
XML 65 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash and cash equivalents $ 928,000,000 $ 1,925,000,000 $ 1,734,000,000  
Restricted cash and restricted cash equivalents included in Other current assets 149,000,000 188,000,000 208,000,000  
Restricted cash equivalents included in Other long-term assets 48,000,000 55,000,000 52,000,000  
Cash, cash equivalents, restricted cash and restricted cash equivalents $ 1,126,000,000 $ 2,168,000,000 $ 1,995,000,000 $ 607,000,000
XML 66 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
NOTE A – SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments, Note I – Commitments and Contingencies and Note J – Stockholders' Equity.

Accounting Estimates

To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.

Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the
customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents

Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in Other long-term assets within our consolidated balance sheets are related to deferred compensation plans.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.

We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses is adequate as of December 31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.
 
Revenue Recognition

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers:

•We have a contract with a customer that creates enforceable rights and obligations,
•Promised products or services are identified,
•The transaction price, or the amount we expect to receive, is determinable and
•We have transferred control of the promised items to the customer.
Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Post-Implant Services

We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.

Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a
liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.

Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.

We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.

Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.

Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.

Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.

Indefinite-lived Intangibles and IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological
feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.

For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.

Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.

For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.
Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.

We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and Other, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.

Investments in Publicly Traded and Privately-Held Entities

For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value.

Net gains and losses and impairments associated with our investment portfolio are included within Other, net in our consolidated statements of operations.

Income Taxes

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We
recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.

Legal and Product Liability Costs

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.

Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations. We record such costs into expense over the employee’s future service period, if any.

Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within Restructuring net charges (credits) in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within Costs of products sold, Selling, general and administrative expenses and Research and development expenses within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within Costs of products sold or Selling, general and administrative expenses in our consolidated statements of operations.

Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar.

Foreign currency transaction gains and losses are included within Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.
Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.

Research and Development

We expense research and development (R&D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles and IPR&D above for our policy regarding R&D projects acquired in connection with our business combinations and asset purchases.
XML 67 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions and Strategic Investments
Aug. 06, 2021
Business Combinations [Abstract]  
ACQUISITIONS AND STRATEGIC INVESTMENTS
NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.

On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urological procedures. The agreement, whereby we will purchase approximately 64 percent of the outstanding shares of M.I. Tech, consists of an upfront purchase price of KRW 291.2 billion or approximately $230 million at foreign currency exchange rates locked into at the time of the agreement via forward currency contracts. We are working towards closing the acquisition during the second quarter of 2023, subject to customary regulatory approvals. The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will provide physicians with more treatment options to meet specific patient needs.

On November 29, 2022, we announced our entry into a definitive agreement to acquire 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement provides for an upfront cash payment of $10.00 per share, approximately $615 million, and is expected to close during the first half of 2023, subject to customary closing conditions. The Apollo business will be integrated into our Endoscopy division.

On February 20, 2023, we completed the acquisition of a majority stake in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or approximately $520 million at foreign currency exchange rates as of closing using cash on hand. The Acotec portfolio complements our existing Peripheral Interventions portfolio and will strengthen our presence in China.

2022 Acquisition

On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.
Purchase Price Allocation

The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 

The final purchase price allocation was comprised of the following components:
(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:
Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

2021 Acquisitions

On March 1, 2021, we completed our acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company with a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and an additional revenue-based milestone payment of $216 million made during the second quarter of 2022. The Preventice business is being managed by our Cardiology division.
On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, up to $92 million in additional clinical and regulatory milestone payments, as well as future revenue-based payments. We have made combined milestone and revenue based payments of $114 million to date. The Farapulse business is being integrated into our Cardiology division.

On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that has developed and commercialized energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired. The Lumenis business is being integrated into our Urology division.

On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately-held company which has developed the WOLF Thrombectomy® Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within Other, net. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division.

Purchase Price Allocation

The final purchase price for the acquisitions completed during 2021 were comprised of the components presented below, which represents the determination of the fair value of identifiable assets acquired and liabilities assumed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations.

(in millions)PreventiceLumenisAll OtherTotal
Payment for acquisition, net of cash acquired$706 $1,032 $519 $2,258 
Fair value of contingent consideration221 — 218 440 
Fair value of prior interest269 — 287 556 
$1,197 $1,032 $1,025 $3,254 

The final purchase price allocation for these acquisitions was comprised of the following components:
(in millions)PreventiceLumenisAll OtherTotal
Goodwill$926 $534 $594 $2,053 
Amortizable intangible assets237 423 465 1,125 
Indefinite-lived intangible assets— 69 43 112 
Other assets acquired65 297 9 372 
Liabilities assumed(32)(282)(11)(325)
Net deferred tax liabilities— (9)(75)(84)
$1,197 $1,032 $1,025 $3,254 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.
In 2022, we recorded certain measurement period adjustments primarily related to our prior year acquisition of the surgical business of Lumenis. We recorded an accrued income tax liability within Other non-current liabilities within our consolidated balance sheet of $183 million related to uncertain tax positions assumed in connection with the acquisition. We expect to be indemnified for the majority of such tax obligations and we recognized a corresponding indemnification asset of $177 million within Other non-current assets within our consolidated balance sheets. Interest and penalties accrued on the tax liability are being recorded within Income tax expense (benefit) and corresponding adjustments to the indemnification asset are being recorded in Other, net within our accompanying consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note Note G – Supplemental Balance Sheet Information for further details regarding our indemnification asset.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:
Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Preventice:
Amortizable intangible assets:
Technology-related$215 910%
Other intangible assets22 810%
$237 
Lumenis:
Amortizable intangible assets:
Technology-related$388 1211%
Other intangible assets35 1111%
Indefinite-lived intangible assets:
IPR&D69 N/A12%
$492 
All Other:
Amortizable intangible assets:
Technology-related$465 1216%-17%
Indefinite-lived intangible assets:
IPR&D43 N/A17%
$508 

2021 Divestiture

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of five facilities and approximately 280 employees globally.

In 2020, we recorded Goodwill impairment charges of $73 million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020.
Contingent Consideration

Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
Balance as of December 31, 2020$196 
Amount recorded related to current year acquisitions440 
Contingent consideration net expense (benefit)(136)
Contingent consideration payments(15)
Balance as of December 31, 2021$486 
Contingent consideration net expense (benefit)35 
Contingent consideration payments(371)
Balance as of December 31, 2022$149 

The payments made during 2022 were primarily related to our 2021 acquisitions of Farapulse and Preventice. As of December 31, 2022, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $417 million. The net expense of $35 million recorded in 2022 related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to Farapulse. The net benefit of $136 million recorded in 2021 related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&D program. Refer to Note C – Goodwill and Other Intangible Assets for further details.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of December 31, 2022Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$13 millionDiscounted Cash FlowDiscount Rate1%-2%2%
Probability of Payment10%-25%22%
Projected Year of Payment2023-20252024
Revenue-based Payments$136 millionDiscounted Cash FlowDiscount Rate6 %-14%7%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to our R&D, regulatory and commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2022.
Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:
As of December 31,
(in millions)20222021
Equity method investments$188 $259 
Measurement alternative investments(1)
216 142 
Publicly-held securities(2)
2 10 
Notes receivable1 — 
$407 $412 
(1)    Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations.
(2)    Publicly-held equity securities are measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations.

These investments are classified as Other long-term assets within our consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.
In 2021, we recorded a $178 million loss on our investment in Pulmonx Corporation presented in Other, net associated with the remeasurement of our investment during the period to fair value based on observable market prices, as well as the disposition of our remaining ownership. As of December 31, 2022, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $232 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.
XML 68 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangible Assets
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
 As of December 31, 2022As of December 31, 2021
(in millions)Gross Carrying AmountAccumulated
Amortization/
Write-offs		Gross Carrying AmountAccumulated
Amortization/
Write-offs
Technology-related$12,397 $(7,378)$11,957 $(6,754)
Patents486 (394)494 (398)
Other intangible assets1,960 (1,400)1,900 (1,325)
Amortizable intangible assets$14,843 $(9,173)$14,351 $(8,476)
Goodwill$22,820 $(9,900)$21,888 $(9,900)
IPR&D112 126 
Technology-related120 120 
Indefinite-lived intangible assets$232 $246 

The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of Baylis Medical completed in the first quarter of 2022.

Intangible asset impairment charges were $132 million in 2022, $370 million in 2021 and $460 million in 2020. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management’s decision
to discontinue commercialization of the VICI VENOUS STENT™ System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&D program due to the incremental time and cost required to complete the program and bring the technology to market. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management’s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.

The following represents our goodwill balance by reportable segment.
(in millions)MedSurgCardiovascularTotal
Balance as of December 31, 2020$3,707 $6,243 $9,951 
Goodwill acquired544 1,520 2,064 
Foreign currency fluctuations and other changes(5)(21)(27)
Balance as of December 31, 2021$4,246 $7,741 $11,988 
Goodwill acquired— 1,030 1,030 
Foreign currency fluctuations and other changes(10)(88)(98)
Balance as of December 31, 2022$4,237 $8,684 $12,920 

In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing.

In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.

Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing.

Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2022 is as follows (in millions):
Fiscal Year
2023$781 
2024741 
2025683 
2026665 
2027625 
These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December 31, 2022.
XML 69 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Hedging Activities and Fair Value Measurements
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS
NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; net investments in certain subsidiaries; and, during 2022 prior to our acquisition of M.I. Tech, the purchase price of M.I. Tech, which was denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within AOCI to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense in our consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December 31, 2022 and 2021, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in
2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net in our consolidated statements of operations.

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the KRW denominated purchase price of M.I. Tech. As of December 31, 2022, we had entered into $228 million in aggregate notional amount of these contracts.

Interest Rate Hedging Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2022 and December 31, 2021.

In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within AOCI was a $8 million loss as of December 31, 2022 and a $24 million loss as of December 31, 2021.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2022 and December 31, 2021. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of December 31,
20222021
Forward currency contractsCash flow hedge$2,725 $3,996 
Forward currency contractsNet investment hedge365 493 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated4,235 3,892 
Total Notional Outstanding$8,321 $9,378 
(1)    Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.

The remaining time to maturity as of December 31, 2022 is within 48 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature within the next year. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.
The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Year Ended December 31, 2022
Forward currency contracts
Cash flow hedges$276 $(62)$214 Cost of products sold$3,956 $(209)$47 $(162)
Net investment hedges(2)
41 (10)32 Interest expense470 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
61 (14)47 Other, net38 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense470 16 (4)13 
Year Ended December 31, 2021
Forward currency contracts
Cash flow hedges$268 $(60)$208 Cost of products sold$3,711 $(54)$12 $(42)
Net investment hedges(2)
56 (13)43 Interest expense341 (13)3 (10)
Foreign currency-denominated debt
Net investment hedges(3)
82 (19)64 Other, net(218)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense341 5 (1)4 
Year Ended December 31, 2020
Forward currency contracts
Cash flow hedges$(99)$22 $(77)Cost of products sold$3,465 $(83)$19 $(64)
Net investment hedges(2)
(37)8 (29)Interest expense361 (24)5 (19)
Foreign currency-denominated debt
Net investment hedges(3)
(89)21 (68)Other, net(362)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense361 5 (1)4 
(1)    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2)    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3)    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
As of December 31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging InstrumentFASB ASC Topic 815 DesignationLocation on Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contractsCash flow hedgeCost of products sold$223 
Forward currency contractsNet investment hedgeInterest expense10 
Interest rate derivative contractsCash flow hedgeInterest expense(3)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)Location on Consolidated Statements of OperationsYear Ended December 31,
202220212020
Net gain (loss) on currency hedge contractsOther, net$(53)$(16)$73 
Net gain (loss) on currency transaction exposuresOther, net21 (12)(105)
Net currency exchange gain (loss)$(31)$(27)$(32)
Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
Location on Consolidated Balance Sheets(1)
As of December 31,
20222021
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$196 $183 
Forward currency contractsOther long-term assets149 169 
  345 352 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets36 42 
Total Derivative and Nonderivative Assets $381 $394 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$— $32 
Forward currency contractsOther long-term liabilities1 6 
Foreign currency-denominated debt(2)
Other long-term liabilities952 1,011 
  953 1,049 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities52 22 
Total Derivative and Nonderivative Liabilities$1,005 $1,071 
(1)We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2)Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 December 31, 2022December 31, 2021
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$673 $— $— $673 $1,632 $— $— $1,632 
Publicly-held securities2 — — 2 10 — — 10 
Hedging instruments— 381 — 381 — 394 — 394 
Licensing arrangements— — 127 127 — — 246 246 
 $674 $381 $127 $1,182 $1,642 $394 $246 $2,282 
Liabilities        
Hedging instruments$— $1,005 $— $1,005 $— $1,071 $— $1,071 
Contingent consideration liability— — 149 149 — — 486 486 
Licensing arrangements— — 159 159 — — 281 281 
 $— $1,005 $308 $1,313 $— $1,071 $767 $1,838 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $673 million invested in money market funds and time deposits as of December 31, 2022 and $1.632 billion as of December 31, 2021, we held $256 million in interest-bearing and non-interest-bearing bank accounts as of December 31, 2022 and $293 million as of December 31, 2021.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We own the contractual right to receive 50 percent of the future Zytiga™ Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these instruments. Royalty payments we receive reduce the fair value of the financial asset and are presented within Proceeds from royalty rights, and payments we remit to inventors reduce the fair value of the financial liability and are presented within Payments for royalty rights within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, Transfers and Servicing. Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as Non-cash impact of transferred royalty rights in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.

We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2022. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement.
The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2022 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of December 31, 2022Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Financial Asset$127 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2023-20252024
Financial Liability$159 millionDiscounted Cash FlowDiscount Rate12%-15%13%
Projected Year of Payment2023-20262024
(1)    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2020$365 
Proceeds from royalty rights(163)
Fair value adjustment (expense) benefit44 
Balance as of December 31, 2021$246 
Proceeds from royalty rights(141)
Fair value adjustment (expense) benefit22 
Balance as of December 31, 2022$127 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2020$407 
Payments for royalty rights(166)
Fair value adjustment expense (benefit)41 
Balance as of December 31, 2021$281 
Payments for royalty rights(145)
Fair value adjustment expense (benefit)23 
Balance as of December 31, 2022$159 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations was $8.203 billion as of December 31, 2022 and $10.196 billion as of December 31, 2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
XML 70 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Contractual Obligations and Commitments
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $8.935 billion as of December 31, 2022 and $9.065 billion as of December 31, 2021, with current maturities of $20 million as of December 31, 2022 and $261 million as of December 31, 2021. The debt maturity schedule for our long-term debt obligations is presented below:
Issuance DateMaturity DateAs of December 31,
Coupon Rate(1)
(in millions, except interest rates)20222021
October 2023 Senior Notes(4)
August 2013October 2023$— $244 4.125%
March 2024 Notes(4)
February 2019March 2024504 850 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,067 — 0.750%
May 2025 Senior Notes(4)
May 2015May 2025— 523 3.850%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior Notes(4)
February 2019March 2026255 850 3.750%
December 2027 Senior Notes(3)
November 2019December 2027960 1,021 0.625%
March 2028 Senior Notes(3)
March 2022March 2028800 — 1.375%
March 2028 Senior Notes(4)
February 2018March 2028344 434 4.000%
March 2029 Senior Notes(4)
February 2019March 2029272 850 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031800 — 1.625%
March 2034 Senior Notes(3)
March 2022March 2034534 — 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.750%
March 2039 Senior Notes(4)
February 2019March 2039450 750 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior Notes(4)
February 2019March 2049650 1,000 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2023 - 2049(76)(76)
Unamortized Gain on Fair Value Hedges2022— 3 
Finance Lease ObligationVarious5 6 
Long-term debt $8,915 $8,804 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)    Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2)    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2022 and 2021, respectively.
(4)    Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within Current Debt Obligations within our consolidated balance sheets as of December 31, 2021.
Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:

Fiscal Year
2023$— 
2024504 
20251,567 
2026255 
2027960 
Thereafter5,700 

Revolving Credit Facility

On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility as of December 31, 2022 or December 31, 2021.

Financial Covenant

As of December 31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
 Covenant Requirement
as of December 31, 2022		 Actual
as of December 31, 2022
Maximum permitted leverage ratio(1)
3.75 times 2.57 times
(1) Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions due to our funding of these acquisitions using cash on hand.

The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2022, we had $265 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $1.455 billion in the aggregate. As of December 31, 2022, we had $866 million of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.
Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2022 and 2021.

Senior Notes

We had senior notes outstanding of $8.986 billion as of December 31, 2022 and $9.121 billion as of December 31, 2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in Interest expense within our consolidated statements of operations.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):

As of December 31, 2022As of December 31, 2021
Factoring ArrangementsAmount
De-recognized		Weighted Average Interest RateAmount
De-recognized		Weighted Average Interest Rate
Euro denominated$161 2.4 %$141 2.1 %
Yen denominated194 0.6 %223 0.6 %
Renminbi denominated13 3.1 %11 3.2 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $135 million as of December 31, 2022 and $134 million as of December 31, 2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2022 and December 31, 2021, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.
Future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were as of December 31, 2022 (in millions):
Fiscal YearUnrecorded Purchase Obligations
2023$755 
2024119 
202571 
202635 
202719 
Thereafter21 
 $1,021 
XML 71 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Leases
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Lessee, Operating Leases
NOTE F – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, Leases, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 54 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

Our operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Refer to Note E – Contractual Obligations and Commitments for information regarding our finance leases. The following table presents supplemental balance sheet information related to our operating leases:
As of December 31,
(in millions)20222021
Assets
Operating lease right-of-use assets in Other long-term assets
$386 $435 
Liabilities
Operating lease liabilities in Other current liabilities
61 71 
Operating lease liabilities in Other long-term liabilities
347 389 
The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
As of December 31,
20222021
Weighted average remaining lease term10 years10 years
Weighted average discount rate3.3%2.6%

Our operating lease cost under FASB ASC Topic 842 was $91 million in 2022, $90 million in 2021 and $92 million in 2020.

The following table presents supplemental cash flow information related to our operating leases:
Year Ended December 31,
(in millions)20222021
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows from operating leases$91 $87 

Right-of-use assets obtained in exchange for operating lease obligations were $43 million and $68 million for the years ended December 31, 2022 and 2021.

The following table presents the maturities of our operating lease liabilities as of December 31, 2022 (in millions):
Fiscal yearOperating Leases
2023$80 
202466 
202555 
202643 
202734 
Thereafter214 
Total future minimum operating lease payments492 
Less: imputed interest(84)
Present value of operating lease liabilities$408 
XML 72 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Supplemental Balance Sheet Information
 12 Months Ended
Dec. 31, 2022
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying consolidated balance sheets are as follows:
Trade accounts receivable, net
 As of December 31,
(in millions)20222021
Trade accounts receivable$2,079 $1,886 
Allowance for credit losses(109)(108)
 $1,970 $1,778 

The following is a rollforward of our Allowance for credit losses:
Year Ended December 31,
(in millions)202220212020
Beginning balance$108 $105 $74 
Cumulative effect adjustment for adoption of ASU 2016-13n/an/a10 
Credit loss expense35 28 49 
Write-offs(35)(25)(27)
Ending balance$109 $108 $105 
Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset’s contractual life.

Inventories
 As of December 31,
(in millions)20222021
Finished goods$1,171 $1,029 
Work-in-process147 128 
Raw materials548 452 
 $1,867 $1,610 

Approximately 27 percent of our finished goods inventory as of December 31, 2022 and approximately 30 percent as of December 31, 2021 was at customer locations pursuant to consignment arrangements or held by sales representatives.

Other current assets
 As of December 31,
(in millions)20222021
Restricted cash and restricted cash equivalents$149 $188 
Derivative assets232 226 
Licensing arrangements60 132 
Other290 254 
 $731 $799 
Property, plant and equipment, net
 As of December 31,
(in millions)20222021
Land$137 $109 
Buildings and improvements1,695 1,523 
Equipment, furniture and fixtures3,297 3,287 
Capital in progress598 605 
 5,728 5,525 
Less: accumulated depreciation3,282 3,273 
 $2,446 $2,252 

Depreciation expense was $333 million in 2022, $352 million in 2021 and $333 million in 2020.

Other long-term assets
 As of December 31,
(in millions)20222021
Restricted cash equivalents$48 $55 
Operating lease right-of-use assets386 435 
Derivative assets149 169 
Investments407 412 
Licensing arrangements67 114 
Indemnification asset172 — 
Other271 225 
 $1,500 $1,410 

Accrued expenses
 As of December 31,
(in millions)20222021
Legal reserves$231 $264 
Payroll and related liabilities830 848 
Rebates352 350 
Contingent consideration74 289 
Other674 686 
 $2,160 $2,436 
Other current liabilities
 As of December 31,
(in millions)20222021
Deferred revenue$220 $208 
Licensing arrangements79 138 
Taxes payable232 209 
Other230 228 
 $761 $783 

Other long-term liabilities
 As of December 31,
(in millions)20222021
Accrued income taxes$597 $442 
Legal reserves212 284 
Contingent consideration75 197 
Licensing arrangements80 143 
Operating lease liabilities347 389 
Deferred revenue289 276 
Other434 489 
 $2,035 $2,220 
XML 73 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE H – INCOME TAXES

Our Income (loss) before income taxes consisted of the following:
Year Ended December 31,
(in millions)202220212020
Domestic$(1,119)$(648)$(660)
Foreign2,260 1,724 581 
$1,141 $1,076 $(79)
The related expense (benefit) for income taxes consisted of the following:
Year Ended December 31,
(in millions)202220212020
Current
  Federal$51 $18 $(29)
  State19 33 (35)
  Foreign381 127 151 
451 178 87 
Deferred
  Federal(92)(256)(26)
  State(32)(3)(6)
  Foreign117 117 (53)
(7)(142)(85)
$443 $36 $2 

The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:
Year Ended December 31,
202220212020
U.S. federal statutory income tax rate21.0 %21.0 %(21.0)%
State income taxes, net of federal benefit0.7 %2.5 %16.6 %
Domestic taxes on foreign earnings15.3 %6.8 %155.4 %
Effect of foreign taxes(3.8)%(14.3)%(40.7)%
Acquisition-related4.4 %(8.1)%(16.7)%
Research credit(4.5)%(3.0)%(43.0)%
Valuation allowance(1.3)%0.8 %(42.0)%
Goodwill impairment charges— %— %3.7 %
Compensation-related0.6 %(0.6)%(7.7)%
Non-deductible expenses0.4 %0.4 %64.4 %
Uncertain tax positions7.7 %1.2 %(96.8)%
Intra-entity asset transfers— %— %10.2 %
Return to provision(2.1)%(5.7)%(37.3)%
Change in tax rates(0.2)%1.9 %51.8 %
Other, net0.7 %0.4 %6.0 %
38.9 %3.3 %2.9 %
Significant components of our deferred tax assets and liabilities are as follows:
 As of December 31,
 (in millions)
20222021
 Deferred Tax Assets:
 
Inventory costs and related reserves$19 $10 
Tax benefit of net operating losses and credits511 620 
Reserves and accruals304 324 
Restructuring-related charges6 14 
Litigation and product liability reserves103 127 
Investment write-down38 31 
Compensation related136 130 
Federal benefit of uncertain tax positions9 8 
Intangible assets3,668 3,546 
Capitalized R&D160 67 
Property, plant and equipment2 14 
Other— 35 
 4,954 4,926 
Less: valuation allowance(1,004)(1,014)
 3,950 3,912 
 Deferred Tax Liabilities:
  
Unrealized gains and losses on derivative financial instruments117 79 
Other34 — 
151 79 
 Net Deferred Tax Assets
3,799 3,833 
Prepaid on intercompany profit264 205 
 Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,062 $4,038 

Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):
Location on Consolidated Balance SheetsAs of December 31,
Component20222021
Prepaid on intercompany profitPrepaid income taxes$264 $205 
Non-current deferred tax assetDeferred tax assets3,942 4,142 
Deferred Tax Assets and Prepaid on Intercompany Profit 4,206 4,348 
Non-current deferred tax liabilityDeferred tax liabilities144 310 
Deferred Tax Liabilities 144 310 
Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,062 $4,038 

As of December 31, 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $464 million. As of December 31, 2021, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $560 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $47 million as of December 31, 2022, and $60 million as of December 31, 2021. These tax attributes expire periodically beginning in 2023.

After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.004 billion as of December 31, 2022, and $1.014 billion as of December 31, 2021. The decrease in the valuation allowance as of December 31, 2022, compared to December 31, 2021, is primarily due to the release of valuation allowances on certain U.S. state net operating losses and tax credit carryforwards due to the repatriation of foreign earnings, offset by the concurrent build of the valuation allowance on
other state attributes. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $56 million in 2022, a charge of $81 million in 2021 and a benefit of $78 million in 2020.

We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $162 million in 2022, $149 million in 2021 and $64 million in 2020. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on Net income (loss) per common share - assuming dilution was $0.11 for 2022, $0.10 for 2021 and $0.04 for 2020. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $21 million in 2022, $27 million in 2021 and $30 million in 2020. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on Net income (loss) per common share - assuming dilution was $0.02 in each of the years 2022, 2021 and 2020. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $17 million in 2022 and $0 in 2021 and 2020. The impact on Net income (loss) per common share - assuming dilution was $0.01 in 2022 and de minimis in 2021 and 2020.

As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December 31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. As of December 31, 2020, we had $261 million of gross unrecognized tax benefits, of which a net $183 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 Year Ended December 31,
(in millions)202220212020
Beginning Balance$255 $261 $455 
Additions based on positions related to the current year88 8 28 
Additions based on positions related to prior years177 41 6 
Reductions for tax positions of prior years(20)(36)(186)
Settlements with taxing authorities(1)(2)(27)
Statute of limitation expirations(8)(17)(15)
Ending Balance$492 $255 $261 
We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2016 and substantially all material state and local income tax matters through 2014. We have concluded substantially all foreign income tax matters through 2015.

In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91 million to release the reserves related to these years. We received a refund of $62 million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $77 million accrued for gross interest and penalties as of December 31, 2022, $43 million as of December 31, 2021, and $41 million as of December 31, 2020. Net tax expense related to interest and penalties was immaterial in 2022, 2021 and 2020. The increase in our net tax expense related to interest and penalties as of December 31, 2022, compared to December 31, 2021, is related to reaching settlements with taxing authorities.

It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $75 million.

For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&P) that we previously deferred from U.S. income taxes. As a result of various audit activities, the revised amount of transition tax was approximately $937 million as of December 31, 2022, as compared to $938 million as of December 31, 2021. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun
remitting the required installment payments, with a balance remaining of $386 million as of December 31, 2022. In addition, we have provided for U.S. state income taxes of $14 million on all U.S. dollar-denominated E&P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.
XML 74 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $443 million as of December 31, 2022, and $548 million as of December 31, 2021, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of our legal accrual for transvaginal surgical mesh product claims is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in Other current assets of $149 million as of December 31, 2022, and $188 million as of December 31, 2021. Refer to Note A – Significant Accounting Policies for additional information.
We recorded litigation-related net charges of $173 million in 2022, $430 million in 2021 and $278 million in 2020, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity. The charges recorded in 2020 were also inclusive of a reserve related to claims made by a coalition of state attorneys general, which has since been settled.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. The Company has also asserted patents against Cook in Germany and the United Kingdom. Trials are scheduled in the United Kingdom in February 2023 and in Germany in April 2023.

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. The Company intends to appeal the jury's verdict.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. While our U.S. case count has remained materially the same over the past three years, we have increased our reserve to account for changes in our estimates regarding settlement and litigation activity. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims and expect that more cases will go to trial in the coming years than have gone to trial in the past several years. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh
products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. Under the terms of the Court-approved Scheduling Order, Counsel for Mr. Errichiello was required to file an Amended Complaint on or before June 4, 2021, which they did. The Amended Complaint seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. In response, the Company brought a Motion to Dismiss the Amended Complaint which it filed on July 19, 2021. On December 20, 2022, the Court granted in part and denied in part the Company’s motion to dismiss. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund and Diane Nachbaur, two stockholders of the Company, on July 26, 2021, and July 29, 2021, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items.
Matters Concluded Since December 31, 2021

On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen and BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021 and alleged that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen’s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On December 17, 2021, the court granted BTG’s motion to dismiss the qui tam action. On January 10, 2022, the court granted the parties’ stipulation of dismissal with prejudice as to the claims of the direct purchaser plaintiff, whose claims had been stayed in the October 12, 2021, order compelling arbitration.

On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolved the dispute. The settlement did not have a material impact on our financial position or results of operations.

On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro Corp. (Nevro) in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro's Senza™ Spinal Cord Stimulation (SCS) System. The Company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On July 29, 2022, the parties reached a confidential settlement agreement, pursuant to which the Company agreed to make a payment to Nevro of $85 million to resolve all pending litigation between the parties, including this matter and the 18-cv-664 and 21-cv-258 matters described below.

On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro’s Senza™ I and Senza™ II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringed five Nevro patents. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.

On February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of Delaware (21-cv-258). The complaint alleged infringement of five Nevro patents by certain of the Company’s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.
The Company was previously named a defendant in multiple filed product liability cases involving our Greenfield Vena Cava Filter, which we discontinued marketing and actively selling in the fourth quarter of 2018. Most of the filed cases were part of a consolidated matter in Middlesex County, Massachusetts. We had also received notice of multiple additional unfiled claims. As of December 31, 2022, we have entered into master settlement agreements, the last of which was finalized on January 12, 2023, to resolve all but a small handful of these cases and claims.
XML 75 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
STOCKHOLDER'S EQUITY
NOTE J – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2022, our MCPS had an aggregate liquidation preference of $1.006 billion.

Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations.

Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $100 per share plus accumulated and unpaid dividends.

Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between 2.3834 and 2.9197 shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023.

The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions.

During 2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared and we paid quarterly cash dividends of $14 million, or $1.3750 per MCPS share to holders, representing dividend periods through November 2022. On January 30, 2023, the Committee declared a cash dividend of $1.3750 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. We have presented cumulative, unpaid dividends within Accrued expenses within our consolidated balance sheets as of December 31, 2022.

Common Stock

We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Holders of common stock are junior to holders of MCPS in terms of liquidation preference.

On May 27, 2020, we completed an offering of 29,382,500 shares of common stock at a public offering price of $34.25 per share. The net proceeds from the common stock offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. We used a portion of the net proceeds from the May 27, 2020 MCPS and
common stock offerings to repay remaining amounts outstanding under our previous term loan credit agreement that matured on April 20, 2021 and to pay related fees, expenses and premiums. The remaining proceeds were used for general corporate purposes.

In 2020, we repurchased approximately 15.7 million shares of our common stock pursuant to our 2013 share repurchase program for a total of approximately $535 million in cash, which represented the full amount remaining under the existing authorization.

On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 and had the full amount available under the authorization as of December 31, 2022.

There were approximately 263 million shares in treasury as of December 31, 2022 and 2021.
XML 76 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Inventive and Purchase Plans
 12 Months Ended
Dec. 31, 2022
Stock Incentive and Purchase Plans [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
NOTE K – STOCK INCENTIVE AND PURCHASE PLANS

Employee and Director Stock Incentive Plans

In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 175 million as of December 31, 2022. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee.

Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs), RSUs and deferred stock units (DSUs) issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.

The following presents the impact of stock-based compensation on our consolidated statements of operations:
 Year Ended December 31,
(in millions, except per share data)202220212020
Cost of products sold$12 $11 $9 
Selling, general and administrative expenses167 147 130 
Research and development expenses41 36 30 
 220 194 170 
Income tax (benefit) expense(32)(29)(28)
 $188 $165 $142 
Net impact per common share - basic$0.13 $0.12 $0.10 
Net impact per common share - assuming dilution$0.13 $0.12 $0.10 
Stock Options

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 Year Ended December 31,
 202220212020
Options granted (in thousands)
3,287 3,822 3,819 
Weighted-average exercise price$44.02 $37.69 $41.79 
Weighted-average grant-date fair value$13.64 $10.77 $10.44 
Black-Scholes Assumptions   
Expected volatility28 %29 %23 %
Expected term (in years, weighted)
6.15.95.8
Risk-free interest rate1.42%-3.87%0.66%-1.20%0.27%-1.72%

Expected Volatility

We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.

Expected Term

We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.

Risk-Free Interest Rate

We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.

Expected Dividend Yield

We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.
Information related to stock options under stock incentive plans are as follows:
Stock Options
(in thousands)
Weighted
Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 201923,065 $19 
Granted3,819 42 
Exercised(3,096)13 
Cancelled/forfeited(666)27 
Outstanding as of December 31, 202023,122 $24 
Granted3,822 38 
Exercised(4,796)13 
Cancelled/forfeited(699)26 
Outstanding as of December 31, 202121,448 $29 
Granted3,287 44 
Exercised(2,745)17 
Cancelled/forfeited(502)34 
Outstanding as of December 31, 202221,489 $32 5.9297 
Exercisable as of December 31, 202213,674 27 4.6258 
Expected to vest as of December 31, 20227,535 41 8.238 
Total vested and expected to vest as of December 31, 202221,209 $32 5.9$296 
The total intrinsic value of stock options exercised was $72 million in 2022, $137 million in 2021 and $84 million in 2020.

Non-Vested Stock

We value RSAs, RSUs and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:
Non-Vested
Stock Award Units
(in thousands)
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 201911,079 $29 
Granted3,609 41 
Vested(1)
(4,147)25 
Forfeited(554)34 
Balance as of December 31, 20209,987 $34 
Granted4,240 $39 
Vested(1)
(3,823)$31 
Forfeited(658)36 
Balance as of December 31, 20219,745 $37 
Granted3,854 $45 
Vested(1)
(3,482)$36 
Forfeited(680)44 
Balance as of December 31, 20229,438 $41 
(1)The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.

The total vesting date fair value of shares that vested was approximately $150 million in 2022, $148 million in 2021 and $172 million in 2020.
Market-based RSU and DSU Awards

During 2022 and 2021, we granted market-based RSU awards, and in 2020, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Healthcare Index over a three-year performance period. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based RSU's and DSUs that satisfied the market performance criteria.

We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 202220212020
AwardsAwardsAwards
Stock price on date of grant$44.19 $37.50 $42.16 
Measurement period (in years)
2.92.92.9
Risk-free rate1.71 %0.20 %1.37 %
We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.

Free Cash Flow Performance-based RSU and DSU Awards

During 2022 and 2021, we granted free-cash flow performance-based RSU awards, and in 2020, we granted free-cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based RSUs and DSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Executive Compensation and Human Resources Committees of our Board of Directors, based on our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st of each year and ending December 31st. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs and DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs and DSUs that satisfied the performance criteria.

The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2022:
2022 AFCF2021 AFCF2020 AFCF
Fair value, net of forfeitures to date (in millions)
$7 $12 $6 
Achievement of target payout88 %131 %89 %
Year-end stock price used in determining fair value$46.27 $42.48 $35.95 

We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.

Expense Attribution

We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.
We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, Compensation – Stock Compensation allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December 31, 2022, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Unrecognized Compensation Cost

We expect to recognize the following future expense for awards outstanding as of December 31, 2022:
 Unrecognized
 Compensation Cost
(in millions) (1)
Weighted Average Remaining
Vesting Period
(in years)
Stock options$38  
Non-vested stock awards181  
 $219 1.7
(1)Amounts presented represent compensation cost, net of estimated forfeitures.

Employee Stock Purchase Plan

In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan now provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2022, there were approximately 11 million shares available for future issuance under the employee stock purchase plan. We temporarily suspended our global employee stock purchase plan for the offering period for the second half of 2020 due to cost-savings initiatives in response to the COVID-19 pandemic and resumed the plan beginning with the offering period for the first half of 2021.

Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
Year Ended December 31,
202220212020
Shares issued or to be issued (in thousands)
2,850 2,578 1,387 
Range of purchase prices$31.68 -$32.31 $29.98 -$36.11 $29.84 
Expense recognized (in millions)
$28 $24 $10 
XML 77 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Weighted Average Shares Outstanding
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
NOTE L – WEIGHTED AVERAGE SHARES OUTSTANDING

Year Ended December 31,
(in millions)202220212020
Weighted average shares outstanding - basic1,430.5 1,422.3 1,416.7 
Net effect of common stock equivalents9.2 11.5 — 
Weighted average shares outstanding - assuming dilution1,439.7 1,433.8 1,416.7 

The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:
Year Ended December 31,
(in millions)202220212020
Common stock equivalents(1)
n/an/a14
Stock options outstanding(2)
636
MCPS(3)
242414
(1)    Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our Net loss position in this period.
(2)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(3)    Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information.

We base Net income (loss) per common share - assuming dilution upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.
In 2022, 2021 and 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income (loss) was reduced by cumulative Preferred stock dividends, as presented in our consolidated statements of operations, for purposes of calculating Net income (loss) available to common stockholders.
XML 78 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
SEGMENT REPORTING
NOTE M – SEGMENT REPORTING

In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our consolidated statements of operations and are included in the reconciliation below. Refer to Note N – Revenue for net sales by reportable segment presented in accordance with U.S. GAAP.
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.
 Year Ended December 31,
Net sales202220212020
MedSurg$5,057 $4,616 $3,844 
Cardiovascular8,161 7,212 5,913 
Total net sales of reportable segments 13,218 11,828 9,756 
Other(1)
(60)13 219 
Impact of foreign currency fluctuations(476)47 (65)
$12,682 $11,888 $9,913 

Year Ended December 31,
Income (loss) before income taxes202220212020
MedSurg$1,625 $1,524 $1,156 
Cardiovascular2,113 1,888 1,043 
Total operating income of reportable segments 3,737 3,412 2,198 
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(436)(406)(424)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs
(789)(1,070)(1,208)
Amortization expense(803)(741)(789)
Other(1)
(60)4 143 
Operating income (loss) 1,649 1,199 (80)
Other income (expense), net(508)(123)1 
Income (loss) before income taxes$1,141 $1,076 $(79)
(1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

Operating income of reportable segments as a percentage of net sales of reportable segmentsYear Ended December 31,
202220212020
MedSurg32.1 %33.0 %30.1 %
Cardiovascular25.9 %26.2 %17.6 %

Year Ended December 31,
Depreciation expense202220212020
MedSurg$88 $91 $90 
Cardiovascular245 261 240 
Total depreciation expense of reportable segments333 352 330 
Other(1)
— — 3 
Consolidated depreciation expense$333 $352 $333 
As of December 31,
Total assets20222021
MedSurg$2,501 $2,178 
Cardiovascular5,205 4,417 
Total assets of reportable segments7,706 6,595 
Goodwill12,920 11,988 
Other intangible assets, net5,902 6,121 
All other corporate assets5,941 7,525 
 $32,469 $32,229 

As of December 31,
Long-lived assets20222021
U.S.$1,241 $1,190 
Ireland478 436 
Costa Rica246 185 
Other countries481 440 
Property, plant and equipment, net2,446 2,252 
Goodwill12,920 11,988 
Other intangible assets, net5,902 6,121 
Operating lease right-of-use assets in Other long-term assets
386 435 
 $21,653 $20,795 
XML 79 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
NOTE N – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:
Year Ended December 31,
202220212020
BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$1,341 $880 $2,221 $1,222 $919 $2,141 1,000 $780 $1,780 
Urology1,257 516 1,773 1,120 463 1,583 918 368 1,286 
Neuromodulation715 202 917 713 196 909 610 151 761 
MedSurg3,312 1,599 4,911 3,055 1,578 4,633 2,528 1,299 3,827 
Interventional Cardiology Therapies744 1,485 2,228 778 1,431 2,209 728 1,247 1,975 
Watchman915 103 1,019 729 100 829 253 71 324 
Cardiac Rhythm Management1,337 763 2,100 1,214 805 2,019 992 712 1,704 
Electrophysiology275 310 585 128 237 365 118 169 287 
Cardiology3,271 2,662 5,932 2,850 2,572 5,422 2,091 2,199 4,290 
Peripheral Interventions1,048 850 1,899 996 824 1,820 888 689 1,577 
Cardiovascular4,319 3,512 7,831 3,846 3,396 7,242 2,979 2,888 5,866 
Other1
— — (60)10 4 13 193 27 219 
Total Net Sales$7,632 $5,111 $12,682 $6,911 $4,978 $11,888 $5,701 $4,212 $9,913 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

Year Ended December 31,
Geographic Regions202220212020
U.S.$7,632 $6,901 $5,508 
Europe, Middle East and Africa2,526 2,518 2,097 
Asia-Pacific2,116 2,070 1,781 
Latin America and Canada469 386 307 
Other1
(60)13 219 
Total Net Sales$12,682 $11,888 $9,913 
Emerging Markets(2)
$1,715 $1,429 $1,138 
(2)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying consolidated balance sheets. Our deferred revenue balance was $509 million as of December 31, 2022 and $484 million as of December 31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the
average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $156 million in 2022 that was included in the above contract liability balance as of December 31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period.

In 2020, we recorded $179 million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX™ Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed.

Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.
XML 80 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Changes in Other Comprehensive Income
 12 Months Ended
Dec. 31, 2022
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
NOTE O – CHANGES IN OTHER COMPREHENSIVE INCOME

The following table provides the reclassifications out of Other comprehensive income, net of tax:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(86)214 36 163 
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(150)1 (157)
Total other comprehensive income (loss)(94)63 37 6 
Balance as of December 31, 2022$(1)$269 $1 $269 
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2020$218 $36 $(47)$207 
Other comprehensive income (loss) before reclassifications12 208 8 228 
(Income) loss amounts reclassified from accumulated other comprehensive income(137)(38)3 (173)
Total other comprehensive income (loss)(125)170 11 56 
Balance as of December 31, 2021$93 $206 $(36)$263 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.
The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by immaterial income tax impacts in 2022 and in 2021.
XML 81 R25.htm IDEA: XBRL DOCUMENT v3.22.4
New Accounting Pronouncements
 12 Months Ended
Dec. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Pronouncements, Policy
NOTE P – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2022, we implemented the following standards, which did not have a material impact on our financial position or results of operations.

ASC Update No. 2021-05

In July 2021, the FASB issued ASC Update No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis.

ASC Update No. 2022-06

In December 2022, the FASB issued ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.

Standards to be Implemented

In March 2022, the FASB issued ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.

In March 2022, the FASB issued ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.

In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.

In September 2022, the FASB issued ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50). Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No.
2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.

No other new accounting pronouncements, issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.
XML 82 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Retirement Plans (Notes)
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
Compensation and Employee Benefit Plans [Text Block]
NOTE Q – EMPLOYEE RETIREMENT PLANS

Defined Benefit Pension Plans

Domestic Retirement Plans

Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan.

We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied.

U.K. Plan

As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.

Other International Retirement Plans

In addition, we maintain retirement plans covering certain international employees.
We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2022 and 2021, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:
 As of December 31, 2022
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded
PBO Recognized
Domestic Retirement Plans$50 $55 $— $55 
Other International Retirement Plans140 152 101 51 
 $190 $207 $101 $105 

 As of December 31, 2021
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded PBO Recognized
Domestic Retirement Plans$56 $59 $— $59 
U.K. Plan209 209 205 3 
Other International Retirement Plans214 234 130 103 
 $478 $502 $336 $166 

A rollforward of the changes in the PBO for our retirement plans is as follows:
 Year Ended December 31,
(in millions)20222021
Beginning obligations$502 $532 
Acquired plans— 4 
Service costs13 17 
Interest costs3 3 
Actuarial (gain) loss(54)(7)
Plan curtailments/settlements(191)— 
Plan amendments and assumption changes(25)(6)
Benefits paid(6)(22)
Impact of foreign currency fluctuations(37)(20)
Ending obligation$207 $502 

The critical assumptions associated with our employee retirement plans for 2022 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans5.32%n/a2.00%
Other International Retirement Plans2.62%2.27%3.00%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.
The critical assumptions associated with our employee retirement plans for 2021 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans2.40%n/a1.50%
U.K. Plan0.70%0.70%n/a
Other International Retirement Plans0.82%2.16%2.60%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.

A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 Year Ended December 31,
(in millions)20222021
Beginning fair value$336 $355 
Acquired plans— 1 
Actual return on plan assets(2)5 
Employer contributions16 12 
Participant contributions1 2 
Plan curtailments/settlements(185)— 
Actuarial gain (loss)(25)(4)
Benefits paid(9)(22)
Impact of foreign currency fluctuations(32)(13)
Ending fair value$101 $336 

For our defined benefit plans, excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.

Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.

The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:
As of
December 31, 2021
(in millions)Level 1Level 2Level 3Total
Buy-in contracts$— $— $205 $205 
Total assets$— $— $205 $205 
Changes in the fair value of the U.K. Plan Level 3 assets were as follows:
(in millions)Buy-in Contracts
Balance as of December 31, 2021$205 
Actual return on plan assets0 
Employer contributions1 
Plan curtailments/settlements(160)
Actuarial gain (loss)(24)
Benefits paid(2)
Impact of foreign currency fluctuations(22)
Balance as of December 31, 2022$— 

Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December 31, 2022. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:
(in millions)Post Retirement Benefits
2023$15 
20248 
202513 
202614 
202714 
2028 - 203270 

Defined Contribution Plan

We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.
XML 83 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Schedule II
 12 Months Ended
Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
Description (in millions)
Balance at
 Beginning of Year
Cumulative effect adjustment for adoption of ASU 2016-13(1)
Credit loss exposure(1)
Write-offs(2)
Balance at
End of Year
Year Ended December 31, 2022:
Allowances for credit losses$108 n/a35 (35)$109 
Year Ended December 31, 2021:
Allowances for credit losses$105 n/a28 (25)$108 
Year Ended December 31, 2020:
Allowances for uncollectible accounts$74 10 49 (27)$105 
(1) Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.
(2) Represents actual write-offs of uncollectible accounts.
XML 84 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Significant Accounting Policies Significant Accounting Policies (Policies)
 3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Significant Accounting Policies [Abstract]    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]  
Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.
Subsequent Events, Policy [Policy Text Block]  
Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments, Note I – Commitments and Contingencies and Note J – Stockholders' Equity.
Use of Estimates, Policy [Policy Text Block]  
Accounting Estimates

To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.
Cash and Cash Equivalents, Policy [Policy Text Block]  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.

Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in Other current assets within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the
customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents
Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in Other current assets within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in Other long-term assets within our consolidated balance sheets are related to deferred compensation plans.
Concentration Risk Disclosure [Text Block]  
Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.

We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.
We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our Allowance for credit losses is adequate as of December 31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase.
Revenue Recognition, Policy [Policy Text Block]  
Revenue Recognition

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers:

•We have a contract with a customer that creates enforceable rights and obligations,
•Promised products or services are identified,
•The transaction price, or the amount we expect to receive, is determinable and
•We have transferred control of the promised items to the customer.
Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Post-Implant Services

We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.
Standard Product Warranty, Policy  
Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a
liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.
Inventory, Policy [Policy Text Block]  
Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to Cost of products sold over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.
We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.
Property, Plant and Equipment, Policy [Policy Text Block]  
Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.
Business Combinations Policy [Policy Text Block]  
Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in Other, net equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.

Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration net expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.
In Process Research and Development, Policy [Policy Text Block]  
Indefinite-lived Intangibles and IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological
feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.
For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]  
Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within Cost of products sold; Selling, general and administrative expenses and Research and development expenses, as appropriate within our accompanying consolidated statements of operations, and include in Amortization expense only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.
For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]  
Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.
We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, Intangibles - Goodwill and Other, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit.
Investment, Policy  
Investments in Publicly Traded and Privately-Held Entities

For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in Other, net within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value.
Net gains and losses and impairments associated with our investment portfolio are included within Other, net in our consolidated statements of operations.
Income Tax, Policy [Policy Text Block]  
Income Taxes

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We
recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See Note H – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.
Legal Costs, Policy [Policy Text Block] In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
Legal and Product Liability Costs

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.
Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]  
Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations. We record such costs into expense over the employee’s future service period, if any.
Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within Restructuring net charges (credits) in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within Costs of products sold, Selling, general and administrative expenses and Research and development expenses within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within Costs of products sold or Selling, general and administrative expenses in our consolidated statements of operations.
Foreign Currency Transactions and Translations Policy [Policy Text Block]  
Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar.
Foreign currency transaction gains and losses are included within Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.
Derivatives, Policy [Policy Text Block]  
Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.
Research and Development Expense, Policy [Policy Text Block]  
Research and Development

We expense research and development (R&D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles and IPR&D above for our policy regarding R&D projects acquired in connection with our business combinations and asset purchases.
XML 85 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measures and Disclosures (Policies)
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Derivatives, Policy [Policy Text Block]
Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.
Fair Value Measurement, Policy [Policy Text Block] FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
XML 86 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Commitment and Contingencies (Policies)
 3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Legal Costs, Policy [Policy Text Block] In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
Legal and Product Liability Costs

We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our consolidated statements of operations. See Note I – Commitments and Contingencies for discussion of our individual material legal proceedings.
XML 87 R31.htm IDEA: XBRL DOCUMENT v3.22.4
New Accounting Pronouncements (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]  
ASC Update No. 2020-10 Codification Improvements ASC Update No. 2021-05In July 2021, the FASB issued ASC Update No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis.
ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method In March 2022, the FASB issued ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.
ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) In March 2022, the FASB issued ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.
ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.
ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) In September 2022, the FASB issued ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50). Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.
ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848
ASC Update No. 2022-06

In December 2022, the FASB issued ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.
XML 88 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Retirement Plans Employee Retirement Plans (Policies)
 12 Months Ended
Dec. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI.
XML 89 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions and Strategic Investments (Tables)
 12 Months Ended
Dec. 31, 2022
Business Acquisition [Line Items]  
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the purchase price to the specific intangible asset categories as follows:
Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Preventice:
Amortizable intangible assets:
Technology-related$215 910%
Other intangible assets22 810%
$237 
Lumenis:
Amortizable intangible assets:
Technology-related$388 1211%
Other intangible assets35 1111%
Indefinite-lived intangible assets:
IPR&D69 N/A12%
$492 
All Other:
Amortizable intangible assets:
Technology-related$465 1216%-17%
Indefinite-lived intangible assets:
IPR&D43 N/A17%
$508 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
Balance as of December 31, 2020$196 
Amount recorded related to current year acquisitions440 
Contingent consideration net expense (benefit)(136)
Contingent consideration payments(15)
Balance as of December 31, 2021$486 
Contingent consideration net expense (benefit)35 
Contingent consideration payments(371)
Balance as of December 31, 2022$149 
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of December 31, 2022Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$13 millionDiscounted Cash FlowDiscount Rate1%-2%2%
Probability of Payment10%-25%22%
Projected Year of Payment2023-20252024
Revenue-based Payments$136 millionDiscounted Cash FlowDiscount Rate6 %-14%7%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment [Table Text Block]
The aggregate carrying amount of our strategic investments was comprised of the following:
As of December 31,
(in millions)20222021
Equity method investments$188 $259 
Measurement alternative investments(1)
216 142 
Publicly-held securities(2)
2 10 
Notes receivable1 — 
$407 $412 
(1)    Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying consolidated statements of operations.
(2)    Publicly-held equity securities are measured at fair value with changes in fair value recognized in Other, net within our consolidated statements of operations.
Baylis Medical  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
The final purchase price allocation was comprised of the following components:
(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the purchase price to the specific intangible asset categories as follows:
Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
2021 Acquisitions  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block] in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations.
(in millions)PreventiceLumenisAll OtherTotal
Payment for acquisition, net of cash acquired$706 $1,032 $519 $2,258 
Fair value of contingent consideration221 — 218 440 
Fair value of prior interest269 — 287 556 
$1,197 $1,032 $1,025 $3,254 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
The final purchase price allocation for these acquisitions was comprised of the following components:
(in millions)PreventiceLumenisAll OtherTotal
Goodwill$926 $534 $594 $2,053 
Amortizable intangible assets237 423 465 1,125 
Indefinite-lived intangible assets— 69 43 112 
Other assets acquired65 297 9 372 
Liabilities assumed(32)(282)(11)(325)
Net deferred tax liabilities— (9)(75)(84)
$1,197 $1,032 $1,025 $3,254 
XML 90 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill [Table Text Block]
The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
 As of December 31, 2022As of December 31, 2021
(in millions)Gross Carrying AmountAccumulated
Amortization/
Write-offs		Gross Carrying AmountAccumulated
Amortization/
Write-offs
Technology-related$12,397 $(7,378)$11,957 $(6,754)
Patents486 (394)494 (398)
Other intangible assets1,960 (1,400)1,900 (1,325)
Amortizable intangible assets$14,843 $(9,173)$14,351 $(8,476)
Goodwill$22,820 $(9,900)$21,888 $(9,900)
IPR&D112 126 
Technology-related120 120 
Indefinite-lived intangible assets$232 $246 
Schedule of Goodwill [Table Text Block]
The following represents our goodwill balance by reportable segment.
(in millions)MedSurgCardiovascularTotal
Balance as of December 31, 2020$3,707 $6,243 $9,951 
Goodwill acquired544 1,520 2,064 
Foreign currency fluctuations and other changes(5)(21)(27)
Balance as of December 31, 2021$4,246 $7,741 $11,988 
Goodwill acquired— 1,030 1,030 
Foreign currency fluctuations and other changes(10)(88)(98)
Balance as of December 31, 2022$4,237 $8,684 $12,920 
Schedule of Expected Amortization Expense [Table Text Block]
Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2022 is as follows (in millions):
Fiscal Year
2023$781 
2024741 
2025683 
2026665 
2027625 
XML 91 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Hedging Activities and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2022
Derivative [Line Items]  
Schedule of Notional Amounts of Outstanding Derivative Positions (Table Text Block) The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of December 31,
20222021
Forward currency contractsCash flow hedge$2,725 $3,996 
Forward currency contractsNet investment hedge365 493 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated4,235 3,892 
Total Notional Outstanding$8,321 $9,378 
Derivative Instruments, Gain (Loss) [Table Text Block]
The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to Note O – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Year Ended December 31, 2022
Forward currency contracts
Cash flow hedges$276 $(62)$214 Cost of products sold$3,956 $(209)$47 $(162)
Net investment hedges(2)
41 (10)32 Interest expense470 (10)2 (8)
Foreign currency-denominated debt
Net investment hedges(3)
61 (14)47 Other, net38 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense470 16 (4)13 
Year Ended December 31, 2021
Forward currency contracts
Cash flow hedges$268 $(60)$208 Cost of products sold$3,711 $(54)$12 $(42)
Net investment hedges(2)
56 (13)43 Interest expense341 (13)3 (10)
Foreign currency-denominated debt
Net investment hedges(3)
82 (19)64 Other, net(218)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense341 5 (1)4 
Year Ended December 31, 2020
Forward currency contracts
Cash flow hedges$(99)$22 $(77)Cost of products sold$3,465 $(83)$19 $(64)
Net investment hedges(2)
(37)8 (29)Interest expense361 (24)5 (19)
Foreign currency-denominated debt
Net investment hedges(3)
(89)21 (68)Other, net(362)— — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense361 5 (1)4 
(1)    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2)    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3)    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]
As of December 31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging InstrumentFASB ASC Topic 815 DesignationLocation on Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contractsCash flow hedgeCost of products sold$223 
Forward currency contractsNet investment hedgeInterest expense10 
Interest rate derivative contractsCash flow hedgeInterest expense(3)
Derivatives Not Designated as Hedging Instruments (Table Text Block)
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)Location on Consolidated Statements of OperationsYear Ended December 31,
202220212020
Net gain (loss) on currency hedge contractsOther, net$(53)$(16)$73 
Net gain (loss) on currency transaction exposuresOther, net21 (12)(105)
Net currency exchange gain (loss)$(31)$(27)$(32)
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Table Text Block) The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
Location on Consolidated Balance Sheets(1)
As of December 31,
20222021
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$196 $183 
Forward currency contractsOther long-term assets149 169 
  345 352 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets36 42 
Total Derivative and Nonderivative Assets $381 $394 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$— $32 
Forward currency contractsOther long-term liabilities1 6 
Foreign currency-denominated debt(2)
Other long-term liabilities952 1,011 
  953 1,049 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities52 22 
Total Derivative and Nonderivative Liabilities$1,005 $1,071 
(1)We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2)Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 December 31, 2022December 31, 2021
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$673 $— $— $673 $1,632 $— $— $1,632 
Publicly-held securities2 — — 2 10 — — 10 
Hedging instruments— 381 — 381 — 394 — 394 
Licensing arrangements— — 127 127 — — 246 246 
 $674 $381 $127 $1,182 $1,642 $394 $246 $2,282 
Liabilities        
Hedging instruments$— $1,005 $— $1,005 $— $1,071 $— $1,071 
Contingent consideration liability— — 149 149 — — 486 486 
Licensing arrangements— — 159 159 — — 281 281 
 $— $1,005 $308 $1,313 $— $1,071 $767 $1,838 
The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2022 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of December 31, 2022Valuation TechniqueUnobservable InputRange
Weighted Average(1)
Financial Asset$127 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2023-20252024
Financial Liability$159 millionDiscounted Cash FlowDiscount Rate12%-15%13%
Projected Year of Payment2023-20262024
(1)    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2020$365 
Proceeds from royalty rights(163)
Fair value adjustment (expense) benefit44 
Balance as of December 31, 2021$246 
Proceeds from royalty rights(141)
Fair value adjustment (expense) benefit22 
Balance as of December 31, 2022$127 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2020$407 
Payments for royalty rights(166)
Fair value adjustment expense (benefit)41 
Balance as of December 31, 2021$281 
Payments for royalty rights(145)
Fair value adjustment expense (benefit)23 
Balance as of December 31, 2022$159 
XML 92 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Contractual Obligations and Commitments (Tables)
 12 Months Ended
Dec. 31, 2022
Short-term Debt [Line Items]  
Schedule of Long-term Debt Instruments [Table Text Block]
Issuance DateMaturity DateAs of December 31,
Coupon Rate(1)
(in millions, except interest rates)20222021
October 2023 Senior Notes(4)
August 2013October 2023$— $244 4.125%
March 2024 Notes(4)
February 2019March 2024504 850 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,067 — 0.750%
May 2025 Senior Notes(4)
May 2015May 2025— 523 3.850%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior Notes(4)
February 2019March 2026255 850 3.750%
December 2027 Senior Notes(3)
November 2019December 2027960 1,021 0.625%
March 2028 Senior Notes(3)
March 2022March 2028800 — 1.375%
March 2028 Senior Notes(4)
February 2018March 2028344 434 4.000%
March 2029 Senior Notes(4)
February 2019March 2029272 850 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031800 — 1.625%
March 2034 Senior Notes(3)
March 2022March 2034534 — 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.750%
March 2039 Senior Notes(4)
February 2019March 2039450 750 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior Notes(4)
February 2019March 2049650 1,000 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2023 - 2049(76)(76)
Unamortized Gain on Fair Value Hedges2022— 3 
Finance Lease ObligationVarious5 6 
Long-term debt $8,915 $8,804 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)    Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.
(2)    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.
(3) These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2022 and 2021, respectively.
(4)    Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within Current Debt Obligations within our consolidated balance sheets as of December 31, 2021.
Transfer of Financial Assets Accounted for as Sales [Table Text Block] Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
As of December 31, 2022As of December 31, 2021
Factoring ArrangementsAmount
De-recognized		Weighted Average Interest RateAmount
De-recognized		Weighted Average Interest Rate
Euro denominated$161 2.4 %$141 2.1 %
Yen denominated194 0.6 %223 0.6 %
Renminbi denominated13 3.1 %11 3.2 %
Long-term Purchase Commitment
Fiscal YearUnrecorded Purchase Obligations
2023$755 
2024119 
202571 
202635 
202719 
Thereafter21 
 $1,021 
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]
As of December 31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility.
 Covenant Requirement
as of December 31, 2022		 Actual
as of December 31, 2022
Maximum permitted leverage ratio(1)
3.75 times 2.57 times
(1) Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.
Contractual Obligation, Fiscal Year Maturity
Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:

Fiscal Year
2023$— 
2024504 
20251,567 
2026255 
2027960 
Thereafter5,700 
Commercial Paper [Member]  
Short-term Debt [Line Items]  
Schedule of Short-term Debt [Table Text Block]
Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2022 and 2021.
XML 93 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Supplemental Balance Sheet Information Related to Leases The following table presents supplemental balance sheet information related to our operating leases:
As of December 31,
(in millions)20222021
Assets
Operating lease right-of-use assets in Other long-term assets
$386 $435 
Liabilities
Operating lease liabilities in Other current liabilities
61 71 
Operating lease liabilities in Other long-term liabilities
347 389 
Lease, Cost The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
As of December 31,
20222021
Weighted average remaining lease term10 years10 years
Weighted average discount rate3.3%2.6%
Supplemental Cash Flow Information Related to Leases
The following table presents supplemental cash flow information related to our operating leases:
Year Ended December 31,
(in millions)20222021
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows from operating leases$91 $87 
Maturities of Lease Liabilities The following table presents the maturities of our operating lease liabilities as of December 31, 2022 (in millions):
Fiscal yearOperating Leases
2023$80 
202466 
202555 
202643 
202734 
Thereafter214 
Total future minimum operating lease payments492 
Less: imputed interest(84)
Present value of operating lease liabilities$408 
XML 94 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Supplemental Balance Sheet Information (Tables)
 12 Months Ended
Dec. 31, 2022
Supplemental Balance Sheet Information [Abstract]  
Trade accounts receivable, net [Table Text Block]
Trade accounts receivable, net
 As of December 31,
(in millions)20222021
Trade accounts receivable$2,079 $1,886 
Allowance for credit losses(109)(108)
 $1,970 $1,778 

The following is a rollforward of our Allowance for credit losses:
Year Ended December 31,
(in millions)202220212020
Beginning balance$108 $105 $74 
Cumulative effect adjustment for adoption of ASU 2016-13n/an/a10 
Credit loss expense35 28 49 
Write-offs(35)(25)(27)
Ending balance$109 $108 $105 
Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset’s contractual life.
Schedule of Inventory, Current Inventories
 As of December 31,
(in millions)20222021
Finished goods$1,171 $1,029 
Work-in-process147 128 
Raw materials548 452 
 $1,867 $1,610 
Schedule of Other Current Assets [Table Text Block] Other current assets
 As of December 31,
(in millions)20222021
Restricted cash and restricted cash equivalents$149 $188 
Derivative assets232 226 
Licensing arrangements60 132 
Other290 254 
 $731 $799 
Property, plant and equipment, net [Table Text Block] Property, plant and equipment, net
 As of December 31,
(in millions)20222021
Land$137 $109 
Buildings and improvements1,695 1,523 
Equipment, furniture and fixtures3,297 3,287 
Capital in progress598 605 
 5,728 5,525 
Less: accumulated depreciation3,282 3,273 
 $2,446 $2,252 
Schedule of Other Assets [Table Text Block] Other long-term assets
 As of December 31,
(in millions)20222021
Restricted cash equivalents$48 $55 
Operating lease right-of-use assets386 435 
Derivative assets149 169 
Investments407 412 
Licensing arrangements67 114 
Indemnification asset172 — 
Other271 225 
 $1,500 $1,410 
Schedule of Accrued Liabilities [Table Text Block] Accrued expenses
 As of December 31,
(in millions)20222021
Legal reserves$231 $264 
Payroll and related liabilities830 848 
Rebates352 350 
Contingent consideration74 289 
Other674 686 
 $2,160 $2,436 
Other Current Liabilities [Table Text Block] Other current liabilities
 As of December 31,
(in millions)20222021
Deferred revenue$220 $208 
Licensing arrangements79 138 
Taxes payable232 209 
Other230 228 
 $761 $783 
Other long-term liabilities [Table Text Block] Other long-term liabilities
 As of December 31,
(in millions)20222021
Accrued income taxes$597 $442 
Legal reserves212 284 
Contingent consideration75 197 
Licensing arrangements80 143 
Operating lease liabilities347 389 
Deferred revenue289 276 
Other434 489 
 $2,035 $2,220 
XML 95 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Our Income (loss) before income taxes consisted of the following:
Year Ended December 31,
(in millions)202220212020
Domestic$(1,119)$(648)$(660)
Foreign2,260 1,724 581 
$1,141 $1,076 $(79)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] The related expense (benefit) for income taxes consisted of the following:
Year Ended December 31,
(in millions)202220212020
Current
  Federal$51 $18 $(29)
  State19 33 (35)
  Foreign381 127 151 
451 178 87 
Deferred
  Federal(92)(256)(26)
  State(32)(3)(6)
  Foreign117 117 (53)
(7)(142)(85)
$443 $36 $2 
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Significant components of our deferred tax assets and liabilities are as follows:
 As of December 31,
 (in millions)
20222021
 Deferred Tax Assets:
 
Inventory costs and related reserves$19 $10 
Tax benefit of net operating losses and credits511 620 
Reserves and accruals304 324 
Restructuring-related charges6 14 
Litigation and product liability reserves103 127 
Investment write-down38 31 
Compensation related136 130 
Federal benefit of uncertain tax positions9 8 
Intangible assets3,668 3,546 
Capitalized R&D160 67 
Property, plant and equipment2 14 
Other— 35 
 4,954 4,926 
Less: valuation allowance(1,004)(1,014)
 3,950 3,912 
 Deferred Tax Liabilities:
  
Unrealized gains and losses on derivative financial instruments117 79 
Other34 — 
151 79 
 Net Deferred Tax Assets
3,799 3,833 
Prepaid on intercompany profit264 205 
 Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,062 $4,038 

Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):
Location on Consolidated Balance SheetsAs of December 31,
Component20222021
Prepaid on intercompany profitPrepaid income taxes$264 $205 
Non-current deferred tax assetDeferred tax assets3,942 4,142 
Deferred Tax Assets and Prepaid on Intercompany Profit 4,206 4,348 
Non-current deferred tax liabilityDeferred tax liabilities144 310 
Deferred Tax Liabilities 144 310 
Net Deferred Tax Assets and Prepaid on Intercompany Profit$4,062 $4,038 
Summary of Income Tax Contingencies [Table Text Block] A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 Year Ended December 31,
(in millions)202220212020
Beginning Balance$255 $261 $455 
Additions based on positions related to the current year88 8 28 
Additions based on positions related to prior years177 41 6 
Reductions for tax positions of prior years(20)(36)(186)
Settlements with taxing authorities(1)(2)(27)
Statute of limitation expirations(8)(17)(15)
Ending Balance$492 $255 $261 
Tax rate
The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:
Year Ended December 31,
202220212020
U.S. federal statutory income tax rate21.0 %21.0 %(21.0)%
State income taxes, net of federal benefit0.7 %2.5 %16.6 %
Domestic taxes on foreign earnings15.3 %6.8 %155.4 %
Effect of foreign taxes(3.8)%(14.3)%(40.7)%
Acquisition-related4.4 %(8.1)%(16.7)%
Research credit(4.5)%(3.0)%(43.0)%
Valuation allowance(1.3)%0.8 %(42.0)%
Goodwill impairment charges— %— %3.7 %
Compensation-related0.6 %(0.6)%(7.7)%
Non-deductible expenses0.4 %0.4 %64.4 %
Uncertain tax positions7.7 %1.2 %(96.8)%
Intra-entity asset transfers— %— %10.2 %
Return to provision(2.1)%(5.7)%(37.3)%
Change in tax rates(0.2)%1.9 %51.8 %
Other, net0.7 %0.4 %6.0 %
38.9 %3.3 %2.9 %
XML 96 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Incentive and Purchase Plans (Tables)
 12 Months Ended
Dec. 31, 2022
Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]  
Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]
The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2022:
2022 AFCF2021 AFCF2020 AFCF
Fair value, net of forfeitures to date (in millions)
$7 $12 $6 
Achievement of target payout88 %131 %89 %
Year-end stock price used in determining fair value$46.27 $42.48 $35.95 
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following presents the impact of stock-based compensation on our consolidated statements of operations:
 Year Ended December 31,
(in millions, except per share data)202220212020
Cost of products sold$12 $11 $9 
Selling, general and administrative expenses167 147 130 
Research and development expenses41 36 30 
 220 194 170 
Income tax (benefit) expense(32)(29)(28)
 $188 $165 $142 
Net impact per common share - basic$0.13 $0.12 $0.10 
Net impact per common share - assuming dilution$0.13 $0.12 $0.10 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 Year Ended December 31,
 202220212020
Options granted (in thousands)
3,287 3,822 3,819 
Weighted-average exercise price$44.02 $37.69 $41.79 
Weighted-average grant-date fair value$13.64 $10.77 $10.44 
Black-Scholes Assumptions   
Expected volatility28 %29 %23 %
Expected term (in years, weighted)
6.15.95.8
Risk-free interest rate1.42%-3.87%0.66%-1.20%0.27%-1.72%
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Information related to non-vested stock awards is as follows:
Non-Vested
Stock Award Units
(in thousands)
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 201911,079 $29 
Granted3,609 41 
Vested(1)
(4,147)25 
Forfeited(554)34 
Balance as of December 31, 20209,987 $34 
Granted4,240 $39 
Vested(1)
(3,823)$31 
Forfeited(658)36 
Balance as of December 31, 20219,745 $37 
Granted3,854 $45 
Vested(1)
(3,482)$36 
Forfeited(680)44 
Balance as of December 31, 20229,438 $41 
(1)The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]
Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
Year Ended December 31,
202220212020
Shares issued or to be issued (in thousands)
2,850 2,578 1,387 
Range of purchase prices$31.68 -$32.31 $29.98 -$36.11 $29.84 
Expense recognized (in millions)
$28 $24 $10 
Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]
We expect to recognize the following future expense for awards outstanding as of December 31, 2022:
 Unrecognized
 Compensation Cost
(in millions) (1)
Weighted Average Remaining
Vesting Period
(in years)
Stock options$38  
Non-vested stock awards181  
 $219 1.7
(1)Amounts presented represent compensation cost, net of estimated forfeitures.
Market-based awards, valuation assumptions [Table Text Block]
We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 202220212020
AwardsAwardsAwards
Stock price on date of grant$44.19 $37.50 $42.16 
Measurement period (in years)
2.92.92.9
Risk-free rate1.71 %0.20 %1.37 %
Share-based Compensation, Stock Options, Activity [Table Text Block]
Information related to stock options under stock incentive plans are as follows:
Stock Options
(in thousands)
Weighted
Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 201923,065 $19 
Granted3,819 42 
Exercised(3,096)13 
Cancelled/forfeited(666)27 
Outstanding as of December 31, 202023,122 $24 
Granted3,822 38 
Exercised(4,796)13 
Cancelled/forfeited(699)26 
Outstanding as of December 31, 202121,448 $29 
Granted3,287 44 
Exercised(2,745)17 
Cancelled/forfeited(502)34 
Outstanding as of December 31, 202221,489 $32 5.9297 
Exercisable as of December 31, 202213,674 27 4.6258 
Expected to vest as of December 31, 20227,535 41 8.238 
Total vested and expected to vest as of December 31, 202221,209 $32 5.9$296 
XML 97 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Weighted Average Shares Outstanding (Tables)
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares [Table Text Block]
Year Ended December 31,
(in millions)202220212020
Weighted average shares outstanding - basic1,430.5 1,422.3 1,416.7 
Net effect of common stock equivalents9.2 11.5 — 
Weighted average shares outstanding - assuming dilution1,439.7 1,433.8 1,416.7 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:
Year Ended December 31,
(in millions)202220212020
Common stock equivalents(1)
n/an/a14
Stock options outstanding(2)
636
MCPS(3)
242414
(1)    Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our Net loss position in this period.
(2)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(3)    Represents common stock issuable upon the conversion of MCPS. Refer to Note J – Stockholders' Equity for additional information.
XML 98 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.
 Year Ended December 31,
Net sales202220212020
MedSurg$5,057 $4,616 $3,844 
Cardiovascular8,161 7,212 5,913 
Total net sales of reportable segments 13,218 11,828 9,756 
Other(1)
(60)13 219 
Impact of foreign currency fluctuations(476)47 (65)
$12,682 $11,888 $9,913 
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
Year Ended December 31,
Income (loss) before income taxes202220212020
MedSurg$1,625 $1,524 $1,156 
Cardiovascular2,113 1,888 1,043 
Total operating income of reportable segments 3,737 3,412 2,198 
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(436)(406)(424)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs
(789)(1,070)(1,208)
Amortization expense(803)(741)(789)
Other(1)
(60)4 143 
Operating income (loss) 1,649 1,199 (80)
Other income (expense), net(508)(123)1 
Income (loss) before income taxes$1,141 $1,076 $(79)
(1) In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.
Segment operating income as percentage of net sales [Table Text Block]
Operating income of reportable segments as a percentage of net sales of reportable segmentsYear Ended December 31,
202220212020
MedSurg32.1 %33.0 %30.1 %
Cardiovascular25.9 %26.2 %17.6 %

Year Ended December 31,
Depreciation expense202220212020
MedSurg$88 $91 $90 
Cardiovascular245 261 240 
Total depreciation expense of reportable segments333 352 330 
Other(1)
— — 3 
Consolidated depreciation expense$333 $352 $333 
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
As of December 31,
Total assets20222021
MedSurg$2,501 $2,178 
Cardiovascular5,205 4,417 
Total assets of reportable segments7,706 6,595 
Goodwill12,920 11,988 
Other intangible assets, net5,902 6,121 
All other corporate assets5,941 7,525 
 $32,469 $32,229 
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]
As of December 31,
Long-lived assets20222021
U.S.$1,241 $1,190 
Ireland478 436 
Costa Rica246 185 
Other countries481 440 
Property, plant and equipment, net2,446 2,252 
Goodwill12,920 11,988 
Other intangible assets, net5,902 6,121 
Operating lease right-of-use assets in Other long-term assets
386 435 
 $21,653 $20,795 
XML 99 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue (Tables)
 12 Months Ended
Dec. 31, 2022
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue [Table Text Block] The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:
Year Ended December 31,
202220212020
BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$1,341 $880 $2,221 $1,222 $919 $2,141 1,000 $780 $1,780 
Urology1,257 516 1,773 1,120 463 1,583 918 368 1,286 
Neuromodulation715 202 917 713 196 909 610 151 761 
MedSurg3,312 1,599 4,911 3,055 1,578 4,633 2,528 1,299 3,827 
Interventional Cardiology Therapies744 1,485 2,228 778 1,431 2,209 728 1,247 1,975 
Watchman915 103 1,019 729 100 829 253 71 324 
Cardiac Rhythm Management1,337 763 2,100 1,214 805 2,019 992 712 1,704 
Electrophysiology275 310 585 128 237 365 118 169 287 
Cardiology3,271 2,662 5,932 2,850 2,572 5,422 2,091 2,199 4,290 
Peripheral Interventions1,048 850 1,899 996 824 1,820 888 689 1,577 
Cardiovascular4,319 3,512 7,831 3,846 3,396 7,242 2,979 2,888 5,866 
Other1
— — (60)10 4 13 193 27 219 
Total Net Sales$7,632 $5,111 $12,682 $6,911 $4,978 $11,888 $5,701 $4,212 $9,913 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

Year Ended December 31,
Geographic Regions202220212020
U.S.$7,632 $6,901 $5,508 
Europe, Middle East and Africa2,526 2,518 2,097 
Asia-Pacific2,116 2,070 1,781 
Latin America and Canada469 386 307 
Other1
(60)13 219 
Total Net Sales$12,682 $11,888 $9,913 
Emerging Markets(2)
$1,715 $1,429 $1,138 
(2)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.
XML 100 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Changes in Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2022
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
The following table provides the reclassifications out of Other comprehensive income, net of tax:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(86)214 36 163 
(Income) loss amounts reclassified from accumulated other comprehensive income(8)(150)1 (157)
Total other comprehensive income (loss)(94)63 37 6 
Balance as of December 31, 2022$(1)$269 $1 $269 
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2020$218 $36 $(47)$207 
Other comprehensive income (loss) before reclassifications12 208 8 228 
(Income) loss amounts reclassified from accumulated other comprehensive income(137)(38)3 (173)
Total other comprehensive income (loss)(125)170 11 56 
Balance as of December 31, 2021$93 $206 $(36)$263 
XML 101 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Retirement Plans (Tables)
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
Pension and Other Postretirement Plans, Policy [Policy Text Block] We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] The outstanding obligation is as follows:
 As of December 31, 2022
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded
PBO Recognized
Domestic Retirement Plans$50 $55 $— $55 
Other International Retirement Plans140 152 101 51 
 $190 $207 $101 $105 

 As of December 31, 2021
(in millions)
Accumulated Benefit Obligation (ABO)Projected
Benefit
Obligation (PBO)		Fair value of Plan AssetsUnfunded/Underfunded PBO Recognized
Domestic Retirement Plans$56 $59 $— $59 
U.K. Plan209 209 205 3 
Other International Retirement Plans214 234 130 103 
 $478 $502 $336 $166 
Schedule of Changes in Projected Benefit Obligations [Table Text Block]
A rollforward of the changes in the PBO for our retirement plans is as follows:
 Year Ended December 31,
(in millions)20222021
Beginning obligations$502 $532 
Acquired plans— 4 
Service costs13 17 
Interest costs3 3 
Actuarial (gain) loss(54)(7)
Plan curtailments/settlements(191)— 
Plan amendments and assumption changes(25)(6)
Benefits paid(6)(22)
Impact of foreign currency fluctuations(37)(20)
Ending obligation$207 $502 
Schedule of Defined Benefit Plans Disclosures [Table Text Block]
The critical assumptions associated with our employee retirement plans for 2022 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans5.32%n/a2.00%
Other International Retirement Plans2.62%2.27%3.00%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.
The critical assumptions associated with our employee retirement plans for 2021 are as follows:
Weighted Average Discount RateWeighted Average Expected Return
Weighted Average Rate of Compensation Increase(1)
Domestic Retirement Plans2.40%n/a1.50%
U.K. Plan0.70%0.70%n/a
Other International Retirement Plans0.82%2.16%2.60%
(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.
Schedule of Changes in Fair Value of Plan Assets [Table Text Block] A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 Year Ended December 31,
(in millions)20222021
Beginning fair value$336 $355 
Acquired plans— 1 
Actual return on plan assets(2)5 
Employer contributions16 12 
Participant contributions1 2 
Plan curtailments/settlements(185)— 
Actuarial gain (loss)(25)(4)
Benefits paid(9)(22)
Impact of foreign currency fluctuations(32)(13)
Ending fair value$101 $336 
Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.

The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:
As of
December 31, 2021
(in millions)Level 1Level 2Level 3Total
Buy-in contracts$— $— $205 $205 
Total assets$— $— $205 $205 
Changes in the fair value of the U.K. Plan Level 3 assets were as follows:
(in millions)Buy-in Contracts
Balance as of December 31, 2021$205 
Actual return on plan assets0 
Employer contributions1 
Plan curtailments/settlements(160)
Actuarial gain (loss)(24)
Benefits paid(2)
Impact of foreign currency fluctuations(22)
Balance as of December 31, 2022$— 
Schedule of Expected Benefit Payments Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:
(in millions)Post Retirement Benefits
2023$15 
20248 
202513 
202614 
202714 
2028 - 203270 
XML 102 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Significant Accounting Policies Significant Accounting Policies (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Significant Accounting Policies [Line Items]      
Selling, general and administrative expenses $ 4,520 $ 4,359 $ 3,787
Production Related Impairments or Charges     $ 149
Payment of contingent consideration 371 $ 15  
Farapulse      
Significant Accounting Policies [Line Items]      
Payment of contingent consideration $ 114    
XML 103 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions and Strategic Investments (Details)
 2 Months Ended 12 Months Ended
Nov. 29, 2022
USD ($)
Jun. 15, 2022
USD ($)
Jun. 15, 2022
KRW (₩)
Nov. 08, 2021
USD ($)
Sep. 01, 2021
USD ($)
Aug. 06, 2021
USD ($)
Mar. 01, 2021
USD ($)
Feb. 23, 2023
USD ($)
Feb. 23, 2023
KRW (₩)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Feb. 20, 2023
Business Acquisition [Line Items]                          
Proceeds from disposal of certain businesses and assets                   $ 5,000,000 $ 826,000,000 $ 15,000,000  
Business Combination, Contingent Consideration, Liability                   149,000,000 486,000,000 196,000,000  
Goodwill                   12,920,000,000 11,988,000,000 9,951,000,000  
Payments to Acquire Businesses, Net of Cash Acquired                   1,542,000,000 2,258,000,000 3,000,000  
Fair value of contingent consideration                   (149,000,000) (486,000,000) (196,000,000)  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases                   0 440,000,000 0  
Intangible asset impairment charges                   132,000,000 370,000,000 460,000,000  
Contingent consideration net expense (benefit)                   35,000,000 (136,000,000) (100,000,000)  
Payment of contingent consideration                   371,000,000 15,000,000    
Goodwill impairment charges                   0 $ 0 $ 73,000,000  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Specialty Pharmaceuticals [Member]                          
Business Acquisition [Line Items]                          
Disposal Group, Including Discontinued Operation, Consideration             $ 800,000,000            
Divestiture, agreement, transfer of facilities             5            
Divestiture, agreement, transfer of global employees             280            
Preventice Solutions, Inc. [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Contingent Consideration, Liability                   221,000,000      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                   269,000,000      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net                   1,197,000,000      
Goodwill                   926,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   237,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                   0      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                   65,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                   (32,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                   0      
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination             $ 925,000,000            
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage             22.00%            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill                   237,000,000      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High             $ 216,000,000            
Payments to Acquire Businesses, Net of Cash Acquired             706,000,000     706,000,000      
Fair value of contingent consideration                   (221,000,000)      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain             196,000,000            
Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest             $ 300,000,000            
Preventice Solutions, Inc. [Member] | Technology-Based Intangible Assets [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 215,000,000      
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                   9 years      
Preventice Solutions, Inc. [Member] | Technology-Based Intangible Assets [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   10.00%      
Preventice Solutions, Inc. [Member] | Other Intangible Assets [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 22,000,000      
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                   8 years      
Preventice Solutions, Inc. [Member] | Other Intangible Assets [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   10.00%      
Farapulse, Inc.                          
Business Acquisition [Line Items]                          
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination           $ 450,000,000              
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage           27.00%              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High           $ 92,000,000              
Payments to Acquire Businesses, Net of Cash Acquired           268,000,000              
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain           222,000,000              
Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest           $ 125,000,000              
Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]           3 years              
Lumenis LTD                          
Business Acquisition [Line Items]                          
Business Combination, Contingent Consideration, Liability                   $ 0      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                   0      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net                   1,032,000,000      
Goodwill                   534,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   423,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                   69,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                   297,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                   (282,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                   (9,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill                   492,000,000      
Payments to Acquire Businesses, Net of Cash Acquired         $ 1,032,000,000.000         1,032,000,000      
Fair value of contingent consideration                   0      
Accrued Income Taxes, Noncurrent                   183,000,000      
Business Combination, Indemnification Assets, Amount as of Acquisition Date                   177,000,000      
Lumenis LTD | In Process Research and Development [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 69,000,000      
Lumenis LTD | In Process Research and Development [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   12.00%      
Lumenis LTD | Technology-Based Intangible Assets [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 388,000,000      
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                   12 years      
Lumenis LTD | Technology-Based Intangible Assets [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   11.00%      
Lumenis LTD | Other Intangible Assets [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 35,000,000      
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                   11 years      
Lumenis LTD | Other Intangible Assets [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   11.00%      
Devoro Medical, Inc.                          
Business Acquisition [Line Items]                          
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination       $ 320,000,000                  
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage       16.00%                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 67,000,000                  
Payments to Acquire Businesses, Net of Cash Acquired       251,000,000                  
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain       57,000,000                  
Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest       $ 80,000,000                  
All Other 2021 Acquisitions                          
Business Acquisition [Line Items]                          
Business Combination, Contingent Consideration, Liability                   $ 218,000,000      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                   287,000,000      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net                   1,025,000,000      
Goodwill                   594,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   465,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                   43,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                   9,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                   (11,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                   (75,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill                   508,000,000      
Payments to Acquire Businesses, Net of Cash Acquired                   519,000,000      
Fair value of contingent consideration                   (218,000,000)      
All Other 2021 Acquisitions | In Process Research and Development [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 43,000,000      
All Other 2021 Acquisitions | In Process Research and Development [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   17.00%      
All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 465,000,000      
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                   12 years      
All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member] | Minimum [Member]                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   16.00%      
All Other 2021 Acquisitions | Technology-Based Intangible Assets [Member] | Maximum [Member]                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   17.00%      
2021 Acquisitions                          
Business Acquisition [Line Items]                          
Business Combination, Contingent Consideration, Liability                   $ 440,000,000      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                   556,000,000      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net                   3,254,000,000      
Goodwill                   2,053,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   1,125,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                   112,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                   372,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                   (325,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                   (84,000,000)      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High                   417,000,000      
Payments to Acquire Businesses, Net of Cash Acquired                   2,258,000,000      
Fair value of contingent consideration                   (440,000,000)      
Baylis Medical                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net                   1,463,000,000      
Goodwill                   988,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   657,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                   112,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                   (287,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                   (7,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill                   657,000,000      
Payments to Acquire Businesses, Net of Cash Acquired                   1,463,000,000      
Baylis Medical | Technology-Based Intangible Assets [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 622,000,000      
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                   11 years      
Baylis Medical | Technology-Based Intangible Assets [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   11.00%      
Baylis Medical | Other Intangible Assets [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                   $ 36,000,000      
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                   11 years      
Baylis Medical | Other Intangible Assets [Member] | Weighted Average (Member)                          
Business Acquisition [Line Items]                          
Discount Rate, Fair Value Input                   11.00%      
M.I. Tech Co., Ltd                          
Business Acquisition [Line Items]                          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 615,000,000 $ 230,000,000 ₩ 291,200,000,000                    
Business Acquisition, Percentage of Voting Interests Acquired   64.00% 64.00%                    
M.I. Tech Co., Ltd | Subsequent Event [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value | ₩                 ₩ 20.00        
Acotec Scientific Holdings Limited | Subsequent Event [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value               $ 520,000,000          
Business Acquisition, Percentage of Voting Interests Acquired                         65.00%
Apollo Endosurgery, Inc.                          
Business Acquisition [Line Items]                          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 10.00                        
Business Acquisition, Percentage of Voting Interests Acquired 100.00%                        
Farapulse                          
Business Acquisition [Line Items]                          
Payment of contingent consideration                   $ 114,000,000      
XML 104 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Contingent Consideration (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Aug. 06, 2021
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases $ 0 $ 440 $ 0  
Payment of contingent consideration 371 15    
Contingent consideration net expense (benefit) 35 (136) (100)  
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
Business Combination, Contingent Consideration, Liability 149 $ 486 $ 196  
2021 Acquisitions        
Business Combination, Contingent Consideration Arrangements [Abstract]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 417      
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
Business Combination, Contingent Consideration, Liability 440      
Farapulse, Inc.        
Business Combination, Contingent Consideration Arrangements [Abstract]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 92
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest       $ 125
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
Business Combination, Contingent Consideration, Liability $ 13      
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
contingent consideration liability, probability of payment 100.00%      
Business Combination, Contingent Consideration, Liability $ 136      
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
contingent consideration liability, probability of payment 10.00%      
Discount Rate, Fair Value Input 1.00%      
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
Discount Rate, Fair Value Input 6.00%      
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
contingent consideration liability, probability of payment 25.00%      
Discount Rate, Fair Value Input 2.00%      
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
Discount Rate, Fair Value Input 14.00%      
Weighted Average (Member) | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
contingent consideration liability, probability of payment 22.00%      
Discount Rate, Fair Value Input 2.00%      
Weighted Average (Member) | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]        
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]        
contingent consideration liability, probability of payment 100.00%      
Discount Rate, Fair Value Input 7.00%      
XML 105 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Strategic Investments (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Schedule of Investments [Line Items]    
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity $ 232  
Equity Method Investments 188 $ 259
Measurement alternative investments (1) 216 142
Equity Securities, FV-NI 2 10
Notes receivable 1 0
Investments 407 $ 412
Unrealized Gain (Loss) on Investments $ 178  
XML 106 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross $ 14,843 $ 14,351  
Finite-Lived Intangible Assets, Accumulated Amortization (9,173) (8,476)  
Goodwill, Gross 22,820 21,888  
Goodwill, Impaired, Accumulated Impairment Loss (9,900) (9,900)  
Indefinite-lived Intangible Assets (Excluding Goodwill) 232 246  
Intangible asset impairment charges 132 370 $ 460
Goodwill (Roll Forward)      
Goodwill 12,920 11,988 9,951
Goodwill, Translation and Purchase Accounting Adjustments (98) (27)  
Goodwill, Acquired During Period 1,030 2,064  
Goodwill, Impairment Loss 0 0 (73)
Other Intangible Assets (Textuals) [Abstract]      
Future Amortization Expense, Year One 781    
Future Amortization Expense, Year Two 741    
Future Amortization Expense, Year Three 683    
Future Amortization Expense, Year Four 665    
Future Amortization Expense, Year Five 625    
MedSurg [Member]      
Goodwill (Roll Forward)      
Goodwill 4,237 4,246 3,707
Goodwill, Translation and Purchase Accounting Adjustments (10) (5)  
Goodwill, Acquired During Period 0 544  
Cardiovascular [Member]      
Goodwill (Roll Forward)      
Goodwill 8,684 7,741 $ 6,243
Goodwill, Translation and Purchase Accounting Adjustments (88) (21)  
Goodwill, Acquired During Period 1,030 1,520  
In Process Research and Development [Member]      
Goodwill and Other Intangible Assets      
Indefinite-lived Intangible Assets (Excluding Goodwill) 112 126  
Technology-Based Intangible Assets [Member]      
Goodwill and Other Intangible Assets      
Indefinite-lived Intangible Assets (Excluding Goodwill) 120 120  
Technology-Based Intangible Assets [Member]      
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross 12,397 11,957  
Finite-Lived Intangible Assets, Accumulated Amortization (7,378) (6,754)  
Patents [Member]      
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross 486 494  
Finite-Lived Intangible Assets, Accumulated Amortization (394) (398)  
Other Intangible Assets [Member]      
Goodwill and Other Intangible Assets      
Finite-Lived Intangible Assets, Gross 1,960 1,900  
Finite-Lived Intangible Assets, Accumulated Amortization $ (1,400) $ (1,325)  
XML 107 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements (Details)
€ in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
units
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net $ 8 $ 24    
Derivative, Notional Amount 8,321 9,378    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax (214) (208)    
Cost of Goods and Services Sold 3,956 3,711 $ 3,465  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 150 38    
Interest Expense 470 341 361  
Other Operating Income (Expense), Net 38 (218) (362)  
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax 8 137    
Derivative Asset, Fair Value, Gross Asset 381 394    
Derivative Liability, Fair Value, Gross Liability 1,005 1,071    
Net currency exchange gain (loss) (194) 0 0  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Equity Securities, FV-NI 2 10    
Derivative Asset 149 169    
Licensing arrangements, asset 67 114    
Business Combination, Contingent Consideration, Liability 149 486 196  
Cash 256 293    
Debt Instrument, Fair Value Disclosure 8,203 10,196    
Other Noncurrent Liabilities [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Licensing arrangements, liability 80 143    
November 2019 Aggregate Offering [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Long-term Debt | €       € 900
December 2027 Notes [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Long-term Debt $ 960 1,021    
Debt Instrument, Interest Rate, Stated Percentage 0.625%      
Licensing arrangement assets (Member)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Discount Rate, Fair Value Input 15.00%      
M.I. Tech Co., Ltd        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount $ 228      
Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Licensing arrangements, asset 127      
Licensing arrangements, liability 159      
Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 673 1,632    
Equity Securities, FV-NI 2 10    
Derivative Asset 381 394    
Licensing arrangements, asset 127 246    
Assets, Fair Value Disclosure 1,182 2,282    
Foreign Currency Contracts, Liability, Fair Value Disclosure 1,005 1,071    
Business Combination, Contingent Consideration, Liability 149 486    
Licensing arrangements, liability 159 281    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,313 1,838    
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 673 1,632    
Equity Securities, FV-NI 2 10    
Derivative Asset 0 0    
Licensing arrangements, asset 0 0    
Assets, Fair Value Disclosure 674 1,642    
Foreign Currency Contracts, Liability, Fair Value Disclosure 0 0    
Business Combination, Contingent Consideration, Liability 0 0    
Licensing arrangements, liability 0 0    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0 0    
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 0 0    
Equity Securities, FV-NI 0 0    
Derivative Asset 381 394    
Licensing arrangements, asset 0 0    
Assets, Fair Value Disclosure 381 394    
Foreign Currency Contracts, Liability, Fair Value Disclosure 1,005 1,071    
Business Combination, Contingent Consideration, Liability 0 0    
Licensing arrangements, liability 0 0    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,005 1,071    
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Money Market Funds, at Carrying Value 0 0    
Equity Securities, FV-NI 0 0    
Derivative Asset 0 0    
Licensing arrangements, asset 127 246    
Assets, Fair Value Disclosure 127 246    
Foreign Currency Contracts, Liability, Fair Value Disclosure 0 0    
Business Combination, Contingent Consideration, Liability 149 486    
Licensing arrangements, liability 159 281    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 308 767    
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Licensing arrangement assets (Member)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Licensing arrangements, asset 127 246 365  
Proceeds from Royalties Received (141) (163)    
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 22 44    
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Licensing arrangement liabilities (Member)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Licensing arrangements, liability 159 281 407  
Payments for Royalties (145) (166)    
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 23 41    
Designated as Hedging Instrument [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value 345 352    
Derivative Instruments in Hedges, Liabilities, at Fair Value 953 1,049    
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value $ 952 1,011    
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)        
Derivative Instruments, Gain (Loss) [Line Items]        
Forward Currency Contracts, Time to Maturity | units 48      
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Noncurrent Assets [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value $ 149 169    
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Current Liabilities [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value 0 32    
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Noncurrent Liabilities [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Liabilities, at Fair Value 1 6    
Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Prepaid Expenses and Other Current Assets [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments in Hedges, Assets, at Fair Value 196 183    
Not Designated as Hedging Instrument [Member] | Other Nonoperating Income (Expense) [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments (53) (16) 73  
Foreign Currency Transaction Gain (Loss), before Tax 21 (12) (105)  
Net gain (loss) from foreign currency transaction exposures (21) 12 105  
Net currency exchange gain (loss) (31) (27) (32)  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 4,235 3,892    
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Other Current Liabilities [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value 52 22    
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Prepaid Expenses and Other Current Assets [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value $ 36 42    
Weighted Average (Member) | Licensing arrangement assets (Member)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Discount Rate, Fair Value Input 15.00%      
Weighted Average (Member) | Licensing arrangement liabilities (Member)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Discount Rate, Fair Value Input 13.00%      
Minimum [Member] | Licensing arrangement liabilities (Member)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Discount Rate, Fair Value Input 12.00%      
Maximum [Member] | Licensing arrangement liabilities (Member)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Discount Rate, Fair Value Input 15.00%      
Cash Flow Hedging [Member] | Foreign Exchange Contract (Member) | Cost of Sales [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 223      
Cash Flow Hedging [Member] | Interest Rate Contract [Member] | Interest Expense [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net (3)      
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 2,725 3,996    
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Cost of Sales [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 276 268 (99)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax (62) (60) 22  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 214 208 (77)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (209) (54) (83)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 47 12 19  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (162) (42) (64)  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Interest Expense [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 0 0 0  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 0 0 0  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 0 0 0  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 16 5 5  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax (4) (1) (1)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 13 4 4  
Net Investment Hedging [Member] | Foreign Exchange Contract (Member) | Interest Expense [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net 10      
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member)        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 365 493    
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract (Member) | Interest Expense [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 41 56 (37)  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (10) (13) 8  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 32 43 (29)  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax (10) (13) (24)  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax 2 3 5  
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax (8) (10) (19)  
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, Notional Amount 997 997    
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign currency denominated in debt [Member] | Interest Expense [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 61 82 (89)  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (14) (19) 21  
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 47 64 (68)  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax 0 0 0  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax 0 0 0  
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax $ 0 $ 0 $ 0  
XML 108 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Contractual Obligations and Commitments (Details)
€ in Millions, $ in Millions
 3 Months Ended 12 Months Ended
May 27, 2020
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
Dec. 31, 2022
Rate
Mar. 31, 2022
USD ($)
May 10, 2021
USD ($)
Dec. 31, 2020
EUR (€)
Debt Instrument [Line Items]                      
Total debt   $ 8,935 $ 8,935 $ 9,065              
Debt, Current   20 20 261              
Long-term Debt and Capital Lease Obligations   8,915 8,915 8,804              
Deemed Consolidated EBITDA [Member]     1,000                
Exclusion from EBITDA for Restructuring Charges   500 500                
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA   265 265                
Litigation and Debt Exclusion from EBITDA   1,455 1,455                
Letters of Credit Outstanding, Amount   135 135 134              
Legal payments remaining to be excluded from calculation of consolidated EBITDA   866 866                
Purchase Obligations, Future Minimum Payments Due, Current   755 755                
Purchase Obligations, Future Minimum Payments, Due in Two Years   119 119                
Purchase Obligations, Future Minimum Payments, Due in Three Years   71 71                
Purchase Obligations, Future Minimum Payments, Due in Four Years   35 35                
Purchase Obligations, Future Minimum Payments, Due in Five Years   19 19                
Purchase Obligations, Future Minimum Payments, Due Thereafter   21 21                
Purchase Obligations, Future Minimum Payments Due   1,021 1,021                
Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months   0 0                
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two   504 504                
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three   1,567 1,567                
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four   255 255                
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five   960 960                
Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five   5,700 5,700                
Proceeds from long-term borrowings, net of debt issuance costs     3,270 0 $ 1,683            
Gain (Loss) on Extinguishment of Debt   194                  
May 2022 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage                 (3.375%)    
Short-term Debt                 $ 250    
Actual, Covenant [Member]                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             2.57        
Requirement, as of March 31, 2021                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             3.75        
Requirement, as of December 31, 2021 and through remaining term of facility                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             3.75        
Requirement, four quarters following material acquisition                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             4.75        
Requirement, fifth quarter following qualified acquisition [Member]                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             4.50        
Requirement, sixth quarter and thereafter following qualified acquisition [Member]                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             4.25        
Requirement, seventh quarter following qualified acquisition                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             4.00        
Requirement, eighth quarter and thereafter following qualified acquisition                      
Debt Instrument [Line Items]                      
Maximum Leverage Ratio             3.75        
the 2018 Facility [Domain] | Revolving Credit Facility [Member]                      
Debt Instrument [Line Items]                      
Line of Credit Facility, Maximum Borrowing Capacity                   $ 2,750  
November 2019 Aggregate Offering [Member]                      
Debt Instrument [Line Items]                      
Long-term Debt | €                     € 900
May 2022 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (4.125%)        
Long-term Debt   0 0 244              
October 2023 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (3.45%)        
Long-term Debt   504 504 850              
March 2024 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (0.75%)        
Long-term Debt   1,067 1,067 0              
May 2025 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (3.85%)        
Long-term Debt   0 0 523              
June 2025 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (1.90%)        
Long-term Debt   500 500 500              
March 2026 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (3.75%)        
Long-term Debt   255 255 850              
December 2027 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (0.625%)        
Long-term Debt   960 960 1,021              
March 2028 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (4.00%)        
Long-term Debt   344 344 434              
March 2029 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (4.00%)        
Long-term Debt   272 272 850              
June 2030 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (2.65%)        
Long-term Debt   1,200 1,200 1,200              
November 2035 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (6.75%)        
Long-term Debt   350 350 350              
March 2039 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (4.55%)        
Long-term Debt   450 450 750              
January 2040 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (7.375%)        
Long-term Debt   300 300 300              
March 2049 Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (4.70%)        
Long-term Debt   650 650 1,000              
Unamortized Gain on Fair Value Hedges                      
Debt Instrument [Line Items]                      
Long-term Debt   0 0 3              
Finance Lease Obligation                      
Debt Instrument [Line Items]                      
Long-term Debt   5 5 6              
Senior Notes [Member]                      
Debt Instrument [Line Items]                      
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net   76 76 76              
Long-term Debt   8,986 8,986 9,121              
March 2028 Senior Notes                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (1.375%) (1.375%)      
Long-term Debt   800 800 0   € 750          
March 2031 Notes                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (1.625%) (1.625%)      
Long-term Debt   800 800 0   750          
March 2034 Notes                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage             (1.875%) (1.875%)      
Long-term Debt   534 534 0   500          
the Offering - aggregate principal amount                      
Debt Instrument [Line Items]                      
Long-term Debt | €           3,000          
March 2025 Notes                      
Debt Instrument [Line Items]                      
Debt Instrument, Interest Rate, Stated Percentage | Rate               (0.75%)      
Long-term Debt | €           € 1,000          
the Offering - early redemption of combined aggregate principal SN                      
Debt Instrument [Line Items]                      
Long-term Debt   3,275 3,275                
Euro Denominated Factoring Arrangements [Member]                      
Debt Instrument [Line Items]                      
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   161 $ 161 $ 141              
Average interest rate of de-recognized receivables     2.40% 2.10%              
Yen Denominated Factoring Arrangements [Member]                      
Debt Instrument [Line Items]                      
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   194 $ 194 $ 223              
Average interest rate of de-recognized receivables     0.60% 0.60%              
Renminbi Denominated Factoring Arrangements [Member]                      
Debt Instrument [Line Items]                      
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 13 $ 13 $ 11              
Average interest rate of de-recognized receivables     3.10% 3.20%              
5.50% MCPS, Series A [Member]                      
Debt Instrument [Line Items]                      
Preferred Stock, Dividend Rate, Percentage 5.50%                    
XML 109 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Leases (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating Leased Assets [Line Items]      
Operating Lease, Liability, Current $ 61 $ 71  
Operating Lease, Liability, Noncurrent $ 347 $ 389  
Operating Lease, Weighted Average Remaining Lease Term 10 years 10 years  
Operating Lease, Weighted Average Discount Rate, Percent 3.30% 2.60%  
Operating Lease, Cost $ 91 $ 90 $ 92
Operating Lease, Payments 91 87  
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 43 68  
Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months 80    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two 66    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three 55    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four 43    
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five 34    
Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five 214    
Lessee, Operating Lease, Liability, to be Paid 492    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (84)    
Operating Lease, Liability 408    
Operating Lease, Right-of-Use Asset $ 386 $ 435  
Operating Lease, Liability, Current Other current liabilities Other current liabilities  
Minimum [Member]      
Operating Leased Assets [Line Items]      
Lessee, Operating Lease, Term of Contract 1 year    
Maximum [Member]      
Operating Leased Assets [Line Items]      
Lessee, Operating Lease, Term of Contract 54 years    
Lessee, Operating and Finance Leases, Option to Extend 10 years    
XML 110 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Other Current Assets [Abstract]      
Restricted cash and restricted cash equivalents included in Other current assets $ 149 $ 188 $ 208
Derivative Asset, Current 232 226  
Licensing arrangements 60 132  
Other Assets, Miscellaneous, Current 290 254  
Other Assets, Current 731 799  
Trade accounts receivable, net      
Trade accounts receivable 2,079 1,886  
Allowance for credit losses (109) (108)  
Trade accounts receivable, net 1,970 1,778  
Allowance for doubtful accounts      
Accounts Receivable, Allowance for Credit Loss (beginning balance) 108 105 74
Cumulative effect adjustment for adoption of ASC 2016-13     10
Net (credits) charges to expenses 35 28 49
Utilization of allowances (35) (25) (27)
Accounts Receivable, Allowance for Credit Loss (ending balance) 109 108 105
Inventory, Net [Abstract]      
Inventory, Finished Goods, Net of Reserves 1,171 1,029  
Inventory, Work in Process, Net of Reserves 147 128  
Inventory, Raw Materials, Net of Reserves 548 452  
Inventories 1,867 1,610  
Property, plant and equipment, net      
Land 137 109  
Buildings and improvements 1,695 1,523  
Equipment, furniture and fixtures 3,297 3,287  
Capital in progress 598 605  
Property, plant and equipment 5,728 5,525  
Less: accumulated depreciation 3,282 3,273  
Property, plant and equipment, net $ 2,446 $ 2,252  
Supplemental Balance Sheet Information (Textuals)      
Percent of finished goods at consignment 27.00% 30.00%  
Depreciation $ 333 $ 352 333
Other Assets, Noncurrent [Abstract]      
Restricted Cash Equivalents included in Other long-term assets 48 55 52
Operating Lease, Right-of-Use Asset 386 435  
Derivative Asset 149 169  
Investments 407 412  
Licensing arrangements, asset 67 114  
Other, Other Long-term Assets 271 225  
Other long-term assets (total) 1,500 1,410  
Accrued expenses      
Legal reserves 231 264  
Payroll and related liabilities 830 848  
Accrued Rebates, Current 352 350  
Contingent consideration 74 289  
Other 674 686  
Accrued liabilities, current 2,160 2,436  
Other Liabilities, Current [Abstract]      
Deferred Revenue, Current 220 208  
Accrued Royalties, Current 79 138  
Taxes Payable, Current 232 209  
Other Sundry Liabilities, Current 230 228  
Other current liabilities 761 783  
Other long-term liabilities      
Operating Lease, Liability, Noncurrent $ 347 $ 389  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities Other long-term liabilities  
Other long-term liabilities $ 2,035 $ 2,220  
Operating Lease, Liability, Noncurrent $ 347 $ 389  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities Other long-term liabilities  
Cumulative effect adjustment for adoption of ASC 2016-13     $ 10
Indemnification asset $ 172 $ 0  
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]      
Operating Lease, Right-of-Use Asset $ 386 $ 435  
Other Noncurrent Liabilities [Member]      
Other long-term liabilities      
Accrued Income Taxes, Noncurrent 597 442  
Estimated Litigation Liability, Noncurrent 212 284  
Business Combination, Contingent Consideration, Liability, Noncurrent 75 197  
Licensing arrangements, liability 80 143  
Deferred Revenue 289 276  
Other Accrued Liabilities, Noncurrent 434 489  
Accrued Income Taxes, Noncurrent 597 442  
Estimated Litigation Liability, Noncurrent 212 284  
Business Combination, Contingent Consideration, Liability, Noncurrent 75 197  
Licensing arrangements, liability 80 143  
Deferred Revenue 289 276  
Other Accrued Liabilities, Noncurrent $ 434 $ 489  
XML 111 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Details - Rate Table)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Schedule of Income Tax Rate Reconciliation [Line Items]      
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate 21.00% 21.00% 21.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes 0.70% 2.50% 16.60%
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent 15.30% 6.80% 155.40%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential (3.80%) (14.30%) (40.70%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense 4.40% 8.10% 16.70%
Effective Income Tax Rate Reconciliation, Tax Credits, Research (4.50%) (3.00%) (43.00%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance (1.30%) 0.80% (42.00%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses 0.00% 0.00% 3.70%
effective income tax reconciliation, compensation-related 0.60% (0.60%) (7.70%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 0.40% 0.40% 64.40%
Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions 7.70% 1.20% (96.80%)
Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers 0.00% 0.00% 10.20%
Effective Income Tax Rate Reconciliation, Return to provision (2.10%) (5.70%) (37.30%)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent (0.20%) 1.90% 51.80%
Effective Income Tax Rate Reconciliation, Other Adjustments 0.70% 0.40% 6.00%
Reported tax rate 38.90% 3.30% 2.90%
XML 112 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes Income Taxes (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Loss Carryforwards [Line Items]          
Income (Loss) from Continuing Operations before Income Taxes, Domestic   $ (1,119) $ (648) $ (660)  
Income (Loss) from Continuing Operations before Income Taxes, Foreign   2,260 1,724 581  
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest   1,141 1,076 (79)  
Current Federal Tax Expense (Benefit)   51 18 (29)  
Current State and Local Tax Expense (Benefit)   19 33 (35)  
Current Foreign Tax Expense (Benefit)   381 127 151  
Current Income Tax Expense (Benefit)   451 178 87  
Deferred Federal Income Tax Expense (Benefit)   (92) (256) (26)  
Deferred State and Local Income Tax Expense (Benefit)   (32) (3) (6)  
Deferred Foreign Income Tax Expense (Benefit)   117 117 (53)  
Deferred Income Tax Expense (Benefit)   (7) (142) (85)  
Income Tax Expense (Benefit)   443 36 2  
Deferred Tax Assets, Inventory   19 10    
Deferred Tax Assets, Operating Loss Carryforwards   511 620    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals   304 324    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges   6 14    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies   103 127    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses   38 31    
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost   136 130    
Federal benefit of uncertain tax positions   9 8    
Deferred Tax Assets, Goodwill and Intangible Assets   3,668 3,546    
Deferred Tax Assets, in Process Research and Development   160 67    
Deferred Tax Assets, Property, Plant and Equipment   2 14    
Deferred Tax Assets, Other   0 35    
Deferred Tax Assets, Tax Deferred Expense   4,954 4,926    
Deferred Tax Assets, Valuation Allowance   (1,004) (1,014)    
Deferred Tax Assets, Net of Valuation Allowance   3,950 3,912    
Deferred Tax Liabilities, Derivatives   117 79    
Deferred Tax Liabilities, Other   34 0    
Deferred Tax Liabilities, Gross   151 79    
Deferred Tax Assets, Gross   3,799 3,833    
Deferred Tax Assets, Prepaid on Intercompany Profit   264 205    
Net Deferred Tax Liabilities and Prepaid on Intercompany Profit   4,062 4,038    
Deferred Tax Assets   4,206 4,348    
Deferred Tax Liabilities, Net   144 310    
Deferred Tax Assets, Operating Loss Carryforwards, Domestic   464 560    
Deferred Tax Assets, Operating Loss Carryforwards, Foreign   47 60    
Other Comprehensive Income (Loss), Tax   56 81 (78)  
Free Trade Zone Regime Tax Incentive   162 149 64  
Tax Incentives in Puerto Rico   21 27 30  
Unrecognized Tax Benefits that Would Impact Effective Tax Rate   410 177 183  
Unrecognized Tax Benefits   492 255 261 $ 455
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions   88 8 28  
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions   177 41 6  
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions   (20) (36) (186)  
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities   (1) (2) (27)  
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations   (8) (17) $ (15)  
Tax Adjustments, Settlements, and Unusual Provisions $ 91   62    
Income Tax Examination, Penalties and Interest Accrued   77 43    
Decrease in Unrecognized Tax Benefits is Reasonably Possible   75      
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability   937 $ 938    
One-time transaction tax post-1986 E&P - net payment   $ 586      
Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution   $ 0.11 $ 0.10 $ 0.04  
Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution   $ 0.02      
transition tax payment remaining   $ 386      
Tax incentives in Malaysia   $ 17 $ 0 $ 0  
Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution   $ 0.01      
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense   $ 14      
Prepaid Expenses and Other Current Assets [Member]          
Operating Loss Carryforwards [Line Items]          
Deferred Tax Assets   264 205    
Deferred tax assets [Domain]          
Operating Loss Carryforwards [Line Items]          
Deferred Tax Assets   3,942 4,142    
Deferred tax liabilities [Domain]          
Operating Loss Carryforwards [Line Items]          
Deferred Tax Liabilities, Net   $ 144 $ 310    
XML 113 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Details)
$ in Millions
 12 Months Ended
Jan. 31, 2023
USD ($)
Aug. 05, 2022
USD ($)
Dec. 31, 2022
USD ($)
Unit
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Loss Contingencies [Line Items]          
Accrual for legal matters that are probable and estimable     $ 443 $ 548  
Restricted cash and restricted cash equivalents included in Other current assets     149 188 $ 208
Litigation Settlement, Expense     $ 173 $ 430 $ 278
Litigation Settlement, Amount Awarded to Other Party   $ 85      
Brazil CADE - # of individuals for alleged anti-competitive behavior | Unit     29    
Subsequent Event [Member]          
Loss Contingencies [Line Items]          
Litigation Settlement, Amount Awarded to Other Party $ 42        
XML 114 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Jan. 30, 2023
May 27, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 14, 2020
Class of Stock [Line Items]            
Preferred Stock, Shares Authorized     50,000,000 50,000,000    
Preferred Stock, Shares Issued     10,062,500 10,062,500    
Net proceeds from issuance of preferred stock in connection with public offering     $ 0 $ 0 $ 975  
Payments of Dividends     $ 55 $ 55 28  
Common Stock, Shares Authorized     2,000,000,000 2,000,000,000    
Common Stock, Par or Stated Value Per Share     $ 0.01 $ 0.01    
Net proceeds from issuance of common stock in connection with public offering     $ 0 $ 0 $ 975  
Stock Repurchase Program, Authorized Amount           $ 1,000
Stock Repurchase Program, Number of Shares Authorized to be Repurchased         15,700,000  
Payments for repurchase of common stock     0 $ 0 $ 535  
Dividends, Cash     $ 14      
Treasury Stock, Shares     263,289,848 263,289,848    
5.50% MCPS, Series A [Member]            
Class of Stock [Line Items]            
Preferred Stock, Shares Issued   10,062,500        
Preferred Stock, Dividend Rate, Percentage   5.50%        
Preferred Stock, Liquidation Preference Per Share   $ 100 $ 100      
Net proceeds from issuance of preferred stock in connection with public offering   $ 975        
Preferred Stock, Liquidation Preference, Value     $ 1,006      
Preferred Stock, Dividends, Per Share, Cash Paid     $ 1.3750      
5.50% MCPS, Series A [Member] | Minimum [Member]            
Class of Stock [Line Items]            
Convertible Preferred Stock, Terms of Conversion     2.3834      
5.50% MCPS, Series A [Member] | Maximum [Member]            
Class of Stock [Line Items]            
Convertible Preferred Stock, Terms of Conversion     2.9197      
5.50% MCPS, Series A [Member] | Subsequent Event [Member]            
Class of Stock [Line Items]            
Preferred Stock, Dividends, Per Share, Cash Paid $ 1.3750          
Common Stock [Member]            
Class of Stock [Line Items]            
Stock Issued During Period, Shares, New Issues   29,382,500        
Shares Issued, Price Per Share   $ 34.25        
Net proceeds from issuance of common stock in connection with public offering   $ 975        
XML 115 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Incentive and Purchase Plans (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Feb. 17, 2021
Oct. 01, 2020
Feb. 18, 2020
Dec. 31, 2019
Feb. 21, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Fair value of market based awards $ 12 $ 11 $ 8          
Share Price $ 46.27 $ 42.48 $ 35.95 $ 44.19   $ 37.50   $ 42.16
Unrecognized Compensation Cost - Stock Options $ 38              
Stock Issued During Period, Shares, Employee Stock Purchase Plans 2,850,000 2,578,000 1,387,000          
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased $ 31.68 $ 29.98            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 9,438,000 9,745,000 9,987,000       11,079,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 41 $ 37 $ 34       $ 29  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3,854,000 4,240,000 3,609,000          
Measurement period - market based awards 2 years 10 months 24 days 2 years 10 months 24 days 2 years 10 months 24 days          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1.71% 0.20% 1.37%          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 45 $ 39 $ 41          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (3,482,000) (3,823,000) (4,147,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value $ 36 $ 31 $ 25          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (680,000) (658,000) (554,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value $ 44 $ 36 $ 34          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 21,489,000 21,448,000 23,122,000       23,065,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3,287,000 3,822,000 3,819,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 44.02 $ 37.69 $ 41.79          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (2,745,000) (4,796,000) (3,096,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 17 $ 13 $ 13          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period (502,000) (699,000) (666,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price $ 34 $ 26 $ 27          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $ 297              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 5 years 10 months 24 days              
Stock-based compensation expense $ 220 $ 194 $ 170          
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000            
Common Stock, Capital Shares Reserved for Future Issuance 175,000,000              
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense $ (32) $ (29) (28)          
Share-based compensation, net of tax benefit $ 188 $ 165 $ 142          
compensation expense, per share - basic $ 0.13 $ 0.12 $ 0.10          
compensation expense, per share - diluted 0.13 0.12 0.10          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 13.64 $ 10.77 $ 10.44          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 28.00% 29.00% 23.00%          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 6 years 1 month 6 days 5 years 10 months 24 days 5 years 9 months 18 days          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value $ 72 $ 137 $ 84          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 32 $ 29 $ 24       $ 19  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 13,674,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 27              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 4 years 7 months 6 days              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $ 258              
Options expected to vest 7,535,000              
Options expected to vest, weighted average exercise price $ 41              
Options expected to vest, weighted average remaining contractual life 8 years 2 months 12 days              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 38              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 21,209,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 32              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 5 years 10 months 24 days              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 296              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value $ 150 $ 148 $ 172          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 60,000,000              
Amount of employees total compensation eligible for GESOP purchase 10.00%              
Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) 85.00%              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 11,000,000              
Unrecognized Compensation Cost - Non-vested stock awards $ 181              
Unrecognized Compensation Cost $ 219              
weighted average remaining vesting period 1 year 8 months 12 days              
annualweightedaverageforfeiturerate 5.00%              
Voting power of all classes of stock 10.00%              
Exercise price of the fair market value of our common stock on the date of grant 110.00%              
Qualified options exercise price $ 0              
Fair value of the Free Cash Flow (FCF) performance awards $ 7 $ 12 $ 6          
Target payout of Free Cash Flows (FCF) performance awards 88.00% 131.00% 89.00%          
Employee Stock Ownership Plan (ESOP), Compensation Expense $ 28 $ 24 $ 10          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 10,000,000              
Minimum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Range of the target number of performance-based DSUs awarded 0.00%              
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased     $ 29.84          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1.42% 0.66% 0.27%          
Range of the target number of market-based DSUs awarded 0.00%              
High end of range [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Range of the target number of performance-based DSUs awarded 150.00%              
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased $ 32.31 $ 36.11            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3.87% 1.20% 1.72%          
Range of the target number of market-based DSUs awarded 200.00%              
2011 LTIP Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common Stock, Shares Authorized         171,000,000      
Cost of Sales [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense $ 12 $ 11 $ 9          
Selling, General and Administrative Expenses [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense 167 147 130          
Research and Development Expense [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense $ 41 $ 36 $ 30          
XML 116 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Weighted Average Shares Outstanding (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Weighted Average Number of Shares Outstanding, Basic 1,430,500 1,422,300 1,416,700
Weighted Average Number Diluted Shares Outstanding Adjustment 9,200 11,500 0
Weighted Average Number of Shares Outstanding, Diluted 1,439,700 1,433,800 1,416,700
Share-based Payment Arrangement, Option [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,000 3,000 6,000
5.50% MCPS, Series A [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 24,000 24,000 14,000
Share-based Payment Arrangement [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount     14,000
XML 117 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
reportablesegments
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Segment Reporting Information [Line Items]      
Number of reportable segments | reportablesegments 2    
Net sales $ 12,682 $ 11,888 $ 9,913
Depreciation 333 352 333
Operating income allocated to reportable segments 1,649 1,199 (80)
Amortization expense (803) (741) (789)
Other expense, net (508) (123) 1
Income (loss) before income taxes 1,141 1,076 (79)
Goodwill 12,920 11,988 9,951
Intangible Assets, Net (Excluding Goodwill) 5,902 6,121  
Operating Lease, Right-of-Use Asset 386 435  
Long-Lived Assets 21,653 20,795  
Property, Plant and Equipment, Net 2,446 2,252  
Impact of foreign currency fluctuations on net sales (476) 47 (65)
Other      
Segment Reporting Information [Line Items]      
Net sales (60) 13 219
Revenues from contracts with customers, disaggregated - performance measurement (60) 13 219
United States [Member]      
Segment Reporting Information [Line Items]      
Net sales 7,632 6,911 5,701
Long-Lived Assets 1,241 1,190  
United States [Member] | Other      
Segment Reporting Information [Line Items]      
Net sales 0 10 193
IRELAND      
Segment Reporting Information [Line Items]      
Long-Lived Assets 478 436  
Other countries [Member]      
Segment Reporting Information [Line Items]      
Long-Lived Assets 481 440  
COSTA RICA      
Segment Reporting Information [Line Items]      
Long-Lived Assets 246 185  
MedSurg [Member]      
Segment Reporting Information [Line Items]      
Net sales 4,911 4,633 3,827
Depreciation 88 91 90
Operating Income (Loss) Allocated to Reportable Segments $ 1,625 $ 1,524 $ 1,156
Segment operating income as percentage of net sales 32.10% 33.00% 30.10%
Assets (segment reporting) $ 2,501 $ 2,178  
Goodwill 4,237 4,246 $ 3,707
Revenues from contracts with customers, disaggregated - performance measurement 5,057 4,616 3,844
MedSurg [Member] | United States [Member]      
Segment Reporting Information [Line Items]      
Net sales 3,312 3,055 2,528
Cardiovascular [Member]      
Segment Reporting Information [Line Items]      
Net sales 7,831 7,242 5,866
Depreciation 245 261 240
Operating Income (Loss) Allocated to Reportable Segments $ 2,113 $ 1,888 $ 1,043
Segment operating income as percentage of net sales 25.90% 26.20% 17.60%
Assets (segment reporting) $ 5,205 $ 4,417  
Goodwill 8,684 7,741 $ 6,243
Revenues from contracts with customers, disaggregated - performance measurement 8,161 7,212 5,913
Cardiovascular [Member] | United States [Member]      
Segment Reporting Information [Line Items]      
Net sales 4,319 3,846 2,979
BSX Reportable Segments      
Segment Reporting Information [Line Items]      
Depreciation 333 352 330
Revenues from contracts with customers, disaggregated - performance measurement 13,218 11,828 9,756
Total allocated to reportable segments [Member]      
Segment Reporting Information [Line Items]      
Operating income allocated to reportable segments 3,737 3,412 2,198
Assets (segment reporting) 7,706 6,595  
Corporate Expenses including hedging activities [Member]      
Segment Reporting Information [Line Items]      
Operating Income Unallocated to Segment (436) (406) (424)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs      
Segment Reporting Information [Line Items]      
Operating Income Unallocated to Segment (789) (1,070) (1,208)
Corporate Segment      
Segment Reporting Information [Line Items]      
Assets (segment reporting) 5,941 7,525  
Consolidated BSX [Domain]      
Segment Reporting Information [Line Items]      
Assets (segment reporting) 32,469 32,229  
Other      
Segment Reporting Information [Line Items]      
Depreciation 0 0 3
Operating income allocated to reportable segments $ (60) $ 4 $ 143
XML 118 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
countries
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Disaggregation of Revenue [Line Items]      
Emerging Markets total number of countries | countries 20    
Net sales $ 12,682 $ 11,888 $ 9,913
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price     179
Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability 509 484  
Change in Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price     179
Contract with Customer, Liability, Revenue Recognized 156    
UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 7,632 6,911 5,701
Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 5,111 4,978 4,212
EMEA [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 2,526 2,518 2,097
APAC [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 2,116 2,070 1,781
Latin America and Canada [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 469 386 307
Emerging Markets [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 1,715 1,429 1,138
country_US excluding Other Net Sales      
Disaggregation of Revenue [Line Items]      
Net sales 7,632 6,901 5,508
Global Endoscopy (Endo) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 2,221 2,141 1,780
Global Endoscopy (Endo) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 1,341 1,222 1,000
Global Endoscopy (Endo) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 880 919 780
Global Urology and Pelvic Health Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 1,773 1,583 1,286
Global Urology and Pelvic Health Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 1,257 1,120 918
Global Urology and Pelvic Health Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 516 463 368
Global Neuromodulation (NM) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 917 909 761
Global Neuromodulation (NM) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 715 713 610
Global Neuromodulation (NM) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 202 196 151
Global Peripheral Interventions (PI) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 1,899 1,820 1,577
Global Peripheral Interventions (PI) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 1,048 996 888
Global Peripheral Interventions (PI) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 850 824 689
Interventional Cardiology Therapies      
Disaggregation of Revenue [Line Items]      
Net sales 2,228 2,209 1,975
Interventional Cardiology Therapies | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 744 778 728
Interventional Cardiology Therapies | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 1,485 1,431 1,247
Cardiac Rhythm Management      
Disaggregation of Revenue [Line Items]      
Net sales 2,100 2,019 1,704
Cardiac Rhythm Management | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 1,337 1,214 992
Cardiac Rhythm Management | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 763 805 712
Electrophysiology (EP)      
Disaggregation of Revenue [Line Items]      
Net sales 585 365 287
Electrophysiology (EP) | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 275 128 118
Electrophysiology (EP) | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 310 237 169
Watchman      
Disaggregation of Revenue [Line Items]      
Net sales 1,019 829 324
Watchman | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 915 729 253
Watchman | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 103 100 71
Global Cardiology Reporting Unit      
Disaggregation of Revenue [Line Items]      
Net sales 5,932 5,422 4,290
Global Cardiology Reporting Unit | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 3,271 2,850 2,091
Global Cardiology Reporting Unit | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 2,662 2,572 2,199
Other      
Disaggregation of Revenue [Line Items]      
Net sales (60) 13 219
Other | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 0 10 193
Other | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 0 4 27
MedSurg [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 4,911 4,633 3,827
MedSurg [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 3,312 3,055 2,528
MedSurg [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 1,599 1,578 1,299
Cardiovascular [Member]      
Disaggregation of Revenue [Line Items]      
Net sales 7,831 7,242 5,866
Cardiovascular [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Net sales 4,319 3,846 2,979
Cardiovascular [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Net sales $ 3,512 $ 3,396 $ 2,888
XML 119 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Changes in Other Comprehensive Income (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]      
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ (1) $ 93 $ 218
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax 269 206 36
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax 1 (36) (47)
Accumulated Other Comprehensive Income (Loss), Net of Tax 269 263 207
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax (86) 12  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 214 208  
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax 36 8  
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 163 228  
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax (8) (137)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (150) (38)  
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax 1 3  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (157) (173)  
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (94) (125) 76
Net change in derivative financial instruments 63 170 (137)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax (37) (11) 1
Other Comprehensive Income (Loss), Net of Tax $ 6 $ 56 $ (63)
XML 120 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Retirement Plans (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation $ 190 $ 478  
Defined Benefit Plan, Benefit Obligation 207 502 $ 532
Defined Benefit Plan, Plan Assets, Amount 101 336 355
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 105 166  
Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets 0 1  
Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets 0 4  
Defined Benefit Plan, Service Cost 13 17  
Defined Benefit Plan, Interest Cost 3 3  
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment (25) (6)  
pension benefit obligation, benefits paid (6) (22)  
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) (37) (20)  
Defined Benefit Plan, Plan Assets, Payment for Settlement (185) 0  
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) (2) 5  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) (54) (7)  
Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO 191 0  
Defined Benefit Plan, Plan Assets, Contributions by Employer 16 12  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 1 2  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) (25) (4)  
Defined Benefit Plan, Benefit Obligation, Benefits Paid (9) (22)  
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) (32) (13)  
Expense related to matching contributions 123 $ 118 $ 102
Defined Benefit Plan, Expected Future Benefit Payment, Year One 15    
Defined Benefit Plan, Expected Future Benefit Payment, Year Two 8    
Defined Benefit Plan, Expected Future Benefit Payment, Year Three 13    
Defined Benefit Plan, Expected Future Benefit Payment, Year Four 14    
Defined Benefit Plan, Expected Future Benefit Payment, Year Five 14    
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $ 70    
Domestic Plan      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate 5.32% 2.40%  
Executive Retirement Plan Rate of Compensation Increase 2.00% 1.50%  
U.K. Plan      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return   0.70%  
Executive Retirement Plan Discount Rate   0.70%  
Other International Plans      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return 2.27% 2.16%  
Executive Retirement Plan Discount Rate 2.62% 0.82%  
Executive Retirement Plan Rate of Compensation Increase 3.00% 2.60%  
Fair Value, Inputs, Level 3 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) $ (22)    
Defined Benefit Plan, Plan Assets, Payment for Settlement (160)    
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) 0    
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) (24)    
Defined Benefit Plan, Plan Assets, Benefits Paid (2)    
Defined Benefit Plan, Plan Assets, Contributions by Employer 1    
Other Contract      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount   $ 205  
Other Contract | Fair Value, Inputs, Level 1 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount   0  
Other Contract | Fair Value, Inputs, Level 2 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount   0  
Other Contract | Fair Value, Inputs, Level 3 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount   205  
Executive retirement plan [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation 50 56  
Defined Benefit Plan, Benefit Obligation 55 59  
Defined Benefit Plan, Plan Assets, Amount 0 0  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 55 59  
International retirement plans [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation 140 214  
Defined Benefit Plan, Benefit Obligation 152 234  
Defined Benefit Plan, Plan Assets, Amount 101 130  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 51 103  
U.K. Plan      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation   209  
Defined Benefit Plan, Benefit Obligation   209  
Defined Benefit Plan, Plan Assets, Amount $ 0 205  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position   3  
U.K. Plan | Fair Value, Inputs, Level 1 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount   0  
U.K. Plan | Fair Value, Inputs, Level 2 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount   0  
U.K. Plan | Fair Value, Inputs, Level 3 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount   $ 205  
XML 121 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Schedule II (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]        
Accounts Receivable, Allowance for Credit Loss (beginning balance) $ 108 $ 105 $ 74  
Cumulative effect adjustment for adoption of ASC 2016-13     10  
Net (credits) charges to expenses 35 28 49  
Utilization of allowances (35) (25) (27)  
Accounts Receivable, Allowance for Credit Loss (ending balance) $ 109 $ 108 105  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount     $ 105 $ 74
XML 122 bsx-20221231_htm.xml IDEA: XBRL DOCUMENT 0000885725 2022-01-01 2022-12-31 0000885725 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000885725 bsx:SeniorNotedue2027Member 2022-01-01 2022-12-31 0000885725 bsx:A550MCPSSeriesAMember 2022-01-01 2022-12-31 0000885725 2021-06-30 0000885725 2023-01-31 0000885725 2021-01-01 2021-12-31 0000885725 2020-01-01 2020-12-31 0000885725 2022-12-31 0000885725 2021-12-31 0000885725 us-gaap:PreferredStockMember 2021-12-31 0000885725 us-gaap:PreferredStockMember 2020-12-31 0000885725 us-gaap:PreferredStockMember 2019-12-31 0000885725 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0000885725 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000885725 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000885725 us-gaap:PreferredStockMember 2022-12-31 0000885725 us-gaap:CommonStockMember 2021-12-31 0000885725 us-gaap:CommonStockMember 2020-12-31 0000885725 us-gaap:CommonStockMember 2019-12-31 0000885725 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000885725 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000885725 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000885725 2020-12-31 0000885725 us-gaap:CommonStockMember 2022-12-31 0000885725 us-gaap:TreasuryStockMember 2021-12-31 0000885725 us-gaap:TreasuryStockMember 2020-12-31 0000885725 us-gaap:TreasuryStockMember 2019-12-31 0000885725 us-gaap:TreasuryStockMember 2022-01-01 2022-12-31 0000885725 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000885725 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000885725 us-gaap:TreasuryStockMember 2022-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000885725 us-gaap:RetainedEarningsMember 2021-12-31 0000885725 us-gaap:RetainedEarningsMember 2020-12-31 0000885725 us-gaap:RetainedEarningsMember 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000885725 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000885725 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000885725 us-gaap:RetainedEarningsMember 2022-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000885725 2019-12-31 0000885725 2021-08-06 2021-08-06 0000885725 bsx:MITechCoLtdMember 2022-06-15 0000885725 bsx:MITechCoLtdMember 2022-06-15 2022-06-15 0000885725 bsx:ApolloEndosurgeryIncMember 2022-11-29 0000885725 bsx:ApolloEndosurgeryIncMember 2022-11-29 2022-11-29 0000885725 bsx:MITechCoLtdMember 2022-11-29 2022-11-29 0000885725 bsx:AcotecScientificHoldingsLimitedMember us-gaap:SubsequentEventMember 2023-02-20 0000885725 bsx:MITechCoLtdMember us-gaap:SubsequentEventMember 2023-01-01 2023-02-23 0000885725 bsx:AcotecScientificHoldingsLimitedMember us-gaap:SubsequentEventMember 2023-01-01 2023-02-23 0000885725 bsx:BaylisMedicalMember 2022-01-01 2022-12-31 0000885725 bsx:BaylisMedicalMember 2022-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000885725 bsx:BaylisMedicalMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:BaylisMedicalMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 bsx:PreventiceSolutionsIncMember 2021-03-01 2021-03-01 0000885725 bsx:PreventiceSolutionsIncMember 2021-03-01 0000885725 bsx:FarapulseIncMember 2021-08-06 2021-08-06 0000885725 bsx:FarapulseIncMember 2021-08-06 0000885725 bsx:FarapulseMember 2022-01-01 2022-12-31 0000885725 bsx:LumenisLTDMember 2021-09-01 2021-09-01 0000885725 bsx:DevoroMedicalIncMember 2021-11-08 2021-11-08 0000885725 bsx:DevoroMedicalIncMember 2021-11-08 0000885725 bsx:A2021AcquisitionsMember 2022-01-01 2022-12-31 0000885725 bsx:PreventiceSolutionsIncMember 2022-01-01 2022-12-31 0000885725 bsx:LumenisLTDMember 2022-01-01 2022-12-31 0000885725 bsx:AllOther2021AcquisitionsMember 2022-01-01 2022-12-31 0000885725 bsx:PreventiceSolutionsIncMember 2022-12-31 0000885725 bsx:LumenisLTDMember 2022-12-31 0000885725 bsx:AllOther2021AcquisitionsMember 2022-12-31 0000885725 bsx:A2021AcquisitionsMember 2022-12-31 0000885725 bsx:PreventiceSolutionsIncMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 bsx:PreventiceSolutionsIncMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:PreventiceSolutionsIncMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 bsx:PreventiceSolutionsIncMember us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000885725 bsx:PreventiceSolutionsIncMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:PreventiceSolutionsIncMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 bsx:LumenisLTDMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 bsx:LumenisLTDMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:LumenisLTDMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 bsx:LumenisLTDMember us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000885725 bsx:LumenisLTDMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:LumenisLTDMember us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 bsx:LumenisLTDMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000885725 srt:WeightedAverageMember bsx:LumenisLTDMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0000885725 bsx:AllOther2021AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 bsx:AllOther2021AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:MinimumMember bsx:AllOther2021AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 srt:MaximumMember bsx:AllOther2021AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000885725 bsx:AllOther2021AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000885725 srt:WeightedAverageMember bsx:AllOther2021AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0000885725 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember bsx:SpecialtyPharmaceuticalsMember 2021-03-01 0000885725 bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-12-31 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-12-31 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-12-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0000885725 us-gaap:PatentsMember 2022-12-31 0000885725 us-gaap:PatentsMember 2021-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0000885725 bsx:MedsurgMember 2020-12-31 0000885725 bsx:CardiovascularMember 2020-12-31 0000885725 bsx:MedsurgMember 2021-01-01 2021-12-31 0000885725 bsx:CardiovascularMember 2021-01-01 2021-12-31 0000885725 bsx:MedsurgMember 2021-12-31 0000885725 bsx:CardiovascularMember 2021-12-31 0000885725 bsx:MedsurgMember 2022-01-01 2022-12-31 0000885725 bsx:CardiovascularMember 2022-01-01 2022-12-31 0000885725 bsx:MedsurgMember 2022-12-31 0000885725 bsx:CardiovascularMember 2022-12-31 0000885725 bsx:November2019AggregateOfferingMember 2020-12-31 0000885725 bsx:December2027NotesMember 2022-12-31 0000885725 bsx:MITechCoLtdMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000885725 bsx:ForeignCurrencyDenominatedInDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2022-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2022-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000885725 bsx:LicensingArrangementAssetsMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:LicensingArrangementAssetsMember 2022-01-01 2022-12-31 0000885725 srt:MinimumMember bsx:LicensingArrangementLiabilitiesMember 2022-01-01 2022-12-31 0000885725 srt:MaximumMember bsx:LicensingArrangementLiabilitiesMember 2022-01-01 2022-12-31 0000885725 srt:WeightedAverageMember bsx:LicensingArrangementLiabilitiesMember 2022-01-01 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2020-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2021-01-01 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2022-01-01 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementAssetsMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2020-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2021-01-01 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2022-01-01 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bsx:LicensingArrangementLiabilitiesMember 2022-12-31 0000885725 bsx:May2022NotesMember 2022-12-31 0000885725 bsx:May2022NotesMember 2021-12-31 0000885725 bsx:October2023NotesMember 2022-12-31 0000885725 bsx:October2023NotesMember 2021-12-31 0000885725 bsx:March2024NotesMember 2022-12-31 0000885725 bsx:March2024NotesMember 2021-12-31 0000885725 bsx:May2025NotesMember 2022-12-31 0000885725 bsx:May2025NotesMember 2021-12-31 0000885725 bsx:June2025NotesMember 2022-12-31 0000885725 bsx:June2025NotesMember 2021-12-31 0000885725 bsx:March2026NotesMember 2022-12-31 0000885725 bsx:March2026NotesMember 2021-12-31 0000885725 bsx:December2027NotesMember 2021-12-31 0000885725 bsx:March2028SeniorNotesMember 2022-12-31 0000885725 bsx:March2028SeniorNotesMember 2021-12-31 0000885725 bsx:March2028NotesMember 2022-12-31 0000885725 bsx:March2028NotesMember 2021-12-31 0000885725 bsx:March2029NotesMember 2022-12-31 0000885725 bsx:March2029NotesMember 2021-12-31 0000885725 bsx:June2030NotesMember 2022-12-31 0000885725 bsx:June2030NotesMember 2021-12-31 0000885725 bsx:March2031NotesMember 2022-12-31 0000885725 bsx:March2031NotesMember 2021-12-31 0000885725 bsx:March2034NotesMember 2022-12-31 0000885725 bsx:March2034NotesMember 2021-12-31 0000885725 bsx:November2035NotesMember 2022-12-31 0000885725 bsx:November2035NotesMember 2021-12-31 0000885725 bsx:March2039NotesMember 2022-12-31 0000885725 bsx:March2039NotesMember 2021-12-31 0000885725 bsx:January2040NotesMember 2022-12-31 0000885725 bsx:January2040NotesMember 2021-12-31 0000885725 bsx:March2049NotesMember 2022-12-31 0000885725 bsx:March2049NotesMember 2021-12-31 0000885725 us-gaap:SeniorNotesMember 2022-12-31 0000885725 us-gaap:SeniorNotesMember 2021-12-31 0000885725 us-gaap:InterestRateSwapMember 2022-12-31 0000885725 us-gaap:InterestRateSwapMember 2021-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2022-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2021-12-31 0000885725 bsx:May2022NotesMember 2022-03-31 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:The2018FacilityDomain 2021-05-10 0000885725 bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember 2022-12-31 0000885725 bsx:ActualCovenantMember 2022-12-31 0000885725 bsx:RequirementAsOfMarch312021Member 2022-12-31 0000885725 bsx:RequirementFourQuartersFollowingMaterialAcquisitionMember 2022-12-31 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2022-12-31 0000885725 bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember 2022-12-31 0000885725 bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember 2022-12-31 0000885725 bsx:RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember 2022-12-31 0000885725 us-gaap:CommercialPaperMember 2022-01-01 2022-12-31 0000885725 bsx:TheOfferingAggregatePrincipalAmountMember 2022-12-31 0000885725 bsx:March2025NotesMember 2022-12-31 0000885725 bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember 2022-12-31 0000885725 2022-10-01 2022-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2021-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2021-01-01 2021-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2021-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2021-01-01 2021-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2021-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2021-01-01 2021-12-31 0000885725 srt:MinimumMember 2022-12-31 0000885725 srt:MaximumMember 2022-12-31 0000885725 srt:MaximumMember 2022-01-01 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2022-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0000885725 bsx:DeferredTaxAssetsDomain 2022-12-31 0000885725 bsx:DeferredTaxAssetsDomain 2021-12-31 0000885725 bsx:DeferredTaxLiabilitiesDomain 2022-12-31 0000885725 bsx:DeferredTaxLiabilitiesDomain 2021-12-31 0000885725 2021-07-01 2021-09-30 0000885725 us-gaap:SubsequentEventMember 2023-01-31 2023-01-31 0000885725 2022-08-05 2022-08-05 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 2020-05-27 0000885725 bsx:A550MCPSSeriesAMember 2022-12-31 0000885725 srt:MinimumMember bsx:A550MCPSSeriesAMember 2022-01-01 2022-12-31 0000885725 srt:MaximumMember bsx:A550MCPSSeriesAMember 2022-01-01 2022-12-31 0000885725 bsx:A550MCPSSeriesAMember us-gaap:SubsequentEventMember 2023-01-30 2023-01-30 0000885725 us-gaap:CommonStockMember 2020-05-27 2020-05-27 0000885725 us-gaap:CommonStockMember 2020-05-27 0000885725 2020-12-14 0000885725 bsx:A2011LtipPlanMember 2020-10-01 0000885725 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000885725 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000885725 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000885725 srt:MinimumMember 2022-01-01 2022-12-31 0000885725 srt:MinimumMember 2021-01-01 2021-12-31 0000885725 srt:MaximumMember 2021-01-01 2021-12-31 0000885725 srt:MinimumMember 2020-01-01 2020-12-31 0000885725 srt:MaximumMember 2020-01-01 2020-12-31 0000885725 2021-02-17 0000885725 2020-02-18 0000885725 2019-02-21 0000885725 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0000885725 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000885725 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000885725 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000885725 bsx:A550MCPSSeriesAMember 2022-01-01 2022-12-31 0000885725 bsx:A550MCPSSeriesAMember 2021-01-01 2021-12-31 0000885725 bsx:A550MCPSSeriesAMember 2020-01-01 2020-12-31 0000885725 bsx:MedsurgMember 2020-01-01 2020-12-31 0000885725 bsx:CardiovascularMember 2020-01-01 2020-12-31 0000885725 bsx:BSXReportableSegmentsMember 2022-01-01 2022-12-31 0000885725 bsx:BSXReportableSegmentsMember 2021-01-01 2021-12-31 0000885725 bsx:BSXReportableSegmentsMember 2020-01-01 2020-12-31 0000885725 bsx:OtherMember 2022-01-01 2022-12-31 0000885725 bsx:OtherMember 2021-01-01 2021-12-31 0000885725 bsx:OtherMember 2020-01-01 2020-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2022-01-01 2022-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2021-01-01 2021-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2020-01-01 2020-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2022-01-01 2022-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2021-01-01 2021-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2020-01-01 2020-12-31 0000885725 bsx:SpecialChargesMember 2022-01-01 2022-12-31 0000885725 bsx:SpecialChargesMember 2021-01-01 2021-12-31 0000885725 bsx:SpecialChargesMember 2020-01-01 2020-12-31 0000885725 bsx:OtherMember 2022-01-01 2022-12-31 0000885725 bsx:OtherMember 2021-01-01 2021-12-31 0000885725 bsx:OtherMember 2020-01-01 2020-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2022-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2021-12-31 0000885725 us-gaap:CorporateMember 2022-12-31 0000885725 us-gaap:CorporateMember 2021-12-31 0000885725 bsx:ConsolidatedBSXDomain 2022-12-31 0000885725 bsx:ConsolidatedBSXDomain 2021-12-31 0000885725 country:US 2022-12-31 0000885725 country:US 2021-12-31 0000885725 country:IE 2022-12-31 0000885725 country:IE 2021-12-31 0000885725 country:CR 2022-12-31 0000885725 country:CR 2021-12-31 0000885725 bsx:OtherCountriesMember 2022-12-31 0000885725 bsx:OtherCountriesMember 2021-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2020-01-01 2020-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2020-01-01 2020-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2020-01-01 2020-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2020-01-01 2020-12-31 0000885725 country:US bsx:MedsurgMember 2022-01-01 2022-12-31 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2022-01-01 2022-12-31 0000885725 country:US bsx:MedsurgMember 2021-01-01 2021-12-31 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2021-01-01 2021-12-31 0000885725 country:US bsx:MedsurgMember 2020-01-01 2020-12-31 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2020-01-01 2020-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2022-01-01 2022-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember 2022-01-01 2022-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2021-01-01 2021-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember 2021-01-01 2021-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2020-01-01 2020-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:InterventionalCardiologyTherapiesMember 2020-01-01 2020-12-31 0000885725 bsx:WatchmanMember country:US 2022-01-01 2022-12-31 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:WatchmanMember 2022-01-01 2022-12-31 0000885725 bsx:WatchmanMember country:US 2021-01-01 2021-12-31 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:WatchmanMember 2021-01-01 2021-12-31 0000885725 bsx:WatchmanMember country:US 2020-01-01 2020-12-31 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:WatchmanMember 2020-01-01 2020-12-31 0000885725 bsx:CardiacRhythmManagementMember country:US 2022-01-01 2022-12-31 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:CardiacRhythmManagementMember 2022-01-01 2022-12-31 0000885725 bsx:CardiacRhythmManagementMember country:US 2021-01-01 2021-12-31 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:CardiacRhythmManagementMember 2021-01-01 2021-12-31 0000885725 bsx:CardiacRhythmManagementMember country:US 2020-01-01 2020-12-31 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:CardiacRhythmManagementMember 2020-01-01 2020-12-31 0000885725 bsx:ElectrophysiologyEPMember country:US 2022-01-01 2022-12-31 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:ElectrophysiologyEPMember 2022-01-01 2022-12-31 0000885725 bsx:ElectrophysiologyEPMember country:US 2021-01-01 2021-12-31 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:ElectrophysiologyEPMember 2021-01-01 2021-12-31 0000885725 bsx:ElectrophysiologyEPMember country:US 2020-01-01 2020-12-31 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:ElectrophysiologyEPMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2020-01-01 2020-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalCardiologyReportingUnitMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2022-01-01 2022-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2022-01-01 2022-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2021-01-01 2021-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2021-01-01 2021-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2020-01-01 2020-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2020-01-01 2020-12-31 0000885725 country:US bsx:CardiovascularMember 2022-01-01 2022-12-31 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2022-01-01 2022-12-31 0000885725 country:US bsx:CardiovascularMember 2021-01-01 2021-12-31 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2021-01-01 2021-12-31 0000885725 country:US bsx:CardiovascularMember 2020-01-01 2020-12-31 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2020-01-01 2020-12-31 0000885725 bsx:OtherMember country:US 2022-01-01 2022-12-31 0000885725 bsx:OtherMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 bsx:OtherMember country:US 2021-01-01 2021-12-31 0000885725 bsx:OtherMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 bsx:OtherMember country:US 2020-01-01 2020-12-31 0000885725 bsx:OtherMember us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 country:US 2022-01-01 2022-12-31 0000885725 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000885725 country:US 2021-01-01 2021-12-31 0000885725 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000885725 country:US 2020-01-01 2020-12-31 0000885725 us-gaap:NonUsMember 2020-01-01 2020-12-31 0000885725 bsx:USExcludingOtherNetSalesMember 2022-01-01 2022-12-31 0000885725 bsx:USExcludingOtherNetSalesMember 2021-01-01 2021-12-31 0000885725 bsx:USExcludingOtherNetSalesMember 2020-01-01 2020-12-31 0000885725 us-gaap:EMEAMember 2022-01-01 2022-12-31 0000885725 us-gaap:EMEAMember 2021-01-01 2021-12-31 0000885725 us-gaap:EMEAMember 2020-01-01 2020-12-31 0000885725 srt:AsiaPacificMember 2022-01-01 2022-12-31 0000885725 srt:AsiaPacificMember 2021-01-01 2021-12-31 0000885725 srt:AsiaPacificMember 2020-01-01 2020-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2022-01-01 2022-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2021-01-01 2021-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2020-01-01 2020-12-31 0000885725 bsx:EmergingMarketsMember 2022-01-01 2022-12-31 0000885725 bsx:EmergingMarketsMember 2021-01-01 2021-12-31 0000885725 bsx:EmergingMarketsMember 2020-01-01 2020-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2022-12-31 0000885725 bsx:InternationalRetirementPlansMember 2022-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2021-12-31 0000885725 bsx:UKPlanMember 2021-12-31 0000885725 bsx:InternationalRetirementPlansMember 2021-12-31 0000885725 us-gaap:DomesticPlanMember 2022-12-31 0000885725 bsx:OtherInternationalPlansMember 2022-12-31 0000885725 us-gaap:DomesticPlanMember 2021-12-31 0000885725 bsx:UKPlanMember 2021-12-31 0000885725 bsx:OtherInternationalPlansMember 2021-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000885725 us-gaap:OtherContractMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel1Member bsx:UKPlanMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel2Member bsx:UKPlanMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member bsx:UKPlanMember 2021-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0000885725 bsx:UKPlanMember 2022-12-31 0000885725 2018-01-01 2018-12-31 iso4217:USD iso4217:USD shares shares pure iso4217:KRW iso4217:EUR bsx:units utr:Rate bsx:Unit bsx:reportablesegments bsx:countries 0000885725 --12-31 2022 FY false http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 10-K true 2022-12-31 false 1-11083 BOSTON SCIENTIFIC CORPORATION DE 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 Common Stock, $0.01 par value BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share BSX PR A NYSE Yes No Yes Yes Large Accelerated Filer false false true false 53200000000 0.01 1434780104 Ernst & Young LLP Boston, Massachusetts 12682000000 11888000000 9913000000 3956000000 3711000000 3465000000 8727000000 8177000000 6448000000 4520000000 4359000000 3787000000 1323000000 1204000000 1143000000 47000000 49000000 45000000 803000000 741000000 789000000 0 0 73000000 132000000 370000000 460000000 35000000 -136000000 -100000000 24000000 40000000 52000000 173000000 430000000 278000000 -22000000 78000000 0 7078000000 6978000000 6528000000 1649000000 1199000000 -80000000 470000000 341000000 361000000 -38000000 218000000 362000000 1141000000 1076000000 -79000000 443000000 36000000 2000000 698000000 1041000000 -82000000 55000000 55000000 33000000 642000000 985000000 -115000000 0.45 0.69 -0.08 0.45 0.69 -0.08 1430500000 1422300000 1416700000 1439700000 1433800000 1416700000 698000000 1041000000 -82000000 -94000000 -125000000 76000000 63000000 170000000 -137000000 -37000000 -11000000 1000000 6000000 56000000 -63000000 704000000 1096000000 -145000000 928000000 1925000000 1970000000 1778000000 1867000000 1610000000 264000000 205000000 731000000 799000000 5760000000 6317000000 2446000000 2252000000 12920000000 11988000000 5902000000 6121000000 3942000000 4142000000 1500000000 1410000000 32469000000 32229000000 20000000 261000000 862000000 794000000 2160000000 2436000000 761000000 783000000 3803000000 4274000000 8915000000 8804000000 144000000 310000000 2035000000 2220000000 0.01 0.01 50000000 50000000 10062500 10062500 0 0 0.01 0.01 2000000000 2000000000 1696633993 1688810052 17000000 17000000 263289848 263289848 2251000000 2251000000 20289000000 19986000000 -750000000 -1392000000 269000000 263000000 17573000000 16622000000 32469000000 32229000000 10062500 10062500 0 0 0 10062500 10062500 10062500 10062500 1688810052 1679911918 1642488911 0 0 29382500 7823941 8898134 8040507 1696633993 1688810052 1679911918 0 0 0 0 0 0 0 0 0 17000000 17000000 16000000 0 0 0 0 0 0 17000000 17000000 17000000 -2251000000 -2251000000 -1717000000 0 0 -535000000 -2251000000 -2251000000 -2251000000 19986000000 19732000000 17561000000 0 0 975000000 0 0 975000000 303000000 254000000 221000000 20289000000 19986000000 19732000000 -1392000000 -2378000000 -2253000000 698000000 1041000000 -82000000 0 0 -10000000 -55000000 -55000000 -33000000 -750000000 -1392000000 -2378000000 263000000 207000000 270000000 -94000000 -125000000 76000000 63000000 170000000 -137000000 37000000 11000000 -1000000 269000000 263000000 207000000 17573000000 16622000000 15326000000 698000000 1041000000 -82000000 -22000000 78000000 0 1136000000 1093000000 1123000000 -63000000 -124000000 -82000000 220000000 194000000 170000000 132000000 370000000 533000000 -1000000 250000000 333000000 35000000 -136000000 -100000000 32000000 34000000 58000000 -194000000 0 0 125000000 78000000 244000000 220000000 279000000 -335000000 321000000 346000000 65000000 209000000 134000000 265000000 -255000000 408000000 -28000000 1526000000 1870000000 1508000000 588000000 554000000 376000000 12000000 14000000 12000000 1542000000 2258000000 3000000 24000000 -279000000 146000000 5000000 826000000 15000000 -70000000 -82000000 -87000000 -56000000 -15000000 0 -2011000000 -1597000000 -411000000 335000000 15000000 49000000 75000000 85000000 97000000 250000000 0 2950000000 0 0 2245000000 -1000000 0 -714000000 0 0 1919000000 0 0 1916000000 3184000000 0 1260000000 3270000000 0 1683000000 55000000 55000000 28000000 0 0 975000000 0 0 975000000 0 0 535000000 53000000 50000000 59000000 136000000 110000000 111000000 -548000000 -95000000 293000000 -9000000 -6000000 -2000000 -1042000000 173000000 1388000000 2168000000 1995000000 607000000 1126000000 2168000000 1995000000 662000000 302000000 207000000 450000000 338000000 359000000 0 440000000 0 -70000000 -82000000 -87000000 928000000 1925000000 1734000000 149000000 188000000 208000000 48000000 55000000 52000000 1126000000 2168000000 1995000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE A – SIGNIFICANT ACCOUNTING POLICIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets are related to deferred compensation plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is adequate as of December 31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a contract with a customer that creates enforceable rights and obligations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Promised products or services are identified,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transaction price, or the amount we expect to receive, is determinable and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have transferred control of the promised items to the customer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Business Combinations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration net expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangibles and IPR&amp;D </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Intangible Assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold; Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as appropriate within our accompanying consolidated statements of operations, and include in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to impairments of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Publicly Traded and Privately-Held Entities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Investments - Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on our investment balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses and impairments associated with our investment portfolio are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H – Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs Associated with Exit Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record employee termination costs in accordance with FASB ASC Topic 712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement and Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. We record such costs into expense over the employee’s future service period, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold, Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development (R&amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Indefinite-lived Intangibles and IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for our policy regarding R&amp;D projects acquired in connection with our business combinations and asset purchases.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the accounts of Boston Scientific Corporation and our subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs during 2022, 2021 or 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Accounting Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K for further discussion.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider cash equivalents to be all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments collected by us for servicing previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash Equivalents</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span>within our consolidated balance sheets are related to deferred compensation plans. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including distributors, hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach to determine the reserve to record at accounts receivable commencement for certain customers, applying country or region-specific factors. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We write-off amounts determined to be uncollectible against this reserve. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2022, 2021 and 2020; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other countries. Further, the ongoing site-of-service trend of shifting procedure volumes in the U.S. toward non-hospital settings, particularly ambulatory surgery centers and office-based labs, continues. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions, as appropriate. We believe our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span> is adequate as of December 31, 2022; however, if significant changes were to occur in the payment practices of government customers, or if there is an increase in bankruptcies among our ambulatory surgery center or office-based customers, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts may increase. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a contract with a customer that creates enforceable rights and obligations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Promised products or services are identified,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transaction price, or the amount we expect to receive, is determinable and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have transferred control of the promised items to the customer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Implant Services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide non-contractual services to customers, where necessary, to ensure the safe and effective use of certain implanted devices. Because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our CRM business, which include implantable defibrillator and pacemaker systems. These products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a </span></div>liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of first-in, first-out cost or net realizable value. We utilize a standard costing system, capitalizing variances between estimated and actual production costs during periods of normal production, and amortize to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over inventory turns. We expense manufacturing variances during periods of abnormal production, or less than 75 percent of manufacturing capacity. During 2020, we recorded $149 million of abnormal manufacturing variances attributable to lower production levels resulting from the COVID-19 pandemic and lower than forecasted demand for our products. We did not record any abnormal production variances during the years ended December 31, 2022 or 2021.</span></div>We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. 149000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Business Combinations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we acquire a company in which we previously held an equity stake, we attribute a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Boston Scientific, according to priority of equity interests. We record a gain or loss in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the difference between the implied fair value of our prior ownership and the book value immediately prior to the acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration net expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangibles and IPR&amp;D </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which are foundational to our ongoing operations, as well as IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div>For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Intangible Assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various. In addition, we classify internal use software as an intangible asset within our accompanying consolidated balance sheets, and amortize over a two to 15 year useful life. Due to the operational nature of these assets, we record the amortization of our internal use software within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold; Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as appropriate within our accompanying consolidated statements of operations, and include in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> only that associated with intangible assets acquired in a business combination or asset acquisition, as well as internally-developed patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information related to impairments of intangible assets.</span></div>For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2022 annual impairment assessment, following the reorganization of our operational structure in the first quarter of 2022, we identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span>, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components into a single Rhythm Management reporting unit. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Publicly Traded and Privately-Held Entities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For publicly-held equity securities for which we do not have the ability to exercise significant influence, we measure at fair value with changes in fair value recognized currently in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations. For privately-held equity securities for which we do not have the ability to exercise significant influence, we apply the measurement alternative approach and measure these investments at cost minus impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We account for investments in entities for which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Investments - Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on our investment balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. For our investments for which we apply the measurement alternative, if the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. For our equity method investments, if we determine an impairment is other-than-temporary, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses and impairments associated with our investment portfolio are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span>in our consolidated statements of operations. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize interest and penalties related to income taxes as a component of income tax expense. As part of the Tax Cuts and Jobs Act (TCJA), we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and report it as part of continuing operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note H – Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Product Liability Costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities and product liability litigation. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of our individual material legal proceedings.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs Associated with Exit Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record employee termination costs in accordance with FASB ASC Topic 712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement and Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. We record such costs into expense over the employee’s future service period, if any. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold, Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated statements of operations. Impairment of right of use lease assets and lease termination costs directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span> in our consolidated statements of operations. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate. We show the net effect of these translation adjustments within our consolidated financial statements as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We translate revenues and expenses at the average exchange rates in effect during the year. For any significant foreign subsidiaries located in highly inflationary economies, we re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span>in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on our hedging instruments.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development (R&amp;D) costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Indefinite-lived Intangibles and IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for our policy regarding R&amp;D projects acquired in connection with our business combinations and asset purchases.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our consolidated financial statements. Further, transaction costs were immaterial to our consolidated financial statements and were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, we announced our entry into a definitive agreement with Synergy Innovation Co, Ltd, to purchase its majority stake of M.I. Tech Co., Ltd., (M.I. Tech), a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urological procedures. The agreement, whereby we will purchase approximately 64 percent of the outstanding shares of M.I. Tech, consists of an upfront purchase price of KRW 291.2 billion or approximately $230 million at foreign currency exchange rates locked into at the time of the agreement via forward currency contracts. We are working towards closing the acquisition during the second quarter of 2023, subject to customary regulatory approvals. The M.I. Tech stent portfolio complements our existing Endoscopy portfolio which will provide physicians with more treatment options to meet specific patient needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, we announced our entry into a definitive agreement to acquire 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement provides for an upfront cash payment of $10.00 per share, approximately $615 million, and is expected to close during the first half of 2023, subject to customary closing conditions. The Apollo business will be integrated into our Endoscopy division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2023, we completed the acquisition of a majority stake in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or approximately $520 million at foreign currency exchange rates as of closing using cash on hand. The Acotec portfolio complements our existing Peripheral Interventions portfolio and will strengthen our presence in China.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Acquisition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which has developed the radiofrequency (RF) NRG™ and VersaCross™ Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expands our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price was comprised of the amount presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:84.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.292%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, we completed our acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company with a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We had been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $196 million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and an additional revenue-based milestone payment of $216 million made during the second quarter of 2022. The Preventice business is being managed by our Cardiology division. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. The transaction consisted of an upfront cash payment of $450 million, up to $125 million upon achievement of certain clinical and regulatory milestones and additional revenue-based payments over the next three years. We had been an investor in Farapulse since 2014 and held an equity stake of approximately 27 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $222 million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $268 million, net of cash acquired, up to $92 million in additional clinical and regulatory milestone payments, as well as future revenue-based payments. We have made combined milestone and revenue based payments of $114 million to date. The Farapulse business is being integrated into our Cardiology division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2021, we completed our acquisition of the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that has developed and commercialized energy-based medical solutions, including innovative laser systems, fibers and accessories used for urology and otolaryngology procedures. The transaction consisted of an upfront cash payment of $1.032 billion, net of cash acquired. The Lumenis business is being integrated into our Urology division. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2021, we completed our acquisition of the remaining shares of Devoro Medical, Inc. (Devoro Medical), a privately-held company which has developed the WOLF Thrombectomy® Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The transaction consisted of an upfront cash payment of $320 million and up to $80 million upon achievement of certain clinical and regulatory milestones. We had been an investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent. We remeasured the fair value of our previously held investment based on the allocation of the purchase price according to priority of equity interests which resulted in a $57 million gain recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price for the remaining stake consisted of an upfront cash payment of $251 million, net of cash acquired, and up to approximately $67 million in future milestone payments. The Devoro Medical business is being integrated into our Peripheral Interventions division. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price for the acquisitions completed during 2021 were comprised of the components presented below, which represents the determination of the fair value of identifiable assets acquired and liabilities assumed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of prior interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation for these acquisitions was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recorded certain measurement period adjustments primarily related to our prior year acquisition of the surgical business of Lumenis. We recorded an accrued income tax liability within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our consolidated balance sheet of $183 million related to uncertain tax positions assumed in connection with the acquisition. We expect to be indemnified for the majority of such tax obligations and we recognized a corresponding indemnification asset of $177 million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets. Interest and penalties accrued on the tax liability are being recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and corresponding adjustments to the indemnification asset are being recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying consolidated statements of operations. The outcome of these matters is subject to uncertainty and ultimately, the amount of tax due and the related indemnification reimbursement we receive will be dependent on the outcome of tax return examinations by relevant authorities. Refer to Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note G – Supplemental Balance Sheet Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding our indemnification asset.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Preventice:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lumenis:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">All Other:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Divestiture</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of five facilities and approximately 280 employees globally. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $73 million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments made during 2022 were primarily related to our 2021 acquisitions of Farapulse and Preventice. As of December 31, 2022, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $417 million. The net expense of $35 million recorded in 2022 related to an increase in expected revenue-based payments as a result of over-achievement of net sales performance, primarily related to Farapulse. The net benefit of $136 million recorded in 2021 related to a reduction in the contingent consideration liability for certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned, or, for milestones that would not be achieved due to management's discontinuation of the associated R&amp;D program. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:19.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D, Regulatory and Commercialization-based Milestones</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$136 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected contingent payment amounts related to our R&amp;D, regulatory and commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Publicly-held equity securities are measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recorded a $178 million loss on our investment in Pulmonx Corporation presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span> associated with the remeasurement of our investment during the period to fair value based on observable market prices, as well as the disposition of our remaining ownership. As of December 31, 2022, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $232 million, which represents amortizable intangible assets, IPR&amp;D, goodwill and deferred tax liabilities. 0.64 291200000000 230000000 1 10.00 615000000 0.65 20.00 520000000 1463000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1463000000 1463000000 1463000000 1463000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:84.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.292%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 988000000 657000000 112000000 287000000 7000000 1463000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 622000000 P11Y 0.11 36000000 P11Y 0.11 657000000 925000000 300000000 0.22 196000000 706000000 216000000 450000000 125000000 P3Y 0.27 222000000 268000000 92000000 114000000 1032000000.000 320000000 80000000 0.16 57000000 251000000 67000000 in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of prior interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 706000000 1032000000 519000000 2258000000 221000000 0 218000000 440000000 269000000 0 287000000 556000000 1197000000 1032000000 1025000000 3254000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final purchase price allocation for these acquisitions was comprised of the following components:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preventice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lumenis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div> 926000000 534000000 594000000 2053000000 237000000 423000000 465000000 1125000000 0 69000000 43000000 112000000 65000000 297000000 9000000 372000000 32000000 282000000 11000000 325000000 0 9000000 75000000 84000000 1197000000 1032000000 1025000000 3254000000 183000000 177000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Preventice:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lumenis:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">All Other:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 215000000 P9Y 0.10 22000000 P8Y 0.10 237000000 388000000 P12Y 0.11 35000000 P11Y 0.11 69000000 0.12 492000000 465000000 P12Y 0.16 0.17 43000000 0.17 508000000 800000000 5 280 73000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded related to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 196000000 440000000 -136000000 15000000 486000000 35000000 371000000 149000000 417000000 35000000 -136000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:19.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D, Regulatory and Commercialization-based Milestones</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$136 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div> 13000000 0.01 0.02 0.02 0.10 0.25 0.22 136000000 0.06 0.14 0.07 1 1 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Measurement alternative investments are privately-held equity securities or agreements for future equity without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying consolidated statements of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Publicly-held equity securities are measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div> 188000000 259000000 216000000 142000000 2000000 10000000 1000000 0 407000000 412000000 178000000 232000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:29.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of Baylis Medical completed in the first quarter of 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible asset impairment charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $132 million in 2022, $370 million in 2021 and $460 million in 2020. The impairment charges recorded in 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which is now part of our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges. The impairment charges recorded in 2021 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of VENITI, Inc., which is now part of our Peripheral Interventions business. These charges resulted from management’s decision </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to discontinue commercialization of the VICI VENOUS STENT™ System following a voluntary recall, due to cost to remediate and time to return to market. In addition, during 2021, we impaired the IPR&amp;D assets established in connection with our acquisition of Millipede, Inc. which is now part of our Cardiology business. The charges resulted from the cancellation of the mitral valve IPR&amp;D program due to the incremental time and cost required to complete the program and bring the technology to market. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management’s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our goodwill balance by reportable segment.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. We have revised prior periods to conform to the current year presentation. There was no impact to the reporting units identified for purposes of our annual goodwill impairment testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion of our goodwill and intangible asset impairment testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2022 is as follows (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December 31, 2022. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:29.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization/<br/>Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,476)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 12397000000 7378000000 11957000000 6754000000 486000000 394000000 494000000 398000000 1960000000 1400000000 1900000000 1325000000 14843000000 9173000000 14351000000 8476000000 22820000000 9900000000 21888000000 9900000000 112000000 126000000 120000000 120000000 232000000 246000000 132000000 370000000 460000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our goodwill balance by reportable segment.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency fluctuations and other changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3707000000 6243000000 9951000000 544000000 1520000000 2064000000 -5000000 -21000000 -27000000 4246000000 7741000000 11988000000 0 1030000000 1030000000 -10000000 -88000000 -98000000 4237000000 8684000000 12920000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2022 is as follows (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 781000000 741000000 683000000 665000000 625000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currency Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities; forecasted intercompany and third-party transactions; net investments in certain subsidiaries; and, during 2022 prior to our acquisition of M.I. Tech, the purchase price of M.I. Tech, which was denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecasted. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax (OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Foreign currency translation adjustment (CTA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we reclassify amortization of the excluded component from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of December 31, 2022 and 2021, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We reclassify these gains and losses to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the KRW denominated purchase price of M.I. Tech. As of December 31, 2022, we had entered into $228 million in aggregate notional amount of these contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Hedging Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Designations and Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2022 and December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was a $8 million loss as of December 31, 2022 and a $24 million loss as of December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2022 and December 31, 2021. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which generally offset. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining time to maturity as of December 31, 2022 is within 48 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature within the next year. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note O – Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. No amounts were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to current period earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recurring Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:31.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $673 million invested in money market funds and time deposits as of December 31, 2022 and $1.632 billion as of December 31, 2021, we held $256 million in interest-bearing and non-interest-bearing bank accounts as of December 31, 2022 and $293 million as of December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the changes in the fair value of our contingent consideration liability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We own the contractual right to receive 50 percent of the future Zytiga™ Drug royalty payments from the licensee and remit such payments to the inventors associated with the intellectual property. We recognized a financial asset and associated liability for our licensing arrangements at fair value in our consolidated balance sheets using the fair value option in accordance with FASB ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these instruments. Royalty payments we receive reduce the fair value of the financial asset and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from royalty rights,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and payments we remit to inventors reduce the fair value of the financial liability and are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of cash flows. We sold our right to receive and retain the other 50 percent of the future royalty payments in 2019 for an upfront cash payment, which we accounted for as a secured borrowing in accordance with FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although we sold these rights, we continue to recognize at fair value the future royalty payments as a financial asset and associated liability. Royalty payments associated with the rights we sold no longer impact our cash flows, and we present this activity as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-cash impact of transferred royalty rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the supplemental information to our consolidated statements of cash flows. We reduce the fair value of the financial asset and associated liability when such non-cash activity occurs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of the financial asset and associated liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2022. However, increases or decreases in the financial asset would be offset by increases or decreases in the financial liability, other than for timing of receipt and remittance; as such our earnings are not subject to material gains and losses from the licensing arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2022 include the following significant unobservable inputs:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our strategic investments and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the fair values of our intangible assets including goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our outstanding debt obligations was $8.203 billion as of December 31, 2022 and $10.196 billion as of December 31, 2021. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our debt obligations.</span></div> 900000000 0.00625 228000000 8000000 24000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2725000000 3996000000 365000000 493000000 997000000 997000000 4235000000 3892000000 8321000000 9378000000 900000000 48 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note O – Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior periods, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. No amounts were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to current period earnings.</span></div> -276000000 62000000 -214000000 3956000000 209000000 47000000 -162000000 41000000 -10000000 32000000 470000000 -10000000 2000000 8000000 61000000 -14000000 47000000 38000000 0 0 0 0 0 0 470000000 -16000000 -4000000 13000000 -268000000 60000000 -208000000 3711000000 54000000 12000000 -42000000 56000000 -13000000 43000000 341000000 -13000000 3000000 10000000 82000000 -19000000 64000000 -218000000 0 0 0 0 0 0 341000000 -5000000 -1000000 4000000 99000000 -22000000 77000000 3465000000 83000000 19000000 -64000000 -37000000 8000000 -29000000 361000000 -24000000 5000000 19000000 -89000000 21000000 -68000000 -362000000 0 0 0 0 0 0 361000000 -5000000 -1000000 4000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 223000000 10000000 -3000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -53000000 -16000000 73000000 21000000 -12000000 -105000000 -31000000 -27000000 -32000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span>, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Foreign currency-denominated debt is the €900 million debt principal designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div> 196000000 183000000 149000000 169000000 345000000 352000000 36000000 42000000 381000000 394000000 0 32000000 1000000 6000000 952000000 1011000000 953000000 1049000000 52000000 22000000 1005000000 1071000000 900000000 <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:31.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,838</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2022 include the following significant unobservable inputs:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 673000000 0 0 673000000 1632000000 0 0 1632000000 2000000 0 0 2000000 10000000 0 0 10000000 0 381000000 0 381000000 0 394000000 0 394000000 0 0 127000000 127000000 0 0 246000000 246000000 674000000 381000000 127000000 1182000000 1642000000 394000000 246000000 2282000000 0 1005000000 0 1005000000 0 1071000000 0 1071000000 0 0 149000000 149000000 0 0 486000000 486000000 0 0 159000000 159000000 0 0 281000000 281000000 0 1005000000 308000000 1313000000 0 1071000000 767000000 1838000000 673000000 1632000000 256000000 293000000 127000000 0.15 0.15 159000000 0.12 0.15 0.13 365000000 163000000 44000000 246000000 141000000 22000000 127000000 407000000 166000000 41000000 281000000 145000000 23000000 159000000 8203000000 10196000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings and Credit Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total debt outstanding of $8.935 billion as of December 31, 2022 and $9.065 billion as of December 31, 2021, with current maturities of $20 million as of December 31, 2022 and $261 million as of December 31, 2021. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.125%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.850%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Gain on Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Current Debt Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December 31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks and terminated our previous facility (2018 Revolving Credit Facility). The 2021 Revolving Credit Facility will mature on May 10, 2026, with one-year extension options, subject to certain conditions. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the Revolving Credit Facility as of December 31, 2022 or December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement<br/>as of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual<br/>as of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57 times</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times for the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition, for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. It steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for qualified acquisitions due to our funding of these acquisitions using cash on hand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2022, we had $265 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $1.455 billion in the aggregate. As of December 31, 2022, we had $866 million of the litigation exclusion remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to maintain compliance with this covenant could require us to seek to further renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2022 and 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had senior notes outstanding of $8.986 billion as of December 31, 2022 and $9.121 billion as of December 31, 2021. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi denominated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding letters of credit of $135 million as of December 31, 2022 and $134 million as of December 31, 2021, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2022 and December 31, 2021, we had not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum purchase obligations, relating primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business, were as of December 31, 2022 (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecorded Purchase Obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8935000000 9065000000.000 20000000 261000000 <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.125%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.850%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Gain on Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Coupon rates are semi-annual, except for the euro-denominated notes, which bear an annual coupon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective November 15, 2021, the interest rate payable decreased by 0.25 percent and began accruing at a rate of 6.75 percent following upgrades to our credit ratings. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of December 31, 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. In addition, in the first quarter of 2022, we repaid $250 million of 3.375% May 2022 Senior Notes classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Current Debt Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December 31, 2021.</span></div> 0 244000000 0.04125 504000000 850000000 0.03450 1067000000 0 0.00750 0 523000000 0.03850 500000000 500000000 0.01900 255000000 850000000 0.03750 960000000 1021000000 0.00625 800000000 0 0.01375 344000000 434000000 0.04000 272000000 850000000 0.04000 1200000000 1200000000 0.02650 800000000 0 0.01625 534000000 0 0.01875 350000000 350000000 0.06750 450000000 750000000 0.04550 300000000 300000000 0.07375 650000000 1000000000 0.04700 76000000 76000000 0 3000000 5000000 6000000 8915000000 8804000000 250000000 0.03375 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of our long-term debt outstanding as of December 31, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 504000000 1567000000 255000000 960000000 5700000000 2750000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement<br/>as of December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual<br/>as of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57 times</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Ratio of total debt to deemed consolidated EBITDA, as defined by the credit agreements, as amended.</span></div> 3.75 2.57 3.75 1000000000 4.75 4.50 4.25 4.00 3.75 500000000 265000000 1455000000 866000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We did not have any commercial paper outstanding as of December 31, 2022 and 2021.</span></div> 8986000000 9121000000 3000000000 1000000000 0.00750 750000000 0.01375 750000000 0.01625 500000000 0.01875 3270000000 3275000000 194000000 Amounts de-recognized for accounts and notes receivable, which are excluded from <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi denominated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 161000000 0.024 141000000 0.021 194000000 0.006 223000000 0.006 13000000 0.031 11000000 0.032 135000000 134000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecorded Purchase Obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 755000000 119000000 71000000 35000000 19000000 21000000 1021000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE F – LEASES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. In accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 54 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease right-of-use assets are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and corresponding liabilities are presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding our finance leases. The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414">61</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328">71</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost under FASB ASC Topic 842 was $91 million in 2022, $90 million in 2021 and $92 million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligations were $43 million and $68 million for the years ended December 31, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturities of our operating lease liabilities as of December 31, 2022 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P1Y P54Y P10Y The following table presents supplemental balance sheet information related to our operating leases:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMS0xLTEtMTE4ODMz_ab73b0cb-ecc1-491e-8821-61a79a5c8414">61</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMTgvZnJhZzo5OGZmMDkzMzA4ZGY0ZGY3YWVjZGExMjQ5YjkwNjg2ZC90YWJsZTowZmU1ZDllMDc3NTY0Y2Q4YjBlMTBkNDRjZDJiMjhjZi90YWJsZXJhbmdlOjBmZTVkOWUwNzc1NjRjZDhiMGUxMGQ0NGNkMmIyOGNmXzUtMy0xLTEtMTE4ODMz_43c9cd01-39b0-44b3-957a-47c573a6c328">71</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 386000000 435000000 61000000 71000000 347000000 389000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td></tr></table> P10Y P10Y 0.033 0.026 91000000 90000000 92000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 91000000 87000000 43000000 68000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturities of our operating lease liabilities as of December 31, 2022 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 80000000 66000000 55000000 43000000 34000000 214000000 492000000 84000000 408000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in our accompanying consolidated balance sheets are as follows:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset’s contractual life. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 27 percent of our finished goods inventory as of December 31, 2022 and approximately 30 percent as of December 31, 2021 was at customer locations pursuant to consignment arrangements or held by sales representatives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">799</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $333 million in 2022, $352 million in 2021 and $333 million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da">386</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602">435</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663">347</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55">389</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Note: Effective January 1, 2020, we adopted FASB ASC Topic 326 using the modified retrospective method, which requires that we recognize credit loss reserves when financial assets are established if credit losses are expected over the asset’s contractual life. 2079000000 1886000000 109000000 108000000 1970000000 1778000000 108000000 105000000 74000000 10000000 35000000 28000000 49000000 35000000 25000000 27000000 109000000 108000000 105000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1171000000 1029000000 147000000 128000000 548000000 452000000 1867000000 1610000000 0.27 0.30 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">799</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 149000000 188000000 232000000 226000000 60000000 132000000 290000000 254000000 731000000 799000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 137000000 109000000 1695000000 1523000000 3297000000 3287000000 598000000 605000000 5728000000 5525000000 3282000000 3273000000 2446000000 2252000000 333000000 352000000 333000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMS0xLTEtMTE4ODMz_85d5c18a-0ea6-47a7-9737-396a583435da">386</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTpiNjkyNDJjMGFjNjk0YjY1YmJkM2Q2ZDU3ZDNkNWI3Yi90YWJsZXJhbmdlOmI2OTI0MmMwYWM2OTRiNjViYmQzZDZkNTdkM2Q1YjdiXzMtMy0xLTEtMTE4ODMz_064505ed-34c1-408a-8d2b-33f55d5dd602">435</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 48000000 55000000 386000000 435000000 149000000 169000000 407000000 412000000 67000000 114000000 172000000 0 271000000 225000000 1500000000 1410000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 231000000 264000000 830000000 848000000 352000000 350000000 74000000 289000000 674000000 686000000 2160000000 2436000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 220000000 208000000 79000000 138000000 232000000 209000000 230000000 228000000 761000000 783000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMS0xLTEtMTE4ODMz_1e4528b7-af4b-4a08-83a7-002de0d6a663">347</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA3MDBhOGY2ZWExZjQxNzFiNzVlODA4MTA2OGE0NTJiL3NlYzowNzAwYThmNmVhMWY0MTcxYjc1ZTgwODEwNjhhNDUyYl8xMjQvZnJhZzo4Mjg3NmJhZTg2MjA0MGUwYTc0OTE3ZWMyMWM2OTc1Ni90YWJsZTphMDU2NTI0ZjhmZGQ0MjJkODQ2MjU0MzFmY2NhNmQxMy90YWJsZXJhbmdlOmEwNTY1MjRmOGZkZDQyMmQ4NDYyNTQzMWZjY2E2ZDEzXzYtMy0xLTEtMTE4ODMz_5aacfa36-a6e5-4e51-897e-af10225d8a55">389</span> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 597000000 442000000 212000000 284000000 75000000 197000000 80000000 143000000 347000000 389000000 289000000 276000000 434000000 489000000 2035000000 2220000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE H – INCOME TAXES </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related expense (benefit) for income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic taxes on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intra-entity asset transfers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:70.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.729%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs and related reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit of net operating losses and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and product liability reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:50.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $464 million. As of December 31, 2021, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $560 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $47 million as of December 31, 2022, and $60 million as of December 31, 2021. These tax attributes expire periodically beginning in 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we recorded a valuation allowance of $1.004 billion as of December 31, 2022, and $1.014 billion as of December 31, 2021. The decrease in the valuation allowance as of December 31, 2022, compared to December 31, 2021, is primarily due to the release of valuation allowances on certain U.S. state net operating losses and tax credit carryforwards due to the repatriation of foreign earnings, offset by the concurrent build of the valuation allowance on </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other state attributes. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $56 million in 2022, a charge of $81 million in 2021 and a benefit of $78 million in 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100 percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years. This tax incentive resulted in income tax savings of $162 million in 2022, $149 million in 2021 and $64 million in 2020. The tax incentive for 100 percent exemption from income tax is expected to expire in 2027, with the 50 percent exemption to expire in 2031. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.11 for 2022, $0.10 for 2021 and $0.04 for 2020. We also benefit from tax incentives in Puerto Rico through a Grant of Industrial Tax Exemption (Grant) which applies a reduced tax rate to our taxable profits, resulting in income tax savings of $21 million in 2022, $27 million in 2021 and $30 million in 2020. This Grant expires in 2034, with an option to extend for an additional 15 years. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.02 in each of the years 2022, 2021 and 2020. Additionally, we benefit from tax incentives in Malaysia which allow a full tax exemption on manufacturing of specific medical device products, which will expire in 2029, with an option to renew for an additional five-year term. This incentive has resulted in income tax savings of $17 million in 2022 and $0 in 2021 and 2020. The impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $0.01 in 2022 and de minimis in 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. As of December 31, 2021, we had $255 million of gross unrecognized tax benefits, of which a net $177 million, if recognized, would affect our effective tax rate. As of December 31, 2020, we had $261 million of gross unrecognized tax benefits, of which a net $183 million, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation expirations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2016 and substantially all material state and local income tax matters through 2014. We have concluded substantially all foreign income tax matters through 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, we received notification from the IRS regarding the examination of our 2014 through 2016 tax years stating that the Joint Committee on Taxation completed its review, and the IRS examination was resolved. Due to the resolution of these tax years, we recorded a net tax benefit of $91 million to release the reserves related to these years. We received a refund of $62 million from the IRS reflecting the net balance of amounts owed to us by the IRS after consideration of tax and interest due for these years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income taxes as a component of income tax expense. We had $77 million accrued for gross interest and penalties as of December 31, 2022, $43 million as of December 31, 2021, and $41 million as of December 31, 2020. Net tax expense related to interest and penalties was immaterial in 2022, 2021 and 2020. The increase in our net tax expense related to interest and penalties as of December 31, 2022, compared to December 31, 2021, is related to reaching settlements with taxing authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $75 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2017, we were required under the TCJA to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&amp;P) that we previously deferred from U.S. income taxes. As a result of various audit activities, the revised amount of transition tax was approximately $937 million as of December 31, 2022, as compared to $938 million as of December 31, 2021. We anticipate offsetting this liability against existing tax attributes, reducing the required payment to approximately $586 million, which will be remitted over an eight-year period. We have begun </span></div>remitting the required installment payments, with a balance remaining of $386 million as of December 31, 2022. In addition, we have provided for U.S. state income taxes of $14 million on all U.S. dollar-denominated E&amp;P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&amp;P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -1119000000 -648000000 -660000000 2260000000 1724000000 581000000 1141000000 1076000000 -79000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related expense (benefit) for income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 51000000 18000000 -29000000 19000000 33000000 -35000000 381000000 127000000 151000000 451000000 178000000 87000000 -92000000 -256000000 -26000000 -32000000 -3000000 -6000000 117000000 117000000 -53000000 -7000000 -142000000 -85000000 443000000 36000000 2000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes at the federal statutory rate to the actual expense (benefit) for income taxes is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic taxes on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intra-entity asset transfers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div> 0.210 0.210 0.210 0.007 0.025 0.166 0.153 0.068 1.554 -0.038 -0.143 -0.407 -0.044 -0.081 -0.167 0.045 0.030 0.430 -0.013 0.008 -0.420 0 0 0.037 0.006 -0.006 -0.077 0.004 0.004 0.644 0.077 0.012 -0.968 0 0 0.102 -0.021 -0.057 -0.373 -0.002 0.019 0.518 0.007 0.004 0.060 0.389 0.033 0.029 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:70.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.729%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs and related reserves</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit of net operating losses and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and product liability reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal benefit of uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains and losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:50.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Consolidated Balance Sheets</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Component</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid on intercompany profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Tax Assets and Prepaid on Intercompany Profit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,062</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 19000000 10000000 511000000 620000000 304000000 324000000 6000000 14000000 103000000 127000000 38000000 31000000 136000000 130000000 9000000 8000000 3668000000 3546000000 160000000 67000000 2000000 14000000 0 35000000 4954000000 4926000000 1004000000 1014000000 3950000000 3912000000 117000000 79000000 34000000 0 151000000 79000000 3799000000 3833000000 264000000 205000000 4062000000 4038000000 264000000 205000000 3942000000 4142000000 4206000000 4348000000 144000000 310000000 144000000 310000000 4062000000 4038000000 464000000 560000000 47000000 60000000 1004000000.000 1014000000.000 -56000000 -81000000 78000000 162000000 149000000 64000000 0.11 0.10 0.04 21000000 27000000 30000000 0.02 17000000 0 0 0.01 492000000 410000000 255000000 177000000 261000000 183000000 A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation expirations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 255000000 261000000 455000000 88000000 8000000 28000000 177000000 41000000 6000000 20000000 36000000 186000000 1000000 2000000 27000000 8000000 17000000 15000000 492000000 255000000 261000000 91000000 62000000 77000000 43000000 75000000 937000000 938000000 586000000 386000000 14000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE I – COMMITMENTS AND CONTINGENCIES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accrual for legal matters that are probable and estimable was $443 million as of December 31, 2022, and $548 million as of December 31, 2021, and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of our legal accrual for transvaginal surgical mesh product claims is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $149 million as of December 31, 2022, and $188 million as of December 31, 2021. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded litigation-related net charges of $173 million in 2022, $430 million in 2021 and $278 million in 2020, primarily related to ongoing litigation associated with our transvaginal surgical mesh products principally in the U.S. and Australia, as well as costs associated with certain other legal matters. We increased the accrual associated with transvaginal mesh claims to account for changes in our estimates regarding settlement and litigation activity. The charges recorded in 2020 were also inclusive of a reserve related to claims made by a coalition of state attorneys general, which has since been settled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant. In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. The Company has also asserted patents against Cook in Germany and the United Kingdom. Trials are scheduled in the United Kingdom in February 2023 and in Germany in April 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. The Company intends to appeal the jury's verdict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. While our U.S. case count has remained materially the same over the past three years, we have increased our reserve to account for changes in our estimates regarding settlement and litigation activity. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims and expect that more cases will go to trial in the coming years than have gone to trial in the past several years. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Investigations and Qui Tam Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. Under the terms of the Court-approved Scheduling Order, Counsel for Mr. Errichiello was required to file an Amended Complaint on or before June 4, 2021, which they did. The Amended Complaint seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. In response, the Company brought a Motion to Dismiss the Amended Complaint which it filed on July 19, 2021. On December 20, 2022, the Court granted in part and denied in part the Company’s motion to dismiss. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund and Diane Nachbaur, two stockholders of the Company, on July 26, 2021, and July 29, 2021, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters Concluded Since December 31, 2021</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaint filed on behalf of the United States, 29 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. In May 2020, a class action complaint was filed in New Jersey federal court against Janssen and BTG by a direct purchaser of Zytiga on behalf of similarly situated entities. The complaint was amended in February 2021 and alleged that BTG and Janssen violated antitrust laws by attempting to enforce certain patents against potential generic competitors. On October 12, 2021, the court granted BTG and Janssen’s motion to compel arbitration in the direct purchaser action and stayed all direct purchaser proceedings. On December 17, 2021, the court granted BTG’s motion to dismiss the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action. On January 10, 2022, the court granted the parties’ stipulation of dismissal with prejudice as to the claims of the direct purchaser plaintiff, whose claims had been stayed in the October 12, 2021, order compelling arbitration.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments were due pursuant a transaction agreement regarding Labcoat Limited, a company Boston Scientific purchased in 2008 that provided coating technology for drug-eluting stents. Labcoat sought monetary damages related to an earn-out provision. On March 25, 2022, the parties agreed to a confidential settlement which resolved the dispute. The settlement did not have a material impact on our financial position or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro Corp. (Nevro) in United States District Court for the District of Delaware (16-cv-1163) alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro's Senza™ Spinal Cord Stimulation (SCS) System. The Company sought lost profits, a reasonable royalty and a permanent injunction. At a trial held in October and November 2021 regarding six of Boston Scientific's originally asserted patent claims, a jury granted Boston Scientific a monetary award, finding that each asserted claim was valid, that four of the six claims were infringed by Nevro, and that two of the claims were willfully infringed by Nevro. On July 29, 2022, the parties reached a confidential settlement agreement, pursuant to which the Company agreed to make a payment to Nevro of $85 million to resolve all pending litigation between the parties, including this matter and the 18-cv-664 and 21-cv-258 matters described below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in United States District Court for the District of Delaware (18-cv-664), and amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation were infringed by Nevro’s Senza™ I and Senza™ II SCS Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our SCS systems infringed five Nevro patents. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2021, Nevro filed a complaint against the Company in the United States District Court for the District of Delaware (21-cv-258). The complaint alleged infringement of five Nevro patents by certain of the Company’s spinal cord stimulation systems. Nevro sought lost profits, a reasonable royalty and a permanent injunction. On July 29, 2022, the parties agreed to a confidential settlement, described above. </span></div>The Company was previously named a defendant in multiple filed product liability cases involving our Greenfield Vena Cava Filter, which we discontinued marketing and actively selling in the fourth quarter of 2018. Most of the filed cases were part of a consolidated matter in Middlesex County, Massachusetts. We had also received notice of multiple additional unfiled claims. As of December 31, 2022, we have entered into master settlement agreements, the last of which was finalized on January 12, 2023, to resolve all but a small handful of these cases and claims. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span> 443000000 548000000 149000000 188000000 173000000 430000000 278000000 42000000 29 85000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE J – STOCKHOLDERS' EQUITY </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2022, our MCPS had an aggregate liquidation preference of $1.006 billion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of MCPS will be entitled to receive, when, as and if declared by our Board of Directors, or an authorized committee thereof, out of funds legally available for payment, cumulative dividends at the annual rate of 5.50% of the liquidation preference of $100 per share, payable in cash or, subject to certain limitations, by delivery of shares of common stock or any combination of cash and shares of common stock, at our election; provided, however, that any unpaid dividends on the MCPS will continue to accumulate as described in the Certificate of Designations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, no dividend or distribution will be declared or paid on shares of our common stock, and no common stock will be purchased, redeemed or otherwise acquired for consideration by us or any of our subsidiaries unless, in each case, all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid, or a sufficient amount of cash or number of shares of common stock has been set apart for the payment of such dividends, on all outstanding shares of MCPS. In the event of our voluntary or involuntary liquidation, winding-up or dissolution, no distribution of our assets may be made to holders of our common stock until we have paid holders of our MCPS, each of which will be entitled to receive a liquidation preference in the amount of $100 per share plus accumulated and unpaid dividends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier converted, each share of MCPS will automatically convert on June 1, 2023, subject to postponement for certain market disruption events, into between 2.3834 and 2.9197 shares of common stock, subject to customary anti-dilution adjustments. The number of shares of common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding June 1, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MCPS is not subject to any redemption, sinking fund or other similar provisions. However, at our option, we may purchase or exchange the MCPS from time to time in the open market, by tender or exchange offer or otherwise, without the consent of, or notice to, holders of MCPS. The holders of the MCPS will not have any voting rights, with limited exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared and we paid quarterly cash dividends of $14 million, or $1.3750 per MCPS share to holders, representing dividend periods through November 2022. On January 30, 2023, the Committee declared a cash dividend of $1.3750 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. We have presented cumulative, unpaid dividends within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated balance sheets as of December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs. Holders of common stock are junior to holders of MCPS in terms of liquidation preference. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 27, 2020, we completed an offering of 29,382,500 shares of common stock at a public offering price of $34.25 per share. The net proceeds from the common stock offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. We used a portion of the net proceeds from the May 27, 2020 MCPS and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">common stock offerings to repay remaining amounts outstanding under our previous term loan credit agreement that matured on April 20, 2021 and to pay related fees, expenses and premiums. The remaining proceeds were used for general corporate purposes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we repurchased approximately 15.7 million shares of our common stock pursuant to our 2013 share repurchase program for a total of approximately $535 million in cash, which represented the full amount remaining under the existing authorization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. We did not repurchase any shares of our common stock during 2022 and had the full amount available under the authorization as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were approximately 263 million shares in treasury as of December 31, 2022 and 2021.</span></div> 50000000 10062500 0.0550 100 975000000 1006000000.000 0.0550 100 100 2.3834 2.9197 14000000 1.3750 1.3750 2000000000 0.01 29382500 34.25 975000000 15700000 535000000 1000000000 263000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE K – STOCK INCENTIVE AND PURCHASE PLANS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee and Director Stock Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Board of Directors and stockholders approved amendments to our 2011 Long-Term Incentive Plan effective October 1, 2020 (Amended and Restated 2011 LTIP), authorizing for issuance up to 171 million shares of our common stock. The Amended and Restated 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, restricted stock units (RSUs), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based RSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 175 million as of December 31, 2022. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the Amended and Restated 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards (RSAs), RSUs and deferred stock units (DSUs) issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the impact of stock-based compensation on our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - assuming dilution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Black-Scholes Assumptions</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years, weighted)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Term</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk-Free Interest Rate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expected Dividend Yield</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not historically paid cash dividends on our common stock and currently we do not intend to pay cash dividends on our common stock. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to stock options under stock incentive plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,674 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $72 million in 2022, $137 million in 2021 and $84 million in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Vested Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value RSAs, RSUs and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Award Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt">The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vesting date fair value of shares that vested was approximately $150 million in 2022, $148 million in 2021 and $172 million in 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based RSU and DSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we granted market-based RSU awards, and in 2020, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&amp;P 500 Healthcare Index over a three-year performance period. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based RSU's and DSUs that satisfied the market performance criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price on date of grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Cash Flow Performance-based RSU and DSU Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we granted free-cash flow performance-based RSU awards, and in 2020, we granted free-cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based RSUs and DSUs is based on our adjusted free cash flow (AFCF) measured against our goal set by the Executive Compensation and Human Resources Committees of our Board of Directors, based on our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of each year and ending December 31st. The number of RSUs and DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based RSUs and DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, in general, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based RSUs and DSUs that satisfied the performance criteria. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 AFCF</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, net of forfeitures to date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achievement of target payout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year-end stock price used in determining fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expense Attribution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation – Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately five percent to all unvested stock-based awards as of December 31, 2022, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Compensation Cost</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize the following future expense for awards outstanding as of December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Cost</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an additional 10 million shares that may be issued under our global employee stock purchase plan. Our global employee stock purchase plan now provides for the granting of options to purchase up to 60 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2022, there were approximately 11 million shares available for future issuance under the employee stock purchase plan. We temporarily suspended our global employee stock purchase plan for the offering period for the second half of 2020 due to cost-savings initiatives in response to the COVID-19 pandemic and resumed the plan beginning with the offering period for the first half of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued or to be issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of purchase prices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 171000000 175000000 0.10 1.10 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the impact of stock-based compensation on our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact per common share - assuming dilution</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12000000 11000000 9000000 167000000 147000000 130000000 41000000 36000000 30000000 220000000 194000000 170000000 32000000 29000000 28000000 188000000 165000000 142000000 0.13 0.12 0.10 0.13 0.12 0.10 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Black-Scholes Assumptions</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years, weighted)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72%</span></td></tr></table> 3287000 3822000 3819000 44.02 37.69 41.79 13.64 10.77 10.44 0.28 0.29 0.23 P6Y1M6D P5Y10M24D P5Y9M18D 0.0142 0.0387 0.0066 0.0120 0.0027 0.0172 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to stock options under stock incentive plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,674 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 23065000 19 3819000 42 3096000 13 666000 27 23122000 24 3822000 38 4796000 13 699000 26 21448000 29 3287000 44 2745000 17 502000 34 21489000 32 P5Y10M24D 297000000 13674000 27 P4Y7M6D 258000000 7535000 41 P8Y2M12D 38000000 21209000 32 P5Y10M24D 296000000 72000000 137000000 84000000 Information related to non-vested stock awards is as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Award Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date <br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.43pt">The number of shares vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div> 11079000 29 3609000 41 4147000 25 554000 34 9987000 34 4240000 39 3823000 31 658000 36 9745000 37 3854000 45 3482000 36 680000 44 9438000 41 150000000 148000000 172000000 0 2 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the market-based RSU and DSU awards to be approximately $12 million for 2022, $11 million for 2021 and $8 million for 2020. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price on date of grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 12000000 11000000 8000000 44.19 37.50 42.16 P2Y10M24D P2Y10M24D P2Y10M24D 0.0171 0.0020 0.0137 0 1.50 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 AFCF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 AFCF</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, net of forfeitures to date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achievement of target payout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year-end stock price used in determining fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7000000 12000000 6000000 0.88 1.31 0.89 46.27 42.48 35.95 0.05 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize the following future expense for awards outstanding as of December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Cost</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock awards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div> 38000000 181000000 219000000 P1Y8M12D 10000000 60000000 0.10 0.85 11000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.919%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued or to be issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of purchase prices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="7" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2850000 2578000 1387000 31.68 32.31 29.98 36.11 29.84 28000000 24000000 10000000 <div style="margin-top:20pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE L – WEIGHTED AVERAGE SHARES OUTSTANDING</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,439.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,433.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,416.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> position in this period.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - assuming dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reduced by cumulative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as presented in our consolidated statements of operations, for purposes of calculating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) available to common stockholders</span>. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,439.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,433.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,416.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1430500000 1422300000 1416700000 9200000 11500000 0 1439700000 1433800000 1416700000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of weighted average shares outstanding - assuming dilution because their effect in the periods presented below would have been antidilutive:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock equivalents pursuant to our employee stock-based compensation plans, which are anti-dilutive in 2020 due to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> position in this period.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div> 14000000 6000000 3000000 6000000 24000000 24000000 14000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE M – SEGMENT REPORTING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve, and, in particular, benefit our Cardiology customers and patients. Following the reorganization, we have aggregated our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our consolidated statements of operations and are included in the reconciliation below. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note N – Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for net sales by reportable segment presented in accordance with U.S. GAAP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,828 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,756 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income of reportable segments as a percentage of net sales of reportable segments</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying consolidated statements of operations is as follows (in millions, except percentages). We have revised prior periods to conform to the current year presentation.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,057 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,828 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,756 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5057000000 4616000000 3844000000 8161000000 7212000000 5913000000 13218000000 11828000000 9756000000 -60000000 13000000 219000000 -476000000 47000000 -65000000 12682000000 11888000000 9913000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div> 1625000000 1524000000 1156000000 2113000000 1888000000 1043000000 3737000000 3412000000 2198000000 -436000000 -406000000 -424000000 -789000000 -1070000000 -1208000000 803000000 741000000 789000000 -60000000 4000000 143000000 1649000000 1199000000 -80000000 -508000000 -123000000 1000000 1141000000 1076000000 -79000000 <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income of reportable segments as a percentage of net sales of reportable segments</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.321 0.330 0.301 0.259 0.262 0.176 88000000 91000000 90000000 245000000 261000000 240000000 333000000 352000000 330000000 0 0 3000000 333000000 352000000 333000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2501000000 2178000000 5205000000 4417000000 7706000000 6595000000 12920000000 11988000000 5902000000 6121000000 5941000000 7525000000 32469000000 32229000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1241000000 1190000000 478000000 436000000 246000000 185000000 481000000 440000000 2446000000 2252000000 12920000000 11988000000 5902000000 6121000000 386000000 435000000 21653000000 20795000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE N – REVENUE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,396</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,866</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,701</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M – Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying consolidated balance sheets. Our deferred revenue balance was $509 million as of December 31, 2022 and $484 million as of December 31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $156 million in 2022 that was included in the above contract liability balance as of December 31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, we recorded $179 million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX™ Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on our accounting policies relating to revenue recognition.</span></div> The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,396</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,866</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,911</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,701</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M – Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,913</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.</span></div> 1341000000 880000000 2221000000 1222000000 919000000 2141000000 1000000000 780000000 1780000000 1257000000 516000000 1773000000 1120000000 463000000 1583000000 918000000 368000000 1286000000 715000000 202000000 917000000 713000000 196000000 909000000 610000000 151000000 761000000 3312000000 1599000000 4911000000 3055000000 1578000000 4633000000 2528000000 1299000000 3827000000 744000000 1485000000 2228000000 778000000 1431000000 2209000000 728000000 1247000000 1975000000 915000000 103000000 1019000000 729000000 100000000 829000000 253000000 71000000 324000000 1337000000 763000000 2100000000 1214000000 805000000 2019000000 992000000 712000000 1704000000 275000000 310000000 585000000 128000000 237000000 365000000 118000000 169000000 287000000 3271000000 2662000000 5932000000 2850000000 2572000000 5422000000 2091000000 2199000000 4290000000 1048000000 850000000 1899000000 996000000 824000000 1820000000 888000000 689000000 1577000000 4319000000 3512000000 7831000000 3846000000 3396000000 7242000000 2979000000 2888000000 5866000000 0 0 -60000000 10000000 4000000 13000000 193000000 27000000 219000000 7632000000 5111000000 12682000000 6911000000 4978000000 11888000000 5701000000 4212000000 9913000000 7632000000 6901000000 5508000000 2526000000 2518000000 2097000000 2116000000 2070000000 1781000000 469000000 386000000 307000000 -60000000 13000000 219000000 12682000000 11888000000 9913000000 1715000000 1429000000 1138000000 20 509000000 484000000 156000000 179000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE O – CHANGES IN OTHER COMPREHENSIVE INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on our net investment hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our cash flow hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss), net of tax</span> were reduced by immaterial income tax impacts in 2022 and in 2021. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 93000000 206000000 36000000 263000000 -86000000 214000000 36000000 163000000 -8000000 150000000 1000000 -157000000 -94000000 63000000 -37000000 6000000 -1000000 269000000 -1000000 269000000 218000000 36000000 47000000 207000000 12000000 208000000 8000000 228000000 -137000000 38000000 3000000 -173000000 -125000000 170000000 -11000000 56000000 93000000 206000000 36000000 263000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE P – NEW ACCOUNTING PRONOUNCEMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements. During 2022, we implemented the following standards, which did not have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2021-05</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB issued ASC Update No. 2021-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-06</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the FASB issued ASC Update No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standards to be Implemented</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities— Supplier Finance Programs (Subtopic 405-50). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncements, issued or effective in the period had or are expected to have a material impact on our consolidated financial statements.</span></div> ASC Update No. 2021-05<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB issued ASC Update No. 2021-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments</span>. The amendments in Update No. 2021-05 revise lessor lease classification guidance and require accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a day-one loss. Update No. 2021-05 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We adopted Update No. 2021-05 in the first quarter of 2022 on a prospective basis. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-06</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the FASB issued ASC Update No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-06 defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, in order to align with the March 2021 U.K. Financial Conduct Authority announcement that updated the intended cessation date of all currencies and tenors of the London Interbank Offered Rate (LIBOR) to June 30, 2023. Update No. 2022-06 was effective immediately at issuance.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. Update No. 2022-01 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the corresponding period. We do not expect the adoption to have a material impact on our financial position or results of operations.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326: Troubled Debt Restructurings and Vintage Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-02 makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. Update No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Update No. 2022-02 should be applied prospectively, with the option of modified retrospective adoption for the recognition and measurement of troubled debt restructurings. Early adoption is permitted on any date on or after the issuance of this update for any entity that has adopted the amendments in Update No. 2016-13. We do not expect the adoption to have a material impact on our financial position or results of operations.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance and the amendments in this update should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities— Supplier Finance Programs (Subtopic 405-50). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-04 enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. Update No. </span>2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on the newly required roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted and should be applied retrospectively to each period in which a balance sheet is presented, except for the amendment on roll forward information, which should be applied prospectively. We do not expect the adoption to have a material impact on our financial position or results of operations. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE Q – EMPLOYEE RETIREMENT PLANS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and other key contributors. Participants may retire with benefits once retirement conditions have been satisfied. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our 2019 acquisition of BTG plc. (BTG), we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom employees. During the second quarter of 2022, we transferred the benefit obligation and associated assets of the pension plan to third party insurers, and as a result, were relieved from primary responsibility of the benefit obligation and the related plan assets. The transaction did not have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other International Retirement Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we maintain retirement plans covering certain international employees. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2022 and 2021, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded<br/>PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the PBO for our retirement plans is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments and assumption changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:42.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.155%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2021 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For our defined benefit plans, excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-in contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the U.K. Plan Level 3 assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Buy-in Contracts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are estimated based on the same assumptions used in determining our benefit obligation as of December 31, 2022. Actual benefit payments will depend on future employment and compensation, average years employed and average life spans, in addition to other factors. Changes in any of these factors could significantly impact these estimated future benefit payments. Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Retirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span>. The outstanding obligation is as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded<br/>PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:44.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">in millions)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligation (ABO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected<br/>Benefit<br/>Obligation (PBO)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded/Underfunded PBO Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 50000000 55000000 0 55000000 140000000 152000000 101000000 51000000 190000000 207000000 101000000 105000000 56000000 59000000 0 59000000 209000000 209000000 205000000 3000000 214000000 234000000 130000000 103000000 478000000 502000000 336000000 166000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the PBO for our retirement plans is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments and assumption changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 502000000 532000000 0 4000000 13000000 17000000 3000000 3000000 -54000000 -7000000 191000000 0 -25000000 -6000000 6000000 22000000 -37000000 -20000000 207000000 502000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:42.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.155%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions associated with our employee retirement plans for 2021 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Expected Return</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Rate of Compensation Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Rates of compensation increase were not weighted by relative fair value. As such, the amount represents the median of the inputs and is not a weighted average.</span></div> 0.0532 0.0200 0.0262 0.0227 0.0300 0.0240 0.0150 0.0070 0.0070 0.0082 0.0216 0.0260 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the transfer, the U.K. Plan utilized the insurance buy-in methodology and based its discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2021. We believed this to be a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate was calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assumed that all pension increases would continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which would be based on Consumer Price Inflation (CPI). We based our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy was to invest in fully matching assets. This was achieved through the purchase of two buy-in policies (Buy-in contracts), which provided payments designed to equal all future benefit payments due from the fund. As of December 31, 2021, the Buy-in contracts represented 100 percent of the total plan assets, as compared to the target percentage of 100 percent, and are considered Level 3 investments.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-in contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the U.K. Plan Level 3 assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Buy-in Contracts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments/settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 336000000 355000000 0 1000000 -2000000 5000000 16000000 12000000 1000000 2000000 185000000 0 -25000000 -4000000 9000000 22000000 -32000000 -13000000 101000000 336000000 0 0 205000000 205000000 0 0 205000000 205000000 205000000 0 1000000 160000000 -24000000 2000000 -22000000 0 Benefit payments expected to be paid during the next ten years for our Domestic Retirement Plans and our Other International Retirement Plans are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Retirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 15000000 8000000 13000000 14000000 14000000 70000000 We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $123 million in 2022, $118 million in 2021 and $102 million in 2020. 123000000 118000000 102000000 42 <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:36.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/> Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative effect adjustment for adoption of ASU 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit loss exposure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Write-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at<br/>End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for credit losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for uncollectible accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents actual write-offs of uncollectible accounts.</span></div> 108000000 35000000 35000000 109000000 105000000 28000000 25000000 108000000 74000000 49000000 27000000 105000000 EXCEL 123 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 125 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 126 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 498 641 1 false 137 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://www.bostonscientific.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.bostonscientific.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Operations Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheets Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 0000006 - Statement - Consolidated Balance Sheet Paranthetical Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical Consolidated Balance Sheet Paranthetical Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure) Statements 9 false false R10.htm 0000010 - Disclosure - Significant Accounting Policies Sheet http://www.bostonscientific.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Acquisitions and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments Acquisitions and Strategic Investments Notes 11 false false R12.htm 0000012 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 12 false false R13.htm 0000013 - Disclosure - Hedging Activities and Fair Value Measurements Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements Hedging Activities and Fair Value Measurements Notes 13 false false R14.htm 0000014 - Disclosure - Contractual Obligations and Commitments Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitments Contractual Obligations and Commitments Notes 14 false false R15.htm 0000015 - Disclosure - Leases Sheet http://www.bostonscientific.com/role/Leases Leases Notes 15 false false R16.htm 0000016 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 0000019 - Disclosure - Stockholders' Equity Sheet http://www.bostonscientific.com/role/StockholdersEquity Stockholders' Equity Notes 19 false false R20.htm 0000020 - Disclosure - Stock Inventive and Purchase Plans Sheet http://www.bostonscientific.com/role/StockInventiveandPurchasePlans Stock Inventive and Purchase Plans Notes 20 false false R21.htm 0000021 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 21 false false R22.htm 0000022 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 0000023 - Disclosure - Revenue Sheet http://www.bostonscientific.com/role/Revenue Revenue Notes 23 false false R24.htm 0000024 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 24 false false R25.htm 0000025 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 25 false false R26.htm 0000026 - Disclosure - Employee Retirement Plans (Notes) Notes http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes Employee Retirement Plans (Notes) Notes 26 false false R27.htm 0000027 - Disclosure - Schedule II Sheet http://www.bostonscientific.com/role/ScheduleII Schedule II Notes 27 false false R28.htm 0000028 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies) Sheet http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies Significant Accounting Policies Significant Accounting Policies (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 28 false false R29.htm 0000029 - Disclosure - Fair Value Measures and Disclosures (Policies) Sheet http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies Fair Value Measures and Disclosures (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 29 false false R30.htm 0000030 - Disclosure - Commitment and Contingencies (Policies) Sheet http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies Commitment and Contingencies (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 30 false false R31.htm 0000031 - Disclosure - New Accounting Pronouncements (Policies) Sheet http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies New Accounting Pronouncements (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 31 false false R32.htm 0000032 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies Employee Retirement Plans Employee Retirement Plans (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 32 false false R33.htm 0000034 - Disclosure - Acquisitions and Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables Acquisitions and Strategic Investments (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments 33 false false R34.htm 0000035 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) Tables 34 false false R35.htm 0000036 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables Hedging Activities and Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements 35 false false R36.htm 0000037 - Disclosure - Contractual Obligations and Commitments (Tables) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables Contractual Obligations and Commitments (Tables) Tables http://www.bostonscientific.com/role/ContractualObligationsandCommitments 36 false false R37.htm 0000038 - Disclosure - Leases (Tables) Sheet http://www.bostonscientific.com/role/LeasesTables Leases (Tables) Tables http://www.bostonscientific.com/role/Leases 37 false false R38.htm 0000039 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 38 false false R39.htm 0000040 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 39 false false R40.htm 0000041 - Disclosure - Stock Incentive and Purchase Plans (Tables) Sheet http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables Stock Incentive and Purchase Plans (Tables) Tables 40 false false R41.htm 0000042 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 41 false false R42.htm 0000043 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 42 false false R43.htm 0000044 - Disclosure - Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueTables Revenue (Tables) Tables http://www.bostonscientific.com/role/Revenue 43 false false R44.htm 0000045 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome 44 false false R45.htm 0000046 - Disclosure - Employee Retirement Plans (Tables) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansTables Employee Retirement Plans (Tables) Tables http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes 45 false false R46.htm 0000047 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details) Sheet http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails Significant Accounting Policies Significant Accounting Policies (Details) Details http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies 46 false false R47.htm 0000048 - Disclosure - Acquisitions and Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails Acquisitions and Strategic Investments (Details) Details http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables 47 false false R48.htm 0000049 - Disclosure - Contingent Consideration (Details) Sheet http://www.bostonscientific.com/role/ContingentConsiderationDetails Contingent Consideration (Details) Details 48 false false R49.htm 0000050 - Disclosure - Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/StrategicInvestmentsDetails Strategic Investments (Details) Details 49 false false R50.htm 0000051 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables 50 false false R51.htm 0000052 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details 51 false false R52.htm 0000053 - Disclosure - Contractual Obligations and Commitments (Details) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails Contractual Obligations and Commitments (Details) Details http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables 52 false false R53.htm 0000054 - Disclosure - Leases (Details) Sheet http://www.bostonscientific.com/role/LeasesDetails Leases (Details) Details http://www.bostonscientific.com/role/LeasesTables 53 false false R54.htm 0000055 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 54 false false R55.htm 0000056 - Disclosure - Income Taxes (Details - Rate Table) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable Income Taxes (Details - Rate Table) Details http://www.bostonscientific.com/role/IncomeTaxesTables 55 false false R56.htm 0000057 - Disclosure - Income Taxes Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails Income Taxes Income Taxes (Details) Details 56 false false R57.htm 0000058 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsandContingencies 57 false false R58.htm 0000059 - Disclosure - Stockholders' Equity (Details) Sheet http://www.bostonscientific.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.bostonscientific.com/role/StockholdersEquity 58 false false R59.htm 0000060 - Disclosure - Stock Incentive and Purchase Plans (Details) Sheet http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails Stock Incentive and Purchase Plans (Details) Details http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables 59 false false R60.htm 0000061 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 60 false false R61.htm 0000062 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 61 false false R62.htm 0000063 - Disclosure - Revenue (Details) Sheet http://www.bostonscientific.com/role/RevenueDetails Revenue (Details) Details http://www.bostonscientific.com/role/RevenueTables 62 false false R63.htm 0000064 - Disclosure - Changes in Other Comprehensive Income (Details) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails Changes in Other Comprehensive Income (Details) Details http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables 63 false false R64.htm 0000065 - Disclosure - Employee Retirement Plans (Details) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails Employee Retirement Plans (Details) Details http://www.bostonscientific.com/role/EmployeeRetirementPlansTables 64 false false R65.htm 0000066 - Disclosure - Schedule II (Details) Sheet http://www.bostonscientific.com/role/ScheduleIIDetails Schedule II (Details) Details http://www.bostonscientific.com/role/ScheduleII 65 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate - bsx-20221231.htm 4 bsx-20221231.htm bsx-20221231.xsd bsx-20221231_cal.xml bsx-20221231_def.xml bsx-20221231_lab.xml bsx-20221231_pre.xml ex1055-2020grantxnqagreeme.htm ex1056-2020grantxrsuagreem.htm ex1057-2020grantxrsabodawa.htm ex1058-2020grantxdsubodawa.htm ex1065-2021grantxnqagreeme.htm ex1066-2021grantxrsuagreem.htm ex1067-2021grantxtsragreem.htm ex1068-2021grantxfcfagreem.htm ex1069-2021grantxrsabodawa.htm ex1070-2021grantxrsubodawa.htm ex1072-amendmentto2021revo.htm ex1076-2022grantxnqagreeme.htm ex1077-2022grantxrsuagreem.htm ex1078-2022grantxtsragreem.htm ex1079-2022grantxfcfagreem.htm ex1080-2022grantxrsabodawa.htm ex1081-2022grantxrsubodawa.htm ex1083-offerletterartbutch.htm ex1084-offerletterjeffmirv.htm ex1085-arnonxemployeedirec.htm exhibit21-listofsubsidiari.htm exhibit23-2022eyconsent.htm exhibit311-ceo302202210xk.htm exhibit312-cfo302202210xk.htm exhibit321-ceo906202210xk.htm exhibit322-cfo906202210xk.htm bsx-20221231_g1.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 129 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bsx-20221231.htm": { "axisCustom": 1, "axisStandard": 32, "baseTaxonomies": { "http://fasb.org/srt/2021-01-31": 2, "http://fasb.org/us-gaap/2021-01-31": 1793, "http://xbrl.sec.gov/dei/2021q4": 43 }, "contextCount": 498, "dts": { "calculationLink": { "local": [ "bsx-20221231_cal.xml" ] }, "definitionLink": { "local": [ "bsx-20221231_def.xml" ] }, "inline": { "local": [ "bsx-20221231.htm" ] }, "labelLink": { "local": [ "bsx-20221231_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20221231_pre.xml" ] }, "schema": { "local": [ "bsx-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 970, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 11 }, "keyCustom": 102, "keyStandard": 539, "memberCustom": 80, "memberStandard": 51, "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.bostonscientific.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.bostonscientific.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Acquisitions and Strategic Investments", "menuCat": "Notes", "order": "11", "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments", "shortName": "Acquisitions and Strategic Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "ie694fa78bfaf418ea29ff3377d47a961_D20210806-20210806", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Goodwill and Other Intangible Assets", "menuCat": "Notes", "order": "12", "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Hedging Activities and Fair Value Measurements", "menuCat": "Notes", "order": "13", "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements", "shortName": "Hedging Activities and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Contractual Obligations and Commitments", "menuCat": "Notes", "order": "14", "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitments", "shortName": "Contractual Obligations and Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Leases", "menuCat": "Notes", "order": "15", "role": "http://www.bostonscientific.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Supplemental Balance Sheet Information", "menuCat": "Notes", "order": "16", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation", "shortName": "Supplemental Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "17", "role": "http://www.bostonscientific.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "18", "role": "http://www.bostonscientific.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "19", "role": "http://www.bostonscientific.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.bostonscientific.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Stock Inventive and Purchase Plans", "menuCat": "Notes", "order": "20", "role": "http://www.bostonscientific.com/role/StockInventiveandPurchasePlans", "shortName": "Stock Inventive and Purchase Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Weighted Average Shares Outstanding", "menuCat": "Notes", "order": "21", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding", "shortName": "Weighted Average Shares Outstanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "22", "role": "http://www.bostonscientific.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Revenue", "menuCat": "Notes", "order": "23", "role": "http://www.bostonscientific.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Changes in Other Comprehensive Income", "menuCat": "Notes", "order": "24", "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome", "shortName": "Changes in Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:NewAccountingPronouncementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - New Accounting Pronouncements", "menuCat": "Notes", "order": "25", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements", "shortName": "New Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:NewAccountingPronouncementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Employee Retirement Plans (Notes)", "menuCat": "Notes", "order": "26", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes", "shortName": "Employee Retirement Plans (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i63c80cf97e92455e89254f71abde961e_D20180101-20181231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Schedule II", "menuCat": "Notes", "order": "27", "role": "http://www.bostonscientific.com/role/ScheduleII", "shortName": "Schedule II", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i63c80cf97e92455e89254f71abde961e_D20180101-20181231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "28", "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Fair Value Measures and Disclosures (Policies)", "menuCat": "Policies", "order": "29", "role": "http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies", "shortName": "Fair Value Measures and Disclosures (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "3", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "id3c92b44387a41f7a1514e03a3b9733c_D20221001-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Commitment and Contingencies (Policies)", "menuCat": "Policies", "order": "30", "role": "http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies", "shortName": "Commitment and Contingencies (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "bsx:NewAccountingPronouncementsPolicyTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo202010CodificationImprovementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - New Accounting Pronouncements (Policies)", "menuCat": "Policies", "order": "31", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies", "shortName": "New Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "bsx:NewAccountingPronouncementsPolicyTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo202010CodificationImprovementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies)", "menuCat": "Policies", "order": "32", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies", "shortName": "Employee Retirement Plans Employee Retirement Plans (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Acquisitions and Strategic Investments (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "shortName": "Acquisitions and Strategic Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables", "shortName": "Hedging Activities and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Contractual Obligations and Commitments (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables", "shortName": "Contractual Obligations and Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.bostonscientific.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Supplemental Balance Sheet Information (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables", "shortName": "Supplemental Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.bostonscientific.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "menuCat": "Statements", "order": "4", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Stock Incentive and Purchase Plans (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables", "shortName": "Stock Incentive and Purchase Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Weighted Average Shares Outstanding (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables", "shortName": "Weighted Average Shares Outstanding (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "42", "role": "http://www.bostonscientific.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "43", "role": "http://www.bostonscientific.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Changes in Other Comprehensive Income (Tables)", "menuCat": "Tables", "order": "44", "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables", "shortName": "Changes in Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementPlansPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Employee Retirement Plans (Tables)", "menuCat": "Tables", "order": "45", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables", "shortName": "Employee Retirement Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementPlansPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details)", "menuCat": "Details", "order": "46", "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i4ce8949302fd45a289a81b01d928d53a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProductionRelatedImpairmentsOrCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Acquisitions and Strategic Investments (Details)", "menuCat": "Details", "order": "47", "role": "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "shortName": "Acquisitions and Strategic Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "ib279fd9ff9e24cabbeea019d2dce793a_I20210301", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Contingent Consideration (Details)", "menuCat": "Details", "order": "48", "role": "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "shortName": "Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "ibc9e93fb57d049aba15e55858f4ab28e_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Strategic Investments (Details)", "menuCat": "Details", "order": "49", "role": "http://www.bostonscientific.com/role/StrategicInvestmentsDetails", "shortName": "Strategic Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "5", "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PrepaidTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Goodwill and Other Intangible Assets (Details)", "menuCat": "Details", "order": "50", "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Fair Value Measurements (Details)", "menuCat": "Details", "order": "51", "role": "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Contractual Obligations and Commitments (Details)", "menuCat": "Details", "order": "52", "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "shortName": "Contractual Obligations and Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i8722c1d4d5cd4a7f9e485658e623e39d_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "53", "role": "http://www.bostonscientific.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Supplemental Balance Sheet Information (Details)", "menuCat": "Details", "order": "54", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails", "shortName": "Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Income Taxes (Details - Rate Table)", "menuCat": "Details", "order": "55", "role": "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable", "shortName": "Income Taxes (Details - Rate Table)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Income Taxes Income Taxes (Details)", "menuCat": "Details", "order": "56", "role": "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "shortName": "Income Taxes Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "57", "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "58", "role": "http://www.bostonscientific.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i182a1036891e4f75bb208c20f52223a2_I20201214", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bsx:Fairvalueofmarketbasedawards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Stock Incentive and Purchase Plans (Details)", "menuCat": "Details", "order": "59", "role": "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "shortName": "Stock Incentive and Purchase Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bsx:Fairvalueofmarketbasedawards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Balance Sheet Paranthetical", "menuCat": "Statements", "order": "6", "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "shortName": "Consolidated Balance Sheet Paranthetical", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Weighted Average Shares Outstanding (Details)", "menuCat": "Details", "order": "60", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "shortName": "Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportablesegments", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Segment Reporting (Details)", "menuCat": "Details", "order": "61", "role": "http://www.bostonscientific.com/role/SegmentReportingDetails", "shortName": "Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportablesegments", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "bsx:EmergingMarketsTotalNumberOfCountries", "reportCount": 1, "unique": true, "unitRef": "countries", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Revenue (Details)", "menuCat": "Details", "order": "62", "role": "http://www.bostonscientific.com/role/RevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "bsx:EmergingMarketsTotalNumberOfCountries", "reportCount": 1, "unique": true, "unitRef": "countries", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Changes in Other Comprehensive Income (Details)", "menuCat": "Details", "order": "63", "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "shortName": "Changes in Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Employee Retirement Plans (Details)", "menuCat": "Details", "order": "64", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "shortName": "Employee Retirement Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i8722c1d4d5cd4a7f9e485658e623e39d_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Schedule II (Details)", "menuCat": "Details", "order": "65", "role": "http://www.bostonscientific.com/role/ScheduleIIDetails", "shortName": "Schedule II (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i87a7639e46664d8fa457ee6d81350081_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i5b0b26deeb85428db3cd49a32a784be2_I20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "7", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i5b0b26deeb85428db3cd49a32a784be2_I20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i1b040767773e4f94a046df2b061c0e48_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i768fc9449917456fa6ad3dc07b48a7de_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure)", "menuCat": "Statements", "order": "9", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure", "shortName": "Consolidated Statements of Cash Flows Consolidated Statement of Cash Flows (Supplemental Disclosure)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20221231.htm", "contextRef": "i87a7639e46664d8fa457ee6d81350081_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 137, "tag": { "bsx_A2011LtipPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2011 LTIP Plan [Member]", "label": "2011 LTIP Plan [Member]", "terseLabel": "2011 LTIP Plan [Member]" } } }, "localname": "A2011LtipPlanMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "domainItemType" }, "bsx_A2021AcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Acquisitions", "label": "2021 Acquisitions [Member]", "terseLabel": "2021 Acquisitions" } } }, "localname": "A2021AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_A550MCPSSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.50% MCPS, Series A", "label": "5.50% MCPS, Series A [Member]", "terseLabel": "5.50% MCPS, Series A [Member]" } } }, "localname": "A550MCPSSeriesAMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/Cover", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "bsx_ASCUpdateNo202010CodificationImprovementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2020-10 Codification Improvements", "label": "ASC Update No. 2020-10 Codification Improvements [Policy Text Block]", "terseLabel": "ASC Update No. 2020-10 Codification Improvements" } } }, "localname": "ASCUpdateNo202010CodificationImprovementsPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method", "label": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method [Policy Text Block]", "terseLabel": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method" } } }, "localname": "ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)", "label": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) [Policy Text Block]", "terseLabel": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)" } } }, "localname": "ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.", "label": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. [Policy Text Block]", "terseLabel": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions." } } }, "localname": "ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)", "label": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) [Policy Text Block]", "terseLabel": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)" } } }, "localname": "ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848", "label": "ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 [Policy Text Block]", "terseLabel": "ASC Update No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848" } } }, "localname": "ASCUpdateNo202206ReferenceRateReformTopic848DeferralOfTheSunsetDateOfTopic848PolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_AccruedRebatesCurrent": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Rebates, Current", "label": "Accrued Rebates, Current", "terseLabel": "Accrued Rebates, Current" } } }, "localname": "AccruedRebatesCurrent", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_AcotecScientificHoldingsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acotec Scientific Holdings Limited", "label": "Acotec Scientific Holdings Limited [Member]", "terseLabel": "Acotec Scientific Holdings Limited" } } }, "localname": "AcotecScientificHoldingsLimitedMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_ActualCovenantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Actual Covenant.", "label": "Actual, Covenant [Member]", "terseLabel": "Actual, Covenant [Member]" } } }, "localname": "ActualCovenantMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_AllOther2021AcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other 2021 Acquisitions", "label": "All Other 2021 Acquisitions [Member]", "terseLabel": "All Other 2021 Acquisitions" } } }, "localname": "AllOther2021AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of employees total compensation eligible for GESOP purchase", "label": "Amount of employees total compensation eligible for GESOP purchase", "terseLabel": "Amount of employees total compensation eligible for GESOP purchase" } } }, "localname": "AmountOfEmployeesTotalCompensationEligibleForGesopPurchase", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_Annualweightedaverageforfeiturerate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends", "label": "annualweightedaverageforfeiturerate", "terseLabel": "annualweightedaverageforfeiturerate" } } }, "localname": "Annualweightedaverageforfeiturerate", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_ApolloEndosurgeryIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Apollo Endosurgery, Inc.", "label": "Apollo Endosurgery, Inc. [Member]", "terseLabel": "Apollo Endosurgery, Inc." } } }, "localname": "ApolloEndosurgeryIncMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "xbrltype": "stringItemType" }, "bsx_BSXReportableSegmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSX Reportable Segments", "label": "BSX Reportable Segments [Member]", "terseLabel": "BSX Reportable Segments" } } }, "localname": "BSXReportableSegmentsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_BaylisMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Baylis Medical", "label": "Baylis Medical [Member]", "terseLabel": "Baylis Medical" } } }, "localname": "BaylisMedicalMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "label": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "terseLabel": "Brazil CADE - # of individuals for alleged anti-competitive behavior" } } }, "localname": "BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]", "label": "Business Combination, Consideration Transferred, Additional Revenue Payment, period", "terseLabel": "Business Combination, Consideration Transferred, Additional Revenue Payment, period [Line Items]" } } }, "localname": "BusinessCombinationConsiderationTransferredAdditionalRevenuePaymentPeriod", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "durationItemType" }, "bsx_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High, Including Prior Interest", "label": "Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest", "terseLabel": "Business combination, contingent consideration arrangements, range of outcomes, value, high, including prior interest" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighIncludingPriorInterest", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_CardiacRhythmManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardiac Rhythm Management", "label": "Cardiac Rhythm Management [Member]", "terseLabel": "Cardiac Rhythm Management" } } }, "localname": "CardiacRhythmManagementMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_CardiovascularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardiovascular [Member]", "label": "Cardiovascular [Member]", "terseLabel": "Cardiovascular [Member]" } } }, "localname": "CardiovascularMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash flow impact of deferred income tax expense (benefit)", "label": "Cash flow impact of deferred income tax expense (benefit)", "terseLabel": "Deferred and prepaid income taxes" } } }, "localname": "CashFlowImpactOfDeferredIncomeTaxExpenseBenefit", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_CompensationExpensePerShareBasic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "compensation expense, per share - basic", "label": "compensation expense, per share - basic", "terseLabel": "compensation expense, per share - basic" } } }, "localname": "CompensationExpensePerShareBasic", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_CompensationExpensePerShareDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "compensation expense, per share - diluted", "label": "compensation expense, per share - diluted", "terseLabel": "compensation expense, per share - diluted" } } }, "localname": "CompensationExpensePerShareDiluted", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_ConsolidatedBSXDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated BSX", "label": "Consolidated BSX [Domain]", "terseLabel": "Consolidated BSX [Domain]" } } }, "localname": "ConsolidatedBSXDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_ConsolidatedBalanceSheetParentheticalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated Balance Sheet (Parenthetical)", "label": "Consolidated Balance Sheet (Parenthetical) [Abstract]" } } }, "localname": "ConsolidatedBalanceSheetParentheticalAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "xbrltype": "stringItemType" }, "bsx_ConsolidatedCashFlowSupplementalDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated Cash Flow Supplemental Disclosure [Abstract]", "label": "Consolidated Cash Flow Supplemental Disclosure [Abstract]", "terseLabel": "Consolidated Cash Flow Supplemental Disclosure [Abstract]" } } }, "localname": "ConsolidatedCashFlowSupplementalDisclosureAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "xbrltype": "stringItemType" }, "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "contingent consideration liability, probability of payment", "label": "contingent consideration liability, probability of payment", "terseLabel": "contingent consideration liability, probability of payment" } } }, "localname": "ContingentConsiderationLiabilityProbabilityOfPayment", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bsx_CorporateExpensesincludinghedgingactivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate Expenses including hedging activities [Member]", "label": "Corporate Expenses including hedging activities [Member]", "terseLabel": "Corporate Expenses including hedging activities [Member]" } } }, "localname": "CorporateExpensesincludinghedgingactivitiesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CovenantAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant.", "label": "Covenant [Axis]", "terseLabel": "Covenant [Axis]" } } }, "localname": "CovenantAxis", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "bsx_CovenantDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant.", "label": "Covenant [Domain]", "terseLabel": "Covenant [Domain]" } } }, "localname": "CovenantDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_December2027NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2027 Notes", "label": "December 2027 Notes [Member]", "terseLabel": "December 2027 Notes [Member]" } } }, "localname": "December2027NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_DeemedConsolidatedEBITDA": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deemed Consolidated EBITDA", "label": "Deemed Consolidated EBITDA", "terseLabel": "Deemed Consolidated EBITDA [Member]" } } }, "localname": "DeemedConsolidatedEBITDA", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DeferredTaxAssetsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets", "label": "Deferred tax assets [Domain]", "terseLabel": "Deferred tax assets [Domain]" } } }, "localname": "DeferredTaxAssetsDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Prepaid on Intercompany Profit", "label": "Deferred Tax Assets, Prepaid on Intercompany Profit", "terseLabel": "Deferred Tax Assets, Prepaid on Intercompany Profit" } } }, "localname": "DeferredTaxAssetsPrepaidonIntercompanyProfit", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DeferredTaxLiabilitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities", "label": "Deferred tax liabilities [Domain]", "terseLabel": "Deferred tax liabilities [Domain]" } } }, "localname": "DeferredTaxLiabilitiesDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Acquired and Established Plan Changes, PBO", "label": "Defined Benefit Plan, Acquired and Established Plan Changes, PBO", "terseLabel": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets" } } }, "localname": "DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets", "label": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets", "terseLabel": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets" } } }, "localname": "DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DefinedBenefitPlanPlanAssetsActuarialGainLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined benefit plan, plan assets, actuarial gain loss", "label": "Defined benefit plan, plan assets, actuarial gain loss", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)" } } }, "localname": "DefinedBenefitPlanPlanAssetsActuarialGainLoss", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return", "label": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return", "terseLabel": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return" } } }, "localname": "DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO", "terseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement, PBO" } } }, "localname": "DefinedBenefitPlanPlanAssetsPaymentForSettlementPBO", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]" } } }, "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DevoroMedicalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Devoro Medical, Inc.", "label": "Devoro Medical, Inc. [Member]", "terseLabel": "Devoro Medical, Inc." } } }, "localname": "DevoroMedicalIncMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_DiscountRateFairValueInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "terseLabel": "Discount Rate, Fair Value Input" } } }, "localname": "DiscountRateFairValueInput", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "bsx_DivestitureAgreementTransferOfFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divestiture, agreement, transfer of facilities", "label": "Divestiture, agreement, transfer of facilities", "terseLabel": "Divestiture, agreement, transfer of facilities" } } }, "localname": "DivestitureAgreementTransferOfFacilities", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "integerItemType" }, "bsx_DivestitureAgreementTransferOfGlobalEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divestiture, agreement, transfer of global employees", "label": "Divestiture, agreement, transfer of global employees", "terseLabel": "Divestiture, agreement, transfer of global employees" } } }, "localname": "DivestitureAgreementTransferOfGlobalEmployees", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "integerItemType" }, "bsx_EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers", "label": "Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers", "terseLabel": "Effective Income Tax Rate Reconciliation, Intra-entity intangible asset transfers" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIntraEntityIntangibleAssetTransfers", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "bsx_EffectiveIncomeTaxRateReconciliationReturnToProvision": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Return to provision", "label": "Effective Income Tax Rate Reconciliation, Return to provision", "terseLabel": "Effective Income Tax Rate Reconciliation, Return to provision" } } }, "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions", "label": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions", "terseLabel": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "bsx_ElectrophysiologyEPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Electrophysiology (EP)", "label": "Electrophysiology (EP) [Member]", "terseLabel": "Electrophysiology (EP)" } } }, "localname": "ElectrophysiologyEPMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_EmergingMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Markets [Member]", "label": "Emerging Markets [Member]", "terseLabel": "Emerging Markets [Member]" } } }, "localname": "EmergingMarketsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_EmergingMarketsTotalNumberOfCountries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Markets total number of countries", "label": "Emerging Markets total number of countries", "terseLabel": "Emerging Markets total number of countries" } } }, "localname": "EmergingMarketsTotalNumberOfCountries", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "integerItemType" }, "bsx_EquipmentFurnitureAndFixturesGross": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equipment, furniture and fixtures Gross.", "label": "Equipment, furniture and fixtures Gross", "terseLabel": "Equipment, furniture and fixtures" } } }, "localname": "EquipmentFurnitureAndFixturesGross", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_EuroDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro Denominated Factoring Arrangements [Member]", "label": "Euro Denominated Factoring Arrangements [Member]", "terseLabel": "Euro Denominated Factoring Arrangements [Member]" } } }, "localname": "EuroDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_ExclusionFromEbitdaForRestructuringCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exclusion from EBITDA for Restructuring Charges", "label": "Exclusion from EBITDA for Restructuring Charges", "verboseLabel": "Exclusion from EBITDA for Restructuring Charges" } } }, "localname": "ExclusionFromEbitdaForRestructuringCharges", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ExecutiveRetirementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive retirement plan [Member]", "label": "Executive retirement plan [Member]", "terseLabel": "Executive retirement plan [Member]" } } }, "localname": "ExecutiveRetirementPlanMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "domainItemType" }, "bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of the fair market value of our common stock on the date of grant", "label": "Exercise price of the fair market value of our common stock on the date of grant", "terseLabel": "Exercise price of the fair market value of our common stock on the date of grant" } } }, "localname": "Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_ExpenseRelatedToMatchingContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expense related to matching contributions", "label": "Expense related to matching contributions", "terseLabel": "Expense related to matching contributions" } } }, "localname": "ExpenseRelatedToMatchingContributions", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_FairValueOfFreeCashFlowFcfPerformanceAwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the Free Cash Flow (FCF) performance awards", "label": "Fair value of the Free Cash Flow (FCF) performance awards", "terseLabel": "Fair value of the Free Cash Flow (FCF) performance awards" } } }, "localname": "FairValueOfFreeCashFlowFcfPerformanceAwards", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Fairvalueofmarketbasedawards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of market based awards", "label": "Fair value of market based awards", "terseLabel": "Fair value of market based awards" } } }, "localname": "Fairvalueofmarketbasedawards", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_FarapulseIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Farapulse, Inc.", "label": "Farapulse, Inc. [Member]", "terseLabel": "Farapulse, Inc." } } }, "localname": "FarapulseIncMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_FarapulseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Farapulse", "label": "Farapulse [Member]", "terseLabel": "Farapulse" } } }, "localname": "FarapulseMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bsx_FederalBenefitOfUncertainTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Federal benefit of uncertain tax positions", "label": "Federal benefit of uncertain tax positions", "terseLabel": "Federal benefit of uncertain tax positions" } } }, "localname": "FederalBenefitOfUncertainTaxPositions", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ForeignCurrencyDenominatedInDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign currency denominated in debt", "label": "Foreign currency denominated in debt [Member]", "terseLabel": "Foreign currency denominated in debt [Member]" } } }, "localname": "ForeignCurrencyDenominatedInDebtMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ForwardCurrencyContractsTimetoMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forward Currency Contracts, Time to Maturity in Months", "label": "Forward Currency Contracts, Time to Maturity", "terseLabel": "Forward Currency Contracts, Time to Maturity" } } }, "localname": "ForwardCurrencyContractsTimetoMaturity", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "integerItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "stringItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "domainItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "stringItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "stringItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "bsx_FreeTradeZoneRegimeTaxIncentive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Free Trade Zone Regime Tax Incentive", "label": "Free Trade Zone Regime Tax Incentive", "terseLabel": "Free Trade Zone Regime Tax Incentive" } } }, "localname": "FreeTradeZoneRegimeTaxIncentive", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution", "label": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution", "terseLabel": "Free Trade Zone Regime Tax Incentive, impact on Net income (loss) per common share - assuming dilution" } } }, "localname": "FreeTradeZoneRegimeTaxIncentiveImpactOnNetIncomeLossPerCommonShareAssumingDilution", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "perShareItemType" }, "bsx_GlobalCardiologyReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Cardiology Reporting Unit [Member]", "label": "Global Cardiology Reporting Unit [Member]", "terseLabel": "Global Cardiology Reporting Unit" } } }, "localname": "GlobalCardiologyReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)", "label": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)", "terseLabel": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)" } } }, "localname": "GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_GlobalEndoscopyEndoReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]", "label": "Global Endoscopy (Endo) Reporting Unit [Member]", "terseLabel": "Global Endoscopy (Endo) Reporting Unit [Member]" } } }, "localname": "GlobalEndoscopyEndoReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalNeuromodulationNmReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]", "label": "Global Neuromodulation (NM) Reporting Unit [Member]", "terseLabel": "Global Neuromodulation (NM) Reporting Unit [Member]" } } }, "localname": "GlobalNeuromodulationNmReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "terseLabel": "Global Peripheral Interventions (PI) Reporting Unit [Member]" } } }, "localname": "GlobalPeripheralInterventionsPiReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]", "label": "Global Urology and Pelvic Health Reporting Unit [Member]", "terseLabel": "Global Urology and Pelvic Health Reporting Unit [Member]" } } }, "localname": "GlobalUrologyandPelvicHealthReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GoodwillTextualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill (Textuals) [Abstract]", "label": "Goodwill (Textuals) [Abstract]", "terseLabel": "Goodwill (Roll Forward)" } } }, "localname": "GoodwillTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Impact of foreign currency fluctuations on net sales", "label": "Impact of foreign currency fluctuations on net sales", "terseLabel": "Impact of foreign currency fluctuations on net sales" } } }, "localname": "ImpactOfForeignCurrencyFluctuationsOnNetSales", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Taxes [Abstract]", "label": "Income Taxes [Abstract]", "terseLabel": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "xbrltype": "stringItemType" }, "bsx_IndemnificationAsset": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indemnification asset", "label": "Indemnification asset", "terseLabel": "Indemnification asset" } } }, "localname": "IndemnificationAsset", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_InternationalRetirementPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International retirement plans [Member]", "label": "International retirement plans [Member]", "terseLabel": "International retirement plans [Member]" } } }, "localname": "InternationalRetirementPlansMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "domainItemType" }, "bsx_InterventionalCardiologyTherapiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interventional Cardiology Therapies", "label": "Interventional Cardiology Therapies [Member]", "terseLabel": "Interventional Cardiology Therapies" } } }, "localname": "InterventionalCardiologyTherapiesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_InventoryStepUpAmortization": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory Step Up Amortization", "label": "InventoryStepUpAmortization", "terseLabel": "Inventory step-up amortization" } } }, "localname": "InventoryStepUpAmortization", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_January2040NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2040 Notes [Member]", "label": "January 2040 Notes [Member]", "terseLabel": "January 2040 Notes [Member]" } } }, "localname": "January2040NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_June2025NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2025 Notes", "label": "June 2025 Notes [Member]", "terseLabel": "June 2025 Notes [Member]" } } }, "localname": "June2025NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_June2030NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2030 Notes", "label": "June 2030 Notes [Member]", "terseLabel": "June 2030 Notes [Member]" } } }, "localname": "June2030NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_LatinAmericaandCanadaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Latin America and Canada [Member]", "label": "Latin America and Canada [Member]", "terseLabel": "Latin America and Canada [Member]" } } }, "localname": "LatinAmericaandCanadaMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "terseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LesseeOperatingAndFinanceLeasesOptionToExtend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating and Finance Leases, Option to Extend", "label": "Lessee, Operating and Finance Leases, Option to Extend", "terseLabel": "Lessee, Operating and Finance Leases, Option to Extend" } } }, "localname": "LesseeOperatingAndFinanceLeasesOptionToExtend", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "bsx_LicensingArrangementAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing arrangement assets", "label": "Licensing arrangement assets [Member]", "terseLabel": "Licensing arrangement assets (Member)" } } }, "localname": "LicensingArrangementAssetsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_LicensingArrangementLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing arrangement liabilities", "label": "Licensing arrangement liabilities [Member]", "terseLabel": "Licensing arrangement liabilities (Member)" } } }, "localname": "LicensingArrangementLiabilitiesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_LicensingArrangements": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Licensing arrangements", "label": "Licensing arrangements", "terseLabel": "Licensing arrangements" } } }, "localname": "LicensingArrangements", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LicensingArrangementsAsset": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Licensing arrangements, asset", "label": "Licensing arrangements, asset", "terseLabel": "Licensing arrangements, asset" } } }, "localname": "LicensingArrangementsAsset", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LicensingArrangementsLiability": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Licensing arrangements, liability", "label": "Licensing arrangements, liability", "terseLabel": "Licensing arrangements, liability" } } }, "localname": "LicensingArrangementsLiability", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LitigationAndDebtExclusionFromEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exclusion of litigation payments and any debt Issued to fund tax deficiency payments", "label": "Litigation and Debt Exclusion from EBITDA", "terseLabel": "Litigation and Debt Exclusion from EBITDA" } } }, "localname": "LitigationAndDebtExclusionFromEbitda", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LumenisLTDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lumenis LTD", "label": "Lumenis LTD [Member]", "terseLabel": "Lumenis LTD" } } }, "localname": "LumenisLTDMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "bsx_MITechCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "M.I. Tech Co., Ltd", "label": "M.I. Tech Co., Ltd [Member]", "terseLabel": "M.I. Tech Co., Ltd" } } }, "localname": "MITechCoLtdMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2024NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2024 Notes", "label": "March 2024 Notes [Member]", "terseLabel": "March 2024 Notes [Member]" } } }, "localname": "March2024NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2025NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2025 Notes", "label": "March 2025 Notes [Member]", "terseLabel": "March 2025 Notes" } } }, "localname": "March2025NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2026NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2026 Notes", "label": "March 2026 Notes [Member]", "terseLabel": "March 2026 Notes [Member]" } } }, "localname": "March2026NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2028NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2028 Notes [Member]", "label": "March 2028 Notes [Member]", "terseLabel": "March 2028 Notes [Member]" } } }, "localname": "March2028NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2028SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2028 Senior Notes", "label": "March 2028 Senior Notes [Member]", "terseLabel": "March 2028 Senior Notes" } } }, "localname": "March2028SeniorNotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2029NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2029 Notes", "label": "March 2029 Notes [Member]", "terseLabel": "March 2029 Notes [Member]" } } }, "localname": "March2029NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2031NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2031 Notes", "label": "March 2031 Notes [Member]", "terseLabel": "March 2031 Notes" } } }, "localname": "March2031NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2034NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2034 Notes", "label": "March 2034 Notes [Member]", "terseLabel": "March 2034 Notes" } } }, "localname": "March2034NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2039NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2039 Notes", "label": "March 2039 Notes [Member]", "terseLabel": "March 2039 Notes [Member]" } } }, "localname": "March2039NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2049NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2049 Notes", "label": "March 2049 Notes [Member]", "terseLabel": "March 2049 Notes [Member]" } } }, "localname": "March2049NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market-based awards, valuation assumptions [Table Text Block]", "label": "Market-based awards, valuation assumptions [Table Text Block]", "terseLabel": "Market-based awards, valuation assumptions [Table Text Block]" } } }, "localname": "MarketBasedAwardsValuationAssumptionsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "bsx_MaturitiesOfLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturities of Lease Liabilities", "label": "Maturities of Lease Liabilities [Table Text Block]", "terseLabel": "Maturities of Lease Liabilities" } } }, "localname": "MaturitiesOfLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_MaximumLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement.", "label": "Maximum Leverage Ratio", "terseLabel": "Maximum Leverage Ratio" } } }, "localname": "MaximumLeverageRatio", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "pureItemType" }, "bsx_May2022NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2022 Notes [Member]", "label": "May 2022 Notes [Member]", "terseLabel": "May 2022 Notes [Member]", "verboseLabel": "May 2022 Notes [Member]" } } }, "localname": "May2022NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_May2025NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2025 Notes [Member]", "label": "May 2025 Notes [Member]", "terseLabel": "May 2025 Notes [Member]" } } }, "localname": "May2025NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_Measurementperiodmarketbasedaward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement period - market based awards", "label": "Measurement period - market based award", "terseLabel": "Measurement period - market based awards" } } }, "localname": "Measurementperiodmarketbasedaward", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "durationItemType" }, "bsx_MedsurgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MedSurg [Member]", "label": "MedSurg [Member]", "terseLabel": "MedSurg [Member]" } } }, "localname": "MedsurgMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_NetCurrencyExchangeGainLoss": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net currency exchange gain (loss)", "label": "Net currency exchange gain (loss)", "negatedTerseLabel": "Debt extinguishment costs", "terseLabel": "Net currency exchange gain (loss)" } } }, "localname": "NetCurrencyExchangeGainLoss", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Deferred Tax Assets and Prepaid on Intercompany Profit", "label": "Net Deferred Tax Assets and Prepaid on Intercompany Profit", "terseLabel": "Net Deferred Tax Liabilities and Prepaid on Intercompany Profit" } } }, "localname": "NetDeferredTaxAssetsAndPrepaidOnIntercompanyProfit", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_NewAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Accounting Pronouncements, Policy", "label": "New Accounting Pronouncements, Policy [Text Block]", "terseLabel": "New Accounting Pronouncements, Policy" } } }, "localname": "NewAccountingPronouncementsPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "bsx_NonCashImpactOfTransferredRoyaltyRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash impact of transferred royalty rights", "label": "Non-cash impact of transferred royalty rights", "terseLabel": "Non-cash impact of transferred royalty rights" } } }, "localname": "NonCashImpactOfTransferredRoyaltyRights", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_Nonvestedstockawardsexerciseprice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-vested stock awards exercise price", "label": "Non-vested stock awards exercise price", "terseLabel": "Qualified options exercise price" } } }, "localname": "Nonvestedstockawardsexerciseprice", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_November2019AggregateOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November 2019 Aggregate Offering", "label": "November 2019 Aggregate Offering [Member]", "terseLabel": "November 2019 Aggregate Offering [Member]" } } }, "localname": "November2019AggregateOfferingMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_November2035NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November 2035 Notes [Member]", "label": "November 2035 Notes [Member]", "terseLabel": "November 2035 Notes [Member]" } } }, "localname": "November2035NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_October2023NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 2023 Notes [Member]", "label": "October 2023 Notes [Member]", "terseLabel": "October 2023 Notes [Member]" } } }, "localname": "October2023NotesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_Onetimetransactiontaxpost1986EPnetpayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "One-time transaction tax post-1986 E&P - net payment", "label": "One-time transaction tax post-1986 E&P - net payment", "terseLabel": "One-time transaction tax post-1986 E&P - net payment" } } }, "localname": "Onetimetransactiontaxpost1986EPnetpayment", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OperatingIncomeLossAllocatedToReportableSegments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Income (Loss) Allocated to Reportable Segments", "label": "Operating Income (Loss) Allocated to Reportable Segments", "terseLabel": "Operating Income (Loss) Allocated to Reportable Segments" } } }, "localname": "OperatingIncomeLossAllocatedToReportableSegments", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OperatingIncomeUnallocatedToSegment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Income Unallocated to Segment", "label": "Operating Income Unallocated to Segment", "terseLabel": "Operating Income Unallocated to Segment" } } }, "localname": "OperatingIncomeUnallocatedToSegment", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OptionsExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options expected to vest", "label": "Options expected to vest", "terseLabel": "Options expected to vest" } } }, "localname": "OptionsExpectedToVest", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "bsx_OptionsExpectedToVestWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options expected to vest, weighted average exercise price", "label": "Options expected to vest, weighted average exercise price", "terseLabel": "Options expected to vest, weighted average exercise price" } } }, "localname": "OptionsExpectedToVestWeightedAverageExercisePrice", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options expected to vest, weighted average remaining contractual life", "label": "Options expected to vest, weighted average remaining contractual life", "terseLabel": "Options expected to vest, weighted average remaining contractual life" } } }, "localname": "OptionsExpectedToVestWeightedAverageRemainingContractualLife", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "durationItemType" }, "bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other countries [Member]", "label": "Other countries [Member]", "terseLabel": "Other countries [Member]" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_OtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Current Assets", "label": "Other Current Assets [Abstract]", "terseLabel": "Other Current Assets [Abstract]" } } }, "localname": "OtherCurrentAssetsAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_OtherIntangibleAssetsTextualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Intangible Assets (Textuals) [Abstract]", "label": "Other Intangible Assets (Textuals) [Abstract]", "terseLabel": "Other Intangible Assets (Textuals) [Abstract]" } } }, "localname": "OtherIntangibleAssetsTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_OtherInternationalPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other International Plans", "label": "Other International Plans [Member]", "terseLabel": "Other International Plans" } } }, "localname": "OtherInternationalPlansMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "bsx_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_OtherNet": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other, net", "label": "Other, net", "terseLabel": "Other, net" } } }, "localname": "OtherNet", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_OtherOtherLongTermAssets": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other, Other Long-term Assets", "label": "Other, Other Long-term Assets", "terseLabel": "Other, Other Long-term Assets" } } }, "localname": "OtherOtherLongTermAssets", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PaymentOfContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of contingent consideration", "label": "Payment of contingent consideration", "terseLabel": "Payment of contingent consideration" } } }, "localname": "PaymentOfContingentConsideration", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PaymentsForRoyaltyRights": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for royalty rights", "label": "Payments for royalty rights", "negatedTerseLabel": "Payments for royalty rights" } } }, "localname": "PaymentsForRoyaltyRights", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_Paymenttonetsharesettleemployeeequityawards": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment to net share settle employee equity awards", "label": "Payment to net share settle employee equity awards", "negatedTerseLabel": "Cash used to net share settle employee equity awards" } } }, "localname": "Paymenttonetsharesettleemployeeequityawards", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_Pensionbenefitobligationbenefitspaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "pension benefit obligation, benefits paid", "label": "pension benefit obligation, benefits paid", "negatedTerseLabel": "pension benefit obligation, benefits paid" } } }, "localname": "Pensionbenefitobligationbenefitspaid", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PercentOfFinishedGoodsAtConsignment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of finished goods at consignment", "label": "Percent of finished goods at consignment", "terseLabel": "Percent of finished goods at consignment" } } }, "localname": "PercentOfFinishedGoodsAtConsignment", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "bsx_PreventiceSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preventice Solutions, Inc.", "label": "Preventice Solutions, Inc. [Member]", "terseLabel": "Preventice Solutions, Inc. [Member]" } } }, "localname": "PreventiceSolutionsIncMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from (payments for) investments and acquisitions of certain technologies", "label": "Proceeds from (payments for) investments and acquisitions of certain technologies", "negatedLabel": "Proceeds from (payments for) investments and acquisitions of certain technologies" } } }, "localname": "ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_RDRegulatoryandCommercializationbasedMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D, Regulatory and Commercialization-based Milestone [Member]", "label": "R&D, Regulatory and Commercialization-based Milestone [Member]", "terseLabel": "R&D, Regulatory and Commercialization-based Milestone [Member]" } } }, "localname": "RDRegulatoryandCommercializationbasedMilestoneMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_RangeofthetargetnumberofmarketbasedDSUsawarded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of the target number of market-based DSUs awarded", "label": "Range of the target number of market-based DSUs awarded", "terseLabel": "Range of the target number of market-based DSUs awarded" } } }, "localname": "RangeofthetargetnumberofmarketbasedDSUsawarded", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_RangeofthetargetnumberofperformancebasedDSUsawarded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of the target number of performance-based DSUs awarded", "label": "Range of the target number of performance-based DSUs awarded", "terseLabel": "Range of the target number of performance-based DSUs awarded" } } }, "localname": "RangeofthetargetnumberofperformancebasedDSUsawarded", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_RenminbiDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renminbi Denominated Factoring Arrangements", "label": "Renminbi Denominated Factoring Arrangements [Member]", "terseLabel": "Renminbi Denominated Factoring Arrangements [Member]" } } }, "localname": "RenminbiDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, as of December 31, 2021 and through remaining term of facility", "label": "Requirement, as of December 31, 2021 and through remaining term of facility [Member]", "terseLabel": "Requirement, as of December 31, 2021 and through remaining term of facility" } } }, "localname": "RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementAsOfMarch312021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, as of March 31, 2021", "label": "Requirement, as of March 31, 2021 [Member]", "terseLabel": "Requirement, as of March 31, 2021" } } }, "localname": "RequirementAsOfMarch312021Member", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, eighth quarter and thereafter following qualified acquisition", "label": "Requirement, eighth quarter and thereafter following qualified acquisition [Member]", "terseLabel": "Requirement, eighth quarter and thereafter following qualified acquisition" } } }, "localname": "RequirementEighthQuarterAndThereafterFollowingQualifiedAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementFourQuartersFollowingMaterialAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, four quarters following qualified acquisition", "label": "Requirement, four quarters following material acquisition [Member]", "terseLabel": "Requirement, four quarters following material acquisition" } } }, "localname": "RequirementFourQuartersFollowingMaterialAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, seventh quarter following qualified acquisition", "label": "Requirement, seventh quarter following qualified acquisition [Member]", "terseLabel": "Requirement, seventh quarter following qualified acquisition" } } }, "localname": "RequirementSeventhQuarterFollowingQualifiedAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, sixth quarter following qualified acquisition [Member]", "label": "Requirement, sixth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]" } } }, "localname": "RequirementSixthQuarterFollowingQualifiedAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, fifth quarter following qualified acquisition [Member]", "label": "Requirement, fifth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, fifth quarter following qualified acquisition [Member]" } } }, "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA.", "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "verboseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_RevenueBasedPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "revenue-based payments [Member]", "label": "revenue-based payments [Member]", "terseLabel": "revenue-based payments [Member]" } } }, "localname": "RevenueBasedPaymentsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenues from contracts with customers, disaggregated - performance measurement", "label": "Revenues from contracts with customers, disaggregated - performance measurement", "terseLabel": "Revenues from contracts with customers, disaggregated - performance measurement" } } }, "localname": "RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Line Items]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Line Items]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationLineItems", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "stringItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Table]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Table]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationTable", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "stringItemType" }, "bsx_Segmentoperatingincomeaspercentageofnetsales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales", "terseLabel": "Segment operating income as percentage of net sales" } } }, "localname": "Segmentoperatingincomeaspercentageofnetsales", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "percentItemType" }, "bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales [Table Text Block]", "terseLabel": "Segment operating income as percentage of net sales [Table Text Block]" } } }, "localname": "SegmentoperatingincomeaspercentageofnetsalesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "bsx_SeniorNotedue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Note due 2027 [Member]", "label": "Senior Note due 2027 [Member]", "terseLabel": "Senior Note due 2027 [Member]" } } }, "localname": "SeniorNotedue2027Member", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "domainItemType" }, "bsx_ShareBasedCompensationNetOfTaxBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation, net of tax benefit", "label": "Share-based compensation, net of tax benefit", "terseLabel": "Share-based compensation, net of tax benefit" } } }, "localname": "ShareBasedCompensationNetOfTaxBenefit", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_SignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policies [Abstract]", "label": "Significant Accounting Policies [Abstract]", "terseLabel": "Significant Accounting Policies [Abstract]" } } }, "localname": "SignificantAccountingPoliciesAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "xbrltype": "stringItemType" }, "bsx_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bsx_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bsx_SpecialChargesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special Charges [Member]", "label": "Special Charges [Member]", "terseLabel": "Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs" } } }, "localname": "SpecialChargesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_SpecialtyPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty Pharmaceuticals", "label": "Specialty Pharmaceuticals [Member]", "terseLabel": "Specialty Pharmaceuticals [Member]" } } }, "localname": "SpecialtyPharmaceuticalsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_StatementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "statement [Axis]", "label": "statement [Axis]", "terseLabel": "statement [Axis]" } } }, "localname": "StatementAxis", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" ], "xbrltype": "stringItemType" }, "bsx_StatementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for statement [Axis]", "label": "statement [Domain]", "terseLabel": "statement [Domain]" } } }, "localname": "StatementDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" ], "xbrltype": "domainItemType" }, "bsx_StockIncentiveAndPurchasePlansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Incentive and Purchase Plans [Abstract]", "label": "Stock Incentive and Purchase Plans [Abstract]", "terseLabel": "Stock Incentive and Ownership Plans [Abstract]" } } }, "localname": "StockIncentiveAndPurchasePlansAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "xbrltype": "stringItemType" }, "bsx_StockIssuedDuringPeriodValueNewIssuesCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, New Issues (Common stock)", "label": "Stock Issued During Period, Value, New Issues (Common stock)", "terseLabel": "Common stock issuance (Value in excess of par)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bsx_StockIssuedDuringPeriodValueNewIssuesPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, New Issues (Preferred stock)", "label": "Stock Issued During Period, Value, New Issues (Preferred stock)", "terseLabel": "Preferred stock issuance (Value in excess of par)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesPreferredStock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants.", "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]", "terseLabel": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]" } } }, "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "bsx_SupplementalBalanceSheetInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Balance Sheet Information.", "label": "Supplemental Balance Sheet Information [Abstract]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "SupplementalBalanceSheetInformationAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "xbrltype": "stringItemType" }, "bsx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Balance Sheet Information Related to Leases", "label": "Supplemental Balance Sheet Information Related to Leases [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information Related to Leases" } } }, "localname": "SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_SupplementalBalanceSheetInformationTextualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Balance Sheet Information (Textuals)", "label": "Supplemental Balance Sheet Information (Textuals) [Abstract]", "verboseLabel": "Supplemental Balance Sheet Information (Textuals)" } } }, "localname": "SupplementalBalanceSheetInformationTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_SupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Cash Flow Information Related to Leases", "label": "Supplemental Cash Flow Information Related to Leases [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to Leases" } } }, "localname": "SupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Target payout of Free Cash Flows (FCF) performance awards", "label": "Target payout of Free Cash Flows (FCF) performance awards", "terseLabel": "Target payout of Free Cash Flows (FCF) performance awards" } } }, "localname": "TargetPayoutOfFreeCashFlowsFcfPerformanceAwards", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense", "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense" } } }, "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_TaxIncentivesInMalaysia": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax incentives in Malaysia", "label": "Tax incentives in Malaysia", "terseLabel": "Tax incentives in Malaysia" } } }, "localname": "TaxIncentivesInMalaysia", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution", "label": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution", "terseLabel": "Tax Incentives in Malaysia, impact on Net income (loss) per common share, assuming dilution" } } }, "localname": "TaxIncentivesInMalaysiaImpactOnNetIncomeLossPerCommonShareAssumingDilution", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "perShareItemType" }, "bsx_TaxIncentivesInPuertoRico": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Incentives in Puerto Rico", "label": "Tax Incentives in Puerto Rico", "terseLabel": "Tax Incentives in Puerto Rico" } } }, "localname": "TaxIncentivesInPuertoRico", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution", "label": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution", "terseLabel": "Tax Incentives in Puerto Rico, impact on Net income (loss) per common share, assuming dilution" } } }, "localname": "TaxIncentivesInPuertoRicoImpactOnNetIncomeLossPerCommonShareAssumingDilution", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "perShareItemType" }, "bsx_TaxRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Rate [Axis]", "label": "Tax Rate [Axis]", "terseLabel": "Tax Rate [Axis]" } } }, "localname": "TaxRateAxis", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "stringItemType" }, "bsx_TaxRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Rate [Domain]", "label": "Tax Rate [Domain]", "terseLabel": "Tax Rate [Domain]" } } }, "localname": "TaxRateDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "domainItemType" }, "bsx_The2018FacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "the 2018 Facility", "label": "the 2018 Facility [Domain]", "terseLabel": "the 2018 Facility [Domain]" } } }, "localname": "The2018FacilityDomain", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_TheOfferingAggregatePrincipalAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "the Offering - aggregate principal amount", "label": "the Offering - aggregate principal amount [Member]", "terseLabel": "the Offering - aggregate principal amount" } } }, "localname": "TheOfferingAggregatePrincipalAmountMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "the Offering - early redemption of combined aggregate principal SN", "label": "the Offering - early redemption of combined aggregate principal SN [Member]", "terseLabel": "the Offering - early redemption of combined aggregate principal SN" } } }, "localname": "TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_TotalAllocatedToReportableSegmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total allocated to reportable segments [Member]", "label": "Total allocated to reportable segments [Member]", "terseLabel": "Total allocated to reportable segments [Member]" } } }, "localname": "TotalAllocatedToReportableSegmentsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_TransitionTaxPaymentRemaining": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transition Tax Payment Remaining", "label": "Transition Tax Payment Remaining", "terseLabel": "transition tax payment remaining" } } }, "localname": "TransitionTaxPaymentRemaining", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_UKPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.K. Plan", "label": "U.K. Plan [Member]", "terseLabel": "U.K. Plan" } } }, "localname": "UKPlanMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "bsx_USExcludingOtherNetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US excluding Other Net Sales", "label": "US excluding Other Net Sales [Member]", "terseLabel": "country_US excluding Other Net Sales" } } }, "localname": "USExcludingOtherNetSalesMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_UnrecognizedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Compensation Cost", "label": "Unrecognized Compensation Cost", "terseLabel": "Unrecognized Compensation Cost" } } }, "localname": "UnrecognizedCompensationCost", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_UnrecognizedCompensationCostNonVestedStockAwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Compensation Cost - Non-vested stock awards", "label": "Unrecognized Compensation Cost - Non-vested stock awards", "terseLabel": "Unrecognized Compensation Cost - Non-vested stock awards" } } }, "localname": "UnrecognizedCompensationCostNonVestedStockAwards", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_UnrecognizedCompensationCostStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Compensation Cost - Stock Options", "label": "Unrecognized Compensation Cost - Stock Options", "terseLabel": "Unrecognized Compensation Cost - Stock Options" } } }, "localname": "UnrecognizedCompensationCostStockOptions", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_VotingPowerOfAllClassesOfStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting power of all classes of stock", "label": "Voting power of all classes of stock", "verboseLabel": "Voting power of all classes of stock" } } }, "localname": "VotingPowerOfAllClassesOfStock", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "bsx_WatchmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Watchman", "label": "Watchman [Member]", "terseLabel": "Watchman" } } }, "localname": "WatchmanMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_WeightedAverageRemainingVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "weighted average remaining vesting period", "label": "weighted average remaining vesting period", "terseLabel": "weighted average remaining vesting period" } } }, "localname": "WeightedAverageRemainingVestingPeriod", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "durationItemType" }, "bsx_YenDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yen denominated factoring arrangements.", "label": "Yen Denominated Factoring Arrangements [Member]", "terseLabel": "Yen Denominated Factoring Arrangements [Member]" } } }, "localname": "YenDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20221231", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "country_CR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COSTA RICA", "terseLabel": "COSTA RICA" } } }, "localname": "CR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "IRELAND" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]", "verboseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r973", "r974", "r975" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r973", "r974", "r975" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r973", "r974", "r975" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r973", "r974", "r975" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r976" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r977" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.", "label": "Entity Listing, Par Value Per Share", "terseLabel": "Entity Listing, Par Value Per Share" } } }, "localname": "EntityListingParValuePerShare", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "perShareItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r978" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r973", "r974", "r975" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r970" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r972" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bostonscientific.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "APAC [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r1126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Contractual Obligation, Fiscal Year Maturity" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r687", "r854", "r875", "r906", "r907", "r940", "r959", "r969", "r1020", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]", "verboseLabel": "High end of range [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r687", "r854", "r875", "r906", "r907", "r940", "r959", "r969", "r1020", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r488", "r856", "r942", "r967", "r1022", "r1118" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r488", "r856", "r942", "r967", "r1022", "r1118" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r642", "r687", "r830", "r854", "r875", "r906", "r907", "r940", "r959", "r969", "r1020", "r1112", "r1113", "r1114", "r1115", "r1116" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r642", "r687", "r830", "r854", "r875", "r906", "r907", "r940", "r959", "r969", "r1020", "r1112", "r1113", "r1114", "r1115", "r1116" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r437", "r692", "r1004" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario, Unspecified [Domain]", "verboseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r421", "r919" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleII" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r489", "r490", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r909", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r943", "r968", "r1022" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r489", "r490", "r890", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r909", "r910", "r943", "r968", "r1022" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis]", "verboseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r437", "r692", "r981", "r982", "r1004" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2021-01-31", "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r906", "r907", "r1111", "r1113", "r1116" ], "lang": { "en-us": { "role": { "documentation": "Average of a range of values, calculated with consideration of proportional relevance.", "label": "Weighted Average [Member]", "terseLabel": "Weighted Average (Member)" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r60", "r373", "r494", "r869", "r925", "r932" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Trade accounts receivable, net", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r46", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal": { "auth_ref": [ "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable from change in methodology.", "label": "Accounts Receivable, Change in Method, Credit Loss Expense (Reversal)", "terseLabel": "Cumulative effect adjustment for adoption of ASC 2016-13" } } }, "localname": "AccountsReceivableChangeInMethodCreditLossExpenseReversal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bostonscientific.com/role/ScheduleIIDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r494", "r495" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r22", "r339", "r353" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued Income Taxes, Noncurrent" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Accrued liabilities, current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r10", "r11", "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued Royalties, Current" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r156" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r69", "r74", "r1064" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r380", "r384", "r386", "r387", "r781" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "verboseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r71", "r73", "r74", "r374", "r870", "r883", "r887" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r70", "r74", "r290", "r878", "r879", "r924", "r985", "r986", "r987", "r1001", "r1002", "r1003" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired Finite-lived Intangible Asset, Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r28" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r698", "r699", "r700", "r1001", "r1002", "r1003", "r1101" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r365", "r366", "r367", "r368", "r369", "r425", "r426", "r427", "r428", "r437", "r497", "r498", "r505", "r506", "r507", "r508", "r509", "r510", "r548", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r726", "r727", "r728", "r729", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r822", "r858", "r859", "r860", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r920", "r921", "r922", "r923", "r924" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r496", "r511", "r514", "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss (ending balance)", "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss (beginning balance)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIIDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r375", "r496", "r511" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedLabel": "Allowance for credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedLabel": "Utilization of allowances", "negatedTerseLabel": "Utilization of allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIIDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r102", "r139", "r147" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 10.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization expense", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r337", "r352", "r413", "r472", "r478", "r484", "r504", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r746", "r751", "r783", "r966", "r1018", "r1019", "r1109" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r64", "r413", "r504", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r746", "r751", "r783", "r966", "r1018", "r1019", "r1109" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r124", "r499", "r522", "r863" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Notes receivable" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r302", "r307" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r8", "r155" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r953", "r956" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r272", "r273", "r953", "r956" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]", "verboseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "auth_ref": [ "r269", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination", "verboseLabel": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements [Abstract]", "terseLabel": "Business Combination, Contingent Consideration Arrangements [Abstract]" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r744", "r992" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration net expense (benefit)", "verboseLabel": "Contingent consideration net expense (benefit)" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r280", "r281", "r743" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "negatedLabel": "Fair value of contingent consideration", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r280", "r282" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r280", "r282" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Business Combination, Contingent Consideration, Liability, Noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "verboseLabel": "ACQUISITIONS AND STRATEGIC INVESTMENTS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination.", "label": "Business Combination, Indemnification Assets, Amount as of Acquisition Date", "terseLabel": "Business Combination, Indemnification Assets, Amount as of Acquisition Date" } } }, "localname": "BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "verboseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r274", "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations Policy [Policy Text Block]" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]", "terseLabel": "Finance Lease Obligation" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r39", "r888", "r889", "r966" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r39", "r104" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r14", "r105", "r335" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r96", "r104", "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period", "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r96", "r326" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease)\u00a0in cash, cash equivalents, restricted cash and restricted cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Change in Contract with Customer, Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]", "terseLabel": "Class of Stock Disclosures [Abstract]" } } }, "localname": "ClassOfStockDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r413", "r441", "r442", "r444", "r446", "r454", "r455", "r504", "r549", "r551", "r552", "r553", "r556", "r557", "r587", "r588", "r591", "r595", "r783", "r908", "r980", "r996", "r1005" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/Cover", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r55", "r163", "r344", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r162", "r172", "r546", "r547", "r894" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r1001", "r1002", "r1101" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bostonscientific.com/role/Cover", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares, Issued", "verboseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,696,633,993 shares as of December 31, 2022 and 1,688,810,052 shares as of December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r198", "r201", "r216", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r289", "r292", "r392", "r394", "r401", "r865", "r872" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r86", "r400", "r864", "r871" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r155" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Capital in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r603", "r604", "r615" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract with Customer, Liability [Abstract]" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r941" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "terseLabel": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r616" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "auth_ref": [ "r25", "r26", "r186", "r189", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for preferred stock.", "label": "Preferred Stock, Convertible, Terms", "terseLabel": "Convertible Preferred Stock, Terms of Conversion" } } }, "localname": "ConvertiblePreferredStockTermsOfConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CorporateMember": { "auth_ref": [ "r1008" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.", "label": "Corporate Segment [Member]", "terseLabel": "Corporate Segment" } } }, "localname": "CorporateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r80", "r856" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold", "verboseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "auth_ref": [ "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.", "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "terseLabel": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r265", "r999", "r1094" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Current Federal Tax Expense (Benefit)" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r999", "r1094" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Current Foreign Tax Expense (Benefit)" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r265", "r723", "r733", "r999" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Current Income Tax Expense (Benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r265", "r999", "r1094" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "Current State and Local Tax Expense (Benefit)" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r343", "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "terseLabel": "Total debt" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Debt, Current", "verboseLabel": "Current debt obligations" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r181", "r410", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r574", "r581", "r582", "r584" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "CONTRACTUAL OBLIGATIONS AND COMMITMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r20", "r21", "r338", "r341", "r350", "r418", "r558", "r559", "r560", "r561", "r562", "r564", "r570", "r571", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r810", "r935", "r936", "r937", "r938", "r939", "r997" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r572", "r782", "r936", "r937" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r52", "r559" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "negatedTerseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53", "r418", "r558", "r559", "r560", "r561", "r562", "r564", "r570", "r571", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r810", "r935", "r936", "r937", "r938", "r939", "r997" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r186", "r189", "r190", "r191", "r327", "r328", "r330", "r348", "r418", "r558", "r559", "r560", "r561", "r562", "r564", "r570", "r571", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r583", "r810", "r935", "r936", "r937", "r938", "r939", "r997" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r329", "r570", "r585", "r936", "r937" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]", "terseLabel": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r265", "r999", "r1095" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Deferred Federal Income Tax Expense (Benefit)" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r265", "r999", "r1095" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Deferred Foreign Income Tax Expense (Benefit)" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r705", "r706" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r102", "r265", "r724", "r732", "r733", "r999" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r23", "r24", "r340", "r349", "r718" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "terseLabel": "Deferred Tax Liabilities, Gross" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r705", "r706" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r376" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r265", "r999", "r1095" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred State and Local Income Tax Expense (Benefit)" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Deferred Tax Assets, Goodwill and Intangible Assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r719" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Deferred Tax Assets, in Process Research and Development" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Deferred Tax Assets, Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r1092" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r1092" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Deferred Tax Assets, Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Deferred Tax Assets, Property, Plant and Equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.", "label": "Deferred Tax Assets, Tax Deferred Expense", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": { "auth_ref": [ "r263", "r1093" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r720" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r255", "r1092" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred Tax Liabilities, Net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDerivatives": { "auth_ref": [ "r263", "r1093" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.", "label": "Deferred Tax Liabilities, Derivatives", "terseLabel": "Deferred Tax Liabilities, Derivatives" } } }, "localname": "DeferredTaxLiabilitiesDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r263", "r1093" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Deferred Tax Liabilities, Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r650" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Defined Benefit Plan, Accumulated Benefit Obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r633", "r951" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r626" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "auth_ref": [ "r202", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "terseLabel": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Executive Retirement Plan Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Executive Retirement Plan Rate of Compensation Increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r621" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "terseLabel": "Defined Benefit Plan, Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r628", "r680" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r667", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r635", "r644", "r678", "r949", "r950", "r951", "r952" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year One" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r632", "r643", "r644", "r645", "r949", "r950", "r951" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "terseLabel": "Defined Benefit Plan, Plan Assets, Amount" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r627" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r620", "r624", "r655", "r672", "r951", "r952" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Defined Benefit Plan, Interest Cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r629" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r637", "r1084" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Benefits Paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r636" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r634" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r622", "r654", "r671", "r951", "r952" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Defined Benefit Plan, Service Cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r640" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r102", "r154" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r102", "r467" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r378", "r379", "r782", "r926" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r378" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative Asset, Current" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative, Name [Domain]", "verboseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r65", "r304", "r332", "r377", "r926" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative Asset, Fair Value, Gross Asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r65", "r304", "r332", "r377", "r926" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Derivative Liability, Fair Value, Gross Liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r303", "r305", "r311", "r313", "r926" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r300", "r303", "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r300", "r303", "r311", "r313", "r317", "r318", "r759" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "auth_ref": [ "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r378", "r379", "r782", "r926" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Foreign Currency Contracts, Liability, Fair Value Disclosure" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r1098", "r1099" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r294", "r296", "r297", "r300", "r301", "r308", "r311", "r314", "r316", "r318", "r761" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r294", "r296", "r300", "r301", "r315", "r417" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives, Policy [Policy Text Block]" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r614", "r942", "r943", "r944", "r945", "r946", "r947", "r948" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r1022" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveandPurchasePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r152", "r153", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r538", "r993", "r1016" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedTerseLabel": "Loss (gain) on disposal of businesses and assets" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r953", "r956" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r192", "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Dividends, Cash" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockCash": { "auth_ref": [ "r192", "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.", "label": "Dividends, Preferred Stock, Cash", "terseLabel": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r192", "r347" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Dividends, Preferred Stock, Stock", "terseLabel": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r1085", "r1086", "r1087" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r402", "r429", "r430", "r431", "r432", "r433", "r438", "r441", "r444", "r445", "r446", "r450", "r771", "r772", "r866", "r873", "r930" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net income (loss) per common share \u2014 basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r402", "r429", "r430", "r431", "r432", "r433", "r441", "r444", "r445", "r446", "r450", "r771", "r772", "r866", "r873", "r930" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net income (loss) per common share \u2014 assuming dilution" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r447", "r448", "r449", "r451" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r798" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of foreign exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Reported tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r415", "r708", "r735" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r735", "r1090" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r1089", "r1090" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "effective income tax reconciliation, compensation-related" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r1090", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credits, Research" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedTerseLabel": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r1088" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of plan compensation cost recognized during the period.", "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense", "terseLabel": "Employee Stock Ownership Plan (ESOP), Compensation Expense" } } }, "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan.", "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased", "terseLabel": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased" } } }, "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r185", "r367", "r396", "r397", "r398", "r422", "r423", "r424", "r426", "r434", "r436", "r453", "r508", "r602", "r698", "r699", "r700", "r728", "r729", "r770", "r800", "r801", "r802", "r803", "r804", "r806", "r878", "r879", "r880", "r924" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r40", "r125", "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r780" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Measurement alternative investments (1)" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r321", "r773", "r774", "r778" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r572", "r644", "r645", "r646", "r647", "r648", "r649", "r774", "r827", "r828", "r829", "r936", "r937", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r773", "r774", "r775", "r776", "r779" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r572", "r644", "r649", "r774", "r827", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r572", "r644", "r649", "r774", "r828", "r936", "r937", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r572", "r644", "r645", "r646", "r647", "r648", "r649", "r774", "r829", "r936", "r937", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r323", "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasuresandDisclosuresPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "verboseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r572", "r644", "r645", "r646", "r647", "r648", "r649", "r827", "r828", "r829", "r936", "r937", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r777", "r779" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r500", "r501", "r513", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r583", "r600", "r761", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r933", "r1010", "r1011", "r1012", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Future Amortization Expense, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Future Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Future Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Future Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Future Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r532", "r534", "r535", "r537", "r857", "r861" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r146", "r861" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r140", "r145" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r792", "r794", "r796", "r797" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Net gain (loss) from foreign currency transaction exposures", "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r808" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r926", "r949", "r963" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract (Member)" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet": { "auth_ref": [ "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.", "label": "Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net", "terseLabel": "Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net" } } }, "localname": "GainLossOnCashFlowHedgeIneffectivenessNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r303", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r83", "r123", "r979" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedTerseLabel": "Net loss (gain) on investments and notes receivable" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r750", "r993" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Gain (Loss) on Disposition of Assets" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r102", "r179", "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r128", "r130", "r862", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r529", "r530" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill, Gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r529", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r102", "r129", "r132", "r136" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment charges" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r133", "r134", "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Goodwill, Translation and Purchase Accounting Adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r78", "r413", "r472", "r477", "r483", "r486", "r504", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r783", "r931", "r1018" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r300", "r759" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r102", "r150" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r993", "r1015" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Goodwill and other intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r44", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "In Process Research and Development, Policy [Policy Text Block]" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r414", "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r77", "r334", "r345", "r362", "r472", "r477", "r483", "r486", "r867", "r931" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r414", "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r953", "r956" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r539", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]", "verboseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r415", "r709", "r716", "r722", "r730", "r736", "r740", "r741", "r742" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r1091" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Income Tax Examination, Penalties and Interest Accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r416", "r435", "r436", "r470", "r707", "r731", "r738", "r874" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)", "verboseLabel": "Income Tax Expense (Benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r395", "r703", "r704", "r716", "r717", "r721", "r725" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r98", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income Taxes Paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r101" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r101" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).", "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "terseLabel": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option" } } }, "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r101" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Increase (decrease) in operating assets and liabilities, excluding purchase accounting:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r101" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r533", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r149" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r142", "r149" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "verboseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r138", "r144" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r329", "r346", "r399", "r466", "r809" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r404", "r407", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r926", "r949", "r962" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract [Member]" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r962" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Unamortized Gain on Fair Value Hedges" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r31", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Inventory, Finished Goods, Net of Reserves" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r61", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r13", "r62", "r452", "r526", "r527", "r528", "r855", "r927" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r33", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Inventory, Raw Materials, Net of Reserves" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r32", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Inventory, Work in Process, Net of Reserves" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "terseLabel": "Investment [Table Text Block]" } } }, "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r503", "r1117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment, Policy" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r360" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Land": { "auth_ref": [ "r7", "r42" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r1107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs, Policy [Policy Text Block]" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentandContingenciesPolicies", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r820" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "auth_ref": [ "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": { "auth_ref": [ "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "auth_ref": [ "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "auth_ref": [ "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [ "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r820" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r1106" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lessee, Operating Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r342", "r357", "r966", "r998", "r1013", "r1103" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r51", "r413", "r504", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r747", "r751", "r752", "r783", "r966", "r1018", "r1109", "r1110" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r47", "r997" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r47", "r997" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r55", "r163", "r170" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Legal reserves" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveNoncurrent": { "auth_ref": [ "r55", "r163" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 6.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.", "label": "Estimated Litigation Liability, Noncurrent", "terseLabel": "Estimated Litigation Liability, Noncurrent" } } }, "localname": "LitigationReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 9.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation-related net charges (credits)", "verboseLabel": "Litigation Settlement, Expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r21", "r341", "r355", "r571", "r586", "r936", "r937" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r21" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": { "auth_ref": [ "r1000" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive": { "auth_ref": [ "r1000" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": { "auth_ref": [ "r1000" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": { "auth_ref": [ "r1000" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": { "auth_ref": [ "r1000" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": { "auth_ref": [ "r1000" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table Text Block]", "terseLabel": "Long-term Purchase Commitment" } } }, "localname": "LongTermPurchaseCommitmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r178" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r173", "r174" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "verboseLabel": "Accrual for legal matters that are probable and estimable" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money Market Funds, at Carrying Value" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "verboseLabel": "Allowance for doubtful accounts" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r406" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by (used for) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r406" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash provided by (used for) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r96", "r100", "r103" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r429", "r430", "r431", "r432", "r438", "r439", "r443", "r446", "r472", "r477", "r483", "r486", "r931" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss) available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging [Member]" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-Lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r1009" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "verboseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r472", "r477", "r483", "r486", "r931" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)", "verboseLabel": "Operating income allocated to reportable segments" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r815", "r965" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r812" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r812" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r812" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r814", "r816" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r811" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r819", "r965" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r818", "r965" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r50" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Noncurrent", "terseLabel": "Other Accrued Liabilities, Noncurrent" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r17", "r336", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "verboseLabel": "Assets (segment reporting)" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r63", "r966" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "totalLabel": "Other Assets, Current" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Current", "terseLabel": "Other Assets, Miscellaneous, Current" } } }, "localname": "OtherAssetsMiscellaneousCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "totalLabel": "Other long-term assets (total)", "verboseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other Assets, Noncurrent [Abstract]" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r68", "r71", "r793", "r795", "r799" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r74", "r76", "r397", "r800", "r802", "r806", "r985" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r382", "r384" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Net change in derivative financial instruments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r382", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r382", "r384", "r753", "r754", "r760" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r384", "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r384", "r388", "r756" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "auth_ref": [ "r385" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "auth_ref": [ "r383", "r384", "r755", "r760" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": { "auth_ref": [ "r383", "r384", "r755", "r760" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r67" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r758" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r76", "r185", "r391", "r394", "r400", "r800", "r805", "r806", "r864", "r871", "r985", "r986" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r69", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r69", "r71" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Net change in defined benefit pensions and other items", "terseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax", "verboseLabel": "Net change in defined benefit pensions and other items" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "auth_ref": [ "r71", "r75", "r389", "r661" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r72", "r396", "r400", "r707", "r737", "r739", "r800", "r803", "r806", "r864", "r871" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherContractMember": { "auth_ref": [ "r926", "r949", "r964" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is classified as other.", "label": "Other Contract [Member]", "terseLabel": "Other Contract" } } }, "localname": "OtherContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Other Current Liabilities [Table Text Block]" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r50", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other Liabilities, Current [Abstract]" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "totalLabel": "Other long-term liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "verboseLabel": "Other long-term liabilities [Table Text Block]" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other Operating Income (Expense), Net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r50", "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other Sundry Liabilities, Current" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r95" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment of contingent consideration previously established in purchase accounting" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Payments for (Proceeds from) Hedge, Investing Activities", "negatedTerseLabel": "Proceeds from (payments for) settlements of hedge contracts" } } }, "localname": "PaymentsForProceedsFromHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r988", "r989" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Proceeds from royalty rights" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r93" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for repurchase of common stock", "terseLabel": "Payments for repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for Royalties", "negatedTerseLabel": "Payments for Royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r93" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Cash dividends paid on preferred stock", "terseLabel": "Payments of Dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r89" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Payments for acquisitions of businesses, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment and internal use software" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "auth_ref": [ "r207", "r212", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "terseLabel": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]" } } }, "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r207", "r212", "r213", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Pension and Other Postretirement Plans, Policy [Policy Text Block]" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r667", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r219", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Preferred Stock, Dividends, Per Share, Cash Paid" } } }, "localname": "PreferredStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r26", "r186", "r187", "r996", "r1021" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred Stock, Liquidation Preference Per Share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r411", "r591" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred Stock, Liquidation Preference, Value", "terseLabel": "Preferred Stock, Liquidation Preference, Value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r26", "r587" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r26", "r587" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r26", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares; issued 10,062,500 shares as of December 31, 2022 and 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r37", "r38" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r3", "r5", "r934", "r1014" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r87" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from disposal of certain businesses and assets" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r91" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from issuance of common stock in connection with public offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r91" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Net proceeds from issuance of preferred stock in connection with public offering" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r92" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from borrowings on credit facilities" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "auth_ref": [ "r990", "r991", "r994" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.", "label": "Proceeds from (Repayments of) Commercial Paper", "terseLabel": "Net increase (decrease) in commercial paper" } } }, "localname": "ProceedsFromRepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRoyaltiesReceived": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for royalties during the current period.", "label": "Proceeds from Royalties Received", "negatedTerseLabel": "Proceeds from Royalties Received" } } }, "localname": "ProceedsFromRoyaltiesReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r88" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "terseLabel": "Proceeds from short-term borrowings, net of debt issuance costs" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r91" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductionRelatedImpairmentsOrCharges": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.", "label": "Production Related Impairments or Charges", "terseLabel": "Production Related Impairments or Charges" } } }, "localname": "ProductionRelatedImpairmentsOrCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r372", "r390", "r393", "r405", "r413", "r425", "r435", "r436", "r472", "r477", "r483", "r486", "r504", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r745", "r748", "r749", "r772", "r783", "r867", "r931", "r960", "r961", "r987", "r1018" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r157" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r155" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r157", "r358", "r868", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r157", "r895", "r896" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r157" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Property, plant and equipment, net [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r155" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r403", "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Net (credits) charges to expenses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIIDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "totalLabel": "Purchase Obligations, Future Minimum Payments Due" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueAfterFifthYear": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, after Year Five", "terseLabel": "Purchase Obligations, Future Minimum Payments, Due Thereafter" } } }, "localname": "PurchaseObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInFifthYear": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Five", "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Five Years" } } }, "localname": "PurchaseObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "order": 6.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Four", "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Four Years" } } }, "localname": "PurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "order": 4.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year One", "terseLabel": "Purchase Obligations, Future Minimum Payments Due, Current" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "order": 5.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Two", "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Two Years" } } }, "localname": "PurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Three", "terseLabel": "Purchase Obligations, Future Minimum Payments, Due in Three Years" } } }, "localname": "PurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r328", "r810" ], "lang": { "en-us": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "verboseLabel": "Average interest rate of de-recognized receivables" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r74", "r76", "r397", "r800", "r804", "r806", "r985" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r119", "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r118", "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r117", "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r94" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedLabel": "Payments on borrowings from credit facilities" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSeniorDebt": { "auth_ref": [ "r94" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.", "label": "Repayments of Senior Debt", "negatedLabel": "Payments on long-term borrowings and debt extinguishment costs" } } }, "localname": "RepaymentsOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r94" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedTerseLabel": "Payments on short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r251" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r14", "r104", "r107" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash and restricted cash equivalents included in Other current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "auth_ref": [ "r891", "r892", "r893", "r983", "r984", "r995" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash equivalents included in Other long-term assets", "verboseLabel": "Restricted Cash Equivalents included in Other long-term assets" } } }, "localname": "RestrictedCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r102", "r543", "r544", "r1017" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "verboseLabel": "Restructuring net charges (credits)" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r192", "r356", "r701", "r882", "r887", "r966" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r367", "r422", "r423", "r424", "r426", "r434", "r436", "r508", "r698", "r699", "r700", "r728", "r729", "r770", "r878", "r880" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r959", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r959", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r199", "r200", "r619", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r682", "r683", "r693", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r199", "r200", "r619", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r682", "r683", "r693", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r463", "r464", "r476", "r481", "r482", "r488", "r489", "r492", "r613", "r614", "r856" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r928", "r929" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition, Policy [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r817", "r965" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "verboseLabel": "Trade accounts receivable, net [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r951", "r1072", "r1073" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r74", "r1104", "r1105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.", "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "terseLabel": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]" } } }, "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r53", "r186", "r189", "r190", "r191", "r327", "r328", "r330", "r348", "r936", "r938", "r1000" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable": { "auth_ref": [ "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting pension and other postretirement benefit arrangements with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]", "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "auth_ref": [ "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r303", "r311", "r759" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Table Text Block)" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r218", "r242", "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r773", "r774" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r135", "r137" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r135", "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r999" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions (Table Text Block)" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Other Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of Other Current Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r310", "r1100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Derivatives Not Designated as Hedging Instruments (Table Text Block)" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r115", "r116", "r120", "r135" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r219", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r221", "r232", "r235" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-based Compensation, Stock Options, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table Text Block]", "terseLabel": "Schedule of Short-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r56", "r182", "r183", "r184", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r454", "r587", "r588", "r589", "r591", "r595", "r600", "r940", "r980", "r996" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]", "terseLabel": "Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "verboseLabel": "Schedule of Weighted Average Number of Shares [Table Text Block]" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Expected Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r486", "r492", "r542", "r545", "r1118" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r460", "r461", "r462", "r472", "r475", "r480", "r484", "r485", "r486", "r487", "r488", "r491", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT REPORTING" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r101" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r223", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r238", "r246" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending Balance (Shares Issued)", "periodStartLabel": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r18", "r338", "r354", "r966" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term Debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r108", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Standard Product Warranty, Policy" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r370", "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r486", "r492", "r531", "r540", "r542", "r545", "r1118" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r25", "r26", "r27", "r185", "r413", "r441", "r442", "r444", "r446", "r454", "r455", "r504", "r549", "r551", "r552", "r553", "r556", "r557", "r587", "r588", "r591", "r595", "r783", "r908", "r980", "r996", "r1005" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/Cover", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r59", "r185", "r367", "r396", "r397", "r398", "r422", "r423", "r424", "r426", "r434", "r436", "r453", "r508", "r602", "r698", "r699", "r700", "r728", "r729", "r770", "r800", "r801", "r802", "r803", "r804", "r806", "r878", "r879", "r880", "r924" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r422", "r423", "r424", "r453", "r856" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsConsolidatedStatementofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r1007" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Share-based Payment Arrangement [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r217", "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r26", "r27", "r185", "r192" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r26", "r27", "r185", "r192" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issuance (Shares)", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the number of shares issued.", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "terseLabel": "Stock-based compensation (Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r26", "r27", "r185", "r192", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveandPurchasePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r287", "r288", "r291", "r367", "r368", "r397", "r422", "r423", "r424", "r426", "r434", "r508", "r602", "r698", "r699", "r700", "r728", "r729", "r770", "r800", "r801", "r806", "r879", "r880", "r924", "r998", "r1013", "r1103" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodStartLabel": "Total Stockholders' Equity", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r195", "r412", "r588", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDER'S EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPeriodIncreaseDecrease": { "auth_ref": [ "r185", "r192" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in stockholders' equity during the period.", "label": "Stockholders' Equity, Period Increase (Decrease)", "terseLabel": "Stock Issuance (Par value)" } } }, "localname": "StockholdersEquityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r807", "r823" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r807", "r823" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r807", "r823" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events, Policy [Policy Text Block]" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r257", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of Income Tax Contingencies [Table Text Block]" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r253", "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "Tax Adjustments, Settlements, and Unusual Provisions" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": { "auth_ref": [ "r1097" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability", "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Taxes Payable, Current" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "auth_ref": [ "r331" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "terseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "terseLabel": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r500", "r501", "r583", "r600", "r761", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r1010", "r1011", "r1012", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax": { "auth_ref": [ "r381", "r758" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge.", "label": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax", "negatedTerseLabel": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax", "terseLabel": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax" } } }, "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r58", "r193" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r58", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r58", "r193", "r194" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost - 263,289,848 shares as of December 31, 2022 and 2021" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r185", "r192", "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r365", "r366", "r367", "r368", "r369", "r425", "r426", "r427", "r428", "r437", "r497", "r498", "r505", "r506", "r507", "r508", "r509", "r510", "r548", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r726", "r727", "r728", "r729", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r822", "r858", "r859", "r860", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r920", "r921", "r922", "r923", "r924" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Unrealized Gain (Loss) on Investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r702", "r710" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r711" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r713" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r712" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r711" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r714" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r715" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r111", "r112", "r113", "r456", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r419", "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r1102" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow [Member]" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r1006" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r440", "r446" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Assuming dilution" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r438", "r446" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperations", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1006": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1070": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1071": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1072": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1073": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1074": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1075": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1076": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1077": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1078": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1079": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1080": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1081": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1082": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1083": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1084": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1085": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1086": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1087": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1088": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1089": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1090": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1091": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1092": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1093": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1094": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1095": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1096": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1097": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1098": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1099": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1100": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1104": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1118": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1119": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1120": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1121": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1122": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1123": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1124": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1125": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1126": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3,4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28511-109314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28446-109314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r908": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r909": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r911": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r912": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r913": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r914": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r915": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r916": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r917": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r918": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r919": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r971": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r972": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r973": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r974": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r975": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r976": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r977": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r978": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r982": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" } }, "version": "2.2" } ZIP 130 0000885725-23-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-23-000008-xbrl.zip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�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©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ʎ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

]5@$V9.G[H+)13& MJC#\][GB'7)-JNG?=O?12X= #I6(IHK8T9^9FL@L4<-C%]S%04'RSFY?>V7/ M-@> :_+M&:-G;KEY5= :N^^^+>)NPZ@Y@V#@YO-)!TU67FP0<0/JO9 MO)G;?2YE0247JR.#V99T?P\_H%4QIMN!_/C-'T9A>7\(C'/'_"M^#SH$M%D_F$(-0;%Y!O&4ZG__!U.)_TIP [(RQKJ9HKMJ=E M*/AXXH'2B/K(\^Y_3FUO"N.Z\YCV(UP@^,WS<*_1]D*9;(Z M'%FRD;&:8__+(*@E"%MR*4FT#R,"[UX6^Z/UZN?L@^I[?PNOK7Z,_\[9RARW M$/+$<'9U+!Z#;\2>*B5D"?YR5R&=F?PC*1P?5J1N^Y5K^XW5][VMB(P+5O%" M>7^SO@!'R>X-)-'!R&)-AN4N+_X2W;'1^>S.,JNJ]]GZ=MY:9#!$X>SZ,/>KN-"$\4B^6YALG+?3KV0.3H_2. M3!N!D;8B,#Y$-@(YN8_J$LA2?E79K^6^VI].']8(>,0 MDF.&:/^#Q0++/B@G.F.E)_'JZ^H]*5*VPQ5ZF7HOO=-:]UTYLOY=C M89E-2N7YJW M%UF'>W2Z1O6X"T[ 7+>LRE7[5M-48[TRZ]A-QVD^GI>"TQG ?62=)4VH@Z%Y M.V_1VIP]VA(@^N+S> \#6=SU[@/OTJ:<<\URZ32;W]C' M(+37;24O35UQQCK!,=?KD_2'F"Y@_-(590KA^S?'0!71C-,T6ZIW -9M<5_E+HX9&W<.0X>X$46FN0\!FK*;-CST,_OW0\#/ M]D?63:IE_GM4.3(>/:X^'TJI(OELNN&=C$P)#@63OR9-CU64+6^*ZE[+SN[P MZY<#+K82XLZ)"4-8QAC&O :JAY!*NR50"?LHVO&,RD/ BUO1S>5OP+%%@-6; M]0=N]M[2RUUWZ+^F7^0F7#+2?TU;\77P>_A#\_8$QY2^AL%F7QQD^4HF:T,3 M$%-*M4?V7D0CO5%8#F@RE)0X_ZOYE*3U]^E:'=VX@0;(\Z<[/3@$!@KZ27\E,)[&$C0I$N81G?7G(H1VY;P M"J?2$Z2@L6.=@7R.=0DOZ\%C1H8O+1#=#'_K[R[92:+";08I(KB[(C _43ZW M'C$5H\LWK92=[C\*DTW Z4(961!?"6FLF!WFS9B5$4.9)EO9 ;^!-=M+$>_JZ_M$#XJ@>G3U-?!(9G,4Y9RH7I7+P[N[\KY_-H7C(X VZ M\!:$Y%)CC!T;1'&4)RR+W2F8NA;EK-_W0O+SPSS9^U';ZR8RC$1]M/>@&6U\ MTA4>BD]?%FIYWT3:2Y:>=;+9V8;FD-%G[AX)_2'8+_-LWZIK??40F+.S:4BF MV()7(Z6+.AVNP6-QB#4^GGGIA;=?6&-#W.E=]$;@U_^+F@>)&[D6N"]%YH"L M*]=5&W/@I%#C%69)@W68"$(+K,-G,?)$B]WF=08]R$H/XV67W ;-;=&4'V]9 M\K&Z?EF8D5VGR,#E%T,A;:$SW5]OV3W (QRHQC0-\G*3;MT*+%F&GRR"UK^9 M?V6ZT=#E70K3FYO<\MEY=Q6!.R1 Z,@33%-RKU0H.;='?(]LGL7 OE*,_W8" MER7-'9J\^O 0T/KOQ0I(??!_O;2-__VU5?U?R\.WO QU8-G2.P9XT@>C(70= M$QD&'3E*GJYN.E"AQ'W]/3(28VG;"6)6. M=1@SL'7U29N9S+H3K>WG))DGQ MF4H'K)_M)3DPX)8+H3<)NTA")6MG<:YE:;F>*T[S%'ZI=AP059*HRCM^0S"= M]E_39\6*5W$"V?GA9U,!_]J)S&?Q9%[Z!8A UGZ2ZR'P\W5M4FE;4^J.^/%B M^0+Q*\/R]Q6]O.2.\CUXR-!\7Z ;*50K9+\R[4XS>94FAR$]C=(-Q2)]#EHV M7NP*<2_[Y)\ZDUD8A6Y[S4#7;U;C'V3!TV^5KO&7DZUO24H)& ]IGHL7_R.\ MSU M7$4DR__9%>SY?XVCD/T*-/Y#X)4!G@LY][^Z09(AO<:\_]JD"053JKN^ M;@7*9:X[M:>NNW0WI.1,V39D"!BSJR7(95P](M_@65P>6X7LM8%Z!UZG/#XH MOF LTJ17K$ :_3"MJEKV,?IYGZ8-$\_&C82R-A/#V:\R8B3OA_@B#;]EZ0GM M)6:[Z]E^%5C+0#[]H0A9IB8*RMV7F0HH<21T#%=R!)OK\IS7Y>,:6+=%"9"0"76H2P.>$"ONV!' MPJ>IF.:LLF.[7CY/WA;\B&3VYSKA UZ]DK.8"VN \&.\QQ)QHNK&"T0( "(' M)#+'D_:W!KF_3(Q'E;#V#-LNVF/Z,0^-CX+F7FKHA,[CKT!WI3A!Z=.?]-WO MANU*<8]E45)*>(N,PO';*8= />^&&6%)%#]=BT+#<_ORWH0KKC8$)+5:X$XN M-I.37=\7F,E>$WNVJ&$'>V;,P<"A*YVLQ#&695]DX_ C#[)W>>['D\VE(HD! MX7=)V=F2%^;F?ID>B3,@RO/G[D\TDK_$!'Q"A% 5:3)@=M7H6S"7@$X*M[T< MVAZPI@W.1+E,?[LBGM5V*@[*35?R-18YJ,3X?0B#S6_WS!;(9+]KU)TIN).6 MM7PD)U)5+G_5DP\NJ0;0I,E6?9%^VW2Q G[K \[!0W;<:U._'O@[ MUA;5#ONG;P=\SS^S^)[Y\:?FH:#4JZ%[[[9=H',X? 1JA64&#UXE*#;)W_NY M7F'^O8SYR8B,KM*8 :=[S\2Q:^5,;+*KQ8U'_EXG7:=S*KV&VQ&,7Y3!<;T/ MFM$K1I2^Z0PJNIN^X=%Z#>#0WIBID34NG:&5(!$G\4\CWBIO?_K$#F9O&1J4U) MTSK01'?AXH-RS_>%X?%9[+EA 08[EV1U[('O(TA]# M@+'^=&<9QT\@=%[Y+"]( &6JUOI2.;9 K#2R]YK! M04>G1>@AH!J&.3B5BHDTOQ>K!+*01H;/;A3@4HRE0+N!LY_CS7Z=K4T.#+U' M,.'@RCGN&0>(&]WN&'0K8XJ36(K>=R H;,:00AE"K4Y]TT,AJ]/P+@6K,U2_ MOYW&5P0\""RNJW [ M_7$CG#.LF-V!6IW.\9XB.\[ZPRN+)K)G:\=5V@4Z1"P?=Z3[XJ>S Z7)LR&/ MV]\:$/UD(\\%?+-+BN4GS]*$M"C=,;';E^=E*MZ:Q=0N.P_9S]K6I=T.7 S] MD*J3<<3 F_GN6GAS_KMKXSFJSE%7LRP#@0RKA?83$HW$->2UD,P(JN5L6 M_F RT&*]%^,K/.D5LU;:VWU/S@$-2S8,8]?Z7SC@#REE%W61SFX@Y4 M(/8#DL7(K:JYXAU"E50TO?O!*R>DXD*&BM3W4>0\+S%YDX7J M&#L[]6O?+I5F6@8"_BALP=#+EBS=(H_;-4\;S7.5Q?NJ/6\=_8YC9A7\%V7) M-+=_1PK'_CM2P#AUJN!'.7NPJF>AR=IN4)-)#_E!SPKL<""3X->J$XFL/U7D M&(X]1F,A:_["K@[)L)%PJ5N!5X:/8I=S68A]Y=^JQ*^F)D3UE/!FT4\@6+XB M?8/!D^C^ V:SC%HCLTK0Q7+Z]\(=H#"EM,EU (J%8\UAE%3**(*1I(\>'& : MT?.BIF0%1CY]?):G>E\;^Q#7JUO$4?C.,"=%:GQ$*!.EM),O9F#/_62A'M-X MUCC-@[!Y:NSB9'5@V*CFEY,MS?4-B;>3V)YZ7.4WN7D% ([$L3!(_@!T/HM@ M.9AA^H=7%'&.M-7QU@K(H?_H@S9VGTG_!(3& =]^K\1!C;11H-+J$"SS$&A, M1"=U<\"OV^6;?)715PO#\:3))LREOJ,[PK'8:CCP23JV^9O+):B,DVP3" MQO"1D 74^Q 0VS\$^ES4Z=G8V2\XD@N?"W$[GB&"SW]@P$';^I_A7B@/0H4T M:UMXF92<%(;D]-N]%'2R<>+NB8:4[\I";5;3-YJ%+4)>*OZNWI9$"(,Q9/4K M"=1!.@MI+!4=N+)SO&WF=UKT1[FLD\TJ%]//?\N-'[+^4\(338EH<=F>CR1D MU V=(@7EO2S6N/M*&/2CRM!"DBF&!^62 ^ZJXTV<=:_[H\IQ?I3T=R%KR1I7WGS."VNJ@00 MN@5HJ(PBPJDJB./@BY5CLXCK)&)_P4SC%EKMSV!"U!2?AM$0(*ZA87R7!)3P MCD% 98=!&V@FI![%,+"T'R7'CU+P_6#P:T1#:^3C*/.(.BD!MA_=: 9[L*=A MWF_'(=>;*PZ!2L[4O='K^.#^HLA^9X?D<"@ PJZ2Z,]R/2KFG+&"+Y^_ MNJ/\Z-NJK[1=39B,,"DB$>\FL&!!FDFKA$=;M*AZ3/U;_C5$U<'"N[Y,Z76J M]PSD"P#:V!7:5;BN!Z^X"6Q9?6ANM7SZ4:=,0]HA>JA'>D'<):,/ MX]_)2\IB&(_+F=PIC9ET.SS>?ZC2KN&AF[5F%M0QE?@)7S>1X&9T*T-[_JY]Z;P_C,^;REY$& M8P@X/OCU06RY#5=[XVQVR53OK3L:UI+!$;+"7.?Y.R+]]SWI[(FL0VJA!)ZR M%5PJ77ZFR5ZTIJ>'NSK4)JZ;'%-908)*VQO1;^D3..[? M8P)PXW%W.*ZOSR)U2.-H06(9_B/'?OL3:59DD:6JRF9!@%)P!1 K2_^ (UT; M$XG]%"L)Y44X$)P0=H1-8Q\;%Y^76)A?NFMC-NW#PM6R.+L1B8=Y!O*TDMAA MA.5!(5V4YM9!]4E'L)3 $PX!CM?[.X,2J[Y#K"\!!.^EKQ@>C \J"<6VQ3WV MT(B5< AP+S\]4[C ;:S=IFRI[#6TH__31=J7F2']\87(^MHRZAD:_W,P;]DP M6!S,(^AP7Q26;6KT !+F'^/KF;X1]?W$F$(*:-\.JKJ%P 6*Z $Z=\7X8>6' M9>EXLI]]67GN,2NW9U+J<4-GFVUO,H)YCB[$%<,34"!XC2[W7V9YN=B12T#KN\@QZO$:/H@8*EZ_#L,TX=MJI_+B$ MCL;68AVY4L(4++*U"'P^_SL5.Q1!I1T M.]%TP+O%(F :GI=?;P#'NW (>(\)1%TU#0WA>+ID$,'++%!VC[_%0"Z=XV\6 MG6/Z$% H7>&-T;)C)%9.6#V$'^J-2D2)ZKR+\1F281I'F%7U,=5L?B]H_%SV MJB/3S=+K;GQN)H.C"C-2(17T7$%C"RDCN2MY=9RG"\O]=^"%]E]%5,\'2YC) MZZ[-"@-P]B&;,_.Y!?OAVNCLS:2^3)E=I^VY=1EC0/*826V8TY?3A M9N> :=&0GNLSYI-W/&DZ>[!$FF0I'&*1;$E:9N :TO)179;=Y*9<<[SF_8BA M.,6/W\@,_C-++N$='IMGI7.T>)"@!)D7>'49T.7&#.9]64",WM7).UF?X?<' M3[R0]QKZG,A3N15W9LAEL#.P%F'*,-6KV&G[U0L3DI>;?5\U)!A[/;28RGZ1 M/O5!R.='9-#@BX33<&&J"C%K7@^_/9!QS=9N ,6-T*GRO]^:$S S-7'J6=OW M)1.?0R!><&&R \9,TR6A^]4@5)4^&2D&$WN]M3S3;OLTXL-H>M!Q(2\,UD"A M"_C7GYG%E523%0_U0'+"?2[9V^HQF$;7V6E)</V,%29GKNK7S:C>[GADIK^C?OZ(\!PL\B98X\X5U9'<'?2[B&=9 XC8^B>-3,M+D89"E\/[(6[_F M]L&,P6=_&O6:(_D;K[LL6M1;GM#HM;_&=LOR"ESGNPSD@!&"<(>!"3#9&G0C M1$N[G\()D?WJX@69V.Y<"K0XRJ499^D/T.S 4&*-PQ7&<./A=D/%.E/RI.[2 M=_#)$8>.AHX4 E79=5'^C=4]2>^/5Y+DGLGNH2>"0=75Y* _6?-IIE\#:PK@ MC2A!E]&P]1FQXN45C>&Y#Q/HZ<28F)6L.!@7+:3V8PU#IN(>T4QKK(2,RZI\ M&:N.MQ%HRR:JW@.8BS54:F>T#7GY_?2V%Q[2 XV"5/$Y#E?%]=I WEL!"5-]3N[ M-W E^ ;+3I7AF#,S1"SDY*;/N-#504[2U,JQQGU,JK$T0^P4O#LQ-(L=2@D, M-U1.5\[/YN0S#!T$$+N,:),X*&@*QAI2_)KLN!9TME,[]4[X-]O[H337CII[ M)[)&*ILI;GU@?0":_9]N8]!GJL_KW+PB?,/#1.K(FGL(69)R%W0CW]_=[#Y# MXDVFF;[99 NNW;BRN"G-6@ @N,*6!H%8+?I72*-#.A)?#I$P4B*@6>"7MSA5 M;"E8XW3)T6?%YU\'O%CD?J.1@B*8G[>Y;QN;C@@ H:P]$/"40@KB"-?(_?_! MWIN'0_7&_\-'1-G7D&6$HNPBRC*IB"1*D;VR9T\8&3.6+%G#!T6,0I3L^SH8 M2Y'LV]AF4(1A1AHGLWBF[^^/YWK^_EW7\WNNZ^F/US7C#V?N< M^[ZQ*C%? []%N,IC'AW""0]8 M^DUK4H1S)73[F0-7:.^\WI+88O?0)SSVGQDUOY_=O'0/&QIRX61,B[F?^IJ. MH];1^RY/&?'M.XK*NT*_@A2%;F:E'0)O':T92G&4,:+2K/$0&F+#Z>!H.R(> MA. AD721^A683E<^A)B[R")L]K]11=SM = MD@27*0!K=-2'O%M^Y'*M1S1H"?*7^<@]7I,(3MHKX#G.Z'O70^!+"ER589:T ME@[\FRM+%10PDD*C<(&WV/4.R3%%#8F3$ZJ-XWN#+@V-S\^?\$DK8&]VO*J\\SA($)AT*&1.$ UC+$-0A4(,FO*8HT+]!CE#/X^+U3_?MDZM"#_(FGG&7 M(D;#Y89T7U.T9 +.E5 ^%M8_*]ZG"DZ3[2:]*Q2W.Z3[ ST#Q PUU&%(2Y>G M#PRL(&Y=+.)\.TZWD-UR[P+S((SRU7F7X5B,B"GQ2[]8_RYPSP]E9-\H-.XU M1*Q-#9*,D*7R$QLZZ++$X(S "^UX"9."'&F-/RY.EUAM;HO:7CR=^I'Z=3>M M4^A J#%$C^?9!]=W,S]3AMQ=_3R&(X8X#3B8QK7+RCH+6.[)E'.VMG_XVUO! M2=SRKL//&-T5E1:Y%7#K7014&HJK1-5LHUU)_"I)6(GGC0>LQ3Y<#753:;5Z M>3T*]6"@*>W.RY1$CB8&*DS]5$ M0NYEIN_)+[<"DZI9HIY<27) MC4, #XWAW.J=)=3-$ ;5-NP&.9HRAC68P"&*$1Q.ZJ<*7ETIB2/LF1]O.Z^( MG&VY$/WH1XC%-YO5K#L%+ND<:NP?2WE$9.GU, SY7@N:%O4=E"AQN'+0HR\> M^^WB;$.OTI[AF0Q'Y6Y8?+J"-0[&M\NAH'PN%5EF#4K^7QZS FQ MS$98;_T4O_:Q4*(HRCZ+V7=>8JGZ$.!'_O6D(N]-VKQP/AP]V<9O3^P>?#GY M_>[3V_),W;LP-LG)Z_CI+301A3]3JFG.1M4?T="S$&BTB!HR&SBB>N^T=TWT M_!&F_AL 59>6HZ\(:R2+TMZ=:I_6APP'?JIO&M^NT[LSB^^X[R[?5;ZKGJ[* M$1TEPM_F.Q2>RI"&PDG9J0YQJN#$F:J6L=76](.0JG9VN0:WV-FVYB.U\D'? MN(^+LK&BC75O$[.[.C1)RM'+$F&82V[E%>OJ?[!NA4'>E7IE@>LC,O=X59=AT(1^QI:SAQ>;2$Q-5Y/>F3T+E1ES*U*/W5 M)J%?A%V]I[IS-=W+,8(/5I T-GH9D@TAWFNW7$%U0R0\'36((2FZMXO@NA/E MRXU9>C(66<>\_5ZFU7?S'OG\]I@LM<>8QWN")$<]$68VV<&V8&,#:EG6@;E! M#Z;*]=?1M5)YV0^;C!9=O/GMC2Q+F0/$IS?T/Q1CO:RT3FB1JY9L[(U&S7P" M1&"K5U0'!F!2*<I].I&OO=^9I?2M=-#4X LKP M3;@4I]I;-8O*D_IJFU:6]]>K;$W>K\>ZS)&_N,@,O0[\UG-OMO6MYS$V>%_8])JV>MX-'H\H;#O$!.JHQB$ K.OS=HQ4^/GB MFB=7FYML;B>%NL8"A8JJTSG^5FE3W9"IQ(,H4$-9Y^4O'3I6CU)5F&A?SX$6#O$-V][,:*K.SY/ MZUZL@:)P64E1QN650J-OQY.2?MM;EQ-T@Z&#C'3 ?5(/0[FDGEHK=G]5CDW MLT_*>*5['>B6_Q>U.^5V)NSAF6-6MQ6ZGZ5E>O,:^2+FT8UBB+DE8@P([4+P M37[R45+.0=8,O=BN])-U4M9(T?[5'84+4G195QLF0%,0X@S7'Q*W.D)UP-.T M>EINQ@7:;&1]T7T8H?U Q!^CJ]HE498!!E#4X6=!PP_*A3B&(:)#1H(,.1_H?VV!^,,*F2>&G4UX*%#.M9K4>Z[ZA- M=,LFL77EK,74,^I0X>8%2\]]_P]=:C=BQ-BJN[3U4A00.8,H\X$(_=.@ <7 MGMZ/=@$ODC9,]LJU;AP"5XF5/<*1<[ M/GL('&F3*>@H#R,Y=S_!/E<6,)M\V)YC\/G/HYC7 M!^4Q%24EW]24RE<5%&_IL5=)T35[0"0Y$+3$ZUDIF5\#77$+8G?BOZLP:,:# M-5"GQ!ECN//KF'#0XT^'A1"32Y(:?DGY9T;\VLX2I[L#S"%1=7HV)W6&KBS? M;C"[ 7OQ1]CMVN- JJRD^M*#2AF-7/,*6.]%#^!]3=:ZYY[%$?E>&>6-($$F MD51VUH#4&PYYK<\LUPMX!B!_'W8T5B[!"F^!0_@%O=\2BC/])9O5MCV.IN[Q MS2D_.P^!+%<1H_L1PH,W:=MJ="9DE_.V+@=QTX2XE-HF%+2L9WJCT>Y^??*% MWX_"7HT<-;^@Y2@N_ST:OK0@=+"^+LY[62J)-VPZB<%9-5!T>;.Q98(N"%J9 MOA9IRS!XW^^[JW91L4^U^(5<^A.S_W&1Z+JE)(8F%!P")^ J)>L=O.F3WIA9 M#P2D.C!(I^W3>Q,)L,[_&&#*U"4N4Q8<2X:2>3'A6\25M<*)NF2U!Y0"0Q^;3345#E"A%SH]4UV[0J1=25N2#D M=C.:WZL>&\KP^8R8[8S"AEG3(O15P<:;I.SG?B6-[=>JIC2^QOOYN,4D&OUL M_?XP#OG?2Y%++V?$?T,;^PDD/ K[Z]H(50>/CMN=Y;JT/LS:_.E2GD$(5[G@ M[9[>>W8IS& 0*5&<=#1EQ:+&1"[9X-MD MMMB$>Y74R7X023E+/05:?SI3CC>/X/;S<0LL1OV>6/+TD,+'HVAF0-[&*_EIS[#'[N E:T98\8799& MBL'5B'$]@Z9V3B(PRZLDA_JRUU)Q]N-OVXS?))TP.%=UY[JH(--N*I7_M#E5 MK2/O$'A81D?OE(>7-%2W07!(;JK>J+4QL2&R&/0SL?8\T6]()* M]S.E]VGO/+.>Z6>ZY3O4IZ".&+"M^@.>UT MZT_M]O_K\Z?QZ M9Z%Y!7G.M]W&GYB!K\S.VLZ;9D1S#)H#KCGV?5Q7!E\.Z<9ZU^:^5MRS._8) M'WKCXVMVHX\<0H:B,MKW)&( A!38:$K2H@J$D%<3>[B*ADK7+V3O"]L&9)R5 M+'YOSVIU#?[ ^,,IRW[N"%S%^;U&PM\E^K/&MMOD7/V(@4836]0KO_I/#^V\ M4'S+>_6$V-/'+Q2RG@0GK0+J!IH'EBM.<1VB8%IAGEPO0G*,:OK^Q!+9S/:; MSJOH!\E=]KQB&9_7T$?F[SX\T ME[0&XS%^S$M WO]\_VKCE@*IK&NI9IAP/*0,;DX<&OKJ;VM6HE#^;BBP:.&% MQ6MX21<+RU-9.":@OQAY^928>/[B[Q].?$A&@GJ^=*(^9++-B;B/.=C^A+^Z M(7S!A!S'KOJVR$(T0APP68Z GD+B"E'UWRL)/@'X0=0Q6)A5 XC$O_Y>3Y^; M\+GYZ,]PRGR3(V%E/WD>#UUNM$[<=\ MYS37YH&T&=R' ]7*XFW]8U2]%J)#Y7,YHDKLMNY9+ZD<+N[P,XNF\D6B?Z;X M9FRG$( M<&($M43^N*0K)*:J(3Y*JB,7)>L/%G#H2#1WA]A&S6,$/Y$GAJKRP43 KGT[ ML=#.]N;H>59Y1PV6#^>*DG"9;/5.8"2QM=M)J,YU#.Z,+U?HP3Z&YF1AR]_9 MR_I%,5?@@AN.B\5R'Q=D^A6RI4()@(61"R*I"L7KP@<7BO%#)\9,FU5DC5*L MEK7XCLH26+CMV'Z(6_]8^KNQP5F-D;!4 LUKB>ZPHT .P:=V0N*0K+9X*@^N M71@C8*^2K=F'\OB@\>%-3&A >[:VMARS^-TC3:ZJ.+9C9S#$,1B_JDSK0J:>C"R/70*(1(^3*HTW7 ]GQJ[VV+ \_-J,^W+'6T_MQH;=CV M=G^_DO(^XE)!H*,IY2Z(BIV MG_M&+=-4NT> \6!KY:T])E"4"%UI['4"SU3V<85=F=95'_9[["]R&_2[$ =>B%H/K+?BF<\QS:(Q54O%!&.H^O*,8[,<,NF!]W?#Q%\ HM M6W3B>'$J9II?D;T4>'3<236?259>6^&@>64I!L$-EKPOCDN"JQ3!WHWIOEJ9 M_%38Q)>[*6>/N ["WAB9OK234I()E M*G<,MH_3.K&!.6O4 .(:!B*@<6&TS8&AM#W8VP$J,[_MKC4E::]W:FL_S"_, M :CK8"9#MC3 D!6>""T(-X(')F:;T4L_-88RK"'NG7PD>Q*6=5XLAD_KVSU1 M,HME.BNA,(&4"DI_J_5RIAC#*KH]K702ESAO2%FM?'5ICGQ]_4/?+3VFO8MD0LF-\<52JOL'[V$LR4X?IUQ&#M#:.=3@S"%3U$^R[Q2:*; MQPY2#X(3T,'H./2MR6Y8"4X8HR*^.>:5+PL&XE5XO>X\YW]\J>*%5Y __C+' M:TGU?@"XB&/?$0K&DWHGH^Y36)/B\]>&JHV MMUHJ/K M\QGKL!/\ JI]!+3T6E3P7N68.1_H9$R*30LHVL2:I306S7.:.9?.R1)OG'^C MKGUN*;Y28>P0>,0([\^4JS1-H<_I@@G$2RVMGFDMA2I72@WNZ8',^1[,PT@< MZA 0HZLB1I!<*G 'DL[U,8UDY5!^/78OL8L^/SH,6H?R,)\[WP?'G"O+^_3L M >ICUFMQ!?''"4<^)A?( \[C/\WM4]I&V'Z@J2](O5C M(&S46PWU#:2X& VHT)QM<_JQH*%+8CTOXKM<&$E9-D2H_Q# R,'_USMC/-33 M6TAP$H ?@>*:[)4\4JI4A+^\I8\,['6L(GD1!50 M(0^D>]&4'6S[;Z5["'^5O+-Q8(_YGJ[5Q51=W?291]1R-(:AGO\SKS"5G ?J M?00%\-G1]10S_67!-A)W\0=#R74EYS2QQY]NX4YE/% _SSV8BDJ==(J''H>+ MDIQO)IJ34#%UJ8*SW::&DN5NV9*6?%&?[_,_3]DP6.[PHU5U<,($<$M;5TF^ M@UV2_&.Z*D?['*0N-AVA"8I]<\1Y/:5 MC@!:R]/R,#*,0?N(Q_GJ%&8A^EPMR3%#L9EOP\O/Z&GU(43&X.;.8L(I2G=&Y79?_7915(^+ M''@)*^#YYI3B1+RK)T-^#NI\@E\"G7!^_ [@8*_MTX.@KR'5UT[5-CY]Z(]/ M-UJ*;]R]\C&Z.1YK\$L%E$92LW*WQDF2JG[MLVJI$TFC!Z2=,72M2%FS+AP!5:,:=W#=A3C/PANXQ.P4Q"K(= M>G6 @-[2+$&N\UM/YBN#Q__>G:_Y>W=>$F;>TU+[KF\:V_%_WYU_$"RZW&'' MZ+W.C_T4R1IY]D*G:H ;$'-=CM!G\"H*09\3AE:3L\M*$G3/?]R$6)>!RK#0P(OF:@L6F4Z_/=Y>Y3V2)?=#FR),/RZ!X^&&F]!2X _?PLJN MC%,-"X=7=#).IY1X9_3X MQ3^4#*[+-TE8 ^']3&KDZOF9M8[7BQFK M[%$^.R[^&-M0D[6\ABLK+#PB>I__F R+0,[W-@&B-7X?XW E[! X!A/ Z MU MY*N<\2H7OMY8FV6\R]WG,6IB'^%O;B'/_,N:SI'\[0/1?X_VK0)*VKQ$"2$? M]0,QR.>' )G5H)^RXUBRDOH/)/K7OC3*EZFL:JJT5@JYOJI.YI,=\.8+D-B M4;65U&+U:7I_WMU#8&5?[%EKX$[-9@3U1(R\G>CC@?"=SK M+RIR;P00Y/DGLU^^5 S>'B,$A8EN59:_;:]I,DH("WO.(QZ/X?Q4]#!2_,$! M0T^[_\<M!5KY+; JX\7:K?ZGQE[++PW0_C,]OD+KX2L+<$ MR@D3+I(PY#<.?M:DJ8QW5W&)(M1_9!^32DRG^WQMA54 MZ4K!W\.*,,PQ7H4JX$Z_(XHOG!N>@NZE_.A(_KM#DX?P$T-BMIVIF]>QE&)W MS<_BBDE*BQI0BW0^^N8SZ_626#H37)WH%U\XS:B7:]VV)UKYGN2\SWV+G5LX M%71N]49:K%BTJN[N\6';]38[7#E;/Y;K6]RR@[#Y])Y7OEO51'DZS#[ZY0UM M&:E=[DN_+D/^3JV\@/15X0$I5X@\72Q$&JTD_FD>_]V,V^GWA^HZC-BW@*S! MLU\^ [P!.31NIV]M@_CAK4%B"5ZRZJ QN@.R+@F9M/.GA!>G<\1P[6>Z2-5\ M$/>YPZIC_;X4J_;_V,7N__,PAG*^5-2=;1B M+SG$M&:J+K=N=UM14^QI4Y3K-W]2TSF,E#@?MFZ]@-O\[QN"<#YB/P%-C 6U M,'1^2O!P_2'PT-/?)KS0C9#O_E]BJ^_^WX>>&UYE]^9R;.6!=PGRP"<549@P M!LFG@=Q""<&0-T@7,G\HHA].*1:V1C];\_).N['J@EM)FB((,@W#Y/ [,1TG M?ZK_S.J;TW,J_K?C>S1B9>T<3WB7/?!/DGAP9_3_?>?_P M#__P#__P#__P#__P#__P#__P#__P#__P#__P#__P#__P#__P#__P_P.\+JZX MNLS6F\I*5?*1HPOP"'CFBYK9!GJZ*W_PK[JN^-94B+L'\-=)FPG28)K:EGB6 MH,7^!XGG(33C#P$^9'=G]C)K">,KJ]VZ_OE6XONL(03'8T=3*1LADT&!'Z?^ MJ#==_':Q'#K'0>X;1[H.J5P9__34AOIP98??C.PCC FNN/K5].@O"%.\P]9' MX&A>BG"A$'"@Y5]LQ:FNL-N!(2_22ND25#.PL!Q6AO>^]"WQ;7_1O%>':'VK MRB%P;(_?KK6/I*X; Y^P2C07%,2CCV1+U M*M@R+"Z\'\TCBHXRODO69RZF"GI)<(RJ_%\(L&L8T MPO5/Y&\<[!J(6_2UV[PBK_WNA?%LA5)<;!'3MMD]-AIY?'7M/)AGSR]@P^=K ML[(.1'47:EJ$)&VD58-75X+/]P+A^\2? MSY1?^^Y;AV2\D0TH_2(W/<-M(L5M!M?AH0K.]>EK)!P"#J 710ML[5L\4IWV MWR8][,I8#*77V3146&$B8BM@V@<(WS?:V%69S27G$_T(9D0:W RO\X+_OLC5 MTI_6]X4O"/"]K&'J8CERKY]3KXN9AUQ&JVH[13FW_LP^I[W\!WK9P>TJ=P9^ M087UQ\](Y@!H9V1"A7]/5G?9 QSSHA:[+6CZ=S'A;#"Z*X><#.E+C:"? 8ZN44L]PI8F@9S*F)@TKC877F8U(+L3>JHW_,O[C1,M#2B?<-= H>^9$UZZ MPKRJL._)$><6 >F?\TBW8:"?>WVP_PI M7P-^+XS[^=8Q$>Y:AO!<-=H @@07,)4-'O-J^ NCN^1?/: M!6QW[K!R.=Y>J<3:=74NQ)PY M?O?H_*SC9?$1MD]WQ@U^;YHV!1(N&R#ZS.)+5*_2KA/"6XH#$2(-. MF).=Q!+JZ3C;B4.@MBV5H%+]!]JJ@M:_F]OB+ *Q/3C[S(*Y]%V&!E!G&<)= MQ\J6=IG[76[;[1_<_1K QEFF(1E5QS;N(G+!4:4$IB'X;XHK8E92E)9&/=*2 MN7SU$U@!/A]KTR&GGC-%O6)+^\QY1Y/E>_67[I1;UZOA%TEVL#7\3JRNR>FJ MVG!GT_H)VX7[5?&#_)\MM47[MMR9BX&GH47S"FNIV#+R)#%["ZV?7#COF9.: MV.93#CQ=XO(8; F]VS"R'3KSJ?,C3NT1MR ^GF2W YYU3Z*+S]]?HMK2WK39 MX'B..]Q,DPCPM?WIL^_/7&@@LO#R%@>KS+M\'"34PDXH&;R-)Q4&ML8V^5I5?16Y]&-WN"16A7G<]0D;9+3)SI$X;Z@#G$.@]6KJ"^# M+=/OM7J]$ F/'5"*M8EP:IN[^9RY?SLG0H_B7S2OM_D=A34G[X[J'X/M]N.G M8^&GR^"WP>S@1"GB=GSPGW,#]X_;*U0]*@R>-#J%<,,>&Y;#04#YKUE(OCK4 M4;@7Z/0)?F*B'IEM-A%D&JV7C'$!.&/ER5']8K'?69)[ R]#/*/S_W-[J7H( M2+>AR*]HA6TJ%'6XZ@3<85GG%?:N4>JM,6IG[6-A[3_2!E_Z IJKKE28_+PL M66O@;?T*\14M\IY6H'\4M%P^VI7Y_?,C095& M$_4Z?QSLWFNL:WCQ/L<-)RT_*+ %R!$+.$Y%_C3"*71#G9VP'+:T]QV\ M@RM#3E<:B;2\J9(@O_=7.9/H/I^N264.(OD"SKW4_G,NE9!)<8%YD8V(QR8J M[TBX]X;TG,G$+]6%WK&G=NJF7'Z45BJGE')+\ D,.!#P+QX*1''#[](O@6'X M5/[VJMH,FS%"$&N#E:+T^6LUWM]8@[?[_,^G3.XV]IG/47I1[ @Y6'1W,+1V M.HEJXU[\[52JS?B4D_2ZH-7\JX:'J;D2YC< BGH"=6\*BBO3ER/27P=\>(RN MA2;7#>G/A@P%AVM=\7\9^?>-A> =MM$R,/)L^S6@D< M/(YM%D=^9+5EDY&T8JH8Y>9]6(8E4:/1.D<_L31/=6G^\D/3URQ>IV"3'3ZO M_-6[;AFLB*/N+_2%4DN9)BQU>TM\&>.U:$C*_UF@<7^PVF7N>7DVS5^H+B1V MA7YBAW"6I(/7HDJC9YV(,;Z'P(M^>:CF$W(#7KQ+)R,H3RO?=?6Q_6V2 M,;>'4@)@>U:+78N=\<'!9-+$$!CFA/,YO:22>+%N!,]TT$2=U_ZXMUR[W3V? M]X'BWA2FKK[@%6V]9PP2?H'6W>LGZ!$SX9Y!>!.XF(+3L"LM5W.VV6^!@-E1 MZY\.,6MO&6&KOVTVK\>EO '87ND,,&FR"HFO]]O28[LST8- SA! L_=Z7SFM1OCGLB'%.2" MJ.X0_2YL.#>Y%38WG:_W\Y6*+:/Y;[M$U^47]0Z!<_]+BQ]K\10#EQ+D"UB& MV.>:A7[M]T&Q[S?QY@0!XAP>[LB>:]M(BETZ[V"WPG_?S>J6\^Y]_0O;WZ=]O"_HQ2^X!K^?$68 MLG7:[VXZ&; >B9 PU JI+O3_*_%:[%?)>D,W_FGIFFI]G\/=4O\4ZQWW[?P\ M>>:1KB&ET)U.GH0QJ@^H@T>*VWM4XK_4ESG[8^TS7NK]7V@=NJ6I/C$(W&74GPY_^7V[7S[\5J,E=8GU>GL'FD+_,LQ^; MSK!#C"UR3: ]PV6Q1>PV;O/SW[/WW-%I+@7=MA2O9!"7<3L2E MN.BZ)7[3H#.5RP03C2'I[F]'=LZ_EDY>R(VY>U4C[,7%/QT6_0F_72\* AOR M14. DHRJK1FF7./E?*IY,:!=);A!I4V@<440W@XIN"GI3 Q1!U<_W>/ C,F& MNK=-8D.2OH;P-5^^>4VDC,!I\TIYBY-7?W^LJ#G7K#Y]]W048=DJ1]9G(.6N MKT581. 08%>DR"9XXD@MW+ ,^7#]4M9[F5_T?B^EX8Q67UJ\G6A77\ T:X0& MHV]XG)X1S6<&R46'0&PK:!FVX@0:(?&"%/WR"]ED2".M%IDMKAZ:2RTEH;3$ M OH6VR:1LSKDTE9:"12OK>7(WD3TH\H\2Y\YE?.[ C'#?0@L>10C[_]XO9NC(VE8>Q=*!/HXBO@DOZ[($-4"_.W8L MORIMUP@/=FBXKVH$2IZ^;SNLLB S#D#>/K^&KX8N6[[.^XW^2_NLCP M-PS[Q%"AH**_G'A=-*_*CIM0:-.03JIZF*E=C^99XN SQT M:PF\YIU#]$)A'?VP543E)9D!!]3FP8Y?\T[_J%W4"//Z^VWQL+$UANWY/QUI M_C\&H66G^OV(!Z3&+BBO"1M&2689]<+;QV$O7.9>[(6Y\[R?UK>NGN7(.B5J M0S[*)NL\Y_FII+2 YRMJ=IA^G/"1R@Z.XE9)4 R!;3DNAGKU76*R+\4R5EA2 M;*+PSVMIZ],N2=G7F#W=,*IS56N69+!E0I^5/N=TE*ZS:6LX54G<,:TS4]ZV MN_M+_XMJ6%Z_!+-/DXVPK*\:7UH"3>KA9O3O"HZ>Q4N@S[**$+*[?/JW [/5 M]&^=X!!B?@%IWE3W%&<3!DX*[N;0]>H:DH)NH_R2B\B/$SZ(*-=^:&#A\I'M.YT8C?!5S*M M!ZR?E)G7'+*([U,\@C M@WB/-B@T#F7ZR(?POKDVR^1:VIOT]]>,NC,54O^+[ U#4?FG5_H3$4IP.9)< M;)M?V)G*2IC*G9/^$R4O!Q6)-=4&,H> @()L8NM%A4;=*..CJ!14M5PR]#$R M-7OZ$.!M0P9X$NW,TF?KD,=^^EK9I4LE?O-,&?GPNFW^XB(%)L;*%1KW=_EN ML_K1(#\LLWE-XN?:.M+1]C8U7Z5JOHI,(Q-9'*!NHGEPJ?[/["' DG$(I!62 MDPZ!ZAP5FFC(90D>ZHFK?=DM/%O#A1XG^+\(P%)[>.WL/ZI)NO!=ERWFJ=PY M(7 (,%76ZHO!3F#P)9@E+M#<-$:J:O0IJ/@H12TR?D1YYX-4M=X7V>GN):*M MSP4_\ Z*YW>1$4R#<6+'5KM^_K ;P$#WUY.FUR^@2@T^WL&)KOWJW(TF6ONEV ;A=XLG M]K3R9ZH/@?OV,[> WW\X(.#Q IYRM#=/'!G"?PBXJ;QX)O&[Q9YG2Z&L[,$F M2OF'R->JICW,NSU";Z@?E7]\^>@AD(IV1G)P&04W-XTJ*VNX9J:89PK\.'T( M1/2M1\\:AF43N#X:O*,R@YE(_ZX']<2I8H5M;;R/"W3\=V4N$O>R1;'%>BO0 M-4#6.[%T,V3_=C5=D[/:!:&F2N4"PKU(/#WG8=<['66GRPM3O))5;K9TI%P, MK,9JO^[47F-)"G"2H5ZD->O:K)C/7.^#B"O729SDX5T?'^*\]%3:KT;[>HR! M=P?]6@D89^!TF\HP?^EJ*SL4X=\\M#/IZ//Z+(? @!A='G4 ;ST$1J?JF#;S M>6A-: \_[/5NLA:2&<'_\V04UK8[9[&]XNO#&DJ84;E2^T?=T73>*K%$J'?$ M,:4%^@"D$9+8(4/UG$)P4A\0S2HC]67N7Q[O:5#7FMT./E?;Q]N*V])_5--: M6/"(ASDDD$'%Q5%"7>I,"3XI^#.ON6= X*GMX=,3WWKRJ:C/3"/6D7"CVPQN MQN&M.@6_X#\D/>?T@SZ8B#6O!!!7(O3>^V&G>SJ$:2W+H,1RN;!I'7&J_GWN M$L\F[Y_$@/.AKIT9@4)]Z[[...9,#5.>J,LY+5>F'P*X,D?FB:+K%I<6N7:0IK8O'A MT<53[L:Q>J>1_7_WSHWZ.S4Z-IF(ZO1[3C_6["S7:UJFY^93$GCU88S::[;] MJ\:[D##+GY_92M91C?7]46CG/,B*=:\#/W;X[O2V2^(UXG:LA&RKZ$/>,U;> MOGQM,0'V;U*?C[BJ^QRJ?:*$6Z&;#;#;Y.B9IO+RW[;;! MA;&2AWR72UCXQ4HW'7<7U6AMZ/5KX)4P]V'&E5[]") ALU!R!7&?<)M(WK>O MJ<[%8/O2H#/U[=Q_NM+[?)HW^YRU'XC$?+_/RY[S9^TRK1;J <&ZVY*.+FW] M)NY@U&$"U]N]CI+8$BL@6C454]W2II+S90H^F >JI_][>6YMRYIR@>H,!E&N M46^3^GL6!# YCADKB1?=6FM'*KY6B?4U7>]\DUSHJ-*/>RI/V7XS"\.=# MH(XM4?]2(U4P%T^C=K 3#\"#\5OI*ER>TGMB=A2^TV"")VKHCWULKLR3E4>D M8:@AG)G64:%[G=1O#(:3!O'&H _IS)\3XV:3.;-IOJ*OMIX?M_Z:[%##]SSE M4[]XT"<5+.3[WP5#X4<[#X'7K@@T\EX!S[L.!<3D'<00I#8_;065^$S#JD.M M];@W7.O=S8HS'0_Z!Y('58\)/1G.PK(%1L#O0%*7&K;+\9_;7!\2KW>K@@AC MQ$@.5^_7."L/XWDQB(<3"H*ITM*>30=^I8+GO/.E)Z&>C%0[>'U4<4MENWCMJ?;7;XEIAUOR/$IA$O''AF-6YHO\>7#[G MM3;,3U^ G-#7@-N3>"*1;JE'/"7E:XBKL5R6O?E2:3$OO3//Z-48"?I:84TO M^B==>>!6!75?BD"+TSE RLI.S\[)GR=9X^&6^*&K%KQ@,+'-Z\.'7Y8N+K5 MR,U917_S]J=.1*-V];YILO6DG]*H_ES(LMW;(.G4W-58(-[<_NA%9EKAA@?S M=P@H#^D??N&H3EQZK@^!/R)R.G*2IC++E4NX^K(6W5Z7VM1YYRX[RU '9EC8 M'@[K&/O\8 MVDBX&!"K"G"21TPY-2Q,=Z$D/*"<^N+@+?-XE-#O'OZNHIZU+W5)JV5FC>DW MRAKF2^_=V1I00Y7EZI7]2B1;1^K^78[V#NVMIMDCP7 G\YHLA5/RG%]XT[%" M0=I_S/\KU2:PHZ3JVGY=9]U;4A^N+78(,B13Z4JV[IGGRYY5!M] M_G,((%69M3%"LV_.!C193Y_TZR- ^I8 7_VSL"MW)YY^>6J:;/O9GJL)MARL M9LRD[?I4OE.2O5%O$[G:@.I1LC/3KOPXJ6C!\FB'OHO;J_@4#7))U M)Y1H)G%C^Q?]^ K)=]$?GJA0_E@A>-CPDC?WW7#1&;H&4PC>G2IX?05)$,6+ M24#Q*MWA,O:D^AI=[&_::B5K:LG9S*ECT_#/CM<-%^A50;@+W(MH7#]ADG35 MD/9VSRD:6L>#H>ET8>D-D4\7[$S2.H85JOP4I+Y(MWRV*'!!9A*+K^NX,(:( ME@=Y"EH3]'OU=DQ3!^GT:JU)ROU/%E*B>TS/PE"VW]&XMZ.?H TE6W'2$;)( M?KL/_JS&)Y.SF/3ZY7YF7(:\2U!#E0>B^-^2A/HQ2P*]N#_X>I)WSKVQ]5_S M/KLK[6JJC6[SQ["R\K<,1(996PR,!^P2 &H(K1KZ\#6=G3Z4L]]S",3GJ[>! M,22GVY.*^-S;Z3;Z0X]3UIY=;]K.>*^E:L'&GIB"O -UKS\$$MF(X_3>O/.' M@,FCRAQ&G:AD]MOR*DT]2+Z/7/=QND$?]A;&"6-N'@(CU>]1U,R$"-V-03)T M_!&MNMR$IE7MW0G:\H]?]W;!;K (KGZRCRQ/WBS,U 8T77S<3S&EM;0_Q MJ:ST+TC^(I+I%7(C5O? )Z^]<]ZM/9-]CD7"5#'722;SF!T8Z(#^&Z=XNI"U MR C?-IL5,].MK'AXJY?QY;#K,6$%97^>4U7-)65*%=,5_C3U0-^#LC_Y>Q?RTG_7F(]6R*$#O$* ?#WF[ M<<"V98ESF:3V4"P7';!7I7']?J>_)D-P\Y_UBH3ZJ2H/2:UT]@"27*\[3<8( M="[ X%OEAH^'7G0^);XBE=L#C2L.CUSV"3,%O7!Z=C9-*3I* I?'75MA>(L7 M@KS7[&-N1Q2<>\#D]'>W4^4VE3!(IX3ULF1-\W2'-"R*TB.LSI?%X&OIOECZ M=^,V9Q* M<85A+U[S:9'N,N4V$AOJ] Y!,;G]Y9 ^>$> M#!%-ODI:^,KO/1&4&S3B(X3XI3D>ZLO6%#\PCPS.8_BUI4,@XS1HH/>UQ!\"I9-Q]-@)IKV2+7()71"",:><>#I,.YW2SARS M$;X92H=\*/F MU%G)<)NJPH48 "Y#<8%A;&C5:,\='OH@G1N=-=Q]8)_X 39\N\$W\D+M]?5K M-SX#%UD][_+JMDVO:T7K0@JI4&)%)A[-,W.U>+W%H<46:].I6FU4"(3EK^:; MR.:;P349?9H*.H5J85#"<'<2Y, O 1Y6=FN9_H"CO>U)XZN5D?8OKUYJZ]M* M3N[O[A7P*-%*.Q0VH,R(([#!_ARSO(JWI>M9B0%<]=L[9V<&$F.Q!GTB>WIE M:Y7Q2XURB;IBE&.@SDIF163A\++$8]BCW%O_F9&O\<@.W,!C KZG?'HV78+L MNHI>':2?0\ZH0??@]TAL_?:55+Y^_$,">="<)A%X67(17=]/T"%-]5*O$V5P MV\D!N/LS_3X?P?'>?Y3X47?^Y''RD<@SZ"SCW:)V=-M-GA M>41@#V *RY"8-V($39L&,\G=E('47S)&. 4%@?V7L1=/A;>28:.$/4@$E.OI MYK7[!$*;5HE10@%WUNANP'R^^8?*1*3[:3YDEV.'_K4(:0A7:Z8CD]]YTXL' MJQE@#D 3/C@8VMH_7O(SY^Z34+>-[QA53E#' MXIR.0/0(TQOE%'P+$A#.E.6?JG6$Y6=E(Q; 5FTP;=F.V MH>K,&?ZVZ#K<"@LS1I,G!=K(G8@/I3X,(X9U[GJ0#,C-&O+*IR^]L8BXOQI> M],.L+9/=W*#VHM!/%,_?@7 ",0:MV: :@#IX"?U#H(^TQ*6_ALF97.?M.E?S M^GK.23W,8%"0G.B\=F7^6["8\I3^-=A3.*%-H(21F2836"YEY>N//R%5^A.% M7I$F5V->B&>\R3G()BO12G1Y*&9PK=8)N,S;?KP.X8)KXEWBAK1\71I&T-7E M'G=J+(; DND=80C +S)X]8(DW#O'=>;732(ZIL[!%%_?'U];Z:65;:!,@&R1 MHJ13OXK%CHI2RO>3PW5(O\BKI%LH4G$'%YR=> W*AY#"]IV>J*@\+8VYA>.O M$7+Y'G+FA[OAG:[01Y=_(4'I%#&<2@ILF'J748U,I#XN$4U>.4]UG**/(F0G MWJ72^1-1O$:-BCA1:>NLC>L6"_[#;P[^/" 7<*%Y$7/(.LC6T,>?PHS/[F1) M%9;' K0\1HEE'1@+S_S\F?.])]/#Z%TULTYX4>9%BK436(SWXZ*>;P8CP\NZ M._BBS4Y63[S<228DL%V_16@WQK+)^3-G.-I0PCQM@RLI$M1[B7=2SA:D&J8O MJUQD9M)PT;UY?OY2Q;&?3EQ@;<_)WC4JWU7,DR-S+FUV9V?-E7PD*\^]?T9J MTB54$?\V!MQ7;XJ$*@.;Z5!^C5?8E]+*G:A-0'"WEO".6HS;'( MNUH-[&AK;BS56!/R/E+=2-,O$,)P8^(K(J0WE?MMUHY9RI6I_=M'F$U.F"@D MD][X^@\,#'P]WE]*__+,,>\=?1!]W*>N:27E*VAGEGGSL:!.>XU.,S/X>O85 MI5IS[!#H%B,>0!+D>KB*8##XU9Q9:XKAVSC*S4[!4@S?#Q\L.ZF+>2Z")Q[M M?/[[WP@(]?SA''/$/H,1.%*+AI[=76KH3Z"KTT>&B$LXRIM990Y%X+OHJ2K_W,W-85!VJ:>2RYX*F=07J8CQPSM!8#?( MM\MGO,_J;?\\1C&-_9,8I5O"DE?,"W^;>9EM8=27+^*K:.M+U?-[E<*T3^C' MYER(+TN,V1DP)/G]:M;TF:FL0/U+SA&FT05Q"R_"\@,F$_I2AP#*V% M=A6*QJ")]U*QS(9CT@E*9U9,\[=A>(>$VM"I6X3(_J4U\*N%0DD%TF M^J<\D2<[9.%GB268.8@0.&P^)6Q*[,W[>+,OR$FS)'^-6[TT_LU9\PZ3!X+3 MC.M= ^F!)BWQZ4J4VU,]&#\253^G='4K>.1^4;RR,U^9:'!=.J=KE:A]U+TF MD;7O3C,[5QO;&*[N+6*TY;_"\-[_K&\;IKT)S;;PA=J?@0HX%>4B3P)K':=@ M47['0+:>G-]UMX<"BG]F6X_V*@?K& IHLXGC,OLERE93XZ!_RX0GHTQ@5F*F MH@L-EB5.AKZ-N_7&'P"/ZVT.@:,SZ MAWLGZL]59*_ (6">C3RX-!6A%]AU"#0*$[@HQJ!CWP[.K]M!QL+.]+ZEW73] M;-(%)S^/R>+&^NLYZE=., >X$UXR'6U%SUXE+Y-">E*3<_J[4I,DC]4357I\ M]!=*8KP=.H8#JQ1T'XJBV![^$II<<+C*:\2ZO48_WEXXYPFI-L>($%Y*Y8\M M_[BZD&_Z(>^%WA_H2^:"2B8PZ1T$5&+K;H_VS,:<%V4GH6EL=U8/]B O"WC@ MM!JT]PS431NN@Z>Q7<[H0_'#S>7CKA.IIYN/=A\7EU")TV\A^]8BJ,8-K MP@C&M:DW[T8>7?(Z!$[J\\/".R"+ME_\D 'XLXF+GHZ/1497+0/E7;CJ\IV^]=J6:-+]7LE;\(^'.* MN,,4[S5\X&@B08@W'*[LF-!B]*44>V<]64;X=)(W:Q*XG+Z_HUM8\%3NB7K5R,>W/%J#_ M9@3MLY.P=!1Q!A;6#:VKQ+1K84[ZQ9^Q<]#J713[KSXNQ\EO)\08IW+.[H?5 M[5_>YV![D+D0Z8"X M]ZC)FIT[A,E)CSZVQ(;T1F(+\5L(+A(RBBZ"]20Y]B*%^C)#-$+4!A(VV.LR M6G!E55"5J]B.^;CN!BVG6I^*2)*CSH6:5(R:P;)?G5G+P@4[^>9 %?&S5CY4 M9U&17B!@20SJ/=R=][KJA MPAOQ2/ G13'U*)A(SB%"8MN"RKUL4[O"N)[0X#*TVA.#IHG1YUY-N=)U\74 M%3V45WL+?_@[SJ^C*!6OF/7"4LTU- 2*>XM=8\@\-LP6?)#/D=JKFGQN8<_T M_V+O/:.:BMY_SU $Z=)!2E207J0K @&1)B(BTL&H@( T 1&4D%"D20?1*79OZ']]OY8F.T,'(/\T(?OKY54 M^0@M55"%"GHM$_M3/8N/WI_IDPJ??<,P]#'8["UCE!+,E-[^_,!1?XU(+?V0 MF#5!*)-T9O*KP^WZV266>XT6YUS'&E_'K;G+MP=>>03' E!2B"%00\PV!N+* M5SC<6&_/#A8[;^7 Q]]:OZI_36#1MK>_U"WW=$AK@+;,JX2LAPQ,_:PMZ7.H M\.7Q2V/K*&%STD!P7V;=U0,4B)#GXO+#11^)361-[3LN'/]RKE[/VK6I$!=M)G^U/8 M3&V;XKDQ5+[-:[.'>POIW?R.[Y3R)A$AH>JUIYVZEO4\ZG:O#"9E+PIUXOMI M7$!D5?BFT;R><6GXD[V!N??N,ZI-%\]&+,0T[QT^"?ITZO-KU)F6UF'6?EW( MYV/0B>+YH'D:;P[DCQ171,+.'L4A/ $O3- G9>-R*TI]FIVM8P(D%2^/034F M7ROWI#PM?(4R6F G<0G3;(U1X+^Y#L<@\WOEM+[ZD\<@[#MPDU* J%MM^:-2 MR1CBP=_TB2B#-T=T:O+F\B*[ ZQ5P('1[$ZHU96YW:55_Z93-!N^88'LNI=$ MMCTW[3Q2G]4,Y,$1>'THY7R"Q>PWXFIM9^5)!D7>K-7S:H-L8WR330Z7I*/O M<-&OVC_';.=>[=N[HK^L]%0BD!?%X88TNPU,\UQ9A!>=*BN (*ZWB'._KQ._ M"-^S7DMTD8X"!ZI?G/S"#IHA0@FA%$?:M%"8@1I@043TDKM ?&T+.DDJCJX_ MQ42J3R :KU84X:[$W])I/HF2 O1)[W[C*ZB"[MVGOZ-PA9.L0/RD2?M,4Z30 M(6QN/F/Q#IN@]:V$,S&&%R%)1V)'!8^7N<3(8< ]K_*3\];I?;I!<24WWV.7 M39=I'RSN1^3*=&F0'J2ZE]&1R$>/)^A!9NG?A/B-MO:%8GZYCQV)0K\,7&T. M?IP 150,H9;Z^J%LQR!?GN=0]D."U/7V::I7 R&LY8IUHU%^@<8&X5&G0"A+ MQV_\)E7@LBL IEC[0CGY>X* _X*;-?BY UA M)NEHUSQ"X3%(7N[H%9J01\NQN!VJ?&[Y-KU5SSI:!(ED?F@$-UT5\0@\'5)\ MD?- 83LQ ,#*@TFF2F(=":.+5Y2K- M/^*NVNE5_0MZ?Y2K)[+2*W)=(^68RJ<1_GM+K.0QT?A;XX51[X/_08^T-_ITERA5A@3M$X.PA\_? M(@EVI:]?K%W=B')9<749XAK(KC[X9*&V^8R:'.^7H4_OY>T56W\1.[;$,8J^ MW2U?RZ2-R';+ZP'EZD*;K[5-K>_J/B%" +GX] HCBC=MV/FUFL+/>8/S++N:9ML,ZY-*^0(6T5*/1##!W?.>YB3EZ@*:5A=;% M(E;7++//J8CYL(JX3\U7O?@S3V,7A^ Y#13 ?^-E:>DOH@Q<9_X=ZPUM=!AT MX^MS G2(]X?Z"U20O@%M&U1RPXAXR^!Y'VP+H_?$PECKE,&NL#TNJ+W1KI10Z%V3 M[3^8Q#GS H#.=DEN55,1&G?[7I_-D9TT/JNXGJAA.7Z$88J0,&;5A#1 M5XF#+7@Q#K,HE_!Z"R$1OY?._=+)'HG&_KRJKOZ9GS8U&7:[E(ZJ(0_W%FF# M$"&J(Z"/JS'KME20N!+(MJK6-HMW3^GRRGCT*$QPL8BC%I=>W*4 G[4OT-E) M?D_U(RHX;S])+C.KVB)!%9DC9\X)9"@RBEI>N,O#6>H0!XSBR7C2_/-0--?/ M-0; 1";_@Y-5Q>JYR9!L@4H;4N$[C7A](\FO_8C>#-+0S@%=&%! '792TMB' MI<1?EWE4QEC;#78;+9/[V9^A'W M(DL987P=Y>M(]2P@: MC6A")G5X4AQ@-P!9_!LQR^DF,$]5ZW2 $G-EH+\Q4^OO=L;/ E,7EU-@?R98 M]%S(P38\5,%M_#>;J!U='EO>PHE\:T+:GS8FWI&&1O M<:]A5BE@A'?%U1Q8>F346YPYS"Q^5O [5 2H'@,BD8STL0?KLD3T>2A@4EQ M9S.5-]@C7C?AB0S%$Y$#;Z[\R7P+TM#XQA!U[4\@(<.!_.ZHR8"3RM&8<2<\ MT 1,S :2Q_RG7TJ%F_V^4'P3L45T**1]S9.$?(%@WQMPIW>WV2>\!ZHMI][Y MLP_U?]AVEW.)R'=+FS,=S,7+;$T6)E4_7,B+:].C3! MEA37-9_35LO-9?Z@2P_.!X#?M(XX8D1&0$Q0"YCRT?L.7I(M.1*)/Q'7/U0%Z^OUWZYI MQZ#]7[001VB=[$X@'IEP#.* :P"LZ[7(\JTEGE0ULK>F2U/^O8-[!?)D>=9[ M=A?\)Y[Q[$Z=L&:B?84V)1 $2UI2#?BIBL2 0NRE\DS-39+^2GH(K*Y!ZI2] M]R"3O.@2"RYJG %E\.!D[3).6IO:M,FX+S3Y0P M;4_2[)3&'4MOZ7[+_E*'\C_*/ 8%6*GBS0;\';KA%X''=(GH4GEJLA$3;AY! M.AW@>7[:T\QQ$)O>_LTUOGL !(O&HD7A4W2+TF.F%U&]M<9 _$+7^0?3]ZTL M^_:AZ[T7V&T(0"Y(9VAGS#3A6P9"T9B^VS68CX&\4)\]Y9Y<,@XE_4; M:'HS^^O5-]S1*CO[[CL M9))"PL99XU'64OKG GSIK(7-^>LGA/BX%^45]V3DJ7:9WA!E7'57BI7V)]4, M9RB <(4%UE-6?&TE41\F&ZMRSXE< MKOY0& \273FJ1OM;&)P$A@P!7ZPUNS6):1V=>,K"L^0JY5Y+2A;3>/?NR$*_ M*M/#!@TY)H/SV X452ABJ#H[ES@>43>X=RBF@MYL>BJ15D:"']#8(TD5M@#T M7;B["RDGM;I7F>HB'2/W@:[GYY,],M]0KAK7:@_WB7^/TI\?0#9Y$=PHD(6A M=4PRF+5#JQ)@\S2NM,)=+M=QAOD%Y8WODJ/F.;Y^>9Q E"-CNU<7$ M_PH$4<]E7Y]3*I_=S?1J'7EQ6P[X/"W:)UF<_A!W#,*9 7CR4SJT.,(2<*)X0Q1)PQ"M")(+IL?O8"+#/E%,Y/S MA-4E=^@]<\=B;X0:)7$BG*??DQ?1XVT@N,/@#.4<=TW3 7]\:,B_W?W/\*O2 M[Z(@/':]']-8T?-C#Z9:8ESN0SOS$E (WXV.O&6L'!T4K->W$7VNOU,XWB#G M+[W?. /IJ'!&1?2+(O ,56-][E..Q^QA#M@TYVED%]Q,(GA3_59@H:2Z6V(>;?/X- M2")!78V43E^_ 2LTG[C6N/Q4^GV[_VBC?UH8E]$6T9SA_/Y1HI[K$ M?WONK-G70XK\_7J^J/%,-N6W#K;I+_]0%((O+TK4&. MD(=NBH-Y2V,#FMH%*^MK%PFCGUY>XE,Y;W8SSEC\U.JS^5*8X\PA(0R'2&X\ MV2 Y;+AU#&6 2K]^F]YX$=-@%Z9N]_.A2Y?7[WYITM MWY_W+GY^XP;VFW/H.^X!NF$#_SGW7L0@, [-/XRG*=P;"OS% 7WGN,1B!8)- M_WO]9 H^G@&$&4YILNGYD*3Z]Q,?(WAZ73)&KOTS>\WMG\I]NAJ MBLK*<#,=O&03,NPV:CXR,>VA])?/#E.P( /Y8 MOQ2(UUW.B%)2[%. MRL)=G=*'A?0YYUC-S %*ZW-3OKEG1!5:M;VU@0CO%"#ZS=G:N%N*%B#_-26.:"7!>IB &9G0CZTWZ M0,56IV[UB1IU5(8JC7URF$ WD,LBRN!#X.;G5U2Q=]J+4]QE\U/X)I0).K-)=8KYJS?D,MX MDX\M1QT03R[[\^F4:]M.,6M/[H@/"1ZUFV6O!.2ZPK4F$#VVI22A*LI-^,0S M@V2O"LP:!TK'LO'K8ES.Y^W5;B'YC]T[]S.J>EAYOH06\Y@FX'\3VJO#@U5% M'6&\Q!0#'-(>(.UX2V1Y1!S%$VXF$G*[D:0(1] MV%J*'(RN]7$ WYM[?'F02SF%$C(?XW[1_\.5+)MH4(SBD-@@I"7OZ"3RI+7? MG]\(:H[3/]3:)"%Q",)9DLXZ:[^_5-^2.KN]>*SO<.&^Q_GW/O^:G+,WR3=1':*#N$Y*;1(8(]%"$1 MGO\M:V)8Z9&SH5GATT>;O+WY>*6GLO7Q[MU:^[)Q$!_,\N5UV?AU( ZW%U,D M8,#:FD[(?:;_=3RY:LV9MQWF67&K/WH?*1? 7693KZA#XU!^=!!^&2>4&70V M^6H'23SKC@XQ)O-]E0%:J9[6]/>LK^^)U$9M,DE:F_A^2-RFDOT%"V.4+D-Z MGP##G^C_G 3]QI^41V,_3TH?;"Z(7,L60N&&7BY Y9QJOCGMW#)?7G43@4NP M7OO+@V\A))-.P"%61&NL0XPF1AC 6#=:$J WY[V\=_RD[J;&O"?E]H[Q*G?< M_73S0TBZXE'NH2\7*XV]G7)E:6M$W/YSR5CP&%\<5-WI@^=+$F8\;+)*I@VZ M9$G6!EK+X5-Y& F$%UK0R4=2_DN-/9>#:=="S+<35\]RE%S]N2XW8J&-RW[D MAP<)A**6 _$M.\OK>QQ.M*EC$!<5XH53?K+A-]_?)=B*4&&].*;;F,5XV_.% M1+[8BTT?P;\,8FP"ZAEVKPZ-TL( M,Q$H%C=O];F;W[T2))X8E*7/L\6:\*L3TN\L]*;:QT%MS:<@KB/L21ZO>.G' MMG@SZ/U2\&"4IG H'DM:,\FM0J[#XQ;&@OQJ;O*7Z2 MV[1YOD"I7B&R67"-P6K\_:*%=.KL(Z7G_G\2("&VHI:\*>XS41 9&)AB!I_Z M6S$$2=O#HJ.?Q>7U6PNZ>-NW3*U,#*KR-&K7#XA/N/%:%XB/2)(9GH!_19VF MV)*YCEY^/WI)XQXK?3A?]_".\IS*LLV%&^E/;U.8DT6^ASJ&Y^_^$ HL_'F/;:E5PY^!";];93=LN%) M.)36!+.AEPH>$,:C8FAG@&5(JIZ^=IQ0)\HLM+QQII]NM1/U1Y2TU8:X.X/F MNA:D-%WAGPRK\S$ M AD,^S2N]C-TL*SX'MKZ3$++Q+CEF/!["\9D)U)ZG[+[(%*0IF0M.#0 $;OF M_'--QT%(:./WJQ9YQ=R[^7;G[>ZG<">(0IO-=I9)IS%X2!S"&Q+#Z[(&'!C' M[CPKBGWT,_F]RS>46"+G$_,?W?5OWK)G#&N0VVJGC>7UTJ^!J,M #QZUE$ > M(Z*I"IV7L6\PO59@V\?IT/FFPIGI5W8]H:;>^#]LH(SHQ:C!1S?@>X L$64! MG"56]!DP3^MHOWF[6//>\DS?^!]EZ0_JCR9V)LP,7=?;W;I>%KMK,HQ2'68" M?NW%T2[,[)S5T?G=IK71U*%@J"K5_;,ZNWOD3 CT)$SJ*)\F$QY&8TO''X/B MGZ7'J2AWA%2NNNK7ILWVWK'S\1_-Z!GE?!Y0LX0V-;\D4&B-$F!81]8%1H=B MXA'UF#X,9WCAC>QK\XW++/&[HV;VWLB)S(_7LGB8'\O6A.>E=9T MO\MII; M=(&WOKBMIQ[2@*M=_%EH.!C M$#^5H9QJ3R_SWZ_>"+#/,X81;EF?N^'H=:?W_04(AREP>4 M5KQ'D1+07F;EPQ/;:#]%50F0?>%Y3[J^0=-%)",1=4&L[A@$9II-G_G<*N!O MT,BP?PPBK%*D,?#9(K:IO0[%RH%W5!-BV2)ZZA>;A_?4ID]XCY[ 3X/;DI(H&H72G!S946GTB4G7-V US9C0]=MCL\HUD M4SO8*7B?TL6A3KKAIXC0Q@QTB7>2\'L"U/OS 8'4(/RL7/LL8<_IW>S9C+I0 M4^,FC_LK?V!R5]F?S:?!9-N.RB'W+)KV6*R)@_3TK8C>^'*^8^97C0HU^:-$ MU/GX15?)U.LF[G1Q$"\*N$IQ2Z<9[UB ,Q@0JSN*6+Q MKFU<57#I;^UJ+[K$/"P2)2;I;7H^!V37S9SE:TS^#D!(OE9'55W"U%#@'DZ0 M--XE.7L,:JA]W)\1<*O>]8)2*ZNO\FS4V&O!$::4H[\.FG%TGK>F&-(F:)K_ M=C"\$(SAM?AK8"X#+0#^5'7'7\7SL= ,VTEORY27J]_ZSAEJNX__* MK/G+3.C_8/HVN>!%]B'M]5WLN(=')K=]*:A(U_-\-.NZ=7]SHGEVW4OE!\C@ MSN_[ZOP;[(G%OU#<1'3O,2@-0K0&)\$5H?%K3(7KF!X,KUMDL[),[Z;G=Z2\ MM +>5QO[Z5:/J)L-FX(1TV&^J;SV/K+T9Z"3 MGV&R%"OX.)*_"PR?)B,;K;M]+?6]H+DGFDFL<0&>O&],GCSWNG*MZH207BW6 MV/2##I\AI;G B& (?@,1[%*'?X4V_GX>"#\->&&5]WHWYJ1\E:']SM]+KUOX M893>:7N7]-9_XWMGNC0N&!(+-:@SST;7'Q,9CETXT%6L1/;7:\ MA=M_<(_&&;"<.28C.+M@BQ'4VR?3C31ZHB.I_! <3S+M).VS(@XE]B/KQ^F% MN8!=^(AFYO":2R*YV>952"RF*1C9/-F-EJ#>.*I$/T *A+OWS3Y.[6*> M_B5W>O[6[*$BA^4KD9C[N9,\N=ZN?2MBQE\/D0J"WZ+-0=D0WGO) MX*8^8)(F\(>$CJ:J/?:G0M[]#,N@)^+*U3S#;CZ8XU)A1 M3.$KO.=*$0WI"3-:#'8GIA@,M](/.QQ^L-=>9F>?8NW#@#LL29OK83M@E,_? MH3Z75-7UP"35>5-_?D/C1V<;?(SU)JZF-YW6?"S=# G7?=#5 MABQ:!Q:,X. M12Q%&?U@JG',_Y*3&6:_Y+;RK_LX;&26;CZMA*]K.7 )J7\7W9K^1%::DNTJ M3$C%O@E<-]L9(O'W&8A]C+1U^W(X&#,SH6/GXUK_IK@.](C'=JDST\%?BAU$ M1"[$=NL>@WHQBPZXWW$PVW*+TO#8&TT%EZOE)9S>N8P! M)]R1(YD1\"3D.C+I4-G88N;QMAB",]SSUTE1H750B.;4M^ RK)+(HZN;7^;G M(USFHEYU2\@QC,UT.=&[0C;U/"EP$+68]KM/DFW:<[YI4Z?R =;>SWM):>[65#V]3C",><3Z SXG;[:4[ M;]33'U:1YSKE1?ACY)A&T9ZJ\;^A)]$/Z'-^AQ?=3)&L*/\QI?RK&;MF-X;* MU_7@XY8.$V5]_:#S3J;I"650.))0@74+6_?::2=Q]-)$9S'V\TV*@B]F1K7M M?%PF4C]RG&(%%5D__&.\OK^RN;N&;5FTM67MF3CB^ MJ]5*&TGW*=Q,*-,]:(GCI$.9J%- M@>LV^R/-<*_IUFZB!2OAWE\E39./L1H)Y/!/)IPTVGBBY-\4=2^V*+RV;PC2 M\'L0O*A!SB3)#J"CNR1;2)CG>J[?W2)Z!C='BBY9BDK,RE:\KY<49@WE8!0D1" 6WBOG]8IX)Q',#O:-*B'OZ26/BF!-P/H04=G5&HJ;1 M*J)O*=-JBL])D"2>^I'/<*7R-N@2@V_+40[""YH$5S]ZIX5?&B.7!MNEU\R2'I_T2CO18?7)Y^03=GO''K-=4?=''![I7=H'IK.& M@IJ66UKZDH/[OI<._]2>L;@SL1U8R*0>XQY9FCKV6IQ/7;>HZ4"5L$F1_@EI MK(B#Z7\(A]@DFP*9.#%TBW=+]J54Z0VG=P] A,OXU,Q$7+8XBW3D]1(F =XL M.2:L#<45/N>,B)_ORX,V"&Y,IE'3SVL!>R'EHD^0:_4*+YFDSL.(EWY>%%RC M]4#K(8FT$ZADO4B2U,WTVT )7C[E;U)J_[L9]4'3]'!Q? M"\XW/Q7S)!V#/#'1\,M$6<)GTO;0Z;T$KUFJXKKR,6CQ6?:8V/FY -Y!0<>/ M?XSTHJ%^LT\.;@C\?P&<:71PMJ.KV3O890#Y'W"6^1_@[/X/G+M2Y&\M3SA[ M#UY!=OY"-5_P7IZE?-HR!(O"5Y#UDVEZ/OA)%I@?<$E)GF36*Y+BT*^0LY]IM(4'<9B24@_5!3RT'K)ME<'RGV(B3Z R1;:Q^V$(H6W M=7:FE@U'KY8OJ24+9_KT[NVW12+G).@PF7H?$P#4 6F% MLE0,()Y+2K7Z8@ S_UUJX6?]/TO5&8X76 -^.3&]5\&>%#DZ8Y/^S-3U]P ( M'DB],@OQ@2S/]]\1)WY_BW4SQLKVB7%L='Y15=E+)S_?:7_IS^ >_"1WJ5 [ M_FQ^(L>=3,IC^K1UDB*LB D]JO$&DJVS'2>>^>-)/"_*/UFK*#Z^6\5RVDCJ MO4(@C!%ZLOAHYZBN1>)BZ?[1/AU!-WC2,1\=GL,B*7);& X]91_NPLIP9\P$ MF!HT?P),S9A'NGK$HRC P^8PM/#(\?5;VO#_7@^,F:F^18 .=A6VMEP'A?BRFER":Y* MZ_*#9MWRK&&5FJ\?10:=S#E-38,R7\><9(G2HY!U@%84[,E1H9XH'L5OYB/4 M6CT4/,_F+IK&N[%JQ4>X-0[?\5V9;W30($[BUI*(>=VZPK'42_06*9/Z,#>W MKCW _[W!@.00QZ06_#G_D;]W9)+!Y554G7 M*3BOXQ8VG&+!+V.[-9'$=]308Q"/Z3$H#OGOFVC'(&+T,>CN43;%ZW/RV %\ MI"'@\S+M-_A)U_R] NW7=,NY@6PRB],*E*1-0/A@EXH7M4MJ'A9PK9:]>:=> M;:4X>*58R9 Y>V6^$#X(9@I5Y:;U=8D!]TA@XPB.J@^_++E<+ KL9$<^=;1= MMI3B/3"3N\2:VM<9J4UWD*^G1I#E:H;@0@Q;(WI)D<9&.FK"IJK^ZQ1B-%%] M_)KW[R5]3':8__=3[.K,3R08/'BQ:@^XC,AS'!EVA=D$VL"39OJ11Q' M\, T<(*L?46\/OWS+)[W1Z03))C>; S?&I!B,!1%H;5#"K2+5KV9UB,5L=9I M-<<@;&4!NG]+[_(%HO02^Y),P_>!C7R34HN6!T?X[[<,]AX>H)*1K#0=VM@Q MJ%DVR4 ;)DT,I"I!.,)K5^.K2UQ&]0X?G/2X@MY6]T@QKWVQ<.)E.G1Z]?7? M:;IV;TP2M'#0I72Z<+M$GI_LTR!N]CU3RES=HO$7$#R^A!8V*)@1V]XU!,E2;YJ?OD!0/6-SZ^?E-+=OAHQ&:/Q;[, M5@%#3_8_/37&96 MK6U?RF8?&/N6:"RY&G$EGACCBS+):H_?XAD?4D)<(V?.9/L<@V2B#.2/*@WH M(C8$;='IAHI[WY$LM"%6),#0!"L+F:1;\_SMXO%WAS;.$'F<(3@38)LFF7H, MXH#0>+>.03@F6@]%ECQ9*)SW_2C[P6IAR]&N 2&RIA'?4J,RF_(@2J^!7$DL MK\%C%H?6K1,TQ62^A-;8&K4W-C2:VOF4A0_?/I$(RHHH.( N3&+=:+$4+B $ M%]9?P_!A5Z;QJU*HO\RZR?US1>2-J)7GT:^^W6)_G1+;(WB(LZ6%.!H8$/W3 M^U69@=C>I?P,G[;OR*#RE5?#W%*YVJDO-L^<$L&G7P,!/#ADWS%H"466H,T0 M(=&PLV74!X#W?*!!9I#RH7V84/D5QRK[3"<&Z5P1CXEK];MG@+Q!-#<,VG[4 M? RB'D\P;8B]&?5>F+-G-7FX/SX@]ON/ZET, M%U6'XD$;_JO4Q4C.*4M\4DQZDUK4F"RKT6.I, M-G*&@ID1GI@4B"#$1UD#WT)@_VN?7OE#FW8C#BZ9VSEZO%/S,?24:Q#NWZ.S73.DT:';NT8++) S-5H6 MHL2 B3UK%J>BP()]PO?4UV*C-WX"YY[*8]'UH#@(3"W M__3S9!I;,I&>@$5O<);)*/&M%OM]MQ_;>N?,Y8\J_")[Z.0NMYG> M+T2+\ X2#TXL4B)"-[EE8M7O_A_359Z"E'!.ILL+3@X.5F( M")(O"L3=""D <+._W:O>7C#@Z&[ O#H;Y MS%E,U[O=91\-UQY@>78<:L-ER38DAR@])[SB'ZK/.N!1\-LQ9M?)M% -NE*J MY,@G=:^S+G5\0O=^5Z?W 2;MI:!^^O8_F6*AR<._0.O#8@DT,0")U3\CJ M*R]):$"GM0PDSXV/UO;*6\K)@CZ9VC&=(;F9[6P3F=91 SQ+^YOD%* 3UPYE ML/3TF',6CL>V6FPRO/76&1VU9KQT?L1/[0'E?3$[9 MA$M3G8YJ$ _2DYZL<;7&FL]\\%<)W7^0A&B0\>',NHI[I:;8+LXTTT5<@C?Z M0YQ!^Y-+R-YG+>D0+YXD _$IOT*;N28KEMV9B6E1N_(<_-F;0F<8+79-@M ? M>?J0?'2HS-)CPZD*^P1[=YV=I6'(U:)N$N\PB*!S'F\5@M,28M>ZGB]%1D3, M$ Z+>5[H:1!5A^P1Q-O6PC!K9-^L;+2JIG1CK)/ZP$;'NYFO['ZKZ#U3_.XQ MB,N+]@7= .[?8X7_CRHD:*D*U+0M;7>=;L^^_]-9_I36 M &2(O_YG,5UZF6\B_Q\MQ/"*'1>ZM<8A=UJ(O_LD969+9YH(VCUOV^LSOQ;( M'I3Z\97&]DBP;=\YCT?12^LK!%N)X>Z2^72PEGNK+[EMGW-\'G3-7W7J MOP/R$+O9Y_\*R+S'H)[K!LQ48^ 5DETOD(@Q@?)N%YWX6M;AK^SX-$VB9M55 M_EZG\;*<)^L3,#H&_9IY3Q I/B&E1402M"CJL!M ),5L"3X-8:A1^O4&[BBT MW"\IV/K2-%1PB?<-FT*I@.-^>S37Z8\K%DR[2SZL32#X8ZH],$*Q@\^N\78" MOCAD5 N:(\\Q]4,3@M>W(%/M? .L/G'Q73K[6,:U)#'?"W837)&A%$7X9%O@ M#IIH:TR4B!M&?VI>#:J$[BR2JUNY/;(E\MY5ZL69C$CS18;XB]T(EF-:3P?. M_UOM@[$!D?C/D"&X)+*OI2"MG=SN6)%[B;/NJ8(.+*6;;F<+*/>S_14V.T$P M=THP/:(72KRW2^3.NK#" M'A5^#.*%>1Q507RL3Z["+L_"63\3B_R=A>OF8- /F 9C?R9YOD+O4:D SXOV MG,#J\AX*\X&-7+H46E4UG: ME7O>RCG0WW[=C,-X4=KI ;JG\(5QD# ]$, %32P$GD4R4;SN6'9")G)U#M8E M QS]'@RM203-=A31IYZ-QN6VNJK_'?>QI;6O[V$E8:_CGQ+,8#)-@*B1-N>->;&A3Z3V9(8 M'RFP4@OK9I$A9#FG-! 0?":T]CT[4 +Q!@23H+#0QN!RQ(I8FA[@OIX0+SOS M&"GZ4U4@R%+O>H"_AT7FXC4-_XM!\ZQO)123 .- BCG]EB''H"8#\"),I158 M)&[4?OLTU<1U>F^D@&LS1!&4I?G06NE#%(N*W:O31[(*%A/PE^W>3/O;=.O/ MA/"Q3D4TF?6DIQCH$&'.]F]\4GBWR;QO=C@WD9I;5?ITU]"; _CKZ7^ CSNTH5-+DD?=@F=^GWZ<)A"M6.H]LL!7K1YC+18N^ /] M$;6#(;'BH-3S:_I 0ZUE)9TD!X5EUB.U JY/^=3EJ0QKORE<39R8S+GJS; - M=?+#K^4%2B+I;%5"8T/1A0W!/#FP!UAUZ!O$'C6ASJ\A-RW%BV#&G\>X4A8H M8_,2WO38OZ?'?GYH,G:-;YK*A-OJ,*ERVN[=C0CW?*&>&5ET>S5?U$@LWTS\ M .HK>&E2].\M@B8##MR\8L[F(L:PD+J M,E=O7!*+O4L8@.&QT"59\);Y'7)V8'H$LOFFWC7,V4 M^EG,_$[(\KT-"&F<_R$S.Z3?:5'B,ZBQ+,#P9YO" Q\_!HG ^>$+&#X]3Y+* M%-2D]D?:?OB+-3M?W^K%[TU%YB5NR[UO^OT<;FK3; M20A<0(+. (0EO !4@(KSZ%+4JMYP>FZ4=";0[<=P3HC'/H2$1E'%'4\XK]='X MA7HA)N;#G[[EI703[PR2>_?B?X__,11E!PR4IJ@\;UVWX5)SC^GN^L=<.^S( M['9;VM*:Q#AOV/ WA8W\VQ[[CMR_:J *=%VP07\;Z))!K&@<@V[DOF3X64+^ M"$@=@TS2NYFVUY/!M,O7T$UA/?(2-@87@!.K:8RHI)TDV2D>[:YK1YD(;-$Q M"&0@#_^,X.EP6D> CD$^VW^;7[4(YR&6=4A/ZX7NOA[J;3V*(I MZLOC6;)]5K7/U9$$PO5][F>1],J/(X7UHTY2(116ZGD#^6F8UM%;U4ROH[I* M8U]R/HN!.750;#FS>^2;@QE4#;ZTQ@O(K[\E'M"$P4E['9?(_G:E4[3^';1W MZQ_UU&;YB[AGA)]/49X BM3>C6:D&A3,I^M9N>-J=,WD^5?K5#48LNH&BSN> M<[^]O1YUN4!Q$\J(Z+F"]D(G+GT[;9I*DAD(%4N"O;K_I2; CSGEA@!KD:9K MW2!+L 53U4 DE_0(9Z!TBE0JPX,'%T'W%OP%9FH:?GV M5:"?#)_IPD\V"9''"H^,L-&&$B<$\1AAM.]>+)I1RZ@\'#]4\"3UO3_WTC.E M%@>Y4@_A%P)AKFFF6(UEK71B.OD'($'JZQ?ZR_.\XZE/2.V*AW$YQF724[.B M=J%_.,9TZ.*5&QH_O)F^=KB1I'JA/-]G[Y,@+S0#N2VKKMVMLW*Y&?]EU?R" M]E7I>YU=GKC@IX+33*_G-[VH@E7H]?='K]./KL\<@WZ,73OBOW,"I"PX#C,' M8\9*+>PYZHG@W_G5PW&,T M'Q!R,]U^ZM?%$P-E.V>>YVI,177S'I[A3?-F"GB![? D+7:A!.!2K+^UL M?%__FG209$[Y'_61\R,JI]SO9Y0$_>SG9IM@^(!*P32Q]DXN_M[9QA^#1!?" MX=]QG!F+GY[6>A@&?3+F:R ,2UT.RGP!^J6@.&S 29L'GT1[BXWX=;#A?96] M;%ZH7CK\(Y4[]^W,1:5S^;ROF+Y$&0[_$MRZ(T.R3\5VLOQVF?]EJ2]L5F^M M_OT8=//-O?CS6[E/SG";@VT-3S1X(LWQ*8AG1K+8RM9(Q=8F(SZG---:S.)4>D<-9 M6E]EDYG]^1FD%Y$B>0K8P"[HV6$C'^A'&!68Q:G@7YAWA5[TE#]7+2\J?DIW MBM73Y.Q=Q;$N==H7, ?""]. 2J=ZWL-1"I^K&S_ ?6_-9!C$<5Z;;#F3NAR4 MF3+%6F5SQXCH1?X$F% ,URP]L=9B3KZZ*39/)RM&Q)M;SC+TW!,83NF6+&5D M,:NL+5E7'42=@)WO(A*0R:$+C;Y(WCM<$,LTQ]*0D$?7HF+OOQ9OVW]TJ9A[ M[<6?V4$,\>;DX@%N+UF&N-9 DOP_GA=9TX]20[7%3ZV%]S]F:X<@M3*RH9'8AEY^ M )TAZ&F0'[?3EHKV->OW71FS_@PT^]T=BY^@V]^O*&X@VYP4G^SSP5NW++>E MU*V6$G&DBU,YDQ]L>NOJ>4V?>.X:UO 1=F7Y^R;8<1 MI9H+81F5E]VYLGJ.05&/BWF*Y5",0 DEG$[=.K4JJ>OIB4*Y2[6\13,3<^N_ M<)P,DH'98G^\F+7G^MR+M;:@'%WJX8IXAP07-Z).DA+,LNQ#O'#!Z/57WY@N M2W"+BC&+7V!E/@W:^5$+7I\?W&.DI:>N,X+=>9K&\D6E[FK!E($*WE1DV'O,*7GV;P.<7/=+)ZF$JYA3?)Z'FK^"\7S4-)K,?"=F4G> M6.8[&"O#I\?WA@E;;F*AQ3SZ)%F"*+&DIVUU+A5%O4Z$)U0O9;2AEEQ6 MKIAS,@WNL]C&<)_\86+;>%35Q0E=D1;"",/8@BX?#;\C*6=K1(+R9-"Z.S16 M0)8<11?L.I@+$9W^V)I X%(Z_!$##@8@Q!O(94530*W2][?S[UZH^ B8;+DF7OA4 MYDF:,%.FON?*9HMV[HR=%1?7HVOM7$3Q0=&%:CQ6WO!K1 M[UQ3GE3B))L?%(E0'Q"PW!V/> W2S3+/5SE+A0;]19EH>F M>K;6M\6LU%T\!D&EKURX))X[=&F2%02VM'%:2DA\3% U:IW;#)GQSVP>9# M2Y)G1<0CUWMNF++1BY!JLNXOU?-7>:X.]3#7627S8?NN%I(=$ 5.E9CN>XB^[B=U&FOMD6Z>)!M1J MBR49/D@3""X^B.EFBDV+CS+8>?=)]3E$HN,$:;MOQA?.0-)")FD""]+EF&!+ M#MX,Z:3>#H\T0T_1VKS_$K)G-47_"5E(9.1_#UG02#=3ZQEVT,*[+I^9?U\U M;TAK6#\Q74.3=2R;U1VL7UET,PIP?(U 9=$G(LW2_?5F;/K;4'KV+=V)#JE9 M61TLL.ILN#/RN.+923N.?):5;_ZB>$V&$A/8GW7(\@%6. XF^RX\^R:0_*#- MOM%#B(NK;'QF7"IC2.J/A6B&W-V^H)MLMUC,45Y$L]1&2"*-?U;/"M=Y1=_A MRA<<_]*=JQ^J%22!NR=_A)_A?0%:>L#.IL?C?%!)YU#5YPWA4=XVU!O$B.WS MU+J[;82J5^C?C'_RE8=6MPEW5.DEQ$$$#T*2H3QZ$*QUG'TPUV57-&]XGFW\ MOHCDTJ0<8\;NA^&!Y(OITHGD(I'8_"I$CPK"ZQ?@H!,_WQ<_2KNLS32@&B:[ M?.MNQXJ::D/ERLVH-Z:@8IZ/.NPZ$:U M6V.5QAHF73.#JQNYO(J@IV??W0][F6IX(DE4@.&P$]D/X?QY1Q--C"MOOQ>R MGFJP&H#2#*^P;VV)JVM:NQ!!SU?KB\LL!-!I/_/?Y?&?_%]H$I+(BMF9FN]Z@$6':Q.>H;\MJ$R%4 MTZXL@!6'6N:W!JI*K4F^ W#>KWHGJR'+-8\K2UP2W#D2FW-:C/OCV/ZT,;EM M[K >@V0"B4AQ1'\^Y% 'A5B>B)AB_>?@8 MQ'D,\E.-@PIT1&(I2 FJQ.PAWE>EZ".;\GKKJ@%V=&A,-?_,2[8+TOOD37;S M+306A3XP&J*[EL?;QR EWZ\T"'R)#W;BJ+P#@@4GPB7KZ@";=47&K?6D+ NC M;!]["V$QQ@_1QIQJ' IJW9H,&Y*:)*^=,,J3< -,GU !+9UX#!I0UO/WC @J M-RO#7%F.4E-L^Q"6'1.[$XGH0VE;K(B*>UKLO> M.KHIX^_6]V=$>%Z)5X(U4^I8ND$Q?2(7:WG( !&S$_F4:-U_^A@4'Z@G*)S^ M+'E&>S,4S\KZ1!&"Q_2 D\"GT-@\,/LO?7NQ M=KK] :[6-H5RX@IVMOHGZD@IN>;2S?=Y+KO[[:L9@OVH8D>I<"'8><"A(AQ" M.U7#ZG1N^MQ7U28NW4L;7QXH,->;SRCRB=9?V7P8 P*Q;T(\P0MDZ*+M(.14 MV;3>G?DN-I+$YM('/24R*E4M5N*#C/J;(7<_R!DE/G5'0E77*1H&P0*7ABG/ MPFRKPH]!?6NGOQ@,US]T-JVJ- L,\;UH\]VTKI7GS&K&AZA=O/AKAR+X.+1) MN/\8M.0[ !:EFKQU=#X&]:)F[A7-]ZJ[.HEL=G1RO-K_MM]N^OU6JV0P)]$$ M%"+) 4 H!K1AN!X)F4C3H/,>.@U^!HCYU<1D@'87;6LP.S]LZ7]PX<']&U1& M0W86ALE11$O+$#@*KD6"1G48$=7\"3"OTH>]OI_=36:D9]]ZX5BM0.T=C:2ZB,I'@DWC_PO['WIM%0A^__^ B1-5MVHRC*EB7K,%2V M)"3[ENR$)!F99BQ9LH90A+(D6Y-=:,9.9-^WS(PB6V;$>&L6O^ESOH_^C_X/ M?N=\?P\^9\[U['WN>^[W==VO9<[C>]B)/B4P9 .XM.N4\J[4.Y_#F?5OJ[@AL-)SU: M8*1.-I,DGKG24(W!!U=3^&) +&ADIQ/TAR_US3%HVSO_&'2M 37N2%G[ISZ= MCU$)CLC>T?A"&8)WI>"VR%K! ME6=.'2G[.@NRQ0)]C^#X:($$T)[/+OQ2@FM4S/'(.\7>R_, MI'Y;%;[S,=V+#+:P3,HL9@/!#5B\-RO;4-&0];Z> MS7ZQ7W+G2Y94^6OA?10+-54/ F=H)Y:GT100XXX'!8<]J0$VWK5U4_L!7ZZ* MFCU-^N[I?C93.?.[8\S#9-8.T!_2,8C"MTN")^/HK\3G_89V]?DK4%''X2K_ MN,[OADON]ZP+#4ZSUNDH!S\Y2B"=)O9'0;V1/+ MK$5_)">[ 9&KJ/IK^/LM M5\G&1,>EOH%$2_-SN-.)/;4YDI>SXQ^"),7<=KX0NTG!,R6$YAZWJ 5J3A8Q MH/MONX;LHP*V70NG#T9K"I(PJ=37]F>__GQ9]R:V?P':,-M)E2/U X*$R1X] M*> Y=_?N"4-QU/,P>Z_GYHT_'G:E5$Y"!LXMH,Y5B2]]?2/&AH7Z!2]LX=RB MPBPX86;8]5@X#S$ ?[+V0QF=X'/]F'O;K=ZD"+LSPR=^ZELBK-J;+JNN_3L@ M')#\@1),U@&"^Q4N/"<4FI;0ELW%M!=*DZ4O:MHPEC[(V0.DY?3&-QFV7!6I M[XY![NDL@)$%^PB$KV)#N>>>BXXI@>RZVY4]D*EILA*%A#E+D.M"72..04R> M,_?R5E;CL\O,'T*4 JH=EC9R.^N5Z7",S[=6[BCW6;E[!A2H6?2YW^4C^;Q3>C@$X,EK[=VF8@(>1K MII6+Z@55W_VUG^[/J%YTN!>>"0R4F3 %>H-^-.;]6I/A6,,>/]T<@X,W(;:H,4I6H25KJ)3 M"S"?+D===.P[QX9TSM0/9Z7\Q$OAGEE#JA)?B!-H+OH^,3@&#N\<@ MEZU]*U]&C9[6*3U1 JV\BJ[Y^]%% 0I+;U9_7I='Z@<05TFJ )' MM57" $: MR89;,W88WK :F[S!H=OC0;O8AN:YTJ\BI2I&[ MB*[P$Y127XBK;LH,*JJ">0@T5S4'[)1BHK]L-5U'14/%M-066'FU$[?GO M!36PF!EHW5+?>#$_WT#+]7/*EU1/"]U8BHW2UQQ=C%Q-V%ZI,<8%)V(8&LD* M,OC9A -8D.6&ML#WPF;+U&^.^@1C495/U[*&+GIIL:1?HZ^R&E:,? X^B?2Q M.+T13'*J080@_<>4)9PL@H-^V21(,?P$WMLR4_^&6P0@K'7A'!IBJBF@(E:R\N M+3K.+UW[F/BCN=;ET_5.28Y:#@Y)*= 3!GVP+=:UV.3QR00Y'_3(U MZ>LJ3!1C]Q(KEU8UC6#\3-??F3-BQZ VMQ+1JC_UM%,/E(F'I*91*@=]__^U MJ;1D42(+P;BO4VNA =RI2$&]LW/7\)&!W+===*Y.7M'L(7UZEVDE/+=R4;F7 M#<0JV5 -+,=J=0/:.[>(D8?( 2;?GH.Z+>94JSYW:C5H-4[ M79-:>KOJ9*;O7GZ>.UO,N_AN<4A6,0:NCF M,6AE*P_T]P_I)C6-)@B$DYX27BZLQZA!^8 $MXF: W,?Z]D& !6D&*0HY>!Y M>Z]*/,G-EY$Q):,E$\Y(DB!\*>]$ A=9^C'Q"&$51YBA6A92/'YO,*7>L>&& M:N95]J^6?".<3[<(QC033%3H8O=?!)(@H@W$DL*/02\Q\$A=%HJ4P@%YP09T MUQ?!.XFYCP$N-O>(!HLO'H,"84JXWM=-G\9^(P*\YPMT% MZDH$=MR:5[83"%N]*_4^*6'+,EUY%@GM9KC 2T]M^V]/W)^8,1#C. M:(,A^8S/EU0>WQ Z82"P0%MT:U[OUO4@/27Z/$.(;6VL%O$!R3?SOAF4=$K7 MSB] ?'8$^?3&3LL; EMO/$%"4=S_3H4Y'X.^)E%4CT$M1;0WO[0X)_6B(VQ'87_5M#NV5BI7K]+1YD-3_HF:Q\6EH-;+S)M1[^5*? M60GQ''M=;**"VN)GZ=#8*):L*$0I5X0:PQ_Z*(N>;@)0[XT:KBONE:Z!RM@F M)I(HE(@/V1IVHW_7-LIM^T:E."C;@7A@NRZ6BJ#X2TBCDS0R5AM-2U*=_&-< M+-7V^-D6\]0Z!E/V5D[Q]6 (5IC%:R9 FUYZ6"D<3. ?+U .8[;Q\TI\[I$> M<\UD(COSIN>E2Q60CT\9:6PE6%VG[N_2@#%Q]-:XG=LDG*^B>.OQ><;@YC^K M.;I'3*Q?33V\(8R7_HXQD< -X=N,[P$NI9-2P$,+[E()BPSHLS"6;+1SL)]Y M^2M/+9EORVV0M18+X();7PUWYS'H-%H+KD<8:59*U!/:X%F"E7?7?V5BC6E M^P)O')4![G&V(US+RP'YU!2$BL:.>1A1YG8]X%4,,\9-J"T89=4X.D0(YKUY MJ,SLQ@B6=Q?NT.3X!7V&9>P]!F%?'8-8]HL61%;Q@OVCSUN?HI+;;2JV)AP< M.1UY(+9M'FFF$FIP%*719#8]P[T+RU?T#J&&Z'342-53@7'CW;J7;PWA@I]3 M="-)^8L%2F8<>2_OQM^!39CTW1(73O]NRJH3=0(=1L]6..7N.-+3)0 /[N!. M;JW)C6W,%P\YX(1:34N3=0LVV_U$ [,)E=6?>L^=D7KP\E (94LMA@:9F]D# MC5CN.$Q]4WTQT-WKV$@70^:[;PTQM0U-_5H90A_V1$#_VQ['=PS=AGU M#F)&OH$8E! 'D!K)1LUT3V1=9\_Q:!Y8N\:BQQVZ@EZ/%NVFV&'R<7 M.T V;H!T^O8H%B,"/S^-/@?KOE9'M"V_4**8\;ZS6C_W,4F]]EE&^X73%_.BD]@B8\=DS+_F#\OK_4Z56^98R. M7XCJ Y7/]RHC=T([I-3HU9&.V?-E/P9Y,._N)47I^0,XLAI@=$AC2\4%)SS1 M32 )/J.XN#/3ZDO];@76_)9*O="2)UX1)17J^>Q#Q]>!3E Z79)A2]WJ+;JH M["0MHFUS,C!DZB '" W M'7C*T@7_=Q&$'I+ 8HWZ5T&O>>C65H<(04Z*@JE*36^Y+P-Q'UV +-JID[F' M>PV'#V$7.CUSC,Z_*>G*?W4@'<=46#I)GST/6A<*T/U=[I][4O3AM]IK9PA7%7LY%O6E:YE>E @72J_36%=8@H&20.C^HS 9 M"E\Y:0 ("R!K ^$=-#6B43X6Q0=X+W40@/@->8^V1F\_R3S![)BZ5TDQ=$]U M2SU;FC&!N!NWCYE;H;$Y$08/.PB&Q3 G_,V ]YO:"JWWFWB'-3*[U%C8T.[- M+V1!)Y?3N.2X_[^5BS(MIOQ/Y;[ZG\KU^I_*K?P)7]<2OM!ZD6(70'Z([#2" M\U7"Q K,<+M=<\S3W[_\A,ZOMS@(=Z0F@G[G#MIL9/"GJ8"DJ:UJ<=0B3" J M'@D.&P8%T/./4I@UGAE;?-ZC$O&PQV$ZFNGH86DB-+&C.PGT"_[_>UO0J1M; M@!38A;N012F!A"LS9524#W919VY_Z+V1K7KXF5E.$=SG1;26"(:(,8>0U%L.Y\>1DLH]$0<^KNLQ.Z$_1"'>X$64](^#SDWI1*>37\]L+=57);Z$JY&L,/-\)-<(K$Z5D]TM;ZV$ M1".\;:0KLZ:B/W^"+NB]QVC3,_N:)CZ#N !_"(R3#98V^'S1HD27)=+?Z]9B MPMF_KX]<31.]:S*%N?H-^^@^(D51FPYE?YI)QG2)5(R8@![\E*&]=++[588( MHWT50W9:0?V4_NYE'8-N*%3ML_1\EZXE),0?F(=:9[R;;!@R#0XJO:-X6W:L M[9/5UZX*+!UA7]KE4UBH;RE\9%.8T9^>[R>FO*?5(LW6)\OR(AT4!@H\THQ< MZF2E [.U-D8;G_SO7__XW_B_?)WF\U4+IE]0'HA&.(Z^_S?./"$EA-?OB"#> ML>8(/]9N_6W=V7TIXS=SX+B^L*L@ 9V%Q7#/_7IRIB"PU)>D?*3>I!Z2B(]C M,;018]B6LTV29];V6> RJOZ!QYMKM)@?TZ-G^D?SH M!835P'XYY2K@AH,F_67W15\F_,['F\L7="W2'\H690J^F5(5>O@R=M?%G)\! M5\A-34 SP;CMTVW&T8*_>/QY3-<-=:<4'MT+&<\:4>2/'>@0TNR-C)_LLUBU M*(Z"2/6L?,)TN D%I%?[%[$WG H3EO;SS&1U7/9\K.7]*#7;/FO$7B)@CJ*+ M*U#JTA8O3'VW,9.GE^$#S@[T\&#KYKBDQ9;XEEEXO^:&+&,O!$D6I/ "[_!^ M\&OXX/B_%TIJ;M(\#Y-%]?]@7":.[A=?C.#]!)H7N?_T^ F8FTSOM M>G5%497F@4E%M/PZE3,(URMA1X MM5@ES^?:P3%6T6MYP(Y20' +@MX!"LZ#-0<;3 ES M>/^5O=E\]M;#8C]V318920D8R]N/F/XB3LH_"@_UE5 :NP\Q+OEV3;>P)*BN MO^717=8C^\?N,3H\+@K\#/A"1FHR@A6N.E,\3=$BS%ZMFSZ;.Q+_V]=QS<2M MWLC+>\XXL*7??Q>B2TCO1/,1XU'X&M%N$==SZB0 M _IQ^!&=!/K1SDXHHEL*#F1#^K/V*^]ACS9O'QV6WVJR1XS+0'6P\/ZLV9G6 MSEX%?M#,[KM1)? M L9\WW++ 59D>8H, 'XRBV8E7$A_N\D1K_J4_X+3BW(M*[6X-XQ9+[@AC&-V M%JNH9S0NX(W:*& &IT^?3E8);G! ^CG)K_ADI1>HZ%EW_'ABYV0(TO [^&C= MB3E%$2?LWIZ] F8'?,S&E Z^7O];T%=TOU;W1W1![ W]HT05DX=/@H,=MWS? M4@CO6/(O1@C3Z@4MEF%A35"V)/YS.B=B '.R M70JG:]WM:->=SMU9[(^VQ#1FCIF3:OEV4VZ,?GXC!^]0UH3,HL;UQ=;*"+O= MCOTQ2!P7>FP[B")'LM_&U*Y%.RX.Z)\P_D1L8';F>L/V=0I]D@*=:6?TPB;3 M39)O,^)TG5= (&^ 6H!)4J:!/3$ZIO_/Q[4D4%7Y1M/"K:( =P^FQTV/:^4O M=_)&911'"=SABF)([_H\+(>#QC: Q?T1:I/T[#C FJT3M@];I\X,-MOQ9+ZV MRZH03E*=!5C*PAIF6!I!<',BF?1Y$BV(&)^%:>8J4[>5CO(ZL'_Y.S$AIA*WO*).OTX:_"P/T%\8(9QQ_)&[=CU!K MHO4EK71I"Z=9\W][=SA8>S$X]ZS';=-[&$65@/VL7E?V,7A8J6D9+/?Z)/Q: MV<##&<>:TG!+Y0/9S3N%%D$'(S EK%(W'5>>3T%DL-SL0("E3G3[1$-D9$2B M=*9&\1#/1%R) M;2CB_=*J]L#9U8 ,V+16WF@)8_H3U54"F).U*>J H/@@P-?9ZA;_X[-EEK-C MS\V]#[]JY'A_&FF?Z8M &1='J8:MT&>4'0_:3_6Q:)Q^5#7PS>Z,W8OJ3]\2 M*ELOGTVH%<#;NGV";I/+MY*KKA'*Z;HNP);KC$FA"0,3^("C3Z^$_$5SP_48 M9 BR++KVJ67<(ST]#NAOW"W4\3;:>[W.=J^;JAU]L7 M%-7(OVSMO19P?3^E6#C>4O5K6F49L_-QP<\^0DY >)02'LU#))OP8[ZI01BO M/0,FXY^KH@:,*8\%NH%1$A10)3*:3]R_LIN@+;#3E!64\_BL B6G.?J4'&^# ME[VD=,'G?IFT@+D/;[E\.J"<<"4"JGO\EQ[W&-VR7["I*,I;U[U3^%#"\7EUN2&=M65'-0>RY? MLVB6N;306)3#9,3;=C,R)+4-UJ> $)QR+A6;I+,LT># BM!7SLH527%2:":#QNDA<8WI/"7YI;-) 9'/N#+/"ET: M-&#BF?L[&UN^S4+6[:\^!OESQTF -72:(P)%\^'KFGMF$;#1P)8=-_UQ?8'J M1UN!ZB/L9B;G&AJCS\B^C3YA+"+;5?E!",0%$F/+]SLHIP->3@*=(&C"Q)P: M_+),M[9K ?ZIP^--D<8O=67#8P.:&?T*@VGHF%9.:Y.&6;6V+QJ634E_+-KB M=GXKO+<<'Q*ML#,29Y7,2'_29OBO$Q2WGB!@C%-,5L_ CG+YH84FUEH"/@>J MM87%R+RJ?/>B,B7H4J+JK^+6)-FW)_X;_XW_QG_CO_'?^-^,%Y_X&RULI@+5 MGNIMTFAK,[O7_9Z/AT$.B6]?R)*(5BX_XE&)(];X=_<$5^]:/=R* M;(&8G59.J X6\=?. MR<)2']-U8(/@W][&9W\<'.L$^6[5UAO%W8EYV,'!6.C+Z)_3;DTR!3*(JOB$ M+IL9M#QP WH2]FEEF)ODJ6Z]@'K1!F^>5TM;^OEY1!/EMZ03JL]5.GP!UPLO M)QL@IM$*@#79&2X.N)1N+"CT)U \ZG<.!<>^S8:L>:<N6 M[2].MG[F,^=_)^6\8^A[2^C-)ZFS_OT[9\FVOXI 7A-JHN87CD%]*SQ7ME,% M._]J*H2&?97P:!(R/"U)Z9%( ,7=>RNQT6+58M='0.UTKQK29E)I K 3@N=Q M8\%Y:WN/?KC+Y%S).-6AY1GT)4%(#;7(AQ?L6.'S0XA3R]IY/'"1G$;!=?-P M?<+4<$B)J9*A0_9SF(K6$,_2M@U3%'>=P?+ VZ:+GP:RC%"B)XV$.=IC=$22 M_NYQZLT$M%64-#?%J.<$' N,426HK M)/0=Y<&D'@]B#,W80!!,:GQO.'Y@?NDJ23#HZ,XM%QHY]5WVXMK=THMK47J+ M"NE/-+BR?R(;RG\- M$K5X"F49]^7%)E0#=US-R9=I$Q(BU ]H_GE@MMOO2N5KQPFR14MGSN"&C0/^ MGJ9[@BV'WMXG319)6'C_Z&)R;PY2U D[VH%B-""R])/&GC?*56TDS?D=@\(O M 5XCRQN?4Y+X6U'?^D&,VU^Z\RR4GZQAH!!CLC]M'%RO5U:Z"6Y@Z1KF@)WY M^\,1_1F[\3IO>BX(5&4N*A M3=!&J?.K =9"&9[.#Q=?QH!^_&"8B=(>[KA=%22,&DT_19L#-\KL7 Q^BD^/ M*3H%O^*#E?6&57]L=WC8AZ>\6^@T*3P[^_'DM%3P*Q,M4O"\(&GL&!1'_@A+ MZ'!5)2P5G@1J<74[%;\4S8RE_3?C[>W_1#DPW+;@*%5E?,%P(' VL$'IEK9= M%&UNI;'O.5D:.#EJVS;Y8[;=L&IPIE4O@7T[H(+_Q/9PC,UIE1]1IO)ON1Z" M=,D/\*G=>93M6N#Y,8B9B5C*L_47&=4N@UL\%96I(+%_32Q.Y8&XYYN!FK1W M247NKM'DRXCOCH=I:$4+@L^J1BQ+E-[%ZT*+-2U0KW:OE &;:X)S?9==3,*- M0;CZJ ZP7Q#_V[5V**F=^J&A:%X&IP*,WAG_W3@?A,JZ6?>I,<.#UQGRT 3R ME>OQA;DB>8'T6UJH>^-*:64E<\MUSR(3I5Y5[C%X,:50S4%NQ5D/2I?^@4\X MFT;ZUD24N*'&@[ F<)Y&N3#0$UHOTBSQ[G MO3PD#!XJRSGW\EQ^F6US:UZ(,M@M&3)E-^T_=[BKSUV/0=:A+2'R6(F)!0 [Z6PG(MQJL5VD6K#=WO_KVC M:K37-^%R424WNUM,_]4E_HY M^O3&UP.S="WY1U0MZ3W:=*CDO0]N+/YQQO<>F+ ^.-7QEMOS#\M$#D8#8D6^ MA9A;845(S,/=B46Q[8+A6"T.0<%6YO? KOS.VMW3]2SWGNT:9'I><@A7XF!9 M<6.CG?.#GD&+ >%]3X2SR'+.=6E_F5_K9S!^."_&C;?.UOS-"0J[\YKB%]!Y M# I$I2T<@[:7R9"M0@AA^'W^TZHY9T=#?NWJVZ8,O",93;8:1@,<(?'\#+_W MXVK=WM#8J&688' B@F<"8H';C5GAWMU7<)Q6DO^8.FB\UK.5'8BJE%,TOL?P M/F"E>7U'G*SC[.A&>0H(NGOA BIFEC;UA%LZXA)'-"(.>>KO\O*\UKC[I_,M M]_B@8P=!*;4A./$[YSC<"D?NQ8Q?2;;?E?\MF$IL8?*4N/,GIOS%0^YSS?!. M?:Y_J?_^G]1'BKA,@1KR*S0X\&@MZJ=CT/U@$<3H,8B^7Y488>$WQU!JZ8)+ MUP3V_Y:U3UBS%?R'; /5FQZ"8:" M>T?[<=)WWFFUA*D+7V#G-? &@2&* CUHU^6Q#S]/=4+VE&?@;D 5$=F%;+#K M#F:'&7=>WBKB.L@L[Q'9FG.^L8#P\M+,EK:?9&,XFFX=8QGSR'.\&S*PKE86 M-0Q2]!6;'<4(H>7AKG0R$20L=GWG)MS47N_^XN%+Y&HE"?*BBUX[W#IORN2W M%X4("VKO+D=+&8WNM)8U(M,QG @<2QTY+#")L)]J&455]#U MZ_86822=D'I>[@O7YQ#>1_E2:2\9]@4='>\UC<>:M!Z+M NRET=FZLY@67/^_3)";@L6!D:##QM M#Y*WZ]WQ$?6O>!^CD(E-:>W/1%C"6""K:@R3WJG=*WLH.7J]^;IQT;ZYL86! MQ6 9GI]CSC@%F.N=8&IN5CQE8EEX\G&.PKQ-&I>RF^@OC!@FJ"CUK[/$)8)/ M-X839MPUZ^\]B9UJKX40/C$+'4W\UA(7.G=R^8U''H@J^OTBO7X )9S@S@&1 MLJSD!L_BZQR MI5.C>/DO"[/Q8T\[=-XMF47>@RX<.E'?OB>FQ\(C<+_@JD35SERC19OZAH&8 MD"]93RYZ7[I6(L?Y3 B4D":H']&,\\V)-$4XTYC% M,\G^A8\0Z*-K5X6PJC=R-2[%0K];H*P M6\'/W?A^AB4YR9H]S1N>#[^DWMEJW,G\4H#ME#PV1I;.P1WC+3X"1VO?E>F; M+/ZK_Y4,;!&SD0WF!U/=8K![[-<+/\@A:[&NV>3SM.]V4&&]L_Y@-O0%P!PM M3K&=''^U\ZHWN?.HH&N]$5+WTSTUHA?[ P^)4+7JFKUTG U=6WUDDC ^EY-!!Z=2&7YO M=""U%>K/Z43R H*+G0%KBT\S[:%X!4=Q.:/),/[P)",9%=5+VLJ@0*MX(3\^ M2(@^V-0J[ZB*Q$.M; 0O9.&"JI!X)W8%<%\K5[EB0=7&#"NQ'ZQ3'&8J/F_@ M,FC@\>,YZEB[X+)F\C^"\S\99^ M&&'5'#T7I9V*ST&+$RSHPSJU&NW(LZLWR#L(Q0F?DLGBXQID)K4>H;IWHO$ ]*%?X\.AY'X#D!C206:A')21E6;X %G7W_\+Z9<> MVR0!;1Y?N=J(:6N-%[WHP]O:SS\L4O\)%'3VH3[61UAS&/3D@ Z^FKM&N_?_ MN2W.MC+AM\S%^>V!H_X:'*M_Z'1EOJ3+C;K!%/4?N-XQ;9NCW?FG6N)$/_Q' M%S%Z_T<5K:72!_G'FN'"G24/WC*7ECRH1@GX9_HBA*;4;DJ8BRVA7HP ?/@8Q4:COZ>K#%LXS!7''+XK+6$SM-'[>[TDVBK?'*4M? M-A%Z+OWB][>:K#8Q+KF-O/_U]AG_KX44P#A'+;CS-T'R -6XA7<#Y&:[R:,BM(%)?W6KAH1NQ^GW*.WB MS#[>.B?E#N$.C4O]8Q=U/S N0SWH3/XDO L\C\(=)C3,23T[!GEV1L VM?(V M?7OJM73W?NN/&K+IV%5NY2FD/U>+W)&YTY1T> L3O?,QT%LTTW[Y1BO/+X-S M[=TD0R"['&Y+S4.(PQ(L"K6NYUWYTCCX;C0[E(VU_!IM.[%[Z>XAZL[T%3D7 MJ5MM4TH?I1IJ&^/66PH?LXN%5.;XW(.!0*9Z,5&0*E(P]15%G'P)IGX,ZD9S MM4Q[3@;]3CWH]C]$1*ALWU&*JJS*-AR9!C_R*8,78AI9^M,7I?#]21 H66OE M%YH3>(JK0(^&K)K;+BN*''S5N2&?,7!YT;GRV8"S:EV.C02&$$["I).^ #)$ M#VM";MR!!?=0\=SR_,*R:ZLIY[>=8#DCJ4OA08Q#WK=+1&>S7)_2:_=^9N\Q MR$O7*M!!;P9]H8ULRSJRRHR>B%SU7D*H,0P#L:07U&+D/; $S$]/U\UWA8YT-IC,U#$PYA$\F+3'8*]"FG$5]VL^4=.V_93*C?H""J.= MG($&["Z@NAZOG(;+K;IPXUCB?N,YB_TT\NYKA&MLE@0OR'C'D>2?*8,>=[(: MS01MD=2H->T^JZC$[_* '#'=O'$"?0EP@:^&>D>?G0J<]5Y?T+/$0H+8L"HF MK#8+ ;]6HG?NK3"W@_YZ7)QTTI\<1N6F"*&');YYH(:2@%#7Q0CZ HH)HR13 M!9(%M^8TI?X->'LKM:WC%S0B<)9:Y*XOD4%((.40:5GD2-@A%MEC?EN4>@Z_ MO$NYJ+)@R!@!XRN-,#QIL50?TU_B5&3M^IH,0XS-NM5;;&_4P,I-\C0AYJ%J MVH]3UXI;R#=3,Q?M3S\VJD.S2NYT8F='D80[4&XWN!RQO N\(*??[#,%D:DR M+-^\"GTY?-]3I2\E\B*5XD-KB[YS#/+CO#U+ZJ"VT-C@2A-E(KDQD;M MT>19!\4#K92J8!!K]$OI=#8>B5.L(9D1^Z@X*5(O(6XVF6).#.UY(@J[!^;P M%WEY1OW!@H[CBK1#O-)R<4;*&2T?MQ6WX=(CX&8G_!@#'H"G,AS Q9']#41D(7D]6I"WD-?9OZ^#!J5"! MW=D[K>.[']]!/9O2EC^JO\IDM;%DYM@S$7RLN9S5\5$4AV@F!R"FM)F0O U0 M49@3+CSNX(3/^"/1&KV+Z/'3TG)M:KPF/-%0Y2"3I0]O*U"Y[YK;\VFL5$A. M-?P5'";QZ[$R5G:4PEE"T4?-0N?7-KL.L=S=#OMU)PMDXALF@QMCW?6&A*PR M^O0[*+*,>(M83)-=OPN2](N@T9F>^%@$&3_\I6"Z/%&-K.F1J4-.W/[]T:,M MZ2K[N=9DCT8W\%ELT"6M(N"B3^HN6IBVL,) ,7_O.P$DWYZ\/Q-@?N[DI<,L M:D4/W1JE.22*G8C >K=!G^?:"H()CMS/0N8;O&$094AX-*NT.4G!*DKS%[PI M.7910'"G(EA\E,*?3G(WM=2.C^Z ?G=JOHL\P4"1/;'>PRE'(DY A#_ KTMH M$]+>S)Q!?1C"/E7LNNBHR7]*0G+/J38"Q.0Q#'T4]]!";Y&L21O[+DM%83S) MH_R 537\(I'E_E^K/!Q'T^._S_Q3UYC//D_-'F]Z8;)D]\8;'4>$NU-D:N0N MU>4+=UI/4AWP:!&Z&)571WIA^ LQ1(=EY 9G*@C^A\P'6*SVO2/?H80V$U!I M$)VRK<=ZY^16V:N&P"H*IG$' ]DULX,Z*OA[FK?$GVK^92$%$E/S +/58]!. M!%['9CHL,CG5B)-7ZU1P_<;C@"9VV"( [[T*4UW80H411:@?12&[0H*'=5W(HLO:7!%&Y[ M5SO8M<"7T0+KMEWV$3$)YE0+3H(*HB_"\*L]A;)-(F4Y1;AEKP:RPKGO;H4" M,9*LG/4!/D+K3,JBZ77P*]1"B%L$(;@5/BW1 M&W_'1552XE&00([^MX>JA2#4&4"4[#]'&X:R/8+&@T4HJ5#^G M]6:N[4+UY8]S$@MW!FN5XUA>?+YM(-QQ@(E%-FBD_ #"B6#\>B]5&MQ$SG'T M#$("B*?KS3\N6CIK9M[6PI)[)TJ3A20RT@[V?5+;I;SH[Y@U "$R5?AH,BQ9 MN(%<$B"3JY1]B?]!S?2M&4W=>C$LT_ E).H@C5>YKD2Q75F MN&#<^.&@E+#N-59*1^1S!E15./-().(1PSJ2@<8,^)!"@& /;-$I=M1VI*GW M:]>_5M*_][0>RW<:/5DMUV?Q!ZZ1EHA7RG=XR"%P=L %6[WIB'D69AU1O:D. M<_=J]97.-N-*Y7_U>2FPCXR-P@]4"A_ M5^D6 MZ[5;/;^5C0MM)9>P>_UK][',H*,A&INO73^XX5\;R-^[W*7^KI(.2G<1MC:9 MFS,2QG6G](]!\"0J_X+Q+4W\?_YI6TKD9J5-'8/J^M,4H\P59WM.,4^MQZ5Z MM#=F9=&V3(S)\1C#\) W]Z*@VE!LD0JRZQ39GS99Q'W?:7#,SBK7JJG!>N]: MT\[TU;05Z4T,@6'#S04N0\VEB!("\';ID+!WZF701(@?="%,*XP]^[55>W_& MLVN^E\I*(9YI_!P,24=@$HL-,7QGD7P;UO6M>L%38[?\?!VCY:VIYR[FY M-U1=P\CFG5QRH)];O6%!;H*:N%:[&]':V3(/FA"847K)I:FTGNFH*0=GA?"1 M8F24?_OOH".S+]#Y#A9,"FT!'M[8E% B9@^7VHIX2L&_BME=E+ME]T&TF =U M^!H8$958))20(B<;+>;HY8%D0YS;&*U8X#PQ.&L[^:,E1VI-UI3#">]UEZ># MD4/OUU^[)-K ,:A6$<.=)KJ:V[\XB4@T+BCFY67!>Q^ M)#Y=>L'Z=P7OTZO$3A$CA*TDM7M477B.(]NE7OB2TZKXNO@@) (^2U6VS .QH>0#C.3[O-_ M9X? M9R%Y61SQ/P*#]+OU7WHIW91-1;3207O L[I[FI+_9IS%W6,L[G61D4+ MKN:PF9";1,$GX,&$IFB\S\0^\LROYAFS\/-(R_V44 MPE+(\RX"1M$G/,W=IB^%&0*X!Q/02MOF4OV6^E>*N.PI.9WG\^P]O1+O7N(L M]/^ #C[J-GS]_K MV><(9P;+/QRONFI#2HG"[C.EH_E30O[:15.N4FLA"H194@XAM[,@P&3ZW#3% M@DG5P7]0B@S>E;B3*K2[DB5MJ.GZ49:Q'RV(['1&L\#PWY_;RZ[C7M%* +3@Y7Z?#[]$BAO\ M?@Y,E(:>\WGA@K;M[.9Q">X9G3?#'H/Z3N:Y"<)UQJXXS1\**^6,&3S^D1E1 MJ%#WI.B+VYMC$!C-WDE7F1O4#WJ\L!*<8O.'SA+@([#P'1846:36;BHO)Z_5 MY_E\)J09YFWG'#^R!'J\0G 8!N/%$*SC5\Q2D3>S<)$!ZB^Z3'I8I(/2I,6GIK2%KC.LAW:\3":K2S"KEICAV#B.!R$Q#'NSW4ZH M12BIE'"E.;UA-%'O#&"#VW%W7+TQ<6]B(J)0C)(R+'U;I2J,Y;')NB^3[>AV M)_D6Q8NPLF.%).M18$4W9Z]\K?[^QVQVOX671]F>\CTQ\;UZJG-LK8,#J^3Z MSQ$"2Q(R<&7!NOM)>')#H$7'"AL=?*\K[A-UW[6TJ7\[E::?EN7S\(5!X&LA M31#V2*8;?!)H[H 2;(.9_/2TB62*(=%@_..%MNG"*2WTHEHP@F2$4. /1@218:EO?E:]/45XLH!_OS :(R#[O"\HQA3\_;34S1@X_L.#7Y77 Q,%14X&'H' M8U,^&:59(-^_27JHH]1TE1/QVKX)I.&U#L\V;D/!D]3DVOK+\_ G]7M20KN\:V&6&(K/NR+V?6[,*2>!VU#GD9#$@@E?7!K/ [1%2OBP4) M3RV @XE9MR9G>VE"1.;,]\VEQ,!JQ^%(/L,'B0)7L7V##U@N&8W'R.U"%XM( MU=-(;RC3K]. ];7T'GI>Z-1,"DKU>5!]U_@HW 1G(A\.\:_X_-!SY$$IF)F* MSOF&6%JIE*JJFFQ61GW<+5H3C0#]T=E]AFF.(R7E32%%(%)^ MU=4(?^"QN.+*@+#E32/;1IU\J)(6:/^!%NHJ?>UPVC3M'/4]A!T?P"TZU^FQ MFLZZ4I-6.O/\9[]V2[#"X(^=I^.#U24_!T]DJ"T00UM;-W7C]6FNF#A$R7^J; MX]DY=6_T,LF]]%*<.,5U0_7%24U;J46:+&W:[0S4$SF?U46@&)M#>U?HD/G! M>=XO1YWP-M9_@-_L7(> 9U>#VR7F\^\MC0?[/H,!::Y\IB<)_4,_G5U,\>PP MER]6G%^M=H9J*7[(X)-D)0J_(,DIW_9>*W@QL$>QGU61>>_'NN;FW5&69IL7PQ6 ^<+,13R/-'C6=8C/VUOC=8_DVVD)^FP "R M4XQR'>*.ARX(NCH];G"QMJM%G]E>3''U6-'KFA/NV_81PV-N:'83>7 M6-O9_5U.9]_)]ZARU\WZZLNZ4[Z;DO++/XPS!,$]0YU]-QZ8F#\_%;U ]7?G2,;$O [W_LIAHL$O)N99P8QB4J.3HQM\-LI0V-:'_.]RPF:+&= M4F/X>YLK O4"B:U:V?.24-REY9>''(."0^QFAU:VW"21G7;'H!]?*2Y%1]1) MS/['2Z!MJ$?1<]?3DT@OMV>DYD*Y\4!%/.%GIBG'PK.+YRX_?\B6,Z#7UYY% M8_,BWX!?MIA']A9R-Q-OI>*5> ,P/LWU$_N+<[]+4S/Q6C?KF#Q^5B9^95J5 M!_T.Z:,-8P@WE:*/0?QZ( J4&/39HP9=6^/;U#P;>/+]0+R#%$>/HJ:PKMSR M/W_4J8H P2\3.='-/MC#F3!V/Z:FG8^NIN%B-[5Y>,ZIKV=\OL5] S1"?4TQ MX-[.HA/H'\+'-B)HV$,BH63XPY+3 "B?>F[--'"GJS#M.]PJ3O<4:#5OCSM> M3YY:#PU(YV[N46('VKJA+.WBB.T%]?PKS^QN+_55W]%1>S'0^[!4\'SXW1?Y M)BB#?V>RGWY!>A1]]G_F/6@1R(F'.<[13WZ<)PTD3\SM N ,WXC1/V\\ZA MXF]N]:F][M._-R(DZ\W&%/1-WUDC&=EIH CZ=UVX_7[32$-K8_T-_J!S)Z?. M,CX0V\'?)S/>!E(I*$"!)0'9=.,H$#>A5K,,7>V"ISVA?$?> MYR%O'"[$A$ M(!B7G"ZQSB6(*Y"J-[O1>=#.D];LU MJF>1'>%G8WMM<[Z6;=G6BRJXW7" C]8MR3()2)^PFHJ_;?SP\WGS2-0?U @= M4I8GEN%WJ.\])YW"$XKVT+! M$ $".[;;3SL\E6+HO1 W\J7F E#][H0M W\\.I;10N)2**U/;7^ MWR^#)[E%W8 A V (-Q3YTOR::8*AB:*4@YCLI;-Q0A]-A#D>9V+.6@9,0>^G MS[-T0QMFTR'0RE]0'KL.-\%]I_OVHWX/WT=(&JDHWG,XL?A5 M"18\2ABQB*Q%I(?@P?QNOD6"$,;W@0%M%?9FTI8YC*%ZZAB MPK(A& ,W0:L0$,]1YPM&WK26O=0H'ME33X-!>KA_#E0SV#IC8TZR;CB%K:^ M:"I^T :6+FY.N/[XW9R9;L?HTC.3+UR%>8W2[+^*\=9)?31V]DF9?6O)Z":N MZE98*$I]A_%%+6K@-5(D :F*7U!.A#@L"-C8^KA),@L+A1UAG\&6@B19%ANO M5H$<7B513TP'[S04Z&W2]MR9RZK-U2:4CVSXS\@CHD0H!P3DC@/9C#;O.)L8 M1&/T10@1?*(>#?75)KL0]7T*'90S6D!8]3XCV=I/+AUG_$%]Q/)^U$( 21Q( MQ38!G?@:0;Q;]],GY.W;W^?GC3E(6RW!4IXAEU_*!;/U3D>YOX@ EU4=!A"K M:&SG":.K,C&4BUA=IU66WBVDN(MK@(+X^^1RO_$%1T=F_='+7G>6(FQ^GF38 M#'6KJSKT98P#?A)#C0!N0GE/H>YLK%Y!\<+1,(P7P(SY3B:)'73 J[_4,,8["SRQ,# ?&.PID(]@N;G2G@@#%K<56= ?B@OF9 M:%.-D2:E$:$Z9[L_R6/^3WM?'@UE&/_[BK*;[&29"A$AV M94@8-69$]ITBQ%3VI,FN,).]LA799.>^\?]Z]YS M[IUSOF?.><_,^\Y\G^_WL[SS/,]H* G@]>E9D[HLF9@/>T9C+LS*97R?Y]QG MQ_V!L.)4BAF#.\#C;$P_@M&W YPKBC*'S"&I!^97$-/9%,2''2!Q7V$;.[]C M*C?6V]6Z^E.4N&;OXTN+>M&7LD)B MF_W3:I;.99!*:?6-=33-$6HLB9.6+# MQ0J*\^:O73D_\&ZF>)?1VADA<@7_C5_KGFN!X7X.T>WW>$ISL[D1K&65(J9/O.!_*R#C3GAZ]ENTTZ MU0>DJ@_VFMV*MW)"U.#-*.0=8*\H0I+S%2'/46!%L)]RH&#,C6A;G.PRXS?X M2F;DIM6#Q$.1]$K!#7^Y]!\]8=Z5AE7T9$8JV$T/852-8G:Q1$;OV0O8DK^; M&XKZ=>]K>#\#/WBP3\CD?0;LJ\3\+;4F].=B]%AWM0H=1QA#A,$GT5P8-VK7\H>3%N\&=-9-4/E4\_CN?LSVTNN8?>YFG//R@X M?V+YGR6WIGOAYH?X.0,WU(=5(^H+O9WMS@W;[!GS\4J;M?ZDE.@DQ;-&:B11 M$ZM9XF-FAVDD6-K[:EON2J+I8) SFIKF[R%[<4K+QA&;9 M7 5+N&G)0AZFP7Z!]25-9%.0T2_!:8HHA +M)(HCA'U#[6##QVV;R(H7(3Q[O%>C]M'VS3>LWGB-\4XBUBZ9;SE)][C["EKG/EKZA >"SL %# MTY*NH-IK\#*9V&EWD-1%DF%=_Y5C])\9/_3?,ZZ_>Y>QUWX=A15WQ+,BE6!9 M;E]WDJ9%")=1J%2M\/.1T>B'141CW$@;X _^;XW)7U(TMK[L'=.3T_<^AT@; MV[Q 0W95/+TZ)/,<-H(L_ZY5++/_A;9BID?E5)"KXI-#A&).Z%;W?Z41^R^- M>V@K_W,: 93W:OD<:4K!B5T),Y]"J?3.[OO:BO2N.%>D^NVO,(]:VRKQSF.9 M6'3.A'$\/!1UD.A.'1V6DGCK:Y3:WR;8>QP_2)H0YMC7,>IW@+?].\ V(ACQ M\AL/G^-##4?3G@0*VX0+)%DOB./IUB\MVN]G M* (VNYH1T5QPMH]]GY->SFT1\?KOKA^4#S:D:N.%)AJZ,S(MG#0.]E<<@WQT MWPI)[97'/]\!?-.G93M(M>M)K?PEJ"J;T4.-=,_.=K%*+Y6C+OZH+*O3%=GH$!/>JI;J^><'7_7Y>:IP+75C!F\7,<@D(G=0[50=J9P.P^] MBTW49IE66E+\$-+VY#R7M6$W_BL;;P)$8O47>V#W^'KBQ8J?;(\/5S=\BXD3 M.>KX'HHLQ=AR9J&U:;%,,?PCCCY::BP4*G!';^7PS7N-K;Z9UXJS++[*"X8Y M'/1$S33?['S.!XWXM]\(YTN1.BU^]0$YF0BIWU9:3_-L:&S+E_',FIJU]2JR M=GRX^UJ"0*0S:MT"JHJ",Y[B.((M]!%*^4.6FDXZ7:L]/V464]2X'76E_MW2 MY]^J%RT\1']\?N9].\.)\(O]$.O)11G6X1W@41\EOLNUSY68@-L;>.'% Z3[ MP5:C8+-THP^_SM6$H0M+*H2B)*/O-"9S"V4*M(MD:JEWMCQ00%*3F=;(@AYA MH4^H<::@;=1W]/-K40E[C4PAK;;.[?O*>]>G5,@W$DLXGWU#*WQF3PRC;?V\ M2U;V1?[N-9TZ[A'WS5J/L&OX]*_>E[>L>2P Z"MB8SDKW[Y[%KMXC3#$WD+^ M!L?CN>Y"![8?Y=JY ]3@8H_\A8LO[PN@S-[9/=="2#J\)W!A_Q,O_LRDO^M3 MG>???<7>1B2:1%)9[ZN_E\>LWC+W/XQAM:JET^'9*#>_F0$Z]"K'S0JG6Q^6^E, MJW;$&[,C2MI_(\]=NSEC(I,B[:P\*&#>'>E]RQU9.GG2VYSI\0E_*U^GLB:]]U:D7;M@'W$H(^?OQAAA%:R;8X") MM*8>9:FSUB2WKWB#!E_83WT+^@(3/4K#L\1[*6JOX2*M?K0Z!V0-6-6Y_6V\ MUO>WHG7 PM7YN[*$3^Z>_O=F\WYI\/ZQR2V#Q1C.0_=B/4B\+&MP96X'2+X? M\\L)=^:X=H*X(_M/KZ4(P*^P))&'F#/?P<]HFHQUQN-7,ZK%".0ME MGZ$_OOA[._Q_VZU987KA#5;9S&OH TUTQ^I:W_NCKWOZG(>=$/JK34(\NVV MQZ$''L^_NYY5UC:R-;X$84D$+@<2-#$CQWRK6SJ'\-.?O/H^9XR0YBJ7-XV\ M?Q'J>7YOKL*Y<)4:/JL'EM-^SY42GI3^NI_3'*I]N3O_H\3)TNF>C9<5*<5[ MPKWF?[BW;P7G(%ZVGF&>XGSA(O0.P'7<^%[S$!LPC];9Y>SG,;M_A"HQ'&!R MRNJN2NH)QQFFO.O]*N!#S+_^/+"O%]GKF5+Q+3YQ9(@7_X2YKJ4R @L(A].< M/ZVZL],#97[B<8=:;N<\+)!_+*L*N?SC]3.(I87R"-.-,V*$JX-^J-H!E"V] M\O_.I$N7Y=YY@\Y;>BR1LDKLRS*)_;#_K&&N>IR(/\/.A6THV%YP?T-T9%= :TJHW;=QMM/XW M'GR_>6;DWK2=.:[/Y@VA)\XYX^_5;UJ2*5GGTHP#%0-CN!ITNH4RAMM3C)V' M\K'4:UI3;!E:?CPA#W:]E3N%5WR^UX1#VQL)L1 E3M@S7H&I=%G*V2Y(#$DN MP#\]G;7?;)TJ+)!C^#[1X^K";.4C5=F$JH,5FJPH*]PW==,FH!T3I4_(LX5$Q4,W$*Z'5 DU]HOY7&_;^3KJJVKR1JY3I0M3L>9 M!F>GOFS1G4#":33\U'/<%OL_WAX%/W/8]T7\N1OU0"I7/NBU8J>X!JJ0/ 2Q M6%SJ@ M4$TAW3WY6^.:1F3!$%XYO3$G?#D>>'Y_!*F(.7T5+@6<\1(2AN_#3L23$=1KZK&AI"2B*-[L0&"1>4O6X@:S M:SI_[4=QT<5!_IRP*NOAHE;: R'@;\">38[<#L 1RJORV3">8$G3PZ2;X\/[ M]MTXW_\Q4CBRTC-%K.^N>=4:?@K"L89V$9DRH7"V6@[Q*#P0$;T#-#@US6GI M)NP DFMHI5#D7 1L%!E"SKG7&F5[Y-Q5R)% 1\_4]ZP6F[_XEGID"H-4S[\J M6XWZM8OH,VHF6U$P4;PL/>72I]3A_E9":[[,"G(? (O)<-8+) 7"_C<=O'3L M[Z;S?VQ>'4##<3Y\V@%>M*&U:27N'($6.A]V9)4K1-R0B'N<#]@-+Y+@#K J M@MM6^,)//#J <4<5,#ZR7[ N,>W0CJ V;=+_KW9$:$C "[?KDQ_>_F0$;:4& M&Z0YBURX==%#Y,3^7=TGV2;X0=V)Z0O12/!P+U7[_J>"IRK-249_G%L>-2W5 M^/#L #*<(YAON%KN=>+?@-D4V62# KQ"+\7/5=2(,38XYNDGD[#F-2U1.;/% M>Y=?X9B]X0JNOIQ:7H$&0%[:_,61/S]9]G1XKY%390#6$1+NJ-LU4YK9P973OENT-*'TYIY-1SD[0#;7D\KW7US\) MY)D)QV:)LT-FD+PY5OP%#=[1 +0^,P)ES^586L%WD-1Q0Y.0!&^80?&\WK_' MNOW[@NI7B[R,76WE#!D=_'5'(/;=M02IL?7Z3&@#+< \X9"_I M:IZ7$!TG&?I*:NHL7T#OP2@SVW\;$\+40&>.D!)]Q0*T)3/-O7LP:FW-=4F; ME[UD[E\Y?*PU-P007CWR,LIB$/:KN2GUR][22QM6JS+GFTQ(-86M=['MMD3?RJ08S=/.QQ^P/V=+9:/S'W-2Y.0@^E_,L'#0L MLF>?U%+@"%XV,"*]W8SU;,X\$&=:;5-D(Z?Y*OF=C6I1E!"P@8O%R<%]AZ:+ MD)*H%G)ZFAF<5D">S:O\5#;1:823IO[H?)YFX?E;!:V4=4!5&E'@XR1_YX_N MY.8\LG<'V,,93J=YSX?E^5(>^$W+$$;,/%\L#RGR =:_KXF["X69D)\(-?,> MD??K6X//X8I,:.H)AC@YS&>LPMS7^F1F;N:?$SI]+EI5$K=_'Y3HU>DX]^J3 M\I6@JPOYTZ ITP<="-K15SIV &X+U1DHGHHL21IW(8N\[2FRO9(EL"\U\;3 MKI^#IPI?I<36GN0#>+;EB&$$0Z[63<-\(VBS<\B@ZROP+O7V2(.2U^DQ;<* M%#[$#_IX8)\\ST27#)!R]_[XI$UAZ_B2+DL&UJ'D; ^J>-YMH;Y!6QH<>W._ M2N D-/.Y6.^E8RY^W;H<'BP*_IZM03]%Y&&]A P0EC!C=-=&-8HN2(@>JE-,.K,BO4K(78 MH\4JE:(U216GPJ+Z^YJU(]OH0J:C();B.-S+.H^M72-\EKJY1;CLO\P9T]K M<@3;:?/SX\D1[*@JP MV*V05L^S[M)$%6:>PG1QCM.^P94;S!4HZIVB]]?,CZ/J;)M(%G1(WSAXL>_%R^FKY MU![JTR<'4YON=O*\^T1I\V-$L;/0!^C,N=Z.(3Y4+F5W3N(\F]>^,?G,^.L? M*065K8]L]AV7'RU)LQ0(KH]3D(IIY^,=XASP@3?QMT-W(U!DF ;*FW)T1$6V MB:.0?BI1V"I*GD]M?^H,(';EF-Y%ZZTTK66(,&=DC)=QI0G\.J]]:*FCIKVT M8?%%J9O55UO%7^Y[.)VUC5+0I5=U[V M4?V$2T3 .HEZ.6&O9U[7"W5U'V;-YZ6B)4-^ZB7F>5TJU^/P]8VB?4M]ATKL MQ%H\R_W&%%*2^2J/^)\RVK.@K=VR"]N6]C+*A!3'T6._)?J1(,1TM#H%)X:6 MHSFN/OK9*#EQ-B(X9%\6;XN-<%9IG/$M8_<#1IE%)$8(NPJF^A,.+0?YF197 MEW,X^CF3^'I[<5^4;8#3@7?1L8#($QNAMX*/CR[%@,(T=P9^%"8 [OG- M!;EZV,,RE$ODGL]V.NVM>KXJKJY/]_9*FKIF]1<+=6797,ZZX'N(G073N8.K M;^*VDP+K(KA)AN[UXRBU->6/V$?"%!1:DD_"/)(,$MUG79%,MPRM#LT-MZY?3ZGYK;VJ=#4U*XL1;W3]B<(7E-'C6^= M?&V?4+2?W.3T@^,-Z MRI5?V"7W/MJ8"^0NKB?4W ;\R.LP72^3D#*LNN$V_[R]P#+!G);61"[T@M;[ MNG0_'I,-YHVF?XR5@UA&1U"[@9 =@!>C<8WE"\+)$,6KJ^)^^?>!^63 M*%<)E?M#=X"H\7ZL\ YP)UV&=8%="].>.-3F6XZ&@'ZWYR]E5KL?6+MT3B\B MX8B46?B%HQ%[(9=OJ#-5.5]D2;6XU75N8W*? M:V+ ,[=S:A"5#_U=A,5/ZG$7CQ[5>C"/7PVEDR@>'"FX%-?"/7:, MYN'U*:+U5:]L9!L0,?X!$<618Q=BY'PQ_+3"IMSRJ5V_9\[SY&^$\?87.9C4 M[36/XK':]1"A0L)\A')%EB5!BP2.B]7U+_Q+::5,570DNZ852V;;,U*_&4"%49*6!4/I M[1SYS&O?^P2B77\GO^+.(>7^7J-TRN(Y/,5$?<;$^]5O"/M M>.KSKB@38'?DIZ:14O06,P0SN&^):D?T; ^U0_>"Y5RWF+ZWDVO(DV%:ZM1-QMR63$T= M/ZI858?27W&5>I'OSBN #U>"@:+N8@5 X<[[TOV9 R&ERSEC#C8R8?IG)5YH M93[SO*#UP'?5A_Y]]O!#N -S3A_9X6L[#[]Z;4^JGA1[<"2F)%OO9' M9GZ]/L]LH)-8XIUD[048#_UL=VIP:?.WT-[D4R/JS:9Y_MKB%U?A,T>JY)1B MWRI5?2'>29\,9R2!;#JOZY=Z8O(^1#Q!T&\7:6#X]%EJC6:O1'^\/T^)^--;XN^1/^#' .> MWSBJ.%,'[*.D4V-I[I2P=)V<(D5:6F=%Z6BG6GO7X%+?Q4?&?*$'"5E@YO,9 ML(Y,2C*P59%K_?:GJDI#I+J!+^OTQY8TL3U7O9-^+AM]X>_!U<6OMGG3;!G: M=/Y.2)I)7(QO\:_PW%T,*G)4N]BFWT90\ER%Q*7]#O&*L'X/2NL.0!Y:)3&O MH06_7OXG2SF:H&X73K3,72@%9 M)Y'>1TY/:!6EJ&4LFXPV3?Y 75 V$E$^(=NX$.HD__'S>$^1)#L?ZT^,-A&! M"=/XN]=W_^) ZBP#2F?\&(&Y3L%WKP0PS9IYUV)U]U^/ G9%F3F3U=O9?N1X MEG3,AQR3S>0W9@\H/<,Z#>GB*_J'^*?*1MZ,W-: 'KE3O>M-<,]1*>E+?_%4 M"#=UO91<:LR_U*7JY! 4:&E#5.GWS1[-_N?7T T"ED%GG:3]&+;LI'6,(#C> MA96$[0<;6B/IB"[KVZVCK;49KE;G)P./RGON]?^/SB'.%\+JSR41/7+0)Z1'+6Z= ISR"KG'R*?]]">AY"=%%]^4+!C9FT%*L;[VD[JV(#WR)5AE M-8Y'\].-+2ZS4RG?U?,.7L_^<2YOU]5$KZV[ C,1[9[(2*W\79D64"57,(8Q M0;OG;H/KP(ER]AM$I)ECM";]4XI!C_R#'_737DB)H9:S74@,2Q#'M$)EVXWM M +[V>%A(&:\#[C8_1)TNJ)S)0ISL^&GP6.>+3<:E*'/KB%Z#>A>J:&)M7#I])R= MPRWSA=_2_U90Q8JJYG0WIF3)'M_]=#X;YT[;C-D!D!4-;,,&K (HX:86>-LX MN%OD9/[>SG[AY(MWG8\O$M86LZ5X*,0&_&IO,6:4Q+_&@E:Z%6HR#N=LVHXZ MF"\._N#A25H(='+R]/Q(KCT!I.<6NOPT@!__>4F,N-!ENRS=F!P HX]40IM8RMA;9<87VO6%N]._T&"B7)<7>V\'>+1"YF!7 M'L%9B0A[?(>;*V5]=G6)9-T44!-6#/CP]JI8^_ZM")UK?OR =;LUS]P4".^LR_\Z\UO M9OKS?M8J5Y^/ZNIH*]%,]J[_L%Z8SWDLX5<.JC"%6?;TI9Y4Z#P_56M>&"F^ MDJ^O^MX^;M7:[X'OWK@4PNC5+RJBTP<=Y*.\0J(A)%/[:HWGD (B$C^)#Z<4+9',@U8P>R7 M<"^<+.L82,6^7-Y^AKA5T+FO\:F#6^VIZI8A@1.#TC:\QS,3EI.8)?C[I]X- MP<\!()2/>^)ZLI,@(?K#0RD%NS&0/-WSKC]Y[9.1BI-N91^>0Z>CE8J-A"L6LG7'DVM?'\W4U UY=7: M34%>]3>B]S6NA\Q&MR8!-.BD @/[#2;!^811 IWG*^ZQK1:%(ZV&+CCZ733%8ZX7MA"G=R T("2L&7 M7FD!YA/ M;?TWU&OSIGR"XEU&V[O/UZRG_$<,L!,GT#,#Z41?=)CN=L[00S$34*Z$8I_ MAWC1IT&_UU-<&2_>*GLT?T!W<"+0T>/:Q<"IB7NA'T6,&C?$3,;')PP"S(0 M,,L5/AU"F4U &U9USD%CC9PU ]999\H^J8WN (^=1<9^JF5>R;!W*%&VU-%W MPMXD38QWDVHA7RE-GJ>9_)DUBO68,FE,B\DCO9$5_ MI^UY,.[.],5\"H,VY'86N.D90E;ATC_K"KY#KDY91]\&?$A0XQRFLUK$;NFX ML#DV?]/O8G[:2.6=[Y\N M.J_W[(\FYL[*#C"'@]8L)1(](B]3JAL;(CRQQ2OA8^561;->$46S,N]XRAV2 MI#]_?A3[<7#=GYU:O_VU:>,Y;\Y"I!9E?6J:<8CNG4+0]84J<(3 M.D.HM2? M'VDG*"U;-[])2_:)($3C-W: >XZ/JYY?#$[##+^,@IN8A=/2&1/L2@,B>,HL M(I(,C2L2>?;J3JZ)UGK6]I&-%@<;I;KOQJ>KOSP+O@RZ+?ZX-S(*$,EI\&'KR$+%GFO[#*<.V1@%)3EF63D(7'_,AK1O.TB;I\$> M Y6DE1N[F??0$+HL59IY?&5V#^UUCMY*^+A,5E>H8,JEVX>'K?IVNQ>^"NY^ ML)'BW<;G%66VP@BAB973\'/PJ%;HZX:67U/*J0'EWPVK(/BIK9+I08OGD$2N?QB:P/?":6TZ,%/T [IT>@)A?X#'\)]J8VW?LDJ' MI)!8OI?ZFB^C]U!^Y V>]63Z8'K"$?5J2W&L@+G""#,HW;FCFGAN- \>'O2B ML^3RT=V/M7X\>?L!&70E;OY7\!D @P7QY]AM,#7PSOR'W+$B@%9=N&#G%TZA MPGYD^1Y4$;-2/A4;1WX2:V\6H&+XIWPUFZGS\Q][H#]MBH9D7B^0V:63]Y%W 3L@PW>OKJ($8=(O.I[)S9 MV==J[%Q&0*=M0F_>YN9!,B'XP]#][=&X7T8<3'T]#[V)ZL<\ *YW0^71)^B= M<_@$_WIHHLGI76.+0Y?5 AH$+#P5J2IAO1Z>M^+?'5GW[U:V^!@ ?_:YQ(#[1^V,*>"3MX4E-X6MFF,,A-V M!-4ID!A2K0KZ.&A:W?D2E7QV)$M4]^JW//="NBO4;VHX]WW\5WV M\=OVW5"^%66I<0>*G8)3U+2;6G5_SH:!1TI%IL!-L:-!$7PQ&<$NRM(TPI,Y MG.CR^SWQ[F)YQ8OM5HS-AP M&5(.)IR0JM*E".*'=&.P=4M49Z;TK%^1).CN.;<#)) @Z^M3C-&_5=D!ABW' M'LUROR'6!_D5,')^&YE4WIY7!F] MH;JCLPR%L/N]?]B :27B==#)*>S)T],1_+'M85MAG.R?#HB!EQ.P2JF+=P*0 M\N^3^'7WV=4C'?U%*OSGYCS"I,,#M(&["!F,W$^1_HK@/Q)*;.J#3Z@RG$2AY,TJ-9M^ERWM6%3=IDM:F MTJM3**EW7$/52C%KFC__>9'8NH-)KIF?V$G"D4GQ,]H>/I)9?=?$_(KD* \(U2IB6FCZ '%C-O MLN3 @N*^,O5XLP-US#,Z;^1UQ"8+AW(>"@0*_.H@U$^3B-4*/KP#1%_((QFB M,FN>E*0DTE]W=M# MZ?@CAKJR*_9(;Y$Q8TA0S=5V.8&6[U<6:MJONXN?_0/U#"A]#LGBLM=D2 ]" M"NL/C8%+WO.]5T];>G0*ZU,]\#\"D2>U$41BT.T)IK!A)WHQ8UVGTEE/XX71"-?&_IR:DDL]%:>,*#)'0M*B"1^G;9. +01CB)T: M2/1Q)8J"I':3#12<@H]U[1]N\++_/J,1M"S5SZ,IO2E]4TYT32AC)@*>] <_ M/4)!Q+TQ$XSTG8,(3'FO"Z(RL73N4=?#HPJT%C:N!\E>O_.X9UD=@8U?R MCX98*!]FJG+ZWD-7"VA%$(%E9[M7"'O]&[_R7R?6O%D[%WM$5OWV;D?'Z\]X MLFQ4<8;_)M:0Y#C]2Y0@NG^^1W'7_0[$?S$H#GM71V%)46037UVS-1S 8OOP M+A!!CE65'77,1C6;BCI1O"<*=HZ=0^1^;Y8"NXQ@BF+>R#X?(-PS]2C7Q65R M1K__U?BQSWRO+NXV]5 27#+\VW!HYAYKV8>WF^@'GPSO)#6D=RR;J5?/P'(C M^#K6SX\^3S'+">PDU2^U M,W< GI4+]\#)^>:1];D$TXF9'H&T,Y>C+)P\M'H<)SPD,U<>8JY?2@)8OVC8 M:'C@>C1L;R,82>Z<(\K\S#G,,#?NDJW3NN[B&LUW,R(M3ZCY VKA@YP\X*Q? MB6U78=G.Z_* \5VS.F#FH2KZB,-[SG"R@PV4::YZ$7MO[8IIX''VG.-DPZDR MJ36VZ33'(/8""AX+H$>\:7@**0U^Z[O?!\1>0SOC2R"N"H59LG^0LIJJ?%I+ M8NC@FMB<.SKIZ(4@R&P ?@(QATT@>B,FB18TXZ2BSW9W>A;7KKG:YY7&2US8 MT)%[E174:1:*CYQ.">G67 A=C)))TGB^IS9G/0FL8Q3]6TWE!JY0;K-<05/* M(AA /^/Q^\VAW3F#6QWS(?Y\Q4?EL$]&>\(/JV8SJ@WP&\\A@\L%'"%U;R^# M^N3VS6&-*YPI2P]%VLF DHIUW%_W\@NCY;13A]/ M-)@<7NRS'BG#UG[XR/PB+U2VUWC@Q^F$=U!4]$DFT]>@GF?#GOJ=J0WV,=+& M".)N* .MVM4V6(RA5FY"O?\7\1]DA6#V2%#P-\?U:4N&X7OV"Z29\3R6 M;^43EX22"-)(?:[F@.0&O2(/'WZZZS,7$_R/*LQ('VC>+E;^\]"'=PXBO8QH M*N\BBEY'26R/?%"6KFM-K YDN97/U-JIGK[UL?/CQ;!$>L[.P MGM\A##O0GO_1O:JR4=WR/'RHG=/IB?%PM5,YPMDUNUZ]>G,!^*2:9=\PMY@+ M+00P[BP5=NP.X+,^V=NEK$;?[-P!)% !:/O(ROXZ5.!VA-I(@[EY[4^/@ HG MCXQG(FERY/$,=@?G,UQQ!_#332S:1^>GJH63N6KRAF)A8#5:DCS3IS33'G>Z MJR[U-2!R/BUL0<.N:YS$])F*#+& 'OLWY="\E^I)PU\8_F/N("K;[2(Z21A^ MHQ,C(/=$@VZJH>88-RS'&YWN5X M7;_Y^6WQ^ZUGO/VWL)/R\VL2Q$*%8 OH'LYGW%M\.M8+.=5YE3[0F_":Y4XN M]#N3,W1Q%._I\U=09_'HD '!:?CH2$=PKKK?[RS1<%R=_>J[>>@C8D-XSWK" MU,)[=Q2VQUG"MJRZL,^,[++PT:Q;8U=AR3WU_.WI "[I+<$?%0F#6\6<$663 M,322TJ=D3]:>,7;OW#8[=CA_T#L_LTN M0L,?_DXXSS+7@W*44= M&/-G'0K"76F#-;*XTA49?=_-2SO _<,7BWE^!MFA;S$/U+\K;JT>X(L0PUOKT-.6?^$W!_.(#. M9IIA^F;U0%?F+;0W6/BZK\PXCN5&9)[0?B._)JNOE:YW#F@]_+,W?WMB\=_M M?/2_C6\ -L[LW_07'N0>U"D[F/;U7XWC+0V'\S5:FSO7MIY<75I4JBIBE\"] ML'M8'J L[3>Y/!E]K12TI0<6*7P3_>9WHC5)CI)YRTISHZ???:8R!J?Q M5TAKY+G^" &?:A9$,C3;< 9()>]_21JP:FV"'1EYDV=VPO;NK\-$' M7.MT#^52778K+K\9":H,Q5);M2BDJ4/CY_-=!\2FG6M&5I&>[?J]?+ES>OMW MJQ9;73B^5=7PC2/(^7Y#8QC1N:^\!\Y[U5=??7+-L-ID^RIW2K[%P%'IW MG)>K Z(BPE?7F;I@+SF<&D/'43!U.CFS"G3,#K#ZHZ'9N_EZ_YM_U4XK+U;V M:V:_X_"#R8PD]C/#=5Z4DZU<0\M*LLWM "NG),6S05E&UQS3OU^>:F,BVPZ- M6"B?)=O'A)]EV'_E2/GEZKG>V $Z)"&QZVL!Q >*=R,?!I3<&_S^2\QZ\)@) MA7"+G;P#>..G=.?,1_&=]OO*XPRQT:]UY]^Y1HS9).0;'[_^BM"3L5'B@;S# M7/$M1MK3N1 ^M(LS"*WG?E+75W[OC=M]67IT"'F /3\[Y8M1S7O97*?]<&AH M+Z1>,^N-8^/2G>RD%0R4\PDK1]#C?+TA"[8S+>]@E!J5I80/)9(1(NL^Q86N M]TWKO'D0D,V9FC/\0D<*$!O':&&(2%JUU.PODC0"4I+Z"OMW@$$ M9FO'-XE3SJ(R[C#$S%1J]H9R,Q7AZG"1UWK&O.;+^(?WXZOA=!S#&VRC0!4Q M _L&XT.>H](N!U>BU+NNV89FJSUQWQ]U41\VO,_((NQ'G-]Z-Y]WFXB^!;1( M^2 [APO!^&G]'F5E:/UN4CQ+FK9R]KUL?*>R?%Z1:R5P\YAEL\B5)SH>6Y:- MH[M3[V]2\YC[?B$4#]#.)L$45IPXHEQO%^[T]8W:;NU\-R8L$U6QE< )8P._Q@;OJ[ GDH]E9;DY$S[% B!(0CS)F UHH5AG Y+BX7)@Z6S\EYA V_ MH/,VM'7GOSN"01B9%P>K5F1^6\BLK^F]Q81C>N'BH>M3 "N<_;SANZD3/?69 MEZCLJ6%!/SOSH,\E60"/Y3M'MQG"1G<5=1@N9-$LQ_4(\5R!J@NBXEDZ\SIY MW/%!,HPGS(CUQE.LH;J(:QN,@)ZUD);R0*['\WP?;#5SC^LKANRGM3B"?11L M.JX^-#T%K56YO.T+;&SL*RJ_[F%QI0T:&F-@?A>A8-XJ% N]=#Z$16NYJ M#+V D0"2R/A$;'U9^8NIY2*Y8%CFW "0^]!3!/][X:V V\7&&U;8(X&MLGH9[^HYZ?Q=QUF*= VV\<3QMZ/U3U?=+.\U#1E:96\ M:%*1'6MVME.Y> '^(* 8>?TB?]\.0+.'3Q*[<;6;'[[;=L".Y=IG7VD>#S24 M"M AER:Z:5T_+7%&K(;&5Y MJ0%_:K"PQ76!*ZDU@E=8U+[P%805%58?8'[6!;@TFY/A\(7GC-3%_Q__Z]CE MGG_8YS^W[$\9_FHA\&[=]HP4<.G_H7#8YZ+!\_H=YTI]_?_QX?B_/?AW)O\; M4$L#!!0 ( (."5U;>VW6ZT\L! K.$P 4 8G-X+3(P,C(Q,C,Q7VQA M8BYX;6SLO7MSY#B2)_C_?@I<]]ILE5F@B@^0!+MG9DWYJM9M5BHG4]6]8V5G M87A*W Y%J$E&5N9\^@/XB* 4+X $*5;?V>Y4*R62&7VW<0_^%__OM_^V__^G]!^+]??7H/ MWFS8]D&L2_ Z%Z04'/R6E??@;UP4?PO/X+<_N M[DL0>$'X_*_YGW :82$\ F4D,40>&/[=5_:"[_>G#];V%UM9^FZ8_57W>7%MFQ"]5C M_1__]\_O/[-[\4!@MBY*LF9Z@"+[4U']\OV&D;+"_*)"_^'?_QL -1SY9B4^"0GT__[RZ?KDD.F/^HH?U^).6_:CR+,-_UR2 MO'Q/J%@IZ:NGE=\>Q;_]H<@>'E>B_=U]+N3QQZ[R_,E3M92IEM*/M91_/#78 MCP/$=R1O>2BK ^$J=3^XDO$_=0,HQ]TADRK<1KJ[H@JOI9BS47-ED\> M#3+^;W]0/RVW!;PCY''Y>?NHM-)S'UF])L7]N]7FM^NUW.0/%9%?T:+,"2N7 MC! :A$$$8]]#$"5) M/4BV$O-I,2\0]@DW.1*^?\B+H''\L;(;.U MX*_$6OU0?E0OTA4KMR3/R.HGDJW?;XIBR2(_$9C'D+#(@XB*4/G<6$ B%4,E M-)(!8LMR-QE?_*0,QK3YG,H3WH;+;ZH1&30R RWT8O>O&[K*[BJK+,!.%:!U M =]I;;ZW(S 3FYB1EV.D1R:NL4"VIC(+V)S2F,FXDU*8!1#/Z MY.*56LGRUYN'1[$N:E[,<_5.5;SYZMO^DH_DF_[5U6\DYV__LT]6=\\ZD<4?Q6%\B.OU[6GOB0\9$Q&,>1!G"H/#2%(PU"[GRBD M6)$CC?43=&Z01V)X* + .@@ .@WT+VN00%4,"Q M#03H( $J*$"IL -& M0PP$44=2 6+J34[UFAO[HG-Z:B1S:^;TI]M[QQ&9S MZUY/)?RT_OG$)CEP\*<>O]\T^WJ;YVJ0SZ6:&*[67 >B5[?DZ]NO6F31S.]+ M%&&$I4=A*"6"*,82DB@)81J&,B$)$^HKMUDC&(TZMU5"(S2HI 9DS4$E-U"" M@T9R\%TCN^6:P,P*9E.(S'4W1 MXNORZO/K7QZY>OB'C4)4N>7O,T*S559FHJC"*)G(WV5KO:?V,=_1!_9J6 MF\>,(2^*O(^;5<:^W8JOY2NE\]^701(RA'D$!?<91!A1F%+IZSW'* UQE!(O M,B&S$62;&^4I]4"M'_BP^4%OV@;00PO0T1) T"H*&DU!JRKXKE46*&UAY!G2 MXAA6/T^>+VS+D2G6N1G!K[6R0&L+*G5/QYI'-RUOLA J#VNN)GXBY._(U,-G MW!&!K^=E-8">:P,_:&;:,4:<9#X>$:IVUAYSB)Z1/G8O^'8E;N2K;9&M15%< M,;4&*K)JM?/J6^=?^V\>A5RB0+W<$?-]B$@<0!JE$L;(CV(>C<>)/2C8'BSUG%Y)9^Y/%>,900-X\B5ZN4]=U[ M0=2'V;B&WYH8=?%F*ZZD^F8_;5;J47?_*8CR%;^(98I\FOJAA#A@!*(DH)"& MF$'J8=]7T-#0$S;L,D28N=%/KH7T5FG+WT2"JK/R@A/4HA8(B#5:2R^"'""J)=&86*7MW=DE+D1Z;M-+K*[ M-:CW'-@W\'JSKA(EBR>?ZCN2Y>"O9*6^TS=9P5:;8IM;L\ M05*&B ]3E(80!9Z F+, 1G%*?(_X8>C[IAM8&RW44H)&S(5:LK ?S/<=H.#BC?^B'N%BN><\ 9+[O,ARHB;9/K%XDJQV0\Q"-D^Q'G M!>]N*URXTI[?_D9*=O] ULW[EJAU9)3$"4R\)(:(IQY,$^T !9PSZDGI8V+* M:T\?/3<^:Z4S_T2?0769N_H#,#)GM8+UX*EG()CS4W\P)N*EBR^$%1<=5_<, M!SV[83+N.2YHEW-.7&''-5QDR\^";7/E![_]RNYUBN8'98VE5JYHD,0"8Y$2S^ALU*D!YL8[K8R@%1)H*2CO:12^^E>O*Y? MI*3.G6X>K-96[[Y\R)9J+12%H10PP8)!) 2"-(U]2,(TY;[/:4"Y3:#DV"!S M^Y";$Q%[(1?@W5_AAVN[&,A1.,U"($-!&OF3/H7/HHDLE>["(>>0*(S]*1L!8/_9'NCJ]F/=/W[:3_1 K8,/\_"* MN9W@?;?)ID%'H'H-H 6"(_2H4(.608 M^1 Q'RL?'F%("6(!5I-_$EB=79J'6G.CH>E.<38H=0]R+D"+%V@ Q5B0$/6 MV0R:R]%@J_?7C)KG(>R,IH7)7T@-T. 7<48GC_O8_7=R+ME*M7^24\M]S#G= MF>9>TO5S2QJYU(@Z=R!3DJ]+]5.1\2JU8[/>;8G71R#4%5>LS+[4"0 !XC1* M)-8O;011B! DU(]@P@2G"?(2FL;+;F&]B\P]2!XCPKU84- E[[8@J*^[K^?Q1B7&OJYP2QC;;ZG:[27N8=5)5DVK#=BKXVXFVO,< MPY-$NV=SPB?Q0+)U^\=;D3_X2T;]V$MQ#!FA!"(9>!!'%$-$:.ICZ@EF5Z+" M5H"Y+<@.,ED//-.=$O450*MA>0["UDAF_#HF]"-3JF/4[<]1](3.[>$*6R&F M/7'1$Z*#8QA]G]./$)O,US;Q]5:YQ05AE?-\M>;5/U<5*1<'Q^-9S&-$& S\ M5$+DQ3%,_3"&U$^D1P).1&J5*-Q;DKE1Y$$R<5>5JA)-5QG0E#SH7?I@N"7- MZ',2^XS,H^.;QII:!\/JE&/[2S,IV0X&[3GK#G]@/_J])5]?;TL]QO^]H85R MXJ/ M4Q]B@@F4"26AE)+&U&IOTIUH-J@*%GM@]6\23D$B,OA(D7<)V;*"%1[ YY&$DA4\9(:G0\\_)0VS0B87#'Q/F3'[8Z>[-A MP.+J"\E6FM&4"UPE4RRC-,$L$ 'T&">Z#E@*<>![T*<^\61"L0CI)!F1%P2= M&WTY2"FK-=ZY/&HMW"I=K8 KM2?*4KSTEAAZIC.P_=B.Z@N;?;J<0$.;S"/+ M[Y*POX^\/4/(G67BF8[7LYL(*>[U_^E\OR]DI9WL3Z(H\XR52E+UAZLU?_J+ MSI5U+O?UFN5ZS_2-J/]7_7NUU0W(VV."GT@IWDHI='-5G$B)!8>A]-5$%J 4 MIE*$$/LL9)Z@3,;)LMPUC+W<.F-2\:VFMQ/-=5WRW =1@JP1'WS'&P6^_Y<_ M^K'WYVP-F-)W4?T7B+W:"Y#O$*G_J..\SW_7N<&R,\JT;Y39I#??]V3DJ?!U M]0I476??=E^!O;+U'_4K\/QW3VZH00#7N]>MQ>'[JN9*#<7^O+4& ]1H..P M\R)6=-M*9EH5INU)\R+F.6AN\S)23+QBW.767Q7%]J%.R=?]>[1.?]WH#76] M5Z+E7 KN48$3!/V@.DW/ TA#]1,+>>K%D@H1&A7AF5#F?\)U9*? 84?]!6@! M 'L$*O*<:$UI\1Z-O+PM4")G62&*MO_FK5Z97:^5 [ N,E8?V16)CV/.&(R02"'"F$/"> QI MG(A8XB"((JM&"U,(_4\X2=[LR:_1OWMDO,( [$"8](2XSVM4-9!.5>3T&G9N2KY=A.%/^]RC" MDL9IR)&5TW]JI+E1XUY04$D*M*C@UUI8V\3:D_ :NL$N0!O;=^V'E[VG>0D+ MM^[AR=&F]>DN*7W@B%V\H1]1M!T?E7M'LW4U;WP2;'.WSOY+\&NNALID1G;] MVZI6D+G@5VO>Z0U214,$?R.D4%3&;\G7;C,:%#&14J%XA@K%.%@*F(:"0^:3 M. D]$D2"M;5H;LV)9WS)C3[&IU5K;B<@LEV?UH[F>F^SU1UTE6\=FU;]:L^S MVV6[06 !6@RJ> =119 JL>"?S2ZJ'\U MRH"'1AM ]NJ8K\7[6^QR5&,2.XP\4?0V08\V-_UM81XVF<0F$T55C&RC?K52 MC*AG;8/OPRKV,AC+,Z&9_L^>+'(S6/UN8&?XP_HMYZX>-GF9_5?UIM[(Y]VW MEZDGHR!*&$PB/X"(!PG$*(AA(GF:AD2PQ+,*_IP?;F[S3U=:(+[J[0S+G=0+ M\":!FNDQPI#KPTHH3@7$ 98P)HQ%/J4DC4*[JJL. )ZTK.KH$)LM_MR]ER// MQT_PVDBP%]596-T.$Z?+I M#3KK$,5/_^?+$\*Z7C[T]%VU7N?JGS8;_EJU6 M2ZX6'BSP&?1(J,@)I012J:8"Y$4BP#$7B%B=YYY4^KE-)2,%7 X^_T6WE'\+ MQLM%Y"Z_9=,'YYR^.[_/.-W U^9%HW;&YIMM .^R!K_;6)ZQ<<8,ZYD+T7/- MU S^+EMGI7B??3D<\EG9W%\*(;>K]YD42\_SDIA%NI2W7E&%B7+YL:!0"($2 M&@6)E%9=&X<(,[=)( 5;=+ER$"3;NP<0#=P;+'Q3/M]UN:!-(;>:*1P](+*&&( M"T@"EBBV33'$?B!@P!$/:9CP !F5A#$9;&YL:M"QQCPV?Q'IR]LA+O$;F>RF MA_IYO;^L\YU#?DN^ MOA)K(;.R:$^!Z^/CVY4>]YW2Y&.>;?(F@9]\_;BI=RR*I2]1G' ,@RLYL!HUGZR2Y2=^LM.!)O4;W8)Y7/_V>FS>_:/ MS#=,"%[H$:Z+8DL4*#?RLUBKP=YOUG>ZV<\;0+J5N_Z85TI2J(9] '23Y]6>O?KTUZ+R?+@2'V2- M;LKY*6S+11D;QXQ[QX!\;)?\"=JMT%7IP4IL\'YG "VYP_Z-EEBY;=5H.OBT M71DM(3EHP&A[?]]:U;OTSCH$T0D5?Q#E4DK?BSV20!%@163*]X0T]A*(0Y'$ MF'F<4F%7L/KL>'/CKR?)VA>2!WKA:\9%#E$;F8*. +8 2D27Q:F-L'!B.STOD82*8%T+=$04B+B*(D2>A3[!/.4L(1G8;/RZDFALG M=94">ZU JU8]^W<4TPY JYI>2M65,1:@5L]R,\B)G0UWA::VWMC;0Q,9SGZC MR"70;G>,G$@V[=:12S /]I"B^Y@0\VG1?08BJQ;=YYYCO\-^Q?!%KLBZ; MXU8AC5*4AB'DJ40041G"%!,.0R\0D2 \\(71+LZI >9&:K6,"]!*V>-LVU$< M+^^9#T5G;*]O)&#,=\2' C31+G@MY@ZG']QL>9]3_LPV]]';)MO:/B=T=SO[ M['5#NYI>KW51E$W^K:FE5+7&VS=8XQR3-!(>Q'$0J[6Z/OK *($(X4C9.DX" MQ/HU+3T_\-R(K]O+WZ 7PS7RU,2 =F2W/H]ET^ARGZYTM6B/U M]+PP^ NU[#2#Y'1'3L/[>[8>VJRK^FY_R\K[U]NBW#R(?-?E^9-0(V_%/E-^ MF:9^++TT5;9 40)09"D"8&!SWF:\HAXOE6)9KOAY\9?K?3@-R4^:.7O]%S7 M9VDJ'3IG:BP;^=C9QXSN+EM76,GPK2M9WK!<] ZIM]3 M^M'?)U$(=9-N1_-&/7JU>=3>^MOZH'BS6D"I\%+I81A[^ER-H('B/"1@D@B& M/!QXB5V%2H,QYT9TK,Y,-K?VK1V^>7C,Q;UZ8/9%=[Q2Y/=^4^A-9NT%%J4>\"^"WXF? M2+;6?R%2??^*#E>D*#*9L2K0<$N^+@4)8@6/XBHFI%IC<@%3$L4P"&-, \*X M[QD'T=R*-C=R:ZI'=]4#M7[@.ZW']U46!MAK"2HU%T KNKNDTA8\5W>ADSEL M2W<[>P M-5"'!>Z=CS T7MR6)^B47RM>?>O\Z\29JRH4M$QIFK 29C2)(6((@8I"=2D M'TLL&$N$9Y=HZDBNN"]DCQ\6&RO5#XW F@IZ/K;A[OZ 2!3FN/D)\$*$%0 M^!0I#AP3^CBF<,* MY7:\Q*NO6;$4A)'44X9*$MW &B4!Q"P4,&91%!'FXYCAY1>1TXUM4=MG(]E\ MNMWQQON"CRW(P*]:5DO2/(4M91*QA 0PXIBIN4PG!4=,0,GC-!(DQC2QVH5U M@.RDA7W'PM5LGG& ULA32!^@>A>:/0'#*"5AGX_U(L5;3RA\JLSJJSNI[#&W[/3%@WJ> M714W\F>=@!'Z&JSV, <37DQE!%FB*QY+&4/JHT3]AR"&I(=($O1H;79TL+G1 MP9,63:30<9]*9A#Z"Z#%[M4=ZSC.EY,)7*(W,D=9V_QXYJN M6#_F?J#CAR%E5/=FCR%.@P#&B'II[,4Q2XQJBAQ[^-RHM)(/5 *"6D*S+_\H M<.>YO<;>![HE7_5QZVJ]'D622*:TM&Q6L8[G6%UV67HB,/(7Z$1YS#DX(F+7#SCVYYYI:+J\S2M2"*X3X\2ZJ QZE>?*"I6?\>K;_I*F"OC5 M;R3G-X]5ML3;KR)G6:'S(9KI+R5Q&F#N080U1^'8AS0B"/HL"1/FAWX7[2M$%:%1=@(ZR"RM/9KSWP2RN]*)6 M'IG17\K ]HEL8QG!;4J;[.P9 O6&WGE/KG:^R4LR-BEHE0+8&)QLA@4RWK6I5 :TNMF<%^AC-C+E&-\7(A#:*%7H< M/1B HN.S"7TDF?CPP@"P#D\W#'F8_:Y'M3*E9Q:O]-O^DJ.+UT>A$X'+S5\5 MM]]LRZ(D:Z[\R:N[NUSW-^AR;:/9SUNV2U9?E2QCRS+SJY2)-MOKX4V-T= MWA>3H6^#S^;TZ^=RP_Y>4Q5*T@"3,(6AI_Z#XD!]8NJ3A1R%<1R&DH=M,\YD9FO9@688V8'8 MX_^YQK\2<%&U]719#_8,"H[;=!Z.,W%'SI.*'C;?/'UIST!:]B7C8LT+?;1@ M*8GPPSC@D$?(@RAA#%8-DB@7/!%"JG6:4;K_T:?/;16U$VY1G7FVC&4]P3CBGL-DST9(1IPS_'E#L(ZQR]:$ J65'3[,<\8Z+MGK9, M4H:)("%$E"M/("(Q3&-&H R(%_DDP:E,K5/"CHTTMT^X%K29>A:@DG7?D+!' M9M91> WWSER -L7BWQZO?HE.Y[!PG[!T=+3I$X_.*7TT@>CL#7WKKI M=EEL3D@11*- ,#6;IS'7$5@*4X2HFN;CQ$\ID:$([4JM'QMF;A312KEO6-JW MG/I14,VX83A4(Q-##Y1Z5$D_!X+CPNA'AYJX%OHY=0_+GY^]NN\N.2VOUT69 M5\' =R3+ZV4HHXPS(AE,PA1!)#U=2L6/(4M$S"+?DZ%/[/;!CXXS-RK08H*] MG N@):V7KU6'S=6FV-IZ#:<@-MVU'@S\S'QYIX%_FL MPH?[Q.)*F"?8AU169$(]371\Y@3B*A,!IQ(E9)DU? >9&+9_^A3P\_OF-KJC6JE(7 M4WNN3+,+LE.GSU'X/@:[O" FZ>FC>I_T_]7U7IM=N'>;_+,HRU6U M2_?QU8V:BT@<1Q1!(?P0(J;F^I2C$'(_3/PX92@(C+S9GN//;2IJ5&B3!H%6 M8%']=U?%N-V#EYL<['51OW]U8TZ"?4QU>18:V0"C>\OSQ=Y\_AG9!A--/R/9 MPFKJ&8#DF9FGSU,GFW@&J-R==X8\QF[:89OMNLR_+5]_6H9QA (_3F 8$@)1 M(@C$H<1J8DD#0:(XD&:KFOTCYS8YO+[Y?'L%/EV_OC(CFPXXY[F[G\HCT[&! MML:?\Z&"9TKK-!?7H8CF'U44HOJ&.X^:Y+,\%+W]TH[\Q=YG>[O--V_$>O.0 MK4DI^#O"%((Z$VJ?3+7;@O I31#E4 :>KC.53V4-V MQI6R>-AD'I2]@EW'JBK47[4>3*?W[0/7"J8,";S[]4B;+%+CBM MO+;MP^.N*#J. H02'D"$/*0+'TJ(A2]T]<.0>$(9R'R]/D20N4T+6A>PKZ_< M4:<)D"F%ZK3YXLDVS%XKZY)F@^QX>0:9RCHCSRF_-\.83S]3&6BB"6E\0UG- M5"[0/3-W#7K\9+.9"Q"Z\YN3YPVM:'*U+C.>K;9E]D5\%FR;9V4FBK=?V6K+ MU9RK -"G2K;U^WXCVZ2.-K^K;C6**0_4Y)>HQ9!DNI!? C%.8XBE'_ X80@3 MKU\%%!?BS6UV[%;\Z.H']@J"5D.@7T'0T5'?M,MLVN4[#NTTZ^0M,$L4>3G; MCCRWOH19!]1_<8G^2/5BG(CX0O5E7,)[NAZ-TU'L%T]7GU__\LC5XNS#1AG3 M\[W7&[YK?'[]\)AOOM3+M+J=FFZW5W7;6\:4IBGA@UKQTBQ-RF!:4'J!4!'S8_Z&-Z'O0]T-4&=-4Q=\%[F^GRNF@*\$?F M;5O<^S?\'&0+\Z70%#:9:!GD[)NP6NT,!?#,2J?WHR=;Y0Q5OKO"&?PL^RGI MI]6&DM4O2MO-G4[S^2A67S+V%T%6Y?TG\;C)=:7(7]99V02X(S_V)2(>1'Z M=1R/0"S"""98"(^EGEK9^*8SD>781OH_H M%QJ[7M?EZ_9E[*Y8E5Q0?!),9%^J4 =%2>@%<02%SJQ!B*:0Z)*_(L!)2CWF M>3Y?KJOB*?S6/.YE,K;1QY36'].!!.-]4+'[.S]TW4F,U'C2:\RHQOL"?2FO!?YM7HYUG>ZUG"= M>JV##5NR*JYHH9B$E4M*0BD1#B%F$D/D!00221BD$1,XQ 21Q#BCTVC$N1%J M)3382]T<+@#?M8)_#WYM9;=8AIJA?YEEG6,Z,MN^*)SF%.PW]S7"BBNUOPO@M_I7%"F_E1M>NY+ M..P^ E_@.(UP"N/8"W23#*&X/44PD9X?$>0QXEFEI0R096Y%7A+5^*-*(\"1#TB1"Z]Z*$*4L2F& /,3_D.)1&Q54OCC0WVJR% M!5I:^'>ISBMO(Q-8?,F/:,H;CS#E']8R*C_Z!](^P M_K$BHF"&,J!]!I$.: M-/8)Q))X(N5^2E&R+#H)&4=#55/<0>:HK M:)5UY^Z-9 6G+J!K&2=U"T<"^+FK.-8P_>:']\HKO:N"0)]$(?(O0H^BEI+* M?UU*$7BQ\!#$B<.]T.I' M0K.5FJH78"^Y'8&?@]N,C!V!.+8_.1P_:X(T0,8IV9T;;U+B,E#\.0F9W#+= M,>U.WV@918AB*2"."(:(BAA2YGE0<.59>H(@&1OO[PP79VZT-/S :9^6WXY, M>WGS:%J#C4R!OVM;C7^DNY_-)MJVZN)>56MS8DQ7QP3=PC["B>^I&\>[!<3% MZ6]GC><_B29EJKB1G^_5LN!6Y ^Z*/>2):GD"44P84$"41)(2)+(AP'!:>1[ MZL7F48_LUI,#&GVFTZ>T-ADH!5 .9J'EA6HB?@!TD^>;W_0Q2MNV&Z?P-G// MA\$W5?.-QQUH$GS>@Z;E=-E_XP(4CEMPG!IMXBX<%Y0^;,1QZ89^Q%%M^RNO M?O,H!P$;N[WNV\#$R@1FMN 9V9(9Q@JDUX=B Y)1[C :>E(9L MH'C.2%;W]B.GYR4.7I$B8TLB4LHEYM#W::P;# <04X5VRAB2B93$8[%=@^&C MX]A\)].T&-8[#4]VA8""7N\:/51.C:XQ\B]_Q,HW_S.@6@,[&CH.MAGO# 9P M[#CC0366!7AU%B)K5CD+@5,:.3[2I+QQ5MGG1''^8OOPX>O-%[$FZ[(J*D=\ M+ (<$AB&2001XQQBI#R5U LCXB&,$B%- X'=!\_-_6AELR[9]P2MR[&UOAB, MO@/K0GWS<%5?&"8*/+7B_> F2G1,VS/QGB>73Q:Y.29D-P9S].]]HRGJ45M1 MEUQ:5^EW?\O*^]?;HE23;[ZOX^)Y7A#%/H>(!+IC(?8@]4.=GBR") J3$/M& M[&,[\-S8J9&[K8162PY^4Z*#5G;PJW6)'6MSF,9>W(,\>BC&$;X]HC-V8#D. MUA@./G'LQ@Z2PU".Y?W]2.QCOF%"\$*/HW,$=4#Z1JH1U6*EU$<\/BI3B3P7 M_'.I/YZ "N4Q$0\F,==!G@3#5(=[J/1Y)!.*HM2*RRS'GQNEZ<768Z-"_=UE MC1(Z&OK8R@X*+;P^W*_>GK5@509#]6$^;NDJ8^IB=:'Q>=R^QC-COA%-,C(! M?GQBB>N.)3K2@YWXH)+?'0OV!,XI&=K*,"DG]@3H.37V?4S/PLG-:E3H_H$Z M:E5Y[9V.!*^^[2]I-I"JK;RW_]AFY;?.$8XJ%G9[3]8W];;>!RUQ40K^85M% M;P61*?,$@V&[>P! MZ#?0O:X]V%\!L U!$\.9M5QZ%*A !H8JM2S&@CU8P6%93GFR=XM,^J?Y1LS M\J0QQY?%OLCSU(9S6_]Y,NFG+0T]M5$.JD9/+H!]G/9G=?6]>B_PATTIVAY4 M41!2[),4)B),(2*^@"1!(8QDY T MVTIS'C/C8G]:^V;]D]C3Q/F-7NG[<^\WZ[GWV1?"ZH,;U^GK-LR\9WY+5 MNTTNLKOUZZK992:*5]_J'SMUPI,D0B*1,62(2XB02"&E-( QCT,A$C]$">_7 MBV5\X>?&Q-V6'IV2"\H=W&L-*K470"L.*\W;2C39&NR5!XWV8*>^=B,; )H$ M7ON*\B_RAAFN'F;ZWHR]@)CA*S.@2\QTMANIA\P$"KQ0AYGI3'.Z_\R$,O3H MYBRE#JZW1V%OR==/I!2?A$8Z6V5U$P*]F5)K\:R0556,4*I)9BD))2F.&:38 M$Q#YQ(-$^C$D+(D8HR$2GE$JJT.9YC91[M1JDS%U=4RM&7BJFC[NKI2#HBX* MDNVKMQ&M'RA;!2V:&3NR\N75T0O8;N3)ZI_ ;!8-JJ MG^M][6BDZ1ICNX7F2==LQX^VFW>+O.RX!_KH6AUE7//_4--])K]5)0B61%!*=HXUH%.D<[1#*Q N9+U'B14;5S ?*,;?Y]?/;UZ!59P'\ M 'KI G27&CL-JXJ!>QWW_0.Z)0.MUYE#S7I^-S3V>%UMTE0;.'6_7D$"X0D:0)P*#!'G M :2"1- +$D0"1C$Q6]=<'FIV=-KY(CNR#NVB?("P;:1L"&X3QK5L(!L0>SJ% MQDB1HH/A7BBNDQ&J0Q#7F:V+#%T5'F1A1[(4$E9<_CNL<1-6.'P3B-3 SV$/6I3W@: M M=5!H^,-'6MP-/*'JGX=^;BOA7WZW1)M7)LRZIEHEA*QN+0QPPF1$00Z2,K M&%$,N<0^]Z3O>7;?__%AYD8 K9152*4C9U7#T[82_E%'FKB>_#EU#TO%G[VZ'QV\VA;96A2%HAJ:K:NER^=2/%ZQ?VRS MNEE3FQ]65PW5S>_4+W(A/BIFTL'/.[$,XE @CWLP]&(?HC )8(HQURL/@6,9 M>UZ";_M%:M;A)9*[< >_7LR,F)EG,W2KUN0<0%^RC>*!JH_].V1 M= 9_4S_1+:JC>XU# 1W0V^@R0B,U,3HS\ MU*[H,Q>FV1 ;W#J@S=Z2FO6ZB MT%;.U%V0Q$\D6^M?OA)RD^NMSA4IBDQFK VT*X=8N:"2)4G(H22I[NK[32&3Q7 MNMH#4VKWJ'WG[+4PH]7IK3QE-;T7L&R_"GRN+>"^5)\S":>OZ><:W*/%_YP/ MTK>UW5\WJZWRG?-O[[*5SB,+HT@@'J50N;.Z+$^1O-KIG_#(1RL",>E PGT(4I@RF,L60 M,TI]2D)$B-5)J),CS>W3?B-DIOLKOA)K]5,)M."+ZK_-.1,]JU!MW,GW("Y?@[&NY0M"\?$-_4OF@WHVJ M!&3BI31&+(8H81%$,0HA33B'0>I3%+"(A%%HRR/MP^=&'=7KK86SJIIY%#9S M)N@#QL@?OS$.O3[LYPH[_Y9W TS^^3Y7[=@7>W"-_=FNICY%N5DK(M95*Q0' ME"LA'AY7FV]"B"ID3JH>*LN0"S_UE!\@8YVYA*2$6" ) U\0@1@1/!06D1_+ MX6<:TZF6]5M=OJ;< *5%4PR\U@.TBH!:$U"K8GZZQ\8\YWEB#+0GHI"F+-!+ MXVM^0FHDG"40;ZMC3CU0.W.4R>9IDQU7ZJ%B]TA2G]M[]IS=K.]V;95D M&B6QQS'TF%3.6^2%$#-"8" I05$:17%@54&O^_"Y^6U5*8'+G98N@V;FM?6% M8F3*-43!OO_K$77=-GSM#C!MA]+U^W);%>_%%K/RV M#%/*$*)1# 6C4JVS!(-$8JR^7.6DR1@1E@J;[_7,6'/[?+N[WK6T"U#)"_R> M*>?G@#;[QAW!-_(G/P@Y:R(PP,0I+YP;;U*:,%#\.6N8W-*/1#[H>$]Q_S'? M?,FXX*^^_:+6,;JLB#X&4YVF*[,O5>[K%2VJ8NG+,%!.0*3(1*WV H@2+X4X M]A ,1)+*&(L@9:E= RA[(6R^FFFZ0^V$!7MI[6BFARG,V&=<>$'(,=_-KJX9"N^H/HE,5ZB#$IN?6'Z3GG#7A2/RK\:;/A MOV6KU?7#HZ);O*Q!*>Q6L;+L$<* MV0!PIX\;ML(J;VL/LI;7"<)F<\/PMW%D_K<'R9K:SV/@E+Y/##4I19]7]SD- M7[BZ3__ M:9O]2#U4Z&H/:^"F>TIJV^*\&GSXXULPEW+( S"1$JUE T2 5$: M48@#IIB81Q%*21(G9IV^^@HP-WIF.QUTXYN]$F#5:K'0[7-:/:J>.;4F-KW[ M>ACJ\@[$V/"/S$>S1=ZFN^*X%IAHDV($2UBV;>P/X]GVCCT>.V$;R/Y*/VT7 M.> Y_?S[71&W?66@W4*:A53Y^3B 7A2J^46F J91)" F./$3Q)6GG]HX^6?& MFMM4TJESV*V7=7D);0VRF4?J"+J1IX'>J%E[IP9X.'51SXTWJ9]JH/AS9]7D MEKY9[I\?R&K5GC!=IFDH0Q0IAY3[:OW*P@2F@<"0ALB7<9)ZPC,JX7'B^7,C MB2:1NY(1M$+:YK<_1? \&SC 960&L(.D1V;[4<4'YK4_?>;$6>U'%3K,:3]^ M6=]6TNKKSU@IN(XEZM/?7\A*%_?ZH(3>YKEVG&.2!IC+""8-%];[5(#JEK'EN$J M$Y.DRO<+*:70YT@W;/00Q,+W8.0KHB4!13CQ[+:8'!MEFCVECEFJ+9"W+VP6 M,P?.,=0CT_@9C*O&@HW$+EMZ&\/CN)OWY7$G;N1M#,1A#V_S6^TCE%=L4PKV MF66ZN+O,V%\V*Z[6JL7[["%30S:9'Y+Q-(V8!Q'B%"(BE ?(90QQA#R64I;X MOM%1!N,1YS9IU$*#O=2@%1LTC?G,P#2/%SH' M=:( X8 7U"H0:(7/FF[6E4AKU8OG2?8: 9VJ@']&H%&.5!K5]VU MT\_.,W5D:C/G=7H#CCS#&-C.B>FL_6"W2#MUE1V)-JDW[1;.YPZWXZU]37A0MH$L1>P+'Z3[\J>R;# MSXW#.^7A.N+KZ$&MP&)W$I^4GI]5D_IV8*FW+"_WRM_6C%&7B? =Q])#KYH0WQO MV9G&%'@S3AL#SI'9K"OR_VA*,"]:'W'G2G[72GX:7_LV-I9@N6UJ8SKXM"UN M+"$Y:'AC>[]]%/5ZS<7#>E]KKJJ\&Z8X81X*=*A4T5*@*Q^K53;DE!$A9,1H M:)S'>6R N='/,QGKG1GS2-Y1#"]'0831S*#@3!2_M0+**5YY# MX$QX\NAMDT4CSPG=#3Z>O:Y' U9E9Z'-_9F)-5$469>Q2L(P#;$/XXBG$*4" M0GQ&O3I MTW55/:?OV M:.?-8QIX:#LFZ-.S:D>OZ%D. MN3[+5KS;Y)\VW\BJ:ERJ5CE1ZBO6D9'.)61)#+$,."0,22)%S"*6]*B&<&PL MHS=O^EH(K:C57+P3UK)D\C%HS5R=WDA-6O_4%!W[0LIGU'=;4/G80-,65CZC MZD&!Y7/7]MS VW6:/_1NBOVIM>)6?"U?*;G_OD3*^> Q"R AH?9-8A^FDE"( M_43$G$H>)E9I#-82S,V%:170![J/^?U%YT1F 7Z])51=J[4!E3J6!UKM#6:X M SBF&4:/UHQD ?NMP;XHNMTCM)9BVLW"OB =[!KV?E#/$_N[FC,W\EHYP.N[ M3+U)=4Z%CO,K&;)2K+(O@K_]JH]#9>N[ME[-4OE-">))!)GT==T8WX,TCB+( M"4)^P-,$^T8Q>A?"S(U"=]6]=&^Y375Z+-NI5&\U#2[\- NH.B!BZ>V;,& M?%..11=97//#I)%=:8\((;6>CU,8(XXADDA HB@7"BX3E%(_)HC;'=@U'7I^ MFWOOKZ]>7;^_OKU^^QEO/Y??[EY_^;MI\__\D<<^,F?P=O_^.7Z M]C\M:\N;&L.,/,< >&2B[(A]/!IRUO;PG)0>E[V_N= MG@R[O2?EWS;;%==TRLJW4@I=0%87B_E$2K'$E.+ (VIQ'7@Q1#QBD$2I\AZC M,"1Q&H5,6NU8]A-C;H[BR=-#H%2*@$H34*L"=KI4%VIMG)SSNF0X,[8;WQPC M<]](EG!U;,L0R"F.:5T290['L@SA,CR&9?HT^WW2M@S/Z\T#S=;5#M2)RGU7 M>:Y>URK1I/BD?[J1-]M2E^,JJH,/?\GN[J_7C7OZ,<\VN?)EA?I"RJ7D2'"L M[)OX6)]52"54+J-R'M/4CV08^,0\*7@*@>=&TJW.@.V57H"3Y3%)1_$%J'[6 MZ\Y-H_RB/A^Q /<*@$539T:O-!\U!CI.4(%@OF4ZR3MT>3=Z;F_&R//%__]2 MV"2%S^WEF&C/?_>2O.Z^)'O-P1/5P=63E^13^Y+<[%Z2IGG07ZJ79(<"J& MUY=>$JO\@BDM=B9K81(Q)LN%F!+4;H;%I./:>T$?E#BDN*^]JQMYJT0HI,AS MP>MMX6^?U*AEL>0H($D:81A'A$"$@A2FR&19_(7AM1\$AT!VHGF03<0 M6\U?EF"=F8),GS39+&*I6GDK0B^//OY''IB):D(0\];@N,RH0 M1#%#D* D@B%) AYY0D;(L@C\L6'FQMB_J#]N\K***_U$LC50CMZ^&$53JL*V M"/Q1? TW=0>C-O9V;2-@%5@#6L01NF.>1\%QP?>C0TUW8\4 M](NN?,9/8E5--L5]]M@D>7L(A1ZG(?0PTI4^60)Q+"/HAS1@E'L,V_'"R9'F M1@V-H* KJ67._&5TS5C!"68C$T,_N*RIX2(43MGA]&B3$L1%I9]SQ.4;!G;= M_ED0G>RFO=._9>7]+^L-+43^1>Y M42_?O:Z@MO02(B2.,92QU'F^E$(24@]2*42 L&0RYKU:=CL6=&XDU>U:W5$5 M_*9T!5UEFY[6X*FZ"[!3&%0:+\#[??^HG=8].X:[?DEX(DB0!"F,$QE"A!%6 M[P=1'FN,/<;BT!?8\+3\G%Z3:?)R_C_UHIC-JG,P_LB3\@M;W7IV']LD3IV# MT82=U+<8&_+GKLGHX_5H>;!>;\GJ-Z&C*X(31X15%F#_J M+]BK6A\QOT-*TE3I7A+?CPA&$G*&$XA8S& JJAYH2*A%!8Z] MT.B/QH?GL1C8 ?'$ MPR=NA7A>Q<.>B!>N[QG*J@X.O=<'AYZ?*[JJMX2J">SMUT>Q+L1_"I*_4Z_3 MDJ2IEZ)80ASQ&")!=-W#@, P(21*!$T8CZT"5;W$F!N=O-M6$VY78M"(O !: M:*"EMHP.]#.0X=I_=-C'7MG7)R(K#0Y.32XJ\*NV?EUM3$QAOV0?A*3;!7D_ M4:9=;@^"ZV Q/>QI_9ASEV&_:SBM'>VGJW7UR]>YX)E>Q1=J6':_)#PF*!0! MI!'71]*3!*81CB!)*<-^FE":!#W*_/23QNA+GKX0T/[L2J?%>K6,>1Z8TW]H M=-)1NEHK.X+M:4N.^>%_ 5C>7]G1USG08[E,9+/*>'V>9,T_JL^J#=;?2+6>(&I"(ZM=W?1.9:M]D;> \M3W_1C2 "&( M)$\A"1(!O9@' 0HBXL=6_;5<"SBW\$A7O^J$V5[#JI1'5T>]-['3$NS5[%25 M [_V+NCG_%4PFT=>TL C3R4O8EOK"64L SB=4YP+.>FT,A;$SV>6T<;I-[F\ M7I&BN)%519M.%<1=/2;!/>3[THK#E',)4RQI2,.8$9K8S!47QIL; M]5?BZN^^[L7XI#3HY5Y"Y$=-3/?3G56O2KG8K74"Y 5UM!A>4[FU&,U*;PC@CL]WH M=K$FQ*&@.F7*WL),2J%#(7O.K8.?UY=TRZS.T-5%KC^HM[;JN)=ZD?1C1& < MLEA1JJ"0QA0I4S'%JI(1GGIVE'ILF/D19BMEW2Y+RVG5PO "JJ8,-Q2KT?G+ M'J8>E'0.!<>$GDG+J'9''VZGY4T*](S>M[_>/U^NIAL]45G$_422:]((9IQ)6[1D+%+2'E,$G5_PMYF*34J!G9Q'+/C:Q>GRIUMA8E$'4Z M"/B.UE'IT]737_152$3*D*_> @\)-NP52R M3^IK3&R0Y\[+U,/;GQ;LG%M\%'FVX0\D_[LHJ^-"Y#>24M,5#D6H M?)B 02RD#R5-<)1@' ;2*.1D--K-:8@!!+71SI*H2VZ)6VV7 ST\- MSF$#_ M7;[#WF5[^R!R70_KYXJ%BMM-258?MKILGG85E<>8ZY38P)<\$CB!)/6P#DMS7\XYIA/Y"^-4(*OV MX":CSHVV]T*#6NH%J"4&OS;_V[__MY$5S!Q"Y]B.S.!N8+5OZFT#D]M&WD8C M3]N\VP:,@X;=5C<[/:*W##SN)7["((^9#Y' 1'F5A,((IVG".$H%MTJ1.#'. MW*CHY+DJ)T?=AAU:FQ&UV,/DZ@39*,1Q:JPYG.HZ10Z7+N]'!V]$W:]!/;%. MT?HIWQ3%DG#"F1Z+>F)MM691DK5MS+5&4T,0C'/((!;K92@AIH/[I1U% !*+"(X%= MV;ESP\V-&&J)02UR?:IC 6JI04=LVR)T9Q$_SQ;N<1P[O#00PAZ%Z4R0&5B> M[NP0$Q>I,U'WL%2=T5WV >R/8EUDFW63H+6AJ^RNBK$UOU!O2<:7'@NP3C'0 MRXT((HI#2!*FEB"1+XCO2QS@U*+ A^FX1E_%]#4['FO102,JV N_:']7 "V_ M>?S5R J70]G.0)V&:EX*2/,XMFM )PIC#P?6*HIM@]*9(+;18R:+8=LHU0UA M6]W7L\#H)A?9W;JN5LJ^Z$Y6I5QVRD(:@V!5A'X :B5M*Q7ZL;> M9LO:Z:TX\BPSK0'MJYPZQ=MMU5,WHDU;!=4IG =54=T^O6\H,,^^$%TRL(XJ MM#71@R!EG@@9]*2O^1PA2# C$ 62^B$EZM>6L<"CX\R-H/=BMB6*K4K-7T+5 M-!@X&*O1HX&V,/4(!IX%P7$T\/A8$X<#SRI\& \\?WG?@. 5Y^I-*:I:/#?Y MQWSS)5/B+[TXBF6:$DB8ET"$U/J=$I;"F%,B1)!(*:1=*/#X0',CA":"U0B[ MJ*MA*4A!*[!M^.\$OJ:!O^&H31/RZP%8CV#?>30&AOE./'SB -]Y%0]#>Q>N MMP_JW3SJ%6?1ENJ_W?Q5%&7;SZAI9_3VJ\A95HB/>:;>91P(2@CS(1,^T?N( M%*8\%3!,O4BD<42P;\05O4:?&X$T"E3'5ZM6!VI5\$7IL#AL]R0:/<"C5L0\ M3F5OH9QP5.@G"AJZ-X%5$+$WA&)9&:B (.TY0CJ)>VE'DAQ9%5E8[Q19[;[-5J M#+YK=?Y>G\+?-^P%'<5U%\*;\E[D;2VP[SKZ?P\:! IN_=O-0K=7]1 V*VW M)WB7S);N\WI#1IYGY_=R6$<9IK.7TX#%!&)/&ON8S@S/PR@3CCPL5W/7T:66 MY(,HEQ)S$5(>PR .4XB2)- Q6C6]12FF"9&^^D>??,W#H>8V+>VR$4OR%9!* MRG[)FD=0-8W1NL!J]#!M U.G-U2;NZDD=9^Y>1J-4;(WCPSW(AF;MC;Q>\^Q+QK=D5;S;Y%>KE;A3#+4NL]>;AT=19CI@ M_$KWGX2V#.WK66=*G%%_INIS5^F-=/*^M M_.K;_I*/Y)O^U96NX+G;U:XVKG7WH;-9&@R%D@F!H!]Z!"(/ZV!8$D$?!P&/ M$$L2W^H8RT1RSVUM4>D$ZZ*U7<6[9=T!_0:ZUS7:@TK]1;/3IS[L#@0+T(( M&A3:OPKPT3R!9^J7RHQR9_BJC,S?LWM+[*M@36LSMW6T)I)]VDIK6_/ &PV%[B!;63Z[HF8-!L,I+YX9;E(JNZSV<_8Q MN,,^0M]MV-BM>OV1:/?^7I09(RO#U]OZ>3-ZVY_T,7U:D/V[)[)_;TT;]C"; M1T)'@WNB.*9,'&7FIV0XG]'M [!2Y;JV'JHA>Z6V2; MI/YN6VZ5-]7\H?:GBO\4)'^G7L"E))%,2<)@3+T4(B25,^,KSF>A\$(B)$(8 M6^;']9%C;IY.HP9HQ*WZG^H%5'-2H]9E_]=:FP70Z@"MCW6F72_CF3E*$YAD M]/VZD:S1)XEO"):N,_QZR3)U^M\0P([D!@YZW(#(*KV\9*4GEJR=RG'/EJR? MA.Z'HGZOV]SI:6!+5KQ MI?MH[<1Z3!^Y?1E#'8WBOI H0ZLX7:_5DJM:F'_*BK]??:7X_5$.\!J]4"^\XCJ7$W1J CT2P387LFZ?5PG M-/KVU?7MFROS>+-3PU^.^K^4,4>FRG\J*YIO*KR4-2?:V,,D+J['Z,\OY_KK\\0[PL5?!9EN:K6*+I6P2_K;:%6&%41.%U' MO%@BG B,)8$XB3RU%D@"F.IT#Q91$:,DC&4:VJP%K$:?V^*@.@Z_EWX!.O(O M@%K @48%L-?!;M%@9QRS5<1HD(\\5SI%VWJYT0LUI^L/.PDF79#T N?Y"J7? M0_J1WJMMD:U%4;S>/-!L75'KIUV?O&NN1LUDIK/HFK(M[!_;+-?G5[OE6]3? ME#?!JZ)$'Q103<)Z=<<2!9Y(O22%TO="B'SNZ6Z]>BN9$XR3D'FQU=[QZ!+/ MC5Q;A4%'XP78ZPRZ2KBE& MIO^9O _6$\=D-G(ZV8PO]:03U&1&>#ZI33=POXFP.67U3JA;R$I-P3IE8%VT MN0+Z/%,2,Q+ 1"(,$>41>7L8A-9T:PB,4[*\-.:D5&<(P'.B,KVM'\WMSDY3(,/19B0B$FH8 H#3 D41A"'&!.$Y8$:D5MVB/F MU"!SHX)63K 7%-22FC>&.0GH>1YP!=/8Z03V"%EU@KD$0>\N,"3[$ M_#;KF_[E1=V__+][/W@^>"0Y^%+5)(> ;,O[35Y%,8*%YWGM_X&B:J[]9Y"I M%:#ZH[^(TW@1A^$B3L/PC6#B@8H4P.\LMK=#K9B443!RX5 M0/OL\QU&1W+/*YR !JK37F*B\C$NWU@SVIZ#J#.:*GZ/K^!TM6E&L/D\"M>X M5.SW4=5F!%,Z*WDSAFP]"U&*HA#B::"DN!5?RU?*"']?XE2DC/D4!BA,(!)8 MPM0/.4P(DUSY!"$-K/90S@\WM^FZEE:?Z7H2R[/<<;\ L=DLY@ZXD>>74YB! M7[6TH!+797E*(USO_^.7Z\_7M]W;GZY?@^L/?WW[^?;GMQ]N/P_.\CEFA-ZI.@.!?8%\&[ 7>20J MLH-I[)278T._=-[*&3@,DD_.W6V_DW/-9'ZUY9FRZ559*E^K&N/=BMPM_<3W M,(TEI#*2$#&9ZB91 C*L@[\>P5[$3?=R3@\S-V?G^O6[3Z 1%71D!5I8\PV= M,[A>WM)Q@];([-(/**M]G;!9E>:]6K.YW05O_N5B>_[2=3HG@#BR2 PA<^1#A!D%(N(4=>%*2( M>22(K0*H3L6;&]VTVNG]G#.QIDK)?4QIIR?H**KF\RIQUF16G^)%,(Q+OIAY MQXXPOHQE[8.$HQC ;;C/K8C3!NY&@?<@!#?.*/;5!*ZT":L MXB#U!%5+W G%"*"$YA&,8$TX"1A' N*C=($SXPQ-VK74H*NF.:'ND^A>)Y2 M'6$S,B\>P )^K66T*)5["A_S\^L.<)KH*+KY:V1UB/P" &?.@Y^Z<[*CW1=$ M[Y[2OG1IS^KYZS+CV6JK:[%\%FR;5V<\/B@COMGH$^#+))74CWP"4Y0H'SB. M4DC35,(@$C2(TI KVK.JH7]AP+E17U=>L!=X ;3(X-=::-N*^I= -_,W74(Y M,E,.1-&^RKXA-&YK[5\:=-J*^X80'-3=-[W/CG"*O%S>_+967^Q]]EB5&4L( MCJ3T&!2IK_RHF%&8ABB$'DN2 'N^9,BH7_O!D^=&(3OAK$JU'0)VGA4&P3#R MYV^,@/&'?E+;\:]"+/!7^WR45V MM[Y>L\V#.#S])[@,XQ@%4"2AFOMYJLL&I#X4U(L1E@R'=OWCS(:=V^?;2@T: ML4$MMXOCEX9V,','W*,[,BNX ;9/97@+G%P7@C<9>NJZ[Q9P'"GS;G-W/[KZ M:;/AOV6KU?ML+:Y+\5 LD90!QF&BF$DWTN7"ARE'*8SC1*:!Y$D06#'3P0AS M(Z%6P.H@19V;>:W6Z^N[;%]@PHY[#D$UHYE!4(W,*#N4?M72@4H\AZN*DZH[ M)8G#42;E@Y-*/O_T3U_8<_.N)&658_E:-^J^D56@MW)\8\QH&@8")CB((:(Q MA3@.$I@2Q 3F DO*K/;A3HTTMZ^^DJ_:=:FV5OI4>CZ-JN&FE@NL1O[L[6"R MWU:Z!(';':*3HTV[V7-)Z8-]FXLW]*2%[<,#R;_=R)UOH; MM)X?2R\A#(94_0>I!0K$6/J0^1@E@HD$1U9%SDP'GAMI-'+K[Z'C4#^1??C^ MNJE1#$EF!*A'YAS'*-N3DB5D;CG*=/!I*9X&]&6XY1'9FQ7 !J35,6 M$#EE*)-Q)R4G"R">\Y+-K'PNQ6-GM[D]WZ:^?%&4U^NF-J#N 22(SN#6 MGM]/U89QK)PNY6O!A 011'X:0B*4&Z9W>_0/@D161;D=RC8WBCM>151KU\V2 MZ!S/K3747VZKHRXZVM$2:#4''RSI;7LSVGPABXY,KU,;T\5IEJ&PCWWDI;=\ M+WTN9BBP!H=G!@_1;ZKXF(M'DO$FOG^UK@O!U@'HIFSC,O28B .)(4\8AX@B MIMB?2,@\1%"H\XEX;'<2T&!4&RJ8YAA@':9O2SF3'C%Z$[#-.-L9S+NI&QF <1SEK*YM6:1\SSC4^0LZPP@3G\%8IIPR'L<\LJIU8#7Z MW)S-1O@%:,2O/JJG"K3?FVT>:GX/5B I$@[5E%O9)4.,$>S1 ,0RXQR B1/FO*$8PQ22B&#.:$+DL M-R5930CI?KSQ 5WM)5VT#JPK<,UHWPED(U-\B];[+EK.'=.+2+C-83\YVK3) MZY>4/LA:OWA#/^;])+Z(]594G0^;+N=_R\K[U]NBW#R(O.Z,J*8![>2J_\]O MR=SAPQS1OF[6VLH/?E,*@%:#!=CI %HE]!:U.V(: *%3RNHCQZ1D-@"H MYS0WY%'#C@KHAHC50E[]T/ZN\7&?E$I<\R;GMSA>2_'UIBB7(8DB*CT.?:'L MB:*$0>J)0#$D35+/#V,>RSX'"UP*.3<*W67+5ZU'FS"8_GGWAT;3Q=,JL'K= MV6J[ ">+Q6J5^QU>&>7L;C M"'(B?>9[GL^853\OR_'G-H$\.5VU4V !=BI4_+';EVZTL,VMLC.1&=V/"/S( M3.X8\Q[I5[V0OU&.&_'E&&P7/D3GLQ: T+X'D'-*)"B(-A]:J4)(53&?* M)ID]9[(B2E9J=4LJV=TX,-O_G=X4X22Q:M1D,.;<^+J3G-X*#2JI727[GX'?U EU"NKHCN=@//OG^E]& M:)Q<_S/CODRN_V4@3N;Z&]QJ[SQ^%G=Z5MNT?2*RRFTEA?HWT[/=G=C(M5KK MZYV:92A\PGR40!S(0/F080I3'JI_TA '7AI1'OJF/J3-P'.CID9VL!,>U-+K MUI5[^?4GM;;;Y;*VR&7?9[D(K8ZR75RI-DQ_K$:Y_L><(NFQGG/+-G3@)LYHDY@')O072%H[81>1,>I MZWEZM$D=SHM*/W[6TSKZ(.C+Z?E,4GP33E4$RF;%Z MRXC_GVU1ZM=!IS-9&BO7Y MFR=HM)4OOM-R?[_0V]/96NSVH/]?]MYM.6Y<2QM\%41,S/RNB,1N'L #>JYD M6ZKM"9>MMEU[1T==9. H\>]44I5,R:5^^@%XR*2D3!(@08J[9VZJ9(DDUOI M?EC .@&MW:K,8CQ<\A(V<,2MBF;2R*T D4JESG"E!;Y^9O3]+_-23;Q$+.Q] MLEYH%C&/3A>SM]5HU@5S$9/WAE##%OY#]^+W3X:&^=!+ MHZB3(:B-]*O2$MN7W]A!@Y'!P^P*:-QCT__-O& MV/;"TALYV_\$>T^>;IV'*CST_;^09$83R7S0T^WIE,DE@8)I#[F M$ ?4B]* A"(UZMC4/X::"_JW'0ZZ.T#^K)3S+?Z2[%51OBM<^)[V'-*F%*(/(EAVDB$AA[$8\Y M#66<6&TH>\9;< MAYXQY_4+F 'PZN3>\#;W3O4O8J]#1BM7P-\%OQ'-P?Y[H600K_P&V[)(1B)D M&(D8ZUX9B=HCT@#2U$]@*AB*8L9E@HUB.Z<3<7%4UN^NU('51TU!J>H+=R4M M-7[MM=1G/$Z]W0/?B_$N[.EG^^W]TA-.M%,W]+BYF,VW/%#,Q3B,Q\%LXP4> M.=*(Y>=+OCT$HU;R-%5>:5&6H5FSU(]]G_LP$ D((0' MD5TE0K.!;:ACSKK/=3CUN[HXX2__/H#<^U&W(&RG2,Y"PFV)#QQ<"_T+^*.1 MVZ4!; 64>X;L'WI^UC.&XR23F=\]M")T&2G_3=SG.SV&/DWS+K$GCGM_0=0G7!<@?:JS'HJ/VI?Q+2]K1?^G(+LK]5ZN$4I1 M1'D"28(11,0GD(2*E6C(4QRE(?%\JV/!P9(L;9==*:+30P['7EJ7U:'&KCYE MK_59 :61;I]3ZP2T4D!K9<=KPZ?1C.UFF9R).7#B>;$FR-&8.J7-X=+,2J:C M07M)L>,?.+@0W$Z/]5%4__^T+?.8;O.->D91=4+2(UY5A[#KB(4DX7X$?80Q M1![BD&+B0QZ2(, LB'%BV4W3:ORED6PC/GC7*/"+_ES;.OROIDW9'UH/4"MB MZ:NQG28S.IT0_(E)= +ZX)P5C+,71!N"$ G"L(->HP=(7*1K3_6 MD4]7RKXEFXIAV4.QIHKU$-9%.V+D0R0#37H4P22;:Y+Q3]L/Y#[;DTU=-R E 1(! M"B%/90K5WC*&:R,0'%;3>;SA'G[6ACHORKKC9&-]EG#_RX%5^E%#NU);LD MN\W3-\'%75D%XJNL6LP*?G%SLQ,W9"^NU64LNR>;[U_J;X"2**!1A& B:021 M2 G$.IA$L# 1221\)(WV4^-%61H9[6\%:-0!$ BM$=@=5-+EE%BM%""-5N"^ M40M\_V(>?3]R$KN);-ZIF9CEQL^*Y5+B8'K,$RCFFZ:9DBPF_(BL\C#< -N1 MJS%R@-GR.=P T<[YBBAA!MML5T+MK15\70=ET8W M4"EW_&NE7E.TI=JDZB@\F>_ %^UN+?]5ZFR==.QFXLTV 6\QG5.?(,P_DT,2 MFYW"[CKMV8UP2HA14S-+DM03&+B):&5^^CT,$LC;2TEU&("+><*:$G!'Y6LEB.G MV#R*W_+M_K98$Y^%/$8H3*?!'&S$*S5D_E,-JOZXR60F^ 53 MMQ59JQ W#B.2TIBHZ4UU>F3$(1$XAC1$,98T2)*0F1YPNQ)J:?3=TFL%1*D9 M^+-2K($?]S,]4G4UP_^'W6TS;Q#3N;L8&'(<[FSKS M@_&WF,*9CLAG^/BLCLI=0]UQ:.YLJ-F.SUV#TSY(=_[L :7H7AW>E$_?":[> MQ,MB3^BF[&2E__+A5K> *,J+RMIXZR3B"4$14TLM)A %0:([E1)()4FY#(E' MJ6=D M A*)11(&2'A(VAP1CA-G:4M@HPUHJ;,"1X7 ,XW:#:8*D^H 4TRHV='@?-,T M\5(X\0Q9GPFZ =;ID>!(D68]$70#W\L#04=/M4^-N52#[)\^;66^NRN?_UG) M\6DO[I1-Q#T18YI"CWH(HB@-81H* ;TXC!B.2!2;%4#K'F9IA%I)"EJB@C^T ML*"4UI I>Y#M9D!W>$W,;$.ALDJ8Z4=B<,Y,QZ-G2YOI5Z^=.6-PM?WAQ,7W M#[_?<[(77W)M+WO^1['+'M7C'T5QL>6ZAI;V/^3W&4O]Z.H?]2^N\]U>YILL M_TR>Q.XWL;_->54P]ECKQ*-21!Y&D"0Z"C[P=,-+0J!/@C3Q$\)C;%1 >EHQ MET9!2E-0J0J^Y'\#6ENU:.I>;P>%RWU9K2%X5RH-E-:__#NX^L?A]_"@.RB5 M!Y7VYGOJ"=^,_J.09<_K-SUN6\1K,=!CS5E^^U1G-]#/2 M<8 SX>"SG>Y,#V#[Z&>&T:8HFKFFNDVQP#YD6'*U_9 $4DYBR+F,XXCB- V= M%LNTH8,9BV2NP%98-@[K =;L_,4=6!,OH09U,.=MQ.JHZ2"2S,-^"&/?1Q"%C*MM!XX@8X= F M;T_^ J04U#(2O0M0(\?E6)BF=TE.B)"5 W$L4O.Y!E\BYLS+UP5!M__NY)US M>N:Z1'_A<^N\=)C5=$CPR7?7NYP)P0O=WKKDV*KPN2+8"Z;,NVR?B6)-<4(0 MI2&D"4\AHCB&F"4>#&+"N(<)"?QHO2V32/D/NWNY7PDSWAC>B M SW)8)<_DQTE)!EO+SMM)@985.@/ _;-I*7>8SOGN'\"ZA,MH,"X*B! M.TMM('1.33=;&6:UY08"]-*X&_J8H64MRT&*XILHA&Z!K7:P'W43[+SL%EMW MTQ.2>!Z7 4QE$D(4J/TCC4,&&<<)"I$(19C:%;,T&'5I%N&G+:BE!HW8Y=E1 M2_!![?A&S(L9Z3E'>V*JFPKH 84K+8!S7*[29.29BU1:@/&Z-*7-S<.H["K; M9GOQ.7L47#W]TY;K$*WF-Y^4<;^]R>A&5*9C$ZUU45R3W?ZK/!$O4+91.YZP M*YY+?>EAB/3.%X4!@Y@G'(;$#SE11B$-C5IQ[U&,-(IB-+2@V0:FD+V*FP_LIW7&V^GVOVXK*6IZ9,&B+9&]>+&@%F?[&H,0]WEO9QS %(I>)M M$B(82U^WFTM2B%'B0[NJ:!I*&?NBG#$9("H@P]R&->02CE(:!1Q-? M&8,FC/'JR4NCAUHXR_H1KP'SDQ#)P",PI7$ D: 4BT@&9O%3 MHR";)U3J[]G-+1#*1E(;[3(_9C1\W=0Y"I*)>=+X!3+FQ;/:=I&@NJE%@.I? M+\GO]5-G8;JSRC2T=OZ"H3ZK1V5IY;NG;^3G;T112$8VNDWY5ZE/EW>/HECC M6'!)/0H]Z1.(J-K2T@ CB"4*DCA.?!2&=@ZKOB&7QGH'B5= R0P.0J^ $EM_ MU8W@MGZI7NQ-G5(N$9W<(S46S &^)U-\'#N>>H>=V>MD"L-KEY/QG0.[@+-; MP1\VXJN\8&SW('A3<"ZK]WNM9N">LAU$%$ _(LK68HF$A"$,XY1R3J1,(V1D M:]D/O31::B37'TTM.V@)/]J58S$I9CPU#=03\Y5#E.W[B%L#YK:=N/GP\W85 MMX;E57-Q^R<,(S9%DA](<7N]RQ\S+OC[I]\+[>JX4EO1+7L6?'0X%PFP'T>I MVAOYH0Z*9%CMC;A(( YP*F202A%9YI;8"[&\3=1!6). /%=3849KT\([,;UI MHTM+#QKQ 7T"[[0&(-O^ D[!/LFQUG 0G5+> #%FI;[A,+VDP!%/LD^&^72G M7C]E+E[E.Y'=;#\\['9BRYZN-@]L_U =RGW=*HF^DXW><0K.>11@-3EA")&. MCL0"N2E67B5\-KRD)7X@-7R ]E2 .1;G8@'"JV#>;J( MW:1T<^&D4$^](UT0RN:I.I.A/5,"CU/4K3)\!B'7D?=C][S9LH$&J=G.$1KV M /O%X==-3LGF\NY^DS\)4?99OU9OV2TI1-5*2.Q85HB+N_QAN]?U55MW:RI^(FVV[5:J94V/)<"L)N\[IQ MW;WZ;\Y_WF9J+Z!LV*Q06A1K%&,:$65X^X$G(5(&-\2A1V$0(IF@,&(6Z9E+ M4FQI2UN%#6C :5>H(&G*MX)00,1J# "1Y# /@=I]']J_M!(@0HJ4&*E?UFA M53^6[,$!,/5:-LX8#1IH4 ,5;.#= 3B0%4!#=SY%>]FO*:/&GGT<66OW8KK7GB,=^3 @8R9A"AA$(JU(>:J"\S M3ABAW.SS'"?&TC[F1F9P7PF] J1VLHJJ!%.57I"7Z06;HQZVH3:#ILPT_&;J MB9@\)*<2'+QK5/@%9%MPF)I:C7(B3KC 70;JC$'2P2*-(DY38G V(A+QXFQ."ZM-G=Z1];HHK9W2AG 6MH 4:M3 MEK_Y]?+[UVMP7VMD47]W^.3UGTO-,R43L^J_R&Q85#N>95;FJF8\W>S8%2P> M#6I70>+A#Y^OX/!H )X5%![_M&&;@E])MOV<%\77K8ZJN-KD/W6M8K6(JDVY MT*$40F'- M1Y_5:K<&Y:6A;O^ 893V313[7<;V@NMQE/6O_W=Y. LM+O8?R&[WE&UORF/0 MM0C3A/F"0U\RK'LRZO>\>_&[ MX\ERH7;<;// R[C+NII"%1"S[RMOZV3RS!APPBF9F =;L_&AF8WRAY;T*U#% MN#ADP(& .>5!6QEF9<.! +WDQ*&/&9BN=$MV@BJCD;_NZ6F%0:KP"MQ@LP,;N_^=S;IW9-/BUN4\&F$W?>U+')87^5:C;]B(,+WI4M M ,Z(]<]L?_MIR[/'C#^0S]'%"(1($0\PEA9$0,N!! MZ*G%R[+NG3/AEK90'5I7G&6JGTH]<-1O=::N6C&@^^LDLV^V$KW5G$Z\]LP] MG4-*XSG'W76%/'<"SETHSSFT)^KEN1]CZ))19#=;W0#EHJA;\7W:J@%+ATU3 M"RO@@OBAA'$411 A&L'4QVHK0^.$QA'VD(SL5H+>,9='\(W(NL9RT_?R*+5E M_2<;]$V9V"FFDQ/L6#@'4*8Q0(Z9L'_$,$X\9(X\7GH1U9-!ZQ&7QI%-<+7 M1>-?UH@_*C"X]J?=Y!@ZX*:"?&HGG$NT[;UP0U!SZXFSDF!>;]P0<%YYY 8] MQ([TRE"\W=/ZT^7:$RF)$T0A]HEBLC -8(IC#Z9()C$C7AA@8<)DQTM1\WR M,;X6O?G"3OQEJ#/[OFX&]U5^%]LLWWT4=+].A/I68JQ(RXL3W:\!P90EZGL* MB:1AR@(?TZ8#I:G7^M1 1B_<\QZ3$W]BAR:(^19L\NT-5-_U':#Y;I?_5*9: M%7;/E>A _*7;Y#UDQ6UI;3.UQ;1V1I\$W]3G/!C0N5S+]PXM/#C6S4[A+W=>^W\ZK1[7N;D6ZU\V44T18Q'$ 94I"B&1$84HPAPE- M*4L2RG%L=+[1-]#2EN1G#9*1^QFV^ M47<4.@9S_W0XYXT%X7X:",B(IY> 6%G/44"A2"+B^S2AL;"KWGYVJ*513EO2 M_^O_2 ,_^;_+\._]T[];1A2>1]>,7MQ@-C&MM(7\7Z 2$USL][N,/NS+;/1] MKMO7EOZ_"0[-^T%R&U]W?KAYX^-ZU7X5W]9_Q\!@@ZRXSPNR^767/]Q_R??Z M)#W?[K/M@^!?[\6NW'T<(LU/340H)W-T37^%9+-*^EU:LVK3NFU94WAB2?#)TZ,_Z:Q#N/@=!O_,%"6>6,BQ@'V*DYBY..&L>MG M]6VO,2$L"8(88LZ0SM@3,*4LA@$B+)2AYV/DVUAC^J%+L[NT3';L54)C1D6V M"D_,*YVZ6A-#6SFG7WGYX%D_V;8J+[^_9W\;]C'5G^GVYK,NG-.2*AV$WCJ2PND#VF4)!"S*$"8"Q&8>0V,1US:9W@0&)02KPX%I)[T M\M=(;?>A]L-N]A4[!7/B3WPDCM8D8(R-4X;H'W56^C &X26WF-\XC'@N^/]^ M*/;-:Y3R,O M3;D7!#*U2M"W&GUIA-02OCRZ5.*#H_S@N0+@#ZV"902DW>284=5DD$],6RUD MO^_5@DMVO "_WW.UW^W#UIJR!F'DE+[L))B5R@:!\Y+6ACW$/A#C6JC73Y=S MNLJV67$KN ZTU+G\^5;'ENLAUI(Q%H:ZUDA )40D(1!3X<- !))A%B35830#FU$^M-4#2/W'",YDP! M'*-1M0KHL,"H(Z[#Y"FSA7=8J-2.\K"Y;9C=6=?)^;1E^9WX0?ZZK&HUU_F& MZX0%<4ID!#V=_H="%$),_!C&28P23TB&[ S-[N&61LFUM* 2%RAY02TP>%>+ M;-BVQ1!N,]/1'8@3D_$H_*RM13-8G)J'/4/.:@^:J?_2 #2\:^"FEJG5Z6&C M76%E'32=^+P3MVJ [%%40^JC\(]JJ*W@]9C7^L_Y]F);W?,\#UJW]*CZU2M9 MUWX2A %&:AN,$\5.L9= 0BF&,I$D]KU(^"FRB_F?6.(!/L2I-\]'A>M:=<]4 M!N\JI7\!6NT5J!4'M>9E5Z(5(%*QL?Z\+;?5$[\>AAOQ!4SY;%OW.>;:?IL_ MSPRX/1B86.9YCQ+FF8!7AP\S#3LP#'J7,R%X<:7@^GZ;[_8_Q.ZNS';B88A8 M%(20(Y0HHY@+B$.!8$B%8F^!I?JC5=3MN9&69@\W@@+]"H%"B_HRV6Q5]OA5 M^\0RX2PKB@>B7L$AJ6;G\3?C=2>H3GU:\0S0[T= W2:=]4+A-K[V[&CSAM7V M*?TJFK;WAF%$=&NH4&QQV;:5;:@7/E)5?EYK2Q=,JO\5D1 ML%I-.P9S-/%F=#?C/,Y?"?10X?-8+6O5S,FSJ7/'F6[Q=$JPCD2;E8W=POF2 MNAT_?40MZ>N=&G^-2.@+C#PH1!Q E+ 4XL!/(?6$1W! 2.!9=08Y/GII)F$I M&2A%&U!.N4++C."&83 '2?6H/ZRB\#--W5< KAX_?\7>9VJ=K+#[_(H1>4OM M+UQO#.O">HR2-/;B&$JL4PL$BB&FA,$T#KD7LU#ZTK-.7#H]UB(_UO-+ZL!J MAEU@&W[:;B!\6X-D@N*%!KBXSUTZ,][\R4O=BI_,7NJY96" O4ZA$<\# /76 M4"=:;JMTO2#R>4I%"CW&%:=$.A]>V0!J^9<^#F))4R&MPN][AUP:M502K\"K MJ%8M=I5"7 EN&<'?C[T9Q;A%=&*F&0^F?8J ,3YN$PCZAYTWO< 8AE?)!^9W MVH?/?7^XO]^4JPS9O"<;?:3Z_5:(_:>MS'=W52'I)G4X)!Z5D9? P-?-NX00 M,/45-;&0Q'[ 0QDB(_O&/J^V>BO4^PVT75? M:$]IWW1UG"I X[MX5/^]_8\'LE,LOH23&G^KDF9Z8589(/QFK=< %H MQ_(RZO&SK4(N0&@O5DZ>-]#+Q&X%?]B(K_*;8/G--OMOP3]Q)4(U6EENJ1QS MI_ZUY:TZK>IOZI7G/W3YLQ_BK_W[C:XIB1GR NX1Z*7"AT@&/L18,LAQC'P2 M>I0$Q,HSY5:^I:V C7KZ0/2H(#AJV'1E:70LJV"UM 2UFN"/4E&@-06EJK8> M,,867OOW#3XN_7H.99Q7B_@- "_\AQ.-,RX9KZ'C*S6 M>&M._=A/N0])X".(/)Q K'X'@RB-N9^BB#$TI#GOJ<&61O>'(O(ZW*\EYTK7 MWBMLZQIVH6Q&OZZPFYA+A\(VN#EM%QZ3-)L].>";-(_M4OU<,]C.>X91R/NZ M[F?+WOU\Z/ <,(DH\Q1Q)"G7_;U32$(6P(B%?NQ%?I#&J0V%= VV- II9 47 M[?WWYZ&=MSMQ-B,15^A-3"+#@;.F$1-$G-)(YX"STHB)ZB]IQ.B>H8W6F,@> MM6U3=J:^NW_8:[I2'ZHH]I=2"K;/'L5_9F)S^.TWLA?K$/E>*JEN11%X:AN+ M.20D\2&//!D2#W$AHO6CV-'X[NE##D!L!LEI*L--EL\IL M.;@[;G1V!WVMV[,-FS(SLIIA&B8_J&TT #^5"J#6 33BKL!!#5#JH7.BZZG2 MJCBL5C$23,>=XH;),G,KN5& O>XU-^YQ W,!R[KZOXG];:X>^RCJVFOKD*"8 MA5AM[!!F$&&.82I#!A./JYT>CB0V\W+UC+,T@ZSN!E')"5J"6B;:G4'5C-8< M8#4Q;=G#9)_NU@V"V_RU,V/-FY#6K?"K#+.>RX?1P3_(YJ'*31/L=IO]^2#* MFO$/BG#X!U+<7FWRG[7?+HF\U&.(04J)@"CUI-JW11YDQ*=)1"41Q*H2E_G0 M2R.-@^3@(/H*'(4'6GJ@Q1^8SV(Q*68$,PW4$W..0Y2MR<@>,*?\9#'\K)1E M#\M+%AOPA&'$5IUJ?=\KBTGSY"%T-TAQZDM.8,!0 %%$(TA8XL&88L*IC#$2 M5GTJSHRS-,JJ"^ =Y+0.D>[#U8R('* U,>L, 3QAP@7G!E@:"50R@J.00$MI]OV?!;'[PWZ^S#^&]N-?15)=;GAU(<4=O .(YE2'T)D>]%:DEG1"WI*88^X2)DU,><&#F4NH=9VL=<20I: MHJYTF=OSR3@VD'9_U.Z FOC3/H?1@)#7#K#, UK=@#93N*KU"V85BMH/14>@ M:S;?E*E+79>=WM[X?BWN+@Z-\\\&Q[4QTE M-8?*G[9U;)'XN]CPZUV6[W[DK!Q$)*:0)5ELH'P42,2XE M"NS\:3-(O3S?V\&'W1)S!9[I#5J*EU];I7K3M/C@"LJV3>2A %I_4 *@^QBW MGCTLEF#*%\ELD[BPEV/B-6HQ;\7@0(D9YFF2>(LIY7Z3L(T9)N)<],<<0P^H M6G$X0=!MT7Q.&/&D@)S':K,01!'$,A50O26)VB0@)(EY78KVDY>V-2A:AU?F MO>9> ]:_"Q@,P\2DZ@H!BT(/0Y&8R9HW1L2N9L,IK;NJ,CR[?KZZ"Z?$?%99 MX>0%SBSR3ULN[K:9S%A5I*&*Z+_3;H^+XJMLAJ',CRIJ.'[-' M9<]N>7$M=F4)3NVHOB897R=1S$,_YFH^(WTPXE%(191"&1*$I>"1KQYJU8?# M:-RET?%!;%#*K:,T:LE70,E>U;Q?50$;6G[;-AQFDV'&K!- /#%_.D-W0-<. M*ZP<]_ P&WOFCAY6@+SN[V%W^YC(E]>M';FR)L,XD9 &F$.4,@RI%Z2044(] M[@=8AE81OO\B+33K@(X]^0N(IO4C'=0Z\QRP$>$L0B2"#(2)Q:)5^<'VII'_"S(CC-6?=! MVF&E@TX ;&R0.(!M>I-C"&*#JP:=!V.2FD$GAGN3BD'GU3Y7+ZCC#OL(C=^W MQZH3[=Y)'_)B_R7?_D,4^_JX[.(GV?%B'0>,!DS$4!)=A][' A(/(8@B1,,X M2$DZ)8!((CXGM&O4MZ1UK: E&GMFD+ MZKFXH)+7-O7O',#=K.\4MHDI?C!B ](">] 8F1]X[NDS)PKV*/DZ8[#O!GMR M^%BO3E=9PUGPR<0#7U]G,(2E8DT(O"8 (X_^39/OY> MY=H??O_%PTZBJFWJAP>U:]WNUYAA$D="0DZX[N,3JYUCZA$H$A$3(1!3.\CU M/M^3C=GAT[.G6WWDAS&F>WU_Z#$ JX0#I!35[I3I.7AF!TN#(9G\W+@Z/JHE M8]8CHI'(O3X5.7^2NSW53E/JI\29]?!!K&7A2^IQ +Q81 M1%P*9=H3 1/F!S04,8JEU3FRZTKGC?O^'RHWXYCRD7L(TBC-(9()"$D<8PA#U*>)+X(_$"."PX:+MS2B/!4 M?$I1]N0I]0//%7QQV6\RK=.[_^:>40>A2..AGS@\:82 M;QRR-![:_C F!V,,;.2GX__?JT7IV4%YJ_OM^Z?C)?5Z51Z:-[GT2MQR"UV4 MXO^X)=NO]_H1Q56^DR(K*XM7&^MU0 2-I,>@2%-/U\R24)?!@Y*'F'E$)C0@ MZZVX(>JF'Q:]_N93P8BF<$53KQ29CK)*]2#5^CWW3K5 /0)M*^K@0 E$JMC M18\#=[14\*)K:U'\7_$;\ M2K*M_N4WP3:D*(Y)R5+M=7Z0O]9I+.(T2A*8()KHK1N#::)^2OPXH'Y$,.%6 MI?*=2;:T?5O%5,\T W6FU#NMQR^K5IGW4L,5T#H>_OI2T14@6E7MP+5;$=U- M?A()'G,B(?,C!!'Q*<0""\BE4/MV%'DI#P?85_.^ _-;3_\37P4ST^=-ONZ) M#9LWF4UKN\4Y\DZM$G?2S6IS. ?UI47A?H"!F_9#V^8RB.W]TP<]2GE L)8I MC2E#&/HT(1!%80I3Q'S(.<8!#RA'=H>W'6,M;4UO]TXOA=4;F%+!PW$9TCC^+R$1=X%^/]T8=W<\J?KX[^_E;[!,?_BFRFUME M6M4-.;^).T56V?9&1\6J_]5G)SBD'DF$@(1*12,Z[R&-&(8AD\PGC+(0&[5; M-QYQ:63RLQ8:D+IQZ:X1&SQ6#TCQ'P3FD,R4F MC(?6*A/!"J:.] .SY\R6^,ODB+B1$J="=Q3P&)9:Q%U BO< H,\UXQ*5Q=2,P.$JL M#YZKVA"_J1FY>[AK3J_5'Y0V^BQ:ZU,6BK",3^R?$#/CT"G,$U/X"83;(4AU MP0TMNL,B<*;XN"W_UCOJO(7?3$%X5?+-^,:!>]"F95MR99E9'.=5X4P M#[WYJ!]%?LP2*)*4ZM[.'!(9I3 (A9 $>V&4V&U =&CD=&_JI[=5!:M"( M/;@?HM$$&&Y3'<,Z]7YU/*+V^U8+B-QN8$T&GG6HRD*T* M#-GA-KKJD.%PLY4BLE._79_(\LYA=M3EW?TF?Q*B/.+[^G.K/O[;[+XL;?;] MZW4[JKCHZWR3L:?JOX>0Z+7'&8G\@,($RQ0B M'GA0%\B&<4!\23AA'K+:;1J/O#1"U(*7AH8 +=%7H!(;_%'__YBF8+GU-)\2 M,P*L:ONC.YX!\?=@<_ M03EV&9%*7P:MK@/,D1>%(10!(\KFPQAB$JE_\CA6Y!8@+HPZ"(Z086DD5ZI0 M1Z:SEIRVIVCVDV%ZJ#8IQ%/O7;6 !:CEK[:M:A-[,AW@&%'=Q,K5 =+J(W)Y M C<83\<'M[' M7/M7U[%$ 8]X"#'G$40H\F!*: *CB"0>CHD@R*J?C,&82R._1N15N<_:EV=) M![%70 L._JA$M[3M3"; T+_I%M:)">]SOKV!G[/'LN[O]B;3>;QEB9%^' >T MMS)&QG%KJ_YQ9VYK90S$ZY96YK<.K:FPRQX5I^DHWT,J4!/9^_F0+)^&:10C MRF&0$E_M.D4**4XP] 1*B1?)" =6;&0V[-((Z2AU.R'P66C]J.H&1E-AQDON M 9Z8FIQA.Z#.@ U4CBL(& T]9_U;W3TV->!%;%I5S/*KK S[Y\4$ MUA'Q6932&&*$0X@"@B%!/H,BPC(D6/+0XW:-Y ;)8?/-S=-FKAT:WR@":DWJ MPJQEU'RU6_KC9?F/P0D'-I-GN!V=>D*FWI!.-1,C4A@&(#E19I\J<97O=#YX56.0/7W(MZ7'M_B1W8E]_AO9JRWQ_FGM,1&Q,$HA M$U)9@(AP2/Q4\2A1&U7U4Q(C;IHK83;DTJR_6FK0B T.=:$>UQG2INPP5>'BO^F_GSKJ)N#'6@=212&#YHM MB\).L78:A>6= YK]?+_\BVT>>+:]*7-XOXC]=[(11=V;+J0D"74(31Q$.J*& M1Q"G)(!)*'E*4E_RR*@;:O]02R/N,I1I]Z2D!J(1NZ[BHP0'I>06362Z8>XG M:G?@34S077A9MDLT ,ZBUXXS .?JK#/DQ;/KGF,$25>OG.X'S-<9QTB19WUP MS.ZPY]/?U-6W@8?PEWQ_>$NEER0I]R5,J9]"1$FLR_M12-(DH!X*%+<:]44] M-\#2N+.4$6@A02GE@._^)([]-#D6G8G)<2I@S&EP+$ SD=]+H-P07I?R'31W M\K;9R*U+Z#:E=5XWF,C"9^]9Y'DI37$(14AUG5).8.I)#CDB(DY]0E",+8DL M_%<@LG#T]QH.([+!Z,Q$9*Z!L2:RP0#-3&3A%$1V4OE^(@O?E,A."GV"R$Y? M-W,MY[JL91GH4S0U+5\H(!$2J9VT3P@ M,4VEB(VZ&[Z1_$NC800]%=RLHCA5W5Z]])N4E0","CK',,Q5S'OC"&7JZ MEOL:3>TC6_(;-%]MYW'SN(SZS@-U^->H\3QN@IS5>1XIQL!\S[*XM)8TWRI! MZHC*)/2Y[Q$*?43CJFHCUJE+%-/(3R@-L&]4;JUSE*4M>'4!^8.4 R-63R-J MME:,QFEB1K>'R#Y[L@L"MQF2)T>:-PNR2]E7F8Z=%P\,*LV*^[P@FU]W^<.] M(IWZ>%;]6FFPS[8/@M?-PA0S?5%O1OTZ>P(CQ-(0ABE5MC:/0T@2GT(>>1X3 M#(>!M"KL/E".I5%(HP8H]0!:T($L,G1BS'AF!K@G9J)!2-L'G([#R6T$ZD!9 MY@U)'0?8JQC5D8]SU;WP?1G77^9??%#&UTV^RT1Q\5=6K -&".'$@X%$/D2^ M#" FE$&1WHE-=E1 $#GV'*P6>P!]:@=$]!<]/BR$- M3@/VU-3G#F<'G?YZ$9NXD=_Y\=^X3U\O,/UM^/H?8>]B.O1^K7H%_+XEFW+: M!?^1?QC>Z%CC&7BHIC,.(0429!W%8UO"/?48YD1XS=IT;C+?+T1#-Q)#V M4%EQ8B<,'2QX^K[9>*]3[#;3=5]H7P'W<[:ORWU_((4HMV9^&J:)D&K'C!FJ MW/0TYBED*!1^Z#,I R/?PNG'+XW5CA+J/F_":N-[!L!N/AL/R\1D9HF(56W9 M\XJ/KB-[XM&SU8P]KU:[/FS'53/U@7TO9+X39[M ,D("ZA,/QC$BRJ0)?8@) M#R%+(RX(8YS0=(Z&H-UB>J_X)M06FI]1MV!^UY.U(?$1+& 0Q3S"#"J7H[ M9,R@X)QQ+E":8*O")6_Q6OPK=0Q>^OM@=H3[AK,\]0'*&T[P] UDS:;A;=O( M]LBX[&:R9@"/;BEK.,Q 1YP:N=AG3)^"USM6/PJYC%@"D><%$,6ZV)XO?2AB M'A.$&%+@6OG;7@VQ-*)O)"P]/)8>L]?X&3K&1J$RM?^K#8C#_7V_\FY=6:^' MF==C=5;-5XZI\U<.S0S(=WME--]]%+0LD%?N:TE(&$XY@;YDNEI)$$.<)@F, M8DXDBH449FGOG:,L[>LNA81JI#N@Q6QJ90YPCY\&U>Q['PW5Q)_\()0&1'AW MH. X#OO42#-'2WMB>Y='4SDIEY5YH4R%;VHCK(\+4#V(^[.)HHE5NK-X$*.&!EAX\ M%]^NM[SE9/2[4J:!>&IZ60:ZYMZ8:5">R47C$&TKWXT]:!T.'8N'S>;EL5>P M[?H9L"$)\*B,9BL!HA9A(OJ4M)0?U>CZ^%:B4U#EWC9KE MM96BKQ*9UTR)Y%%$\^#VPPAQS+.FULT M#<"OLI(F&F9LO>EJ3)U'NRB$3'IJ(0F1A#0) M$T@\C_F2QQ[#5DE-8X19VJK1-MIJ;.8R2=2<;?71TK=[U6U*(#_G= M7;8O6Z,!Q(SF&8^+J?7"PA]@+=-#,E@1>F4GA61[\&8RZ-8,N&/^4) M9R,T.$IM1YLFB)NQHV,<)R;!3@@G93L+G)R2FLFXLW*7!1 O*UQ&F).F6DLZLD1EL8RKXKFO*OD_,4\ M(O4TDMU\X@2?B=GC%33N/,N]ZH^.3CW]]-D"5#N5:\>H=E]H[TCZIHV97.YO MQ9[L;L1^6W;>R.6]V,E\=Z=WE&5=J8_??R^(+K(C^%JFDA,O]J"?ZCIQ"4$P M]7P?LA!ABFC L#0*0!\X_M(HH51![QN4$J#2 FP/#6Q:BM05NK0JH-;%W TR M9*+ZO4T3PS\QXRP7>7-/U,0S,)-+:I*9L').C<"QPTLUY*FSN:M&J-SV6XUY MS+ =[3$D\DHI]*&J1**+VA]*D511D8<345%<_K7?$35&MB6[I[*QWA<%D&XL MDF\V96*IHGI1[->Q'V//IQ3RQ,,0^5X"TRA!4))4T@@AQ'BTWN=[LC';"4\H MJ]5"=I!XNH^X"8[>E!THZ^CGK/KE7BMFMXN>49S)5G(?! ,PHXZ@N."C*9UU9]T!9XK M#AK-E_.ZF!W6+.0EF-AH&C?_ME-M?1(TPR0X/4&:4MY93YYF /[EB=4<0PZS M4 [583]M[Q_VQ6?Q*#9!?5+C!9Z(6$H@32(?(MT2!X?2AU&(HR3PD?3MO)P= M8RUM[3B6A5Z!2MH5*.4%@65)!1.@S5C;$7P3L^XHY*Q)U 3IR38-=ZL)&:@ M^$L2,KEE&(GH..^O\H+G95WJACUPZ/DX%=#SA+) MZ]@S]T59N\!P2@LG!YJ5#[I4?4D$G=>.C:92=HF:\(QN1!6X=;'EO^8Y_YEM M-B^#J%B$0BFYKAA((>*(0(*%LC9"3]#8"U-LE\8_0(:E\.+92Z.Y M6CS0R&?&7*= ZV:DD5!,;0N9HF!,'AWZGB"%0K"_W>2/_Z;N*OG@3Z1_A-6/ M)0F<>MXL'W>'(LU'VW7)@.@ \>=#MBN;[GS/_MK?_L<#V:DOX2K7T>;*6E7_ MWF0R$_R"J0N+K&67DY@SJ;5Z6GOXG[ M?*?F7[E(IOHE']8F2S9HI>!$G M''J()A#%)(8T3 G$ <<>HU*FB54RSF!)ED8O'Q[N'C:DS+ 69=8K(/Q_/Q15 M>HE4>S[2. BTL^#[!Q!X?@S]T(YZAD^<&3?-,AWS.!P*<%2BG=5>*:)^4ZH" MM"Z@5@:\:]0YG_)@S7*C(75*@\.EF94G1X/VDDC'/W Q__"PV^GV-(0D& M!813% 42^CW2%.P\BYJ4^YE(QK+=6,M'-L23.A5W1$NU"ZG_I)WK2]Y*RR#[\RG(""ALGXC!KDOA?9?IQ"3*(+$3^-4 MXH3CQ+.)KYUD N:(EGT;^.V6**>@SK4DZ8.PJVQ+MDP;U>T%JCH9.Y2Z*$V& MUA*EUJM**_<+DS&0DRQ$_:._R<)C#,JYA<;\ 0/:]%6%F-4PNN=??7"&2:JC M; 04PE?KAQ>E4)OC$.DH/I3X(9:Q<5^^$P,LS>"N2J"S1L@!IY0G8>P_#AX+ MSL1<,Q$N%MWS1N(S5[L\6YSL^N-U@-#5$._4;?-UP.L0^EG+NZ[KAGCB'L7V M01P"I?4!1_'/;'_[0>V?\SO%)1^S@MS<[*J&*M?'W*W?!"D>JM/5M<\D\A(I M89 PQ7I!JHPWS!GTTX1AQ!(_38WYSXE$2R/,1JDJ+X(U:H&?2B_ &L56@+=5 M ["=X0CNCNK9>(-O MS\4X,[K]',+RW /H\L'#3J%^+\17>5GLLSLU1+$.L4 RT.#,U?9F]*Z.Y/8%N6Z5A]D*T+Y?DMV MXF.V>5#\L@Z%" .$4N@C%$"$"(*$Z%HW(HK3&"$?F?>.[A]N:63 6A(#48F\ MT@LN*+34:O'EE>#FUI(!YOVVJULD)V:*MP'1W)YT"^9,QN)X4*W,0'.,.FP\ M@X?,9L"9*]2VSBSN&F9Z'9((=F1;;*IZUEO>U#$\)L=='*(%BC7U<$P)3V' M!(8H8#ZDH?HG#Q+A<1QS81=D,4"&I?%VH\(*M)0HW2F'$@BA*C?>JIAR^-X$JA]/[+#][1 M7T CKGF>U"OTNGEI+"83$XXM'%8)4^?T'IPQ]>J!LZ5,G5.EG3-U]IIA%HVN MO9QOO^]S]E^EG51/-:G49*/[2NC*Y M91A%?Q'[8_VQBT>2;"CY?A6%#-#^*,2OZD-6A<,)8T.8)\#5GU,14L-.]:QG1XS M)IH0](G92>/]O'3C11OO-GG5&JQ J8,[WAH(GE,NLY5A5GX;"-!+SAOZ&/O= MY,?ZV%:7/M*5-G":L@1*7_H0,19"K(L;TB3U68HDD;Y1<-#+!R_-.&ID*WN@ MF^\=GV'5OV\)SQXVVP[QE KMW>')OSOU/%:+&&5A MDJJ-"41)&$#$?0Q3(C 4/$3$"R(?FQWFF RVM,^RW[=#.Y[2[/V+7&$[\ M8<\/GQ-?HS6,B_$T=L/IRL]XPI*R]3+.: C9*&/H81QCXNA'E\60/FW+>+'R M;-ZL$$'7K0OZZDL104M&ZX(-G1B9?^(NL)KITWZ%F9N/N ^!CH_W[*VS?;1] MPK<_UMYK[9L+7N]R_L#*@H+?Q>XQ8Z*HJMZNI8@I"4()"6.ZP: RBVCB4\V.K+[^ZT0^X]9P3:YCO NCO5V M@Y0+2120J=193"1 ,*4201S%"8Y)@@+I655GLAA\:53Q_??KZ\^7OUU^^7'Q M&;R_^'SQY<,E^/[WR\L?X-.7JZ_??KOX\>GK%\O:33:387;N.A7$$U-,6VQ0 MRPU*P4%+#'B21+#)$HP1%P(B/V 01'X. DX29(@M>$V\Z&7 MQFQ:27'_Q=FR&P1FN9;F/K WAG(U@N0/5Y.EQ^+X6== M?.QA>;GT#'C"L(7G_4.1;451?,CO:+8M=^M5E[4;]7CU4Y'QNM/:YXS0;)/M MG]9IB+V0A!@*C\00A:FO=]P"\C!,/10EGN])FQ5H@ Q+6XH:%4!+AQ4X:@&> MJ;$"!T7L"&_(;$4QI3$/ AA'@5J;9)Q"(E&@EBH42Q')!-.P69O>=KZ>KT\3 MSUC9;NU1=_72\;'L.%.LK<#TTV.V,$W\B4R\0KG_.JQ7JA$ .EVRAL@QZ]HU M JB7B]B81]F[<7[?[@3+;[8Z\*_M+?J0%_LR(N9K63BV6',OB7W==R+UPU0M M7RR 5. 0AJ%(TEA2%,7&J;NF@RYMO6K+#=J" RTY@%68&*BE-_<3&4]"OV]M M"F@GYKDW1]7<&S<%NC-YYQRA;.6ZLX6KPY5G_*C97'NVRK5=?=;W#CS]KQW] MSP>YV.UT]6']SKU_.EYR39[TKRY^DAW_K%:@L@GT.HH$PYBK74N*=5M5KL_- MO!!R%C$9>RF3Q*I,>$,9+?NBO%BS>O$< ;C*]>&NRGZ0IAHE0_Q.")E@:=Y@\,\;2 MR*,1$V@Y02GH@-K5YP#MW[4[@&ER=]F4")GOP!T@-=.&^P1B;G;5/1!T;*+/ MW3G;GKE']/86N>_2 7R7/8IBG^T?=N+B9B=*@ZTL+B/%[JNL:343Q9J%*"2I MI%"$5$+DDQ023R)(&6 =)(O@+[6G;M_I$'Z2T8 MP'02#$AS FBG9M&W1M6":"= =R[F=8.R'2E;PM7%TJ:/FH^V+95[QN.V]P[; M&6O']#^T7_K]4ZMT]=5._/D@MNSIXJ^L6),P9(+*%#+I2FUL[9M#W&Y#. 9V8>MX.2W.ST3FF,]F,#K"ULA>M<.HP%LV>,YNE:*56 MVTRTNW&8C?A9K0)"N]A_E'5_#JE6,<8\8*&$//$(1!A[,/5B I/0ER$6,@[- M"O3TC+,T:B[%7)7A'W:FWSD/6;\05URE>]$=J/#S [=+BVVFSVS M1B3W$ \@18DRKU,402Q0 CV!@S!*9.(E@5G)7V?S-D^QW[:$#O'L9G!G&$W, MWS;@6-4MZ%5^=-V"\R/,5K>@5\EVW8+^BT<4D=4'A_K9?Q?\)MO>-%$N5'HR M(@3&5->+E2* V$LD)&G@TR@D7L*$C;5V?JBET755JK01%=2R#HQOZ4#8S(YS M@]O$5# 4LF$U7#O1<%^N]?1P\U=F[53[9!'6[CN&%@/898]DGSV*8PIH\:O: M0>IJK^^?ZJ&^B:J52'&;W9=+'HU)XJ$0P43Z:O.71(DR_-(8!C&2(<&A()39 M%088(L;2J*;Y4-IR#G(3#)P5,PJ:'NN)Z6D(S /2S<>@Y#CU?) H,Z>ACX'K M=4KZJ*<-H\(F\[TN^5@OZ[&0B(D@A2Q&"*(PX=46-_!\EA(:AY@C&Z8[.^"YN-+JVG1F?HV?& M B,PF?C;?P7'!%N\,]H[;KCX?(R9FRR>5/!U8\73EPW[CG6A$++194*:,Z.O MVR-G%&OU$2>48PECXOL0I>H_!"4^I#%.0D8C1@BW^:Y[QEO:=WX4%VAYFPY^ M^;;E]+'LC]B'N!D7.,1Q8FX8!Z$U31@"XY0V^L:V(I\9.K5JL<%]+;>N%_/N05>*D?GN%R ;\0$YR&_M MGS>=$C-*F@;HB=E)^^]+G*_;.&O)0;;]!1R$!Q?], _QZ5LBYMK';SK\W#Y_ M2UA.Q #8/F$8K_W8E8D_3V5-M3(7:,UC$7M^C*%(=),3#\<0RX2HC1$A@<_" M.(WE@*+SKTI2BMFO$5@!0Z$>)0 MR2#T5[J:05"V!M)OK1VEG9@-,^H:".X\%'4 M&YP7\KGCH3.Z^Z4;$X,,RNI MG%?S)7ET7#F,)/XILIM;]?5=/(H=N1%?'O2[_E66E;R*KP_[8J]>=\U*3?>^ M%$4XC7D (U\7R,&^A&F2QC#U/(I3E(381V91QT-%L'G]YPE(;C2 I%*A89#\ M*+P=65C/BAF53(GTQ$33B YJV4$EO&;H2GS0DG\%/F:;,AK?H'&E-2D-1=$I M95D+,2NA#87H)=T-?HY][, 7\?.",9VFH9ZGC+-MKE,@R_WE2[\(CCE!J8RA MSSU%@3&)(2%8I\LPY/-$RC0T+I%C/NS2CI^4Y. H.G@NNYTKRA+_;K*;#M7) MMWL&@)JUA1N#KGGDP#0HSQ0Z,.[UM0HI(W+ XF&SA0[8*]B.'1APMSV] M_S\/6Z&PC-J%]V+._3 B(4RHKW;#R/<@"7@,HS @'N(Q#8A14Z(SSU\:86L1 M]<8U&ES!\!2(_60\$IJ)67<:5,Q)="0Z,['E"Y3<\&*'ZAT$>.JNV9BN0^0V MI75=-K+$U\E^N80'2& _@4$:(&61AA)2*M7.G$91' B?I7YLMRGO'&]Y._"_ M7W[\]=.77\'%AQ^?_O'IQZ?+[^#BRT=P=?'I&_C'Q>??+\%OEQ???_]6-C7^ M/K#8UXA6Q<[@G)@-RQ9GI: S]"(V F6:"E]OWVW82/FS5;TFZ"?\3>@4';9_ MT(&;']0.^T8[/ 6.?!)%D&#M,/ 3IGXB/D2)ER0ABW 2IW;$55?U\7ON-9^>W2Z[]ZQVUY3M%2]^Q>Z 8)41*&/_= HTH=:-+6" M*W!?JCB@D9+;B>_?"+[)=$[,?A/,Y%M,GOE^]4TF<:9=[IM]EE;;9N@2[: M7"GU/N?;FQ]B M=Z<7Z^*KK)J-K7DH=7T :D7JKV,3$)(=,FUE(9ARJ7/4VI5;:UWQ*7Q8B-P M5?B2YKM=_E/M-PN=(5&=@UAW;#%'WXP'G6(Z,>,]AU-+"]4LJI^TO#J4J9+8 M';$9@^.4POI'G96LC$%X24OF-PXLR:T^FYN2V;Z)0NP>Q8<'93AN]^N($T\D M?@(1"21$-.4PY8IWHIB&@FG?M)ECNF^@I='-9W&C=E*[2D9+/CD+IAF-N(!H M8O:X+/;975GFXBBL^I'0LB.FVJ=6$CLLT=V#B=L:W><&F[=(=X_*KZIT]UT_ MC!E.;#/K6)AUB*@7RS"% JM]&^)462RX# (/!2B 3Q8)J$'F0DHE!PR@SGQIJ5%GH4?LD)?9>/+1I=]AA9"RY] ME"C3@J=2*-,BB6":AA*RQ)-Q%*DWQ;-J!?3B^4LC@*-X=:.;P=6=*_C,/O@1 MH$S\H5O@,:(,\S.M)ZJO7(WQ1H63GREXOB+R\\N&?<"_YCG_F6TV%]M7YZ;- MGVH3-B$2"X(QE$F@U_A8J$];!)!)Y/&8(XDPMOFTC4=>VD??2%=F<;]T.JBE MK?G[H#IQ(R?)C$ F@7YB:ID4=6LRLD;0*4V9CSXK@5F#\I+:[!]@1WI<9.N/ M=1Q(Y4._W/*/9"_6NG@%9EPGHNO05$5H,,5> E%$8U\FB2\\H^/2LR,LC<0: M(4$E)5!B BVG&3&=![*;@)S ,[4-8XN,,7GT:G^") K!_G:3/_Z;NK?DAS^1 M_A%6/Y:DE$&2)A)[H9<:[4'.#;"T3[F4$6@A>S*KS.#K_H)=@#+Q!_P2CP'Y>">! M,0]P' O03+&*QB^.56QAE_(=88(G;YLMXJ]+Z';P7N=U UVXM5OXHZ#[WXB. MQM?',]_$?17K5WR5U[MLR[)[LOFT_99OU*-NCI%>$:$>X['>E7D(HB0,(0VQ M#IB/I1=(Z:/4JBG-*&F6QHS'\ BMS@H<%=+]6!N5=-3$02F0;4&MUN"HO7$S M:K:%FVV>)B;KZ:?(WF?M EJWCNU1$LWK_78!WBL7N9.'#J/GLDR:&DJ]\+>D M$-<[W:?U[GD9H8N'_6V^T\5E?^3OQ?%BOB9Q$C%/AM CC$,42@*I2#%,<,32 ME,44,ZNZ\:.D61H]E\J HX"@5F?UNC+742?='9N*UEV&R2YNYM.,G&>;I8G) M>>H)LJ9F)\ ZI>9Q$LU*S4[ >TG-;AYJO_/_0?[ZI+3>:C](\6E[_2!V^_Q; MQO)/=^IEWG_=EGUR67XG=*WO:['[D-_=Y=M2H(NB>+A32T19X4_OY1)/1#SD M$42Z*B7BPM/V\46K-2TJFRY J16%O!:6_/MN=/)[S_O>*LIG9C=_T?. MIODAS5O-ZDR'.V\TNU9'15-,0<<1D]/A9CN:F@*D]I'6),^W7]#+1JY5K*). M=]UGN[)^W[5ZJ9L#6#\.A1]+JM,9/+69$B%,$?%A['%/D(13$1MMILR&6]KB M^TQBL#N(#.ZUS ,.N0T0[U\;W>(X\8KW%A":+TANH9QIF1D+J=5Z88Y0QRI@ M\)#9N-U!+X^A&=E *7X8JE>*#2GZ@C;*F M2_R[6@?+*F!6T \JCUJCH-5+028.9+5'IK78:X#GC&, M[BZE%+ICDC@\_IL:\YO0VF:;K"3:TV*(8DUB/\081XKY0F69,DD@ED3])TD] MEL0(A3*TH;\QPBR-#@^ZM#])K0YXKL^JXQ.V3>(=-9EF?#G7%$W,GVYF9Z7C MY)C35!X7^#IEVE$"SV[K%X M,O)H1'$L(&$D@8C&,20\TK7X411REL@DQG;E9?L'M?F(YRDVV\B\*O==^_); M%8W!;3 =4GC%$";7E5?ZAIV[ M](HA#"=JKYC>:7]<^3E3:UZA^T;M=NI]J7J-'"IIK+W($Y[ #%(OU2WN%#7A M "&(0TY\$O PC2/3H\KNH99F\QVD!:0E[@IL&H'-3]=Z,.X_G'2'W,0L,Q]H MYL>1[L";Z2AR.(A6AY!FN'0<0/8\8+;#1S-%V@>/AG?8L^G53@C=T?AJD_]4 MVPF9[^Z(DI_J()&/WW^_^$EVO#AT+BB]3O=E58LJ;3KEC(=)0J#P%>4BA!7; M) 6-.*"/RJ!+8\UNJ'VTE0&^F#?]T(,48P13'&L-\T) M0XE',,>6S8N<@3W/P=+EW?TF?U*T]UWL'I7Y5\5[UW3W(;_3;ICZE/ABLVFF M(I?E&?+-M@P(KQ.I/^3%OLKJR7?[LF#M)%-F=@CE;!HFMA!&O.[6)TY&F#@] M;.H><=9S)B/E7QXQF=TT; WXD)?=;-5CG[>'4$^KW_38\V.6QC&,L4YT]T4" M4\DIY($D,@U\*A,KUV/OB$M;"XX"O^RPHH8:2"[]L)L1C%,P)R:9D3A:$XTQ M-D[)IG_460G'&(27I&-^X\",1[W"O]<+?'M];QWYO'\Z7E)WI"G-X2;KY]BV MYF7^S]KC@2 A%A"G,E24%7&(?4FA2$(<^D)&,C'*M)E!UJ61W3G#"[2T!?3I MF8%6:USM2=M9>ZVN4Z\2^"SS*2=\6\R8=B'OP,0<_?;3;Y^M.?W$N,WEG%#> M>3,]IP?^51[H#$,ZCB'Y(O;KT,,>H1Z%H=2M1A.B/YW8@U&:!!Y/<40\WU'T MB!IN>=O[_K@11T$B&FQ._51P@2 GB>Z%A*G>K_A0,A[XV(N\$,OU/M^3S;Q0 M'X?\'P*TWOM%82 A$U&@WFK,(/80A@EA?L*D#LRGEDVGW ]3[^I\P$[*YWM MZ!!H,P/%%7P36Q@CD',7W-2"9)ZP)CW@,@*:6JH;AS*U[[%WNU]N!-NK1]\^ M%5F^R6^>+J_KK#5"B8<)HY#[L=05$2*(D8ZO#$0B/,YP%!D5>^X<96G4\4I0 M\.[RVC ]IQO.?I>V$Y F)HC3^ Q(FSP/E+ESV0E@,_F-+5\L*Q=P+PX=WMWS M]\[FN.T5O^V3[;]XV!;AZWUYAK:]J=.*BG7@>XBGRE2-24@@(A&%E*CS&KJG%7RI7US_L*!"T.R8;*T%79128PUSB?CSCX8K>"/VQ$+CNZ MB5\][!]VXD1/\3+NZY@+%864QR).( V]0.V;DA2F/I$0>Q0G7* P)IZ5I\NA M<$OCI48W[9K0 C/=H;:MQ2&/?VP2F],I-G1/O='$3>V/:LU9I1@L-3O5FZ?2 M;O2,VCN@)H#>K'ZAMHU7YAS,#+8VR&SEU<&?E0P9_-+): M>@<]*K^J9=!W_>A*Q+^1#7DJ M,C*D>"FB//!%$D%!(J&SA@G$$9,PC)G/L>=A9%9*RZU82Z.>UY5-&^7>KFCM MF%GO=PZ\S5Q.3(K_TZ9Q<.7AF:;SS>H.3S^M8XH..T#?O.3PF,'>JN"P X Z MR@V[>+KCN+!?=VKH=2@2+\9I#"D25.>4IQ!3EL"$14D2R4C$7N0D6*D<;FGN MH,YP)4::^<3#-\[N& ML8I.@ORI$X6O\MW'_('NY0$1T&KE-)2(2#S M'?BP$SS3&9!% =Y1<9-M]5X.4+6$J$LLZ^@:3I3G1RRDR(,AU8$ 24Q@2A,? M4NS',18!24)<3]3EEK_M-#4"+&>2Q)9//D-F"XA[S"=>2.R@=K>DV 'E=&DQ M''K6)<8.CI=+C>7=PY8<]:"-VBME,JNRCZ^4$FJ0A[N'#=D+_G5_6YK1]SMQ MJZLW-74\_U_RWK4Y;AS;%OPK^#:N".%<$@1)\'Z39;M:,R[+8ZNZY]SZD(&G MQ#ZI3'4RTV7UKQ^ C\Q4/@$D2+'.B8[HLB22V'N!7'CMO?;-:K&072EN/>V^ M4WIJ/BDH,H*:'.:B2"!.N8!%9#:C%&*,Y$1%!779SPYIW-@VHG9] ^;U 5O> M@=H]\,J_5CSW"K0NMNH(=7RU.4O3?KK19-#NMR/3M^K4GBEW\/YT)N<^@ ]* MX4$-')3H^X!V=SCHI0V_04,/2+)\F'W\R1]-AI[)*3?G(&T8-J>YGN#&&,8Y M+R!F>B@H\BB'<:0X*C*22^$4O'*RM;'1>FLLZ*P%G;G@76.PXSSV--1VC!L, MP)XI]#AVX2H!.6$2E-U.MS@H75DYO\L_=C>Y'X%^7ST]T<6+YB6Y>/H\I[/K MF?@F?\RG/_3JKUFE?**\%@F]?EC(.A_8\-RT-'/C?Y3+1U/9^V;^0\ZHGAGO MA%G1)"<44P41X<24V2"P2#,]._Z_+^>/4T;P$/9/Q_\S^MS^' M'S@_3(B>/:?ML?[ 1W$!BW#W6':=!OI6.V1]>26?Q%K[<6*SJ]7M[0 MQ>)%_[+6;YWD*,DBBAF,$Y1"K&0*22H?]+^>Z-+,5L#RD2Z!B5U\7LQ9S?[UJ7"U+)_,3VZ+(KM>L5LZ MYW&Y/AO9,ABT%H=;&CDA$G2)9-?RH$LE)S!VETQN-P\LN'?7*$[?K9;5DM9' M;?_0Z[O'I137FBSH@_SX4RYX6[1[>LNER)K05 _V,#P17H0 M"J"# =0X#*3+Y_A2V5'T"%^5 MOA=?8WM+AI/O\^NS<4CY.=K^UY#U\^N08!)_GLU?J.7Q66H[UL6)OFB(FV.4 MM5KWG4DKT^N/DDZ_SJNR21U;FH,7/9O]7%;+291$.$,J@Y(*HU9;9)#D L,T M83*/$)9(Y"X#9D#;QC8H;K0R:M^NP-J[*[#Q[VI+R+[)&VU\!)V3X(^-F^#C M;/74BAL[II2%? GL!K@WZMJ>![$WZU5_/95P^/>CQ!+ OK?1< D'[%'UEX!- M>-2@HPOZO)I6YM"]/9O-8\EPQ!4L,"-U"!0L4)%"S@7A,F4HHYEU7;F]QX^- MPM<67IF8EN,[NC;(G3^$N0R/OH^Q7T/A(7%W !.'PFD783-4,33+U\6MH-E1 MST\5*=N_:;C"8T<-?E5,[/A5GK/<(Z%"]7956[7L;U(\R%]I.3._?"_5?"%W M Y!,R%^&29(1(6"*:0JQ!@ 6!%$8%2@6,98XB>+)3#Z8"*5[A[EN, NMWOVB M>??W[.QQ;G0T%A"\,_[\<&AW5OFAN^!?=9[O7WF]^?A>;(+W,SCD;) MNH3E;WKRO5K4T^S[^7/)"8H._>U.F7RYY@8NJ^\K]D_)]4U=/-F* M3K_3J3:\6BY*7N_]?)U/2_ZR"=) 2&),"849H@G$DC!(D?Z1*5+D1:'_Q+#M MS'H<+HUM-J]1 0TL>J7^'\ @ Z/D55G:+0C NQH@H!'ZY7\?N\:HL]5 @0U2 MH(4*+.=@"RQ@T +;<#FL)\;1H19KF'$8.J(A='0O'?BC NP5UKG..6Y&'@[!;[WG#T/-FP1L)= M5N60QV%55%ZU,*QHRB'G]C12#E[D]K$*64X^SI::*MH$QJ;R>SE[,.0QQ!D6D!:)@!%+(DEDE.?$*M?\7$-C^X0;6]<)PVMK06.NW1=] M%MW3'W=(S'K^SGWALO[L;;$XP "5Y/_Q,/_QO_0CZH__7]C\$S;_K+_XLP\? MY..W=;'C >OK/>MS2%7.I'@O9_H?2R/$M)YIW"GS8Z/M/$D80PJE& JFR0'G M.8.4QQ3R+!%Q[9F@WAI2^XW'\- .M#$8"F*G;3LW MM$YLJUD^:+!M+S?'MK>E'._T3 4U^8PW\VJYM\5>Q#*/3(%;'G,C=I9KYF9( MF&Q0AA6-,E4X5[J600]'KFYDN!<\_I M/ =*V#S.HZT-F[MYSNF]?,VS-W@6 %)*\N4Z9N.>_OQ&E[+)#%UICFICF.>S M:J(193E-"BBX+/2BE220)GKYRFB*5,18P0JKJ&'WIL=&+@V#ZQ76DOX$VD;' M%$8'S.UXI1\D^][^ZHSN@M%,A05CMPDTTU]1.2W;,+.O;&1D_W"RHDH)W0\F)MM*-.]6F,[:@I''(]T]%!7>HV\O6H M//5:'36@3K458&'UJ4\W.:PNM97[>WK4=G>Y[Y)],)H^0A-8I6==)KI ?'Q_ M>__A>I)17F1,I5 OH!3$2),+Y2R%F8R2I)"J2+F5DNBI1L;&*XV=8-M0T%CJ ML55S%-GS^UTA\.I]"_X85 $0LM^^"H'40!M6'H@Y[4V=@^+$;M316P?;?SIG M_/:.T]EK?8\VV;(;^B.5,ZZ(A*0P,LJQ(;\BQI"R BLE%"$H=Q,5VWJZR[LY MC'18=T)?2P/.V;1\:.:PKJ>2&P!-S0&Y/+&J8SF_R5JMWE3L*Q=FQ*ON%C>/=/$@JPE) 7 KH'A9?IV7#NHI;=[C1OSU3MYBY?)[]\G+,=,$YQ1)S)U M,1C-](HSHY#FDDN,>,&0U3)I\\BQ3:E,"(@>\VLA*-?__Q _A^?WW_\;LS1J?IRL_O MGDG*SF%KCMKW\43D?WMQ0TSM#S4GU6RT]:A!.&C?](YY#OPEO/30!SU6_Z#F M8//C3SY=B48J=#[3,SU]T<+(NWV0S7\;<8MK\<]5M:QG@M=*$XF1H&%1CA(E M*<3"[)JEL9Y\I'HUJ:=Q.<^3.$YB-]7-G@T>&U=:Z-ALW+X"G>-@[7DMZ%7[ M#-YUWF_D;;80N +48!!6L"C(.V0WYQK3F]$S18[KI0@J>A2RIP:30@IB]&@$ MDD)V@8ML4M!V_89#_019?:4OYC"]VX27+!,L51&,F=33S(3EL"B0TJ](9JHN M1+R(K-2-3K0QMD&G-A&T-GJ>8QR"TH[(+P2H9^YUQ,:9'$]X'Y3/#K4S* 6= M<'27-4Y=ZA[>\O>YR4/X.O]3+N[4]71Z8Q399'6GOB]-5'M.<,HCE<%,UA4J M"8=$YA@RFJ,\Q2R3$;);5IYO;'S+S<9>\&P,-JHX=#H%O+'9_%@9J^VC.#P^]\PS0&[Z@\T-W*P:=/7J#M#NW]'^0;]JJ7K]6 MUZRJQ=4F,D8\B0H*,RZ4B2KDL*!%#%.6T8+D&#'EQ'VO'S\V8FNL W]T]CFG MHK["SHZ-_!'IF6KLP?!(+SWD<^"LB]_>S1@U?Y?;;KW*[=)&@E M8IGB7"\2!8\A+M($,L0C**04,L$RXS%W^8"/-32V3WF3OQ@NU?PHR'9?>@CH M>O[F+T3-F0C.01*4$HXV-B@YG'-YER;.7N]'&+_.Y^+//9BJ M5HV T>[/3<.3).,)2;,4YBS1RZ!"24A57$"%:1ZQ0D4X=DHU=[9@;!33.5"7 M)M^8O-;S.O"K4$SDWGMV%-5KG_3,7<-TAS/%>4,:E/O,I3UC;Y"U]="Z-=+TUBUI-/_4S[?S(6S@$=2CB"%3:"T;'O8%$HW0/:2*!UO]^.O?\CRX7$IQ?4/ MN: /\LO*Y-GB6[>C(!*<*8K/O)C:I<>T HJE0<(RASDD..O0.M6OUUD M-ZKT"'S/HTM@S)V'&D_D@@XYKC8,.O1X K0[!/D^YI+C4Q/E_TD[=$@;LPGI M7Q_&R$JOXF6U+/DDI4G!%,,0)5(ON7,N8<%3!ED>*XXPC1AU2B&[P):Q3;E? M)?T \ZZ C3]@XU"7V;,Y?C1IX)U7/H>T?EWIP<-<]3;5]]X'@5?A&H/ MI\5^]KS!@?)%P!T^<[[LD1?&L7PH*SZ=FSJ@FS"+C&/"9)[K2:"/?J-73D#23P3+H0;?)HKEA.M'(UE.W>,9M3J?/>@)S9.1H+O7C[C^6583 M3I,H-V*8#",C.$[TOU*10U3D<9K&&1=N)Z^'&AG;C,O8"(V1H!$X-':"/XRE MKK&LAQ"U8XI+<>J9(7P@8J)3%5NG4_9@W-KHQ'H*FM('Q$31.UJ/O MVLTK4-:.@OD,:%=!V2X\IO7"0\\H 6^26BKC,8" ^FUJ]O1"G.:\M^_FGMGR M?T /VZ>KOFU/#Y3B^L8][I0DVU^'G$BL[:'1P9)Q^P-L.X&WQU8\%5OYHQ2K MJ;Q3]=/?TZI1;Y&SJOZ:ZORZN^=Z:^/:%$LJER_W1LYALTHF18H$BP7,DCB! MF!B94I,/+.(HS0J))(FPR'.]@.-82D;3F"?6U=#/-SN;!T]# MU[*>0_DL"PCMUQIAH1QH[7 II$Z3?WN$3DSF+1XRV.3[\>V_" MJ$RI16YJ*=RW==+-0[_+ASI2MI''UBR,B6)I#I5"#.+8Z/GC"$->I+F*4494 MFMJRL&VC8^/BVFXC"=48;H)>%VO30=7:[E&7S[H7SC-T']CVS--O#ZL]:_L$DUL_:C ^=W5NF]6=[_7<&#%%#LSC[M0-K1X_3>=_;@1L MN(AR(2,$16&V/.(BAK1@!'(EBB1FLZH6J2BYSG.2$P0LJDH\8*DE@32J&2*$DDBPJ"G*03#[4R-NJHC:P#TNMM MSS^,H:"VU)$S#F-J1Q87(]4S2_B Y"Y5> J$L'*$!UL:5G+PE+-[LH(G+PZ5 MCSK)8D:RW)0_(KF$F.O_(T@1B(HH8Z3 .&.! ,V^<\GGLVS]QI>?8OY"B7'ZBO)R:3'<3*9@CQ/,, M%3#B+-9?OT"0IJF"JN B%91@7#B=ENXW,;I1O[80="9Z!5T> -)RM+\(GKZ' M>C=DW$?YH\Z''>+WFQEV?#_JYM[@?OQ*OP_\RWPF9%4^S,Q>1+LGAA!)F$KU MK%Y0:V]QO]YWQ1+S*^Z+>CU62+78_MCHI#$?UO8?4J>L?6ATWH#QPE,KS[67[&BG1^Q[IJ3PL#O3DR=X M0:G+U89!: M/?EMY/@..7=4C>_@Q1Y!,ENQ[=7M[.M*+I;S;R6?3WB>4D%I#@FGF9[QH PR M%2F8Q@G'F&!%(ZOJ"R=;&=O'_RI3I +E##2V F.L0W3&451/?_G!L.KYR^\= M)H>HE1!P#16FX@6;6U#*.3A.1:$XL)-SYK^*,SE[L3L??C.I!'.U?)1+ MNGB0RUDMWC173W3Q7W)9)QY\^/Y[1?^D^H%B(ICBC% !4YZ;BJ:Q)DDD.$0$ MZ=E2%$N$K5-NW9H>&W/6UIM#46T_:!P L[6^6>-#F[AAO "M&_9DX=@SYXFV M/[Q[9M^Q06U/UOU!/A"#AX;>B=O]T#M!^(X/'&P4\'-T>VCP?(+?7N(UU^_> M:FKV)C_(YX7D9:,[*Y^GTOSC>B:NG^:+9?GO^O=?%_-G/5*]?)V:L/>9^/BO M5?ELWMU)2O)<\LB<2PBA1Q.!(,&9@B1-TDQD^I54TF63,91A8QMK/NN%S_\& M=.,=$%ONN6TQ!NL\N[W'M^B2GH>C+9? MD]78.U57==HVZ\KT'FF_V5\NZHO M6;L7;K\R-.!!-S*#&3?H#F=H2'>W/H,_W[,^DF;;Q4(*O^9D(/C[EY_R1.\L.687(T8 MMCJ3)T1[Q9I\G^-[4/3]44ZG)HF>SEXF"2L$+2(%(Y*D$&-:0!(71#,@BY2( M:2%CJS2;PX\?&Z&U!QZUB:"UT?4XZ!5\MN= OJ ,0ZYLW^^<_"JRZ6#]'SIOE,OW*@2IT06'",8(Y3HS[? D!9(KSI-2K1( M$CV%<:J+>Z[!L7W0G;U-"09M\49<,ZC ST'P[>8A(2'MF0X"H7F1#,\IB'H3 MV3G8Z)M)Z)R"X)1 SLG[/ G(J.ZP7=6=+<&F]R^;2]K,DFNS)_>)EHN_T^FJ M$5-K!'H^_GR6W"04:R/CB9(\8;&FKBCE9J\,,4@S_7\I,:6^D4C3R$HZIW]3 M1T=Z1[3.MH6T 'L!![6VC,=7P/@,:J?!EM=7H/,;&,<=Z;*_5\62:$?Q O1- MT6_=]^[DWGNWA!T6^C-WV &E=]CWAJ+^6_04Z"\I,]DHI:S:HIH3S%*5()[! MA.G9,I920HHS#KF(XI0D5!(6N^2&[C?A-&@,D!O:**SPQC@PW=CK*,V_CZ4= M.U^&4,^LNF7<^<*K[GK\1UT/J\:_W\RP6OQ'W=Q3XC]^I9\.?R*E,8X91"+%0$:Z#XL_D:7JT4]Q-ZISU(W MMS7H[JK+IQG+BQ1!2@G10V!FCKT3H6?$JDAB'D68)K9#H'VS8QON-I:;[<_: M=O#9=9KLB/SYX:H?/'L>FLY Z;TS[XBN_6C3#\H#C2R^+Z[3$.&.T(GAP.%A M@U&_NX/;-.]QM^]>QK+5S3%Z>JNJG5C%64XC&D>0-W6@(PE)$5'(B(HHBT3& MB)4"\NEFQD;9&RM!8Z9GEOH14&TW-BZ%JO?-#6>4/+8X3H$0>)OC8%,#;W6< M!BJ/HF G>4/&J/G@(A89S]8Y?WN\K9;6D,Z%MO7YX M6$A-8/)VMER4LZKD]6)UPA".TCQ.81&GA4EYR2%-"(=Y@96,"L29HLXG^&_A MR=CH+, A[[K>60-*DYS1'? NY_6O]54;:*[ &ARP1J?9=O*( WB3]]$A3&#L M;]GXHP@&><'\@@W>LG/#QR*\B3?#ARJ\9:<=C&1X4X/<8_O;@]1/9<7I]#\E M77RAX#O#!RR@$X!X)W)L#1!P^6#W#.M>VL@+/7 M^F8WLN5&Q_1WW=5U1J44'W1#IA+;UX5\*E=/=?:0OK2J5N;DZ69>+:LO610!L$W<$+E938- MG%\9!,#]=,LPC_4E[47Y@]9UZ-?=Z# ]#(QUX M)!G,_($'G:&[97]\&MP"]^"RNG376KI1#Y5=61\CX;(I+9F)G&8\CZ%*!8(X MPA06(J8P95&6X(P(SJWK,MLU.;:AHRDPMS:[GGO>_3G3+>N.JX63W*MZ.G3 M:=;O!]:^MZX/(+HNX=4[H/8A9>&!'2B<+ S 3L%E;EB=""RS?-!@065NCFT' ME#G>>6$!YBYV1!62IA+F6<$ASE0&:9)$L%"8%S(CF/WY\U-R5"O:: MN^]@9WGVZ(U([ZQJ"X9_F>3^9J,[3;Q-*>23L[HC5WEDN\T7LGR8-7O*7$_P M9O.GLJZJ=#LS^Q5M^:ZWL MAVQ^-BM\O5SG"Y-&\$$V_]57W*E[^G.2I[&BB8A@G)C*EQAQDZXL82PEBK(< MXX+0R:P.+3#:";93MQ-O/@-;>WV_5\UGI1T &Q_K M$I'R"E"E!RFCO^DV*PS0PSA'!2LB!$7&4XACDQ.:I5S_B$4<,9SG@KC,P@?J MV@&']K]>G]JM#H;MJ9ZG"_UUDO,*)!RN05PR(2&.9Q3G$B18HC)RH^W,S8Z/6@^G1MZ86ZW@VH MMB>1ET+5^ZFA,TJ7JW"_ J%?K>VFJ;=5U'[E[EG=[-=7>Q-!.9/BO9SI?RS- M7FL7POMIM5PM9/>')N:W,M%\G_28-L$QBQ&C"BI>F+0[31),20(+)9G$0A1) M8:4B=*$=(Z02XP9HS:V/#[:$!AM?-G]MO+EJ8E&-/\Z$X]5YUHS4=Y?T3UG] M](8/L5V"96CF\[)E:&J\!+ #W'G1XRXN4_L;G=*7JJ03A?0R5Z]W(A5?7<)[?=PX 4L\TU2<^ MWF5I?7 :L"BM(UZ75*3=1<*^'NWZSK>J1KMK^HE:M'N77EK H9Z=;G9!JB_S MY0=9E0_U'O-UU<9U;<5\K8\,JSOUJ9S1&2_I=$M"['HF-K^>5Z5YR;K(KQTA M)!JS+*%I 1-,$H@IX9#&(H-*QAE*..>TL*H$/BJOQD;K6R@ #0/8X !H!5HD MMB-,P;M=&:Q?? M4O.7+91GY, 9;1S3(N;\MPQ3@&$'O]%3EXRT]>Z-2(B/H MS./U2L9@G-^@;B1<3/3=/\KEX\VJ6LZ?Y*+3>WM9AXI2H2*E&(4;O2A)TJD14Y-B0L2JSUC=L?=+ZI]W/^?43!_E<#SK1?8Z'_^B^M_EU(7^8 MC0,NO\^GJSHMZW;&V\#%F,=1GA$$,R%2B)'^#&F"!,Q5DA=(_TR0U1GRN8;& M]E%N; 5K8Z],6LE_> 2)GD3X_)YG*-QZ_J*'@\Q^&S04= /MA1Z',,Q>J T< M)S9$3]X^V*ZHC1/;6Z-6UWONCZY8)?^UTD__:)IH7\\D)7F"L@P6*A40)RK5 MLY9,$V?&41HKD<>Q4]S-P5;&1I@;(T%MI>,W?QI1RTVZ2W'J>\KC#)'[3M@I M",+N3!UL:=B=HE/.[NW)%S1=-C90F0'^2XJ*0 M(DIAC+&"F"H"*=(_HCPGC#.*N5UFD[\)8R..PY%HG1>@47W>]N,*M)Y<&L]W MMK/L:*??+NA](S\X^@'B!&T![#F&\*P9;QQ?: O3^=A#ZR<%.4=N&MTYB"L8 MC?5<"4.:YIF>-24%+ 3-(,^*@G%",))NLZ;S;8Z-"K<+V-=&MU^D=\4A%_R] M#D(O1;7O&5< 0"\]C3P%49]GA0?;?[M$N'\)V _U]#YUE;NRQ MABI*\@P3G$ >"SUY)1F&I(AS&"5)DFH4D<#2A:)]@!HD0^\RF.R8U,?YGNGR MK-_.7+CK9%#"6S]\4%;;=6F7NO;^?MG:\IO9O%K)29116E!9P)PFB:8I_2^" M8P29%#DR%G $HKA8UTFX4_KQ>GW5[F=&*9511"F, MLRR&F K],:=8P4SB7&$9HR*V.M>V;&]L'W=G,C V;]55Z:SV."^R0?W\25M@ M+'MFA3>"T?[T+3"< QW"G8,US%&< S8G3N1LGC+8P9R#2]OGR7E:NXS*WPS+;^,N//Y=R5I5ZV?FYK)832=-,9IB;@]@S.%=2^-3LP5V CV3=7 M8.T@Z#P$?VQ\!!]G^KM?U)^]X\97J)ZWFT"^07_V/,2\35H0X1S2V(@H1+DJ2$%CK!*7,2&$46,;$-8^@<;D M^K#1& U>^[4^6]R[;ML[MQ$@2"?;T?_07=B;JXR0]FBP7>U)'E[1?5U/BWY MRR1&BO&T(!"9O&/,<&H*3D:0&RD<5#!$W*H/N1HP-@9OK6L*0-0'J:]=:)3U MS3?>>*'_5?L!_FC_ZWUT[=QU=ES=9X?TS,N#](4S&?L"&I1XG8T8E&1](=HE M5._GN&]F_Z:O?M1@IU_F2UFU&X TS>(((P&%R!.("TX@54D$%4V23#**LI3: M[EX?:F!LY%?;"(R1H+;2?COU('SGMZ$O!:5G MK%PV.?^2 P]AO+EP(TT$ZR M]8OCM'-\ROD36\4';QML;_B4T=N;P2>ONS3XL#N:WPXZC%@J,ZK'DIA!+(BI M+DX8S#,>$Q.BG46Y7]#A7EMC8[7MV+C.V("!AOM8VTW, B'8,P5>"MX%085' M8>DIF'"_O3<*(CSJ^/'@P>.W^%')1MZYNI]W*UA9ZSR;A:N)GKZ?W]#J\>MB M_J,44KQ_,7+AM[/UAN>U60F7RU)NBK(QHF3&%(.)2HR&8"+T6I,JF/*]6 M1L1=S1>_@/GZA(.NO7;CO%Y>"CNR?.NN[IEE=WIY[6"KO=_T\N>NEXV?X.MV M+[=2_;]L);1L_.U%9*3/#@G*[[T8.NC T"?4NR-*KVVY"Z1\YW)&%^7\]UGU M+'FI2BD^S)]H.9O@(E924 0EXLJ$*5#(.,)08)D4692E.+4ZC3K9RM@&@\[0 M*[!E*OBC,=9!4N4XK$CA3.&(0&3JT&.*.&2(I)#D2LGOM]L8Q+[1D=#6 M)MM6 ;9M5>%R=B[Z\ H81T'M:4#)ZC OA.N6Z.#=/. V:I@>'F8/-F@_]+1O M&\;&-]KK#0KP\?WAL,V$2$ZXF5?+24'3.$'/ 'F4$%SG" MB#M)8>PW,3:JWXLS-T9>$NI?XVA'KY>ATS-#N@%S8>#\MN\]QL#7S;QA./NV MFZ18 V/[ MM+L@B 1[1L^\AN_T-QT"E)Z_Z%T\_*-G7@/C'#WC#=# T3-G7QR?Z)F#SI^/ MGGE]V]#1,P>-/A ]<_BZRW0HUJ'9IM3>K.IJ[$U(+*FF- ))8C1A(H(@Q3F' M<9Y)DB0B3WCJ)I]SIL7Q;9*OU1FV\A]:F\&[UFK'A>8YU.UF-@&1[)D4+X/0 M6_7B##"]J& <:_--5#'. '!,)>/<;9[;;8]T(9F>=HF;^9-Y;E-2?;$P(O=F MP'G_LKFD+>YY;50*[YYK5>>_R\K4WIF)KAKH_=S\ZFZUK)9T)O2D[A_2I!KJ M:S0QT ?Y39J3 _W[KJ+%BD[OY>(IGN@E%B)2"9A2B?4DC<2FB'JJYVR%)$4> M905RRO\8CVMCFQ[6;L/:;["-#=@"QP1S;%_7 @1JA(Q<:2N4WJ!4)T:LRP(O MY_6O]54;K*Y AQ9HX0)KO, 68, @YKA#.)J.MMU<'(W!(QJ._KHOI?NFYNCZ M/^Q^Z'C<&W8K=3Q^']N%'9^%GM.6Y9S_US?YK,GG4=OZ=3%_6-"GZ]7R<;XH M_ZV;?YJO9LMX0B5#,8\0U+,' 3&2.:01H9#%4F9QD<W[T$K +#NPX<;3&&YW;+M88G7#9 ]5G2\ MW8^RVNJD7<%23:==H".E:A=:.=D( UC//>&'E3"SG@ C*)$<;&Y0ZSKF\RQ5GK^]/%NEZ M^4GJ)]*I.2I?Z9Y\>77Q1$]G"J7I Q8\UW,=A2)(4.^9 M<@_":C94OUS_O8>IIQ=,0:G2S8)!2=$+G%WZ\WM(#^+/DQP3(JC,("Y2!#&F M M*,41AE,4EBSB1B3O483[8V-B*S4/<-*+<<0D1Y1*1T"7AA!8X'"-G<;7$\ M8L1V@9S';G*/Z?PL'^BT/8ZHUD<*]_/W\N-//ET)*3YI!V[HE*^F]33N3MW, M9]5\6@H]:1,?6;D4=)*@)*6$$I@*:G;7> :+-,HA8@GB>9Z02,:V0:!!+!H; M-=5.@>?6*[!8GX0NYX!)(%O/@'E; -_X9E)$^)9WX./[V_L/U_:QE6'Z]S35 MO4FO]4R'?_$.LX^>';SC!@JW':H#G:)U@X)](KPW3#N#Q0,'A64[@#CL@WL3 M:VZ4?@66N<1<09ZE>@*/D(*,Y!(6-$X1033*"Z>2>+8-CVVLM!8$'DZ2.; 4 M\U]6@GDE^=:>VHI@V.:I="NIN MY6Z.%8NS-(>97CAH'F04$IXCB M28!*G>F5AI<<1VLGGG6!L/4]4% MPC>^;2>CK[T+J!YP67_;T>H;]&+/K'MQ!PXC#A $[IY$ 2ZS[8W$ (( >EP$ M(,SC+\NNNZ<_FQKWFVVK>57=T,7B1&Y6OT\7,,7IC_-66R*>Q'[QRP"_[SJ97[,BX)ZQ[)MQP M,'MGZ#D UDNVGDW[;Y*YYP#,L2P^ET=XTULYDZ)-#S0SY]N9Y@=9+6M]CK2@ MK*!Y"B66>KJ:T@BR@F4PH?JWE*6YD$YZ6*>;&R&)&6M!:VZ]9KP"G<4>"BAG MT+9FJD 8]D].WO#YT)$%*J$9Z%230Y..A?L'>,;F+L\HU:?GZ?Q%RF]R:G8> M/Y>4E=-:8/EFM3!5XR9)EO)"%!PFA&*(8\U^+8 M".8K?=%M3>M=JD5C-)ANK'8,%SV+MQV_!$6Q9XKI;(4=>EO67H'6WH"!F[;0 MA W+/-OJL$&7MB#LA51:W^A'.!UWF=C++H.PE=[A19RH(E)0$*Z9ALL(4E0( M*%1$$::Y9+%3!8_C38V-8M;#;1T W=GJ*&ED@; =MX3!K6=2\87,F4[.HQ&4 M1TXT-RB!G'=[ESDL[O"E#!.OO5:3_&RZS)PK&/WK(J8DS233LY.40?BK7)1S42^M]/R'O9ADX_E"]YV>Y@?O-UO*#](;O7.^Y]ON0?IG\0C, M^L?;&YCVSSJ^S_OG;_%,KBEGY5)^+G\8J:RE?A-*-FTB3ZMKSE=/JWJ*>OVD M/Y[RWTW(&<[R!$4TAXHE0L\A"PP)-CG85,4)0C%7"9G,Y(.Y\=XAT<;9$JO/ MIF@^FSU[^ON$&D=@[0G8N++>EM[R!FR[XYAUX]YQ=CS54S\,E'\3&GOWE!QO M^,+FY;B;,6QRCC=,>QDZ_D]RKV?VS4C^M"L]J:B2',<" 'JF$S/BEM6RY'2ZG3\9N';6 M =\OKI:U_/G>1 M$9U^N8@I33,$TY3$$"?"[*C'*,!XHU^/RU]+'1#"592+. M8)+G&<215) 5B,$LXCQ)!8E3*6TYWK7QL5'])M[I=<7IM1--:>K.#=#Y8<]. MSMUS?@#H$_2>QX$1XFT_*/2)^T!C0W#\G88*7P!/C!C.CQQLX/!U=GO\\'Z& M9T1?63W/*SK]=3%?/>LFIZLZ3+JLM+O:BI44K4'SF4D,+$7[PP0EA,HHCZ%( M&(&X2')8"!Y#GL:13)G,>.*D?NMKR-B&E\X/4#MB MA:5\"V+V#MC*D MN6. M8X2@;^_9;7(.T2<]CSY]=8=[Q.&%6(:-1?0U9M@HQ0LAVXM?O/1Y;A0K9#GY MJ!^\K'7>%IJXZZ?5YU,W9AVP>+F9"SE1,M.]Q+&FS@2;#1@*"QHED"8L5S(B M)".I#9-:MCC_#C MN&_RA]1SM%JOI@WJ_$>Y?+Q954N]3EY!9 M&PW+&>"-V6[T9 &X'3.%!;%G4MI"SU@+-'JMO69/RU@,:I/#T9$]/$&9R*+9 M04G('H9=_G&XTS-AY4E_2 LS^;I3NV%_C0!@.7OX=3X7?Y;3Z20G&8NXRJ%* MZA06FD+"9 05287^?9IQ[K2E[]3ZV.9/6V&QU%@,RK4W@#_2Q8-KPJU;7]@1 M5&\(]\Q5&[O-.G O AF\6QL/.NL#5@OW0BULEH63!)X?40SWH M1M*O>?07[6*;O!X7<<(51Q#).(689 FD*&90",4Q4SR1,G.;41UL9WR3J$:^ M3E2U6%(29SF19YF>I*:QQ 71G^!JX' ML($ W;0U-)S@7=VVHU[@85CMF/YBL'IF] :G+H%D8V+ D@FG$ A;*N%@2\.6 M2#CE[%YIA),77\"J)HUT(1^->FI7V_ M]?3..+#DV[\)@W#MV[\$?A3>;_>$'PAZLG?XX:1?X \.2CTWZ2G3W26(OU]5 MY4Q651=*6%) H>< 2:PR/?83MP59,&2'69CUB*W=X!@, MKYZ'-UN@W"6];0 (*]1]LL5AY;=MG-\3U;:ZR:/H6LG-F#![N%XL3+IK+=>Q M$7AK<_=HAC$7F8)9IC1E*(8@R0L%N3G4YSBFB;0*C+1N<6QTO#8:T(W5VY*/ MX%UCN.5&A#WTIQFE%T![9I7S6+JGH=IAZ5"*+#2F0Y4:.X=MH.)A+O"<*@YF M]9SABG^YN/6JN)?3C9Z1I6WML$_SQ7:HU]^D>- 3^A^R,JE*UZ;T>=WF!).$ M9)D1OQ.Y@E@2KJ?/5$+%4L591$7&F(?LD:,95M_(\)I'K\,@WZUK\^DESB^@ MDLOEM*F<; [%'HUKIA!?'8+BN('OVFMV$\@^.F&@^-,MI,&[5]WP"ZCM-ULB MK0=@XT+ &%0_[,+&H3K:,&PLJA] >_&HGH_Q%02M&ZFJ;[*2IL3Y]4Q\D#_D M=%Y'O'822"S#.3>)]X4I3([R I*4))"A(LN*"/&<.=4UM&IU;'/9VQEHK0:= MV76\]Y;AWC+#-IU@&5 1&MJ^ RE"H.HA2NF 4F!Y2IN6!Q:J= !C7[+2Y68_ MDMH6@]6/_[:N?&@R'Z=S(]>UCMC.\UPF2:I@D4=Z^I9E>LG-8P5C(9%@"F4L MLA(*\6A[;(2UL16T%2\J[X!YERZP(ZJ>@.V9KCPQ=28H#W2"TI1+^X.2E0

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

+._V[R-<9>O;AQQ>K;/H0[I[;>-B>YPBIQFSW&;1:,6S54%_>ABK)T M]R;A[CO;=?0IC=)=*"_SI\5])B_FRXN[Y7Y6&:VOHHOF\V9;*H/7T365LY9E M5GVJ><(805Z4)#%%8IK$#(E9$G,DYB&LDLI^KWCGKQ=>V2VVAX7;?E6W7]ZU M/C6V12UL=\W:0:M,)X>C>MI.&B70*Y.HIE!-HYI!-8MJ#M4\I55S5WK'O1_. M7;K=IMEF][SV-DLO%]OHY[OM9IMG,'\V?!F]N5W?M;\6&78[9Z[?3%/C-?M3 M!HG60?774M"+5ZBF4TJI!BHL@Q4>"=#U?1I_GO]U75'Z/&67X M"CI'+FZ^ZC@>UR-WPB"!7I=$-85J&M4,JEE4 MET0UA6H:U0RJ651SJ.8IK1K#H@+2#W= .L7PY2Z'NR+G+U_7T?^D\ZSUI<_P M&3MG<=B<._9G]2R>,$B@UR513:&:1C6#:A;5'*IY2JMFL:B:],-=DV_,XDV6 MIH$TH@65?K-;,NG7PWA\C$"O2J*:0C6-:@;5+*HY5/.45LUB46KIAULMWY9% MN;[+ E%$JR[]9D.E^>K,\3$"O2J):@K5-*H95+.HYE#-4UHUBD4SIA^NQGQC M%!=?0L^*:'&FWU)V:4Q1CX\1Z%5)5%.HIE'-H)I%-8=JGM*J42QZ,?UP,>8; MHOC+39JE\ZMMFK7F$.W)])LEF+@Q.ST^1J!7)5%-H9I&-8-J%M4MF8/;Y"]?TV4^1;W_6'I;/L/7T#6?<;,;4Z^0'A\BT&N2J*903:.:036+ M:@[5/*55DUET9^(CW9EO2^9#*'<+QMV[&ZUY1-LU<;,3,ZI_OB@Y99! KTNB MFD(UC6H&U2RJ.53SE%;-9%'#B8_4<(A,[M[E:$TE6L")F]V:_F@\JV$,P['8.4EN%IO&2*7E*@6H2U12J:50SJ&91 MS:&:I[1J-(M&3AQNY.RWH=[M*_S3>IMN@GM%A:7.822U!-4$JDE44ZBF4TJJI+?H[\7T_@=HG.T:K.JB6H)I -8EJ"M4TJAE4LZCF4,U36G6# M^Z+Z,PA7?VK1?9E_G:\VT\UV?W> E]''[7['@/=I=I'_]?RZ]=6>\#FZYAG5 M$E03J"913:&:1C6#:O;(8_IL<#Z8C/ZC]:84Z(5X2JN&MV@'#<+MH(\WZVQ; MO)#;&DVTY8-J":H)5).HIE!-HYI!-7O0RB_#Q:/::W4./:6GM&H(BSK0(%P' M>K._F=3+Z.WZ2[J:[V:_@45KV.H<1U)+4$V@FD0UA6H:U0RJ651SJ.8IK9K; MTKV=X)L[L7=W8F_OQ-[?B;W!$WN')_863^P]GMB;/+%W>6)O\_1[E(H&1:EH M$"X5O9O_NO](F$^_I%F^)MVM51>M)?;Y MJ-97-NA)+:HY5/.45DUCT28:A-M$'])_W2VR]/[EH_F^-O1NGEW4JKYKWH=[<>V=YDZ[OKF_(.[KOW M@.B\+3,%P..7W*'(:ZAA;5$E03 MJ"913:&:/FC'ILSH22VJ.53SE%9-8]%@&H8;3)4I\]5NN^E_WW"KM;+ MY?[S;M'M//_&8KZ,YA?YZ,UBMS]@:V#1KA.J):@F4$VBFD(UC6H&U2RJ.53S ME%;-=5&*&L;H!'F(]J)0+4$U@6H2U12J:50SJ&91S:&:I[1J=(M>U#"\C5*' M"3+:B$*U!-4$JDE44ZBF#UIE@CQLF2"C52=488<["&'S]HYNF@O"M4$JDE44ZBF4 MTJH)+^I3PQ$[54:;4ZB6H)I -8EJ"M4TJAE4LZCF4,U36C6Z17-J&-ZJJ<-4 M&>U,H5J":@+5)*HI5-,'K395;LR4T2X4JCE4\Y16#6/1A1J&NU"5F?)F\6MI MIGS?N7BX<=/S)LYHCPK5$E03J"913:&:1C6#:A;5'*IY2JL&OJA;#:?LQ!GM M3Z%:@FH"U22J*533J&90S:*:0S5/:=7H%OVI8?B&;QTFSFAS"M425!.H)E%- MH9H^:+6)<]R8.:.5*%1SJ.8IK9+&45&)&H4K4=69FO,K=E-GRZKIE% MM035!*I)5%.HIE'-H)I%-8=JGM*JT2[Z5:,^.D<>H14J5$M03:":1#6%:AK5 M#*I95'.HYBFM&MVB0C4*[RMU^APY#'4.+5J>0C6!:A+5%*KI4?.>?+6MX0UZ M0HMJ#M4\I5636#2B1N%&5&5^G"ZN;[[YI>76]*(M*E1+4$V@FD0UA6H:U0RJ M651SJ.8IK1KTHFPU&K*S9;1%A6H)J@E4DZBF4$VCFD$UBVH.U3RE5:-;M*A& MX4VH.LR6T?X4JB6H)E!-HII"-7W0CGVL#SVI136':I[2JFDLBE&C<#$JGQ%' M<:\_C>1A/XOH'\EZM]?%_T;_CCZD7];++[LY\MLLO5QL2X,"Q8OP&3O'%FU0 MH9I -8EJ"M4TJAE4LZCF4,U36C7=1=-J-&&GR6AG"M425!.H)E%-H9I&-8-J M%M40K4$U02J2513J*91S:":136':I[2JM$MRE/C\.94 M?KVZ+NZN%_T[^LN?IH/QL.U2?PQ3G6.+%J=03:":1#6%:AK5#*I95'.HY@]: MOU>:8,]ZQ?RZ&L>B$#4^5H@Z^=[P8:ES&M%&%*H)5).HIE!-HYI!-8MJ#M4\ MI5536Y2GQNQM]L9H'0K5$E03J"913:&:1C6#:A;5'*IY2JM&MZA#C8.=#>;> M\.%S=,XSVI%"-8%J$M44JNDCCYNSX7D_;K__ND$OQ**:0S5/:=7P%H6H<;@0 M55V\MB83+4(=M')AO?:*>G)\B&@9$@]KQ7>)7KA"-8UJ!M4LJCE4\Y1634M1 M6!J'"TL_7VS7]V^VQ(-3UI=H&0G5$E03J"913:&:1C6#:A;5'*IY2JLFMR@C MC=DRTA@M(Z%:@FH"U22J*533J&90S:*:0S5/:=7H%F6D<;B,Q*POT2H2JB6H M)E!-HII"-7WD<7,V.!\^M;Q$:T>HYE#-4UHUNT4]:1RN)YVPO$0[2 >MO# < M]8;U!>8)@T3+H&F]_"71BU>HIE'-H)I%-8=JGM(JB9D41:#)L1O/91- M$BVCZ@M,].(5JFE4,ZAF4T:F**NLXD7+LX]&-'IRPOT5(.JB6H)E!- MHII"-8UJ!M4LJCE4\Y1636W1TYFPMW^;H*T=5$M03:":1#6%:AK5#*I95'.H MYBFM&MVB-#0)EX:8Y25:)4*U!-4$JDE44ZBFCSQNS@;GTZ>6EVAM"-4+.V%YB1:%#EJH'GM\B&@9,HH']:4EVM1!-8UJ!M4LJCE4\Y16 M34O1U)F$&Q?V;I6>O+9$"SFHEJ":0#6):@K5-*H95+.HYE#-4UHUMD5)9S)C MUY9H90?5$E03J"913:&:1C6#:A;5'*IY2JM$=UJTA:;AMA"RM@R?HVN>42U! M-8%J$M44JNDCCYNS_OFLU[ZV1*_#HII#-4]IU>P6C:%IEWV#6H.)=H0.6K7V M6E]=GC)(G#)(HA>O4$VCFD$UBVH.U3RE51-3%'6FQ[;V.71CQR4JKYK8HZ4S9S7VF:&4'U1)4$Z@F44VAFD8U M@VH6U1RJ>4JK1K=H"TW#;2%F@8GVB% M036!:A+5%*KI(X^;L\&3W5CT.BRJ M.53SE%;-;M$9FCYW;Y\PT#F8+;ORC$;U!>8)@T3+H.:'+]&+5ZBF4TJJ)*:HZTV-5G8N'NRG$DU/6F&@K!]425!.H)E%-H9I&-8-J%M4T:GB+\M#TN3O\A('. MR6SNRS,;-][%/&&0:!G4[\7]^BH3+>V@FD8U@VH6U1RJ>4JK1&96E'9F)V[Q M,SUAB1FVNJ8'U1)4$Z@F44VAFD8U@VH6U1RJ>4JKYK8H[,S8+7YF:'T'U1)4 M$Z@F44VAFD8U@VH6U1RJ>4JK1K=H#LW^@"U^PN?HG&>T481J M4DJBE4TT<> M-V?#\]X3/5GT.BRJ.53SE%;-;M$>FCUWBY\PT#F8S6UY!O6;BR2G#!(M@X:# M^FU*T(M7J*91S:":136':I[2JHDI2CNST:FZ+PLZ,W>1GAM9W4"U!-8%J$M44JFE4,ZAF4T M:G2+YM#L#]CD)WR.SGE&ZT2H)E!-HII"-7WD<1-:8*+5(51SJ.8IK9K=HCHT M>^XF/V&@O4$VCFD$UBVH.U3RE51-3-'9F M)VWT,^B=LKY$BSFHEJ":0#6):@K5-*H95+.HYE#-4UHUMD579\9N]#-#FSNH MEJ":0#6):@K5-*H95+.HYE#-4UHENOU>41K:??V[KS"/G*1KI%DN83G!T.H. MRPF6DRRG6$ZSG&$YRW*.Y3S&U7(\*.68W1?HP<-RC.X,Q'*"Y23+*9;3+&=8 MSK*<8SF/<;4<#TLY#O>-H*4I6D1BN83E!,M)EE,LIX\]?,[&3^X5Q%Z)93G' ME8+\W!V#C@C=4]KX6HZGI1S_ ;L*'3E)]W"C M]266$RPG64ZQG#[V\#D;GH^>7)2BA266B(T#VES9V! MABV+TA-&B;91DY9%*=H88CG-+'W:^NIMGO^7+ MTN$I==TC7.BF4YQW(>XVI)+K67^L_=E^B(T#VF+9L.-6N\IXP2)XV2 M[ ^@6$ZSG&$YRW*.Y3S&U>)3*@WUPZV/AS=+AR>]61K&NB>)+0>AG& YR7** MY33+&9:S+.=8SF-<+<2EPE"?W;'HP<-RC.Y9Q'*"Y23+*9;3+&=8SK*<8SF/ M<;4;K;1A'*"Y23+*9;3QQX^9\/SR1.[&+%78EG.L9S' MN%J02^VE_G/W,CHB=$]IZC/[GGTX&$Y1G<]8CG!WR,:!LSJ,]H MT4M7+*=9SK"<93G'X38TA#*)2PG6$ZRG&(YS7*&Y2S+.9;S&%?+<*DT%,?L)#9F^T$HE["<8#G) M'+0JAG& YR7**Y33+ M&9:S+.=8SF-<+<"EHE ,%X5BMBB$<@G+"9:3+*=83K.<83G+9B?9>G^^Q]EMXN[F[_&LU7E]'],9O-W?YUJ+?KS7;S,OHI M?6+^RW:(#ESEX]?CQ@3X^"!QRB#)7KUB.F&WS MH%S"P1]Q,[/P23J'&^42EA,L)UE. ML9P^]O YZP=V0?CV8RW[8SB6\QA7BVVI2S1X]JW+PD+W3#9O-C9M;GEPRBC1 M-JKQT1+T\M4#M]L]:OOD]G^:/:MA.M)MCN$<@G+"9:3+*=83A][^.1KPG'\ MY'KRFX^U[(_A6,YC7"VVI5;0X-GW&PL+W3/9O$=8VWKRA%&B;51S/8RK9;?4T1G ]PX;L(T=E$M83K"<9#G%'JA/6Z-_17_XT'8R';5?[XQ&K>X;9 M"A'*"9:3+*<>N-K-DQH39_2LAN4LRSF6\QA7RV:I&C0,[]7S^&FQ4>!]F+#1 M/9-L'0CE!,M)EE,LIUG.L)QE.<=R'N-JV2W5@89#>'[,-G]0+F$YP7*2Y13+ M:98S+&=9SK&;;\+42EA,L)UE.L9QF.<-REN4^;9 M:H62+JC_OU:?1AU"@T2K2.&C;VUD9_ ,5RFN4,RUF6 MW/@HSU,#FXED.U HIUG.L)QE.<=R'N-JB2QU MH$;!=L;K_TE7SU^MLK4HE$M83K"<9#G%X6HY+=:A1N [U^ZY6V?K4J'G[L_ZL M\4GWPZA1:)1H&Q7'@\;AO<:=V4X<*-D+5"RG6XVJ)+-611N%M;SZDJWRA^FGQ M_"4K6U-"N83E!,M)EE,LIUG.L)QE.<=R'N-J^2[5E$;PC=M&;&D)Y1*6$RPG M64ZQG&8YPW*6Y1S+>8RKYGA<*D&-PR6HWW7)&CYWY\P?N,IB=%!?L9XP2+0. M:KR7@UZ]8CG-G U9>A@T;9 MX:F!<2.1;-$(Y33+&9:S+.=8SF-<+9&EHM$X7#0:G8]Z_Q&]>_O^X\OH8YHM MTOS9+[PP#8/=P\=NWX1R@N4DRRF6TRQG6,ZRG&,YCW&U()>*2V/X#G!CMJ*$ M<@G+"9:3+*=83K.<83G+>DO?S1>I5[LX?_?W_4$L# M!!0 ( (."5U:;KT-=IP4 ( C 9 >&PO=V]R:W-H965T/SR_&_(_CRPUE/_D"0*#G*(SY56NV>C2[H2 M81##/4-\%46$O=Q 2#=7';OS>N(AF"]$%K>,WG4+52F000Q M#VB,&,RN.M?VA8>'24#:XI\ -GSK,TI2F5#Z,SGX/+WJ6$F/( 1?)!)$_EO# M&,(P49+]^)6+=HI[)H';GU_5/Z7)RV0FA,.8AM^#J5A<=88=-(49687B@6[^ MACRA7J+GTY"G?]$F:SL8=)"_XH)&>;#L013$V7_RG(/8"L#]'0$X#\#[!CAY M@%,+L-T= 6X>X*9DLE12#AX19'3)Z :QI+542SZD,--HF7X0)]_[HV#R:B#C MQ.@6)#2.WGL@2!#R#^@4/3UZZ/V[#^@="F)T%X2A_'[X95?(NR4Q73]7OLF4 M\0YE&Z,[&HL%1Q_C*4RK EW9S:*O^+6O-UBKZ(%_AAS[!&$+8T6'QON'VXIP M;_]P2Y.-4Y!W4CUGA][7)3 B@GB.TN]@BJXY!\'1CUO9$'T6$/'_5-0S55>M MFDP3%WQ)?+CJR'F UM#9_3G'W;?^DM%S*289TBL0M,M:+HZ]3K-$W0;D$D0 M!N+E!(U7C$$L5# ST5XJFDR1ZU%?#HWU-J)FDT&MB:?M6LO$>T7BO=:)?Z&Q MOSOW7B,QQQW4DE>T&9[7LM?VKV7V_2+[_F'9?T\G^N1I6LLKK6* '(N3U>V#^CI&4 MW![CWQ.D9.D+<"] 6>Y3-/I>^3C;]M(%Q# M[N24F.SF"+'JF+1=/-1FF%*K L4E4&P8J!R&KSC_E:\"R90J2>+F8.K726K[ M=C!)0VI5DJ4!MK6.T 3)!0-0LG0:+'N].DNCYM>46I5E:7]MO?_]?9:?Z(HI M4;I[S(.&''".\AA^VBX-M:UWU 90!FOUJ.PU4#IN':4A.YVC/(8YMTMW;NO- M[^$HR4P VY-FOT$3VPV+;6ZIB(5\%^0(6"G/) )2+, :U M/+U66YIE@8'U!<9=$ ?1*D(_[B": %,N NLE#ET%-JKFF5*KXBNK"GR<=75L M=&'=J)IG2JV*M"PN<,OB(EE,172&QC06C/CJIURO;:?+HTJ$1HL*4VI5A&51 M@?5%Q1UY?ONA-FG]QT;5/%-J57QE(8'[QWFH3=K_L5$USY1:%6E93."6Q<1> M#[5>N^?N_KE$'WHPQ&-4%[BL+O"AU06)I[)BC4GL0P:4)U?3/0ZR-/OX+"!6 M5F9OW$CW Y0^]&"B1FN-[M;6A C8/-WBP5%:;&6__!=GBVTDU^GFB=KY&_O" MRS:#E#+9WI0[PN9!S%$(,REIG0WD5,6R[1[9@:#+= /$A I!H_3C L@46-) M7I]1*EX/DAL4FVY&_P-02P,$% @ @X)75OW$)59S# 854 !D !X M;"]W;W)K&ULQ9Q;;]O*$<>_RD(]*'( .Q+O4FH; ML$7G-(!S:MA)ST/0!XI:R6PH4H>D?.FG[_(B+;DS&LE;"GU))'DXW/_L[;>S M2UZ\I-G/_(GS@KVNXB2_'#P5Q?K3<)B'3WP5Y!_3-4_$7Q9IM@H*\35;#O-U MQH-Y==$J'IJCD3MQZ4G48X_&Z>#W3W+ M"]N?M]X_5^*%F%F0\VD:_Q'-BZ?+P7C YGP1;.+B(7WY.V\$.:6_,(WSZE_V MTMB.!BS"^SF M KN*3"VEBH,?%,'519:^L*RT%M[*#U4PJZN%_"@IZ_VQR,1?(W%=#S(HCB_%=VSKX_^NS#+[^R7UB4L*]1 M' N#_&)8B-*4/H=A<^>;^L[FGCL;)ON:)L53SFZ3.9]W'0R%C)T6>\R-F/ZUE>9**S_ L+>.W0QAV6(\BG?!V$_'(@AHB<9\]\Q=(F_)^]=>5$#:5$%25@$6^+H%3E: <:I^O#'MR,7QN!Q2Q&8^[-CZT,4?2 MIB/?V%Y;R4+%F094&RK$8WM-9+HRG6VXGU2+%U ZU'AS,Q M&N>AF$*#A*>;G*QH#U;B1-6.V#BVHITLG:;V\4[[^!W:";%C(,2S#$4L8C-1 M>K!/%D=3[&0G=D).!]^R8,X%)H7IIARD,AYRT:UG,3]C"4=53_J<#?ITYO?D MK!-'8R2)9T0VF[V11!EF!#O!R%.'=L1*C.WJH$B72U=WB_0,4O=U+""_XCO! M=2S,^#PJ6)R*[H/3FP$TG1LCH!RU4J10-5WRM(]NK-[\M;-YJ2)0T:)J^W MC>BAU8BZ(9[6/>M.]"SV8<:749*4,#*K%U>_H@&W84-2.]$4-7+4Q@:-/!L' M2$,2I$$CY'2SVL0U0O+%0JS863#_MUB;EF!520[FZ;I:)Z8+=OTX%4L@PSTW M+%1J3VC8Q*1/;[X!T=88[0F>I%&#QM'?Q5+Z0SW:BN5S^!1D2YZS(F7\=2TX M=<_@"[G3R1+DC1HE/R2/(N. MFV9O9ZQLG'1.P>@5(WOUYO?EK9MMDB!ITB#9BN/G*(GR)SYGOZ7I/*_C*KK& M0WU7M&.8"#,:GKHLP:Q&IKHPH0NJ&PA)EB9-EJU _)%F/\O$R7V6B@'AR$A MAC1L3PT$8@2&.[J*2'_*JK42K=98^[\]/FDCVT9VH\(19.::E"C]% MEM*4S&C2S'@KN\5BDR51LO9$R39"]Z:$253Z!R M3YW@IYB5 U8*=-DTM5N2"RV:"^]$Y7XJ$RSULEE0X9R+&X51M61"-^X@Y8DF MK&Z\H%:>VM'IPNF*ERQHT2RH-REIT'M(_-*+ G63+LE2A MB!'L3C"CV/;4+;\D/B^7IBCC48"')0W5"1FP<=3K&;,P]#4@"I75@XUO, M,J+U)TMVQX.<+K/%V;L ;*J1">P1&=<3( (/= M*FL&9ON M=F/3]?X#5S =:(+D*68$%@MTR7252URTZ9PA/ARS#T4J^!%E0QO9=79&ZMXT M9F6#!!I=.%WQDN7L WO389AMQ+1$;879O6Y&]^K-[\M;-WRM@XTT!-[QI5AC M9$12V8;P9H*C3YB1"P:(4V0&;LC2.F\.;]:HZCH)9%$?%GD2S M#?.!8PMT$\1(A1R?+INN=DEV-DUVVU[RP&="-WW4S<8VCM5$ FH$AH93) QM MR785[^&+'AKSFV:IFY#3C6,4C0J'T&8:X) N9F5;0/HIV,Z1 M;.>,CECQWK6%3X]:\SH]H5D=JUZ]^7UYZ\948J-#8Z//%UR$L!P:GWFRX?39 M=HP&U::$&8%C&72I=%5+9'1H9-S-!^E;$'=:$BH;@B XOXK8&!90?0I6="0K M.G3>[UOPRG,F.* ^HD,IAGO'R%,,B!'8+:2+I"M9\IU#\UT]9#QNDGGVAHX< MJ'H,^4 S1XS :0JZ=+KJ6\^MT,C7??;F .PYD.,\5P5=S&BL)G;I4NFJEK#G MN$=,$W(]>$AW3Y36!*A/;WY?WKJ1E 3IO#-#N.U!;^V$,QI4#^;%P8$DS @ M)5U$W1!(H'0. .51(3ACCX586*R:797/41(D8216EO=I'E6;53]N7XLR,25& M7G:;;%8-B^.XV[VFOWGS:FVYU2/IU:/I];]^>P.W.$3@[BUD!KO'I MDND^D2?AUZ43F_I]L7%,]T7,"/1%NHBZ(9"LZAY(] MZ5:'A&B7AN@^GVF@;_7>2;A7;W[CK?/8\9YG&ES)XNZA(YYSODJB1136AQGV M[D\T?CIW]U041XS4X8LNCVYCD2#N'@#QPYN-/7?<7L^(]NK-[\M;MR[DLL ] ML"S0V_AMO':G"'7C%S&"&[]T^73UMYYNI[/!]3#;.C'16ABR'U_Y:L8SO$WU MNE3HU9O?E[=N3.52P?7Z7'2Y/5%]$\D^O?E]>>M&4JXXW(./4U6YJ2])F*XX MJY(V!Q$/._0*$ \:V39X$\,I^-Z5?._2?'^;%]&JVIJZ$VUG6<^-QY,NENL& M=-U0\S$R/P1L[L">IU 0773A= M\1*\/1J\U9P]JA7FH\%FW10S\M1-'[HPNF(E*'LT*#?'')M!L9/"/=#487K: MMM0=/\P(+'OI$NI&0**S1Z.SSH3@P>PTG! 0(S@AT(73%2]9U:-9]7^;$#SD M34M@0L",P(1 %U,W#!)9O4-//9UJ0H '&>"$@#P>!2>$D[S#J?42)SI5K3H=.LAXQ(4#Z0R8$Q A."*= 1$\BHG=,"EAG0H!I M7F1"0(S@A- K'0Y;[YY<\6Q9O<,S9]5+%>I7-^Y^W;TG]+IZ.Z;R^XWQR:_? M]BG=U"\?_1IDRRC)6@#(XUM=2722])Q\O<=2HIL*Y04H.J+K M[(7\IC8 FCQG*5>7@XW6VP_CL8HVD#$U$EO@^&8E9,8TWLKU6&TEL#@WRM*Q MZSC!.&,)'RPN\F=W)B MR];P /K+]D[BW;CR$B<9<)4(3B2L+@=7]$-(Y\8@1WQ-8*^.KHFA\BC$-W-S M&U\.'#,C2"'2Q@7#OR=80IH:3SB/[Z73036F,3R^?O7^,2>/9!Z9@J5(_TQB MO;D['^%DM#$^(M$JO)?LB^QSH!$.Z5%5AKC#+*$%__LN13B MR( N:>#6#?P& Z\T\-YKX)<&?JY,0277(62:+2ZDV!-IT.C-7.1BYM9( M/^'FNS]HB6\3M-.+6QZ)#,@?[!D4&8:@69(JE MT^O"J=O@E+KDL^!ZH\@-CR$^=3#&&5;3=%^G>>VV>@PA&A&/GA'7<5W+A);O M-Z<6\_#]YDX+&Z\2W0W^'C!ZXUT*1*S(X0,4FM]#)'B4I G+X^*O3VA+ M;C5DZF_;AR@&\NT#F:3Q06U9!)<#S H*Y!,,%C_]0 /G%YN(?3H+>W)V(K!? M">RW>5_<\(T^0CQ"!92AXTTSLMY$O=R*9[,?XL']_DUJ>%,S)+ MZ^E8S_> P@[0"?])Q7_2$W]#&@CC,?DD(A3A.!_8>!?C4N]DNHXSK3&WP]Q) MC;L51H/ SCZHV <]L;^'+=.R##4,1BPE6"@XN6&2)WRMSL@=R BXMDD16"<_ M\6I26&%.,*M)88'1T63BVZ685E),>Y+BE7H=%R;H0J($"4MM*K2//_1&,^=' M6PE9=AA2?^39+<,.2]\93=]8GJ@WJ]2;]:3>;\(4NAV"L6*2FV=LRY0U;\RL MJ\'W:XO&#IO5BKA%\MU.\H_Z3_I\Q=D9NLRU+)&Y% M-)8P%-):MLI)G%396LAU0\(24M?/:X@WZAY$<%M%@$J$I!!!HPBRQA]?&,KY MW;F$%#6*K5Q=^U<.ZH3;YS1T1D%#;'593KL2,#UTRK2U3_SOR^-WO0'96L?+ M&;S1JYZ3WXD+[;C ;RCE]-#4TKZZVB^8.B1NY3#/($[I),JQ=T(E!F /$=]* M;UIO[1IPU*W+T$YF. \LK<&I,H=VE_;5[]YR+=FY:6?T"P:;QGR1$"[*5XBDQ1SA6ONWC#5V< M=4.=Z;"<6/)#J4Z'I3>U%+=3P0ZM,>VK-SZ4[1O.(EU6;0-M3RP=C2KN\YH$ MG-IC;%Y?3%;.O9]]LVULPKU)L3/+ MIMEIV#;20]]+V[M"W X*:3YO7GX;=OZEC]HRX+@[2JJ?5@>Q5?@Q9>WYM#FKSP\.#F^*4]S.3ZX0KDL(* M7>(V"G.5+ Y.BQLMMOE1XJ/06F3YY098#-( \/U*"/UZ8P:HCJ\7_P)02P,$ M% @ @X)75A3]@?YW#@ DW8 !D !X;"]W;W)K&ULM5UM<]LV$OXK&%^GT\S8L?@J.TT\XYA$SS=)Z[&;=N8Z]P&68(M7 MBE1)R([OUQ] TH( K!#177])*&GQ<+T/ 6(?8L'WCW7S9[O@7)"OR[)J/QPL MA%B].SYN9PN^9.W;>L4K^ M=]]=-6?OZ[4HBXI?-:1=+Y>L>?K(R_KQPT%P\/S%=7&_$.J+X[/W*W;/;[CX MLKIJY*?C#J*-/SNP\%Y\(Y.)ZI!9_%;P1_;K6.B_I3;NOY3?;B< M?SB8*(]XR6="03#YWP._X&6ID*0??PV@!YMSJH;;Q\_HM/OCY1]SRUI^49>_ M%W.Q^'!P;C/SPW1OR'3DF[8(U\N>B(E^J0K2'\DMY_+DH2WFE MM.^/A?1*81_/!@\^]AZ$.SR(R.>Z$HN6Y-6@!.);AV,0D?([) MQ]"+>,-7;TDT.23A) P@A_S-,SZ3S8.N>0@TS_9O#IT]W[_Y!&A.]VX>G'IB M&6VNKZC#BW;@_;+B#1-%=4\^U6U++EC3/,GQ\)$U\Y;\\4E:DTO!E^U_H NG MAXYA:#7FOFM7;,8_',A!M>7- S\X^_X?03KY$2(-$RS#!,LQP2@2F$%VO"$[ M]J$_#R8_**K?D+NF7I(+V36+:JTN@.%2D(,$N>7R&N#&>'-(,GG M\XZ]$GJPI -3=]Z'LZ,@4%?[PS;%@%4:GYA&.6243DPCBN2\04FRH21Y14KD MS5O>FBN($>]IQS+2@TVWPAB&=A@SURB8AK%%B&N4G 06'TBN&WRD&S[25^0C M_RH:5C?SHI*SP'[@/"0_U]*F$DTM[\ 2X[(27/HM(-*\OHTE+77Y"&(KUAE@ M-)FF%FFNT='4ZHX4R76#M.F&M*F7M(MUT_!*$,KGDI]2L2&ID)/[5C+YD5?\ MKA!OH'A[8^I>VG:T79/ 'K%""4Y8-9<3 MA]F8F'OAQ\;\Q VH?9]P3:+(BKEKE^UW<_W.\?:R_L MV%B?NH&TA^[,M0G"J15MP,;N*!3)<2/:P43G7).]XJT']_W"[8<=&^\!;3M0 ML3.B $;!U!Y3 *,3BQ6*Y;L9\JTT-_"&/.-W7 9]OAG#1\?>BS\Z]H$[))R& M=NP!HS"Q;YZ@56I''\E[,_JACGZX7_3M47TT"][SC&8A! 9FAP7(R.8 L'$H M0'+=I$#GX8$W\]OJ ,,@/SKTJ-GX@&;.'J=VZ/L3NPI#9;S9M!UYAOLE?KN'VO4E#9P M,]$XCNQ@NT:1,[X#R;$=Z-?(: .=T@;^G'9S=:M0G[U[-"IA$OP=C20R!S'QB3S @ M(THJF.6+]81;(YS/-E@QNU7.%(+3Z9FV87-?R, MQ._5:&9=92"PI_@9:&3/>5#]HEAH)K=:C0C]:L2S"G?;\T3J.[*N9KP1K*B( MD!ROZK80NQ:4^,%'4^0*"';V )C8&BBJ3Q0+S:1'ZQ7AGGK%=M?[J:[GCT59 M=AWLLA*LNB]N2S[\#O*$JEZ$KN80I:DS3 )626PGU:B>42PTDRTM=(1^H0-D M2_:CJZ:><9GFJ?L<:V:+CKB,/_"R7JG;&T@9J@@2 L_LG>?Z@%'J3%$PW:)8 M:"9?6B\)7Z"72+)DY%')Y-1#<97_M2YV,X6JH82N/F(+X8")DQ*@.D6Q MT$R>M(02OD1"$0O>@'R@:B6A*X,X_<8UL9\JYZA.42PTDP\ME(1(0@E(#ZHB M$KIB1WR:V)((:&4_F\M1/:-8:"9'6A,)7Z")_,;*=3_I/B_+^I')F1Y($:K( M$;H*QE$P<60KV,P=V%"U#BPTQ5?CNH6Q4(SR=$"131"H##(V3E)\"..IL75#2)[? -L;&4!U2F* MA6:2LE5OL.4GYJZA?L*;IT!L&C!658%&+E]!;D:QT$Q2M' 0O4 XN&KXBA5S4E?]4O)9O5RQ MZDDEJ'<%F(GZSS*:+6"]0^J,:H#1Q$Y^4/VB6&@F5UHTB/RB@9J>[1K;.K'@ M!;RA*@B1*P_$D]06$4 K^UE'CNH9Q4(SF=,R0C1:1@#90-4/(E< ! MLHJ<(B=4SR@6FLF&%A&B$2*",3^0/0SD!54XB("*@M@9W8"E%,YJ)52_*!:: MR8J6#:(7R :^U4K^(7J A^ MSCSUA/Z3C2[Q!&H;['P5L'$(0_6*8J&9A&DQ(?:+"5U6VCT$;_A";0[QL*DO M[.L1.S45) =538A=H<"N:L@ &[L8* =LCNS:%(KENAESK1'$?HV -IR37QLV MY^3?=<7)-;\OAD7),O2\4@(.&'%4H2 &%A@X4S/(*+:34L#('@HIEN]FR+4" M$/L5 ".VW4855VO>B)I<%[,:C#5J_A^[J7UHI_^0C?W($["QUX10+,_-2&^5 M^_N3^B]5PV?U?57\;[@+/"^[(6+!!/F]7I?S;CG53)#\[HYWN\ATAM=,P)<] M:N(?NRE];,^C,L HF#ID $8G=I$)EO,F&SJ;C_W9_$XVP$"CYNPQ4.S@E+,! M1F%BY^R046I7;PY&V]LNQ%M(9OQTAAW[,^R=\5/%#+.&LY9W:RG693>_Z6OW MATK.*]X4==_JRK=RR>_"Z+"[R?2)O1X&LK%C#CS[=VZCKY%#QSJ'COTY]$NX MN9*4-/LS@YI^QT EOCVH9("1O7]"#MC8A858GIO4Z(0Z]B?4'FHRCD,-:@8> M ]7X=H%)!ADYE5F047#BT/,:F76L,^O8GUF_A)X;+D3)U<*CECP68J':J1_/ MUV)1-YU< O*$FG7'T(-YFR; QGX>#-K8U>E8KIM[].A4.O>AZ2KOE\/>NW MA+%8^L16+5>/[,]7J[*8,;464]57KT7W[:=B60BVLU/Y/1J]@8^;2Q_9=R+( MQJGF'8S,S9GLPE(LWTVV=!Z=^//H3N^8_W?=BJZ+'&[WE\-.B_]2K=LU*Y7V M_E"T.RD(G+_UU+K"+_RNC-VV+'$S9CL-S%'/2+'03*IT^IWXTV^C!I@MBZKK M$(?RUE.Q3TTM@=Q)WGF:A^42PTD\FM'07].L,O M%3\22L04BCO6[Q \U.R(H^#T)"7Y]VRY^O&*')&*"[)B3[L6L?M/-9HP5Q=( M[/EXAGK*'!6-8J&9S&H%)/$K(/N(U8>DZ 4]2;I:DU ,#Q#*;D/#%6^(_+R4 M/W;[!,LK@+7M>JDFK?.B7*MK!;P.4'61 2W=N@XF;YV=!F KN^="1O8B8HKE MOLF;5D<2OSKB5;S'$7:X)U^H:LF 9@79U@]1SYFCHE$L-/,"T!I,XM=@A+Z+ M=@-Q/^"2AJN]Y267((6HJLJ MCWT1N[0BWG*'!6-8J&9#&J9)O'+-*H+%T87 M_LQ*]M06#.0.56D9T+:YUL0-?_24P+(<9GN#U"YC('Y_Y\I8WX.L(_"<9 M32DF6H:*EJ.B42PTDWPM*Z6O^ J*%%5#0D7+4-%R5#2*A69RKM6FU*\V[;GF MVH\RFEU7+W(K%R CIW(!U2^*A69RH?6B=,\J$Y6:L&&8S6J5FL!=#E430D7+ M4-%R5#2*A6;2O/5BB_05AUG<-U-@HF6H:#DJ&L5",SG7PE.*4MKB1QG-+K#O MQ:F]0W$&6,7N/L:HGE$L-),-K0*E>Y:VJ(&VW"H/\XZVJ#(0*EJ&BI:CHE$L M-)-KK1>EIZ\XVJ+*1ZAH&2I:CHI&L=#,EQ!I^6HZHN!FG](U/]Y8GJ?NTARW M= TP^MI2V;UNA+]*R0WWV[>K'K>O4_4^OXB M>)?W[T?5,/WK6C^SYKZH6E+R.PDY>3N5T6KZ-Z#V'T2]ZM[8>5L+42^[PP5G M<]XH _G[75V+YP_J!)OWT)[]'U!+ P04 " "#@E=6Q;/AP44$ !B%0 M&0 'AL+W=OG M^U,D=:,]X]]%"B#12"L!QQ6(V=J7\3^<; C/B#P%X<7"/]*$O&ONO& MUV3L>#HBH!!+C<#J;P=SH%235!P_2JA3^=2&A]@>"LDRTIC%4%&\N(?/Y>).# ( M@C,&06D0O-6@4QITC@T&9PRZI4'WK1YZI4'OK0;]TJ!OC%4U?&+F,M4HPR?7,>I1=U@?$UD*JB95KY*JURK5@\H] M)[&$!,58I$8.?M0'/[9DAZE9XTD>TZU:@?5R_KM,@:M-AG-U"V$A0#8M[;/6 M""Y5T"8L+&"# W7\[O61@@UCAL<*]DY4#KS7,35A^I4P_59A;HDD:VQ.3^IX M)BGH/?836CRK,Z%H?%%:>9>FV28L[)^DQQ\[9.5DO\=<_FQ*?JN72Y,_.'G.8:^>BM"FOX5-6&0) M5E-S6*DY;%5SQO'?A*+Y-%R@S^@=8BNU3B5D1Q*U'0FS'V&J=B0E*58'D,\Q MRS8@B?XX04M(\8ZH$?^<.W?-6IU?*K)-6#@\6:2"XW7,IK_($JPF\G4E\G6K MR(_;I5!;DMYS%CO]^^T.LB7PQJ-C*^I2R6S"0INPA4U89 E6$]?W7C\H/=O? M!R71DLI6::%5VL(J+;)%JRM]4#KP_Y>]MW13.SL$]=5OWA[*Q:+:I"VLTB); MM$)4]Z TE %?FR*>0+&6J"BV5+U5H7!JRF-'_:$N()J2TRNFJ#[>8;XFN5!? MBBN%]*X&2DA>%/2*AF0;4X!:,BE99BY3P EP/4#=7S$F7QK:0556G?P+4$L# M!!0 ( (."5U:;S[$88@@ !5/ 9 >&PO=V]R:W-H965T?\R?OMU6"2 MCXA%;"-S!%7_/;(UBZ*/7^A^XE;NK MP7) MNR>9I'\F#[]DU4'-,MYFS02Q5_R5+6=#,@F$S*-JV U@CA,RO_IU^J# M. JPIJ\$V%6 W0QP7@EPJ@"G&3!_)6!:!4S/'=*L"IB=&S"O N;G!BRJ@"+[ MX_+3+5+C4DE7ESQ](CQOK6CY@R*_1;3*2)CD4KR57+T;JCBYNI7IYO,NC;:, MB[\3[TL6RF?RH\LD#2/Q$_F9?+IUR8\__$1^(&,B=I0S0<*$?$I"*8;J1?7X M.HPBI2IQ.99J0#EVO*DZ=\O.[5V MD?@+34;$F0R)/;&=C@&MS>'7])G8BR)ZTG4XYFB7;53G5A%N=X1[YX=;'>'^ M^>%=@P_."+>F7>%:)IR#L)R"Y[S"6T=4")+>DT)AY(]?U?ODO62Q^'?'X-Z5 ML&DW+)^/WX@]W;"K@9IP!>./;+#ZVU^L^>0?74E&PEPDS$/"?"0L ,$TK4P/ M6IF:Z*L;57X8YVQ;BF5(;LN)YFTF=RD/_].<&DK)&)E])8.$N25L4<#RM<#C M:C8I_UV.'X_E<&Y#'SF\ 334CT[I'KV3:E^+T36G68CKV^:D3!WULJ>I1: M]JR5YG,;^LCA!2"8EN;Y(-3YA[W03?]'ZD:EFFE_IU'&R WCI0:Z\FZ$ M]\T[$N:6L/GQ=#F:6(V,G]/(1PXK ,&T7%N3^LQ]\B=J[*;4PI\IL.;^^PH" M2G,KFJG&GF[B=S1I5UG4P/4T'QDTEC'-Y?GS1[;/^&9'A?H.\_2!TWAX-(N3 MMW&:);(SB49Z[R0B:2Z4YD%I/I065+1CH5G'A4C7AEUKP_Y&;7S(XCLUU^?^ M2[/D$YF2.W84U;D(,/?<6S=(F@NE>5":7]&TD[W9HF/9$:#ZU;53^W.6T=*I M%_#W:I' :PDU:D>G-J!N'93F5K2%J3 XIPM#N\G,:16&[^&96;5I9IE=L\-9 MUY"LJ=AU)@KJD4%I;D73IL1I,U/('GTH+4#1].S7/IIE-M)^XXR*C#_K9W:= M(H Z:%"::[6M,7ONV,N+Y739U,+937WH& ,434]T[:199BMM-II-_DJNUS>W M*LEJK9[7^=/*69>[WQ#G3$HS8/2?"@M0-%TU=3NG+5 _OQF05TZ M*,V%TCPHS8?2 A1-UTSM%%IFJ[#_;S-F8&_9M#V[[M])7&B_'I3F0VD!BJ9+ MHC84+;.CV)+$RZ*3?*22#7,_<:-.(NA#IZ%HAO>61TFS'-WA:QKR+K17#TKS MH;0 1=.WVM0&I&TV(%OB^#7\DH5;6IB,Y9LL=R.-IK.YC[X:L=N&GM6:/LFC;;RV?UX5VZ4%I/I06H&BZ?FK7 MTC:[EF?.&\/R-ZM.=4#-22C-K6B-V67>G%Z@IB.4%J!HNCQJ8](^84R^MN80 MP[J4E)X7N:%AY\+4W$5O@4 =RHIF38\5,G*:\Y$'[=6'T@(439=(;7W:9NO3 MZ(F0_Y+K, GC+#;:).8N>DL$ZHU":1Z4YD-I 8JF"ZEV4>T9TB:QH58JE.9" M:1Z4YD-I 8JF:Z8V9&VS(;M.DT?&97@7,=*J5;\Q'A>"*EOE5^QT"@GJT4)I M[HG#MT?.TIEV:@9JQT)I 8JF:Z:V8VWS;LF3!8M^/5VPH!XME.9":1Z4YD-I M 8JF"ZGV:.TEM&!!#5HHS872/"C-A]("%$W73&WBVJ>VA0(*%M3*A=+<$X=O MCRZLBT6G9J#>+I06H&CZQ7NUM^N8O=U3!>LVNQ/L2\822;S'_*^ICK% MWV %5EV8XZ] MR!Q[E3GV,O/O81P[M7'L3*%%".H10VDNE.9!:3Z4%J!HNF9JC]@Q[[0MI5)N M@B)NEO]BG1>?,-V^[) :D@_LJ6S1N0/7W$%O&75LA+UPEAW;I*#]>E":#Z4% M*)HND=H2=LR>J+913BU->'AJVXL9V%L2)>WXVD=G.K*;.QR@G7I0F@^E!2B: MKH?:[G7,=N]WOS33W']O^;0O,9'-^>*&7\H[KLF M5-*S1)8WMCJ\>KBWV]OBCF:-UUWKC5_>H:W&E#>,NZ;\(4P$B=B]0DY&"Y5) M7MZ#K7PBTWUQ"["[5,HT+A[N&-TRGC=0[]^GJ7QYDG=PN!/>ZG]02P,$% M @ @X)75J<0 QBF%0 N?P !D !X;"]W;W)K&ULS9UM,5=;W]2HKWUPL MJ^KNU>5E.5^R=5(.\CN6U;^YR8MU4M4_%K>7Y5W!DD5;:+VZ=(9#_W*=I-G% MV]?M=]?%V]?YIEJE&;LNK'*S7B?%CS_8*G]XO[Y); M]I%5G^^NB_JGRSUED:Y95J9Y9A7LYLW%E?V*3MH";<27E#V4!Y^MYE2^YOFW MY@>Z>',Q;&K$5FQ>-8BD_N>>3=EJU9#J>ORK@U[LC]D4//R\HT?MR=6\#K"GA2 =L[4F#4%1B=6\#O M"OCG%AAW!<;G%@BZ L&Y!29=@4DKA^W?K_WCSY(J>?NZR!^LHHFN:%/-E+2#K>I5DI?5L MQJHD797/K9?6YX\SZ]G?GEM_LRZMO M+ZNZ>LU!+N==5?[85L4Y4A7;L=[E6;4LK3!;L(4(N*S/:W]RSN[D_G",Q!F; M#RS7?F$Y0\?15&AZ?G%;4WQV?O&AIGAH+AZQKP/+'A\]>F0N_GY>#:SA\:/' MYQP].%JYV_+<8RIOI/JRZ107UC1?UW>*,FG[ MVJNB2+);5O?>E?7UAW48=YW\:+^^>DB*A?77GS72HA5;E__427M[?$]__.:. M]:J\2^;LS45]2RI9<<\NWO[/?]G^\']ULD3"9DA8B(1%2%B,A!$DC()@@O"] MO? ]$_UME*2%=9^L-LS*;^K[1O&MSI^V^DX:76N[Z2URU"*;9.F^[II?7]X? M*E038HLA,S4D$"-"8]7[B@D)BY$P@H11$$P0TV@OII%13&WO:%T7Z9SI9+,M M[!_\P3U_X(PEY6BBG($G26.F1KFCP60D"4C#\@;-#>,P*C*>5%]E:"HV'DCU M(L@C4NT%L_W](84_I;__4_K&/^7GK&#S_#9+_RW?$:=Y6=6)WC8O?']7'@C7-^M\A^,==(5!S$Z!6\/.3Y0L!.,AO5_DHPU<:-Q MH,3-U#C;#<9*7&@\U;[B0\)B)(P@810$$\07[,47&,4G">O]0\:*M5Y=<^*Y)8="+"Y83;IUU:I^U\L=*(,U/N+/?#EGE6- ME;7TZX^;]5=6Z'0]43K'B>>JG>A4 M$S?V1FIGJXF;Z#I;XT7J*ULD+$;"B'HY;'LXGBC7@X*.*DC2'O+)QN%_GBB5 MGCFNCU59LZ1B5CL^_M*,C[7SE4,ER?6D8>Y4$^-*8YZ9+L:3A&J^&I* M.],1_:':783FZ]1;E4A:#*41*(VB:*)^':Y?QZC?=RPI-\56IG>MKNHA_9FS M?R?0CO6#)45IV4-KO75K',]:)#]TK"F0-0.R0C.KMZR1M!A*(U :1=%$67,7 MQS;.E2.Z97[#MZ[*]<,?TO*;%17U*(]F%:LK7UD?Z@1!VT"VE;3=@]YS M.!C:8R4UT <.';DW/@*4\XC0?'EZRQ;JOT!I!$JC*)HH6^[!V&83YO=E$[^4 M_*H&CC>2%:[&N!-9W1J.+0L;:@5!:3&41J TBJ*)PN9^D'V&(?0DPO[2CN5. MI,DC):E]Z7J!H\F3=9&!XVH294VD9WN:B0;SI>HM8:AI!:41*(VB:**$N0]F MFXVPWR?A7^J;->Z;+XM<$R-[])H81S99S1>PM["A;AF41J TBJ*)PN:.F7W" M,GLR84=Y<K)I%C>X$ZZSO51WJZ+E@3Z=J.FG.'YNO1 M6Z=0*PY*(]IK,O15$Y.BCBL^',_=..?1W3C#S$-S!^.)K%ZH&0>EQ5 :@=(HBB:JEYMQCMF9 M0G:S.V6><(R[&@DC(T?W',U4%^F-)[ZFD]5$ND--9&B^'KUU"G77H#0"I5$4 M3=0I=]><1W?73#K]N7[6549 MKRB0!?CRN(]'1.:+T]OV4+=-2B-0&D411-E MR]TUY]'=-7D>8-,\IMNLA V_WZ5%2SO5X7J:J:BAQGK0!?H3-56=:0-]76\+ M]29+%R,_W6"^8+V% M#'70H#0"I5$4310R=]"<1W?0]#-9-*N*-"O3^?&)5D?C7TV4_ "Z#@U*"Z&T M"$J+H30"I5$43=0\-]><1S?7])I7NN@/K-FQIEGO-LWK]I#,JTVRLCZQ8JUM M#^9JC_H\NVEF]6XV2%H(I4506@RE$2B-HFABL^&&GG/"T&L6T'7-87[8;-CW MYK.^BU<],,=1LFHUR)YX<@ZB"1HKV3343H/28BB-0&D411.5Q>TTQVRGU9UP MW:-M5VCNE@1;5YMJF1?-$G>ML#0VS7#WGZRO\V-GYIKV[NF@MAF4%D-I!$JC M*)JXW1"WUERSM2;J<9KW:]B33#\)(ZL,:H-!:3&41J TBJ*)*CO8*M!L@^D&)B^:593;#2^ME\T*RG2N M%9BK^/C#@>PS3?51\J(P?90L,>Q^?-@-^; [\F&WY'L,R\KEEI5KMJQ.2VR1 MKC:5?MS2L6WGA,KT88K,]&&RSJ >$Y060VD$2J,HFJ@S[C&Y3^ M=K8[\&5C21@M((E$91-%'#W%YR']U>.K;F MNQF0S!L!?\E7-7/5K!0XMNB[JV4@=)/RP&*JCU+&*-HH^7$4\W7IK5>H-02E M$2B-HFBB7KDUY#ZZ-712K\?LGQ-5\W?VS];]L?RCWL\)4!\?:78F:[)#V<'1 M;3O,J-Y- FK[0&D$2J,HFM@DN.WC/OHZ+O.#A9_R9G;UC.<%7-4"&BO33!J; M2-G12Q,4* D'U$J"TF(HC4!I%$43UONJH*CU\I>E5CU(Q# M$Z/(%>HT06DQE$8T5T/>-)RBCBCNVL_](^_IEF9U,DN^KIAI>:"G<9EEZJL^DO,7 ?#J] MFP"2%D)I$9060VD$2J,HFM@$N+OE/?DRL2--H-\SA2>J[77CM_%N_'9\5&DF M]6XT2%H(I4506@RE$2B-HFABH^%FG??D:]:VC>:,P:2GKBES1O*,H+G^O34/ M?9D7E!9!:3&41J TBJ*)FC]XI9?9/>P$VQJ'[71@E5O-7N=:C7I*4C\>N9IU MP.9C]M8IDA9":1&4%D-I!$JC*)JH4^X^>F;W\9A.7U@/NXPDZ3(2MDO*[XXF MY>H",F4K?G-]>FL820NAM A*BZ$T J51%$W4,'%!TWG M2]MTA%GQJ]O;@MTVSXR.&KEN#TD(H+8+28BB-0&D411.; S

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htm IDEA: XBRL DOCUMENT v3.22.4
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2022
Jan. 31, 2023
Jun. 30, 2021
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 1-11083    
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-2695240    
Entity Address, Address Line One 300 Boston Scientific Way    
Entity Address, City or Town Marlborough    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01752-1234    
City Area Code 508    
Local Phone Number 683-4000    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 53,200
Entity Listing, Par Value Per Share $ 0.01    
Entity Common Stock, Shares Outstanding   1,434,780,104  
Entity Central Index Key 0000885725    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Flag false    
Common Stock [Member]      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol BSX    
Security Exchange Name NYSE    
Senior Note due 2027 [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 0.625% Senior Notes due 2027    
Trading Symbol BSX27    
Security Exchange Name NYSE    
5.50% MCPS, Series A [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share    
Trading Symbol BSX PR A    
Security Exchange Name NYSE